<SEC-DOCUMENT>0001213900-22-058355.txt : 20220923
<SEC-HEADER>0001213900-22-058355.hdr.sgml : 20220923
<ACCEPTANCE-DATETIME>20220923153346
ACCESSION NUMBER:		0001213900-22-058355
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		127
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220923
DATE AS OF CHANGE:		20220923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InMed Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001728328
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39685
		FILM NUMBER:		221262179

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 310, 815 W. HASTINGS STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 1B4
		BUSINESS PHONE:		(604) 669-7207

	MAIL ADDRESS:	
		STREET 1:		SUITE 310, 815 W. HASTINGS STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 1B4
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2022_inmedpharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Sep 23 19:20:28 UTC 2022 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:inm="http://www.Inmedpharmaceuticalsinc.com/20220630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>



</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(Mark One)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric><b>&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">June
30</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric>
</span><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For the transition period
from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-39685</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><span style="font-size: 14pt"><b>INMED
PHARMACEUTICALS INC.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British Columbia, Canada</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>98-1428279</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction of <br/>
incorporation or organization)</b></span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS employer<br/>
Identification number)</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">Suite 310 &#8211; 815 W Hastings</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Vancouver</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">B.C</ix:nonNumeric>., <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Canada</ix:nonNumeric></b></span></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>V6C 1B4</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of principal executive office)</b></span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip Code)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(604)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">669-7207</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Exchange Act:</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="border-bottom: Black 1.5pt solid; width: 33%; font-weight: bold; text-align: center">Title of Each Class</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 33%; font-weight: bold; text-align: center">Trading Symbol</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 32%; font-weight: bold; text-align: center">Name of Each Exchange On Which Registered</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle">Common Stock, no par value</ix:nonNumeric></td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol">INM</ix:nonNumeric></td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</td></tr> </table><div>


</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>Securities registered pursuant to Section 12(g) of the Act: None</b></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0 auto; width: 60%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0">Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Indicate by check mark whether the registrant
has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 35%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 20%">&#160;</td> <td style="width: 35%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Smaller reporting company</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td><span style="font-size: 10pt">Emerging growth company</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether the registrant has fi led a report on and attestation to its management&#8217;s
assessment of the effectiveness of its internal control <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">over
financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting fi rm that
prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0">On September 23, 2022 there were <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">908,761</ix:nonFraction> shares of the registrant&#8217;s
common stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0; margin-bottom: 0">Portions
of the registrant&#8217;s definitive proxy statement for the registrant&#8217;s 2021 annual meeting of stockholders to be filed pursuant
to Regulation 14A within 120 days of the registrant&#8217;s fiscal year ended June 30, 2022 are incorporated herein by reference into
Part III of this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>InMed Pharmaceuticals Inc.</b></p><div>

</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; padding-bottom: 1.5pt; width: 8%; vertical-align: top">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; width: 80%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center; width: 10%"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_001"><span style="font-size: 10pt"><b>Part I</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 1.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">Business</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 1A.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_001a"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">46</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 1B.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_002"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_003"><span style="font-size: 10pt">Properties</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004a"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004b"><span style="font-size: 10pt"><b>Part II</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 5.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004c"><span style="font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 6.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004d"><span style="font-size: 10pt">[Reserved]</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 7.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_005"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">73</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 7A.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_007"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">87</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 8.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_006"><span style="font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 9.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_008"><span style="font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 9A.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_009"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 9B.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_010"><span style="font-size: 10pt">Other Information</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">89</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">Item 9C.</td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><a href="#a_011"><span>Disclosure Regarding Foreign Jurisdictions that Prevents Inspections</span></a></p>
</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><b><a href="#a_021">Part III</a></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 10.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_012"><span style="font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 11.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_013"><span style="font-size: 10pt">Executive Compensation</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 12.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_014"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 13.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_015"><span style="font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">90</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 14.</p></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_016"><span style="font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">90</p></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_017"><span style="font-size: 10pt"><b>Part IV</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 15.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_018"><span style="font-size: 10pt">Exhibits and Financial Statement Schedules</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Item 16.</span></td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_019"><span style="font-size: 10pt">10-K Summary</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_020"><span style="font-size: 10pt">Signatures</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">92</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PART I</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Special Note Regarding Forward-Looking
Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form 10-K,
including the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221;, contains forward-looking statements that involve risks and uncertainties. We
make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and
other federal securities laws. All statements, other than statements of historical facts contained herein, regarding our strategy, future
operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market
growth are forward-looking statements. We may, in some cases, use words such as &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;could&#8221;,
&#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;, &#8220;plan&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;,
&#8220;will&#8221;, &#8220;would&#8221;, and similar expressions tha<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t
convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are
not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report on
Form 10-K include, but are not limited to, statements about:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            researching, developing, manufacturing and commercializing cannabinoid-based biopharmaceutical
                                            products will treat diseases with high unmet medical needs;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            continued optimization of cannabinoid manufacturing approaches;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            success in initiating discussions with potential partners for licensing various aspects of
                                            our Product Candidates;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to commercialize and, where required, register Product Candidates and Products in
                                            the United States and other jurisdictions;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to successfully access existing manufacturing capacity via leases with third-parties
                                            or to transfer our manufacturing processes to a contract manufacturing organizations;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            belief that our manufacturing approaches that we are developing are robust and effective
                                            and will result in high yields of cannabinoids and will be a significant improvement upon
                                            existing manufacturing platforms;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            belief that that INM-755 offers specific advantages and will prove to provide the extensive
                                            relief symptomology with the added potential of addressing the underlying disease in EB;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            structure and timing of future INM-755 studies including that we will complete patient enrollment
                                            into our Phase II study in EB in 2022;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            ability of the IntegraSyn<sup>TM</sup> approach to introduce a revenue stream to us before
                                            the expected commercial approval of our therapeutic programs;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to successfully scale up our IntegraSyn<sup>TM </sup>or other cost effective approaches
                                            so that it will be commercial-scale ready after Phase II clinical trials are completed, after
                                            which time we may no longer need to source APIs from API manufacturers;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            success of the key next steps in our manufacturing approaches, including continuing efforts
                                            to diversify the number of cannabinoids produced, scaling-up the processes to larger vessels
                                            and identifying external vendors to assist in the commercial scale-up of the process;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to successfully make determinations as to which research and development programs
                                            to continue based on several strategic factors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to monetize our IntegraSyn<sup>TM</sup> manufacturing approach to the broader pharmaceutical
                                            industry;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to continue to outsource the majority of our research and development activities
                                            through scientific collaboration agreements and arrangements with various scientific collaborators,
                                            academic institutions and their personnel;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            success of work to be conducted under the research and development collaboration between
                                            us and various contract development and manufacturing organizations (&#8220;CDMOs&#8221;);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to develop our therapies through early human testing;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to evaluate the financial returns on various commercialization approaches for our
                                            Product Candidates, such as a &#8216;go it-alone&#8217; commercialization effort, out-licensing
                                            to third parties, or co-promotion agreements with strategic collaborators;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to oversee clinical trials for INM-755 in EB and building the requisite internal
                                            commercialization infrastructure to self-market the product to EB clinics;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to find a partnership early in the development process for INM-088 in glaucoma;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to explore our manufacturing technologies as processes which may confer certain benefits,
                                            either cost, yield, speed, or all of the above, when pursuing specific types of cannabinoids,
                                            and filing a provisional patent application for same;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plans
                                            regarding our next steps, options, and targeted benefits of our manufacturing technologies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            IntegraSyn<sup>TM </sup>or BayMedica derived products being bio-identical to the naturally
                                            occurring cannabinoids, and offering superior ease, control and quality of manufacturing
                                            when compared to alternative methods</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to potentially earn revenue from our IntegraSyn<sup>TM</sup> approach by (i) becoming
                                            a supplier of APIs to the pharmaceutical industry and/or (ii) providing pharmaceutical-grade
                                            ingredients to the non-pharmaceutical market;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            plans to work closely with regulatory authorities and clinical experts in developing the
                                            clinical program for INM-755;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to successfully prosecute patent applications;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to complete formulation development and scale-up, conduct additional preclinical
                                            studies, and initiate and complete IND/CTA-enabling toxicology studies in calendar year 2023
                                            for INM-088;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INM-088
                                            being a once-a-day or twice-a-day eye drop medication that will compete with treatment modalities
                                            in the medicines category, and with the potential of INM-088 assisting in reducing the high
                                            rate of non-adherence with current glaucoma therapies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            belief that with a novel delivery system, the reduction of IOP and/or providing neuroprotection
                                            in glaucoma patients by topical (eye drop) application of cannabinoids will hold significant
                                            promise as a new therapy;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            potential for any of our patent applications to provide intellectual property protection
                                            for us;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to secure insurance coverage for shipping and storage of Product Candidates, and
                                            clinical trial insurance;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to expand our insurance coverage to include the commercial sale of Products and Product
                                            Candidates;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
                                            patentable New Chemical Entities (&#8220;NCE&#8221;) which, if issued, will confer market
                                            exclusivity to us for the potential development into pharmaceutical Product Candidates, license,
                                            partner or sell to interested external parties;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to initiate discussions and conclude strategic partnerships to assist with development
                                            of certain programs;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to position ourselves to achieve value-driving, near term milestones for our Product
                                            Candidates with limited investment;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to execute our business strategy;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
                                            accounting estimates;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
                                            assessment of future plans and operations;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            outlook of our business and the global economic and geopolitical conditions; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            competitive environment in which we and our business units operate.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statements in this Annual Report on Form 10-K reflect our management&#8217;s beliefs and views with respect to future
events</span> and are based on estimates and assumptions as of the date of this 10-K and are subject to risks and uncertainties. We discuss
many of these risks in greater detail under &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing
environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact
of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially
from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on
these forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should read
this Annual Report on Form 10-K and the documents that we reference in this Form 10-K and have filed as exhibits, completely and with
the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking
statements in this Annual Report on Form 10-K by these cautionary statements. Except as required by law, each forward-looking statement
speaks only as of the date of the particular statement, and we undertake no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As used in this Annual Report
on Form 10-K, unless otherwise stated or the context otherwise indicates, references to &#8220;InMed,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to InMed Pharmaceuticals Inc., and our wholly owned subsidiaries.</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a clinical stage
pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs,
targeting the treatment of diseases with high unmet medical needs (&#8220;Product Candidates&#8221;). Together with our subsidiary BayMedica,
LLC, we also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors
(&#8220;Products&#8221;). We are developing multiple manufacturing approaches for synthesizing rare cannabinoids for potential use in
pharmaceutical Product Candidates and Products. Our know-how includes traditional approaches such as chemical synthesis and biosynthesis,
as well as a proprietary, integrated manufacturing approach called IntegraSyn<sup>TM</sup>. We are dedicated to delivering new therapeutic
alternatives to patients and consumers who may benefit from cannabinoid-based products. Our approach leverages on the several thousand
years&#8217; history of health benefits attributed to the <i>Cannabis</i> plant and brings this anecdotal information into the 21st century
by applying tried, tested and true scientific approaches to establish non-plant-derived (synthetically manufactured), individual cannabinoid
compounds as Product Candidates in important market segments including clinically proven, FDA-approved medicines and Products that are
provided to wholesalers and end-product manufacturers. While our activities do not involve direct use of <i>Cannabis</i> nor extracts
from the plant, we note that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has, to date, not approved any marketing application
for Cannabis for the treatment of any disease or condition and has approved only one <i>Cannabis</i>-derived and three <i>Cannabis</i>-related
drug products. Our ingredients are synthetically made and, therefore, we have no interaction with the <i>Cannabis</i> plant. We do not
grow nor utilize <i>Cannabis</i> nor its extracts in any of our Products or Product Candidates; our current pharmaceutical drug Product
Candidates are applied topically, although future drug candidates may utilize other routes of administration; and, we do not utilize THC
or CBD, the most common cannabinoid compounds that are typically extracted from the <i>Cannabis</i> plant, in any of our Products or Product
Candidates. The active pharmaceutical ingredient (&#8220;API&#8221;) under development for our initial two drug candidates, INM-755 for
Epidermolysis bullosa (&#8220;EB&#8221;) and INM-088 for glaucoma, is cannabinol (&#8220;CBN&#8221;). Additional uses of both INM-755
and INM-088 are being explored, as well as the application of novel cannabinoid analogs to treat diseases including but not limited to
neurodegenerative diseases such as Alzheimer&#8217;s, Parkinson&#8217;s, and Huntington&#8217;s.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;<img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin: 0; text-indent: 0.5in; text-align: justify; font-size: 10pt">We believe we are positioned to develop multiple pharmaceutical Product Candidates in diseases
which may benefit from medicines based on rare cannabinoid compounds. Most currently approved cannabinoid therapies are based specifically
on CBD and/or THC and are often delivered orally, which has limitations and drawbacks, such as side effects (including the intoxicating
effects of THC). Currently, we intend to deliver our rare cannabinoid pharmaceutical drug candidates through various topical formulations
(cream for dermatology, eye drops for ocular diseases) as a way of enabling treatment of the specific disease at the site of disease while
seeking to minimize systemic exposure and any related unwanted systemic side effects, including any drug-drug interactions and any metabolism
of the active pharmaceutical ingredient by the liver. The cannabinoids products sold through our B2B raw material supply business are
integrated into various product formats by the companies who then further commercializes such products. We plan to access rare cannabinoids
via all non-extraction approaches, including chemical synthesis, biosynthesis and our proprietary integrated IntegraSyn<sup>TM</sup> approach,
thus negating any interaction with or exposure to the <i>Cannabis</i> plant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;<img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On October 13, 2021, we acquired BayMedica Inc.,
now named BayMedica LLC (&#8220;BayMedica&#8221;). Upon closing of the transaction, BayMedica became a wholly-owned subsidiary of InMed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were originally incorporated
in the Province of British Columbia, under the BCBCA, on May 19, 1981 and we have undergone a number of corporate name and business sector
changes since this incorporation, ultimately changing our name to &#8220;InMed Pharmaceuticals Inc.&#8221; on October 6, 2014 to signify
our intent to specialize in cannabinoid pharmaceutical product development. Our principal executive offices are located at Suite 310 &#8211;
815 W Hastings Street, Vancouver, BC, Canada, V6C 1B4 and our telephone number is +1-604-669-7207. Our internet address is https://www.inmedpharma.com/.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employees and Human Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management team is comprised
of highly experienced pharmaceutical and biotechnology executives with successful track records in researching, developing, gaining approval
for and commercializing novel medicines to treat serious diseases. Each member of our management team has over 20 to 30 years of industry
experience, including our CEO, COO, General Manager, and (Sr.) Vice Presidents of Clinical and Regulatory Affairs, of Preclinical Research
and Development, of Chemistry, Manufacturing and Controls, of Discovery Research, of Chemistry, of Synthetic Biology, of Sales &amp; Marketing
and of Commercial Operations. Together, this team has covered the spectrum of pharmaceutical drug discovery, preclinical research, formulation
development, manufacturing, human clinical trials, regulatory submissions and approval, and global commercialization. Additionally, the
team has significant experience in company formation, capital raises, mergers/acquisitions, business development, and sales and marketing
in the pharmaceutical industry. Our Board is constituted by individuals with significant experience in the pharmaceutical and biotechnology
industries. As of September 1, 2022, including our management team, we had 13 full time employees and we also utilize the services of
several consultants. None of our employees are represented by a collective bargaining agreement, nor have we experienced any work stoppage.
We believe that our relations with our employees are good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are committed to growing
our business over the long-term. As a result of the competitive nature of the industry in which we operate, employees have significant
career mobility and as a result, the competition for experienced employees is great. The existence of this competition, and the need for
talented and experienced employees to realize our business objectives, underlies the design and implementation of our compensation programs.
At the same time, we seek to keep our approach to compensation simple and streamlined to reflect the still relatively moderate size of
our company. We have compensation, leave and benefits programs necessary to attract and retain the talented and experienced employees
necessary to develop our business including competitive salaries, stock options awards to permanent employees, both upon initial hiring
and annually thereafter, and pay annual bonuses to permanent employees contingent on the achievement of corporate and/or personal objectives.
We have developed an Employee Handbook that contains all corporate policies and guidelines for professional behavior. Our policies and
practices apply to all employees, regardless of title. These guidelines include our Code of Business Conduct as well as our policies for
corporate disclosure, insider trading and whistle blower, all of which are posted on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In response to the COVID-19
pandemic, commencing in March 2020, we implemented a work-from-home mandate and ceased all non-essential business travel. In the recent
months, some employees have recommenced limited business travel and some have transitioned back to working on-site in conjunction with
the implementation of additional safety and infection prevention measures including enhanced cleaning, additional personal protective
equipment, and contact tracing protocols. We continue to provide our employees with the option to work from home.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Rationale for Use of CBN in Pharmaceutical Drug Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">CBN is one of several non-intoxicating
rare cannabinoids naturally produced in the <i>Cannabis</i> plant, albeit at significantly lower levels relative to the more commonly
known THC and CBD. Despite their common origin, different cannabinoids have been observed to have distinct physiological properties, we
are specifically exploring these unique effects of CBN, as well as other rare cannabinoids, and their therapeutic potential to treat disease.
Extensive preclinical testing undertaken by us has identified several unique properties of CBN that outperformed both THC and CBD in various
disease-related assays and models. CBN can act with higher potency when interacting with some receptor systems in the body, while acting
with lower potency for others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Rare vs. Major Cannabinoids: Types, Prevalence
&amp; Application</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;<img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The molecular formula is C21H26O2 and the molecular weight is 310.43
g/mol. CBN has no chiral centers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Figure 1 Structural Formula of CBN</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">CBN occurs naturally as a trace component of <i>Cannabis</i>,
or as a degradation product of D9-THC. However, our Product Candidates utilizing CBN contain highly purified, chemically synthesized CBN,
rather than a biological extract from the plant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>CBN as our Lead API</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0">As the API in our lead therapeutic programs in dermatology
(INM-755) and ocular disease (INM-088), CBN has several compelling features, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">A rare cannabinoid with unique physiological properties;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>A natural compound, but designated as a new chemical entity, or &#8220;NCE&#8221; for pharmaceutical development;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Found in trace amounts in the plant and impractical to extract; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our preclinical studies show therapeutic potential for dermatology and ocular diseases.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that we offer
a differentiated approach to selecting and delivering rare cannabinoids vis-&#224;-vis other current competitors, many of whom are exclusively
focused on THC and/or CBD as their therapeutic agents. We believe that rare cannabinoids in general, and CBN in particular, represent
significant opportunities to treat a wide spectrum of diseases with high unmet medical need. In our preclinical testing, CBN has demonstrated
therapeutic potential beyond CBD for several symptoms and disease-modifying effects for dermatological conditions and has demonstrated
benefits beyond CBD and THC for ocular diseases. We believe that a topical application of CBN may maximize the clinical benefit at the
disease site (skin, eye) while minimizing the systemic exposure and any corresponding adverse effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">INM-755, our lead product
candidate, is being developed as a topical skin cream formulation containing CBN for the treatment of symptoms related to EB, a rare genetic
skin disease characterized by fragile skin that blisters easily from minimal friction that causes shearing of the skin layers. The blisters
become open wounds that do not heal well.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to relief of symptoms,
inflammation, pain, and others, we believe INM-755 may impact the underlying disease by enhancing skin integrity in a subset of EB patients.
We have completed more than 30 preclinical pharmacology and toxicology studies to investigate the effects of CBN. Several of these nonclinical
studies explored the effect on important symptoms such as pain and inflammation. In <i>in vitro</i> pharmacology studies, CBN demonstrated
activity in reducing markers of prolonged inflammation. CBN upregulated expression of a type of keratin called keratin 15, or &#8220;K15&#8221;,
which might lead to skin strengthening and reduced blister formation in EB simplex, or &#8220;EBS&#8221;, patients with mutations in another
keratin called keratin 14, or &#8220;K14&#8221;. The anti-inflammatory activity of CBN may be beneficial in healing chronic wounds caused
by prolonged inflammation.	</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following a review of our
toxicology studies, a regulatory application to support our first Phase I clinical study in healthy volunteers with INM-755 (755-101-HV)
was submitted November 4, 2019 and approved December 6, 2019 in the Netherlands. The initial Phase I clinical study evaluated the safety,
tolerability, and pharmacokinetics of INM-755 cream in healthy volunteers with normal, intact skin; the volunteers had cream applied once
daily for a period of 14 days. All subjects in this first clinical trial completed treatment and evaluations by March 27, 2020. A regulatory
application was approved April 17, 2020, for a second Phase I clinical study of healthy volunteers to test the local safety and tolerability
of applying sterile INM-755 cream to small wounds once daily for 14 days. As with the initial Phase I trial, the second trial (755-102-HV)
was conducted with two different drug concentrations and a vehicle control. Enrollment began in early July 2020 and the clinical trial
completed treatment and evaluations at the end of September 2020. The safety of INM-755 will continue to be assessed throughout its clinical
development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">INM-755 cream was well tolerated
in the two Phase I clinical studies in healthy volunteers and, based upon this outcome, we advanced the product candidate into a Phase
II clinical trial in patients with EB (Study 755-201-EB). The 755-201-EB study is designed to enroll up to 20 patients using a within-patient
design in which matched index areas are randomized to INM-755 cream or vehicle (no drug) cream in a blinded manner. InMed will evaluate
the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day treatment period,
the longest period supported by nonclinical toxicology. All four subtypes of inherited EB; EB Simplex, Dystrophic EB, Junctional EB, and
Kindler Syndrome are eligible for this study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the fiscal fourth quarter,
based on the safety data of the first five adult patients who completed treatment with INM-755 CBN cream for the treatment of symptoms
in the Phase 2 clinical trial, an independent Data Monitoring Committee (&#8220;DMC&#8221;) agreed it is safe to allow the enrollment
of adolescent patients, defined as persons aged twelve to seventeen.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The clinical trial is taking
place in seven countries including Austria, Germany, Greece, France, Italy, Israel and Spain.&#160;Enrollment and patient treatment began
in December 2021 and are expected to complete during the calendar year 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">CBN is also the active pharmaceutical
ingredient in our second pharmaceutical drug candidate, INM-088, which is in preclinical studies as a potential treatment for glaucoma.
Current treatments for glaucoma primarily focus on decreasing fluid build-up in the eye. We are conducting preclinical studies to test
INM-088&#8217;s ability to provide both neuroprotection and reduce intraocular pressure in the eye. We compared several cannabinoids,
including CBD and THC, to determine which cannabinoid was the best drug candidate for the treatment of glaucoma. Of all the cannabinoids
examined in preclinical studies, CBN demonstrated the most optimal neuroprotective effect. Notably, exposure of retinal neurons, called
retinal ganglion cells (&#8220;RGCs&#8221;) to increasing concentrations of several cannabinoids, including THC and CBD, resulted in dose
dependent cytotoxicity, or cell death, over time. Importantly, CBN-exposed RGCs demonstrated the lowest level of toxicity among the cannabinoids
used in these experiments. We also verified that CBN has an anti-apoptotic effect on differentiated RGCs when subjected to elevated hydrostatic
pressure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Furthermore, CBN also exhibited
intraocular pressure reduction capability. INM-088 is in advanced formulation development. We selected a final delivery technology (MiDrops<sup>&#174;</sup>,
EyeCRO LLC) based on the extensive data collected from these assessments that included solubility, drug delivery localization and sustained
effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company continues to advance
discovery work for the potential use of a rare cannabinoid to improve neuronal function and provide neuroprotection for treating neurodegenerative
disorders such as Alzheimer&#8217;s disease, Parkinson&#8217;s disease and Huntington&#8217;s disease. To date, screening for this indication
has yielded some meaningful analog candidates and we will continue to proceed with our plan to find an appropriate compound for a pre-clinical
development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For all current and future
pharmaceutical Product Candidates we intend to submit new drug applications (NDAs) (or their international equivalents) in most major
jurisdictions, including the U.S. either alone or with development/commercial partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are actively establishing
a broad patent portfolio to protect our commercial interests in utilizing CBN and other rare cannabinoids across these and other diseases.
We have also filed multiple patent applications for our integrated, biosynthesis-based manufacturing approach. If granted, these patents
may confer meaningful protection to the commercial potential for these technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Rare Cannabinoid Products in the Health and Wellness Sector</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the acquisition
of BayMedica in October of last year, key priorities for the Company in the second half of fiscal 2022 was to accelerate commercial activities
to build out a robust product portfolio as a supplier of raw ingredients to the health and wellness market, as well as to build a robust
patent portfolio of cannabinoid analog compounds. We continue to design and manufacture novel analogs to further support our patents in
the field and we continue to explore the therapeutic potential of these analogs in preclinical testing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2022, we announced
the market introduction of the rare cannabinoid cannabidivarin (&#8220;CBDV&#8221;) and in May launched delta-9 tetrahydrocannabivarin
(&#8220;THCV&#8221;), bringing the BayMedica portfolio to four cannabinoid products. Since October 13, 2021, the date of acquisition,
to June 30, 2022, BayMedica had revenues of approximately $1.1 million. While consumer companies have begun to investigate the use of
rare cannabinoids for new products, this has not translated to immediate, meaningful market demand, resulting in slower than expected
revenue growth. Contributing factors include but are not limited to: recent overarching recessionary pressures leading to hesitation within
the health and wellness sector to invest in, and launch, new rare cannabinoid products; in this nascent market, BayMedica&#8217;s perceived
competitive advantages of certified high purity and reliability and consistency of supply not resonating with the industry product manufacturers;
and, additional downward pricing pressure for cannabinoids in the health and wellness sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Given the above, the timing
of revenues for the BayMedica products has become highly uncertain and is causing management to re-evaluate whether, in the long-term,
the BayMedica commercial activities will achieve margins sufficient to justify further investment in that business line. As a result,
the Company made the decision to refocus on its core business in the pharmaceutical drug development area and reduce our financial exposure
in the health and wellness sector. To make that transition, the Company plans to focus sales efforts on reducing inventory and decreasing
other commercial manufacturing R&amp;D efforts. BayMedica will continue to evaluate opportunities for potential structured supply arrangements
and collaborations and will consider other potential strategic alternatives for the commercial business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Business Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our goal is to develop a pipeline
of prescription-based Product Candidates targeting treatments for diseases with high unmet medical needs as well as to develop proprietary
manufacturing technologies to produce rare cannabinoid Products for various market sectors and to produce their novel analogs for our
use in the pharmaceutical industry, by pursuing the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Advance INM-755 and INM-088 through preclinical and clinical
development, thereby establishing important human proof-of-concept in multiple therapeutic applications</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.15in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Develop and produce novel cannabinoid analogs for use in our drug development program and/or licensing, partnering or sale to external
companies.</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These activities are well
underway, at various stages, for both INM-755 for diseases of the skin and INM-088 for diseases of the eye. Building upon preclinical
data sets, we have the internal capabilities to design and execute, together with multiple external vendors, the preclinical data sets
and clinical studies required to advance pharmaceutical drug candidates towards commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Establishing partnerships for our various technologies, at different stages of development, to expedite their path towards commercialization
in a resource-efficient manner.</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently have an
organization for the sales, marketing and distribution of pharmaceutical products. With respect to the commercialization of each Product
Candidate, we may rely on either i) a &#8220;go-it-alone&#8221; commercialization effort; ii) out-licensing to third parties; or, iii)
co-promotion agreements with strategic collaborators for our Product Candidates. Any decision on a &#8220;go-it-alone&#8221; commercialization
effort versus out-licensing to third parties will depend on various factors including, but not limited to, the complexity, the expertise
required and related cost of building any such infrastructure for our Product Candidates. For INM-755 in EB, we could oversee the clinical
trials, given the relatively small patient sizes expected for such trials, and build the requisite internal commercialization infrastructure
to self-market the product to EB clinics, which are limited in number and provide direct access to the vast majority of EB patients. We
may also choose to partner or out-license INM-755. For INM-088 in glaucoma, because of the potentially large number of clinical trial
participants (possibly several thousand) and the extensive sales effort required to reach a large number of prescribing physicians, we
may consider exploring partnership opportunities early in the development process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Develop multiple cost-efficient manufacturing processes for high quality rare cannabinoids as APIs for our core internal drug candidate
pipeline, for licensing opportunities of non-core drug candidates.</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are developing an integrative
cannabinoid synthesis approach designed to produce bio-identical, economical, pharmaceutical-grade cannabinoids in a cost-efficient manner,
called IntegraSyn<sup>TM</sup>. IntegraSyn<sup>TM</sup> is designed to offer superior yield, control, consistency and quality of rare
cannabinoids when compared to alternative methods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Continue to invent, manufacture and research the potential
of a wide array of rare cannabinoid analogs to treat diseases based on our significant history in cannabinoid research and lead drug
candidate identification.</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Individual cannabinoids affect
a range of different receptors in the human body, including, but not limited to, known endocannabinoid receptors. As such, they are responsible
for a wide variety of pharmacological effects. However, due to the limited research into these varying effects, a full understanding
of the role of each cannabinoid compound remains elusive. As a company, we have been formally investigating the utility of cannabinoids
in treating disease for over 6 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the core of our activities,
we are a pharmaceutical drug development company and a developer and supplier of rare, naturally occurring cannabinoids and their analogs
that is focused on commercializing important cannabinoid-based medicines to treat diseases with high unmet medical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Strengths</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are the only clinical-stage
company with both multiple cannabinoid drug candidates, in multiple therapeutic categories, that also has internal expertise in multiple
manufacturing approaches including chemical synthesis, biosynthesis and a proprietary, integrated biosynthesis-based manufacturing approach,
called IntegraSyn<sup>TM</sup>, to meet the needs of the rapidly evolving markets for rare cannabinoids. Key strengths include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Experienced executive team and board of directors with proven track
records.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">One key critical success factor
in the field of pharmaceutical drug development is the experience and skill set of the individuals leading the company. We have been successful
in attracting and retaining executive and directors with extensive (20+ years) experience in all facets of the pharmaceutical industry,
including fundamental research and development, multiple manufacturing techniques, drug formulation, clinical trial execution, regulatory
approvals, pharmaceutical commercialization, company and capital formation, business development, legal, and corporate governance. Our
leadership team is well-poised to lead us through all facets of drug development and product commercialization, either internally or externally
via partnerships. It is this group of individuals that will help optimize our chances for success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Multiple manufacturing approaches.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The combined manufacturing
technologies from InMed and BayMedica provide us with a competitive advantage to utilize the most cost-efficient methodology (i.e. chemical
synthesis, biosynthesis, IntegraSyn<sup>TM</sup>) for the development and commercialization of new Products and Product Candidates and
provision of rare bio-identical cannabinoids or their analogs to a wide spectrum of markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Leading experts in the therapeutic potential of the rare cannabinoid
CBN.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have invested significant
time and effort in understanding the characteristics and therapeutic potential of our first rare cannabinoid drug candidate, CBN. As such,
we are positioning ourselves to be a world leader in the pharmaceutical development of this rare cannabinoid. We anticipate that CBN will
be the first of several such drug candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Targeting medical applications of rare cannabinoids to treat diseases
with high unmet medical needs.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Significant investment in
understanding the therapeutic potential of CBN has provided us with important insight as to how best to develop this class of compounds
for treating various diseases. We intend to apply this know-how across several diseases that may benefit from cannabinoid-based medicines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Diverse portfolio of patent applications covering a spectrum of
commercial opportunities.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Success in pharmaceutical
markets often rests with the strength of intellectual property, including patents, to protect our commercialization interests. We have
filed several patents on our novel findings and expect to continue to do so. The acquisition of BayMedica brought several additional new
patent families to enrichen our manufacturing as well as drug development opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Cannabinoid Science Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cannabinoids are a class of
compounds that exist throughout nature and can be found in significant numbers and varying quantities in the <i>Cannabis</i> plant. The
two predominant, or major, cannabinoids in the <i>Cannabis</i> plant are THC and CBD. These two exist in relatively large quantities in
the plant and can be easily extracted, which has led to significant research into these two compounds over the previous several decades.
Nevertheless, there are over 140 additional cannabinoid compounds found in the plant, referred to as minor or rare cannabinoids. Each
cannabinoid has one or more specific chemical differences that may confer unique physiological properties in humans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cannabinoid receptors are
found throughout the body and are involved in many different functions, such as pain perception, memory, immune function and sleep. Cannabinoids
act as messengers that bind to cannabinoid receptors, as well as other receptors, signaling the endocannabinoid system into action. The
relevance of the endocannabinoid system on many important physiological processes has made cannabinoids an important target to potentially
treat a number of diseases and symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Two cannabinoid receptors
in the human body are the endocannabinoid receptor 1 (CB1), which is more significant to the central nervous system, and endocannabinoid
receptor 2 (CB2), which is more common with the immune system. Scientific literature suggests that CBN has a greater effect on the immune
system than on the central nervous system; however, information on the effects of CBN on the endocannabinoid system is limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in">Significant investigation is currently underway
to determine the role of cannabinoids in affecting other receptor systems in the human body.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;<img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Products, Product Candidates and Technologies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Development of a Flexible Suite of Processes for the Manufacturing
of Cannabinoids</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration:underline">Introduction:</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">While there are over 140 different
individual cannabinoids in the <i>Cannabis</i> plant, the two most well-known and studied compounds are also the two that occur in the
largest quantities: THC and CBD. Due to their relative abundance in the <i>Cannabis</i> plant, it is also only THC and CBD that can currently
be extracted economically; this also now includes genetically modified plants designed to significantly increase quantities of CBG in
harvested crops. Among other challenges, the expense of extraction &#8211; or that of synthetic manufacturing &#8211; of the remaining
minor or rare cannabinoids, may be orders of magnitude greater than that of THC, CBD and CBG.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nevertheless, like the major
cannabinoids THC, CBD and CBG, these rare cannabinoids may hold very important physiological benefits in humans. The challenge, and opportunity,
that we have identified, and seek to solve, is selecting and engineering the most appropriate manufacturing approach to making a specific
rare cannabinoid, at the desired quantity and requisite quality, which is cost-efficient and consistently yields bio-identical cannabinoids
as compared to the compounds found in nature, among several other benefits. We believe that providing this solution will be a critical
success factor not only for our own drug development strategy, but also for other pharmaceutical and health and wellness companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration:underline">Development of InMed&#8217;s biosynthesis and IntegraSyn<sup>TM</sup>
technologies:</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2015, we commenced the
development of a biosynthesis process for the manufacturing of cannabinoids through a research collaboration with Dr. Vikramaditya Yadav
from the Department of Biological and Chemical Engineering at the University of British Columbia. Utilizing the basis of a specific vector
created for us, Dr. Yadav initiated a Research and Development Project titled &#8220;The Metabolic Engineering of yeast and bacteria for
synthesis of cannabinoids and <i>Cannabis</i>-derived terpenoids&#8221; under a collaborative research agreement. Subsequently, we signed
a Technology Assignment Agreement with the University of British Columbia whereby we retain sole worldwide rights to all patents emergent
from the technology under development in exchange for a royalty of less than 1% on sales revenues from products utilizing cannabinoids
manufactured using the technology and a single digit royalty on any sub-licensing revenues. Other than the 1% royalty, we do not have
any ongoing financial commitments under these arrangements with the University of British Columbia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Microorganisms do not naturally produce cannabinoids
nor the enzymes required for their assembly. However, utilizing genome engineering to modify their metabolism, we have systematically
introduced different aspects of the <i>Cannabis</i> plant&#8217;s metabolic pathways into a bacteria (<i>E. coli</i>), referred to as
a host, and have reported what we believe to be the first-of-its-kind production of fully differentiated cannabinoids in this bacteria.
This research served as the basis for the subsequent development of a new, integrated approach to cannabinoid manufacturing that we refer
to as IntegraSyn<sup>TM</sup>. IntegraSyn<sup>TM</sup> is a flexible, integrative cannabinoid synthesis approach utilizing novel enzyme(s)
to efficiently produce bio-identical, economical, pharmaceutical-grade cannabinoids without the risk and high-resource requirements of
an agriculture growing operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In early research, we utilized
the specific gene sequences from the <i>Cannabis</i> plant that encode the instructions to make specific enzymes that enable cannabinoid
synthesis and subsequently transferred these genes into <i>E. coli</i>. This intervention converts the bacterium into a manufacturing
system that produces substantial quantities of the target cannabinoids. This technology may provide an opportunity for industrial-scale
manufacturing of cannabinoids, which we believe would be a significant improvement over existing manufacturing platforms. Specifically,
direct extraction is quite cumbersome, time-consuming and relatively low yielding for all but a few of the cannabinoid compounds. In contrast,
the use of microorganisms for manufacturing cannabinoids eliminates the need for an agricultural-centric process, including planting,
growing, harvesting and extraction. There are also economic and environmental advantages including substantially reduced resource requirements
(e.g., water, electricity, manpower, etc.). Furthermore, the agricultural approach has several hard-to-remove impurities (e.g., pesticides,
etc.), potentially presenting safety issues. As with all crops, yield fluctuations influenced by the environment present an additional
risk. Only a few of the 100+ cannabinoids can currently be extracted from the plant in sufficient quantities to make the process economically
viable. For certain cannabinoids, chemical synthesis, by comparison, can be challenging and expensive due to the complexity of these molecules
and the ability to economically scale the process. For these reasons, we believe that a modified biosynthetic approach may be superior
to both of these alternatives for pharmaceutical grade production of certain cannabinoids.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cannabinoids are prenylated
polyketides that are derived from fatty acid and terpenoid precursors. The biosynthesis of these molecules involves four metabolic pathways,
two of which originate from central carbon metabolism. The first pathway (the Terpenoid pathway referenced in Figure 1 below) culminates
with the synthesis of geranyl pyrophosphate, or &#8220;GPP&#8221;, and neryl pyrophosphate, or &#8220;NPP&#8221;. These molecules are
terpenoid building blocks, or precursors. The second cannabinoid biosynthetic pathway, or the Polyketide pathway, is a version of a polyketide
biosynthetic pathway and results in the second requisite precursor, either: olivetolic acid, or &#8220;OA&#8221;, and/or divarinic acid,
or &#8220;DVA&#8221;. The polyketide precursors subsequently combine with the terpenoid precursors in the third pathway, which comprises
a single, specialized enzyme in the plant, to yield the &#8216;gateway&#8217; cannabinoids, the cannabinoids that act as precursor molecules
for further differentiation into all others. For instance, OA combines with GPP to yield the gateway cannabinoid cannabigerolic acid,
or &#8220;CBGA&#8221;. The gateway cannabinoids are subsequently modified in the fourth pathway to yield cannabinoids such as tetrahydrocannabinolic
acid and cannabidiolic acid. We refer to the fourth pathway as the down-stream pathway involving the transformation of the acid form of
the cannabinoids into the non-acid form via enzymes called synthases. Synthesis of CBGA is the most dominant pathway in the plant, resulting
in high quantities of the down-stream cannabinoids THC and CBD. Other combinations of the various precursors result in different gateway
cannabinoids which, in turn, leads to diversification into more than 140 different individual cannabinoids.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Figure 1:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;<img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Figure 1: Synthesis of the
gateway cannabinoid CBGA is the most prevalent pathway in the <i>Cannabis</i> plant, leading to high levels of both THC and CBD. Our technology,
IntegraSyn<sup>TM</sup>, is designed to mimic the natural biosynthesis of cannabinoids starting with an <i>E. coli</i> biofermentation
process combined with additional common pharmaceutical manufacturing technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our earlier research led to the successful construction
of the terpenoid biosynthetic pathway and the gateway pathway for synthesis of CBGA and the down-stream diversification pathways for synthesis
of other cannabinoids.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our goal for the biosynthesis
program has always been to achieve the simplest, most efficient, scalable, flexible and economical solution with the least steps and fastest
production cycle, to make bio-identical cannabinoids to those found in nature. While developing our bacterial biosynthesis system, we
further optimized the fermentation conditions and the purification processes. Working with various contract development and manufacturing
organizations (&#8220;CDMOs&#8221;), we have continued development and optimization of our manufacturing processes that led to the development
of IntegraSyn<sup>TM</sup>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IntegraSyn<sup>TM</sup>
integrates various pharmaceutical manufacturing processes to maximize yield and minimize the cost of cannabinoid synthesis, in particular
for pharmaceutical-grade products. We utilize proprietary, high efficiency enzymes produced via the <i>E. coli</i> biofermentation portion
of the IntegraSyn<sup>TM</sup> approach for the production of a cannabinoid. Our enzymes are used in combination with cost-effective yet
sophisticated substrates (or, starting materials) to produce a cannabinoid in bulk via a biotransformation process, which is then further
processed with downstream purification steps including separation, purification and drying. This cannabinoid can be inventoried in bulk
and used either as a finished API cannabinoid product or as a starting material for other cannabinoids. This further differentiation can
utilize any one of several well-established manufacturing approaches &#8211; including enzymatic biotransformation and traditional chemical
synthesis &#8211; to optimize yield, time and cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IntegraSyn<sup>TM</sup>
makes cost-efficient use of sophisticated starting materials, requires fewer costly steps from precursor substrates all the way through
to end-product, and is designed as a high-yield manufacturing process for pharmaceutical use. Furthermore, this manufacturing method is
flexible in shifting production from one cannabinoid to another under GMP conditions. Our initial data demonstrated a substantial increase
in cannabinoid production yield per fermentation batch compared to our traditional biosynthesis method. The final cost of goods for individual
cannabinoids is driven by several factors including, among others: efficiency of the enzyme(s) used; number of manufacturing steps; type
of manufacturing equipment / processes used; and, final yield of the entire manufacturing process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Targeted Benefits of IntegraSyn<sup>TM</sup>:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">A.</td><td style="text-align: justify">Improved yields beyond other standard manufacturing methods for various cannabinoids at pharmaceutical-grade</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">B.</td><td style="text-align: justify">Cost-efficient due to minimization of expensive manufacturing steps and cost-effective use of sophisticated raw materials</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">C.</td><td style="text-align: justify">Flexible, modular approach, able to shift from production of one cannabinoid to another</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">D.</td><td style="text-align: justify">Scalable to meet market demand of cannabinoids for pharmaceutical products or other purposes</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">E.</td><td style="text-align: justify">Sustainable approach with less environmental impact than plant-grow-harvest-extract-purify methods</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.15in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Next steps in the further development of IntegraSyn<sup>TM</sup>,
all of which are currently ongoing, include:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Continue to optimize and scale-up the IntegraSyn<sup>TM</sup> process to larger vessels, whereby protocols will be developed to optimize
the manufacturing parameters associated with the entire process with the Almac Group (UK);</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><sup>&#160;</sup></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Conduct analytical assays to support batch production</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Scale-up process to be GMP ready;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Continue efforts to optimize pathways to further diversify the number of cannabinoids produced using our technology; and</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Identify potential commercial partnership opportunities</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently view our options
for achieving GMP production capabilities as three-fold: (a) building our own dedicated biosynthesis facility; (b) accessing existing
manufacturing capacity via leases with third parties; or (c) licensing our process/know-how to a CDMO with existing infrastructure to
produce the requisite preclinical, clinical and commercial-scale supply of our Product Candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>BayMedica&#8217;s Chemical Synthesis and Biosynthesis Technologies
for the Development and Production of Cannabinoids, Their Variants and Analogs</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">BayMedica, Inc. was founded
by Shane Johnson, MD, Philip Barr, PhD and Charles Marlowe, PhD in September of 2016 with the objective of manufacturing cannabinoids
and novel cannabinoid compounds for use in health and wellness and pharmaceutical markets. BayMedica set out to develop cannabinoid manufacturing
techniques that are &#8216;method agnostic&#8217;, utilizing the most practicable, expeditious and cost-effective means to produce any
particular cannabinoid or novel cannabinoid compound.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Chemical Synthesis for the Development and Production of Cannabinoids</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Chemical synthesis is a well-established,
long-standing, robust and reliable method for the production of myriad compounds for use in both consumer and pharmaceutical products,
including such commonly used medications as vitamin-D and acetaminophen. The production of cannabinoids, in particular CBD and THC, by
synthetic methods was first described in 1965 by Mechoulam, et. al. Although yields were typically less than 10% and the scales were small,
this work paved the way for methods to synthesize these common cannabinoids as well as many rare and novel cannabinoid compounds. Today
several companies such as Noramco, Purisys, Biovectra, Kinetochem and Benuvia reliably manufacture a wide variety of common and rare cannabinoids
to pharmaceutical API standards. However, because price points for these compounds have remained high, their utility in non-pharmaceutical
applications has historically been limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pharmaceutical chemistry methods
have also been of paramount utility in the creation of combinatorial libraries of new chemical entities for drug discovery. We believe
these pharmaceutical chemistry methods will also be of great value in the preparation of novel cannabinoid compounds with enhanced pharmacological
activities and have leveraged our expertise to this end. Using combinations of pharmaceutical chemistry and biosynthesis, the BayMedica
team has generated a wide variety of these compounds with the primary focus being on modifying the pentyl side chain found on many naturally
occurring cannabinoids. We believe that unlike a traditional drug discovery approach using combinatorial libraries, our approach, because
it does not change the core structure of each cannabinoid type, will result in a larger proportion of novel cannabinoids showing pharmacological
activity, thus increasing the probability of a successful drug candidate. Prior to the acquisition by InMed, BayMedica delivered multiple
novel CBN-based cannabinoid analogs to InMed for evaluation. Since that time, we have developed additional New Chemical Entities (&#8220;NCEs&#8221;)
with the ability to expand through existing and novel methods currently under development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Chemical Synthesis-Derived Cannabinoids Under Development or Commercialized
BayMedica</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Cannabichromene (CBC)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The historically high cost
of goods for cannabinoids manufactured by chemical synthesis has largely precluded their widespread adoption for non-pharmaceutical applications.
BayMedica has successfully manufactured and commercialized a rare cannabinoid, CBC, for sale to distributors into the health and wellness
industry. The development of a scalable process for the manufacturing of CBC began in 2018 using well established chemical synthesis protocols.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In calendar 1Q2019, a Material
Services Agreement was completed with a multinational contract research, development and manufacturing organization (&#8220;Chemistry
CDMO&#8221;) to facilitate the optimization and scale-up of BayMedica&#8217;s proprietary CBC manufacturing process using commercially
available starting materials sourced from various manufacturers. We scaled to a batch size of greater than 1kg by calendar 3Q2019 at which
time we contracted a leading U.S. manufacturer to provide the final purification of CBC to greater than 95% purity, a product we call
ProDiol&#8482; CBC. This manufacturer also operates a North American (NA) based toll-processing facility with the capability to process
from 10kg to metric ton quantities of our crude CBC material under food-grade GMP conditions. By late 4Q2019 our Chemistry CDMO had scaled
the process to greater than 10kg, and by year end 2019 to almost 30kg with final purification at the NA contractor. We commenced commercial
sales of ProDiol&#8482; CBC in November 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Large scale manufacturing of crude CBC began at
our Chemistry CDMO in 1Q2020 at &gt;40kg. The emergence of the Covid-19 pandemic significantly impacted sales beginning in calendar 1H2020.
Large scale production continued with several batches of over 100kg and 200kg in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Cannabicitran (CBT)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have developed a process
for the efficient chemical synthesis of CBT through both in-house R&amp;D efforts and via our CDMO. We began scaling this process and
conducted downstream processing and purification trials in late calendar 2H2021. We received initial purchase orders for, and commenced
commercial sales of, CBT in calendar 1Q2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Cannabidivarin (CBDV)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In calendar 1Q2021, BayMedica
acquired a license to utilize novel chemical synthesis technologies to produce and distribute the rare, non-intoxicating &#8220;varin&#8221;
cannabinoid, CBDV, exclusively in the USA and non-exclusively worldwide. BayMedica began R&amp;D and scale up with our Chemistry CDMO
in calendar 2Q2021. Through that partnership, we have developed a novel and efficient method allowing for the scalable preparation of
CBDV. In calendar 4Q2021, via the Chemistry CDMO, we successfully scaled CBDV synthesis to commercial quantities and initiated procurement
of starting materials sufficient to meet expected customer demand. In April 2022, we commenced B2B sales of CBDV to the health and wellness
industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Tetrahydrocannabivarin (THCV)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As part of the calendar 1Q2021
license for techniques to synthesize and produce CBDV, we also acquired the rights to synthesize, sell, and distribute the non-intoxicating
rare cannabinoid THCV exclusively in the USA and non-exclusively worldwide. In calendar 3Q2021, we began researching and developing processes
to convert CBDV to THCV. In conjunction with our Chemistry CDMO and our in-house team, we have developed a robust pilot-scale process
that produces THCV. We developed a purification process to produce the finished THCV material. We began scale-up of our novel process
with this CDMO in calendar 1Q2022 and commenced sales in calendar 2Q2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Analogs of Cannabinoids / New Chemical Entities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the field of pharmaceutical
drug development, the term analog is used to describe structural and functional similarity between an original (or parent) molecule and
one that has been somewhat modified. While any company researching a naturally occurring compound, like cannabinoids, cannot own a patent
on the molecule itself for commercial exclusivity, a modified molecule, which has certain structural and pharmacological similarities
with the original compound, can be patented. As well, modifications of the original molecule (ie, the analog) can be designed to confer
certain improvement in activity of the parent, such as an elevation of the desired physiological effects, a decrease in unwanted side
effects, improvement in aspects related to drug delivery to targeted tissues, etc., or a combination of these targeted outcomes. We have
filed patents covering numerous structural additions and modification of the naturally occurring cannabinoids. Each individual modification
to each individual cannabinoid represents a New Chemical Entity (&#8220;NCE&#8221;) which can be patented. If issued, this patent family
will confer market exclusivity to us for the analogs that we intend to develop into pharmaceutical Product Candidates, license, partner
or sell to interested external parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>BayMedica Yeast Biosynthesis for Cannabinoid Development and Production</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">BayMedica utilizes the yeast
<i>S. cerevisiae</i> as a &#8220;biofactory&#8221; to produce cannabinoids and cannabinoid analogs. Compared to other heterologous systems,
we believe that <i>S. cerevisiae</i> is an attractive host for development of a cannabinoid biosynthesis platform. S. cerevisiae is a
generally recognized as a safe organism that has a long history of successful use in the biotechnology industry for the large-scale production
of a variety of different fermentation products. In particular, <i>S. cerevisiae</i> has previously been engineered to produce high levels
of terpenes and polyketides &#8211; the building blocks of all cannabinoids. Genetic manipulation of <i>S. cerevisiae</i> is straightforward
and advanced genetic tools enable rapid strain engineering for optimized cannabinoid production. Moreover, our team has deep knowledge
and experience engineering <i>S. cerevisiae</i> for the heterologous production of natural products by fermentation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unlike in the <i>Cannabis</i>
plant, our flexible yeast platform allows for the specific production of a single precursor or cannabinoid. This process negates the need
for additional downstream steps to isolate and purify the desired precursor or cannabinoid from other naturally produced compounds found
in a plant-based extraction process. To that end we have engineered strains that produce the precursors and cannabinoids OA, DVA, CBGA,
CBGVA and THCVA at concentrations supporting further scale-up and development for future commercialization. At benchtop scale, we have
developed simple downstream processes for the purification of these compounds. We have evaluated multiple CDMOs capable of both the biosynthesis
scale-up and downstream processing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition to the natural cannabinoids above, we
have leveraged our expertise in pharmaceutical chemistry and yeast biosynthesis to produce a number of novel cannabinoid analogs and variants
of pharmaceutical interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Hybrid Methods as a Platform for Cannabinoid Development and Production</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Unlike other groups, our expertise in the areas
of yeast engineering, biosynthesis and pharmaceutical chemistry allows us to develop in-house technologies for the production of novel
cannabinoid compounds as well as the conversion of &#8220;common&#8221; precursors or cannabinoids into rare natural cannabinoids. For
instance, we have employed methods where we take a biosynthetic starting material and convert it into CBC via chemical synthesis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have also developed technologies whereby chemical
synthesis is used to make novel precursor compounds that are then converted biosynthetically into novel cannabinoids. As part of an announced
collaborative research agreement prior to the acquisition of BayMedica by InMed Pharmaceuticals, BayMedica delivered several novel CBN
analogs to InMed Pharmaceuticals for preclinical evaluation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Competitive Conditions:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other companies deploy a diversified number of cannabinoid
synthesis manufacturing techniques, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Biosynthesis (generation of the final compound inside a single system) using yeast, non-<i>E. coli</i> bacteria, or other approaches
(algae, etc.) as a host organism;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Synthetic chemistry; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Combinations of these above-listed technologies</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Several companies (see chart
below) are active in the cannabinoid manufacturing space including BioVectra, CB Therapeutics, Cellibre, Cronos, Ginko Bioworks, Hyasynth,
Intrexon, KinetoChem, Librede, and Purisys, among several others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Key Milestones:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 21, 2015, we commenced
the development of our biosynthesis process for the manufacturing of cannabinoids through a research collaboration with Dr. Vikramaditya
Yadav from the Department of Biological and Chemical Engineering at the University of British Columbia under a project titled &#8220;The
Metabolic Engineering of yeast and bacteria for synthesis of cannabinoids and <i>Cannabis</i> derived terpenoids&#8221;. On May 31, 2017,
we signed a Technology Assignment Agreement with the University of British Columbia whereby we retain sole worldwide rights to all patents
emergent from the technology under development in exchange for a royalty of less than 1% on sales revenues from products utilizing cannabinoids
manufactured using the technology and a single digit royalty on sub-licensing revenues. Royalties are payable, on a country-by-country
basis, until such time as there is no longer a patent pending, unexpired patent or issued patent derived from the transfer technology,
in any country. On May 15, 2018, we extended our Collaborative Research Agreement, which may be terminated by either party upon 30 calendar
days written notice, with the University of British Columbia for an additional three years. Other than the 1% royalty, we do not have
any ongoing financial commitments under these arrangements with the University of British Columbia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We, in conjunction with our
collaboration partners at the University of British Columbia, continue to advance the production platform for the biofermentation of cannabinoids.
Optimization of the vector continued in parallel with the identification of optimal fermentation conditions and down-stream purification
processes with third party contract manufacturing organizations. Optimization of the fermentation conditions was a project conducted with
the National Research Council Canada at their dedicated fermentation facility in Montreal, Quebec. While we do not anticipate any new
intellectual property arising from this venture, under the terms of this research agreement, the National Research Council of Canada owns
all new IP and we have a sole, fully-paid-up license to all commercialization rights of such IP. This project was initiated in October
2018 and concluded in the second half of 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2019, we entered
into a separate process development collaboration by way of a Master Service Agreement with the Almac Group (UK), or &#8220;Almac&#8221;,
a seasoned GMP pharmaceutical CDMO. Almac was initially tasked to develop a down-stream purification process to support the fermentation
optimization activities at the National Research Council of Canada. In addition, we also engaged Almac to assist in the development of
an &#8220;alternative&#8221; manufacturing process for cannabinoids which integrates the best available technologies across the spectrum
of pharmaceutical drug production. This process is now referred to as IntegraSyn<sup>TM</sup>. In May 2020, we announced our working relationship
with Almac on an integrated approach to augment current biosynthesis-based methods for cannabinoid production. The companies have been
engaged in developing a streamlined cannabinoid manufacturing process, specifically optimizing the upstream cannabinoid assembly processes
as well as downstream purification processes, to achieve cost-efficient, GMP-grade active pharmaceutical ingredients for prescription-based
cannabinoid medications. Almac is an international, privately-owned organization which has grown organically over the past five decades
now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia. We retain all rights to this
new process while Almac retains certain rights-of-first refusal on the production and supply of certain precursors, or starting materials,
for this alternative process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Other Milestones Include:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">September 12, 2017 &#8211; We announced the filing of a provisional
patent application entitled, &#8220;Metabolic Engineering of <i>E. coli</i> for the Biosynthesis of Cannabinoid Products&#8221; (#62/554,494)
pertaining to our biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. We expect that
this patent application, since converted into an application pursuant to the Patent Cooperation Treaty, or a &#8220;PCT Application&#8221;,
and pursued in key jurisdictions throughout the world, will provide significant commercial protection for our <i>E. coli</i>-based expression
system to manufacture any of the 100+ cannabinoid compounds that may have a medical impact on important human diseases. This is the first
in a series of patent applications directed to various aspects of our biosynthesis program. See &#8220;Intellectual Property&#8221;.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">September 25, 2017 &#8211; We announced an update on the significant
advancements in our technology for the microbial biosynthesis of cannabinoids. We have successfully demonstrated an ability to selectively
produce various gateway cannabinoids using genetically engineered microorganisms. These molecules can be functionalized further to produce
any of the 100+ down-stream cannabinoids, or those formed from an enzymatic reaction with the gateway cannabinoid CBGA, found naturally
in the <i>Cannabis</i> plant. We are actively employing this production chassis to synthesize compounds for certain pharmaceutical research
programs. Our biosynthesis program has resulted in what we believe to be two significant firsts: new metabolic pathway for manufacturing
the terpenoid family of cannabinoid precursors that is much more robust than other microbial expression systems tested by us; and o first-ever
production of any fully assembled down-stream cannabinoids in <i>E. coli</i>, beginning with genetic material to produce precursors,
enzymes, and synthases.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">September 10, 2018 &#8211; We announced the filing of a PCT
Application for biosynthesis which claims a priority date from September 5, 2017 (PCT/CA2018/051074). The PCT Application filing is a
conversion from the provisional patent filed in September 2017.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">March 18, 2019 &#8211; We announced the publication of the
first in a series of pending patent applications directed to our biosynthesis platform technology for the manufacturing of pharmaceutical-grade
cannabinoids. International Patent Application International Patent Application No. PCT/CA2018/051074, which published as WO2019046941,
entitled &#8220;METABOLIC ENGINEERING OF <i>E. COLI</i> FOR THE BIOSYNTHESIS OF CANNABINOID PRODUCTS&#8221;, addresses the enablement
and maximization of cannabinoid production through optimization of the precursor substrates needed to support specific cannabinoid synthesis.
This application, as well as two more recently filed U.S. provisional patent applications, covers various elements required to enable
functional cannabinoid synthase production in an <i>E. coli</i> system. We will actively seek to convert these two follow-on provisional
applications, and subsequent provisional patents from new patent families, into additional PCT Applications in all major commercial jurisdictions,
in due course. See &#8220;Intellectual Property&#8221;.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">May 19, 2020 &#8211; We announced the filing of a key Patent
Cooperation Treaty (&#8220;PCT&#8221;) patent application directed to our biosynthesis platform technology for the manufacturing of pharmaceutical-grade
cannabinoids. The PCT patent application entitled &#8220;Compositions and Methods for Biosynthesis of Terpenoids or Cannabinoids in a
Heterologous System&#8221;. This application&#8221; was initially filed as two separate United States Provisional Patent applications
and further addresses the enablement and maximization of cannabinoid production through optimization of the precursor substrates needed
to support specific cannabinoid synthesis</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">September 22, 2020 &#8211; We announced the filing of a PCT
patent application as part of a growing portfolio of intellectual property related to the IntegraSyn&#8482; manufacturing approach for
producing low-cost, pharmaceutical-grade cannabinoids.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">April 26, 2021 &#8211; We announced that the IntegraSyn&#8482;
cannabinoid manufacturing approach has achieved a level of 2g/L cannabinoid yield, a milestone that signals commercial viability and
supports advancement to large-scale production in the coming months. Having achieved a 2g/L yield level, we will now focus on manufacturing
scale-up to larger batch sizes while continuing process and enzyme optimization, targeting increased cannabinoid yield and further reducing
the overall cost of goods. In parallel, we continue to prepare the manufacturing process to be Good Manufacturing Practice (GMP)-ready
for pharmaceutical quality production. The next stage of large-scale production is to produce a batch with a target output of one kilogram
of the selected cannabinoid in the second half of calendar 2021 via a GMP-ready process.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -26.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">June 17, 2021 &#8211; We announced that we increased cannabinoid
yield to 5 g/L with IntegraSyn&#8482; in advance of commercial-scale.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.15in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Research and Development Pipeline of Therapeutic Drug Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>INM-755 for the Treatment of Epidermolysis bullosa (&#8220;EB&#8221;)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Introduction</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">INM-755 (CBN) cream is being
developed as a proprietary, topical, single-cannabinoid product candidate intended as a therapy in dermatological diseases. The first
clinical indication under development is EB. EB is a collective name for a group of genetic disorders of connective tissues characterized
by skin fragility leading to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal
tract, genitourinary and respiratory systems. EB is a debilitating disease affecting a small proportion of people in the United States,
thus earning it an orphan-disease status. The disease has no definitive cure and all current treatments are directed towards symptom relief.
There are, however, a number of products, mainly gene therapies, currently in clinical trials, in which a cure is being explored, according
to several recent scientific publications. Our preclinical research has identified a specific cannabinoid, CBN, that may prove beneficial
to patients: first, by addressing certain key disease hallmarks (which may include wound healing, infection, pain, inflammation); and
second, by regulating the expression of various proteins (keratins) that may compensate for reduced expression of others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The active ingredient in INM-755,
CBN, is an agonist for both cannabinoid (CB) 1 and CB2 receptors, with a higher affinity for CB2, which means it should have a greater
effect on the immune system than on the central nervous system. The distribution of CB1 and CB2 receptors in sensory nerves and inflammatory
cells in the skin make it an attractive pharmaceutical agent for dermal treatments in medical conditions characterized by inflammation
and pain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In preclinical pharmacology
studies, CBN demonstrated activity as an anti-inflammatory and antinociceptive agent. CBN upregulated expression of keratin 15 (K15),
which might lead to skin strengthening and reduced blister formation in EBS patients with keratin 14 (K14) mutations. At the cream concentrations
chosen for clinical development, it does not appear to impede wound healing of partial-thickness wounds. Its anti-inflammatory activity
may be beneficial in healing chronic wounds caused by prolonged inflammation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have completed 20 safety
pharmacology and toxicology studies to investigate the effects of CBN. We have also completed three Phase 1 safety and tolerability studies
in healthy volunteers, two studies of which were conducted with varying concentrations of INM-755 cream and one study of which examined
the non-CBN components of the cream base for INM-755. In December 2021, we began patient treatment in a Phase 2 clinical trial for INM-755
in EB is anticipated to complete during the calendar year 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Science Behind EB</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the most basic level, the
hallmark of EB is poor anchorage of the epidermis to the dermis such that the skin and mucous membranes of the affected individuals tend
to shear and blister on minimal friction. This is due to the genetically inherited defect in certain genes (multiple genes have been shown
to be associated with the different subtypes of EB) that code for some specific proteins that are concerned with maintaining the integrity
of skin and mucous membranes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are four main subtypes
of the condition. Each of these subtypes can display a spectrum of phenotypic severity reflecting the types of mutations in different
genes, together with modifying environmental factors. The types of mutations also determine the mode of inheritance, either autosomal
dominant or autosomal recessive. The following table shows the pattern of inheritance and the defective genes and proteins in each:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Classification of EB Types</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">(a) EBS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This is the most common form
of EB and is characterized by a lack of adhesion of the skin directly above the basement membrane (the basal layer). An estimated 55%
of people with EB have EBS resulting from a genetic defect of the keratins K5 and K14, with the incidence between the two defects estimated
to be essentially equal. The most common form of EBS manifests itself as blistering confined to the hands and feet while in others blistering
can occur all over the body. Blistering generally appears during the neonatal period but it can also manifest itself in later childhood
(or even in adult life). Painful skin blisters are accentuated by friction, especially on the feet where footwear causes increased irritation.
Friction injuries tend to occur more commonly in warm weather and secondary infections are common.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">(b) Junctional EB</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Junctional EB is characterized
by a lack of adhesion of the skin through the basement membrane and affects some 5% of those with EB. The generalized type of junctional
disease (about half of cases of junctional EB) is usually fatal in infancy. This is often as a result of anemia and malnutrition due to
poor feeding caused by the serious blistering in the pharynx and esophagus. The milder form of the disease can cause life-long pain and
disability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">(c) Dystrophic EB, or &#8220;DEB&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">DEB is characterized by a
lack of adhesion of the skin under the basement membrane. Approximately 30% of people with EB have DEB. Patients with DEB tend to develop
blisters that heal with fibrosis, leading to joint contracture, fusion of the fingers, contractures of the mouth membranes and narrowing
of the esophagus. Often the dominant inherited type of DEB is the least severe type and the patient can lead an almost normal life. However,
the severity of the condition does increase with age due to scarring, syndactyly and generalized skin atrophy. Those with recessive DEB
have a high chance of developing a squamous cell carcinoma, often before the age of 35.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">(d) Kindler Syndrome</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This type of EB is rare and
usually becomes apparent at birth or soon after. This condition is called mixed type because blisters appear across the skin layers. The
condition usually improves with time and can disappear. It is the only type that causes patchy discoloring (mottling) of skin exposed
to the sun. Kindler syndrome is recessive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">(e) Epidermolysis bullosa acquisita</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Epidermolysis bullosa acquisita
is a rare type that is not inherited. The blisters result from the immune system attacking healthy tissue by mistake. It&#8217;s similar
to another immune system disorder called bullous pemphigoid. It tends to cause blisters on the hands, feet and mucous membranes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Epidemiology, Morbidity and Mortality</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The most reliable figures
on prevalence and incidence of EB are derived from the National EB Registry, or &#8220;NEBR&#8221;, which collected cross-sectional and
longitudinal data on about 3,300 EB patients in the United States from 1986 through 2002. The prevalence of EB was estimated to be approximately
11 per million and the incidence approximately 20 per million live births. In the United States, assuming that mild cases of EBS are reported
only 10% of the time, the affected population in the United States is approximately 12,500. Other sources cite populations of up to 25,000
in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Generalized blistering caused
by any subtype may be complicated by infection, sepsis, and death especially in infancy. Severe forms of EB increase the mortality risk
during infancy. In patients with EB that survive childhood, the most common cause of death is metastatic squamous cell carcinoma. This
skin cancer occurs most frequently in patients with recessively inherited DEB who are aged 15-35 years. In contrast, dominantly inherited
EBS and DEB and milder forms of junctional EB may not affect a patient&#8217;s life expectancy adversely. Onset of EB is at birth or shortly
after. The exception occurs in mild cases of EBS, which may remain undetected until adulthood or remain undiagnosed. The disease appears
to have equal incidences in both sexes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Current Treatments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a genetic disease, EB has
no cure and, as a designated orphan-disease, there are no approved products specifically to treat this indication. Effective management
of EB patients involves a collaborative approach between several specialists, including surgeons, dermatologists, ophthalmologists, dentists,
psychologists, podiatrists, physiotherapists and geneticists. The aim is to provide support to the patient by alleviating symptoms and
managing complications; in particular, the patient caregivers must assess and act daily to treat the wound and enable wound healing, address
the current level of pain and itch, provide adequate antimicrobial protection, reduce inflammation (as a source of depressed wound healing
abilities) and address the emotional state of the patient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current medications are employed
in control of pain (various types of analgesics including nonsteroidal anti-inflammatory drugs, or &#8220;NSAIDS&#8221;, tricyclic antidepressants,
gabapentin, and narcotics) and pruritus (antihistamines, etc.) and to address complications such as local infection and septicemia (local
and systemic antibiotics). Steroids and phenytoin are also used in managing dysphagia-associated pain. Tetracycline is considered to be
beneficial in improving the blistering and epithelial disadhesion. The complications of these classes of medications are well known and
the drugs are most likely to further complicate the patients&#8217; conditions since they will be used on long-term basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The newer products currently
in research also have challenges. For example, the use of bone marrow was being researched by the University of Minnesota with some promising
results. However, the severe immunosuppression that bone marrow transplantation requires causes a significant risk of serious infections
in patients with large scale blisters and skin erosions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Competitive Landscape</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are developing INM-755,
our proprietary, topical, single-cannabinoid product candidate, as a first-line therapy in all EB patients for symptom relief and may
explore its effects in EBS with a K14 genetic mutation as a therapy to potentially strengthen skin integrity via up-regulation of the
keratin K15.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is only one therapy
approved specifically for the treatment of EB. Filsuvez (Oleogel-S10) has been approved in Europe and Great Britain for the treatment
of skin wounds in patients with dystrophic or junctional EB. For EB patients outside of Europe, or those with other symptoms, there is
still a lack of treatment options in this devastating condition. For those products currently envisioned or in clinical trials as topical
treatments, wound healing and symptom relief are the primary endpoints.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">According to public information, several topical
investigational drug formulations are currently at various stages of clinical development for the treatment of EB, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Amryt Pharma&#8217;s Filsuvez (formerly Oleogel-S10, or AP101),
which is a topical product incorporating a betulin-based active ingredient formulated with sunflower oil. It causes the keratinocytes
to migrate faster and to differentiate into mature epithelial skin cells. This product is currently approved in some jurisdictions for
the treatment of partial-thickness wounds in adults and was recently approved for patients with dystrophic and junctional EB in Europe.
The Phase III double blind study is complete and met its primary endpoint on time to first target wound closure (p=0.013). The 24-month
open label extension study is ongoing (NCT03068780). The product was also submitted to the FDA for approval, where it had been granted
orphan drug, rare pediatric disease and fast track designations. However, in February 2022 after several review extensions, the FDA formally
rejected the application and asked for additional evidence. Amryt plans to work with FDA to address their concerns.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Krystal Biotech&#8217;s Vyjuvek (beremagene gerperpavec, formerly
B-Vec) is a topical gene therapy for dystrophic EB. Vyjuvek uses a modified herpes simplex virus to deliver instructions to generate
type VII collagen (that is mutated in dystrophic EB) to skin cells. Krystal has completed a Phase III study in 31 children and adults
with dystrophic EB, where a significantly greater proportion of Vyjuvek-treated wounds were completely healed at 3 months (71% vs 20%)
and 6 months (67% vs 22%) compared with those given placebo gel. An 18-month open-label extension study is ongoing and expected to conclude
this year. Their marketing application has been granted priority review by FDA, where it has orphan drug, fast track, rare pediatric
and regenerative medicine advanced therapy designations. FDA is not planning to hold an advisory committee meeting as part of Vyjuvek&#8217;s
review. A decision is expected no later than Feb. 17, 2023. Krystal plans to submit a similar application later this year to regulatory
authorities in Europe, where it is also has orphan drug and priority review status.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -26.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Castle Creek Biosciences has a Phase III clinical trial that
is active, but not recruiting. The purpose of this study is to determine whether administration of FCX-007 in addition to standard of
care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic
Epidermolysis Bullosa. DEFI-RDEB is a multi-center, intra-patient randomized, controlled, open-label, Phase III study of FCX-007 for
the treatment of persistent non-healing and recurrent RDEB wounds in approximately 24 subjects.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -26.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">BioMendics, LLC is initiating a Phase I trial to assess the
safety, tolerability and clinical effects of TolaSure when applied to wounded skin for 10 weeks in patients with severe epidermolysis
bullosa simplex (EBS-Dowling Meara). TolaSure is a topical gel intended for the promotion of wound healing. The study intends to enroll
10 patients at 1 clinical site (Stanford University).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -26.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Phoenicis has initiated a double-blind, intra-patient placebo-controlled,
multiple-dose Phase I/II study of PTW-002 topical gel for the treatment of dystrophic EB due to mutations in Exon 73 of the COL7A1 gene.
PTW-002 is a topical anti-sense oligonucleotide (technology acquired from ProQR Tx) and reformulated into a thicker gel. The study intends
to enroll 6 patients at 3 clinical sites in the US.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0">Other approaches have shown promise and are under investigation
for the treatment of EB:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Gene therapies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Skin grafts with gene-modified epidermal sheets;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Stem cell transplants;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Intravenous replacement of recombinant collagen VII (for RDEB);</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Topical/intradermal gentamicin to restore laminin beta3 (JEB/DEB
with nonsense mutations); and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Granulocyte colony-stimulating factor (DEB).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, several companies are pursuing the
symptomatic relief for EB patients, including the patient advocacy organization DEBRA, which is sponsoring a trial using oral cannabinoids
(THC, CBD) to mitigate pain and itch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Regulatory Perspectives</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">According to the National
Epidermolysis Bullosa Registry, the overall incidence is about 20 per million live births and prevalence is 11 per million in the United
States. EB is designated as an &#8220;orphan disease&#8221;, and we plan to seek regulatory designation of INM-755 as such in the U.S.
and similar designations in various jurisdictions. The FDA defines orphan products as &#8220;those intended for the safe and effective
treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the United States, or that affect
more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug&#8221;. The EMA has its
own definition of orphan disease and, under the European definition, EB is also an orphan disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The mission of the FDA Office
of Orphan Products Development, or &#8220;OOPD&#8221;, is to advance the evaluation and development of products (drugs, biologics, devices,
or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. This arm of the agency evaluates
scientific and clinical data to identify and designate products as promising for rare diseases and to further advance scientific development
of such promising medical products. The OOPD also works on rare disease issues with the medical and research communities, professional
organizations, academia, governmental agencies, industry, and rare disease patient groups. The OOPD provides incentives for sponsors to
develop products for rare diseases. The Orphan-Drug Designation program, which is administered by the OOPD, provides orphan status to
drugs and biologics which are defined using the FDA definition above. The Orphan Products Grants Program, which is administered by the
OOPD, provides funding for clinical research that tests the safety and efficacy of drugs, biologics, medical devices and medical foods
in rare diseases or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is worth noting that there
is a common pathway for application of orphan status for a product to both the FDA and EMA, and applicants to the FDA are advised to use
the common application platform. With regards to the data to be used in the application, it is expected that applicants demonstrate that
there is &#8220;promise&#8221; that the drug will be effective in treating said disease. &#8220;Promise&#8221; is interpreted to include
either data from clinical trials, data from case studies/reports, data from appropriate animal models or, on rare occasions where there
is no appropriate animal, data from <i>in vitro</i> experiments in addition to supporting information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
Incentives for Orphan Product Development</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_009.jpg"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Data
Summary of Preclinical Studies for INM-755</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INM-755
is a topical, single cannabinoid cream formulation that is being developed to: (i) strengthen skin integrity in some patients with EBS
(the most common form of EB), and (ii) to treat symptoms of the disease in all patients with EB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have conducted several preclinical studies to identify potential drug development pathways for a product in EB. The following data has
been generated in support of these cannabinoids as a potential therapy in EB:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Enhancing skin integrity and skin regeneration:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
desirable treatment outcome for all subtypes of EB would be enhanced skin integrity to prevent new wounds from forming. For patients
with EBS, an estimated half of them will have a mutation in K14. The goal of modifying keratin production is to target the upregulation
of a potentially compensatory K15. Under normal conditions, K5 and K14 combine (dimerize) to form adhesion at the basal layer within
the epidermis. In EBS, one or both of these keratins are damaged. Our investigational hypothesis is that K15 may be able to compensate
by replacing K14 in this equation and combining with K5 to form the adhesive properties needed for normal skin structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
was studied in a panel of cannabinoids to determine its ability to regulate keratin expression. CBN induced upregulation of K15 in 2
of the 3 experiments. Concentrations of 0.1 &#181;M and 1 &#181;M produced similar effects (approximately 6 to 17-fold increase in
K15 expression). The highest concentration of 10 &#181;M did not increase the size of the effect (approximately 3 to 13-fold increase).
Lack of a dose-response may mean a threshold was exceeded, above which no further effect can occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relative
K15 Expression in Human Keratinocytes (HaCaT), Post-Confluence (48 hours)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_010.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
1 did not exhibit an important effect. The reason for this is uncertain, with one hypothesis being that the cells tested had been through
too many passages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the variation observed across these three studies, these results are encouraging as INM-755 cream may help create stronger skin by upregulating
K15.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemidesmosome
formation also occurs during normal differentiation of keratinocytes as they mature from the basal layer, not only in a wound-healing
situation. Through the upregulation of K15, INM-755 cream applied to intact skin might gradually strengthen the skin and reduce the number
of blisters and eventual wounds. For this effect, it could also be applied to wounds that have completed the initial re-epithelialization
stage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Effects on Wound Healing</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cutaneous
wound healing is a complex process with four main phases: inflammation, re-epithelialization, tissue formation, and tissue remodeling.
In EB wounds, all four phases of cutaneous wound healing can be impacted, leading to chronic non-healing wounds. The wounds of EB patients
are found primarily at or close to the junction of the epidermal and dermal layers. In these partial-thickness wounds, wound closure
is achieved primarily by re-epithelialization rather than through granulation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
major disease symptom in EB is the extensive wounds that can be generated throughout any day by simple friction on the skin, even as
simple as clothes rubbing the skin. In addition to increasing the skin integrity via K15 up-regulation, another key goal would be facilitating
accelerated wound healing via rapid skin regeneration and wound closure. E-Cadherin is major component of epithelium integrity. During
wound healing, transforming growth factor beta, or TGF-&#223;, causes a reduction in E-Cadherin, allowing keratinocyte migration across
the open wound. This is then followed by a return to normal levels of E-Cadherin to rebuild the integrity of the skin. CBN may play a
role in the second phase of wound healing by accelerating the normalization of E-Cadherin expression. Additional studies are warranted
to further explore this effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflammation
is an important early step in wound healing and several of our studies demonstrated CBN has anti-inflammatory activity. Therefore, we
conducted studies to evaluate the effect of CBN on the normal wound healing process. While an early <i>in vitro</i> assay indicated that
high concentration of CBN could cause delays or prevent one of the first steps in wound healing, a subsequent study conducted with the
INM-755 cream formulation did not hinder cell viability, cell migration, or wound closure. This was demonstrated in a wound-healing experiment
conducted in 3-dimensional reconstructed human epidermis, or &#8220;RHE&#8221;, models with fully differentiated skin layers. Punch biopsy
wounds were treated with INM-755 creams at three strengths, which included the intended cream concentrations for the first studies in
healthy volunteers. No delay or inhibition of re-epithelialization was shown in CBN-treated models; the untreated control healed slightly
slower in the first 5 days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A
composite of pictures showing 2D photographic images of the punch biopsy wounds as they heal over time. The re-epithelialization of the
wound is shown by migration and growth of keratinocytes from the outside edge of the wound over time, migrating/growing to the center
of the wound until the wound is closed:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_011.jpg"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One more nonclinical
study was conducted to explore the potential of CBN to interfere with early stage wound healing. In this study, superficial partial thickness
wounds were introduced by a dermatome in an <i>in vivo</i> animal model and treated for 7 days with INM-755 creams at the same three
strengths as used in the RHE models. Wound healing assessments included clinical observations, quantitative wound area measurements on
photographic images and histopathologic examination. Treatment with INM-755 creams at the strengths intended for clinical development
did not cause any delays in wound healing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="" src="image_012.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
to complete the investigation of effects on wound healing before applying INM-755 cream to open wounds in patients with EB, a clinical
study (755-102-HV) was conducted in healthy human volunteers to test the safety of INM-755 cream. In this study in 8 subjects, a within-subject
comparison was made for two concentrations of INM-755 cream, vehicle cream, and no treatment. INM-755 cream was well tolerated and did
not impair normal wound healing in small epidermal (blister) wounds in this study.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Reducing inflammation:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
was tested on two important markers of inflammation: IL-8 and MMP-9, because of their suspected links with blister formation in EBS and
chronic cutaneous inflammation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interleukin-8,
or IL-8, is the most potent chemoattractant for blood neutrophils and important mediator of angiogenesis, or the formation of new blood
vessels. Chronic IL-8 production and neutrophil activation in a skin wound is an unfavorable element of skin pathology as it leads to
extensive inflammation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matrix
metalloproteinases, or &#8220;MMPs&#8221;, are part of the zinc-dependent endo-proteases family which modulate homeostasis of the the
extracellular matrix in skin. In response to skin damage and inflammation, metalloproteinases, including MMP-9, are often up-regulated.
Specifically, exposure of keratinocytes, such as HaCaT cells, to TNF-&#945; induces expression of the inflammatory-related factors such
as IL-8 and MMP-9.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
MMP-9: Consistent results in both studies with a dose-related reduction of MMP-9 expression. The consistency in direction and magnitude
of effect provides convincing evidence for down regulation of MMP-9 by CBN under insult conditions. The reduction was 22% at 4 &#181;M
and about 40% at both 8 and 16 &#181;M. CBN showed a little less anti-inflammatory activity than hydrocortisone in this model, but still
an important reduction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insult
= Tumor Necrosis Factor &#945; (TNF&#945;) and Interferon g (IFNg)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Pain reduction:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
pharmacodynamic endpoint that was studied was pain. Pain is one of the key symptoms in EB and requires significant effort to monitor
and treat. CBN has demonstrated positive pain-relieving effects in NGF-induced in an <i>in vivo</i> pain model. To further demonstrate
this, we utilized <i>in vivo</i> electrophysiology where CBN blocked the pain signals in the neurons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an <i>in vivo</i> of myofascial pain, nerve growth factor, or &#8220;NGF&#8221;, was injected into the masseter muscle, resulting in
local mechanical sensitization lasting about 5 days. On Day 3, CBN was injected into the masseter muscle and the mechanical withdrawal
threshold was assessed with a rigid von Frey hair. The mechanical force was gradually increased until the animal moved its head away
from the stimulus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Behavioral
Effects of CBN in <i>In vivo</i> Model of Myofascial Pain</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_013.jpg"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adapted from Wong
H, Cairns BE. Arch. Oral Biol. 2019;104:33-9.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
injected into the masseter muscle significantly reversed NGF induced mechanical sensitization at 10 minutes post-injection. (Behavioral
study)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
parallel, electrophysiology recordings of single ganglion neurons that innervate the craniofacial muscles were performed (33 masticatory
muscle mechanoreceptors). The electrophysiology effects parallel the behavioral effects. CBN significantly increased the relative mechanical
threshold at 30- and 60-minutes post-injection. The results of this study have been published.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Electrophysiological
Effects of CBN in <i>In vivo</i> Models of Myofascial Pain</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_014.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adapted
from Wong H, Cairns BE. Arch. Oral Biol. 2019;104:33-9.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Antimicrobial activity:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the literature, certain cannabinoid compounds have been shown to have potent antibacterial properties including against various strains
of multidrug-resistant bacteria, including methicillin-resistant S. aureus, or &#8220;MRSA&#8221;. We have screened a number of cannabinoid
compounds by standard methods against a broad range of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Results of this
third-party research demonstrated potent antimicrobial activity for all tested cannabinoid compounds, particularly against Gram-positive
isolates. While these cannabinoids may provide some localized antibacterial benefit, it is unlikely that such effects would encourage
cessation of broad-spectrum, systemic antibiotic usage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
EBS formulation prototype development:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Careful
attention must be paid to any topical product to be administered for the treatment of EB for several reasons. Our target product is designed
to be applied over major portions of the body (if not the entire body), once each day. As such, the patients, who are often children,
will be exposed to the active drug as well as the excipients of the skin cream, possibly for the duration of their lives. Accordingly,
great care must be given that these components will be safe over the long-term and that they will not add to the already painful condition
that the patients are suffering. Key criteria include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
excipients are safe for extensive body surface area exposure for a long duration of time;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
API (cannabinoid) is dosed at the appropriate level &#8211; high enough to provide optimal clinical effect at the treatment site but
low enough to minimize any systemic exposure; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
final formulation can be administered daily with minimal friction to the skin.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have utilized the Franz Cell diffusion method to assess skin penetration rates and depth for a proposed topical formulation for INM-755.
The formulation is applied to skin samples and measurements are taken of how much drug penetrates to which depths in the skin. Using
this method, a preliminary formulation of INM-755 achieved drug delivery to the epidermis and dermis layers as needed. Working with well-characterized
excipients, we have tested several slight variations in formulation to achieve the desired concentration of drug in the skin while simultaneously
avoiding high drug concentrations in systemic circulation (in the blood).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
in mid-2017 to present, we worked with several leading, international preclinical contract research organization to: (i) develop a final
formulation used in INM-755; and (ii) initiate work of an Investigational New Drug Application, or &#8220;IND&#8221; enabling pharmacology
and toxicology studies that are required before INM-755 could be used in future clinical studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Toxicology
and Safety Pharmacology Studies of CBN</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investigational medicinal product, INM-755 (CBN) cream is for topical application on the skin. The cream base has a simple formulation
with known pharmaceutical-grade excipients. It is a pluronic lecithin organogel. Pluronic lecithin organogels have been widely used by
compounding pharmacists for topical preparations since the early 1990s. Therefore, the focus of the toxicology program has been to characterize
effects of the active agent.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
is a new molecular entity, or &#8220;NME&#8221;, not yet approved for medical use in any country. Therefore, we are required to perform
thorough safety testing prior to human administration. The intended route of administration for INM-755 is topical and is anticipated
to result in low systemic exposure via the bloodstream. Despite only nominal risk of meaningful systemic exposure, regulatory authorities
still require that we examine the consequences of systemic exposure on key biological functions and organ systems. For this purpose,
the drug was administered by subcutaneous (SC) injection to achieve high in blood circulation. Topical safety studies using the intended
route of administration and the clinical cream formulation were also conducted. These nonclinical toxicology studies included:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tropical
28-day safety, <i>in vivo;</i></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
28-day safety study, <i>in vivo</i>, with SC administration;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genotoxicity
&#8211; standard battery of required tests for NMEs, including</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
vitro</i> bacterial mutagenicity study (classically the Ames assay) [Organisation for Economic Cooperation and Development test guideline
471 (OECD 471)];</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
vitro</i> micronucleus study in Chinese Hamster Ovary cells [OECD 487]; and</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
vivo mammalian erythrocyte micronucleus study [OECD 474];</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phototoxicity
&#8211; required because CBN has some absorbance in the UVB range; <i>in vitro</i> neutral red dye uptake study in cells from BALB/c
3T3 mice [OECD 432];</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EpiOcular,
<i>in vitro</i> eye irritation study [OECD 492];</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-adjuvant
Buehler method skin sensitization study, <i>in vivo</i> [OECD 406]; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
vivo </i>drug distribution study with SC injection of radiolabeled drug.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the 28-day <i>in vivo</i> dermal toxicity study, INM-755 cream was given as topical daily doses applied to 10% body surface area. The
quantity of cream applied resulted in a thick layer of cream, much more than a typical clinical application. After each daily cream application,
the application sites were covered with a hypoallergenic, waterproof, breathable dressing for 24 hours and then scored for local tolerance.
In this GLP study, systemic toxicity was also fully investigated by standard parameters. Based on clinical and histopathologic review,
no CBN-related dermal toxicity was demonstrated in this study. Systemic exposure was minimal due to the topical route of administration
and no systemic toxicities occurred either. The No Adverse Effect Level, or &#8220;NOAEL&#8221;, was determined to be the highest concentration
of cream tested.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the 28-day <i>in vivo</i> systemic toxicity study, CBN was given as daily SC injections up to the solubility-driven maximum feasible
dose. We have utilized the Franz Cell diffusion method to assess skin penetration rates and depth for a proposed topical formulation
for INM-755. The formulation is applied to skin samples and measurements are taken of how much drug penetrates to which depths in the
skin. Using this method, a preliminary formulation of INM-755 achieved drug delivery to the epidermis and dermis layers as needed. Working
with well-characterized excipients, we have tested several slight variations in formulation to achieve the desired concentration of drug
in the skin while simultaneously avoiding high drug concentrations in systemic circulation (in the blood).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
in mid-2017 to present, we worked with several leading, international preclinical contract research organization to: (i) develop a final
formulation used in INM-755; and (ii) initiate work of an Investigational New Drug Application, or &#8220;IND&#8221; enabling pharmacology
and toxicology studies that are required before INM-755 could be used in future clinical studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Toxicology
and Safety Pharmacology Studies of CBN</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investigational medicinal product, INM-755 (CBN) cream is for topical application on the skin. The cream base has a simple formulation
with known pharmaceutical-grade excipients. It is a pluronic lecithin organogel. Pluronic lecithin organogels have been widely used by
compounding pharmacists for topical preparations since the early 1990s. Therefore, the focus of the toxicology program has been to characterize
effects of the active agent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
is a new molecular entity, or &#8220;NME&#8221;, not yet approved for medical use in any country. Therefore, we are required to perform
thorough safety testing prior to human administration. The intended route of administration for INM-755 is topical and is anticipated
to result in low systemic exposure via the bloodstream. Despite only nominal risk of meaningful systemic exposure, regulatory authorities
still require that we examine the consequences of systemic exposure on key biological functions and organ systems. For this purpose,
the drug was administered by subcutaneous (SC) injection to achieve high in blood circulation. Topical safety studies using the intended
route of administration and the clinical cream formulation were also conducted. These nonclinical toxicology studies included:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
adverse drug-related effects were noted on clinical signs, clinical pathology parameters, ophthalmic evaluations, gross necropsy, organ
weights, or histopathology. CBN was well tolerated at all doses, despite considerable systemic exposure. The NOAEL was determined to
be the highest dose tested.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standard battery of genotoxicity studies was conducted with CBN (2 <i>in vitro</i> and 1 <i>in vivo</i>) and all were negative. CBN did
not cause phototoxicity <i>in vitro</i>. INM-755 cream at low and mid dose levels did not cause eye irritation <i>in vitro</i>. INM-755
cream at the highest tested dose did not cause a sensitization reaction in the <i>in vivo</i> sensitization model.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, we have completed 20 safety pharmacology and toxicology studies to investigate the effects of CBN. We have also completed three
Phase 1 safety and tolerability studies in healthy volunteers, two studies of which were conducted with varying concentrations of INM-755
cream and one study of which examined the non-CBN components of the cream base for INM-755.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Toxicity
to Central Nervous System</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_015.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the well-documented intoxicating effects of THC, all cannabinoid compounds need to be tested for their psychoactive/intoxicating potential.
In a standardized safety pharmacology study, we tested exceptionally high dose levels of CBN (more than 10,000 times the expected systemic
exposure after topical dosing). No central nervous system adverse effects were observed even at the highest dose. 108 different central
nervous system criteria were measured.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
toxicology and safety pharmacology data package covered a broad range of drug concentrations and was designed to support other clinical
programs to treat topical skin conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Summary
of Completed and Contemplated Clinical Development Plans</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
regulatory application to support our first Phase I clinical trial in healthy volunteers with INM-755 (755-101-HV) was submitted November
4, 2019 and approved December 6, 2019 in the Netherlands. The initial Phase I clinical trial evaluated the safety, tolerability, and
pharmacokinetics of INM-755 cream in 22 healthy volunteers with normal, intact skin; the volunteers had cream applied once daily for
a period of 14 days. All subjects in this first clinical trial completed treatment and evaluations by March 27, 2020. Database completion
and data analyses were delayed by pandemic restrictions. Study results were reported November 25, 2020. A blinded interim safety review
from the first 16 subjects in the Phase I study were included in a regulatory application that was approved April 17, 2020, for a second
Phase I clinical trial of 8 healthy volunteers to test the local safety and tolerability of applying sterile INM-755 cream to small wounds
once daily for 14 days. As with the initial Phase I trial, the second clinical trial (755-102-HV) was conducted with two different drug
concentrations and a vehicle control. Enrollment began in early July 2020 and the clinical trial completed treatment and evaluations
at the end of September 2020. Study results were reported January 8, 2021. The safety of INM-755 will continue to be assessed throughout
its clinical development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INM-755
cream was well tolerated in the two Phase I clinical trials in healthy volunteers and the next clinical trial will study INM-755 cream
in patients with EB (Study 755-201-EB). Regulatory applications to support this global trial were filed for review by the National Competent
Authorities and Ethics Committees in 8 countries for 13 clinical sites. Approvals were obtained in all countries (Austria, France, Germany,
Israel, Italy, Serbia, and Spain) as of March 2022. Enrollment and patient treatment began in December 2021 and are expected to complete
during the calendar year 2022. The goal of this Phase II study is to obtain safety and preliminary efficacy of INM-755 cream in treating
symptoms and wound healing in patients with EB, using a within-patient design in which matched index areas are randomized to INM-755
cream or vehicle (no drug) cream in a blinded manner. Up to 20 patients will be enrolled and treatment will be for 28 days, the longest
period supported by nonclinical toxicology studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can make certain scope-estimates in terms of potential clinical trial sizes, timing and endpoints based on the recent clinical pathway
followed by another phytochemical-based topical product for EB, Zorblisa<sup>TM</sup> (Amicus Therapeutics). The key finding from our
review of publicly available information for the Zorblisa<sup>TM</sup> development program is that a clinical program is very focused
for an orphan indication and the clinical trials do not include large numbers of patients. It would not be feasible to conduct large
trials for such a rare disease. Therefore, the clinical studies need to be carefully designed and controlled to allow suitable assessment
of the safety and efficacy of a new therapy in a small number of patients. Broad multicenter trials would be needed to recruit patients
as quickly as possible. We will work closely with regulatory authorities and clinical experts in developing the clinical program for
INM-755.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
average, it takes at least ten years to complete the development of an investigational drug from its initial discovery to the marketplace,
with clinical trials alone taking six to seven years on average. It is not possible with any degree of certainty to estimate how long
it will take to complete clinical trials and potentially obtain marketing approval for INM-755. To the extent that INM-755 may potentially
be designated as either a Fast Track drug, a Breakthrough Therapy, or eligible for Priority/Accelerated Review, our timeline to any potential
marketing approval may be shorter than might otherwise be the case.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to COVID-related delays and other external factors, we plan to complete enrollment in Study 755-201-EB during calendar year 2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Key
Milestones for the EB Program:</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
6, 2015 &#8211; We reported positive response from preclinical research on several cannabinoids (one of which was CBN), tested in various
<i>in vitro</i> assays. By modulating the expression of various keratin genes that are responsible for cytoskeleton intermediate filaments
and/or wound healing using different cannabinoids, we sought to alleviate the EBS symptoms. We believe that these preliminary results
validated our approach as the cannabinoids displayed modulation of expression of various keratin genes.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
18, 2016 &#8211; We reported additional preclinical results demonstrating positive pain-relieving effects of cannabinoids in animal models.
This animal data demonstrated a reduction in both acute and chronic pain (CBN was one of the cannabinoids tested in this study).</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
4, 2017 &#8211; We filed an application with the Canadian Intellectual Property Office a PCT Application, Serial No. CA2017050546 titled,
&#8220;A Cannabinoid-Based Topical Therapy for Diseases and Conditions Associated with Intermediate Filament Dysfunction&#8221;.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
13, 2019 &#8211; We announced that we will conduct all future development with a single cannabinoid skin cream, now designated INM-755.
We determined that the clinical development path forward with its investigational drug candidate for the treatment of EB, previously
referred to as INM-750, will be optimized by transitioning to an alternative formulation. INM-755 is formulated based on one of the two
cannabinoids that comprised INM-750. We believe that pursuing a single-agent formulation, rather than a combination product, will ultimately
improve the probability of development and regulatory success in this complex and rare disease.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
9, 2019 &#8211; We received clinical trial application approval for study 755-101-HV, a randomized, double-blind, vehicle-controlled
Phase I study designed to evaluate the local and systemic safety, tolerability, and pharmacokinetics of INM-755 applied daily on intact
skin in healthy volunteers. Two strengths of INM-755 cream, plus vehicle-only, will be evaluated in 22 adult subjects over a 14-day treatment
period.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
20, 2020 &#8211; We revealed that the active ingredient in INM-755 and INM-088 is the rare cannabinoid, CBN. We are the first company
to conduct human clinical trials with CBN. Extensive preclinical program to support the INM-755 program was exhibited at the EB2020 World
Congress in London UK.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
30, 2020 &#8211; We announced clinical trial application approval in the Netherlands for Study 755-102-HV, a randomized, double-blind,
vehicle-controlled Phase I study designed to evaluate the safety and tolerability of INM-755 (two strengths) applied daily for 14 days
on epidermal wounds in 8 healthy volunteers.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
25, 2020 &#8211; We announced the top-line results of Study 755-101-HV (&#8220;Study 101&#8221;). Study 101 was a randomized, vehicle-controlled,
double-blind, Phase 1 trial, that examined the safety and tolerability of two strengths of INM-755 cream on intact skin in 22 healthy
adult volunteers over a 14-day treatment period. The Study 101 results indicate that INM-755 was safe and well-tolerated on intact skin,
caused no systemic or serious adverse effects. In addition, there were no subject withdrawals due to adverse events. Drug concentrations
in the blood were very low, as expected.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
8, 2021 &#8211; We announced the top-line results of Study 755-102-HV (&#8220;Study 102&#8221;). Study 102 was a randomized, double-blind,
vehicle controlled, single-center study, in 8 healthy adult volunteers to test the tolerability of 14 days of application of the INM-755
cream on epidermal wounds under treatment procedures designed to simulate wound care for Epidermolysis Bullosa (&#8220;EB&#8221;) patients
with open wounds. Results of Study 102 indicate that INM-755 cream was safe and well-tolerated on induced open epidermal wounds, caused
no systemic or serious adverse effects. In addition, there were no subject withdrawals due to adverse events. These data from Study 101
and Study 102 support moving forward into clinical trials in patients with EB.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
28, 2021 &#8211; We announced that we filed Clinical Trial Applications (&#8220;CTAs&#8221;) in Austria, Israel and Serbia as part of
a Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa (&#8220;EB&#8221;). Additional CTAs for 755-201-EB (the
&#8216;201 study) will be submitted to National Competent Authorities (&#8220;NCAs&#8221;) and Ethics Committees (&#8220;ECs&#8221;)
in France, Germany, Greece, and Italy in the coming weeks. Responses from the NCAs and ECs are expected throughout July and August 2021;
timing will vary slightly by country due to differences in local procedures.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2021 - We announced commencement of a Phase II clinical trial, the 755-201-EB study, of INM-755 (cannabinol) cream in the
treatment of EB, marking the first time cannabinol has advanced to a Phase II clinical trial to be studied as a therapeutic option to
treat a disease. The 755-201-EB study is designed to enroll up to 20 patients. InMed will evaluate the safety of INM-755 (cannabinol)
cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day treatment period. All four subtypes of inherited
EB; EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome are eligible for this study.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 21.3pt"></td><td style="width: 10.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 25, 2022 &#8211; We announced, based on the safety data of the first five adult patients
                                            who completed the Phase 2 study, an independent Data Monitoring Committee (&#8220;DMC&#8221;)
                                            agreed it is safe to allow the enrollment of adolescent patients with EB, defined Additional
                                            Indications for INM-755</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a company has gone to the significant investments of bringing a new chemical entity into human clinical trials, the tonal approach is
to investigate as many therapeutic uses of that product in different indications, or specific diseases. We intend to pursue this strategy
as a way to leverage our knowledge of CBN and investment in the development of INM-755 as a topical skin cream. Under the assumption
that we would use the same formulation for other dermatological indications, there should be no need for further Phase I safety studies
allowing us to proceed directly to Phase II safety and preliminary efficacy studies in humans, since the toxicology and initial human
safety studies have been completed; however, the adequacy of the nonclinical and human safety data to support new dermatologic indications
will be determined by the appropriate health authority. We intend to engage with dermatologists to discuss which diseases might best
benefit from INM-755, outside of EB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Additional
Indications for INM-755</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a company has gone to the significant investments of bringing a new chemical entity into human clinical trials, the tonal approach is
to investigate as many therapeutic uses of that product in different indications, or specific diseases. We intend to pursue this strategy
as a way to leverage our knowledge of CBN and investment in the development of INM-755 as a topical skin cream. Under the assumption
that we would use the same formulation for other dermatological indications, there should be no need for further Phase I safety studies
allowing us to proceed directly to Phase II safety and preliminary efficacy studies in humans, since the toxicology and initial human
safety studies have been completed; however, the adequacy of the nonclinical and human safety data to support new dermatologic indications
will be determined by the appropriate health authority. We intend to engage with dermatologists to discuss which diseases might best
benefit from INM-755, outside of EB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>INM-088
for the Treatment of Glaucoma</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Introduction</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glaucoma
is a chronic optic neuropathy that is typically characterized by high intraocular pressure. The cause of glaucoma is understood to be
inadequate or obstructed drainage of the fluid in the eye, or &#8220;aqueous humor&#8221;, through a drainage membrane called the trabecular
meshwork, or &#8220;TM&#8221;, increasing the fluid pressure within the front part of the eye, or &#8220;anterior chamber&#8221;, and
subsequently leading to pressure at the back part of the eye, or &#8220;posterior chamber&#8221;. The increased intraocular pressure
exacts a toll on the nerve cells, called neurons, located at the back of the eye in the retina, thinning the mesh-like tissue in this
region and resulting in damage to the neurons and specifically to the optic nerve, which provides the impulses of sight to the brain.
This damage leads to blindness. Glaucoma is currently the second leading cause of blindness world-wide and is estimated to affect a population
of about 76 million worldwide.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_016.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
glaucoma therapies generally act to lower intraocular pressure either by reducing the aqueous humor production by the cells around the
eye, or the &#8220;ciliary epithelial cells&#8221;, or by increasing fluid drainage through the TM. Nevertheless, we believe that there
is considerable room for improvement of existing drugs, most of which are formulated as eye drops, in terms of increasing the amount
of drug that can be safely delivered to increase its effect, improving the delivery of the drug into the eye, and reducing the common
effect in currently used therapies that, over time, their efficacy diminishes as the body becomes tolerant to these classes of drugs.
Studies have shown that when drugs are delivered as eye drops, less than 5% of the dose penetrates into the eye, indicating that 95%
of the administered drug never reaches its desired target as it is wiped away upon blinking. Thus, there is much room for improvement
on the drug delivery as a means of increasing clinical efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
is the key API in our second drug candidate, INM-088, which is in preclinical studies as a potential treatment for glaucoma. We conducted
studies to test the ability of CBN to provide protection to the neurons at the back of the eye, referred to as &#8220;neuroprotection&#8221;,
and reduce the intraocular pressure in the eye. We compared several cannabinoids, including CBD and THC, to determine which cannabinoid
was the best drug candidate for the treatment of glaucoma. Of all of the cannabinoids examined, CBN demonstrated the most optimal effect
of neuroprotection. Furthermore, CBN also exhibited intraocular pressure reduction capability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Science
behind Glaucoma</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glaucoma
is a group of eye diseases which results in degeneration of neurons, damage to the optic nerve and vision loss. The most common type
is open-angle glaucoma, or &#8220;OAG&#8221;, with less common types including closed-angle glaucoma, or &#8220;CAG&#8221;, and normal-tension
(i.e., no increase in intraocular pressure) glaucoma. OAG develops slowly over time and the patients normally don&#8217;t experience
pain. If left untreated, side vision may begin to decrease followed by central vision, resulting in blindness. CAG can present gradually
or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye and nausea. Vision
loss from glaucoma, once it has occurred, is permanent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
factors for glaucoma include increased pressure in the eye, the thinness of the cornea, a family history of the condition, age over 40
years in African Americans, and age over 60 years for other ethnic groups (especially Mexican Americans). High intraocular pressure (those
with a value of greater than 21 mmHg or 2.8 kPa) is often associated with a greater risk of glaucoma. However, some people may have high
eye pressure for years and never develop damage. Conversely, neurodegeneration and optic nerve damage may occur with normal pressure,
known as normal-tension glaucoma. The mechanism of OAG is believed to be slow exit of aqueous humor through the trabecular meshwork while
in CAG the iris blocks the TM. Diagnosis is typically made by a dilated eye examination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
treated early, it is possible to slow or stop the progression of the disease with medication, laser treatment, or surgery. Currently,
the goal of these treatments is to decrease eye pressure. A number of different classes of glaucoma medication are available. Laser treatments
may be effective in both OAG and CAG. Several of types of glaucoma surgeries may be used in people who do not respond sufficiently to
other measures. Treatment of CAG is a medical emergency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Epidemiology</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global prevalence of glaucoma for population aged 40&#8211;80 years is 3.54%, of which 75% is OAG. As of 2010, there were 44.7 million
people in the world with OAG of which 2.8 million were in the United States. By 2020, the prevalence is projected to increase to 80 million
worldwide and 3.4 million the United States. It occurs more commonly among older people. CAG is more common in women. Both internationally
and in the United States, glaucoma is the second-leading cause of blindness.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Treatments in Glaucoma</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
treatments for glaucoma include medication, laser treatment and surgery. The goals of glaucoma management are to avoid glaucomatous damage,
nerve damage and preserve visual field and total quality of life for patients, with minimal side effects. This requires appropriate diagnostic
techniques and follow-up examinations, and judicious selection of treatments for the individual patient. Although intraocular pressure
is only one of the major risk factors for glaucoma, lowering it via various pharmaceuticals and/or surgical techniques is currently the
mainstay of glaucoma treatment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Treatment
Considerations based on Glaucoma Severity</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
considerations for glaucoma span the therapeutic spectrum from drug intervention to surgery.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_017.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
drug intervention has the greatest potential to generate direct competition for INM-088.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Medicines
for Glaucoma Treatment (Intraocular Pressure-Lowering Drugs)</span></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
prescription eyedrop medications targeting intraocular pressure reduction include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostaglandins
and prostaglandin analogs (&#8220;PGA&#8221;) such as latanoprost, bimatoprost and travoprost to increase the outflow of fluid from the
eye and, thereby, reduce ocular pressure. The adverse effects of PGAs include conjunctival hyperemia, or eye redness, irreversible change
in iris color, discoloration of the skin around the eyes, and droopiness of eyelids caused by the loss of orbital fat;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beta
blockers, most commonly prescribed as drugs to treat hypertension, are also prescribed for glaucoma. With their MOA designed to inhibit
aqueous production, they are one of the oldest approved drug classes for the reduction of IOP. The most commonly used drug in this class
is timolol. Beta blockers are less effective than PGAs in terms of IOP reduction and are typically used twice daily. Beta blockers are
the most commonly used non-PGA drug. They are used as an initially prescribed monotherapy and as an adjunctive therapy to PGAs when the
efficacy of PGAs is insufficient. Beta blocker eye drops have contraindications in their label as a result of potential systemic exposures
from the topical application of the eye drops, potentially leading to cardio-pulmonary events such as bronchospasm, arrhythmia and heart
failure. Other possible side effects include wheezing or difficulty breathing, slowed heart rate, lower blood pressure, impotence and
fatigue;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha
agonists, with their MOA designed to inhibit aqueous production plus their effect on uveoscleral outflow, are less effective than PGAs
and need to be dosed three times daily in order to obtain the desired IOP reduction. In clinical studies, the most frequently reported
adverse reactions that occurred in individuals receiving brimonidine ophthalmic solution, a commonly prescribed alpha agonist, included
allergic conjunctivitis, conjunctival hyperemia, eye pruritus, burning sensation, conjunctival folliculosis, hypertension, ocular allergic
reaction, oral dryness and visual disturbance.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha-adrenergic
agonists such as apraclonidine and brimonidine, both reduce the production of aqueous humor and increase the outflow of fluid from the
eye. Side effects may include dry mouth, red eyes or eyelids, fatigue, low or high blood pressure, blurred vision and light sensitivity;
and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carbonic
anhydrase inhibitors such as dorzolamide and brinzolamide reduce the production of fluid in the eye, but they are associated with blurred
vision, bitter metallic taste in the mouth, dry eyes, red/irritated eyes, headache, and upset stomach.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
their modest efficacy, safety and tolerability profiles, the requirement for two to three doses per day, and the fact that they do not
target the diseased tissue in glaucoma, beta blocker, carbonic anhydrase inhibitor and alpha agonist products account for a significant
portion of the total prescription volume for the treatment of glaucoma based on historical prescription patterns, with beta blocker timolol
being the most widely prescribed non-PGA drug. This is driven by the PGA products not being sufficiently effective as monotherapy for
up to half of all glaucoma patients. Often patients need to take a combination of different drugs and multiple eye drops throughout the
day.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed-dose
combination glaucoma products are also currently marketed in the United States, including Cosopt<sup>&#174;</sup>, the combination of
a beta blocker with a carbonic anhydrase inhibitor, and Combigan<sup>&#174;</sup>, the combination of a beta blocker with an alpha agonist.
There are no fixed-dose combinations of PGAs with other glaucoma drugs currently available in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
side effect profiles, many patients do not take their medications properly. Surgery and laser therapies are intended to physically improve
the drainage of fluid from the eyes and lowering of the intraocular pressure. Patients with OAG can have clogged channels in the TM opened
with laser therapy, filtering surgery (trabeculectomy) or electrocautery. In other cases, small drainage tubes may be implanted in the
eye. Possible complications include pain, redness, infection, inflammation, bleeding, abnormally high or low eye pressure and loss of
vision. Some types of eye surgery may accelerate the development of cataracts. Additional procedures may be needed if eye pressure continues
to increase.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Emerging
Competition for INM-088 in Glaucoma</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the large medical need and potentially significant commercial opportunity, the competitive landscape of glaucoma is intense. As such,
there are currently over 10 medications approved by the FDA for the treatment of glaucoma, which are summarized in the table below, according
to drug class. In addition to the currently approved medications, there are a multitude of other therapies being evaluated in clinical
trials, and many others at the preclinical stage. Finally, it should be noted that there are several laser surgeries, and other forms
of surgical procedures that are currently being performed to treat glaucoma, which also serve as a source of competition to the therapeutic
alternatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2017, the FDA approved RHOPRESSA<sup>&#174;</sup> as the first in a new class of glaucoma treatments known as Rho Kinase inhibitors.
RHOPRESSA<sup>&#174;</sup> is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular
hypertension.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
eye drops for the treatment of glaucoma continue to be developed by our competitors. The following table, which may not be exhaustive,
outlines publicly disclosed development programs for the treatment of glaucoma:</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>New Mechanisms Of Action (MOA)</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 25%"><span style="font-size: 10pt"><b>Brand</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 39%"><span style="font-size: 10pt"><b>MOA / Dosing</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 34%"><span style="font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Rhopressa<sup>&#174;</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">ROCK inhibitor (qd)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>US: </b>Marketed; launched in Apr 2018</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>Europe: </b>Centralized MA granted in Nov 2019</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>Japan: </b>Phase 3</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Rocklatan<sup>&#174;</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">ROCK inhibitor + PGA (qd)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>US: </b>Marketed; launched in May 2019</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>Europe: </b>Centralized MA granted in Jan 2021</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>New PGAs</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt"><b>Brand</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>MOA / Dosing</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Vyzulta<sup>&#174;</sup> (Bausch)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">NO donating latanoprost (qd)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>US: </b>Marketed</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">XelprosTM (Sun)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Latanoprost, without BAK (qd)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>US: </b>Marketed</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">DE-117 (Santen)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">EP2 agonist (qd)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>US: </b>Phase 3</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>Japan: </b>launched in Nov 2018</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">DE-126 (Santen)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">FP/EP3 agonist (qd)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>US and Japan: </b>Phase 2b</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">NCX-470 (Nicox)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">NO donating bimatoprost (qd)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><b>US: </b>Phase 3</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">qd
&#8211; once-per-day dosing (latin: <i>quaque die</i>)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INM-088
is envisioned as a once- or twice-a-day eye drop medication to compete with treatment modalities in the medicines category if approved
for commercialization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to INM-088, we are aware of only one other pharmaceutical-grade cannabinoid-based therapy being evaluated for the treatment
of glaucoma. Specifically, Skye Biosciences Inc. (&#8220;Skye&#8221;, formerly Emerald Biosciences) is developing NB1111 (THC-Val-HS)
for the treatment of glaucoma. NB1111 is a THC prodrug, which has demonstrated intraocular pressure-lowering efficacy in preclinical
models. On August 10, 2021 Skye successfully completed genotoxicity studies of THCVHS required prior to beginning its planned Phase I
clinical study in Australia, which is scheduled to initiate enrollment in 4Q2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investigational
Glaucoma Treatments</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the treatments available for lowering the intraocular pressure, there are some individuals for whom these treatments are either not tolerated
due to side effects or in whom the intraocular pressure is not sufficiently lowered. In these situations, both glaucoma patient and physician
look for alternative therapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
some experimental glaucoma medications explore new ways of controlling intraocular pressure, other treatments are directed at protecting
the optic nerve (neuroprotection) to prevent eye damage, potential vision loss or even blindness. Many ongoing clinical studies are trying
to find neuroprotective agents that might benefit the optic nerve and certain retinal cells in glaucoma.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
investigational treatments are undergoing FDA clinical trials to prove safety and effectiveness. Other potential glaucoma treatments
are strictly in experimental stages and may be years away from the possibility of being available on the marketplace.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cannabis
<i>(THC) to treat Glaucoma</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decades
of anecdotal evidence suggests that the use of <i>Cannabis</i> may play a role in lowering intraocular pressure in glaucoma. However,
no such products have been formally investigated in clinical trials and none is currently approved for the treatment of this disease.
The neuroprotective role of cannabinoids has not heretofore been utilized as a therapeutic strategy in glaucoma, primarily due to great
difficulties associated with the targeted delivery of cannabinoids to intraocular tissues. This class of compound is also relatively
poorly bioavailable due to its low aqueous solubility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
reported attempts for topical delivery of cannabinoids, in particular, the intoxicating drug THC, to the ocular tissues used formulations
based on mineral oil. Until very recently, studies on novel topical ophthalmic formulations of cannabinoids have been largely non-existent.
Nevertheless, the use of marijuana to treat glaucoma has extensive anecdotal evidence and some supporting clinical data. It has been
definitively demonstrated and widely appreciated, that smoking marijuana lowers intraocular pressure in both normal individuals and in
those with glaucoma. Certain drawbacks are associated with the use of (smoked) marijuana to treat glaucoma:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marijuana
has a short duration of action (only 3-4 hours), meaning that to lower the intraocular pressure around the clock it would have to be
smoked every three hours;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marijuana&#8217;s
mood-altering and intoxicating effects, almost exclusively via the chemical THC, would prevent the patient who is using it from driving,
operating heavy machinery, and functioning at maximum mental capacity; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marijuana
cigarettes also contain hundreds of compounds that damage the lungs, and the deleterious effect of chronic, frequent use of marijuana
upon the brain is well established.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
means of administering THC include oral, sublingual, and eye drop instillation. The first two modalities avoid the deleterious effect
of marijuana smoke on the lungs but are limited by the other systemic side effects. Other side effects associated with systemic use of
THC for glaucoma include: impaired lung function, psychosis, anxiety dependence, tolerance, acute cardiac events and central nervous
system-related adverse effects. In one study in which doctors offered some of their patients with worsening glaucoma the option of pills
containing THC and/or smoking marijuana, all of them experienced side effects and 4 of 9 patients had discontinued use by either or both
methods within 9 months due to side effects. Given that glaucoma is a lifelong disease, commonly requiring treatment for decades, these
results strongly suggest that systemic use of THC is not a reasonable treatment option for such patients. The use of eye drops containing
THC, or related compounds, has been investigated, but it has not yet been possible to formulate an eye drop that is able to introduce
the drug into the eye in sufficient concentrations due to the low poor water solubility of the active ingredients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
marijuana may lower the intraocular pressure temporarily, that intraocular pressure-lowering effect is only one consideration in slowing
the optic nerve damage of glaucoma. For instance, there is a growing body of evidence that inadequate blood supply to the optic nerve
may contribute to glaucoma-related damage. Since marijuana given systemically is known to lower blood pressure, it is possible that such
an effect could be damaging to the optic nerve in glaucoma, possibly reducing or eliminating whatever beneficial effect that would be
conferred by lowering intraocular pressure. For this reason, marijuana, or its components administered systemically, cannot be recommended
without a long-term trial which evaluates the health of the optic nerve.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
exciting finding is the discovery of receptors for cannabinoids in the tissues of the eye itself, suggesting that local administration
has the possibility of being effective. Furthermore, there is evidence from research in the brain that there may be properties of the
cannabinoids that protect nerve cells like those in the optic nerve. This raises the hope that cannabinoids could protect the optic nerve
not only through intraocular pressure-lowering but also through a neuroprotective mechanism. However, unless a well-tolerated formulation
of a marijuana-related compound with a much longer duration of action is demonstrated in rigorous clinical testing to reduce optic nerve
damage and preserve vision, there is no scientific basis for use of these agents in the treatment of glaucoma.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
wide variety of topically effective anti-glaucoma drugs that are available today, and a few others in the developmental stage, represent
significant advancement in ocular therapeutics. While these topical ophthalmic preparations have reduced the risk of systemic toxicity
to some extent, their long-term use causes systemic as well as ocular toxicity. Many ophthalmologists generally select the drugs individually
and replace them regularly in order to prevent the habituation phenomenon (reduction in effect of the drug over time due to tolerance)
and negative side effects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Drug
Discovery Process</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have utilized several preclinical investigations to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compile
a list of genes that are associated with development of glaucoma disease from our own in-house curated disease analysis. We grouped these
selected genes based on the glaucoma disease hallmarks such as trabecular meshwork remodeling, retinal ganglion cell survival and genes
involved in extracellular matrix; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Better
understand the relationship among selected glaucoma disease genes, we constructed a protein-protein interaction network and the graphic
view of the interaction network was built for further discovery.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glaucoma
is a neurodegenerative disease in which various triggers (such as elevated intraocular pressure) induce cascades of events, which ultimately
lead to apoptotic retinal ganglion cell death and result in irreversible loss of vision. However, as mentioned above, the goal of all
current glaucoma therapies is to reduce intraocular pressure without including any strategies of neuroprotective treatment. In fact,
some patients often fail to show much improvement even after intraocular pressure reduction, whereas others develop glaucoma in the absence
of elevated intraocular pressure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Key
Preclinical Results for CBN as a Drug Candidate to Treat Glaucoma</span></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INM-088
is an eye-drop CBN formulation being developed for the treatment of glaucoma. The preclinical development program for INM-088 has included
a number of studies comparing a number of cannabinoids, including CBN, THC and CBD, among others, to determine which cannabinoid holds
the greatest potential to treat glaucoma. This preclinical research to date is comprised of both <i>in vitro</i> and <i>in vivo</i> studies
and led to the selection of CBN as the lead drug candidate for further development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope of the <i>in vitro</i> studies to date include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
of the neuroprotective effects of selected cannabinoids on the differentiated retinal ganglion cells, or &#8220;RGCs&#8221;, a thin layer
of neurons responsible for relaying visual signals in the eye, under normal atmosphere pressure and elevated pressure conditions.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notably,
exposure of RGCs to increasing concentrations of several cannabinoids, including THC and CBD resulted in dose dependent cytotoxicity,
or cell death, over time. Importantly, CBN-exposed RGCs demonstrated the lowest level of toxicity among the cannabinoids used in these
experiments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cytotoxicity
and neuroprotective effects of selected cannabinoids</i></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_018.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">661W
cells were treated with selected cannabinoids (0.5, 1.5 and 5 &#181;M) at normal atmospheric pressure for 72 hrs. Data normalized to
vehicle under normal pressure (NP-VC) was considered as 0% cell death. Note, CBN (0.5-5 &#181;M) treatment under normal pressure did
not result in cytotoxicity. Other cannabinoids, including CBD, CBDA, CBC, CBG, CBGA, and CBND, displayed significant toxicity. Enhanced
cell proliferation in the presence of a low concentration of &#8710;9-THC (0.5 &#181;M) was observed in contrast to increased cell death
at higher concentrations (1.5 and 5 &#181;M). Experiments were performed in triplicates, two independent times. The data is presented
as mean &#177; SEM. *p &lt; 0.05 against NP-VC (one-way ANOVA).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, exposure of the RGCs to elevated pressure in a cell-based model for glaucoma (without exposure to cannabinoids) for 72 hours
resulted in high level of cytotoxicity, whereas exposure of these cells to both an elevated pressure (20-40 mmHg) plus CBN, within the
same time-period, resulted in cell survival in a dose dependent fashion. A neuroprotective effect of CBN was also observed under elevated
pressure conditions in the pressurized chamber that is designed to mimic the clinical situation of increased intraocular pressure in
glaucoma. CBN performed better than both CBD and THC in this preclinical model under identical testing conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Comparison
of CBN versus THC-mediated inhibition of elevated pressure-induced cell death</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_019.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
neuroprotective effect of CBN on differentiated 661W cells when cultured for 72 hours under a hydrostatic pressure of approximately 20
to 25 mmHg as compared to &#8710;9-THC. Cell were treated with CBN at 0.5, 1.5, 5, 10 and 15 &#181;M and &#8710;9-THC at 0.5, 1.5 and
5 &#181;M respectively. Vehicle Control (VC) contained 0.15% ethanol. Data presented as Cell Death (%) vs normal pressure Vehicle Control
(taken as 0% cell death). The data is presented as mean &#177; SEM.</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CBN
mediated inhibition of elevated pressure-induced cell death</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_020.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
increases cell survival under elevated pressure. 661W cells were treated with CBN in a dose-dependent manner at increased atmospheric
pressure (40 mmHg) for 72 hours. A) Significant cytotoxicity was observed in untreated cells under elevated pressure in the pressure
chamber (EP-VC) compared to normal pressure vehicle control (NP-VC). Data normalized to normal pressure (NP-VC) was considered as 0%
cell death. B) CBN treatment under elevated pressure protected 661W cells from cell death at 0.5, 1.5 and 5 &#181;M. Data normalized
to elevated pressure vehicle control (EP-VC) that was considered as 0% cell death. Protective effect was significantly different from
pressure chamber vehicle control (EP-VC) at 1.5 and 5 &#181;M (p&lt;0.0001 and p&lt;0.001). CBN treatment of 661W cells at 15 &#181;M
under elevated pressure results in cell death. Data presented as mean &#177; SEM of duplicate independent runs (n=6). Data analyzed
statistically by one-way ANOVA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
of anti-apoptotic effects of CBN on the differentiated RGCs when exposed to elevated pressure conditions.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
the same <i>in vitro</i> model described above, we also looked at a specific, natural self-destruction process called programed cell
death, or apoptosis. We verified that CBN has an anti-apoptotic effect on differentiated RGCs when subjected to elevated hydrostatic
pressure. Exposure of these cells to high-pressure levels in the pressure chamber apparatus, without exposure to cannabinoids, for 6
hours resulted in an induction of apoptosis ranging from 30-60% (n=3). Exposure of these cells under the same conditions concurrently
with CBN prevented apoptosis and resulted in a higher level of cell survival.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CBN
mediated attenuation of elevated pressure-induced apoptosis</i></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_021.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
mediated attenuation of elevated pressure-induced apoptosis. 661W cells were treated in the presence of the indicated concentrations
of CBN at increased atmospheric pressure (~20&#8211;25 mm Hg) for 6 h. Significant apoptosis was observed under elevated pressure in
the pressure chamber (EP-VC) when compared to NP-VC. CBN at higher concentrations (0.5, 1.5 and 5 &#956;M) but not at lower concentrations
(0.015&#8211;0.15 &#956;M) significantly inhibited pressure-induced apoptosis of 661W cells. Experiments were performed in triplicates,
two independent times. The data is presented as mean &#177; SEM. #p &lt; 0.05 against NP-VC analyzed by using an unpaired t-test; *p
&lt; 0.05 against EP-VC analyzed statistically by one-way ANOVA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
of CBN impact on the expression of specific extracellular matrix (ECM) markers on primary human trabecular meshwork (TM) cells under
basal condition and following stress-induction with Transforming Growth Factor Beta 2 (TGF-&#223;2), a cytokine used to alter extracellular
matrix metabolism.</span></td>
</tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key risk factor for the development and progression of glaucoma is elevated IOP, the result of increased resistance to aqueous humor
outflow through the TM. Increased outflow resistance has been strongly correlated with aberrantly elevated levels of TGF-&#223;2, a
cytokine used to alter extracellular matrix metabolism of the TM of glaucoma patients compared to healthy individual. Therefore, evaluation
of CBN effects on the TM observed under elevated TGF-&#223;2conditions mimics the clinical presentation of IOP in glaucoma and is relevant
in the clinical context of the disease. Using human primary TM cells derived from various donors and propagated <i>in vitro</i> at different
cell passages, we were able to demonstrate that several extra-cellular matrix proteins, or &#8220;ECM&#8221; markers, were upregulated
by TGF-&#223;2 induced condition. Furthermore, CBN treated TM cells under basal condition or TGF-&#223;2 induced conditions for a duration
of 72 hours resulted in reduction in the expression of several of these ECM protein markers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CBN
attenuated TGF-&#946;2 induced changes on TM markers Fibronectin (FN)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>and
Collagen 1A (COL1A) in hTM cells</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_022.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
attenuated TGF-&#946;2 induced changes in TM markers Fibronectin (FN) and Collagen 1A (COL1A) in hTM cells. hTM cells were treated with
CBN (0.15, 0.5, 1.5 and 5 &#956;M) for 72 h with or without TGF-&#946;2 (5 ng/mL). Post-treatment, cell lysates were collected, total protein
was quantified by Bradford assay, and ELISA was performed according to the manufacturer&#8217;s instructions. (A) TGF-&#946;2 induced
significant upregulation of FN expression. Note, a significant reduction in basal or TGF-&#946;2 induced FN levels was observed in the
presence of CBN (5 &#956;M). (B) TGF-&#946;2 did not induce upregulation of COL1A level in hTM cells, whereas CBN in a dose dependent manner
(0.5&#8211;5 &#956;M) attenuated COL1A levels in the presence or absence of TGF-&#946;2. Experiments were performed in triplicates, two
independent times. The data is presented as mean &#177; SEM. Changes in the treatment groups were compared to the vehicle control (VC)
group (*) or TGF-&#946;2 induced group (#), and data were analyzed by using one-way ANOVA (p &lt; 0.05).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Role
of CBN in the inhibition of TGF-&#946;2 induced changes in expression of &#945;-SMA and pERK1/2</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_023.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
6: </b>Role of CBN in the inhibition of TGF-&#946;2 induced changes in expression of &#945;-SMA and pERK1/2. Representative immunoblots
showing CBN mediated changes in expression of &#945;-SMA and phospho-ERK1/2 in the presence or absence of TGF-&#946;2. TGF-&#946;2 stimulated
&#945;-SMA expression and increased the level of ERK1/2 phosphorylation when compared to vehicle control. Note the inhibition of &#945;-SMA
expression and ERK1/2 phosphorylation in the presence of CBN in comparison to vehicle control and/or TGF-&#946;2 treatment. GAPDH was
used as the loading control. Histograms in the lower panel represent densitometry analysis of the Western blots (n=3&#8211;4). Changes
in the treatment groups were compared to the vehicle control (VC) group (*) or TGF-&#946;2 group (#), and data were analyzed statistically
by unpaired t-test (p &lt; 0.05).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
of CBN pharmacokinetic profile in the eye and plasma of a preclinical model (rat) by direct intravitreal (IVT) injection into the eye.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first <i>in vivo</i> study was designed to determine the pharmacokinetic profile of CBN in preclinical models, specifically measuring
CBN levels in the eye and plasma following direct bilateral IVT injection. This means that individual injections were made directly into
the vitreous humor (fluid of the central cavity of the eye). Following IVT delivery, CBN levels from the plasma (n=3 per time point)
and the whole eye (n=6 per time point) were measured at several timepoints using a qualified LC-MS/MS method. CBN levels in the plasma
samples were below the detection limit of the assay (0.05 ng/mL). Furthermore, CBN levels in the rat whole eye were shown to be slowly
cleared from the eye with a projected half-life (t1&#8260;2) of approximately 33 hrs.</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Percentage
of CBN remaining in the whole eye following single IVT injection at 10 &#181;M initial dose</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_024.jpg"/>&#160;</p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
of CBN remaining in the whole eye following single IVT injection at 10 &#956;M initial dose. Each point represents the mean of left and
right eye measurements. The concentration-over-time elimination profile of CBN from IVT injection in the whole eye indicates a slow clearance
rate of this cannabinoid, with approximately 11% of the total CBN remaining at 72 h termination time-point (n = 6 eyes per time-point;
values presented as mean&#177;SEM).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Time
dependent elimination of CBN from the whole eye following</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>single
IVT injection at 10 &#956;M initial dose</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_025.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration-over-time
elimination profile of CBN from IVT injection in the whole eye indicates a slow clearance rate of this cannabinoid, with approximately
11% of the total CBN remaining at 72 hrs termination time-point. Rats received a single bilateral IVT injection (5 &#956;L) of CBN (50
&#956;M) to target a final concentration of 10 &#956;M inside the eye. Values measured as ng/g ocular tissue or &#956;M and presented as mean
&#177; SEM. n = 6 eyes per time-point. *596 ng/g represents an extrapolated initial dose intended for delivery inside the eye calculated
based on the actual whole eye tissue weight.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pharmacokinetic
parameters of CBN in the whole eye following</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>single
IVT injection at 10 &#956;M initial dose</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_026.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
was quantified by a qualified LC-MS/MS method in the whole eye homogenates. The analysis of pharmacokinetic parameters was performed
using Pharmacokinetic Solver 2.0 Software. To produce an output, a Non-Compartmental Analysis using the linear trapezoid rule after extravascular
input was performed. CBN was cleared at a slow rate from the ocular tissue with CLivt = ~0.04 mL/h, favorable AUC0-inf ocular exposure
at 250 &#956;mol/mL * h, and relatively long ocular t1/2 =~33 h.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation
of CBN neuroprotective and IOP-lowering effects in a rat preclinical glaucoma model (Rats) by IVT injection.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted a preclinical efficacy study to evaluate neuroprotective and IOP lowering effects of CBN following IVT injection in a rat
episcleral vein laser photocoagulation model of glaucoma. The laser photocoagulation of episcleral veins was done unilaterally on
the oculus dexter (OD) eye of the animals on day 0 and day 7. The contralateral oculus sinister (OS) eye served as control and was
not subjected to lasering. The rats were randomized into 4 treatment groups based on their baseline pERG amplitudes measured at day
- 4: <i>Group 1:</i> vehicle control (0.5% DMSO-PBS); n=11. <i>Group 2:</i> CBN low dose at 5 &#181;M final concentration inside
the eye; n=13. <i>Group 3:</i> CBN high dose at 50 &#181;M final concentration inside the eye; n=11. <i>Group 4:</i> brimonidine
tartrate (Alphagan<sup>&#174;</sup>, 0.5% ophthalmic eye drops, a registered trademark of Allergan PLC) a selective
&#945;2-adrenoceptor agonist clinical reference drug; n=14. Animals in Groups 1, 2 and 3 were administered either vehicle or CBN by
IVT injection at 5 &#181;l volume on day 0, 7 and 15. Animals in Group 4 were topically instilled with brimonidine twice daily at 5
&#181;l volume per eye 4 days before laser photocoagulation and throughout the study duration. The study was terminated on day 21.
High IOP was induced unilaterally by laser photocoagulation of episcleral veins (to approximately 19 mmHg). CBN was delivered by IVT
injection after episcleral laser photocoagulation on three occasions on day 0, immediately after the lasering, and on days 7 and 15
post-lasering. IOP and pERG were monitored at specific time points throughout the study. Significant reduction in IOP (to
approximately 13 mmHg) was observed for the CBN high dose treated group on Days 7 and 17 and significant improvement of pERG
amplitudes for CBN low dose treated group was observed on Day 21 (-39.8% from baseline for vehicle control group, -23.1% from
baseline for the active control (brimonidine tartrate) group, -16.6% from baseline for the CBN low dose group and -41.2% from
baseline for the CBN high dose group). These were the measured outcomes that are useful in evaluating candidates for a potential
glaucoma treatment. In summary, data from this study demonstrated a reduction of IOP and improvement of pERG function following IVT
injection of CBN in the Rat episcleral vein laser photocoagulation model of glaucoma.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CBN
mediated effect on IOP in the rat episcleral vein laser photocoagulation model of glaucoma</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_027.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBN
mediated effect on IOP in the rat episcleral vein laser photocoagulation model of glaucoma. The IOP lowering effect of CBN was analyzed
in the lasered eyes of different treatment groups versus the vehicle control group. At a low dose (5 &#956;M), CBN treatment did not reduce
IOP. At a high dose (50 &#956;M), CBN significantly reduced IOP on days 7 and 17. On day 21, IOP values in all groups normalized to the
baseline levels. Data analyses are presented for the time points with a statistically significant difference. Brimonidine (Alphagan<sup>&#174;</sup>)
was used as a reference control. Data were analyzed statistically by unpaired t-test and presented as mean &#177; SEM. *p &lt; 0.05
against vehicle control (n =11&#8211;14 rats per treatment group).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CBN
mediated changes in the pattern electroretinogram (pERG) in the rat episcleral vein laser</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>photocoagulation
model of glaucoma</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_028.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_029.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pERG amplitudes (&#181;V) decreased in all treatment groups after the IOP elevation induced by episcleral vein laser photocoagulation.
(A) pERG baseline-corrected -Amplitude values (&#956;V) (mean &#177; SEM) of animals in each treatment group were recorded at baseline
before lasering and on days 7, 14 and 21 post-lasering. (B) %pERG reduction from 100% normal baseline values at Day 21. Significant RGC
functional impairment was observed in the vehicle group on day 21 and in the CBN high dose (50 &#181;M) group on days 14 and 21 when
compared to baseline. The pERG amplitudes in the low dose CBN (5 &#956;M) and brimonidine (Alphagan<sup>&#174;</sup>) groups did not differ
significantly from the baseline on both follow-up days 14 and 21, indicating that CBN confers neuroprotective effect on RGCs. Data is
presented as mean &#177; SEM of baseline-corrected values and analyzed statistically by two-way ANOVA followed by Tukey&#8217;s multiple
comparison test (*p &lt; 0.05 against the baseline values; n=11-14 rats per treatment group).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ocular
Formulation Development for INM-088</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a wide variety of topically effective anti-glaucoma drugs that are available today and others in the developmental stage that represent
significant advancements for ocular therapeutics. Ophthalmologists typically prescribe drugs individually and then switch to different
classes of drugs on a regular basis in order to prevent the habituation phenomenon (reduction in effect of the drug over time) and negative
side effects. There is an opportunity for new therapies with low systemic toxicity and those which may not exhibit habituation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
very recently, studies on novel topical ophthalmic formulations of cannabinoids have been largely non-existent. Designing an ideal delivery
system for any ocular disease depends on the molecular properties of the drug substance and incorporating it into the formulation while
taking into consideration parameters such as size, charge, and affinity towards various ocular tissues and pigments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all delivery technologies under examination as candidates for INM-088, key design criteria include, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biocompatibility
and biodegradability of the formulation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Viscous
fluid behavior while inside the container (to facilitate ease of manufacturing, handling and dosing);</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characterized
and defined drug release, absorption and subsequent carrier degradation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optimized
particle size and surface charge to avoid irritation upon application to the eye and to facilitate ocular penetration; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stable
final drug product to ensure drug product quality storage over time.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the delivery technologies under development as a potential delivery vehicle for CBN in ocular disease is our proprietary, stimulus-responsive,
nanoparticle-laden hydrogel vehicle for spatiotemporal and dosage-controlled release of cannabinoids into the aqueous humor of the eye.
This hydrogel is envisioned to be packaged as a liquid and is intended for application as an eye drop. We investigated the compatibility
and effectiveness of our hydrogel formulation with CBN as compared to other third-party ocular drug delivery technologies such as EyeCRO&#8217;s
MiDROPs<sup>&#174;</sup> microemulsion. We conducted an <i>in vivo</i> study that compared both the hydrogel and MiDROPs<sup>&#174;</sup>
formulated with CBN and showed that a similar level of CBN was measured in the retina and retinal pigmented epithelium tissues following
topical administration of each formulation. In early December 2020, we selected a final delivery technology based on the extensive data
collected from these assessments that included solubility, drug delivery localization and sustained effect. This selection resulted in
a licensing agreement with EyeCRO LLC for its proprietary MiDROPs<sup>&#174;</sup> technology. Through this agreement, InMed has secured
an exclusive, global commercial rights for the utilization of MiDROPs<sup>&#174;</sup> for all cannabinoids, cannabinoid analogs and their
variants. One key benefit for our INM-088 program by working with EyeCRO is that their product development and testing with MiDROPs<sup>&#174;
</sup>is already well advanced, having been previously reviewed by the US FDA during a pre-IND meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution
of INM-088 formulation in Ocular Tissue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_030.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocular
pharmacokinetic study of INM-088 following 5 days of bilateral ocular topical administration in New Zealand White Rabbits. INM-088 was
formulated as 0.1% CBN-MiDROPS&#8482; and dosed BID at 50 &#181;l/dose for 5 days via bilateral topical ocular instillation in 3 na&#239;ve
NZW rabbits. CBN level was measured 1 hour following the final dose administration on Day 5, Administration of INM-088 formulation resulted
in measurable CBN concentrations in each of the ocular tissues analyzed in this study. The study was performed independently by EyeCRO
LLC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Next
Steps for the INM-088 in Glaucoma Program:</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to COVID-related delays and other external factors, we plan to accomplish the following tasks for the INM-088 in Glaucoma program in
calendar year 2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Process
and analytical development and scale-up of INM-088 formulation, MiDROPs&#174; with CBN, to enable pre-clinical and clinical supply;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiate
and complete IND/CTA-enabling toxicology studies.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Key
Milestones:</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
24, 2017 &#8211; We announced results from a study co-sponsored by us and University of British Columbia. We believe that this InMed-University
of British Columbia study was the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery into the eye, resulting in
enhanced drug uptake via the cornea and lens. This study further evidences our capacity to conduct a wide spectrum of drug development
activities, including: packaging the cannabinoid as a nanoparticle; formulation of a cannabinoid drug candidate into a novel, tissue
specific delivery vehicle; and confirmation of drug delivery and diffusion into a target tissue.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
14, 2018 &#8211; We announced the filing of a PCT Application (PCT/CA2018/050548) for a cannabinoid-based topical therapy for glaucoma,
which includes the protection of our technology in several countries, including the United States, and claims a priority date from May
8, 2017 (PCT/CA2018/050548). The PCT Application filing is a conversion from the provisional patent filed in May 2017.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
20, 2020 &#8211; We revealed that the active ingredient in INM-755 and INM-088 is the rare cannabinoid, CBN and that we are the first
company to conduct human clinical trials with CBN.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
12, 2020 &#8211; We announced filing of a PCT application entitled &#8220;Compositions and Methods for Use of Cannabinoids for Neuroprotection&#8221;.
This application was initially filed as a provisional patent application pertaining to the potential of cannabinoids in the prevention
of neuron damage associated with glaucoma.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
3, 2020 &#8211; We announced the selection of the final formulation for INM-088, and we secured an exclusive, worldwide license from
EyeCRO LLC for its Microemulsion Drug Ocular Penetration System (&#8220;MiDROPS&#174;&#8221;) eyedrop delivery technology targeting effective,
topical administration of cannabinoids to the eye.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
20, 2021 &#8211; We announced that a peer-reviewed scientific article entitled &#8220;Cannabinol Modulates Neuroprotection and Intraocular
Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma&#8221;, has been published in Biochimica et Biophysical Acta
(BBA - Molecular Basis of Disease), a leading international journal focused on biochemistry and molecular genetics of disease processes
and models of human disease in the area of aging, cancer, metabolic-, neurological-, and immunological-based diseases. The peer-reviewed
article highlights research evaluating the use of cannabinol, or CBN, as a potential treatment option for glaucoma. Several studies were
conducted to evaluate the survival of retinal ganglion cells, modulation of intraocular pressure and its effects on extracellular matrix
proteins using in vitro and in vivo glaucoma models.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.95pt; text-indent: -26.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
13, 2022 &#8211; We announced <span>t</span>he Company recently completed a pre-Investigational New Drug
(&#8220;pIND&#8221;) application discussion with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) regarding manufacturing, preclinical
studies and early clinical development plans for INM-088, a cannabinol (&#8220;CBN&#8221;) formulation in development for glaucoma. The
Company has gained alignment with FDA on the design of the initial Phase 1-2 clinical trial to gather preliminary data on the safety
and efficacy of INM-088 treatment. The FDA has provided guidance for the development program based on a summary of the available preclinical
data, clinical safety data for CBN from the INM-755 program, study designs for additional IND-enabling preclinical studies, and Chemistry
Manufacturing and Controls (&#8220;CMC&#8221;) information. Management expects to file regulatory applications in the first half of the
calendar year 2023, to initiate a human clinical trial.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
indications in ocular disease</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to the strategy being pursued with INM-755, we intend to fully investigate the potential for CBN in INM-088 to treat a wide array of
ocular diseases, in particular, the potential for CBN to provide neuroprotection across several diseases where blindness is the ultimate
outcome. We are currently pursuing preclinical models to more closely study this effect and will leverage the toxicology and Phase I
safety studies across these new indications, if deemed applicable. In addition, we are actively working with our collaborators to test
selected potential CBN-analogs, produced by BayMedica, to demonstrate neuroprotection in other ocular indications such as Age-Related
Macular Degeneration (AMD).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Research and Development Programs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. We have conducted
limited preclinical investigations of the potential of non-THC cannabinoids to treat pain using a topical approach. In September 2018,
we filed a PCT Application in the United States for INM-405 as cannabinoid-based topical therapies for the treatment of pain, which is
an important step in protecting our intellectual and commercial property. The patent cites a range of cannabinoids, alone or in combination,
applied topically to treat various types of pain&#8212;muscle, nerve, arthritis-induced joint pain, etc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Key
In Vivo Results for our Pain Program</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
data from our research program for pain medications were published in the European Journal of Pain (2017) and the Archives of Oral Biology
(2019). Both publications specifically cited data on the use of THC and certain other cannabinoids, alone and in combination, at varying
ratios, in a preclinical pain model. Findings from the published studies include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expression
of cannabinoid receptors on masseter ganglion neurons. Both CB1 and CB2 receptor expression was observed in the trigeminal ganglion neurons
that innervate the masseter muscle, as well as in the neuronal fibers in the muscle itself. This confirms that these peripheral nerves
may be appropriate targets for a cannabinoid therapy;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
of intramuscular injections of THC and certain other cannabinoids, alone and in combination, on nerve growth factor, or &#8220;NGF&#8221;,
induced sensitization. NGF, if injected into a target tissue (muscle), makes the tissue more sensitive to pain, as can be measured by
a mechanical threshold, or &#8220;MT&#8221;, scale. On this scale, a lower number represent a lower pain threshold, or a lower ability
to tolerate a painful stimulus. NGF injection resulted in a lowering of the MT score. Applications of THC and certain other cannabinoids,
either alone or in combination, were associated with an increase of MT, meaning a higher ability to tolerate pain. It should be noted
that the NGF-induced reduction in MT model mimics the type of pain reported by sufferers of temporomandibular disorders, or &#8220;TMD&#8221;.
Importantly, these cannabinoids only affected the muscle into which it was injected; there was no effect on surrounding tissue; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a behavioral analysis in these studies, test subjects treated with peripheral application of THC, the leading intoxicating component
in marijuana, and certain other cannabinoids did not exhibit any effect on motor function. This indicates that the dose of THC used did
not achieve sufficient circulatory distribution to reach the brain where it may exhibit intoxicating effects. However, repeat applications
of THC may still have potential to induce significant undesirable central effect.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
INM-405 research program is at an early-stage and its continued development is subject to available resources and/or our ability to find
funding or strategic partners. Continued investment in our INM-405 research program is under review and we will make a determination
as to its future development based on several strategic factors, including other research priorities, in due course.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
areas of our early research focus have included Chronic Obstructive Pulmonary Disease, or &#8220;COPD&#8221;, neurodegenerative diseases
such as Huntington&#8217;s Disease, and breast cancer. Recently, we have conducted a broad range of research and development activities
to explore other uses of cannabinoids in treating human diseases with unmet medical needs. Our studies have demonstrated the potential
for the use of a rare cannabinoid to improve neuronal function and provide neuroprotection for treating neurodegenerative disorders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, we filed a PCT Application patent application demonstrating neuroprotection and enhanced neuronal function using a rare
cannabinoid for the potential treatment of neurodegenerative diseases such as Alzheimer&#8217;s Disease, Parkinson&#8217;s Disease, Huntington&#8217;s
Disease and others. This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as
potential pharmaceutical therapeutics for diseases with high unmet medical needs. Expanding our patent portfolio to include, in addition
to CBN, an incremental rare cannabinoid for the potential treatment of major neurodegeneration indications. To date, screening for this
indication has yielded some meaningful analog candidates and we will continue to proceed with our plan to find an appropriate compound
for a pre-clinical development program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
programs are at various early stages of development and, as non-core assets, their continued development is subject to available resources
and/or our ability to find funding or strategic partners. Continued investment in each program is under review and we will make determinations
as to which programs to continue based on several strategic factors. In addition, we may choose to partner some or all of these programs
with external parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acquisition
of BayMedica Inc.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2021, we announced the closing of the transaction acquiring BayMedica Inc., renamed as BayMedica LLC, (&#8220;BayMedica&#8221;)
a private company based in the USA specializing in the manufacture and commercialization of rare cannabinoids. We acquired 100% of BayMedica
in exchange for 82,000 our common shares issued to BayMedica&#8217;s equity and convertible debt holders, subject to a six-month contractual
hold period, and a cash component of US$1 million. US$0.5 million of this cash consideration is held in escrow, subject to cancellation,
to satisfy certain potential post-closing indemnification and other claims that we may have under the definitive agreement in the six-
and twelve-month periods following the closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
this transaction, we gained significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various
market sectors, with expertise in three distinct and complementary cannabinoid manufacturing approaches. Our proprietary cannabinoid
manufacturing process, IntegraSyn&#8482;, combined with BayMedica&#8217;s synthetic biology and chemical synthesis capabilities, provides
us with complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and
appropriate quality specifications for the desired market segment. In parallel to cannabinoid manufacturing, the combined company will
continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, a business-to-business
(B2B) supplier to wholesalers and end-product manufacturers / marketers in the health and wellness sector.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BayMedica
is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop
efficient, scalable, and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer
applications. Prior to the acquisition, BayMedica commercialized the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors
and manufacturers marketing products in the health and wellness sector, and revenues of BayMedica&#8217;s initial rare cannabinoid product,
Prodiol<sup>&#174;</sup> CBC (cannabichromene), had grown steadily since sales commenced in December 2019; the predecessor company, BayMedica
Inc., had cumulative revenues of $2.4 million for the 21-month period ending September 30, 2021. Since October 13, 2021, the date of
acquisition, to June 30, 2022, BayMedica had revenues of approximately $1.1 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the acquisition of BayMedica, a key priority for the Company in the second half of fiscal 2022 was accelerating commercial activities
and building out a robust product portfolio as a supplier of raw ingredients to the health and wellness market. In April 2022, we announced
the market introduction of the non-intoxicating rare cannabinoid cannabidivarin (&#8220;CBDV&#8221;) and in May launched the non-intoxicating
cannabinoid delta-9 tetrahydrocannabivarin (&#8220;THCV&#8221;), bringing the BayMedica portfolio to four cannabinoid products. While
consumer companies have begun to investigate the use of rare cannabinoids for new products, this has not translated to immediate, meaningful
market demand, resulting in slower than expected revenue growth. Contributing factors include but are not limited to: recent overarching
recessionary pressures leading to hesitation within the health and wellness sector to invest in, and launch, new rare cannabinoid products;
in this nascent market, BayMedica&#8217;s perceived competitive advantages of certified high purity and reliability and consistency of
supply not resonating with the industry product manufacturers; and, additional downward pricing pressure for cannabinoids in the health
and wellness sector.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the above, the timing of revenues for the BayMedica products has become highly uncertain and is causing management to re-evaluate whether,
in the long-term, the BayMedica commercial activities will achieve margins sufficient to justify further investment in that business
line. As a result, the Company made the decision to refocus on its core business in the pharmaceutical drug development area and reduce
our financial exposure in the health and wellness sector. To make that transition, the Company plans to focus sales efforts on reducing
inventory and decreasing other commercial manufacturing R&amp;D efforts. BayMedica will continue to evaluate opportunities for potential
structured supply arrangements and collaborations and will consider other potential strategic alternatives for the commercial business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
of Our Active Pharmaceutical Ingredients (API)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CBN used in INM-755 and INM-088 is currently sourced from either contract manufacturers or, for smaller quantities, from research material
suppliers, that typically utilize synthetic chemistry. Changes in contract manufacturers or suppliers may require additional verification
of the vendor&#8217;s quality systems, compliance, manufacturing process, testing and equivalency to the currently supplied CBN prior
to use. This is intended to be an interim step to enable us to proceed with developing its formulations, execute preclinical toxicology
studies and progress through Phase I and II clinical trials. Thereafter, we may be able to utilize our IntegraSyn<sup>TM</sup> system
for GMP APIs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bridging
studies consisting of chemical analysis and, possibly, animal bioavailability studies may be required in order to switch our API from
the current external manufacturing sources to our internal IntegraSyn<sup>TM</sup> based APIs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the final formulations (API + excipients + packaging) of INM-755 topical cream and the INM-088 eye drop formulation will
be manufactured by contract manufacturers and sub-component fabricators. The contract manufacturers and sub-component fabricators will
be selected based on their specific competencies in manufacturing, quality standards, and materials. FDA regulations require that products
be produced under current cGMP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent is a monopoly granted by a government for a period of up to 20 years. A patent provides an enforceable legal right to prevent
others from exploiting an invention being a product, device, system, substance, process or method in the country of grant. For an invention
to be patentable, it must be novel, involve an inventive step and useful at the time of filing the initial patent application for that
invention. At 18 months from the initial patent application, the detailed description of the invention is published. In order to secure
patent protection, a patent application is filed with the patent office in each country of interest, the application is considered under
the patent laws of that country, and a patent will issue if the application meets the patentability criteria of that country. After a
patent expires or lapses, anyone can then use the invention.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant of a patent does not guarantee validity and a patent may be challenged by third parties at a patent office by re-examination in
some countries or through the courts by revocation proceedings. The grant of a valid patent does not mean that the invention may be exploited
in a given country without infringing third party intellectual property rights in that country.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
owner of a patent has the exclusive right to prevent others from making, selling, importing or otherwise using the patented invention
for the life of the patent. Patent infringement occurs when someone makes, hires, uses, imports or sells the patented invention, or a
product made by a patented method, or offers to do these things, within the country covered by the patent without the permission of the
owner of the patent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adequate
protection of intellectual property is a means to ensure that we can commercialize our intellectual property and reduce the likelihood
of imitation by competitors. We intend to utilize patents available to protect our IP wherever commercially realizable. In addition,
we also rely on trade-secrets and process know-how to protect our intellectual property. While we cannot patent the naturally occurring
individual cannabinoids used in our Products and Product Candidates, there are a number of other approaches to protect our inventions.
These include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents
on individual or combinations of cannabinoids that provide novel methods for treating diseases;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cannabinoid
delivery technology, formulations designed specifically to increase the safety and efficacy of drug treatments; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
processes for cannabinoids.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent methodologies listed above will be designed with the intention to maximize the protection of our multi-faceted approach to developing
novel cannabinoid medicines. We typically file patent applications in US, Canada, EU and other selected commercially significant foreign
jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>InMed Patent Portfolio, August 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 24%; font-weight: bold; text-align: left">Subject Matter</td><td style="vertical-align: bottom; text-align: center; width: 0.5%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 11%; font-weight: bold">Scope</td><td style="vertical-align: bottom; text-align: center; width: 0.5%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 11%; font-weight: bold; text-align: center">Owner-ship/ Origin</td><td style="vertical-align: bottom; text-align: center; width: 0.5%; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Filing&#160;Status&#160;/<br/>
Filing Date</td><td style="vertical-align: bottom; text-align: center; width: 0.5%; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center">Patent Reference Number</td><td style="vertical-align: bottom; text-align: center; width: 0.5%">&#160;</td>
    <td style="vertical-align: bottom; width: 0.5%; text-align: center">&#160;</td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 9%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Earliest Potential/</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Patent Expiry<sup>2</sup></b></p></td><td style="vertical-align: bottom; width: 0.5%; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; width: 0.5%; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center; width: 19%; font-weight: bold">Jurisdictions</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Metabolic engineering of <i>E. coli </i>for the biosynthesis of cannabinoid products </span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Manufactur-ing Process</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">InMed, UBC<sup>1</sup></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PCT&#160;Application<br/>
 filed 09/05/2018</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">WO/2019/046941</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">2038</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">AU, CA, CN, EP, IL, IN, JP, KR, SG, US</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Compositions and methods for biosynthesis of terpenoids or cannabinoids in a heterologous system</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Manufactur-ing Process</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">InMed, UBC<sup>1</sup></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PCT Application filed 3/6/2020</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">WO/2020/176998</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">2040</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">AU, CA, CN, EP, IL, IN, JP, KR, SG, US</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Ocular drug delivery formulation <br/>(Hydrogel)</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Formulation, Use</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">InMed</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PCT Application <br/>filed 05/08/2018</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">WO/2018/205022 <br/></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">2038</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">AU, CA, CN, EP, IL, IN, JP, KR, MX, SG, US, ZA</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Compositions and methods for use of cannabinoids for neuroprotection</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Use</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">InMed</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PCT Application <br/>filed 04/24/2020</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">WO/2020/215164</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">2040</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">AU, CA, CN, EP, IL, IN, JP, KR, MX, SG, US, ZA</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Topical formulations of cannabinoids and use thereof in the treatment of pain</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Formulation, Use</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">InMed</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PCT Application <br/>filed 09/21/2018</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">WO/2019/056123</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">2038</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">EP, US</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Use</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">InMed</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PCT Application <br/>filed 05/04/2017</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">WO/2017/190249</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">2037</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">AU, CA, CN, EP, IL, JP, SG, US</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Compositions and methods for treating neuronal disorders with cannabinoids</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">Use</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">InMed</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">PCT Application <br/>filed 10/21/2022</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">PCT/CA2021/051487</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top; text-align: center">2041</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: left">Currently pending at &#160;international Stage</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">1</td><td style="text-align: justify">UBC is a co-inventor and has assigned all commercial rights
to InMed in exchange for a royalty of less than 1% on sales revenues from products utilizing cannabinoids manufactured using the technology
and a single digit royalty on any sub-licensing revenues.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">2</td><td style="text-align: justify">Patents typically expire 20 years from their filing dates,
if granted, the patent expiry may be extended by patent agencies and/or health regulatory authorities.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">PCT = Patent Cooperation Treaty. Members in this treaty includes over 150 countries including USA, Canada, Europe and others.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 1, 2022, we have thirteen patent families covering manufacturing, Product Candidates, novel methods for treating diseases including
two for our INM-755 program (WO/2017/190249 and WO/2019/056123), one for our INM-088 program (PCT/CA2020/050547)) and one for treating
neurodegenerative diseases (PCT/CA2021/051487). If these patents applications are granted and all maintenance fees or annuities are paid,
these patents are expected to expire in 2037-2042. In some situations, the patent may be eligible for adjustment or extension of the
patent terms due to delay in the patent office during the prosecution phase. The expiration date above does not include the adjustments
or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 1, 2022, we have one patent family covering cannabinoid delivery technology for the ocular program (WO/2018/205022). If these
patents applications are granted and all maintenance fees or annuities are paid, these patents are expected to expire in 2038. In some
situations, the patent may be eligible for adjustment or extension of the patent terms due to delay in the patent office during the prosecution
phase. The expiration date above does not include the adjustments or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 1, 2022, we have eight patent families covering manufacturing process for cannabinoids of interest (WO/2019/046941, WO/2020/176998,
WO/2018/209143, WO/2020/092823, PCT/US2019/061289, PCT/US2020/066965, PCT/US2021/014226 and PCT/US2022/013140). If these patents applications
are granted and all maintenance fees or annuities are paid, these patents are expected to expire in 2038-2042. In some situations, the
patent may be eligible for adjustment or extension of the patent terms due to delay in the patent office during the prosecution phase.
The expiration date above does not include the adjustments or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patent Cooperation Treaty, or &#8220;PCT&#8221;, is an international patent law treaty, which provides a unified procedure for filing
patent applications to protect inventions in each of its member states. There are 151 member countries within the PCT, enabling near-global
patent coverage through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia,
India and many other countries. We have several filed patent applications currently either in the provisional stage or PCT stage of review
as shown above. None have been granted to date. We retain the full commercial rights to all of these patents with any exceptions noted
in the above table.</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_001a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;
1A. RISK FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of material risks that could affect our business. This summary may not contain all of our material risks, and
it is qualified in its entirety by the more detailed risk factors set forth below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IntegraSyn<b><sup>TM </sup></b>manufacturing approach may prove unsuccessful in achieving yields and/or cost levels required to be economically
competitive with alternative methods of manufacturing.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
prospects depend on the success of our Product Candidates which are at early-stages of development with a statistically high probability
of failure and are subject to lengthy, time-consuming and inherently unpredictable regulatory processes.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Product Candidates contain compounds that may be classified as &#8220;controlled substances&#8221;, the use of which may generate public
controversy and restrict their development or commercialization.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
restrictions, product shipment delays or prohibitions could have a material adverse effect on our business, results of operations and
financial condition.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
federal legislation and actions by state and local governments may permit reimportation of drugs from/to foreign countries where the
drugs are sold at lower prices than in the country of origination, which could materially adversely affect our business and financial
condition.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or particular states may ultimately prohibit the sale of some or all dietary supplements or conventional foods containing cannabinoid
ingredients and our downstream B2B customers may be required to submit a New Dietary Ingredient notification to the FDA, which may not
be accepted without objection.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Regulatory Framework for (non-THC) Cannabinoid Related products is rapidly evolving and changes could delay or prevent commercialization
and result in materially adverse effects on our business.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 coronavirus could adversely impact our business, including several key activities that are critical to our success.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market prices for our common shares are volatile and will fluctuate.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our
technologies or Product Candidates.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately
report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result,
the value of our common shares.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the audit of our financial statements as of and for the years ended June 30, 2022 and 2021, material weaknesses in our
internal control over financial reporting were identified and we may identify additional material weaknesses in the future.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred, and will continue to incur, increased costs as a result of operating as a public company, and our management has been
required, and will continue to be required, to devote substantial time to new compliance initiatives.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred significant losses since our inception, we anticipate that we will continue to incur losses in the future, we currently
have limited commercial revenue and we may never become profitable</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become subject to claims or become involved in lawsuits related to intellectual property.</span></td>
</tr></table><div>



</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely heavily on contract manufacturers over whom we have limited control and our existing collaboration agreements and any that we may
enter into in the future may not be successful.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent upon our key personnel to achieve our business objectives.</span></td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insurance may be insufficient to cover losses that may occur as a result of our operations.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common shares involves a high degree of risk. You should carefully consider each of the following risks, together with all other
information set forth in this Annual Form on 10-K, including the consolidated financial statements and the related notes, before making
a decision to buy our common shares. If any of the following risks actually occurs, our business could be harmed. In that case, the trading
price of our common shares could decline, and you may lose all or part of your investment.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Business and Industry</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
IntegraSyn<sup>TM</sup> manufacturing approach may prove unsuccessful in achieving yields and/or cost levels required to be economically
competitive with alternative methods of manufacturing.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the early-stage of development of the IntegraSyn<sup>TM</sup> program and the risks inherent in research and development, it is too early
to project the commercial viability of cannabinoids produced via this process. Potential negative outcomes from this program include
but are not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
technology fails to produce sufficient quantities of cannabinoids or ones for which we or others have a need; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost structure of the technology is such that it is not commercially competitive with alternate methods of cannabinoid manufacturing
leading to the technology having no value proposition nor incremental value to the Company.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
prospects depend on the success of our Product Candidates which are at early-stages of development with a statistically high probability
of failure.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the early-stage of development, we can make no assurance that our research and development programs will result in regulatory approval
or commercially viable products. To achieve profitable operations, we, alone or with others, must successfully develop, gain regulatory
approval, and market our future products. We currently have no products that have been approved by the FDA, HC, or any similar regulatory
authority. To obtain regulatory approvals for our Product Candidates being developed and to achieve commercial success, clinical trials
must demonstrate that the Product Candidates are safe for human use and that they demonstrate efficacy. We have no products or technologies
which are currently in human clinical trials. Additionally, we have no products for commercial sale or licensed for commercial sale,
nor do we expect to have any such products for the next several years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
potential pharmaceuticals products never reach the stage of clinical testing and even those that do have only a small chance of successfully
completing clinical development and gaining regulatory approval. Our Product Candidates may fail for a number of reasons, including,
but not limited to, being unsafe for human use or due to the failure to provide therapeutic benefits equal to or better than the standard
of treatment at the time of testing. Positive results of early preclinical research may not be indicative of the results that will be
obtained in later stages of preclinical or clinical research. Similarly, positive results from early-stage clinical trials may not be
indicative of favorable outcomes in later-stage clinical trials. We can make no assurance that any future studies, if undertaken, will
yield favorable results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
early-stage of our product development makes it particularly uncertain whether any of our product development efforts will prove to be
successful and meet applicable regulatory requirements, and whether any of our Product Candidates will receive the requisite regulatory
approvals, be capable of being manufactured at a reasonable cost or be successfully marketed. If we are successful in developing our
current and future Product Candidates into approved products, we will still experience many potential obstacles, such as the need to
develop or obtain manufacturing, marketing and distribution capabilities. If we are unable to successfully commercialize any of our products,
our financial condition and results of operations may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if our Product Candidates advance through preclinical studies and clinical trials, we may experience difficulties in managing our growth
and expanding our operations.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited resources to carry out objectives for our current and future preclinical studies and clinical trials. Since our inception
as a pharmaceutical company in October 2014, we have conducted numerous preclinical experiments and are currently conducting early-stage
clinical trials, which is a time-consuming, expensive and uncertain process. In addition, while we have experienced management and expect
to contract out many of the activities related to conducting these programs, we are a small company with less than 20 employees and,
therefore, have limited internal resources both to conduct preclinical studies and clinical trials and to monitor third-party providers.
As our Product Candidates advance through preclinical studies and clinical trials, we will need to expand our development, regulatory
and manufacturing operations, either by expanding our internal capabilities or contracting with other organizations to provide these
capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and
other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial
and management controls, reporting systems and procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we have difficulty enrolling patients in clinical trials, the completion of the trials may be delayed or cancelled.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our Product Candidates advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical
trials, we will need to enroll an increasing number of patients that meet the eligibility criteria for those trials. The factors that
affect our ability to enroll patients are largely uncontrollable and include, but are not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
and nature of the patient population;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inclusion
and exclusion criteria for the trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
of the study protocol;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
with other companies for clinical sites or patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
perceived risks and benefits of the product candidate under study;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
patient referral practices of physicians; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number, availability, location and accessibility of clinical trial sites.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing factors, we may have difficulty enrolling or maintaining the enrollment of patients in any clinical trials
conducted for our products, which may result in the delay or cancellation of such trials. The delay or cancellation of any clinical trials
could shorten any periods during which we may have the exclusive right to commercialize our Product Candidates or allow our competitors
to bring products to market before us, which would impair our ability to successfully commercialize our Product Candidates and may harm
our financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
clinical trials of our Product Candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do
not otherwise produce positive results, we would incur additional costs or experience delays in completing, or ultimately be unable to
complete, the development and commercialization of our Product Candidates.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from regulatory authorities for the sale of our Product Candidates, we must conduct preclinical studies
in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of the Product Candidates. Clinical testing
is expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of preclinical
studies and early clinical trials may not predict the success of later clinical trials and interim results of a clinical trial do not
necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier
trials. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory
approval to market any of our Product Candidates in any jurisdiction. A product candidate may fail for safety or efficacy reasons at
any stage of the testing process. A major risk we face is the possibility that none of our Product Candidates under development will
successfully gain market approval from the FDA or other regulatory authorities, resulting in us being unable to derive any commercial
revenue from them after investing significant amounts of capital in multiple stages of preclinical and clinical testing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we experience delays in clinical testing, we will be delayed in commercializing our Product Candidates, and our business may be substantially
harmed.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or
at all. Our product development costs will increase if we experience delays in clinical testing. Significant clinical trial delays could
shorten any periods during which we may have the exclusive right to commercialize our Product Candidates or allow our competitors to
bring products to market before us, which would impair our ability to successfully commercialize our Product Candidates and may harm
our financial condition, results of operations and prospects. The commencement and completion of clinical trials for our products may
be delayed for a number of reasons, including delays related, but not limited, to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
by regulatory authorities to grant permission to proceed or placing the clinical trial on hold;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">import/export
and research restrictions for cannabinoid-based pharmaceuticals may delay or prevent clinical trials in various geographical jurisdictions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
failing to enroll or remain in our trials at the rate we expect;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of our contract
manufacturers to comply with current good manufacturing practice, or &#8220;cGMP&#8221;, requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
changes to our manufacturing process that may be necessary or desired;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
or failure to obtain clinical supply from contract manufacturers of our products necessary to conduct clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
Candidates demonstrating a lack of safety or efficacy during clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
choosing an alternative treatment for the indications for which we are developing any of our Product Candidates or participating in competing
clinical trials and/or scheduling conflicts with participating clinicians;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports
of clinical testing on similar technologies and products raising safety and/or efficacy concerns;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
investigators not performing our clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent
with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely
or accurate manner;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
of our CROs, to satisfy their contractual duties or meet expected deadlines;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections
of clinical trial sites by regulatory authorities or Institutional Review Boards, or &#8220;IRBs&#8221;, or ethics committees finding
regulatory violations that require us to undertake corrective action, resulting in suspension or termination of one or more sites or
the imposition of a clinical hold on the entire study;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
or more IRBs or ethics committees rejecting, suspending or terminating the study at an investigational site, precluding enrollment of
additional subjects, or withdrawing its approval of the trial; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
to reach agreement on acceptable terms with prospective clinical trial sites.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product development costs will increase if we experience delays in testing or approval or if we need to perform more or larger clinical
trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend study protocols
to reflect these changes. Amendments may require us to resubmit our study protocols to regulatory authorities or IRBs or ethics committees
for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development
costs may have a material adverse effect on our business, financial condition and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Negative
results from clinical trials or studies of others and adverse safety events involving the targets of our products may have an adverse
impact on our future commercialization efforts.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, studies or clinical trials on various aspects of pharmaceutical products are conducted by academic researchers, competitors
or others. The results of these studies or trials, when published, may have a significant effect on the market for the pharmaceutical
product that is the subject of the study. The publication of negative results of studies or clinical trials or adverse safety events
related to our Product Candidates, or the therapeutic areas in which our Product Candidates compete, could adversely affect the price
of our common shares and our ability to finance future development of our Product Candidates, and our business and financial results
could be materially and adversely affected.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
intend to expend our limited resources to pursue our Product Candidates for certain indications and may fail to capitalize on other Product
Candidates or other indications for our Product Candidates that may be more profitable or for which there is a greater likelihood of
success.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we are focusing on research programs relating to our Product Candidates for certain
indications, primarily for the treatment of EB, which concentrates the risk of product failure in the event our Product Candidates prove
to be unsafe or ineffective or inadequate for clinical development or commercialization. As a result, we may forego or delay pursuit
of opportunities with other Product Candidates or for other indications that could later prove to have greater commercial potential.
We may also deem it advisable to refocus our clinical development programs based on clinical trial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
regulatory approval processes of the FDA, HC, the EMA and other comparable foreign regulatory authorities are lengthy, time-consuming
and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our Product Candidates, our business
will be substantially harmed.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market our Product Candidates in any jurisdiction until we receive formal approval from the appropriate regulatory
authorities. For example, prior to submitting an NDA to the FDA or an MAA to the EMA for approval of our Product Candidates, we will
need to complete our preclinical studies and clinical trials. Successfully completing our clinical program and obtaining approval of
an application seeking commercialization approval is a complex, lengthy, expensive and uncertain process, and the regulatory authorities
may delay, limit or deny approval of our Product Candidates for many reasons, including, among others, because:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may not be able to demonstrate that our Product Candidates are safe and effective in treating patients to the satisfaction of the regulatory
authorities such as the FDA, HC or EMA;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
results of our clinical trials may not meet the level of statistical or clinical significance required by the regulatory authorities
for marketing approval;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
regulatory authorities may require that we conduct additional clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
regulatory authorities or other applicable foreign regulatory authorities may not approve the formulation, labeling or specifications
of our Product Candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
contract manufacturing organizations and other contractors that we may retain to conduct our clinical trials may take actions outside
of our control that materially adversely impact our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
regulatory authorities may find the data from clinical studies and clinical trials insufficient to demonstrate that our Product Candidates
are safe and effective for their proposed indications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
regulatory authorities may disagree with our interpretation of data from our preclinical studies and clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
regulatory authorities may not accept data generated at our clinical trial sites or may disagree with us over whether to accept efficacy
results from clinical trial sites outside the United States, Canada or outside the European Union, as applicable, where the standard
of care is potentially different from that in the United States, Canada or in the European Union, as applicable;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
our applications are submitted to the regulatory authorities, the regulatory authorities may have difficulties scheduling the necessary
review meetings in a timely manner, may recommend against approval of our application or may recommend or require, as a condition of
approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA may require development of a Risk Evaluation and Mitigation Strategy which would use risk minimization strategies to ensure that
the benefits of certain prescription drugs outweigh their risks, as a condition of approval or post-approval, and the EMA may grant only
conditional marketing authorization or impose specific obligations as a condition for marketing authorization, or may require us to conduct
post-authorization safety studies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA, DEA, HC, EMA or other applicable foreign regulatory agencies may not approve the manufacturing processes or facilities of third-party
manufacturers with which we contract or DEA or other applicable foreign regulatory agency quotas may limit the quantities of controlled
substances available to our manufacturers; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA, HC, EMA or other applicable foreign regulatory agencies may change their approval policies or adopt new regulations.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our activities are potentially subject to additional regulation by various federal, state and local authorities in
addition to the FDA, including, among others, the Centers for Medicare and Medicaid Services, other divisions of the United States Department
of Health and Human Services, or &#8220;HHS&#8221;, (for example, the Office of Inspector General), the Department of Justice, or &#8220;DOJ&#8221;,
and individual United States Attorney offices within the DOJ, and state and local governments. Because of the breadth of these laws and
the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject
to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described
above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil
monetary penalties, damages, fines, imprisonment, exclusion from participation in government programs, injunctions, recall or seizure
of products, total or partial suspension of production, denial or withdrawal of pre marketing product approvals, private &#8220;qui tam&#8221;
actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including
government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate
our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to
similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance,
anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare
professionals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors, many of which are beyond our control, could increase development costs, jeopardize our ability to obtain regulatory
approval for and successfully market our Product Candidates and generate product revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
intend to conduct clinical trials for our Product Candidates in several international jurisdictions, and acceptance by all regulatory
authorities for such &#8220;international&#8221; data is not certain.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to conduct clinical trials for our Product Candidates both inside and outside the United States. To date, all of our clinical
development has been conducted outside of the United States. Ultimately, we plan to submit NDAs for our Product Candidates to the FDA
and other regulatory authorities upon completion of all requisite clinical trials. As an example, although the FDA may accept data from
clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example,
the clinical trial must be conducted in accordance with FDA regulations relating governing human subject protection and the conduct of
clinical trials, which are referred to as &#8220;Good Clinical Practice&#8221;, or &#8220;GCP&#8221; requirements and the FDA must be
able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. Where data from
foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve
the application on the basis of foreign data alone unless those data are considered applicable to the U.S. patient population and U.S.
medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data is considered valid
without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to
validate the data through an on-site inspection or other appropriate means. In addition, such clinical trials would be subject to the
applicable local laws of the foreign jurisdictions where the clinical trials are conducted. There can be no assurance the FDA or any
other regulatory authorities will accept data from clinical trials conducted outside of the United States or other international jurisdictions.
If the FDA or any other regulatory authorities does not accept any such data, it would likely result in the need for additional clinical
trials, which would be costly and time-consuming and delay aspects of our development plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting
international clinical trials include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
regulatory requirements that could burden or limit our ability to conduct our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative
burdens of conducting clinical trials under multiple foreign regulatory schema;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
currency fluctuations which could negatively impact our financial condition since certain payments are paid in local currencies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing,
customs, shipment and storage requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cultural
differences in medical practice and clinical research; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminished
    protection of intellectual property in some countries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates contain compounds that may be classified as &#8220;controlled substances&#8221;, the use of which may generate public
controversy and restrict their development or commercialization.</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug has a potential for abuse, the NDA or other regulatory submission must include a description and analysis of studies or information
related to abuse of the drug, including a proposal for scheduling (for example, in the U.S. under the federal Controlled Substances Act,
or &#8220;CSA&#8221;). A description of any studies related to overdosage is also required, including information on dialysis, antidotes,
or other treatments, if known. While we believe there would be relatively minimal abuse potential with our Product Candidates given the
low drug concentration and topical route of administration, we could be incorrect or they may be perceived as having the potential for
substance abuse. In either case, there may be a negative effect on our ability to successfully develop or commercialize our Product Candidates.
Since our Product Candidates contain purified substances that are chemically identical to those occurring in nature, they may, therefore,
be classified as &#8220;controlled substances&#8221;, and their regulatory approval may generate public controversy. Political and social
pressures and adverse publicity could lead to delays in approval of, and increased expenses for, our Product Candidates. These pressures
could also limit or restrict the introduction and marketing of our Product Candidates. Despite that fact that our APIs, which are the
ingredients that give medicines their effects, are synthetically made and, therefore, we have no interaction with the Cannabis plant,
adverse publicity from Cannabis misuse or adverse side effects from Cannabis or other cannabinoid products may adversely affect the commercial
success or market penetration achievable for our Product Candidates. The nature of our business attracts a high level of public and media
interest, and in the event of any resultant adverse publicity, our reputation may be harmed. Furthermore, if our Product Candidates are
classified as &#8220;controlled substances&#8221;, they may be subject to import/export and research restrictions that could delay or
prevent the development of our products in various geographical jurisdictions. The successful commercialization of our Product Candidates
may require permits or approvals from regulatory bodies, such as the DEA, that regulate controlled substances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
restrictions, product shipment delays or prohibitions could have a material adverse effect on our business, results of operations and
financial condition.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Research
on and the shipment, import and export of our Product Candidates and the API used in our Product Candidates will require research permits,
import and export licenses by many different authorities. For instance, in the United States, the FDA, U.S. Customs and Border Protection,
and the DEA; in Canada, the Canada Border Services Agency, and HC; in Europe, the EMA and the European Commission; in Australia and New
Zealand, the Australian Customs and Border Protection Service, the Therapeutic Goods Administration, the New Zealand Medicines and Medical
Device Safety Authority and the New Zealand Customs Service; and in other countries, similar regulatory authorities, regulate the research
on and import and export of pharmaceutical products that contain controlled substances. Specifically, the import and export process requires
the issuance of import and export licenses by the relevant controlled substance authority in both the importing and exporting country.
We may not be granted, or if granted, maintain, such licenses from the authorities in certain countries. Even if we obtain the relevant
licenses, shipments of API and our Product Candidates may be held up in transit, which could cause significant delays and may lead to
product batches being stored outside required temperature ranges. Inappropriate storage may damage the product shipment resulting in
delays in clinical trials or, upon commercialization, a partial or total loss of revenue from one or more shipments of API or our Product
Candidates. Once shipment is complete, we or the research contractors we are working with may also suffer further delays or restrictions
as a result of regulations governing research on cannabinoids. A delay in a clinical trial or, upon commercialization, a partial or total
loss of revenue from one or more shipments of API or our Product Candidates could have a material adverse effect on our business, results
of operations and financial condition. The aforementioned examples and lists of various authorities that may currently, or in the future,
affect our ability to conduct research on or import or export our Product Candidates and/or API, should not be construed as exhaustive
or comprehensive in any way.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Healthcare
legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty
and cost for us to obtain marketing approval of and commercialize our Product Candidates.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Particularly
in the United States but also in other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our Product Candidates, restrict or regulate post-approval
activities or affect our ability to profitably sell any Product Candidates for which we obtain marketing approval. One such regulation
is the U.S. federal Patient Protection and Affordable Care Act (P.L. 111-148), or &#8220;PPACA&#8221;, also referred to as the &#8220;Affordable
Care Act&#8221; or &#8220;ACA&#8221;, was signed March 23, 2010, as amended by the Health Care and Education Reconciliation Act, signed
March 31, 2010. The act contains many provisions, with various effective dates. Provisions included in the ACA are intended to expand
access to insurance, increase consumer protections, emphasize prevention and wellness, improve quality and system performance, expand
the health workforce, and curb rising health care costs. The ACA aims to extend health insurance coverage to about 32 million uninsured
Americans by expanding both private and public insurance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may
result in more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive
for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other
healthcare reforms may compromise our ability to generate revenue, attain profitability or commercialize our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increased
scrutiny on drug pricing or changes in pricing regulations could restrict the amount that we are able to charge for our Product Candidates,
which could adversely affect our revenue and results of operations.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
pricing by pharmaceutical companies is currently under increased scrutiny and is expected to continue to be the subject of intense political
and public debate in the United States and other jurisdictions. Specifically, there have been several recent U.S. Congressional inquiries
and hearings with respect to pharmaceutical drug pricing practices, including in connection with the investigation of specific price
increases by several pharmaceutical companies. Additionally, several states have recently passed laws designed to, among other things,
bring more transparency to drug pricing, and other states may pursue similar initiatives in the future. We cannot predict the extent
to which our business may be affected by these or other potential future legislative or regulatory developments. However, increased scrutiny
on drug pricing, negative publicity related to the pricing of pharmaceutical drugs generally, or changes in pricing regulations could
restrict the amount that we are able to charge for our Product Candidates, which could have a material adverse effect on our revenue
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if we are able to commercialize our Product Candidates, they may not receive coverage and adequate reimbursement from third-party payors,
which could harm our business.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability of reimbursement by governmental and private payors is essential for most patients to be able to afford their treatments.
Sales of our Product Candidates, if approved, will depend substantially on the extent to which the costs of these Product Candidates
will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by
government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not
available, or is available only to limited levels, we may not be able to successfully commercialize our Product Candidates. Even if coverage
is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize
a sufficient return on our investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Modernization Act, established the Medicare Part D program and provided authority for limiting the number
of drugs that will be covered in any therapeutic class thereunder. The Medicare Modernization Act, including its cost reduction initiatives,
could decrease the coverage available for any of our approved products. Furthermore, private payors often follow Medicare in setting
their own coverage policies. Therefore, any reduction in coverage that results from the Medicare Modernization Act may result in a similar
reduction from private payors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or
&#8220;CMS&#8221;, an agency within the HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed
under Medicare. Private payors tend to follow CMS to a substantial degree.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intended use of a drug product by a physician can also affect pricing. For example, CMS could initiate a National Coverage Determination
administrative procedure, by which the agency determines which uses of a therapeutic product would and would not be reimbursable under
Medicare. This determination process can be lengthy, thereby creating a long period during which the future reimbursement for a particular
product may be uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, particularly in EU Member States, the pricing of prescription drugs is subject to governmental control. In these countries,
pricing negotiations or the successful completion of Health Technology Assessment, or &#8220;HTA&#8221;, procedures with governmental
authorities can take considerable time after receipt of marketing authorization for a product. In addition, there can be considerable
pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Certain
countries allow companies to fix their own prices for medicines but monitor and control company profits. Political, economic and regulatory
developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained.
Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU member
states, can further reduce net realized prices. In some countries, we or our collaborators may be required to conduct a clinical trial
or other studies that compare the cost-effectiveness of our Product Candidates to other available therapies in order to obtain or maintain
reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the
prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved
for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition,
results of operations or prospects could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, federal exclusion or
debarment, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages,
reputational harm and diminished profits and future earnings.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third-party payors play a primary role in the recommendation and prescription of any Product Candidates for
which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable
fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we market, sell and distribute our products for which we obtain marketing approval. As a pharmaceutical company, even though
we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain
federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable
to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate
include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
U.S. federal healthcare Anti-Kickback Statute impacts our marketing practices, educational programs, pricing policies and relationships
with healthcare providers or other entities, by prohibiting, among other things, persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral
of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal
healthcare program such as Medicare and Medicaid;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
civil and criminal false claims laws and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower
or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false
or fraudulent claims for payment of government funds (including through reimbursement by Medicare or Medicaid or other federal health
care programs), which has been applied to impermissible promotion of pharmaceutical products for off-label uses, or making a false statement
or record to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
U.S. Health Insurance Portability and Accountability Act, or &#8220;HIPPA&#8221;, as amended by the Health Information Technology for
Economic and Clinical Health Act, or &#8220;HITECH Act&#8221;, among other things, imposes criminal and civil liability for executing
a scheme to defraud any healthcare benefit program and also prohibits knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing
or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery
of or payment for healthcare benefits, items or services;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
U.S. federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, requires applicable manufacturers of covered
drugs, devices, biologics and medical supplies to report annually to HHS information related to payments and other transfers of value
to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state laws and
    regulations, such as state anti-kickback laws, false claims laws and privacy and security of health information laws, may apply to
    sales or marketing arrangements, claims involving healthcare items or services reimbursed by non-governmental third-party payors,
    including private insurers, or health information; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain state laws require
    pharmaceutical companies to adopt codes of conduct consistent with the pharmaceutical industry&#8217;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government; restrict certain marketing-related activities including
    the provision of gifts, meals, or other items to certain health care providers; and/or require drug manufacturers to report information
    related to payments and other transfers of value to physicians and certain other healthcare providers or marketing expenditures.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comparable
laws and regulations exist in the countries within the European Economic Area, or &#8220;EEA&#8221;. Although such laws are partially
based upon European Union, or &#8220;EU&#8221;, law, they may vary from country to country. Healthcare specific, as well as general EU
and national laws, regulations and industry codes constrain, for example, our interactions with government officials and healthcare professionals,
and the collection and processing of personal health data. Non-compliance with any of these laws or regulations could lead to criminal
or civil liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such
as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or
entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal,
civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Failure
to comply with the U.S. Foreign Corrupt Practices Act, or &#8220;FCPA&#8221;, the Canadian Corruption of Foreign Public Officials Act,
or &#8220;CFPOA&#8221;, and other global anti-corruption and anti-bribery laws could subject us to penalties and other adverse consequences</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FCPA and the CFPOA, as well as any other applicable domestic or foreign anti-corruption or anti-bribery laws to which we are or may become
subject generally prohibit corporations and individuals from engaging in certain activities to obtain or retain business or to influence
a person working in an official capacity and requires companies to maintain accurate books and records and internal controls, including
at foreign-controlled subsidiaries. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government
official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise
influence a person working in an official capacity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with these anti-corruption laws and anti-bribery laws may be expensive and difficult, particularly in countries in which corruption is
a recognized problem. In addition, these laws present particular challenges in the pharmaceutical industry, because, in many countries,
hospitals are operated by the government, and physicians and other hospital employees are considered to be foreign officials. Certain
payments by other companies to hospitals in connection with clinical trials and other work have been deemed to be improper payments to
governmental officials and have led to FCPA enforcement actions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors,
licensees or agents. We are currently working to get policies and processes in place to monitor compliance with the FCPA and CFPOA. We
can make no assurance that they will not engage in prohibited conduct, and we may be held liable for their acts under applicable anti-corruption
and anti-bribery laws. Noncompliance with these laws could subject us to investigations, sanctions, settlements, prosecution, other enforcement
actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment
from contracting with certain persons, the loss of export privileges, whistleblower complaints, reputational harm, adverse media coverage,
and other collateral consequences. Any investigations, actions or sanctions or other previously mentioned harm could have a material
negative effect on our business, operating results and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
federal legislation and actions by state and local governments may permit reimportation of drugs from/to foreign countries where the
drugs are sold at lower prices than in the country of origination, which could materially adversely affect our business and financial
condition.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face competition for our Product Candidates, if approved, from cheaper generics and/or cannabinoid therapies sourced from foreign
countries that have placed price controls on pharmaceutical products. This is referred to as parallel importation. For instance, the
Medicare Modernization Act contains provisions that may change U.S. importation laws and expand pharmacists&#8217; and wholesalers&#8217;
ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls.
These changes to U.S. importation laws will not take effect unless and until the Secretary of HHS certifies that the changes will pose
no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers.
The Secretary of HHS has so far declined to approve a reimportation plan. Proponents of drug reimportation, including certain state legislatures,
may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing
the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop, including our Product
Candidates, and adversely affect our future revenues and prospects for profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are dependent upon our key personnel to achieve our business objectives.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on key personnel, the loss of any of whom could harm our business. Our future performance and development will depend to a significant
extent on the efforts and abilities of its executive officers, key employees, and consultants. The loss of the services of one or more
of these individuals could harm our business. Our success will depend largely on our continuing ability to attract, develop and retain
skilled employees and consultants in our business. Because of the specialized scientific and managerial nature of our business, we rely
heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. The competition for qualified
personnel in our field is intense. Due to this intense competition, we may be unable to continue to attract and retain qualified personnel
necessary for the development of our business or to recruit suitable replacement personnel. Any delay in replacing such persons, or an
inability to replace them with persons of similar expertise, would have a material adverse effect on our business, financial condition
and results of operations.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could subject us to significant liability and harm our reputation.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations of domestic or foreign regulatory authorities. In addition, misconduct by employees could include intentional failures to
comply with certain development standards, to report financial information or data accurately, or to disclose unauthorized activities
to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could
result in regulatory sanctions and serious harm to our reputation. While prohibited, it is not always possible to identify and deter
employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant
fines or other sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
insurance may be insufficient to cover losses that may occur as a result of our operations.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently maintain directors&#8217; and officers&#8217; liability insurance, clinical trial insurance and property and general liability
insurance and intend in the future to obtain shipping and storage insurance for Product Candidates. This insurance may not remain available
to us or be obtainable by us at commercially reasonable rates, and the amount of our coverage may not be adequate to cover any liability
we incur. Future increases in insurance costs, coupled with the increase in deductibles, will result in higher operating costs and increased
risk. If we were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, or
if we were to incur such liability at a time when we were not able to obtain liability insurance, our business, results of operations
and financial condition could be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>There
may be changes in laws, regulations and guidelines which are detrimental to our business.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to a variety of laws, regulations and guidelines relating to pharmacology, cannabinoids and drug delivery, as
well as laws and regulations relating to health and safety, the conduct of operations, and the protection of the environment. While,
to the knowledge of our management, we are currently in compliance with all such laws, changes to such laws, regulations and guidelines
due to matters beyond our control may cause adverse effects to our operations and financial condition. These changes may require us to
incur substantial costs associated with legal and compliance fees and ultimately require us to alter our business plan. In addition,
if the governments of Canada or the United States were to enact or amend laws relating to our industry, it may decrease the size of,
or eliminate entirely, the market for our Product Candidates, may introduce significant new competition into the market and may otherwise
potentially materially and adversely affect our business, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
affected.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research and development that we carry out either directly or through third-parties involves, and may in the future involve, the use
of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety
procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations,
the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable
for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and
regulations and fire and building codes. Although we maintain workers&#8217; compensation insurance as prescribed by the Province of
British Columbia to cover us for costs and expenses we may incur due to injuries to our employees, this insurance may not provide adequate
coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted
against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur
substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we may collect and store sensitive data, including intellectual property, data from preclinical
studies, clinical trial data, our proprietary business information and that of our customers, suppliers and business partners, and personally
identifiable information of our customers, clinical trial subjects and employees, in our data centers and on our networks. The secure
processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information
technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions.
Although to our knowledge we have not experienced any such material security breach to date, any such breach could compromise our networks
and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of
information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory
penalties, disrupt our operations, damage to our ability to obtain patent protection for our Product Candidates, damage to our reputation,
and cause a loss of confidence in our products and our ability to conduct clinical trials, which could adversely affect our business
and reputation and lead to delays in gaining regulatory approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
expect to face intense competition, often from companies with greater resources and experience than we have.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is highly competitive and subject to rapid change. The industry continues to expand and evolve as an increasing
number of competitors and potential competitors enter the market. Many of these competitors and potential competitors have substantially
greater financial, technological, managerial and research and development resources and experience than we have. Some of these competitors
and potential competitors have more experience than we have in the development of pharmaceutical products, including validation procedures
and regulatory matters. Other companies researching in the same disease areas may develop products that are competitive or superior to
our Product Candidates. Other companies working in cannabinoid research may develop products targeting the same diseases that we are
focused on that are competitive or superior to our Product Candidates. In addition, there are non-FDA approved Cannabis / cannabinoid
preparations being made available from companies in the so-called &#8220;medical marijuana&#8221; industry, which may be competitive
to our products. If we are unable to compete successfully, our commercial opportunities will be reduced and our business, results of
operations and financial conditions may be materially harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we receive regulatory approvals, we intend to market our Product Candidates in multiple jurisdictions where we have limited or no operating
experience and may be subject to increased business and economic risks that could affect our financial results.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we receive regulatory approvals, we may plan to market our Product Candidates in jurisdictions where we have limited or no experience
in marketing, developing and distributing our products. Certain markets have substantial legal and regulatory complexities that we may
not have experience navigating. We are subject to a variety of risks inherent in doing business internationally, including risks related
to the legal and regulatory environment in non-U.S. jurisdictions, including with respect to privacy and data security, trade control
laws and unexpected changes in laws, regulatory requirements and enforcement, as well as risks related to fluctuations in currency exchange
rates and political, social and economic instability in foreign countries. If we are unable to manage our international operations successfully,
our financial results could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controlled
substance legislation may differ in other jurisdictions and could restrict our ability to market our products internationally, which
would result in increased business and economic risks that could affect our financial results.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled
substance legislation may differ in other jurisdictions and could restrict our ability to market our products internationally. Most countries
are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic control of narcotic substances,
including Cannabis extracts. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle to
our obtaining marketing approval for Product Candidates in those countries. These countries may not be willing or able to amend or otherwise
modify their laws and regulations to permit our Product Candidates to be marketed or achieving such amendments to the laws and regulations
may take a prolonged period of time. We would be unable to market our Product Candidates in countries with such obstacles in the near
future or perhaps at all without modification to laws and regulations.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
liability lawsuits against us could cause us to incur substantial liabilities.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of our Product Candidates in clinical trials and the sale of our Product Candidates, if approved, exposes us to the risk of product
liability claims. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise
coming into contact with our Product Candidates. For example, we may be sued if any product we develop allegedly causes injury or is
alleged to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include
allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result
of interactions with alcohol or other drugs, negligence, strict liability, and a breach of warranties. Claims could also be asserted
under local jurisdiction consumer protection acts. If we become subject to product liability claims and cannot successfully defend ourselves
against them, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims
may result in, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
of patients from our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
monetary awards to patients or other claimants;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
demand for our Product Candidates following marketing approval, if obtained;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
to our reputation and exposure to adverse publicity;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
FDA warnings on product labels or increased warnings imposed by the EMA or other regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
costs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distraction
of management&#8217;s attention from our primary business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
of revenue; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
inability to successfully commercialize our Product Candidates, if approved.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current clinical trial liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover,
insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable
cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for our Product Candidates,
we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability
insurance on commercially reasonable terms or in adequate amounts. Large judgments have been awarded in class action lawsuits based on
drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our
favor, could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or
series of claims brought against us could cause our share price to decline and, if we are unsuccessful in defending such a claim or claims
and the resulting judgments exceed our insurance coverage, our financial condition, results of operations, business and prospects could
be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Failure
to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or
data corruption could significantly disrupt our operations and adversely affect our business and operating results.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on information technology, telephone networks and systems, including the internet, to process and transmit sensitive electronic
information and to manage or support a variety of business processes and activities. We use enterprise information technology systems
to record, process and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory,
financial reporting, legal and tax requirements. Despite the implementation of security measures, our information technology systems,
and those of our third-party contractors and consultants, are vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction,
loss of data privacy or other significant disruption. Any such successful attacks could result in the theft of intellectual property
or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations.
Cyber-attacks are becoming more sophisticated and frequent, and our systems could be the target of malware and other cyber-attacks. We
have invested in our systems and the protection of our data to reduce the risk of an intrusion or interruption, and we monitor our systems
on an ongoing basis for any current or potential threats. Nonetheless, our computer systems are subject to penetration and our data protection
measures may not prevent unauthorized access. We can give no assurances that these measures and efforts will prevent interruptions or
breakdowns. If we are unable to detect or prevent a security breach or cyber-attack or other disruption from occurring, then we could
incur losses or damage to our data, or inappropriate disclosure of our confidential information or that of others; and we could sustain
damage to our reputation, suffer disruptions to our research and development and incur increased operating costs including increased
cybersecurity and other insurance premiums, costs to mitigate any damage caused and protect against future damage, and be exposed to
additional regulatory scrutiny or penalties and to civil litigation and possible financial liability. For instance, the loss of preclinical
or clinical data could result in delays in our development and regulatory filing efforts and significantly increase our costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against
us, and adversely impact our operating results.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to various domestic and international data protection laws and regulations (i.e., laws and regulations that address privacy
and data security). The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been
an increasing focus on privacy and data security issues. Numerous laws, including data breach notification laws, health information privacy
laws and consumer protection laws, govern the collection, use and disclosure of health-related and other personal information. In addition,
we may obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are subject to privacy
and security requirements under HIPAA regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU
Member States, Australia and other countries have also adopted data protection laws and regulations, which impose significant compliance
obligations. For example, the collection and use of personal data in the EU is governed by the provisions of the General Data Protection
Regulation, or &#8220;GDPR&#8221;. The GDPR and the national implementing legislation of the EU Member States impose strict obligations
and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse
event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates,
the information provided to the individuals, the rights of individuals to control personal data and the security and confidentiality
of the personal data. In addition, the Australian Privacy Act 1988 (Cth), and other laws in the states and territories in Australia where
we conduct certain of our clinical trials, apply similar restrictions on our ability to collect, analyze and transfer medical records
and other patient data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
claim or series of claims brought against us alleging a failure to comply with these laws, or changes in the way in which these laws
are implemented, could lead to government enforcement actions and significant penalties against us, and adversely impact our operating
results and could cause our share price to decline and, if we are unsuccessful in defending such a claim or claims and the resulting
judgments exceed our insurance coverage, our financial condition, results of operations, business and prospects could be materially adversely
affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
COVID-19 coronavirus could adversely impact our business, including several key activities that are critical to our success.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global outbreak of COVID-19 continues to rapidly evolve. As a result, businesses have closed and limits have been placed on travel. The
extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, such as the ultimate impact of the disease on specific geographies, the duration of the outbreak, travel restrictions
and social distancing in the United States, Canada and other countries, business closures or business disruptions and the effectiveness
of actions taken in the United States, Canada and other countries to contain and treat the disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
spread of COVID-19 throughout the world has also created global economic uncertainty, which may cause partners, suppliers and potential
customers to closely monitor their costs and reduce their spending budget. Any of the foregoing could materially adversely affect our
research and development activities, clinical trials, supply chain, financial condition and cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the COVID-19 outbreak continues to spread, we may need to limit operations or implement other limitations on our activities. There is
a risk that countries or regions outside the United States and Canada may be less effective at vaccinations and containing COVID-19,
in which case the risks described herein could be elevated significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Securities</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
market prices for our common shares are volatile and will fluctuate.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price for our common shares may be volatile and subject to wide fluctuations in response to numerous factors, many of which are
beyond our control, including the following: (i) actual or anticipated fluctuations in our quarterly financial results; (ii) recommendations
by securities research analysts; (iii) changes in the economic performance or market valuations of other issuers that investors deem
comparable to ours; (iv) addition or departure of our executive officers or members of our Board and other key personnel; (v) release
or expiration of lock-up or other transfer restrictions on outstanding common shares; (vi) sales or perceived sales of additional common
shares; (vii) liquidity of the common shares; (viii) significant acquisitions or business combinations, strategic partnerships, joint
ventures or capital commitments by or involving us or our competitors; and (ix) news reports relating to trends, concerns, technological
or competitive developments, regulatory changes and other related issues in our industry or target markets. Financial markets often experience
significant price and volume fluctuations that affect the market prices of equity securities of public entities and that are, in many
cases, unrelated to the operating performance, underlying asset values or prospects of such entities. Accordingly, the market price of
our common shares may decline even if our operating results, underlying asset values or prospects have not changed. Additionally, these
factors, as well as other related factors, may cause decreases in asset values that are deemed to be other than temporary, which may
result in impairment losses. As well, certain institutional investors may base their investment decisions on consideration of our environmental,
governance and social practices and performance against such institutions&#8217; respective investment guidelines and criteria, and failure
to meet such criteria may result in limited or no investment in our common shares by those institutions, which could materially adversely
affect the trading price of our common shares. There can be no assurance that continuing fluctuations in price and volume will not occur.
If such increased levels of volatility and market turmoil continue for a protracted period of time, our operations could be materially
adversely impacted and the trading price of our common shares may be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Raising
additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our
technologies or Product Candidates.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of private and public equity offerings, debt financings, strategic partnerships and
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
existing ownership interests will be diluted and the terms of such financings may include liquidation or other preferences that adversely
affect the rights of existing shareholders. Debt financings may be coupled with an equity component, such as warrants to purchase shares,
which could also result in dilution of our existing shareholders&#8217; ownership. The incurrence of indebtedness would result in increased
fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional
debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely
impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to
default on such indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic partnerships
and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our Product Candidates or grant
licenses on terms that are not favorable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
offerings of debt or equity securities may rank senior to common shares.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we decide to issue debt or equity securities in the future ranking senior to our common shares or otherwise incur additional indebtedness,
it is possible that these securities or indebtedness will be governed by an indenture or other instrument containing covenants restricting
our operating flexibility and limiting our ability to pay dividends to shareholders. Additionally, any convertible or exchangeable securities
that we issue in the future may have rights, preferences and privileges, including with respect to dividends, more favorable than those
of common shares and may result in dilution to shareholders. Because our decision to issue debt or equity securities in any future offering
or otherwise incur indebtedness will depend on market conditions and other factors beyond our control, we cannot predict or estimate
the amount, timing or nature of our future offerings or financings, any of which could reduce the market price of our common shares and
dilute their value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
sales of common shares by officers and directors may negatively impact the market price for our common shares.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to compliance with applicable securities laws, our directors and officers and their affiliates may sell some or all of their common shares
in the future. No prediction can be made as to the effect, if any, such future sales of common shares may have on the market price of
the common shares prevailing from time to time. However, the future sale of a substantial number of common shares by our directors and
officers and their affiliates, or the perception that such sales could occur, could adversely affect prevailing market prices for our
common shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
do not currently pay dividends on our common shares and have no intention to pay dividends on our common shares for the foreseeable future.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
dividends on our common shares have been paid by us to date. We do not intend to declare or pay any cash dividends in the foreseeable
future. Payment of any future dividends will be at the discretion of our Board, after taking into account a multitude of factors appropriate
in the circumstances, including our operating results, financial condition and current and anticipated cash needs. In addition, the terms
of any future debt or credit facility may preclude us from paying any dividends unless certain consents are obtained and certain conditions
are met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are exposed to risks related to currency exchange rates.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently hold the majority of our cash, cash equivalents and short-term investments in U.S. dollars which is our functional currency.
A portion of our current operations is conducted in Canadian dollars. Exchange rate fluctuations between other currencies and the U.S.
dollar create risk in several ways, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">weakening of the Canadian
    dollar may decrease the value of our Canadian dollar cash, cash equivalents and short-term investments;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">weakening of the U.S. dollar
    may increase the cost of operations and products/services sourced in Canada;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exchange rates on non-U.S.
    dollar transactions and cash deposits can distort our financial results; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial product pricing
    and profit margins are affected by currency fluctuations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
as long as we are an &#8220;emerging growth company&#8221; we intend to take advantage of reduced disclosure and governance requirements
applicable to emerging growth companies, which could result in our common shares being less attractive to investors and could make it
more difficult for us to raise capital as and when we need it.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we have taken advantage, and intend to continue to take
advantage, of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404
of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any
golden parachute payments not previously approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
may find our common shares less attractive because we rely on these exemptions, which could contribute to a less active trading market
for our common shares or volatility in our share price. In addition, we may be less attractive to investors and it may be difficult for
us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies in our industry
if they believe that our financial accounting is not as transparent as other companies in our industry. If we are unable to raise additional
capital as and when we need it, our financial condition and results of operations may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of these reporting exemptions until we are no longer an emerging growth company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately
report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result,
the value of our common shares.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required, under Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness
of our internal control over financial reporting. This assessment includes disclosure of any material weaknesses identified by our management
in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control
over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial
statements will not be prevented or detected on a timely basis. Section 404 of the Sarbanes-Oxley Act also generally requires an attestation
from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However,
for as long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of the exemption permitting
us not to comply with the independent registered public accounting firm attestation requirement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compliance with Section 404 will require that we incur substantial accounting expense and expend significant management efforts. We may
not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process,
if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our
internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant
deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial
reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. This
may expose us, including individual executives, to potential liability which could significantly affect our business. If we are unable
to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm
determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins
its audits of internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial
reports, the market price of our common shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC,
or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement
or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file
or submit under the Securities Exchange Act of 1934 is accumulated and communicated to management, recorded, processed, summarized and
reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures
or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more
people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements
or insufficient disclosures due to error or fraud may occur and not be detected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficiencies
in disclosure controls and procedures and internal control over financial reporting could result in a material misstatement in our financial
statements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be adversely affected if there are deficiencies in our disclosure controls and procedures or in our internal controls over financial
reporting. The design and effectiveness of our disclosure controls and procedures and our internal controls over financial reporting
may not prevent all errors, misstatements or misrepresentations. Consistent with other entities in similar stages of development, we
have a limited number of employees currently in the accounting group, limiting our ability to provide for segregation of duties and secondary
review. A lack of resources in the accounting group could lead to material misstatements resulting from undetected errors occurring from
an individual performing primarily all areas of accounting with limited secondary review. Deficiencies in internal controls over financial
reporting which may occur could result in material misstatements of our results of operations, restatements of financial statements,
other required remediations, a decline in the price of our common shares, or otherwise materially adversely affect our business, reputation,
results of operations, financial condition or liquidity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>In
connection with the audit of our financial statements as of and for the years ended June 30, 2022 and 2021, material weaknesses in our
internal control over financial reporting were identified and we may identify additional material weaknesses in the future.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
connection with the preparation and audits of our financial statements as of and for the years ended June 30, 2022 and 2021,
material weaknesses (as defined under the Exchange Act and by the auditing standards of the U.S. Public Company Accounting Oversight
Board, or &#8220;PCAOB&#8221;), were identified in our internal control over financial reporting. A material weakness is a
deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of our annual financial statements will not be prevented or detected on a timely basis. The
identified material weaknesses arose from a lack of resources in our finance function that resulted in material audit adjustments
related to the presentation of pre-funded warrants associated with a financing transaction, and the fair value on the purchase
consideration for the acquisition of BayMedica Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the identified material weaknesses, it is possible that, had we performed a formal assessment of our internal control over financial
reporting or had our independent registered public accounting firm performed an audit of our internal control over financial reporting
in accordance with PCAOB standards, additional control deficiencies may have been identified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have begun taking measures, and plan to continue to take measures, to remediate these material weaknesses. However, the implementation
of these measures may not fully address these material weaknesses in our internal control over financial reporting, and, if so, we would
not be able to conclude that they have been fully remedied. Our failure to correct these material weaknesses or our failure to discover
and address any other control deficiencies could result in inaccuracies in our financial statements and could also impair our ability
to comply with applicable financial reporting requirements and make related regulatory filings on a timely basis. As a result, our business,
financial condition, results of operations and prospects, as well as the trading price of our common shares, may be materially and adversely
affected.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have incurred, and will continue to incur, increased costs as a result of operating as a public company, and our management has been
required, and will continue to be required, to devote substantial time to new compliance initiatives.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we have incurred and are continuing to incur significant legal, accounting and other expenses and these expenses may
increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the
Exchange Act and the rules adopted, and to be adopted, by the SEC. Our management and other personnel devote a substantial amount of
time to these compliance initiatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
these rules and regulations have substantially increased our legal and financial compliance costs and made some activities more time-consuming
and costly. The increased costs have increased our net loss. These rules and regulations may make it more difficult and more expensive
for us to maintain sufficient director&#8217;s and officer&#8217;s liability insurance coverage. We cannot predict or estimate the amount
or timing of additional costs we may continue to incur to respond to these requirements. The ongoing impact of these requirements could
also make it more difficult for us to attract and retain qualified persons to serve on our Board, our Board committees or as executive
officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
sales and issuances of our common shares or rights to purchase common shares pursuant to our equity incentive plan could result in additional
dilution of the percentage ownership of our shareholders and may cause our share price to fall.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may
sell substantial amounts of common shares or securities convertible into or exchangeable for common shares. These future issuances of
common shares or common share-related securities, together with the exercise of outstanding options and any additional shares issued
in connection with acquisitions, if any, may result in material dilution to our investors. Such sales may also result in material dilution
to our existing shareholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common
shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our 2017 Amended and Restated Stock Option Plan, and as amended at our Annual General Meeting in November 2020, our compensation committee
is authorized to grant equity-based incentive awards in the form of options to purchase common shares to our directors, executive officers
and other employees and service providers. As of June 30, 2022, there were 18,163 options to purchase common shares available for future
grant under our stock option plan. Future equity incentive grants under our stock option plan may result in material dilution to our
shareholders and may have an adverse effect on the market price of our common shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Provisions
in our corporate charter documents and certain Canadian laws could delay or deter a change of control.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
in our articles and our by-laws, as well as certain provisions under the BCBCA and applicable Canadian securities laws, may discourage,
delay or prevent a merger, acquisition, tender offer or other change in control of us that some shareholders may consider favorable.
In addition, because our Board is responsible for appointing the members of our management team, these provisions may frustrate or prevent
any attempts by our shareholders to replace or remove our current management by making it more difficult for shareholders to replace
members of our Board. As well, our preferred shares are available for issuance from time to time at the discretion of our Board, without
shareholder approval. Our articles allow our Board, without shareholder approval, to determine the special rights to be attached to our
preferred shares, and such rights may be superior to those of our common shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act in Canada. This legislation
permits the Commissioner of Competition of Canada, or &#8220;Commissioner&#8221;, to review any acquisition of a significant interest
in us. This legislation grants the Commissioner jurisdiction to challenge such an acquisition before the Canadian Competition Tribunal
if the Commissioner believes that it would, or would be likely to, result in a substantial lessening or prevention of competition in
any market in Canada. The Investment Canada Act subjects an acquisition of control of a company by a non-Canadian to government review
if the value of our assets, as calculated pursuant to the legislation, exceeds a threshold amount. A reviewable acquisition may not proceed
unless the relevant minister is satisfied that the investment is likely to result in a net benefit to Canada. Any of the foregoing could
prevent or delay a change of control and may deprive or limit strategic opportunities for our shareholders to sell their shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
securities or industry analysts publish inaccurate or unfavorable research about our business, our share price and trading volume may
decline.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common shares depends in part on the research and reports that securities or industry analysts publish about us
or our business. If one or more of the analysts who cover us downgrade our shares or publish inaccurate or unfavorable research about
our business, our shares price may decline. If one or more of these analysts cease coverage of our company or fail to publish reports
on us regularly, demand for our shares may decrease, which may cause our shares price and trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are incorporated in Canada, with our assets and officers primarily located in Canada, with the result that it may be difficult for investors
to enforce judgments obtained against us or some of our officers.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a company organized and existing under the laws of British Columbia, Canada. Many of our directors and officers and the experts named
in this Annual Form on 10-K are residents of Canada or otherwise reside outside the United States, and all or a substantial portion of
their assets, and a substantial portion of our assets, are located outside the United States. It may be difficult for holders of common
shares who reside in the United States to effect service within the United States upon those directors, officers and experts who are
not residents of the United States. It may also be difficult for holders of securities who reside in the United States to realize in
the United States upon judgments of courts of the United States predicated upon our civil liability and the civil liability of our directors,
officers and experts under the U.S. federal securities laws. Our Canadian counsel has advised us that there is doubt as to the enforceability
in Canada against us or against our directors, officers and experts who are not residents of the United States, in original actions or
in actions for enforcement of judgments of courts of the United States, of liabilities predicated solely upon U.S. federal or state securities
laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversely,
some of our directors and officers reside outside Canada and some of our assets are also located outside Canada. Therefore, it may not
be possible for you to enforce in Canada against our assets or those directors and officers residing outside Canada, judgments obtained
in Canadian courts based upon the civil liability provisions of the Canadian securities laws or other laws of Canada.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Financial Position and Capital Needs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception as a pharmaceutical company in October 2014, we have devoted substantially all of our resources to the development of our
proprietary Product Candidates. We have generated significant operating losses since our inception with an accumulated deficit to June
30, 2022 of approximately $93.5 million. Our comprehensive losses for the fiscal years ended June 30, 2022 and 2021 were approximately
$18.6 million and $9.7 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with
our research and development programs and from general and administrative costs associated with our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses will increase
as we continue the research and development of, and clinical trials for, our Product Candidates. In addition to budgeted expenses, we
may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.
If our Product Candidates fail in preclinical or clinical trials, or do not gain regulatory approval, or even if approved, fail to achieve
market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability
in subsequent periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to our limited operating history and history of losses, any predictions about our future success, performance or viability may not be
accurate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
will require additional capital to fund our operations and if we fail to obtain necessary financing, we will not be able to complete
the development and commercialization of our Product Candidates.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial and increasing amounts
to conduct further research and development, preclinical testing and clinical trials of our Product Candidates, to seek regulatory approvals
and reimbursement for our Product Candidates and to launch and commercialize any Product Candidates for which we receive regulatory approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2022, we had approximately $6.2 million in cash, cash equivalents and short-term investments, which, combined with the net
proceeds from the September 2022 private placement, we currently estimate funds our operations into the second half of fiscal 2023, and
possibly into the first quarter of fiscal 2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing
revenues from the sale of BayMedica inventory as well as the level and timing of the Company operating expenses. Our ability to develop
our research and development programs is subject to accessing additional capital, including through the sale of equity, partnership revenues,
and out-licensing activities. There is no assurance that we will be successful in these efforts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
progress of our Product Candidates for both current and prospective target indication(s) is uncertain because it is difficult to predict
our spending for our Product Candidates up to the time that we seek FDA approval due to numerous factors, including, without limitation,
the rate of progress of clinical trials, the results of preclinical studies and clinical trials for such indication, the costs and timing
of seeking and obtaining FDA and other regulatory approvals for clinical trials and FDA guidance regarding clinical trials for such indication.
Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend
more cash than currently expected because of circumstances beyond our control. For these reasons, we are unable to state unequivocally
the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements,
both near and long-term, will depend on many factors, including, but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
initiation, progress, timing, costs and results of preclinical studies and clinical trials for our Product Candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
change in the clinical development plans or target indications for these Product Candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number and characteristics of Product Candidates that we develop or may in-license;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
terms of any collaboration agreements we may choose to execute;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
outcome, timing and cost of meeting regulatory requirements established by the Drug Enforcement Administration, or &#8220;DEA&#8221;,
the FDA, the European Medicines Agency, or &#8220;EMA&#8221;, Health Canada, or &#8220;HC&#8221;, or other comparable foreign regulatory
authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Th2.0e
cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
effect of competing product and market developments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs and timing of the implementation of commercial scale manufacturing activities; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of establishing, or outsourcing, sales, marketing and distribution capabilities for any Product Candidates for which we may receive
regulatory approval in regions where we choose to commercialize our products on our own.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital
in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or
commercialization of one or more of our Product Candidates or one or more of our other research and development initiatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
doubt about our ability to continue as a going concern may materially and adversely affect the price of our common shares, and it may
be more difficult for us to obtain financing. Any doubt about our ability to continue as a going concern may also adversely affect our
relationships with current and future collaborators, contract manufacturers and investors, who may become concerned about our ability
to meet our ongoing financial obligations. If potential collaborators decline to do business with us or potential investors decline to
participate in any future financings due to such concerns, our ability to increase our financial resources may be limited. We have prepared
our financial statements on a going concern basis, which assumes that we will be able to meet our commitments, realize our assets and
discharge our liabilities in the normal course of business. Our consolidated financial statements do not include any adjustment to reflect
the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that
may result from the outcome of this uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
currently have limited commercial revenue and may never become profitable.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the limited revenues from our BayMedica commercial business, our ability to generate revenue and become profitable depends
upon our ability to obtain regulatory approval for, and successfully commercialize, our Product Candidates that we may develop, in-license
or acquire in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are able to successfully achieve regulatory approval for these Product Candidates, we do not know what the reimbursement status
of our Product Candidates will be or when any of these products will generate revenue for us, if at all. We have not generated, and do
not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses
for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval
process for our Product Candidates. The amount of future losses is uncertain and will depend, in part, on the rate of growth of our expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenue and become profitable depends upon a number of additional factors, including our ability to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
complete development activities, including the remaining preclinical studies and ongoing and planned clinical trials for our Product
Candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in-license
or acquire in the future, Product Candidates and other potential lines of business that we may develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
and submit NDAs to the FDA and Marketing Authorization Applications, or &#8220;MAAs&#8221;, to the EMA, and obtain regulatory approval
for indications for which there is a commercial market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
and submit applications to, and obtain regulatory approval from, other foreign regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
any approved products in commercial quantities and on commercially reasonable terms;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
a commercial organization, or find suitable partners, to market, sell and distribute approved products in the markets in which we have
retained commercialization rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
acceptance among patients, clinicians and advocacy groups for any products we develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
coverage and adequate reimbursement from third parties, including government payors; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">set
a commercially viable price for any products for which we may receive approval.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability.
Even if we are able to complete the processes described above, we anticipate incurring significant costs associated with commercializing
our Product Candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in tax laws and unanticipated tax liabilities could adversely affect our effective income tax rate and ability to achieve profitability.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to income taxes in the United States and Canada. As our operations expand, we may become subject to income tax in jurisdictions
outside of the United States and Canada. Our effective income tax rate in the future could be adversely affected by a number of factors
including changes in the mix of earnings (losses) in countries with differing statutory tax rates, changes in the valuation of deferred
tax assets and liabilities and changes in tax laws. We regularly assess all of these matters to determine the adequacy of our tax provision
which is subject to discretion. If our assessments are incorrect, it could have an adverse effect on our business and financial condition.
There can be no assurance that income tax laws and administrative policies with respect to the income tax consequences generally applicable
to us or to our subsidiaries will not be changed in a manner which adversely affects our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
ability to use our net operating loss carryforwards and other tax attributes may be limited.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of our last fiscal year end, we had non-capital loss, or &#8220;NOL&#8221;, carry-forwards of approximately $62.9 million available to
offset future taxable income in Canada and the United States. These NOL carry-forwards begin to expire in 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under provisions in the Canadian Income
Tax Act, and corresponding provisions of Canadian provincial law, if a corporation undergoes an &#8220;ownership change,&#8221; generally
defined as a greater than 50% change, by value, the corporation&#8217;s ability to use its pre-change Canadian NOLs and other pre-change
tax attributes, such as research and development tax credits, to offset its post-change income may be limited. Specifically, NOLs from
a business before the change of control may be carried forward to taxation years after the change of control, but only if the same business
is carried forward on after the change in control with a reasonable expectation of profit, and only to offset income from that business
or a similar business. We have not performed any analyses under the applicable provisions in the Canadian Income Tax Act and cannot forecast
or otherwise determine our ability to derive benefit from our various federal or provincial tax attribute carryforwards. As a result,
if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset Canadian federal taxable income may be subject
to limitations, which could potentially result in increased future tax liability to us. In addition, at the provincial level, there may
be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase provincial
taxes owed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may experience ownership changes in the future as a result of subsequent shifts in our share ownership, including in any
future offerings, some of which may be outside of our control. If we determine that an ownership change has occurred and our ability
to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax
obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
to accounting standards may adversely impact the manner in which we report our financial position and operating results.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are ongoing projects conducted by the Financial Accounting Standards Board in the United States that are expected to result in new pronouncements
that continue to evolve, which could adversely impact the manner in which we report our financial position and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
success is largely dependent upon our patents, proprietary technology, and other intellectual property.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and operate without infringing on the proprietary
rights of others. Patents and other proprietary rights are essential to our business. We rely on trade secret, patent, copyright and
trademark laws, and confidentiality and other agreements with employees and third parties, all of which offer only limited protection.
Our general policy has been to file patent applications to protect our inventions and improvements to our inventions that are considered
important to the development of our business. In certain cases, we have chosen to protect our intellectual property by treating it as
confidential internal know-how. Our success will depend in part on our ability to obtain patents, defend patents, maintain internal know-how/trade
secret protection and operate without infringing on the proprietary rights of others. Interpretation and evaluation of pharmaceutical
patent claims present complex legal and factual questions. Further, patent protection may not be available for some of the products or
technology we are developing. If we are placed in a position where we must spend significant time and money defending or enforcing our
patents, designing around patents held by others or licensing patents or other proprietary rights held by others, our business, results
of operations and financial condition may be harmed. In seeking to protect our inventions using patents it is important to note that
we have no assurance that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patent applications will
    result in the issuance of patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional proprietary
    products developed will be patentable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents issued will provide
    adequate protection or any competitive advantages;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents issued will not
    be successfully challenged by third parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial exploitation
    of our inventions does not infringe the patents or intellectual property of others; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we will be able to obtain
    any extensions of the patent term.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of pharmaceutical, biotechnology and medical device companies and research and academic institutions have developed technologies,
filed patent applications or received patents on various technologies that may be related to our business. Some of these technologies,
applications or patents could limit the scope of the patents, if any, that we may be able to obtain. It is also possible that these technologies,
applications or patents may preclude us from obtaining patent protection for our inventions. Further, there may be uncertainty as to
whether we may be able to successfully defend any challenge to our patent portfolio. Moreover, we may have to participate in derivation
proceedings, <i>inter partes</i> review proceedings, post-grant review proceedings, or opposition proceedings in the various jurisdictions
around the world. An unfavorable outcome in a derivation proceeding, an <i>inter partes</i> review proceeding, a post-grant review proceeding,
or an opposition proceeding could preclude us or our collaborators or licensees from making, using or selling products using the technology,
or require us to obtain license rights from third parties. It is not known whether any prevailing party would offer a license on commercially
acceptable terms, if at all. Further, any such license could require the expenditure of substantial time and resources and could harm
our business. If such licenses are not available, we could encounter delays or prohibition of the development or introduction of our
product. In the case of intellectual property where we have chosen to protect it by treating it as internal knowhow, there can be no
assurance that others with greater expertise or access to greater resources do not develop similar or superior technology that impairs
the competitive value of our internal know-how.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Patent and Trademark Office, or &#8220;PTO&#8221;, and various foreign national or international patent agencies require compliance
with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Periodic maintenance
fees on any issued patent are due to be paid to the PTO and various foreign national or international patent agencies in several stages
over the lifetime of the patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in
accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could
result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent
applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment
of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering
our Product Candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may become subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property or
claiming ownership of what we regard as our own intellectual property.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability to develop, manufacture, market and sell our Product Candidates, and to use our related proprietary
technologies without violating the intellectual property rights of others. We may become party to, or threatened with, future adversarial
proceedings or litigation regarding intellectual property rights with respect to our Product Candidates, including interference or derivation
proceedings before the PTO or other international patent offices. Third parties may assert infringement claims against us based on existing
patents or patents that may be granted in the future. If we are found to infringe a third party&#8217;s intellectual property rights,
we could be required to obtain a license from such third party to continue commercializing our Product Candidates. However, we may not
be able to obtain any required license on commercially reasonable terms or at all. Under certain circumstances, we could be forced, including
by court order, to cease commercializing the applicable product candidate. In addition, in any such proceeding or litigation, we could
be found liable for monetary damages. A finding of infringement could prevent us from commercializing our Product Candidates or force
us to cease some of our business operations, which could materially harm our business. Any claims by third parties that we have misappropriated
their confidential information or trade secrets could have a similar negative impact on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our preclinical studies are ongoing, we believe that the use of our Product Candidates in these preclinical studies fall within the scope
of the exemptions provided by 35 U.S.C. Section 271(e) in the United States, which exempts from patent infringement liability activities
reasonably related to the development and submission of information to the FDA. As our Product Candidates progress toward clinical trials
and, ultimately, commercialization, the possibility of a patent infringement claim against us increases. We attempt to ensure that our
Product Candidates and the methods we employ to manufacture them, as well as the methods for their uses we intend to promote, do not
infringe other parties&#8217; patents and other proprietary rights. There can be no assurance they do not, however, and competitors or
other parties may assert that we infringe their proprietary rights in any event.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful
and have a material adverse effect on the success of our business.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or misappropriate or otherwise violate our intellectual property rights. To counter infringement or unauthorized
use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or
to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Also, third parties
may initiate legal proceedings against us to challenge the validity or scope of intellectual property rights we own. These proceedings
can be expensive and time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater
resources to defend their intellectual property rights than we can. Accordingly, despite our efforts, we may not be able to prevent third
parties from infringing upon or misappropriating our intellectual property. Litigation could result in substantial costs and diversion
of management resources, which could harm our business and financial results. In addition, in an infringement proceeding, a court may
decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the technology at issue
on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one
or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings,
motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could
have a material adverse effect on the price of our common shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and
products could be significantly diminished.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or
obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our current and former
employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors and other advisors to
protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition,
we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets. Any
party with whom we or they have executed such an agreement may breach that agreement and disclose our proprietary information, including
our trade secrets, and we may not be able to obtain adequate remedies for such breaches.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcing
a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome
is unpredictable. In addition, some courts are less willing or unwilling to protect trade secrets. If any of our trade secrets were to
be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they disclose
such trade secrets, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to
or independently developed by a competitor or other third-party, our competitive position would be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may not be able to protect our intellectual property rights throughout the world.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on all of our Product Candidates throughout the world would be prohibitively expensive. Therefore,
we have filed applications and/or obtained patents only in key markets such as the United States, Canada, Japan and Europe. Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may
be able to export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong
as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and
our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. For example, an April 2016 report
from the Office of the United States Trade Representative identified a number of countries, including India and China, where challenges
to the procurement and enforcement of patent rights have been reported. Several countries, including India and China, have been listed
in the report every year since 1989. As a result, proceedings to enforce our patent rights in certain foreign jurisdictions could result
in substantial cost and divert our efforts and attention from other aspects of our business and could be unsuccessful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
terms may be inadequate to protect our competitive position on our Product Candidates for an adequate amount of time.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the amount of time required for the development, testing and regulatory review of new Product Candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States
and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term
Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited
to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities,
including the FDA and the PTO, and any equivalent regulatory authorities in other countries, may not agree with our assessment of whether
such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request.
If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our
clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to maintain our competitive advantage. For example:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may be able to make compounds that are the same as or similar to our Product Candidates but that are not covered by the claims of the
patents that we own;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
might not have been the first to file patent applications covering certain of our inventions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
property rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
is possible that our pending patent applications will not lead to issued patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal
challenges;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from
patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
patents of others may have an adverse effect on our business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
rely heavily on contract manufacturers over whom we have limited control. If we are subject to quality, cost or delivery issues with
the preclinical and clinical grade materials supplied by contract manufacturers, our business operations could suffer significant harm.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no manufacturing capabilities and rely on contract development and manufacturing organizations, or &#8220;CDMOs&#8221;,
to manufacture our Product Candidates for preclinical studies and clinical trials. We rely on CDMOs for manufacturing, filling, packaging,
testing, storing and shipping of drug products in compliance with cGMP, regulations applicable to our products. The FDA and other regulatory
agencies ensure the quality of drug products by carefully monitoring drug manufacturers&#8217; compliance with cGMP regulations. The
cGMP regulations for drugs contain minimum requirements for the methods, facilities and controls used in manufacturing, processing and
packaging of a drug product. If our CDMOs increase their prices or fail to meet our quality standards, or those of regulatory agencies
such as the FDA, and cannot be replaced by other acceptable CDMOs, our ability to obtain regulatory approval for and commercialize our
Product Candidates may be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
APIs used in all of our Product Candidates are currently sourced from either contract manufacturers or, for smaller quantities, from
research material suppliers, that typically utilize synthetic chemistry as their manufacturing method. This is intended to be an interim
step to enable us to proceed with developing our formulation, execute preclinical toxicology studies and progress through Phase I and
II clinical trials, after which time we anticipate that we will have been able to successfully scale-up our IntegraSyn<sup>TM</sup> manufacturing
approach so that it will be GMP- ready at pharmaceutical grade. Bridging studies consisting of chemical analysis and, possibly, animal
studies may be required in order to switch our APIs from the current external manufacturing sources to our internally manufactured products.
There is no guarantee that we will be successful in scaling up our IntegraSyn<sup>TM </sup>manufacturing process for cannabinoids, or
successfully complete any required bridging studies, or be able to successfully transfer our IntegraSyn<sup>TM</sup> manufacturing process
to a CDMO. The key risks and challenges associated with the development of the IntegraSyn<sup>TM</sup> process include: failure to continue
optimization and development of the process manufacturing steps from the current scale while maintaining the same or greater output of
the selected cannabinoid; equipment and techniques may not be able to be scaled up using existing commercial processing equipment; supply
of the key starting materials for the process may not be secured to ensure stability and security of commercial supply; and, failure
of the large scale process to consistently produce the selected cannabinoid within set specifications and meeting the process parameters
and in process controls to enable the manufacturing process to be validated for GMP commercial production of an API, among others. Failing
to accomplish these or other criteria for the IntegraSyn<sup>TM</sup> manufacturing process with a CDMO may mean that we are not able
to produce certain cannabinoids in a cost-effective manner. This could result in us not being able to successfully commercialize or utilize
our APIs in our Product Candidates, if any, that may obtain regulatory approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
existing collaboration agreements and any that we may enter into in the future may not be successful.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have relationships with scientific collaborators at academic and other institutions, some of whom conduct research at our request
or assist us in formulating our research and development strategies. These scientific collaborators are not our employees and may have
commitments to, or consulting or advisory contracts with, companies that conflict in interests with and pose a competitive threat to
us. Moreover, to the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate
collaborators. Collaboration arrangements are complex and time consuming to negotiate, document and implement. We may not be successful
in our efforts to establish, implement and maintain collaborations or other alternative arrangements if we choose to enter into such
arrangements and our selected partners may be given, and may exercise, a right to terminate their agreement with us without cause. Our
Collaborative Research Agreement with the University of British Columbia may be terminated by either party upon 30 calendar days written
notice. The terms of any collaboration or other arrangements that we may establish may not be favorable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
all of the aforesaid reasons and others set forth in this Annual Form on 10-K, an investment in our common shares and any other securities
that we may offer from time to time involves a certain degree of risk. Any person considering an investment in our common shares or any
other of our securities should be aware of these and other factors set forth in this 10-K and should consult with his or her legal, tax
and financial advisors prior to making an investment in our common shares or any other of our securities that may be offered from time
to time. Our common shares and any other securities that we may offer from time to time should only be purchased by persons who can afford
to lose all of their investment.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1B.</b></span> <b>UNRESOLVED STAFF COMMENTS</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_003"></a></div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2. PROPERTIES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located at Suite 310 - 815 W. Hastings Street, Vancouver, British Columbia V6C 1B4, Canada. This office occupies
approximately 4,477 square feet with a monthly basic rental rate and operating charges of an estimated C$17,402 for the first two years,
C$17,775 for the third and fourth years, and C$18,521 for the fifth year. This lease expires on August 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2019, InMed entered into a facility lease agreement for approximately 4,000 square feet of office space in Vancouver, BC, which
serves as our corporate headquarters. The lease was set to expire in August 2024. The lease has an option to renew for an additional
three-year period at our discretion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe substantially all of our property and equipment is in good condition and that InMed has sufficient capacity to meet its current
operational needs. We further believe that, should it be needed, suitable additional space is available to accommodate any expansion
of our operations, but such space may not be available in the same building, if and when such space is needed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3. LEGAL PROCEEDINGS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we are subject to various legal proceedings, claims and administrative proceedings that arise in the ordinary course of
our business activities. Although the results of the litigation and claims cannot be predicted with certainty, as of the date of this
report, we do not believe we are party to any claim, proceeding or litigation the outcome of which, if determined adversely to us, would
individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome,
litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
However, as of the date of this Annual Form on 10-K, we are not involved in any material pending legal or governmental proceedings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004a"></a></div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004b"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
II</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_004c"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;5.</b></span> <b>MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
Information</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s shares are listed on the on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the trading symbol &#8220;INM&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were approximately 3,729 holders of record of our common stock as of September 19, 2022. On September 19, 2022, the last reported sales
price per share of our common stock was $7.80 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered
Sales of Equity Securities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repurchases
of Equity Securities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004d"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 6. [RESERVED]</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and have therefore omitted the information required by this
Item 6.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>




</div><div><a id="a_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
discussion and analysis contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), and is subject to the safe harbor created by those sections. For more information, see &#8220;Cautionary Note Regarding
Forward-Looking Statements.&#8221; When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties
that impact our business. In particular, we encourage you to review the risks and uncertainties described in &#8220;Risk Factors&#8221;
in this Annual Report on Form 10-K. These risks and uncertainties could cause actual results to differ materially from those projected
or implied by our forward-looking statements contained in this report. These forward-looking statements are made as of the date of this
report, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis should be read in conjunction with our audited consolidated financial statements for the year
ended June 30, 2022, and the related notes thereto, which have been prepared in accordance with U.S. GAAP, included in our
Form 10-K filing. Throughout this discussion, unless the context specifies or implies otherwise the terms &#8220;InMed,&#8221;
&#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to InMed Pharmaceuticals Inc.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>All
dollar amounts stated herein are in U.S. dollars unless specified otherwise.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel
cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs (&#8220;Product Candidates&#8221;). Together with
our subsidiary BayMedica, LLC, we also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids
for various market sectors (&#8220;Products&#8221;). Our know-how includes traditional approaches such as chemical synthesis and biosynthesis,
as well as a proprietary, integrated manufacturing approach called IntegraSyn<sup>TM</sup>. We are dedicated to delivering new therapeutic
alternatives to patients and consumers who may benefit from cannabinoid-based products. Our approach leverages on the several thousand
years&#8217; history of health benefits attributed to the <i>Cannabis</i> plant and brings this anecdotal information into the 21st century
by applying tried, tested and true scientific approaches to establish non-plant-derived (synthetically manufactured), individual cannabinoid
compounds as Product Candidates in important market segments including clinically proven, FDA-approved medicines and Products that are
provided to wholesalers and end-product manufacturers. While our activities do not involve direct use of <i>Cannabis</i> nor extracts
from the plant, we note that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has, to date, not approved any marketing application
for <i>Cannabis</i> for the treatment of any disease or condition and has approved only one <i>Cannabis</i>-derived and three <i>Cannabis</i>-related
drug products. Our ingredients are synthetically made and, therefore, we have no interaction with the <i>Cannabis</i> plant. We do not
grow nor utilize <i>Cannabis</i> nor its extracts in any of our Products or Product Candidates; our current pharmaceutical drug Product
Candidates are applied topically (not inhaled nor ingested); and, we do not utilize THC or CBD, the most common cannabinoid compounds
that are typically extracted from the <i>Cannabis</i> plant, in any of our Products or Product Candidates. The active pharmaceutical
ingredient (&#8220;API&#8221;) under development for our initial two drug candidates, INM-755 for Epidermolysis bullosa (&#8220;EB&#8221;)
and INM-088 for glaucoma, is cannabinol (&#8220;CBN&#8221;). Additional uses of both INM-755 and INM-088 are being explored, as well
as the application of novel cannabinoid analogs to treat diseases including but not limited to neurodegenerative diseases such as Alzheimer&#8217;s,
Parkinson&#8217;s, and Huntington&#8217;s.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we are positioned to develop multiple pharmaceutical Product Candidates in diseases which may benefit from medicines based on
rare cannabinoid compounds. Most currently approved cannabinoid therapies are based specifically on CBD and/or THC and are often delivered
orally, which has limitations and drawbacks, such as side effects (including the intoxicating effects of THC). Currently, we intend to
deliver our rare cannabinoid pharmaceutical drug candidates through various topical formulations (cream for dermatology, eye drops for
ocular diseases) as a way of enabling treatment of the specific disease at the site of disease while seeking to minimize systemic exposure
and any related unwanted systemic side effects, including any drug-drug interactions and any metabolism of the active pharmaceutical
ingredient by the liver. The cannabinoid Products sold through our B2B raw material supply business are integrated into various product
formats by the companies who then further commercializes such products. We plan to access rare cannabinoids via all non-extraction approaches,
including chemical synthesis, biosynthesis and our proprietary integrated IntegraSyn<sup>TM</sup> approach, thus negating any interaction
with or exposure to the <i>Cannabis</i> plant.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our acquisition of Biogen Sciences Inc., a privately held British Columbia pharmaceutical company focused on drug discovery and development
of cannabinoids in 2014, our operations have focused on conducting research and development for our Product Candidates and for our integrated,
biosynthesis-based manufacturing technology, establishing our intellectual property, organizing and staffing our Company, business planning
and capital raising. On October 13, 2021, we acquired BayMedica, Inc., now named BayMedica, LLC (&#8220;BayMedica&#8221;). Upon closing
of the transaction, BayMedica became a wholly-owned subsidiary of InMed. To date, we have funded our operations primarily through the
issuance of common shares and limited Product revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred significant operating losses since our inception and since the acquisition of Biogen Science Inc. and we expect to continue
to incur significant operating losses for the foreseeable future. Our ability to generate product revenue, if ever, that is sufficient
to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our drug
candidates and/or the success of our manufacturing technologies. Our net loss was $18.6 million and $10.2 million for the year ended
June 30, 2022 and 2021, respectively. As of June 30, 2022, we had an accumulated deficit of $93.5 million, which includes all losses
since our inception in 1981. Our accumulated deficit increased between 2014, when we began focusing on the development of cannabinoid-derived
pharmaceuticals following the acquisition of Biogen Science Inc., and June 30, 2022 by approximately $64.6 million. We expect our expenses
and operating losses will increase substantially over the next several years in connection with our ongoing activities as we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            to further advance the research and development of various manufacturing technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            to further advance the INM-755 program, our lead drug candidate for the treatment of EB;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            to further advance the INM-088 program, our drug candidate for the treatment of glaucoma;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investigate
                                            our Product Candidates for additional uses beyond the initial indications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue
                                            the discovery of drug targets based on proprietary cannabinoid analogs for other diseases
                                            with high unmet medical needs and the subsequent development of any resulting new Product
                                            Candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            regulatory approvals for any Product Candidates that successfully complete clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scale-up
                                            our manufacturing processes and capabilities, or arrange for a third party to do so on our
                                            behalf;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">execute
                                            on business development activities, including but not limited to company mergers/acquisitions
                                            and acquisition or in-licensing of externally developed products and/or technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
                                            expand, enforce, defend and protect our intellectual property;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">build
                                            internal infrastructure, including personnel, to meet our milestones; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
                                            operational, financial and management information systems and personnel, including personnel
                                            to support product development and potential future commercialization efforts and our operations
                                            as a public company.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these activities as well as our working capital requirements, we will need substantial additional funding to support our
continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue, if ever,
we expect to finance our operations through product sales, the sale of equity, debt financings or other capital sources, including collaborations
with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements
or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed,
we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our Products and
Product Candidates or grant rights to external entities to develop and market our Product Candidates, even if we would otherwise prefer
to develop and market such Products and Product Candidates ourselves.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with drug development and commercial growth, we are unable to predict the timing or
amount of increased expenses and working capital requirements or the timing of when or if we will be able to achieve or maintain profitability.
If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations
at planned levels and be forced to reduce or terminate our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2021, we closed a $12.0 million private placement. After deducting the placement agent fees and estimated offering expenses payable
by the Company, we received net proceeds of approximately $11.0 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2021, we announced that we commenced our Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis
Bullosa (&#8220;EB&#8221;) marking the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic
option to treat a disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2021, we completed the acquisition of BayMedica Inc. (&#8220;BayMedica&#8221;), a private company based in the U.S. that
specializes in the manufacturing and commercialization of rare cannabinoids. We acquired 100% of BayMedica in exchange for 82,000
common shares issued to BayMedica&#8217;s equity and convertible debt holders, subject to a six-month contractual hold period and $1
million to be held in escrow, subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims
under the definitive agreement in the six- and twelve-month periods following the closing. On April 13, 2022, $300,457 of escrow
payments were made to BayMedica&#8217;s historical equity and convertible debt holders reflecting $199,543 of post-closing
reductions from the escrow. The remaining $500,000 escrow payment, subject to any additional post-closing adjustments, is payable on
the twelve-month anniversary following the closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
announced the launch of B2B sales of the rare cannabinoid Products cannabicitran (&#8220;CBT&#8221;), cannabidivarin
(&#8220;CBDV&#8221;), and tetrahydrocannabivarin (&#8220;THCV&#8221;) on January 19, 2022, on April 21, 2022, and on June 9, 2022,
respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 7, 2022, we filed a prospectus supplement to our S-3 universal shelf filing to incorporate an At- The-Market-Offering Agreement
following which the Company sold 10,759 common shares under the agreement for proceeds of $0.1 million, net of issuance costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2022, we closed a $5.5 million registered direct offering and concurrent private placement of our common shares. After deducting
the placement agent fees and transaction costs, we received net proceeds of approximately $4.5 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 13, 2022, we closed a $6.0 million private placement. Under the terms of the private placement, an aggregate of 691,245 common
shares, or common share equivalents, and investment options to purchase up to an aggregate of 1,382,490 common shares, at an effective
purchase price of $8.68 per common share and associated investment options. The warrants have an exercise price of $8.44 per share, are
exercisable immediately and have a term of seven years. After deducting the placement agent fees, we received net proceeds of approximately
$5.4 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenue consists of manufacturing
and distribution sales of bulk rare cannabinoid Products, which are generally recognized at a point in time. The Company recognizes revenue
when control over the products have been transferred to the customer and the Company has a present right to payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of Sales</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing
costs. Cost of sales also includes production and labor costs for our manufacturing business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development and Patent Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development and patent expenses represent costs incurred by us for the discovery, development, and manufacture of our Products and
Product Candidates and include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">external
                                            research and development expenses incurred under agreements with contract research organizations,
                                            or &#8220;CROs&#8221;, contract development and manufacturing organization, or &#8220;CDMOs&#8221;,
                                            and consultants;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries,
                                            payroll taxes, employee benefits expenses for individuals involved in research and development
                                            efforts;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
                                            supplies; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
                                            and patent office fees related to patent and intellectual property matters.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expense research and development costs as incurred. We recognize expenses for certain development activities, such as preclinical studies
and manufacturing, based on an evaluation of the progress to completion of specific tasks using data or other information provided to
us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern
of expenses incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development
activities are recorded as prepaid expenses. These amounts are recognized as an expense as the goods are delivered or the related services
are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
costs represent a significant portion of our research and development expenses, which we track on a program-by-program basis following
the nomination of a development candidate. Our internal research and development expenses consist primarily of personnel-related expenses,
including salaries, benefits and stock-based compensation expense. We do not track our internal research and development expenses on
a program-by-program basis as the resources are deployed across multiple projects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of our Products and Product Candidates is highly uncertain. At this time, we cannot reasonably estimate or know
the nature, timing, and estimated costs of the efforts that will be necessary to complete the remainder of the development of our Product
Candidates or to develop and commercialize additional Products. We are also unable to predict when, if ever, material net cash inflows
will commence from our Product Candidates, if approved. This is due to the numerous risks and uncertainties associated with development,
including the uncertainty related to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing and progress of preclinical and clinical development activities;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number and scope of preclinical and clinical programs we decide to pursue;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to raise additional funds necessary to complete preclinical and clinical development
                                            and commercialization of our Product Candidates, to further advance the development of our
                                            manufacturing technologies, and to develop and commercialize additional Products, if any;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to maintain our current research and development programs and to establish new ones;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to establish sales, licensing or collaboration arrangements;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            progress of the development efforts of parties with whom we may enter into collaboration
                                            arrangements;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            successful initiation and completion of clinical trials with safety, tolerability and efficacy
                                            profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            receipt and related terms of regulatory approvals from applicable regulatory authorities;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of materials for use in production of our Products and Product Candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to secure manufacturing supply through relationships with third parties or establish
                                            and operate a manufacturing facility;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to consistently manufacture our Product Candidates in quantities sufficient for use
                                            in clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain intellectual property protection and regulatory exclusivity,
                                            both in the United States and internationally;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to maintain, enforce, defend and protect our rights in our intellectual property
                                            portfolio;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            commercialization of our Product Candidates, if and when approved, and of new Products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain third-party payor coverage and adequate reimbursement for
                                            our Product Candidates, if approved;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            acceptance of our Product Candidates, if approved, by patients, the medical community and
                                            third-party payors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                            with other products; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            continued acceptable safety profile of our Product Candidates following receipt of any regulatory
                                            approvals.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of any of our Products or Product Candidates would significantly
change the costs and timing associated with the development of those Products or Product Candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities account for a significant portion of our operating expenses. We expect our research and development expenses
to increase significantly in future periods as we continue to implement our business strategy, which includes advancing our drug candidates
and our manufacturing technologies into and through clinical development, expanding our research and development efforts, including hiring
additional personnel to support our research and development efforts, ultimately seeking regulatory approvals for our drug candidates
that successfully complete clinical trials, and further developing selected BayMedica activities. In addition, drug candidates in later
stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily
due to the increased size and duration of later-stage clinical trials. Accordingly, although we expect our research and development expenses
to increase as our drug candidates advance into later stages of clinical development, we do not believe that it is possible at this time
to accurately project total program-specific expenses through to commercialization. There are numerous factors associated with the successful
commercialization of any of our Product Candidates, including future trial design and various regulatory requirements, many of which
cannot be determined with accuracy at this time based on our stage of development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist of personnel-related costs, including salaries, benefits and stock-based compensation expense, for
our personnel in executive, finance and accounting, human resources, business operations and other administrative functions, investor
relations activities, legal fees related to corporate matters, fees paid for accounting and tax services, consulting fees and facility-related
costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our general and administrative expenses will increase for the foreseeable future to support our expanded infrastructure, operating
as a public company and increased costs of expanding our operations. These increases will likely include increased expenses related to
accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements,
director and officer insurance premiums, and investor relations costs associated with operating as a public company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amortization
and Depreciation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets are comprised of intellectual property that we acquired in 2014 and 2015 and trade secrets, product formulation knowledge, patents
and trademarks that we acquired in October 2021. The acquired intellectual property, patents and trademark are amortized on a straight-line
basis based on their estimated useful lives. Equipment and leasehold improvements are depreciated using the straight-line method based
on their estimated useful lives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-Lived Assets</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assess the recoverability of our long-lived assets whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the
asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of
undiscounted cash flows, we then determine the fair value of the underlying asset. Any impairment to be recognized is measured as
the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group as outlined in Note 6
to the consolidated financial statements. Assets classified as held for sale are reported at the lower of the carrying amount or
fair value, less costs to sell.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share-based
Payments</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
payments is the stock-based compensation expense related to our granting of stock options to employees and others. The fair value, at
the grant date, of equity-settled share awards is charged to our loss over the period for which the benefits of employees and others
providing similar services are expected to be received. The vesting components of graded vesting employee awards are measured separately
and expensed over the related tranche&#8217;s vesting period. The amount recognized as an expense is adjusted to reflect the number of
share options expected to vest. The fair value of awards is calculated using the Black-Scholes option pricing model, which considers
the exercise price, current market price of the underlying shares, expected life of the award, risk-free interest rate, expected volatility
and the dividend yield.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income consists primarily of interest income earned on our cash, cash equivalents and short-term investments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the closing of the BayMedica acquisition, the Company aligned into two operating and reportable segments, InMed Pharmaceuticals (the
&#8220;InMed&#8221; segment) and BayMedica (the &#8220;BayMedica&#8221; segment).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the year ended June 30, 2022 and 2021 for InMed Segment</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended<br/>
                                            June 30,</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    Change</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development and patents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,986</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,338</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,906</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,479</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,427</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    and depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,999</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,938</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,061</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    and other income</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized
    gain on derivative warrants liability</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">243</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(243</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    modification expense</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,314</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,314</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,411</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,203</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,208</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development and Patents Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development and patents expenses increased by $0.6 million in our InMed segment, or 12%, for the year ended June 30, 2022 compared
to the year ended June 30, 2021. The increase in research and development and patents expenses was primarily due to increased activities
related to the INM-755 Phase 2 clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $1.4 million in our InMed segment, or 32%, for the year ended June 30, 2022 compared to the
year ended June 30, 2021. The increase results primarily from a combination of changes including investor relation expenses, accounting
fees and legal fees, and substantially higher insurance fees resulting from our listing on the Nasdaq Capital Market. In addition, acquisition-related
expenses, which were comprised of regulatory, financial advisory and legal fees, totaled $0.2 million for the year ended June 30, 2022
and were included in general and administrative expenses in our InMed segment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance
expense</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
expense is $Nil in our InMed segment for the year ended June 30, 2022, compared to $0.4 million for the year ended June 30, 2021. Finance
expense is comprised of financing transaction costs, from the November 2020 public offering, allocated to the derivative warrants liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrealized
gain of derivative warrants liability</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized
gain of derivative warrants liability is $Nil in our InMed segment for the year ended June 30, 2022, compared to $0.2 million for the
year ended June 30, 2021, which is the change in fair value of derivative warrants liability during the end of the period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
modification expense</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
modification expense was $1.3 million in our InMed segment for the year ended June 30, 2022, compared to $Nil for the year ended June
30, 2021, which is the change in fair value of warrants that were re-priced during the year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
exchange loss</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange loss decreased by less than $0.1 million in our InMed segment, or 28%, for the year ended June 30, 2022, compared to the year
ended June 30, 2021, as a consequence of holding non-US denominated assets and liabilities combined with fluctuations in foreign exchange
rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the year ended June 30, 2022 and 2021 for BayMedica Segment</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended<br/>
                                            June 30,</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    Change</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,089</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,089</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of sales</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">546</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">546</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">544</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">544</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development and patents</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,296</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,296</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">961</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">961</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    and depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
    of intangible assets and goodwill</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,473</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,473</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    and other income</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,189</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,189</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales,
Cost of Sales and Gross Profit</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
realized sales of $1.1 million in our BayMedica segment for the year ended June 30, 2022, the result of manufacturing and
distribution sales of bulk rare cannabinoid Products following the acquisition of BayMedica in October 2021. As the year ended June
30, 2021 pre-dated the acquisition of BayMedica, there are no comparable revenues for InMed in the 2021 period. Accordingly, we
realized cost of goods sold of $0.5 million in our BayMedica segment for the year ended June 30, 2022, with no comparable expenses
in 2021, resulting in a gross profit of $0.5 million for the period. <span>As management has made
the decision to refocus on our core business in the pharmaceutical drug development area and reduce our efforts in BayMedica&#8217;s
commercial business, we do not expect sales to continue at the same rate. BayMedica will continue to evaluate opportunities for
potential structured supply arrangements and collaborations and will consider other potential strategic alternatives for the
commercial business.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development and Patents Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development and patents expenses were $1.3 million in our BayMedica segment for the year ended June 30, 2022. The increase in research
and development and patents expenses was due to the inclusion of BayMedica operating results following the acquisition date. There were
no comparable expenses in 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $1.0 million in our BayMedica segment for the year ended June 30, 2022. The increase is due to the inclusion
of BayMedica operating results following the acquisition date. There were no comparable expenses in 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of intangible assets and goodwill</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Impairment of intangible assets
and goodwill was $3.5 million in our BayMedica segment for the year ended June 30, 2022. For variety of reasons as outlined in Note 6
to the consolidated financial statements, performance of the BayMedica segment has not materialized as expected. As of June 30, 2022,
we determined that the respective fair value of the Company&#8217;s BayMedica reporting unit is less than its carrying amount, including
goodwill. As a result, we recorded a goodwill and intangible impairment loss. There were no comparable expenses in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have only generated limited revenue from Product sales, no sales from any other sources and have incurred significant
operating losses and negative cash flows from our operations. We have only commenced commercial sales with the acquisition of BayMedica
and not yet commercialized any of our Product Candidates and we do not expect to generate revenue from sales of any Product Candidates
for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of common shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2022, we had cash and cash equivalents of $6.2 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for each of the periods presented:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended<br/> June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended<br/> June 30,<br/> 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used
    in operating activities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,584</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,791</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in investing
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(673</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by financing
    activities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,071</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,855</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects
    of foreign exchange on cash and cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">495</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    increase (decrease) in cash and cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,186</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,557</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2022, we used cash in operating activities of $15.6 million, primarily resulting from our net loss of $18.6 million
combined with $2.7 million used in changes in our non-cash working capital, partially offset by non-cash share-based compensation expenses,
impairment of intangible assets and goodwill and warrant modification expense related to the change in fair value of warrants that were
re-priced during the year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2021, we used cash in operating activities of $9.8 million, primarily resulting from our net loss of $10.2 million
combined with $0.5 million used in changes in our non-cash working capital, partially offset by non-cash share-based compensation expenses,
financing expenses allocated to warrants and changes in the valuation of the derivative warrants liability.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended June
30, 2022, cash used in investing activities of $0.7 million resulted from escrow payments made to BayMedica&#8217;s historical equity
and convertible debt holders, settlement of loan receivable from BayMedica and purchases of property and equipment, partially offset by
cash acquired from the acquisition of BayMedica.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2021, we used cash in investing activities of less than $0.1 million, resulting from the purchase of property
and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended June
30, 2022, cash provided by financing activities of $15.1 million consisted of $12.0 million of gross proceeds from a private placement
of our common shares and $5.0 million of gross proceeds from a registered direct offering and concurrent private placement of our common
shares, offset by total transaction costs of $1.8 million and $0.3 million for the repayment of debt assumed in the BayMedica acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2021, cash provided by financing activities of $10.9 million consisted of $8.0 million of gross proceeds from
our initial public offering and $4.5 million of gross proceeds from a private placement of our common shares, offset by total transaction
costs of $1.6 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Funding
Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we
continue the research and development of and the clinical trials for our Product Candidates. In addition, we expect to incur additional
costs associated with operating as a US-listed public company and associated with any required investment into BayMedica&#8217;s R&amp;D
efforts targeting cannabinoid analogs. As a result, we expect to incur substantial operating losses and negative operating cash flows
for the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2014-15,
Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether
there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that the consolidated financial statements are issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
June 30, 2022, we have funded our operations primarily with proceeds from the sale of common stock. We have incurred recurring losses
and negative cash flows from operations since its inception, including net losses of $18.6 million and $10.2 million for the year ended
June 30, 2022 and 2021, respectively. In addition, we have an accumulated deficit of $93.5 million as of June 30, 2022. Our accumulated
deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition
of Biogen Science Inc., and June 30, 2022 by approximately $64.6 million and we expect to continue to generate operating losses for the
foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2021, we closed a $12 million private placement. After deducting the placement agent fees and estimated offering expenses, we
received net proceeds of approximately $11 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, we filed a prospectus supplement to our S-3 universal shelf filing to incorporate an At The Market Offering Agreement following
which the Company sold 10,759 common shares under the agreement for net proceeds of approximately $0.1 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2022, we closed a $5.5 million registered direct offering and concurrent private placement of our common shares. After deducting
the placement agent fees and transaction costs, we received net proceeds of approximately $4.5 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 13, 2022, we closed a $6.0 million private placement. After deducting the placement agent fees, we received net proceeds of
approximately $5.4 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the issuance date of
the consolidated financial statements, we expect our cash and cash equivalents of $6.2 million as of June 30, 2022, combined with the
approximate $5.4 million of net proceeds from a private placement which closed on September 13, 2022, will be sufficient to fund our operating
expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal 2024
(being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory
as well as the level and timing of the Company operating expenses. Our future viability is dependent on our ability to raise additional
capital to finance our operations. In addition, there are a number of uncertainties in estimating our operating expenses and capital expenditure
requirements including the impact of potential acquisitions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the
date that the consolidated financial statements are issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations
with other companies, government contracts or other strategic transactions. We may not be able to obtain financing on acceptable terms,
or at all. The terms of any financing may adversely affect the holdings or the rights of our existing stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
funding requirements and timing and amount of our operating expenditures will depend largely on:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            progress, costs and results of our Phase 2 clinical trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, results and costs of discovery research, preclinical development, laboratory
                                            testing and clinical trials for our Product Candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, results and costs of development of our manufacturing technologies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of and development requirements for other Products and Product Candidates that we
                                            pursue;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs, timing and outcome of regulatory review of our Product Candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to enter into contract manufacturing arrangements for supply of materials and manufacture
                                            of our Products and Product Candidates and the terms of such arrangements;</span></td>
</tr></table><div>



</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            impact of any acquired, or in-licensed, externally developed product(s) and/or technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to establish and maintain strategic collaborations, licensing or other arrangements,
                                            including sales arrangements, and the financial terms of such arrangements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            sales, costs and timing of future commercialization activities, including product manufacturing,
                                            sales, marketing and distribution, for any of our Products and for Product Candidates for
                                            which we may receive marketing approval;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs and timing of preparing, filing and prosecuting patent applications, maintaining and
                                            enforcing our intellectual property and proprietary rights and defending any intellectual
                                            property- related claims;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion
                                            costs of our operational, financial and management systems and increases to our personnel,
                                            including personnel to support our clinical development, manufacturing and commercialization
                                            efforts and our operations as a dual listed company; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs to obtain, maintain, expand and protect our intellectual property portfolio.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these, or other variables with respect to the development of any of our Products and Product Candidates,
could significantly change the costs and timing associated with their development. We will need to continue to rely on additional financing
to achieve our business objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the variables described above, if and when any of our Product Candidates successfully complete development, we will incur
substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements, maintaining our intellectual
property rights, and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this
time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial revenues from either our Products or Product Candidates, we expect to finance our
cash needs through a combination of equity or debt financings and collaboration arrangements. We currently have no credit facility or
committed sources of capital. To the extent that we raise additional capital through the future sale of equity securities, the ownership
interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our existing common shareholders. If we raise additional funds through the issuance of debt securities, these securities
could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts,
and additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements
or other strategic transactions in the future, we may have to relinquish valuable rights to our technologies, future revenue streams,
Products or Product Candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds
through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate development or future commercialization
efforts or grant rights to develop and market Products or Product Candidates that we would otherwise prefer to develop and market ourselves.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the periods presented we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically review our financial reporting and disclosure practices and accounting policies to ensure that they provide accurate and
transparent information relative to the current economic and business environment. As part of this process, we have reviewed our selection,
application and communication of critical accounting policies and financial disclosures. Management has discussed the development and
selection of the critical accounting policies with the Audit Committee of the Board of Directors and the Audit Committee has reviewed
the disclosure relating to critical accounting policies in this Management&#8217;s Discussion and Analysis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements included
as part of this report, which have been prepared in accordance with U.S. GAAP. The preparation of our consolidated financial statements
requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the revenue and expenses
incurred during the reported periods. We base estimates on our historical experience, known trends and various other factors that we
believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of
assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions
or conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full details of our accounting policies are presented in Note 2 of our audited consolidated financial statements for the year ended June
30, 2022. These policies are considered by management to be essential to understanding the processes and reasoning that go into the preparation
of our financial statements and the uncertainties that could have a bearing on its financial results. The significant accounting policies
that we believe to be most critical in fully understanding and evaluating our financial results are research and development costs and
share based payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
&amp; Development and Patents costs</i>:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development and patents costs is a critical accounting estimate due to the magnitude and nature of the assumptions that are required
to calculate third-party accrued and prepaid research and development expenses. Research and development costs are charged to expense
as incurred and include, but are not limited to, personnel compensation, including salaries and benefits, services provided by CROs that
conduct preclinical and clinical studies, costs of filing and prosecuting patent applications, and lab supplies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of expenses recognized in a period related to service agreements is based on estimates of the work performed using an accrual
basis of accounting. These estimates are based on services provided and goods delivered, contractual terms and experience with similar
contracts. We monitor these factors and adjust our estimates accordingly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-based
payments</i></b><i>:</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value, at the grant date, of equity share awards is charged to income or loss over the period for which the benefits of employees
and others providing similar services are expected to be received, generally the vesting period. The corresponding accrued entitlement
is recorded in contributed surplus. The amount recognized as an expense is adjusted to reflect the number of share options expected to
vest. The fair value of awards is calculated using the Black-Scholes option pricing model which considers the following factors:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
                                            price</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            market price of the underlying shares</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            life of the award</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
                                            interest rate</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            volatility</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
                                            yield</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
determines costs for share-based payments using market-based valuation techniques. The fair value of the market-based and performance-based
share awards are determined at the date of grant using generally accepted valuation techniques. Assumptions are made and judgment used
in applying valuation techniques. These assumptions and judgments include estimating the future volatility of the stock price, expected
dividend yield, forfeiture rates and corporate performance. For employee awards, we use the &#8220;simplified method&#8221; to determine
the expected term of options. Under this method, the expected term represents the average of the vesting period and the contractual term.
Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates. If we had made
different judgments and assumptions than those described previously, the amount of our share-based payments expense, net loss and net
loss per common shares amounts could have been materially different.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Intangible Assets:</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assess the recoverability of our long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset
to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted
cash flows, we then determine the fair value of the underlying asset. Any impairment to be recognized is measured as the amount by which
the carrying amount of the asset group exceeds the estimated fair value of the asset group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the sector-wide underperformance of the current market and the uncertainty around the revenues in the health and wellness market,
the Company made the decision to focus on the core business in the pharmaceutical drug development and reduce our financial exposure
to the health and wellness sector. To make the transition we plan to focus sales efforts on reducing inventory and decreasing other
commercial manufacturing R&amp;D efforts in BayMedica. As a result, as of June 30, 2022, the Company determined that intangibles
assets of BayMedica that were associated with manufacturing and commercialization of our health and wellness products were impaired.
Refer to Note 6 of our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair
values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as
goodwill. All assets and liabilities acquired or assumed in a business combination are recorded at their fair values at the date of acquisition.
If the Company&#8217;s interest in the fair value of the acquiree&#8217;s net identifiable assets exceeds the cost of the acquisition,
the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in connection with a business combination,
other than costs associated with the issuance of debt or equity securities, are expensed as incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our acquisition
of BayMedica Inc, on October 13, 2021, goodwill, trade secrets, product formulation knowledge, patents, trademarks, Technology and In-Process
Research and Development Intangible (&#8220;IPR&amp;D&#8221;) intangible assets were recognized.&#160;The fair value of the aggregate
intangible assets was determined to be $2.7 million and goodwill was $2.0 million at the acquisition date. IPR&amp;D was classified as
indefinite-lived and was not amortized. The multi-period excess earnings method was used to determine the fair value of these assets as
at the date of acquisition. All research and development costs incurred subsequent to the acquisition of IPR&amp;D are expensed as incurred.
Patents are expected to have a finite life and are being amortized on a straight-line basis over their estimated useful lives. Amortization
begins when intangible assets with finite lives are put into use.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
June 30, 2022, we have funded our operations primarily with proceeds from the sale of common shares. We have incurred recurring losses
and negative cash flows from operations since our inception, including net losses of $18.6 million and $10.2 million for the year ended
June 30, 2022 and 2021, respectively. In addition, we have an accumulated deficit of $93.5 million as of June 30, 2022. Our accumulated
deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition
of Biogen Science Inc., and June 30, 2022 by approximately $64.6 million and we expect to continue to generate operating losses for the
foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022, we filed a prospectus supplement to our S-3 universal shelf filing to incorporate an At The Market Offering Agreement following
which the Company sold 10,759 common shares under the agreement for net proceeds of approximately $0.1 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2022, we closed a $5.5 million registered direct offering and concurrent private placement and received net proceeds of approximately
$4.5 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 13, 2022, we closed a $6.0 million private placement. After deducting the placement agent fees, we received net proceeds of
approximately $5.4 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the issuance date
of the consolidated financial statements, we expect our cash and cash equivalents of $6.2 million as of June 30, 2022, combined with
the approximate $5.4 million of net proceeds from a private placement which closed on September 13, 2022, will be sufficient to fund
our operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter
of fiscal 2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of
BayMedica inventory as well as the level and timing of the Company operating expenses. Our future viability is
dependent on our ability to raise additional capital to finance our operations. In addition, there are a number of uncertainties in
estimating our operating expenses and capital expenditure requirements including the impact of potential acquisitions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the
date that the consolidated financial statements are issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with
other companies, government contracts or other strategic transactions. We may not be able to obtain financing on acceptable terms, or
at all. The terms of any financing may adversely affect the holdings or the rights of our existing shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We are a smaller reporting company as defined by Rule 12b-2
of the Exchange Act and are not required to provide the information required under this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&#160;</p><div>




</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_031.jpg"/>&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
Financial Statements of</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>InMed
Pharmaceuticals Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the Year Ended June 30, 2022 and 2021</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Suite
310 &#8211; 815 West Hastings Street</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Vancouver,
BC, Canada, V6C 1B4</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Tel:
+1-604-669-7207</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_032.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>InMed
Pharmaceuticals Inc. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(Expressed
in U.S. Dollars)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">June 30,
2022</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">Financial Statements</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_001">Consolidated Balance Sheets</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_002">Consolidated Statements of Operations and Comprehensive Loss</a></span></td>
    <td style="text-align: center">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_003">Consolidated Statements of Shareholders&#8217; Equity</a></span></td>
    <td style="text-align: center">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_004">Consolidated Statements of Cash Flows</a></span></td>
    <td style="text-align: center">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_005">Notes to the Consolidated Financial Statements</a></span></td>
    <td style="text-align: center">F<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9-F-36</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="s_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Independent Registered Public Accounting
Firm</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">InMed Pharmaceuticals Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Opinion on the Consolidated Financial Statements</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheets of InMed
Pharmaceuticals Inc. (the Company) as of June&#160;30, 2022 and 2021, the related	 consolidated statements of operations and comprehensive
loss, shareholders&#8217; equity, and cash flows for each of the years in the two-year period ended June&#160;30, 2022, and the related
notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in
all material respects, the financial position of the Company as of June 30, 2022 and 2021, and the results of its operations and its cash
flows for each of the years in the two-year period ended June&#160;30, 2022, in conformity with U.S. generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Going Concern </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company
has incurred recurring losses and negative cash flows and has an accumulated deficit that raise substantial doubt about its ability to
continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basis for Opinion</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0pt 0; text-indent: 0.25in"></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">KPMG LLP</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chartered Professional Accountants</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">Vancouver, Canada</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 23, 2022</p><div>


</div><p style="margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_001"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>InMed
    Pharmaceuticals Inc. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 6%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    BALANCE SHEETS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    at June 30, 2022 and 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,</b></span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Note</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and
    cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,176,866</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">7,363,126</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">44,804</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">46,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">88,027</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">11,919</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,490,854</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-0; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaids and other assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">797,225</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">956,762</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,597,776</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">8,378,269</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Non-Current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Property, equipment and ROU assets, net</td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd">904,252</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd">326,595</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">2,108,915</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">1,061,697</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">176,637</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">14,655</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">12,787,580</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">9,781,216</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND SHAREHOLDERS'
    EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,415,265</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,134,878</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current portion of lease
    obligations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">404,276</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">80,483</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Acquisition consideration
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:AcquisitionConsiderationPayable" scale="0" unitRef="usd">500,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">3,319,541</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,215,361</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Non-current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease obligations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">389,498</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">189,288</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">3,709,039</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,404,649</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shareholders' Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Common shares, no par value, unlimited
    authorized shares:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-hidden: hidden-fact-5; -sec-ix-hidden: hidden-fact-4; -sec-ix-hidden: hidden-fact-3; -sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">650,667</ix:nonFraction></ix:nonFraction> (June 30, 2021 - <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">322,028</ix:nonFraction></ix:nonFraction>) issued and outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">70,718,461</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">60,587,417</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,
                                            11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">31,684,098</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">21,513,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated deficit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">93,452,587</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">74,852,470</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated other comprehensive
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">128,569</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">128,569</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Shareholders' Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,078,541</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,376,567</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Liabilities and Shareholders'
    Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">12,787,580</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">9,781,216</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Going Concern
(Note 1)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Commitments
and Contingencies (Note 17)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Related Party
Transactions (Note 19)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Subsequent
Events (Notes 10 and 20)</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes form an integral part of these consolidated financials statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_002"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><b>InMed
    Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="5" style="white-space: nowrap; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom; width: 56%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the year ended June 30, 2022 and 2021</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 19%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 17%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="text-align: center"></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year Ended June 30</b></span><b>,</b></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Note</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,089,435</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-6; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">545,889</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">543,546</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating Expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development
    and patents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">7,282,615</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,338,084</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">6,867,030</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">4,479,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Amortization and
    depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,
                                            7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">185,657</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">120,866</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Impairment of intangible
    assets and goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="0" sign="-" unitRef="usd">3,472,593</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">17,807,895</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">9,938,283</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other Income (Expense)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Interest and other
    income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd">96,090</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd">16,017</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" sign="-" unitRef="usd">360,350</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unrealized gain on
    derivative warrants liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" unitRef="usd">242,628</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrant modification
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantModificationExpense" scale="0" unitRef="usd">1,314,307</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Foreign exchange
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd">117,551</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd">163,101</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net loss for the year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other Comprehensive Gain</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Foreign currency
    translation gain</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="0" unitRef="usd">430,443</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total comprehensive loss
    for the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">9,772,646</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss per share for the
    year</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: justify"><span style="-sec-ix-hidden: hidden-fact-15; -sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">Basic and diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">33.17</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">37.96</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Weighted average outstanding common shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left"><span style="-sec-ix-hidden: hidden-fact-17; -sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif">Basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">560,829</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">268,793</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes form an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_003"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>InMed Pharmaceuticals
    Inc.</b></span></td>
    <td style="white-space: nowrap; width: 4%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 10%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 10%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 12%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 10%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 12%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 12%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
    STATEMENTS OF SHAREHOLDERS' EQUITY</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="6" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year
    ended June 30, 2022 and 2021</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Accumulated Other</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Comprehensive</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Additional </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Loss) Income -</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Note</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Common
    Shares</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Paid-in
    Capital</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Accumulated<br/>
    Deficit</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Foreign
    Exchange</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">#</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance June 30, 2020</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">208,828</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">53,065,240</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">17,764,333</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">64,649,381</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">301,874</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,878,318</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Public offering</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">71,200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" unitRef="usd">6,052,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" unitRef="usd">6,052,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Private placement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" scale="0" unitRef="shares">42,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" scale="0" unitRef="usd">2,917,157</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" scale="0" unitRef="usd">1,545,343</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" scale="0" unitRef="usd">4,462,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Reclassification of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">1,763,980</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">1,763,980</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareIssuanceCosts" scale="0" sign="-" unitRef="usd">1,446,980</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareIssuanceCosts" scale="0" sign="-" unitRef="usd">170,798</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareIssuanceCosts" scale="0" sign="-" unitRef="usd">1,617,778</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss and comprehensive income for the period</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="inm:LossAndComprehensiveIncomelossesForThePeriod" scale="0" sign="-" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="inm:LossAndComprehensiveIncomelossesForThePeriod" scale="0" unitRef="usd">430,443</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:LossAndComprehensiveIncomelossesForThePeriod" scale="0" sign="-" unitRef="usd">9,772,646</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">610,193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">610,193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance June 30, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">322,028</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">60,587,417</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">21,513,051</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">74,852,470</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">128,569</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,376,567</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Accumulated Other</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Comprehensive</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Additional </b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Income -</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Note</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Common
    Shares</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>Paid-in</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>Capital</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Accumulated<br/>
    Deficit</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Foreign
    Exchange</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">#</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 16%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance June 30, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">322,028</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">60,587,417</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">21,513,051</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">74,852,470</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">128,569</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,376,567</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Private placement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" scale="0" unitRef="shares">35,600</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" scale="0" unitRef="usd">1,459,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" scale="0" unitRef="usd">10,540,635</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" scale="0" unitRef="usd">11,999,686</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ATM offering, net of issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="inm:ATMOfferingNetOfIssuanceCostsShares" scale="0" unitRef="shares">10,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="inm:ATMOfferingNetOfIssuanceCosts" scale="0" unitRef="usd">146,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:ATMOfferingNetOfIssuanceCosts" scale="0" unitRef="usd">146,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Registered direct and private placement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="inm:RegisteredDirectAndPrivatePlacementShares" scale="0" unitRef="shares">65,002</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="inm:RegisteredDirectAndPrivatePlacement" scale="0" unitRef="usd">754,072</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:RegisteredDirectAndPrivatePlacement" scale="0" unitRef="usd">4,245,508</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:RegisteredDirectAndPrivatePlacement" scale="0" unitRef="usd">4,999,580</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareIssuanceCosts" scale="0" sign="-" unitRef="usd">375,220</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareIssuanceCosts" scale="0" sign="-" unitRef="usd">2,506,795</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareIssuanceCosts" scale="0" sign="-" unitRef="usd">2,882,015</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Agents' warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:AgentsWarrants" scale="0" unitRef="usd">739,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:AgentsWarrants" scale="0" unitRef="usd">739,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Agents' investment options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:AgentsInvestmentOptions" scale="0" unitRef="usd">192,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:AgentsInvestmentOptions" scale="0" unitRef="usd">192,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of pre-funded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="inm:ExerciseOfPrefundedWarrantsinShares" scale="0" unitRef="shares">125,853</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="inm:ExerciseOfPrefundedWarrants" scale="0" unitRef="usd">4,283,969</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:ExerciseOfPrefundedWarrants" scale="0" sign="-" unitRef="usd">4,283,654</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:ExerciseOfPrefundedWarrants" scale="0" unitRef="usd">315</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="inm:ExerciseOfWarrantsinShares" scale="0" unitRef="shares">6,293</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="inm:ExerciseOfWarrantsin" scale="0" unitRef="usd">769,260</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:ExerciseOfWarrantsin" scale="0" sign="-" unitRef="usd">769,260</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Acquisition of BayMedica</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="inm:AcquisitionOfBayMedicainShares" scale="0" unitRef="shares">82,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="inm:AcquisitionOfBayMedica" scale="0" unitRef="usd">3,013,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:AcquisitionOfBayMedica" scale="0" unitRef="usd">3,013,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issued for consulting services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">3,132</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">79,879</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">79,879</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant modification expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantModificationExpense" scale="0" unitRef="usd">1,314,307</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantModificationExpense" scale="0" unitRef="usd">1,314,307</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss for the period</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="inm:LossAndComprehensivelossesForThePeriod" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:LossAndComprehensivelossesForThePeriod" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">697,894</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">697,894</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance June 30, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">650,667</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">70,718,461</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">31,684,098</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">93,452,587</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">128,569</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,078,541</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes form an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_004"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS
    OF CASH FLOWS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended June
    30, 2022 and 2021</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Operating Activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">10,203,089</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Items not requiring cash:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Amortization and depreciation</td><td>&#160;</td>
    <td style="text-align: center">5, 7</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">185,657</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">120,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: center">11</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">697,894</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">610,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: center">12</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">79,879</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">326,133</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">107,828</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Loss on disposal of assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" sign="-" unitRef="usd">11,355</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" sign="-" unitRef="usd">555</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income received on short-term investments</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:InterestIncomeaccruedReceivedOnShorttermInvestments" scale="0" sign="-" unitRef="usd">115</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:InterestIncomeaccruedReceivedOnShorttermInvestments" scale="0" unitRef="usd">131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Unrealized gain on derivative warrants liability</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:UnrealizedGainOnDerivativeWarrantsLiability" scale="0" unitRef="usd">242,628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Unrealized foreign exchange loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:UnrealizedGainOnForeignExchange" scale="0" sign="-" unitRef="usd">1,770</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:UnrealizedGainOnForeignExchange" scale="0" unitRef="usd">445</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Impairment of intangible assets and goodwill</td><td>&#160;</td>
    <td style="text-align: center">6</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="0" unitRef="usd">3,472,593</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Payments on lease obligations</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="0" unitRef="usd">341,862</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="0" unitRef="usd">93,951</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance expense</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:FinanceExpense" scale="0" unitRef="usd">360,350</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Warrant modification expense</td><td>&#160;</td>
    <td style="text-align: center">10</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantModificationExpenses" scale="0" unitRef="usd">1,314,307</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in non-cash working capital:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Inventories</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">2,003,732</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Prepaids and other assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" sign="-" unitRef="usd">190,661</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" unitRef="usd">823,172</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Other non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" unitRef="usd">61,432</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" unitRef="usd">14,161</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">40,008</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">40,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd">811,599</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">346,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" sign="-" unitRef="usd">5,142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">15,583,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">9,790,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Investing Activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cash acquired from acquisition of BayMedica</td><td>&#160;</td>
    <td style="text-align: center">8</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:CashAcquiredFromAcqusition" scale="0" unitRef="usd">91,566</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Acquisition consideration payable</td><td>&#160;</td>
    <td style="text-align: center">8</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">300,457</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">39,108</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">1,725</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Loan receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">8</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansReceivable" scale="0" unitRef="usd">425,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">672,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">1,725</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Financing Activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Shares issued for cash</td><td>&#160;</td>
    <td style="text-align: center">10</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">17,146,114</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">12,472,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Share issuance costs</td><td>&#160;</td>
    <td style="text-align: center">10</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" unitRef="usd">1,784,791</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" unitRef="usd">1,617,778</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Repayment of debt</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd">290,826</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">15,070,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">10,854,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Effects of foreign exchange on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">494,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Increase (decrease) in cash during the period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">1,186,260</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">1,557,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">7,363,126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">5,805,809</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash equivalents end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">6,176,866</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">7,363,126</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 16 for Non-Cash Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes form an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="b_005"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NatureOfOperations-c0_cont_1" escape="true" name="us-gaap:NatureOfOperations"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>1.
NATURE OF BUSINESS AND GOING CONCERN</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_2" id="_NatureOfOperations-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">InMed
Pharmaceuticals Inc. (&#8220;InMed&#8221; or the &#8220;Company&#8221;) was incorporated in the Province of British Columbia on May 19,
1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline
of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high
unmet medical needs. The Company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids
for various market sectors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_3" id="_NatureOfOperations-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s shares are listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the trading symbol &#8220;INM&#8221;. InMed&#8217;s
corporate office and principal place of business is located at #310 &#8211; 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_4" id="_NatureOfOperations-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2014-15,
Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated
whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability
to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_5" id="_NatureOfOperations-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Through
June 30, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred
recurring losses and negative cash flows from operations since its inception, including net losses of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" unitRef="usd">18.6</ix:nonFraction> million and $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" unitRef="usd">10.2</ix:nonFraction> million
for the years ended June 30, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CumulativeEarningsDeficit" scale="6" unitRef="usd">93.5</ix:nonFraction> million as of
June 30, 2022 (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CumulativeEarningsDeficit" scale="6" unitRef="usd">74.9</ix:nonFraction> million). The Company expects to continue to generate operating losses for the foreseeable future.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_6" id="_NatureOfOperations-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of the issuance date of these consolidated
financial statements, the Company expects its cash and cash equivalents of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="inm:CashAndCashEquivalent" scale="6" unitRef="usd">6.2</ix:nonFraction> million as of June 30, 2022, combined with the approximate
$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" unitRef="usd">5.4</ix:nonFraction> million of net proceeds from a private placement which closed on September 13, 2022 (see Note 20), will be sufficient to fund its
operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal
2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory
as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to
raise additional capital to finance its operations. As a result of the recurring losses and requirement for cash in fiscal 2023 or the
beginning of fiscal 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within
one year after the date that the consolidated financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_7" id="_NatureOfOperations-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including
collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing
on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s existing
stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_NatureOfOperations-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its
commitments, realize its assets and discharge its liabilities in the normal course. These consolidated financial statements do not reflect
adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going
concern and such adjustments could be material.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United
States (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;)
for financial information.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the
reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported.
It also requires management to exercise judgment in applying the Company&#8217;s accounting policies. In the future, actual experience
may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions
and estimates are significant to these consolidated financial statements are the estimated fair values of the assets acquired and liabilities
assumed in acquisitions, the estimate of useful life of intangible assets, the application of the going concern assumption, the impairment
assessment for long-lived assets, and determining the fair value of share-based payments and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_COVID19ImpactsPolicyTextBlock-c0_cont_1" escape="true" name="inm:COVID19ImpactsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>COVID-19
Impacts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation id="_COVID19ImpactsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 11, 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. The full extent to which the COVID-19
pandemic may directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses,
research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain,
such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to
contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating
to the preparation of these consolidated financial statements. While there was no material impact to the Company&#8217;s consolidated
financial statements as of and for the year ended June 30, 2022, the Company&#8217;s future assessment of the magnitude and duration
of COVID-19, as well as other factors, could result in a material impact to the Company&#8217;s consolidated financial statements in
future reporting periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Consolidation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical
Ltd., BayMedica, LLC, Biogen Sciences Inc., and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either
directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain
benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany
transactions are eliminated in preparing these consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Foreign
Currency</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -20.55pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
functional currency of the Company and its subsidiaries is the U.S. Dollar. These consolidated financial statements are presented in
U.S. Dollars. References to &#8220;$&#8221; and &#8220;US$&#8221; are to United States (&#8220;U.S.&#8221;) dollars and references to
&#8220;C$&#8221; are to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_BusinessCombinationsPolicy-c0_cont_1" escape="true" name="us-gaap:BusinessCombinationsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Business
Combinations</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_BusinessCombinationsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Business
combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair
values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as
goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair
values at the date of acquisition. If the Company&#8217;s interest in the fair value of the acquiree&#8217;s net identifiable assets
exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in
connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments
with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an
insignificant risk of change in value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Short-term
Investments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve
months. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change
in value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Accounts
Receivable</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Accounts
receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company&#8217;s
best estimate of the amount of probable credit losses in existing accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition
and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected
to affect future collections experience. Expected credit losses on our accounts receivable were immaterial as at June 30, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Inventories</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Inventories
are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value.
Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing
costs and production and labor costs related to manufacturing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. At June 30, 2022,
no amounts had been charged to the valuation allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Deferred
Financing Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_DeferredChargesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity
financings as deferred financing costs until such financings are consummated. After consummation of the equity financing, these costs
are recorded as a reduction to shareholders&#8217; equity generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred financing costs will be expensed immediately as a charge to operating expenses in the consolidated statements
of operations and comprehensive loss. As of June 30, 2022, $<span style="-sec-ix-hidden: hidden-fact-78">Nil</span> (2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" scale="0" unitRef="usd">112,074</ix:nonFraction>) of deferred financing costs were capitalized and recorded
as prepaids and other assets on the consolidated balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Property, Equipment and ROU Assets,
Net </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment
and leasehold improvements are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of
equipment and leasehold improvements comprises their purchase price. The useful lives of equipment and leasehold improvements are reviewed
at least once per year. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated
useful lives as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Computer equipment &#8211; <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" scale="-2" unitRef="pure">30</ix:nonFraction>% per annum</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr> </table></ix:continuation></ix:continuation><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Leasehold
                                            improvements &#8211; lesser of initial lease term or useful life</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment
and leasehold improvements, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The right-of-use assets are initially
measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less
any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the right-of-use asset or the
lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits.
The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition,
the right-of-use assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability
(see Note 2 Lease (i)).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Intangible
Assets, Net </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property
is recorded at cost and is amortized on a straight-line basis over an estimated useful life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">18</ix:nonNumeric> years net of any accumulated impairment
losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:nonNumeric contextRef="c0" continuedAt="_InProcessRDPolicyTextBlock-c0_cont_1" escape="true" name="inm:InProcessRDPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>In-Process
R&amp;D</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation id="_InProcessRDPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In-process
R&amp;D (&#8220;IPR&amp;D&#8221;) is classified as an indefinite-lived intangible asset and is not amortized. IPR&amp;D becomes definite-lived
upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent
to the acquisition of IPR&amp;D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual
basis or more frequently if an indicator of impairment is present.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2.4pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Impairment
of Long-Lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the
asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted
cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount
by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale
are reported at the lower of the carrying amount or fair value, less costs to sell. As of June 30, 2022, the Company determined that
the long-lived assets of BayMedica were impaired (see Note 6) and no assets were held-for-sale.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Goodwill</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company tests goodwill for potential
impairment annually on June 30, or more frequently if an event or other circumstance indicates that the Company may not be able to recover
the carrying amount of the net assets of the reporting unit. The Company&#8217;s operations consist of <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure">two</ix:nonFraction> operating and reportable segments,
InMed Pharmaceuticals (the &#8220;InMed&#8221; segment) and BayMedica (the &#8220;BayMedica&#8221; segment). In evaluating goodwill for
impairment, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. If a Company bypasses the qualitative assessment, or if the Company concludes that it is more likely
than not that the fair value of a reporting unit is less than its carrying value, then the Company performs a quantitative impairment
test by comparing the fair value of a reporting unit with its carrying amount (See Note 6) and records an impairment charge if the carrying
value exceeds the fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:nonNumeric contextRef="c0" continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1" escape="true" name="inm:FinancialAssetsAndLiabilitiesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Assets and Liabilities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_2" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_3" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and
subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are
or elected to be carried at fair value through profit or loss or where changes in fair value are recognized in the consolidated statements
of operations and comprehensive loss in other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_4" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments are subsequently recorded at cost plus accrued interest, which approximates fair value. Accounts receivable are reported
at outstanding amounts, net of provisions for uncollectable amounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_5" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
Liabilities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_6" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities, including accounts payable and accrued liabilities, are initially recognized at fair value net of any transaction costs
directly attributable to the issuance of the instrument and subsequently carried at amortized cost using the effective interest rate
method. This ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried
in the consolidated balance sheet. Interest expense in this context includes initial transaction costs and premiums payable on redemption,
as well as any interest or coupon payable while the liability is outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2.4pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES (cont&#8217;d)</b></span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_7" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Assets and Liabilities (cont&#8217;d)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_8" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">To
determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of
financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three
levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_9" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                               1 &#8211;</span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;Unadjusted
                                            quoted prices in active markets for identical instruments.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_10" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> Level 2 &#8211;</span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;Inputs
                                            other than quoted prices included within Level 1 that are observable for the asset or liability,
                                            either directly or indirectly. Level 2 inputs include quoted prices for similar assets or
                                            liabilities in active markets, quoted prices for identical or similar assets or liabilities
                                            in markets that are not active, inputs other than quoted prices that are observable for the
                                            asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived
                                            principally from or corroborated by observable market data by correlation or other means
                                            (market corroborated inputs).</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation continuedAt="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_11" id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                               3 &#8211;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;Inputs
                                            are unobservable and reflect the Company&#8217;s assumptions as to what market participants
                                            would use in pricing the asset or liability. The Company develops these inputs based on the
                                            best information available. Assets and liabilities are classified based on the lowest level
                                            of input that is significant to the fair value measurements. Changes in the observability
                                            of valuation inputs may result in a reclassification of levels for certain securities within
                                            the fair value hierarchy.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation id="_FinancialAssetsAndLiabilitiesPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities,
approximate their carrying values as at June 30, 2022 and 2021 due to their immediate or short-term maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company records a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset
and liability method. Under this method, it recognizes deferred income tax assets and liabilities for the expected future tax consequences
of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets and liabilities
are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities
are expected to be realized or settled. The Company recognizes the deferred income tax effects of a change in tax rates in the period
of the enactment. The Company records a valuation allowance to reduce its deferred tax assets to the net amount that management believes
is more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions are more likely
than not of being sustained. <ix:nonNumeric contextRef="c0" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">Recognized income tax positions are measured at the largest amount that is greater than fifty percent likely
of being realized.</ix:nonNumeric> The Company records interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Revenue
Recognition</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products
and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers
in exchange for those products and services. ASC 606, <i>Revenue from Contracts with Customers</i> defines a five-step process to recognize
revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations
in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract,
and recognizing revenue when or as the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Revenue
Recognition (cont&#8217;d)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Revenue consists of manufacturing and
distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when
control over the products have been transferred to the customer and the Company has a present right to payment. Sales and other taxes
that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return,
for claims of damaged or non-compliant products, exist with the Company&#8217;s customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense,
when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Revenues
within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance
of when control is transferred to the customer. The time between invoicing and when payment is due is not significant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesVendorAllowancesPolicy-c0_cont_1" escape="true" name="us-gaap:CostOfSalesVendorAllowancesPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cost
of Sales</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation id="_CostOfSalesVendorAllowancesPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Cost
of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing
costs. Cost of sales also includes production and labor costs for the Company&#8217;s manufacturing business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:nonNumeric contextRef="c0" continuedAt="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Shipping
and Handling</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation id="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company records freight billed to customers within Net sales. Shipping and handling costs associated with inbound freight and goods shipped
to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating
expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Earnings
(Loss) Per Share</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Basic
earnings (loss) per common share (&#8220;EPS&#8221;) is computed by dividing the net income or loss applicable to common shares of the
Company by the weighted average number of common shares outstanding for the relevant period. Diluted earnings (loss) per common share
(&#8220;Diluted EPS&#8221;) is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average
number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive
instruments were converted. If the conversion of outstanding stock options and warrants into common share is anti-dilutive, then diluted
EPS is not presented separately from EPS.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Share-based
Payments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
fair value, at the grant date, of equity-classified share awards is charged to income or loss over the period for which the benefits
of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards
are measured separately and expensed over the related tranche&#8217;s vesting period. The corresponding accrued entitlement is recorded
in additional paid-in capital. The amount recognized as an expense is adjusted to reflect the number of share options that vest. The
fair value of awards is calculated using the Black-Scholes option pricing model which considers the exercise price, current market price
of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Share-based
Payments (cont&#8217;d)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Starting
July 1, 2018, the Company accounts for non-employee awards under the guidance provided under ASU 2018-07 and uses an expected term to
value non-employee options on an award-by-award basis.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
expected term of the Company&#8217;s employee stock options is determined using the simplified method and the Company estimates the forfeitures
on the grant date for options issued. The expected term of the Company&#8217;s non-employee stock options is the contractual term of
the options granted and the Company estimates the forfeitures on the grant date for options issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company conducts research and development programs and incurs costs related to these activities, including research and development personnel
compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the
periods in which they are incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:nonNumeric contextRef="c0" continuedAt="_PatentsAndIntellectualPropertyCostsPolicyTextBlock-c0_cont_1" escape="true" name="inm:PatentsAndIntellectualPropertyCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Patents
and Intellectual Property Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation id="_PatentsAndIntellectualPropertyCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty
surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third
parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the
patent.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
reporting </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s operations consist of two operating and reportable segments, the InMed segment and the BayMedica segment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry (See Note 15).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2.4pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">At
inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date,
discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental
borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized
cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in
an index or rate, if there is a change in the Company&#8217;s estimate of the amount expected to be payable under a residual value guarantee,
or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability
is re-measured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit
or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component
and its associated non-lease components as a single lease component for all of its asset classes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement
of the right-of-use asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize
right-of-use assets and lease liabilities for short-term leases that have a lease term of <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseTermOfContract1">12</ix:nonNumeric> months or less. The lease payments associated
with these leases is recognized as an expense on a straight- line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_82" id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fair
                                            Value Measurement</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_82"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
June 2022, FASB issued ASU 2022-03, <i>Fair Value Measurement (Topic 82):</i> Fair Value Measurement of Equity Securities Subject to
Contractual Sale Restrictions. The amendments in this ASU clarify the guidance in ASC 820 on the fair value measurement of an equity
security that is subject to a contractual sale restriction and require specific disclosures related to such an equity security. This
standard is effective for fiscal years beginning after December 15, 2023. The Company does not expect the standard to have a significant
impact on the consolidated financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2.4pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>3.
CUSTOMER CONCENTRATION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" name="us-gaap:ConcentrationRiskCustomer">The
Company had three customers during the year ended June 30, 2022, which individually generated 10% or more of the Company&#8217;s net
sales.</ix:nonNumeric> These customers accounted for <ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="inm:ConcentrationRiskPercentage" scale="-2" unitRef="pure">48</ix:nonFraction>% of the Company&#8217;s sales for the year ended June 30, 2022. As of June 30, 2022, these customers
represented <ix:nonFraction contextRef="c28" decimals="2" format="ixt:num-dot-decimal" name="inm:ConcentrationRiskPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% of the Company&#8217;s outstanding accounts receivable.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InventoryDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>4.
INVENTORIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c0_cont_2" id="_InventoryDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Inventories
consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c0_cont_3" id="_InventoryDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
 2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
 2021</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="0" unitRef="usd">292,577</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd">1,724,851</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">473,426</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,490,854</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_InventoryDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, inventory expensed to cost of goods sold was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">545,889</ix:nonFraction> (2021 - $<span style="-sec-ix-hidden: hidden-fact-83">Nil</span>).</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><b>5. PROPERTY,
EQUIPMENT AND ROU ASSETS, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Property, equipment and ROU assets
consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>June 30,<br/>
2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>June 30,<br/>
2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">$</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">$</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-size: 10pt">Right of Use Assets (leases)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,167,436</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">439,321</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">212,877</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">66,888</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Leasehold Improvements</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">40,409</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">42,986</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Property and equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,420,722</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">549,195</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Less: accumulated depreciation and amortization</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">516,470</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">222,600</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Property, equipment and ROU assets, net</span></td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">904,252</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">326,595</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expense on property, equipment
and leasehold improvements for the year ended June 30, 2022, was $26,426 (2021 - $21,143). Amortization expense related to the right-of-use
assets for the year ended June 30, 2022, was $289,594 (2021 - $76,165) and was recorded in general and administrative expenses.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>6.
IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, the Company recorded goodwill of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillGross" scale="0" unitRef="usd">2,023,039</ix:nonFraction>, definite lived intangible assets of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:ImpairmentOfIntangibleAssetExcludingGoodwill" scale="0" unitRef="usd">216,000</ix:nonFraction>, IPR&amp;D of
$<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="inm:ImpairmentOfIntangibleAssetExcludingGoodwill" scale="0" unitRef="usd">1,249,000</ix:nonFraction> and patents of $<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="inm:ImpairmentOfIntangibleAssetExcludingGoodwill" scale="0" unitRef="usd">1,191,000</ix:nonFraction> in connection with the acquisition of BayMedica, as described in Note 8.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"></p></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company performs an annual impairment
test at the reporting unit level as of June 30 of each fiscal year. As of June 30, 2022, the Company qualitatively assessed whether it
is more likely than not that the respective fair value of the Company&#8217;s BayMedica reporting unit was less than its carrying amount,
including goodwill. For a variety of reasons, performance of the BayMedica segment has not materialized as expected. Contributing factors
include but are not limited to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">market
                                            demand for launched compounds has not materialized as quickly as the Company anticipated;</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">recent
                                            overarching recessionary pressures have contributed to hesitation within the health and wellness
                                            (H&amp;W) sector to invest in, and launch, new rare cannabinoid products;</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_6" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">in
                                            this nascent market, BayMedica&#8217;s perceived competitive advantages of certified, high purity and
                                            reliability and consistency of supply have not resonated with the industry&#8217;s current
                                            product manufacturers; and</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_7" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">additional
                                            downward pricing pressure for cannabinoids in the H&amp;W sector.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_8" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
a result of this sustained decline in performance compared to expectations and continuing market uncertainties, the Company determined
that as of June 30, 2022, it was more likely than not that the carrying value of these acquired intangibles exceeded their estimated
fair value. Accordingly, the Company performed an impairment analysis as of that date using the income method, the relieve from royalty
method and the multi-period excess earnings method. This analysis required significant judgments, including the estimation of future revenues,
royalties, licensing fees, costs, the probability of success in various phases of its development programs, potential post launch cash
flows and discount rates. The Company recorded a goodwill and intangible asset impairment charge for the excess of the reporting unit&#8217;s
carrying value over its fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="margin: 0 0 0 0pt"></p><div>

</div><p style="margin: 0 0 0 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0 0 0 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>6.
IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL (cont&#8217;d)</b></span></p><div>

</div><p style="margin: 0 0 0 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_9" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table provides the Company&#8217;s
goodwill, indefinite and definite lived intangible assets as of June 30, 2022 and 2021. There was no impairment of InMed long lived intangible
assets as of June 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p></ix:continuation><div>

</div><div>

</div><p style="margin: 0 0 0 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_10" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd">2,023,039</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd">2,023,039</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Indefinite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd">1,249,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd">1,249,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Definite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademark and Intellectual Property</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillFairValueDisclosure" scale="0" unitRef="usd">1,736,420</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd">216,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" sign="-" unitRef="usd">786,637</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd">200,554</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillFairValueDisclosure" scale="0" unitRef="usd">965,229</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Definite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueOfAssetsAcquired" scale="0" unitRef="usd">1,191,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" sign="-" unitRef="usd">47,314</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillFairValueDisclosure" scale="0" unitRef="usd">1,143,686</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">2,108,915</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p><div>

</div><ix:continuation id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For goodwill, the Company recognized
an impairment charge of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" scale="0" unitRef="usd">2</ix:nonFraction> million and $<span style="-sec-ix-hidden: hidden-fact-90">Nil</span> during the years ended June 30, 2022 and 2021, respectively. For the identified indefinite
lived assets, the Company recognized an impairment charge of $<ix:nonFraction contextRef="c0" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentChargeOnReclassifiedAssets" scale="0" unitRef="usd">1.2</ix:nonFraction> million and $<span style="-sec-ix-hidden: hidden-fact-91">Nil</span> during the years ended June 30, 2022 and 2021, respectively.
For identified definite lived intangible assets, the Company recognized an impairment charge of $<ix:nonFraction contextRef="c0" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" unitRef="usd">0.2</ix:nonFraction> million and $<span style="-sec-ix-hidden: hidden-fact-92">Nil</span> during the years
ended June 30, 2022 and 2021, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>7.
INTANGIBLE ASSETS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intellectual property</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,736,420</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,736,420</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedPatentsGross" scale="0" unitRef="usd">1,191,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetAcquiredInPlaceLeases" scale="0" unitRef="usd">2,927,420</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetAcquiredInPlaceLeases" scale="0" unitRef="usd">1,736,420</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" scale="0" unitRef="usd">818,505</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" scale="0" unitRef="usd">674,723</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">2,108,915</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">1,061,697</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
intellectual property is recorded at cost and is amortized on a straight-line basis over <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">18</ix:nonNumeric> years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated
useful life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">18</ix:nonNumeric> years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">13</ix:nonNumeric> years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_6" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Amortization
expense on intangible assets for the year ended June 30, 2022 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">159,228</ix:nonFraction> (2021 - $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">99,723</ix:nonFraction>). The Company expects amortization expense
to be incurred over the next five years as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" scale="0" unitRef="usd">161,477</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" scale="0" unitRef="usd">161,477</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" scale="0" unitRef="usd">161,477</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" scale="0" unitRef="usd">161,477</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" scale="0" unitRef="usd">161,477</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:FiniteLivedIntangibleAssetNet" scale="0" unitRef="usd">807,385</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AcquisitionTextBlock-c0_cont_1" escape="true" name="inm:AcquisitionTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>8.
ACQUISITION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_2" id="_AcquisitionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On October 13, 2021, the Company completed
the acquisition of BayMedica, a private company based in the U.S. that specializes in the manufacturing and commercialization of rare
cannabinoids. <ix:nonNumeric contextRef="c47" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity">The Company acquired <ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure">100</ix:nonFraction>% of BayMedica in exchange for i) 82,000 common shares issued to BayMedica&#8217;s equity and convertible
debt holders, subject to a six-month contractual hold period and ii) $1 million to be held in escrow, subject to reduction for certain
post-closing adjustments or satisfaction of indemnification claims under the definitive agreement (the &#8220;BayMedica Agreement&#8221;)
in the six- and twelve-month periods following the closing.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_3" id="_AcquisitionTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Total
consideration for the acquisition of BayMedica is summarized as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_4" id="_AcquisitionTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Purchase
                                            Price<br/>
                                            Consideration<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Estimated fair value of common shares issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="0" unitRef="usd">3,013,500</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" scale="0" unitRef="usd">1,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:Post-closing adjustments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="inm:BusinessCombinationPostclosingAdjustments" scale="0" sign="-" unitRef="usd">199,543</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Estimated fair value of consideration transferred</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd">3,813,957</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_5" id="_AcquisitionTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">82,000</ix:nonFraction> common shares were valued at $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" unitRef="usdPershares">36.75</ix:nonFraction>, being the closing price of the Company&#8217;s common shares on Nasdaq on October 13, 2021.
The cash component is subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims and therefore
is subject to further changes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_6" id="_AcquisitionTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the acquisition, the Company has a $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansReceivable" scale="0" unitRef="usd">425,000</ix:nonFraction> loan receivable from BayMedica and BayMedica has an equal loan payable to the Company.
As a result of the acquisition of BayMedica, the loan receivable and payable is effectively settled between the parties.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_7" id="_AcquisitionTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the acquisition method of accounting, the purchase price of BayMedica has been allocated to the acquired assets and assumed
liabilities based on their estimated acquisition date fair values. The fair value estimates were based on income, estimates and other
analyses. The excess of the total consideration over the estimated fair value of the amounts initially assigned to the identifiable assets
acquired and liabilities assumed has been recorded as goodwill, which is not deductible for income taxes purposes. The goodwill balance
represents the assembled workforce acquired, the combined company&#8217;s expectations of the strategic opportunities available as a
result of the acquisition, and other synergies that will be derived from the acquisition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>8.
ACQUISITION (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_8" id="_AcquisitionTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the final fair value of assets acquired and liabilities assumed as of the acquisition date:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_9" id="_AcquisitionTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Purchase Price</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Allocation</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>($)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets acquired:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" unitRef="usd">91,566</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" unitRef="usd">36,100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" unitRef="usd">487,122</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">131,674</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="0" unitRef="usd">133,911</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" scale="0" unitRef="usd">1,249,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" scale="0" unitRef="usd">1,191,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Trademark</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" scale="0" unitRef="usd">216,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="0" unitRef="usd">2,023,039</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total assets acquired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" unitRef="usd">5,559,412</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Liabilities assumed:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="0" unitRef="usd">1,024,487</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other short-term liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" scale="0" unitRef="usd">598,245</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long-term debt</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="0" unitRef="usd">122,723</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities acquired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="0" unitRef="usd">1,745,455</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Estimated
    fair value of net assets acquired</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" unitRef="usd">3,813,957</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_10" id="_AcquisitionTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; ">Tangible
assets and liabilities were valued at their respective carrying amounts as management believes that these amounts approximated their
acquisition-date fair values.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_11" id="_AcquisitionTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Purchase Price allocation includes certain identifiable intangible assets with an estimated fair value of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" unitRef="usd">2,656,000</ix:nonFraction>. These
intangible assets include trade secrets, product formulation knowledge, patents and trademarks. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_12" id="_AcquisitionTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
IPR&amp;D are related identifiable intangible assets associated with cannabinoid manufacturing processes and includes knowhow and trade
secrets. The multi-period excess earnings method was used to determine the fair value of these assets as at the date of acquisition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_13" id="_AcquisitionTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; ">The
acquired trademark represents the trade name ProDiol&#174;. The fair value of the trademark was determined using the relief from
royalty method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_14" id="_AcquisitionTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
patents consist of patents related to the development of cannabinoid analogs, the fair value of which was determined using the income
approach. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="c49" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">18</ix:nonNumeric> years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>8.
ACQUISITION (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_15" id="_AcquisitionTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Following the acquisition date, the
operating results of BayMedica have been included in the consolidated financial statements. For the period from the October 13, 2021 acquisition
date through June 30, 2022, sales attributable to BayMedica were $<ix:nonFraction contextRef="c50" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" unitRef="usd">1.1</ix:nonFraction> million and operating losses attributable to BayMedica were $<ix:nonFraction contextRef="c50" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" unitRef="usd">5.2</ix:nonFraction>
million. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="6" unitRef="usd">0.2</ix:nonFraction> million
for the year ended June 30, 2022 and were included in general and administrative expenses in the consolidated statements of operations
and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_AcquisitionTextBlock-c0_cont_16" id="_AcquisitionTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the pro forma consolidated results of the Company assuming the BayMedica acquisition had been completed on July
1, 2020:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AcquisitionTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year Ended June
    30</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">1,365,755</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" unitRef="usd">1,904,013</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" sign="-" unitRef="usd">19,260,014</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" sign="-" unitRef="usd">10,705,494</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>9.
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Accounts
payable and accrued liabilities consist of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 24pt"></p><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="0" unitRef="usd">1,166,068</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="0" unitRef="usd">775,129</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:AccruedResearchAndDevelopment" scale="0" unitRef="usd">839,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:AccruedResearchAndDevelopment" scale="0" unitRef="usd">309,901</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee compensation, benefits and related accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="0" unitRef="usd">139,120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="0" unitRef="usd">880,207</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="0" unitRef="usd">270,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="0" unitRef="usd">169,641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,415,265</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,134,878</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 24pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_1" escape="true" name="inm:ShareCapitalAndReservesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>10.
SHARE CAPITAL AND RESERVES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_2" id="_ShareCapitalAndReservesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 7, 2022, the Company effected a one-for-25 reverse stock split of its issued and outstanding common shares. Accordingly, all
common share, stock option, per common share and warrant amounts for all periods presented in the consolidated financial statements and
notes thereto have been adjusted retrospectively to reflect this reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>10.
SHARE CAPITAL AND RESERVES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_3" id="_ShareCapitalAndReservesTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_4" id="_ShareCapitalAndReservesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company&#8217;s authorized share structure consisted of: (i) an unlimited number of common shares without par value;
and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as at June 30, 2022
and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_5" id="_ShareCapitalAndReservesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company may issue preferred shares and may, at the time of issuance, determine the rights, preference and limitations pertaining to these
shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding
up of the Company before any payment is made to the holders of common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_6" id="_ShareCapitalAndReservesTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Common Shares</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_7" id="_ShareCapitalAndReservesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, the Company completed the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_8" id="_ShareCapitalAndReservesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">July
2021 Private Placement Offering:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_9" id="_ShareCapitalAndReservesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfPrivatePlacementOfferingTableTextBlock-c0_cont_1" escape="true" name="inm:ScheduleOfPrivatePlacementOfferingTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Transaction
    Description</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Issue
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Shares Issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">35,600</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">74.325</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">2,645,970</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants
    Issued</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">125,853</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">74.3226</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">9,353,716</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">11,999,686</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allocated to Additional
    Paid-in Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" sign="-" unitRef="usd">10,540,635</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">1,459,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Share Issuance Costs</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" sign="-" unitRef="usd">247,336</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_10" id="_ShareCapitalAndReservesTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
July 2, 2021, the Company closed a private placement of its common shares and issued an aggregate of <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">35,600</ix:nonFraction> common shares and <ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="inm:PrefundWarrants" scale="0" unitRef="shares">125,853</ix:nonFraction>
pre-funded warrants, for gross proceeds of $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd">11,999,686</ix:nonFraction>. The pre-funded warrants were determined to be common stock equivalents. Each
common share and each pre-funded warrant were sold in the offering with a warrant to purchase a common share. Transaction costs were
allocated proportionally between common shares and warrants with $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">247,336</ix:nonFraction> allocated to common shares and the balance of $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="inm:TransactionCostsAllocatedToAdditionalPaidinCapital" scale="0" unitRef="usd">1,786,831</ix:nonFraction> allocated
to additional paid-in capital and recorded as a component of shareholders&#8217; equity in the consolidated balance sheet. <ix:nonNumeric contextRef="c0" name="inm:ExercisedCommonSharesDescription">The 125,853
pre-funded warrants were fully exercised for 125,853 common shares during the year ended June 30, 2022, resulting in a $4,283,654 reclassification
from additional paid-in capital to common shares.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_11" id="_ShareCapitalAndReservesTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">June
2022 Registered Direct and Private Placement Offerings:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_12" id="_ShareCapitalAndReservesTextBlock-c0_cont_11"><ix:continuation id="_ScheduleOfPrivatePlacementOfferingTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Transaction
    Description</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Issue
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Shares Issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c81" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">65,002</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c81" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">21.450</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">1,394,286</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants
    Issued</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c83" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">168,099</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$'</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c83" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">21.4474</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">3,605,294</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">4,999,580</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allocated to Additional
    Paid-in Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" sign="-" unitRef="usd">4,245,508</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" unitRef="usd">754,072</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Share Issuance Costs</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="inm:TotalCommonShareValue" scale="0" sign="-" unitRef="usd">127,884</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>10.
SHARE CAPITAL AND RESERVES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Common Shares
                                            (cont&#8217;d)</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_13" id="_ShareCapitalAndReservesTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
April 22, 2022, the Company issued <ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">10,759</ix:nonFraction> common shares under an at-the-market offering (&#8220;ATM&#8221;) for proceeds of $<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="inm:CommonSharesNetIssuance" scale="0" unitRef="usd">146,533</ix:nonFraction>,
net of issuance costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_14" id="_ShareCapitalAndReservesTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
June 6, 2022, the Company closed a registered direct offering and concurrent private placement of its common shares. In the registered
direct offering, the Company issued an aggregate of <ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">65,002</ix:nonFraction> common shares and <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="inm:PrefundWarrants" scale="0" unitRef="shares">98,169</ix:nonFraction> pre-funded warrants, for gross proceeds of $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd">3,500,002</ix:nonFraction>.
In the concurrent private placement, the Company issued an aggregate of <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="inm:PrefundedWarrants" scale="0" unitRef="usd">69,930</ix:nonFraction> pre-funded warrants for gross proceeds of $<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd">1,499,999</ix:nonFraction>.
The pre-funded warrants were determined to be common stock equivalents. Each common stock and each pre-funded warrant were sold in the
offerings with a preferred investment option to purchase a common share. Transaction costs were allocated proportionally between common
shares and warrants with $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">127,884</ix:nonFraction> allocated to common shares and the balance of $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="inm:TransactionCostsAllocatedToAdditionalPaidinCapital" scale="0" unitRef="usd">719,964</ix:nonFraction> allocated to additional paid-in capital and
recorded as a component of shareholders&#8217; equity in the consolidated balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_15" id="_ShareCapitalAndReservesTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, in accordance with the BayMedica Agreement, the Company issued <ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">82,000</ix:nonFraction> common shares to BayMedica&#8217;s
historical equity and convertible debt holders (See Note 8). In addition, the Company issued <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="inm:CommonSharesConsultingServices" scale="0" unitRef="shares">78,312</ix:nonFraction> common shares for consulting services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_16" id="_ShareCapitalAndReservesTextBlock-c0_cont_15"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Share Purchase
                                            Warrants</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_17" id="_ShareCapitalAndReservesTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
November 16, 2020, <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="inm:IPOWarrantIssue" scale="0" unitRef="shares">71,200</ix:nonFraction> warrants were issued with an exercise price of $<ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">127.75</ix:nonFraction> per share, were immediately exercisable upon issuance,
and expire <ix:nonNumeric contextRef="c62" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6</ix:nonNumeric> years following the date of issuance. On June 6, 2022, the Company amended the warrants to re-price them to $<ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">18.50</ix:nonFraction> per share
with an expiry date of <ix:nonNumeric contextRef="c57" format="ixt:date-monthname-day-year-en" name="inm:WarrantExpiryDate">June 6, 2029</ix:nonNumeric>. Accordingly, the Company has calculated the incremental fair value from the modification to be $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantsModificationExpense" scale="0" unitRef="usd">119,555</ix:nonFraction>
and is recognized as a warrant modification expense in the statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_18" id="_ShareCapitalAndReservesTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
February 12, 2021, <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="inm:IPOWarrantIssue" scale="0" unitRef="shares">27,720</ix:nonFraction> warrants were issued with an exercise price of $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">121.25</ix:nonFraction> per share, were exercisable <ix:nonNumeric contextRef="c64" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6</ix:nonNumeric> months following issuance,
and expire <ix:nonNumeric contextRef="c65" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric> years following the date of issuance. On March 21, 2022, the Company amended the warrants to re-price them to $<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">11.25</ix:nonFraction> per
share with an expiry date of <ix:nonNumeric contextRef="c67" format="ixt:date-monthname-day-year-en" name="inm:WarrantExpiryDate">March 31, 2023</ix:nonNumeric>. Between March 21, 2022 and June 30, 2022, <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantsIssued" scale="0" unitRef="shares">15,606</ix:nonFraction> of the warrants were exercised on a cashless
basis resulting in the issuance of <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="inm:IssuanceOfCommonSharesIssued" scale="0" unitRef="shares">6,293</ix:nonFraction> common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_19" id="_ShareCapitalAndReservesTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
July 2, 2021, <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="inm:IPOWarrantIssue" scale="0" unitRef="shares">161,453</ix:nonFraction> warrants were issued with an exercise price of $<ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">71.20</ix:nonFraction> per share, were immediately exercisable upon issuance, and
expire <ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5</ix:nonNumeric> years following the date of issuance. The pre-funded and common warrants did not meet the criteria to be classified as a liability
award and therefore were treated as an equity award and recorded as a component of shareholders&#8217; equity in the consolidated balance
sheet. On June 6, 2022, the Company amended the warrants to re-price them to $<ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">18.50</ix:nonFraction> per share with an expiry date of June 6, 2029. Accordingly,
the Company has calculated the incremental fair value from the modification to be $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantsModificationExpense" scale="0" unitRef="usd">1,194,752</ix:nonFraction> and is recognized as a warrant modification
expense in the statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>10.
SHARE CAPITAL AND RESERVES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Share Purchase
                                            Warrants (cont&#8217;d)</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_20" id="_ShareCapitalAndReservesTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of changes in share purchase warrants from July 1, 2021 to June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_21" id="_ShareCapitalAndReservesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="inm:ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average <br/>Share Price</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Aggregate
    Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c88" decimals="INF" format="ixt:num-dot-decimal" name="inm:ShareCapitalOfNumberOfBalance" scale="0" unitRef="shares">98,920</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">75,47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c89" decimals="INF" format="ixt:num-dot-decimal" name="inm:ShareBasedPaymentNumberOfGranted" scale="0" unitRef="shares">161,453</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="inm:WeightedAverageSharePriceGranted" scale="0" unitRef="usdPershares">18.50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="inm:ShareBasedPaymentNumberOfExercised" scale="0" sign="-" unitRef="shares">15,606</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:ShareBasedPaymentsWeightedAverageSharePriceExercised" scale="0" unitRef="shares">11.25</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">125,611</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30,
    2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c90" decimals="INF" format="ixt:num-dot-decimal" name="inm:ShareCapitalOfNumberOfBalance" scale="0" unitRef="shares">244,767</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" scale="0" unitRef="usdPershares">41.99</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_22" id="_ShareCapitalAndReservesTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
total intrinsic value of warrants exercised during the year ended June 30, 2022 was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">125,611</ix:nonFraction> (2021 - $<span style="-sec-ix-hidden: hidden-fact-103">Nil</span>).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_23" id="_ShareCapitalAndReservesTextBlock-c0_cont_22"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">d)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Agents&#8217;
                                            Warrants</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_24" id="_ShareCapitalAndReservesTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
July 2, 2021, <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantsIssued" scale="0" unitRef="shares">12,109</ix:nonFraction> warrants were issued for services with an exercise price of $<ix:nonFraction contextRef="c68" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">92.9075</ix:nonFraction> per share, were immediately exercisable upon
issuance, and expire <ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5</ix:nonNumeric> years following the date of issuance. The agents&#8217; warrants did not meet the criteria to be classified as
a liability award and therefore were treated as an equity award and recorded as a component of shareholders&#8217; equity in the consolidated
balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_25" id="_ShareCapitalAndReservesTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of changes in agents&#8217; warrants from July 1, 2021 to June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_26" id="_ShareCapitalAndReservesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" escape="true" name="inm:ScheduleOfChangesInAgentsWarrantsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average <br/>Share Price</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Aggregate
    Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="inm:ShareBasedPaymentSharesNumberOfGranted" scale="0" unitRef="shares">12,109</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="4" format="ixt:num-dot-decimal" name="inm:ShareBasedPaymentWeightedAverageSharePriceGranted" scale="0" unitRef="usdPershares">92.9075</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30,
    2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c91" decimals="INF" format="ixt:num-dot-decimal" name="inm:ShareBasedPaymentNumberOfBalanceAtEnding" scale="0" unitRef="shares">12,109</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c91" decimals="4" format="ixt:num-dot-decimal" name="inm:ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" scale="0" unitRef="usdPershares">92.9075</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_27" id="_ShareCapitalAndReservesTextBlock-c0_cont_26"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">e)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Preferred Investment
                                            Options</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_28" id="_ShareCapitalAndReservesTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
June 6, 2022, <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantsIssued" scale="0" unitRef="shares">233,100</ix:nonFraction> preferred investment options were issued with an exercise price of $<ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">19.75</ix:nonFraction> per share, were immediately exercisable
upon issuance, and expire <ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.5</ix:nonNumeric> years following the date of issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ShareCapitalAndReservesTextBlock-c0_cont_29" id="_ShareCapitalAndReservesTextBlock-c0_cont_28"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">f)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Agents&#8217;
                                            Investment Options</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ShareCapitalAndReservesTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
June 6, 2022, <ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantsIssued" scale="0" unitRef="shares">15,152</ix:nonFraction> preferred investment options were issued for services with an exercise price of $<ix:nonFraction contextRef="c72" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">26.8125</ix:nonFraction> per share, were exercisable
<ix:nonNumeric contextRef="c73" format="ixt-sec:durmonth" name="inm:WarrantsIssuanceTerm">4</ix:nonNumeric> months upon issuance, and expire <ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5</ix:nonNumeric> years following the date of issuance.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. SHARE-BASED PAYMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Option Plan Details</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 24, 2017, and as amended on November 20, 2020, the Company&#8217;s shareholders approved: (i) the adoption of a new stock option
plan (the &#8220;Plan&#8221;) pursuant to which the Board of Directors may, from time to time, in its discretion and in accordance with
regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase
common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (<ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="inm:IssuedAndOutstandingPercentage" scale="-2" unitRef="pure">20</ix:nonFraction>%) of the issued and
outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the new
stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company&#8217;s
previous stock option plan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As at June 30, 2022, there were <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" scale="0" unitRef="shares">18,163</ix:nonFraction>
(June 30, 2021 &#8211; <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" scale="0" unitRef="shares">19,735</ix:nonFraction>) options available for future allocation pursuant to the terms of the Plan. The option price under each
option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board
of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Stock
options granted prior to May 2021 were granted with Canadian dollar exercise prices (United States dollar amounts for weighted average
exercise prices and aggregate intrinsic value are calculated using prevailing rates as at June 30, 2022). Commencing in May 2021, stock
options are granted with United States dollar exercise prices.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of changes in outstanding options from July 1, 2021 to June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price<br/>
$</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" scale="0" unitRef="shares">36,472</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="cadPershares">215.35</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">31,160</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" scale="0" unitRef="cadPershares">34.20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares">12,029</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" scale="0" unitRef="cadPershares">122.38</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" scale="0" unitRef="shares">55,603</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" scale="0" unitRef="shares">128.59</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">June 30, 2022:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:NumberOfVestedAndExercisable" scale="0" unitRef="shares">26,182</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:WeightedAverageExercisePriceVestedAndExercisable" scale="0" unitRef="cadPershares">228.87</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:NumberOfUnvested" scale="0" unitRef="shares">29,421</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:WeightedAverageExercisePriceUnvested" scale="0" unitRef="cadPershares">39.35</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">F-<span style="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>11.
SHARE-BASED PAYMENTS (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Fair Value
                                            of Options Issued During the Period</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Weighted
                                            Average Fair Value at Grant Date of Options Granted:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
weighted average fair value at grant date of options granted during the year ended June 30, 2022, was $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">21.04</ix:nonFraction> per option (year ended June
30, 2021 - $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">49.03</ix:nonFraction>). Assumptions used for options granted during the year ended June 30, 2022 included a weighted average risk-free interest
rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.17</ix:nonFraction>% (year ended June 30, 2021 &#8211; <ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.27</ix:nonFraction>%), weighted average expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">3.1</ix:nonNumeric> years calculated using the Simplified Method
for directors, officers and employees and the contractual life for consultants, weighted average volatility factor of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure">97.15</ix:nonFraction>% (year ended
June 30, 2021 &#8211; <ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure">105.88</ix:nonFraction>%), weighted average dividend yield of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>% (year ended June 30, 2021 &#8211; <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%) and a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="inm:WeightedAverageForfeitureRate" scale="-2" unitRef="pure">5</ix:nonFraction>% forfeiture rate
(year ended June 30, 2021 &#8211; <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="inm:WeightedAverageForfeitureRate" scale="-2" unitRef="pure">5</ix:nonFraction>%).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ii)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Expenses
                                            Arising from Share-based Payment Transactions:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Total
expenses arising from share-based payment transactions recognized during the year ended June 30, 2022, were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">697,894</ix:nonFraction> (2021 - $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">610,193</ix:nonFraction>).
$<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">419,075</ix:nonFraction> was allocated to general and administrative expenses (2021 - $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">405,801</ix:nonFraction>) and the remaining $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">278,819</ix:nonFraction> was allocated to research
and development expenses (2021 - $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">204,392</ix:nonFraction>). Unrecognized compensation cost at June 30, 2022 related to unvested options was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd">292,959</ix:nonFraction>
which will be recognized over a weighted-average vesting period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">1.0</ix:nonNumeric> years.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. LEASE OBLIGATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_2" id="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In conjunction with the acquisition
of BayMedica (Note 8), the Company acquired an operating lease for a corporate office with a remaining term of <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">1.8</ix:nonNumeric> years as at June 30,
2022. On the date of acquisition of BayMedica, the Company recognized right-of-use assets of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">728,115</ix:nonFraction> and a lease liability of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">825,427</ix:nonFraction>,
utilizing the remaining term on acquisition and a <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure">4.0</ix:nonFraction>% discount rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_3" id="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company is committed to minimum lease payments as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_4" id="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Maturity Analysis</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2022</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" scale="0" unitRef="usd">431,169</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">One to five years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:LesseeOperatingLeaseLiabilityPaymentDueYearFive" scale="0" unitRef="usd">396,665</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">More than five years </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-<span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="inm:LesseeOperatingLeaseLiabilityPaymentDue" scale="0" unitRef="usd">827,834</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Excludes estimated variable operating costs of $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd">92,964</ix:nonFraction> and $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="inm:OtherVariableLeaseCost" scale="0" unitRef="usd">60,916</ix:nonFraction> on an annual basis through to April 30, 2024 and August 31, 2024, respectively.</span></td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>13.
BASIC AND DILUTED LOSS PER SHARE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Basic
loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding
during the period. The pre-funded warrants were determined to be common stock equivalents and have been included in the weighted average
number of shares outstanding for calculation of the basic earnings per share number. As the outstanding stock options and warrants are
anti-dilutive, they are excluded from the weighted average number of common shares in the table below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year Ended</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted loss per share</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">33.17</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">37.96</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of common shares
    - basic and diluted</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">560,829</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">268,793</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><!-- Field: Page; Sequence: 118; Options: NewSection; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
INCOME TAXES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax
rate of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">27.0</ix:nonFraction>% (June 30, 2021 &#8211; <ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">27.0</ix:nonFraction>%) to the tax expense:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss before taxes</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense (recovery) at the statutory
    rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd">4,710,669</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd">2,754,834</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation
    allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">4,112,045</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">4,109,545</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd">220,491</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd">613,269</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd">99,490</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign exchange differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" unitRef="usd">591,263</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" sign="-" unitRef="usd">1,074,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share issuance cost
    capitalized in equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" sign="-" unitRef="usd">582,548</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" sign="-" unitRef="usd">390,685</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="0" unitRef="usd">197,131</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="0" unitRef="usd">10,484</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense (recovery)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Deferred
tax assets and liabilities are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-capital losses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" unitRef="usd">17,003,766</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" unitRef="usd">13,742,381</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsPropertyAndEquipmentsNet" scale="0" unitRef="usd">1,004</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsFinancingCost" scale="0" unitRef="usd">702,479</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsFinancingCost" scale="0" unitRef="usd">434,399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd">193,549</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" unitRef="usd">553,392</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd">248,254</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:LeaseLiabilities" scale="0" sign="-" unitRef="usd">51,994</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:LeaseLiabilities" scale="0" sign="-" unitRef="usd">51,108</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsAndLiabilitiesGross" scale="0" unitRef="usd">18,753,434</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsAndLiabilitiesGross" scale="0" unitRef="usd">14,228,892</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsIntangibleAssetsNet" scale="0" sign="-" unitRef="usd">181,845</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" unitRef="usd">16,546</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease obligations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsLeaseObligations" scale="0" sign="-" unitRef="usd">55,260</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:DeferredTaxAssetsLeaseObligations" scale="0" sign="-" unitRef="usd">77,612</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" unitRef="usd">71,806</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" unitRef="usd">259,457</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd">18,681,628</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd">13,969,435</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">18,681,628</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">13,969,435</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A
full valuation allowance has been applied against the net deferred tax assets because it is not more likely than not that future taxable
income will be available against which the Company can utilize the benefits therefrom.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company has non-capital loss carry-forwards of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd">62,921,785</ix:nonFraction> (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd">50,897,706</ix:nonFraction>) available
to offset future taxable income in Canada and the United States. These non-capital loss carryforwards begin to expire in 2026.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. INCOME TAXES (cont&#8217;d)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company recognizes tax benefits
from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities,
based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from any such position
would be measured based on the largest benefit that has a greater than <ix:nonFraction contextRef="c0" decimals="2" format="ixt-sec:numwordsen" name="inm:RecognizedTaxBenefits" scale="-2" unitRef="pure">fifty</ix:nonFraction> percent likelihood of being realized upon ultimate settlement.
It is the Company&#8217;s policy to recognize interest and penalties accrued on any uncertain tax benefits as a component of income tax
expense. There were no uncertain tax positions as of June 30, 2022 or 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company files income tax returns
in the U.S. federal jurisdiction, various state jurisdictions, and Canada. With few exceptions, the Company is no longer subject to U.S.
federal and state tax examinations for fiscal years prior to 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is subject to taxation
at the federal, state, and local levels in the United States and Canada.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>15. SEGMENT INFORMATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">As of the closing of the BayMedica
acquisition, the Company aligned into two operating and reportable segments, the InMed segment and the BayMedica segment. The Company
reports segment information based on the management approach which designates the internal reporting used by the Chief Operating Decision
Maker (&#8220;CODM&#8221;), which is the Company&#8217;s Chief Executive Officer, for making decisions and assessing performance as the
source of the Company&#8217;s reportable segments. The CODM allocates resources and assesses the performance of each operating segment
based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss)
before interest and taxes. The Company has determined its reportable segments to be InMed and BayMedica based on the information used
by the CODM. Other than cash, cash equivalents and short-term investments (&#8220;Unrestricted cash&#8221;) balances, the CODM does not
regularly review asset information by reportable segment and therefore, the Company does not report asset information by reportable segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_3" id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_4" id="_SegmentReportingDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents information about the Company&#8217;s reportable segments for the year ended June 30, 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year
    Ended June 30,</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>InMed</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BayMedica</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>InMed</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BayMedica</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,089,435</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,089,435</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="inm:OtherOperatingExpenses" scale="0" unitRef="usd">13,410,753</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="inm:OtherOperatingExpenses" scale="0" unitRef="usd">6,278,799</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:OtherOperatingExpenses" scale="0" unitRef="usd">19,689,552</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="inm:OtherOperatingExpenses" scale="0" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="inm:OtherOperatingExpenses" scale="0" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">13,410,753</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">5,189,364</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">18,600,117</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">10,203,089</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unrestricted cash</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" unitRef="usd">5,984,622</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" unitRef="usd">192,244</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" unitRef="usd">6,176,866</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" unitRef="usd">7,363,126</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" unitRef="usd">7,363,126</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NonCashTransactionsTextBlock-c0_cont_1" escape="true" name="inm:NonCashTransactionsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. NON-CASH TRANSACTIONS</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_2" id="_NonCashTransactionsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Investing and financing activities that
do not have a direct impact on cash flows are excluded from the statements of cash flows. During the year ended June 30, 2022, the following
transactions were excluded from the statement of cash flows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_3" id="_NonCashTransactionsTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 2, 2021, the Company issued warrants to its placement agent. The fair value of these warrants was $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">739,920</ix:nonFraction> and was included in share issuance costs related to the July 2021 private placement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_4" id="_NonCashTransactionsTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 13, 2021, the Company issued <ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares">82,000</ix:nonFraction> common shares to BayMedica&#8217;s equity and convertible debt holders, pursuant to the BayMedica Agreement. The estimated fair value of these common shares was $<ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="inm:EstimatedFairValueCommonShares" scale="0" unitRef="usd">3,013,500</ix:nonFraction> and was included in the total consideration for the acquisition of BayMedica (see Note 8). On acquisition of BayMedica, the loan receivable from BayMedica of $<ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableFairValueDisclosure" scale="0" unitRef="usd">425,000</ix:nonFraction> was settled (see Note 8).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_5" id="_NonCashTransactionsTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2022, the Company issued <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares">3,132</ix:nonFraction> common shares for consulting services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_6" id="_NonCashTransactionsTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">iv)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 6, 2022, the Company issued <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredUnitsIssued" scale="0" unitRef="shares">15,152</ix:nonFraction> preferred investment options to its placement agent. The fair value of these investment options was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtFairValue" scale="0" unitRef="usd">192,491</ix:nonFraction> and was included in share issuance costs related to the June 2022 registered direct and private placement offerings.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_7" id="_NonCashTransactionsTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">v)</span></td><td><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">15,606</ix:nonFraction> warrants were exercised on a cashless basis resulting in the issuance of <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">6,293</ix:nonFraction> common shares.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_8" id="_NonCashTransactionsTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">vi)</span></td><td><span style="font-family: Times New Roman, Times, Serif">As at June 30, 2022, the Company has unpaid financing costs of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrentAndNoncurrent" scale="0" unitRef="usd">26,587</ix:nonFraction>.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NonCashTransactionsTextBlock-c0_cont_9" id="_NonCashTransactionsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2021, the following transaction was excluded from the statement of cash flows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_NonCashTransactionsTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As at June 30, 2021, the Company has unpaid financing costs of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrentAndNoncurrent" scale="0" unitRef="usd">164,812</ix:nonFraction>.</span></td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>17.
COMMITMENTS AND CONTINGENCIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of agreements with various contract research organizations, as at June 30, 2022, the Company is committed for contract research
services and materials at a cost of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:CostOfServicesDirectsMaterials" scale="0" unitRef="usd">2,910,529</ix:nonFraction>. A total of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="0" unitRef="usd">2,149,619</ix:nonFraction> of these expenditures are expected to occur in the
twelve months following June 30, 2022 and the balance of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:ExpenditureBalance" scale="0" unitRef="usd">760,910</ix:nonFraction> in the following twelve month period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of agreements with various vendors, as at June 30, 2022, the Company is committed for contract materials and equipment at
a cost of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDirectMaterial" scale="0" unitRef="usd">634,092</ix:nonFraction>, expected to occur in the twelve months following June 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia (&#8220;UBC&#8221;),
the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of
certain drug products that are covered by the agreement. To date, no payments have been required to be made.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>17.
COMMITMENTS AND CONTINGENCIES (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of a December 13, 2018 Collaborative Research Agreement with UBC in which the Company owns all rights, title and interests
in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon
filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of a November 1, 2018 Contribution Agreement with National Research Council Canada, as represented by its Industrial Research
Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual
property developed in part with NRC-IRAP contributions, may become repayable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments include guaranteed investment certificates with a face value of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:GuaranteedInvestment" scale="0" unitRef="usd">44,676</ix:nonFraction> (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:GuaranteedInvestment" scale="0" unitRef="usd">46,391</ix:nonFraction>) that are pledged as security
for a corporate credit card.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>


</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are
common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently
holds commercial general liability insurance. This insurance limits the Company&#8217;s liability and may enable the Company to recover
a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and it
believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities
relating to these obligations for any period presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to a technology licensing agreement, the Company is committed to issue, subject to regulatory approval, up to <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:WarrantsToPurchase" scale="0" unitRef="shares">700</ix:nonFraction> warrants to purchase
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="inm:CommonShares" scale="0" unitRef="shares">700</ix:nonFraction> common shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of
the common shares prior to each milestone achievement and the warrants will be exercisable for a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">three years</ix:nonNumeric> for issuance date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company entered into a patent license agreement with a third party (the &#8220;Licensor&#8221;) in an agreement dated February 15, 2021.
The Company is required to make future royalty payments to Licensor based on net sales of licensed products, with minimum payments required
starting in 2021. In December 2021, the Company amended the License Agreement including the deferral of the 2021 minimum payments to
2022. As at June 30, 2022, the Company has paid $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="0" unitRef="usd">300,000</ix:nonFraction> for the minimum payments under the agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of
business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility
that a material loss may be incurred.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FinancialRiskManagementTextBlock-c0_cont_1" escape="true" name="inm:FinancialRiskManagementTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>18.
FINANCIAL RISK MANAGEMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_2" id="_FinancialRiskManagementTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
fair values of short-term investments, accounts receivable, and accounts payable and accrued liabilities approximate their carrying values
because of the short-term nature of these instruments. Cash and cash equivalents are measured at fair value using Level 1 inputs. The
Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>18.
FINANCIAL RISK MANAGEMENT (cont&#8217;d)</b></span></p><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_3" id="_FinancialRiskManagementTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the fair values and carrying values of the Company&#8217;s financial instruments at June 30, 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_4" id="_FinancialRiskManagementTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueByBalanceSheetGroupingTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,
    2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Level
    1</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Level
    2</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,176,866</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,176,866</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">44,804</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">44,804</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">88,027</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">88,027</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total financial assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd">6,176,866</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd">132,831</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd">6,309,697</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,415,265</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,415,265</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">2,415,265</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">2,415,265</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_5" id="_FinancialRiskManagementTextBlock-c0_cont_4"><ix:continuation id="_FairValueByBalanceSheetGroupingTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2021</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">7,363,126</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="0" unitRef="usd">7,363,126</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">46,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">46,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">11,919</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">11,919</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd">7,363,126</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd">58,381</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitRef="usd">7,421,507</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,134,878</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,134,878</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">2,134,878</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">2,134,878</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_6" id="_FinancialRiskManagementTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Market Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_7" id="_FinancialRiskManagementTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Market
risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices.
Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk.
The Company does not currently have significant commodity price risk or equity price risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_8" id="_FinancialRiskManagementTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><i>Foreign
Currency Risk</i>:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_9" id="_FinancialRiskManagementTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Foreign
currency risk is the risk that the future cash flows or fair value of the Company&#8217;s financial instruments that are denominated
in a currency that is not the Company&#8217;s functional currency (U.S. dollar) will fluctuate due to changes in foreign exchange rates.
Portions of the Company&#8217;s cash and cash equivalents and accounts payable and accrued liabilities are denominated in Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_10" id="_FinancialRiskManagementTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Accordingly,
the Company is exposed to fluctuations in exchange rates, primarily against the Canadian dollar.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>18.
FINANCIAL RISK MANAGEMENT (cont&#8217;d)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Risk (cont&#8217;d):</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Foreign Currency Risk (cont&#8217;d):</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_11" id="_FinancialRiskManagementTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company has a net excess of Canadian dollar denominated cash and cash equivalents in excess of Canadian dollar
denominated accounts payable and accrued liabilities of C$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="cad">2,052,109</ix:nonFraction> which is equivalent to US$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="usd">1,592,436</ix:nonFraction> at the June 30, 2022 exchange
rate. The Canadian dollar financial assets generally result from holding Canadian dollar cash to settle anticipated near-term accounts
payable and accrued liabilities denominated in Canadian dollars. The Canadian dollar financial liabilities generally result from purchases
of supplies and services from suppliers in Canada.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_12" id="_FinancialRiskManagementTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Each
change of <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="inm:ForeignCurrencyRiskPercentage" scale="-2" unitRef="pure">1</ix:nonFraction>% in the Canadian dollar in relation to the U.S. dollar results in a gain or loss, with a corresponding effect on cash flows,
of $<ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesGainLoss" scale="0" unitRef="usd">15,924</ix:nonFraction> based on the June 30, 2022 net Canadian dollar assets (liabilities) position. During the year ended June 30, 2022, the Company
recorded foreign exchange loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" unitRef="usd">107,433</ix:nonFraction> (2021 &#8211; gain of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="0" unitRef="usd">80,713</ix:nonFraction>) related to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_13" id="_FinancialRiskManagementTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><i>Interest
Rate Risk:</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_14" id="_FinancialRiskManagementTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Interest
rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at June 30, 2022, holdings
of cash and cash equivalents of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">5,087,615</ix:nonFraction> (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">7,053,329</ix:nonFraction>) are subject to floating interest rates. The balance of the Company&#8217;s
cash holdings of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherMinorityInterests" scale="0" unitRef="usd">1,089,251</ix:nonFraction> (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherMinorityInterests" scale="0" unitRef="usd">309,796</ix:nonFraction>) are non-interest bearing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_15" id="_FinancialRiskManagementTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company held variable rate guaranteed investment certificates, with one-year terms, of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd">44,676</ix:nonFraction> (June 30, 2021 -
$<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd">46,391</ix:nonFraction>).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_16" id="_FinancialRiskManagementTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s current policy is to invest excess cash in guaranteed investment certificates or interest-bearing accounts of major Canadian
chartered banks or credit unions with comparable credit ratings. The Company regularly monitors compliance to its cash management policy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_17" id="_FinancialRiskManagementTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Credit Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_18" id="_FinancialRiskManagementTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Credit
risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual
obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash and cash equivalents,
short-term investments and loan receivable. Cash and cash equivalents and short-term investments are maintained with financial institutions
of reputable credit and may be redeemed upon demand. In the normal course of business, the Company does not provide third party loans.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_19" id="_FinancialRiskManagementTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash
and cash equivalents and short-term investments with high-credit quality financial institutions and management considers this risk to
be minimal for all cash and cash equivalents and short-term investments assets based on changes that are reasonably possible at each
reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 62%"><span style="font-family: Times New Roman, Times, Serif"><b>InMed Pharmaceuticals Inc.</b></span></td>
    <td style="white-space: nowrap; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED
    FINANCIAL STATEMENTS</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">FOR THE YEAR ENDED JUNE 30, 2022 AND 2021</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressed
    in U.S. Dollars)</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>18. FINANCIAL RISK MANAGEMENT (cont&#8217;d)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><ix:continuation continuedAt="_FinancialRiskManagementTextBlock-c0_cont_20" id="_FinancialRiskManagementTextBlock-c0_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Liquidity
                                            Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FinancialRiskManagementTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Liquidity
risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company&#8217;s policy is
to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without
incurring unacceptable losses or risking damage to the Company&#8217;s reputation. A key risk in managing liquidity is the degree of
uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at June 30, 2022,
the Company has cash and cash equivalents and short-term investments of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:ShortTermInvestment" scale="0" unitRef="usd">6,221,670</ix:nonFraction> (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:ShortTermInvestment" scale="0" unitRef="usd">7,409,588</ix:nonFraction>), current liabilities
of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">3,181,316</ix:nonFraction> (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">2,215,361</ix:nonFraction>) and a working capital surplus of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="inm:workingCapitalSurplus" scale="0" unitRef="usd">6,416,460</ix:nonFraction> (June 30, 2021 - $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="inm:workingCapitalSurplus" scale="0" unitRef="usd">6,162,908</ix:nonFraction>).</span></p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>19.
RELATED PARTY TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright
Canada LLP (&#8220;NRF&#8221;). From February 11, 2022 to June 30, 2022, NRF rendered legal services in the amount of $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="inm:LegalService" scale="0" unitRef="usd">345,935</ix:nonFraction> (2021
- $<span style="-sec-ix-hidden: hidden-fact-133">Nil</span>) to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented
the amount of consideration established and agreed to by NRF.</span></p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>20.
SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
July 2022, <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">69,930</ix:nonFraction> of the June 2022 pre-funded warrants were exercised resulting in the issuance of <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">69,930</ix:nonFraction> common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 7, 2022, the Company consolidated all of its issued and outstanding share capital on the basis of one post-consolidation share
for each twenty-five pre-consolidation common shares of the Company in order to regain compliance with all of Nasdaq&#8217;s continued
listing requirements. Accordingly, all common share, stock option, per common share and warrant amounts for all periods presented in the
consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 7, 2022, <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">22,920</ix:nonFraction> of the June 2022 pre-funded warrants were exercised resulting in the issuance of <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">22,920</ix:nonFraction> common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 13, 2022, the Company closed a $<ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" unitRef="usd">6.0</ix:nonFraction> million private placement. Under the terms of the private placement, an aggregate of <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">691,245</ix:nonFraction>
common shares, or common share equivalents, and investment options to purchase up to an aggregate of <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,382,490</ix:nonFraction> common shares, at an effective
purchase price of $<ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">8.68</ix:nonFraction> per common share and associated investment options. The warrants have an exercise price of $<ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares">8.44</ix:nonFraction> per share, are
exercisable immediately and have a term of <ix:nonNumeric contextRef="c119" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">seven years</ix:nonNumeric>. After deducting the placement agent fees, the Company received net proceeds of
approximately $<ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">5.4</ix:nonFraction> million.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 9A. CONTROLS AND PROCEDURES</p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Evaluation of Disclosure Controls and Procedures</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Our management, with the participation
of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures
as of June 30, 2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the
Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by
a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time
periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act
is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate
to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed
and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating
the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as
of June 30, 2022, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls
and procedures were not effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt">Management&#8217;s Report on Internal Control
over Financial Reporting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f)
and 15d-15(f) under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company&#8217;s
principal executive and principal financial officers and effected by the company&#8217;s board of directors, management and other personnel
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">Pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">Provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts
and expenditures are being made only in accordance with authorizations of management and directors of the Company; and&#8239;</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.5in"></td><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">Provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial
statements.</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can
provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 126; Options: NewSection; Value: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management assessed the
effectiveness of our internal control over financial reporting as of June 30, 2022. In making this assessment, management used the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control-Integrated
Framework (2013). Based on this evaluation, management has concluded our internal control over financial reporting as of June 30, 2022
was not effective due to the material weakness in the Company&#8217;s internal control over financial reporting as disclosed below.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding the identified material
weakness, our Chief Executive Officer and our Chief Financial Officer believe the consolidated financial statements included in this Annual
Report on Form 10-K fairly represent in all material respects our financial condition, results of operations and cash flows at and for
the periods presented in accordance with U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt">Ongoing Remediation of Previously Reported Material
Weakness</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span>In
connection with the audits of our consolidated financial statements as of and for the years ended June 30, 2021 and 2020, our management
previously identified a material weakness in the Company&#8217;s internal control over financial reporting, primarily the result of inadequate
resources required to respond to financial reporting matters other than in the normal course of business. In connection with the preparation
of the consolidated financial statements as of June 30, 2022, </span>we identified that we did not maintain effective processes and controls
over financial reporting matters other than in the normal course of business. Because of this deficiency, which is pervasive in nature,
there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected
on a timely basis. In the year ended June 30, 2022, this deficiency resulted in certain material audit adjustments related to the presentation
of pre-funded warrants associated with a financing transaction, and the fair value on the purchase consideration for the acquisition of
BayMedica Inc. <span>The presence of these adjustments is indicative of failures in design and effectiveness
of internal controls. The identified material weakness has not been remediated as of June 30, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Management has implemented a remediation
plan to address the root causes which contributed to the material weakness and is committed to a strong Internal Control over Financial
Reporting (ICFR) environment. <span>Management has designed and implemented revised controls and procedures
which management believes address the material weakness. These controls and procedures include retaining the services of outside consultants
and establishing additional review procedures over the accounting for complex and non-routine transactions. However, the controls have
been operating for a limited period and the requisite testing sample size to ensure the operating effectiveness of the revised controls
and procedures is not yet available. The identified material weakness will not be considered remediated until the applicable remedial
controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.
We expect that remediation of this material weakness will be completed prior to the end of fiscal year 2023.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Changes in Internal Control over Financial Reporting</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than the actions
we have taken and are continuing to take in order to remediate the material weakness described above, there were no changes in our
internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of
the Exchange Act that occurred during the year ended June 30, 2022 that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 9B. OTHER INFORMATION</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span><b>
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENTS INSPECTIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART III</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The information required by Part III is
omitted from this report because we will file a definitive proxy statement within 120 days after the end of our 2022 fiscal year pursuant
to Regulation 14A for our 2022 Annual Meeting of Stockholders, or the 2022 Proxy Statement, will be filed pursuant to Regulation 14A of
the Securities Exchange Act of 1934, as amended. If the 2022 Proxy Statement is not filed within 120 days after the end of the fiscal
year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form
10-K filed not later than the end of such 120-day period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The response to this item is incorporated
by reference from the discussion responsive thereto under the captions &#8220;Management and Corporate Governance,&#8221; &#8220;Section
16(a) Beneficial Ownership Reporting Compliance,&#8221; and &#8220;Code of Business Conduct and Ethics&#8221; in the Company&#8217;s Proxy
Statement for the 2022 Annual Meeting of Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 11. EXECUTIVE COMPENSATION</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The response to this item is incorporated
by reference from the discussion responsive thereto under the caption &#8220;Executive Officer and Director Compensation&#8221; in the
Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The response to this item is incorporated
by reference from the discussion responsive thereto under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management,&#8221;
and &#8220;Equity Compensation Plan Information&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The response to this item is incorporated
by reference from the discussion responsive thereto under the captions &#8220;Certain Relationships and Related Person Transactions&#8221;
and &#8220;Management and Corporate Governance&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our independent
registered public accounting firm is KPMG LLP, Vancouver, BC, Canada, PCAOB Auditor ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">85</ix:nonNumeric>. The information required by this item
will be included in our definitive proxy statement with respect to our 2022 Annual Meeting of Shareholders to be filed with the SEC,
and is incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 128; Value: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART IV</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following documents are being filed as part of this
report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">(1)</td><td style="text-align: justify">The following financial statements of the Company and the report of KPMG LLP are included in Part II, Item 8:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 89.3pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s_001">Reports of Independent Registered Public Accounting Firm</a></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 10%">F-3</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#b_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-5</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-6</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#b_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-7</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b_004">Consolidated Statements of Cash Flows</a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-8</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#b_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">F-9 - F-36</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 89.3pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">(2)</td><td style="text-align: justify">All financial statement supporting schedules are omitted because the information is inapplicable or presented in the Notes to Consolidated
Financial Statements.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                               </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">A list of exhibits filed with this report or incorporated herein by reference is found in the Exhibit Index immediately following
the signature page of this Annual Report.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT</b></span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 89%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td>
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: justify; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex21-1_inmedpharma.htm">Subsidiaries of the Company.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex23-1_inmedpharma.htm">Consent of KPMG LLP.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex31-1_inmedpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex31-2_inmedpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex32-1_inmedpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex32-2_inmedpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>


<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.INS*</td>
    <td>&#160;</td>
    <td>Inline XBRL Instance Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.SCH*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Schema Document.</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.CAL*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.DEF*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.LAB*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.PRE*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>104*</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> ITEM 16. 10-K SUMMARY</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 129; Value: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.3pt; text-indent: 27pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt"><b>INMED PHARMACEUTICALS INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: left"><span style="font-size: 10pt"><b>(Registrant)</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="text-align: left; width: 4%">&#160;</td>
    <td style="text-align: left; width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-size: 10pt">September 23, 2022</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 10pt">/s/ Brenda Edwards</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><b>Brenda Edwards</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><b>Interim Chief Financial Officer<br/>
 and Chief Accounting Officer</b></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 30%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 46%"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 20%"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Eric A. Adams</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">President, Chief Executive Officer and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 23, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>Eric A. Adams</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Brenda Edwards</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Interim Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 23, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>Brenda Edwards</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal&#160;Financial&#160;Officer&#160;and&#160;Principal&#160;Accounting&#160;Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ William J. Garner</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director (Chairman to the Board of Directors)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 23, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>William J. Garner</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Janet Grove</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 23, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>Janet Grove</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Bryan Baldasare</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 23, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>Bryan Baldasare</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Andrew Hull</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 23, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>Andrew Hull</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Nicole Lemerond</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 23, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>Nicole Lemerond</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">92</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="inm:AcquisitionConsiderationPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-2" name="us-gaap:CommonStockSharesAuthorizedUnlimited">Unlimited</ix:nonNumeric>
<ix:nonNumeric contextRef="c5" id="hidden-fact-3" name="us-gaap:CommonStockSharesAuthorizedUnlimited">Unlimited</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-8" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-9" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:InterestIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-11" name="us-gaap:UnrealizedGainLossOnDerivatives" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-12" name="inm:WarrantModificationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-13" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-14" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">33.17</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-15" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">37.96</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-16" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">268793</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-17" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">560829</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-19" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-20" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-21" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-22" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-26" name="inm:ShareIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-27" name="inm:ShareIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-28" name="inm:LossAndComprehensiveIncomelossesForThePeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-29" name="inm:LossAndComprehensiveIncomelossesForThePeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-30" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-31" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-32" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-33" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-34" name="inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-35" name="inm:ATMOfferingNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-36" name="inm:ATMOfferingNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-37" name="inm:ATMOfferingNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-38" name="inm:RegisteredDirectAndPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-39" name="inm:RegisteredDirectAndPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-40" name="inm:ShareIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-41" name="inm:ShareIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-42" name="inm:AgentsWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-43" name="inm:AgentsWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-44" name="inm:AgentsWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-45" name="inm:AgentsInvestmentOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-46" name="inm:AgentsInvestmentOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-47" name="inm:AgentsInvestmentOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-48" name="inm:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-49" name="inm:ExerciseOfPrefundedWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-50" name="inm:ExerciseOfWarrantsin" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-51" name="inm:ExerciseOfWarrantsin" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="inm:ExerciseOfWarrantsin" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-53" name="inm:AcquisitionOfBayMedica" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-54" name="inm:AcquisitionOfBayMedica" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-55" name="inm:AcquisitionOfBayMedica" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-56" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-57" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-58" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-59" name="inm:WarrantModificationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-60" name="inm:WarrantModificationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-61" name="inm:WarrantModificationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-62" name="inm:LossAndComprehensivelossesForThePeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-63" name="inm:LossAndComprehensivelossesForThePeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-64" name="inm:LossAndComprehensivelossesForThePeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-65" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-66" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-67" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-68" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-69" name="inm:UnrealizedGainOnDerivativeWarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-70" name="us-gaap:GoodwillAndIntangibleAssetImpairment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="inm:FinanceExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-72" name="inm:WarrantModificationExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-73" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-74" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-75" name="inm:CashAcquiredFromAcqusition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-76" name="us-gaap:RepaymentsOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-77" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-78" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-79" name="us-gaap:InventoryRawMaterialsAndSupplies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-80" name="us-gaap:InventoryWorkInProcess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-81" name="us-gaap:InventoryFinishedGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-82" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-83" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-84" name="us-gaap:GoodwillFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-85" name="us-gaap:GoodwillFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-86" name="us-gaap:GoodwillFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-87" name="us-gaap:GoodwillFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-88" name="us-gaap:GoodwillFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-89" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-90" name="inm:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-91" name="us-gaap:ImpairmentChargeOnReclassifiedAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-92" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-93" name="us-gaap:FiniteLivedPatentsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" decimals="0" id="hidden-fact-94" name="inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" unitRef="usdPershares">7547</ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-95" name="inm:AggregateIntrinsicValueAtBeginning" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-96" name="inm:AggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-97" name="inm:AggregateIntrinsicValueAtBeginning" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-98" name="inm:ShareBasedPaymentNumberOfBalanceAtBeginning" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-99" name="inm:ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-100" name="inm:ShareBasedPaymentAggregateIntrinsicValueAtBeginning" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-101" name="inm:ShareBasedPaymentAggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-102" name="inm:ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-104" name="inm:LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_0_footnote" xml:lang="en-US">Excludes estimated variable operating costs of $92,964 and $60,916 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of minimum lease payments-->
<ix:nonFraction contextRef="c5" id="hidden-fact-105" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-106" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-107" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-108" name="inm:DeferredTaxAssetsPropertyAndEquipmentsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-109" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-110" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-111" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-112" name="inm:DeferredTaxAssetsIntangibleAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-113" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-114" name="inm:DeferredTaxAssetLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-115" name="inm:DeferredTaxAssetLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-116" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-117" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-118" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-119" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-120" name="inm:OtherOperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-121" name="us-gaap:OperatingIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-122" name="us-gaap:RestrictedCashNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c113" id="hidden-fact-123" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c112" id="hidden-fact-124" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c112" id="hidden-fact-125" name="us-gaap:AccountsReceivableNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c112" id="hidden-fact-126" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c112" id="hidden-fact-127" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c115" id="hidden-fact-128" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-129" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-130" name="us-gaap:AccountsReceivableNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-131" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-132" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-133" name="inm:LegalService" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001728328</ix:nonNumeric>
<ix:nonFraction contextRef="c2" decimals="0" name="dei:EntityPublicFloat" unitRef="usd">0</ix:nonFraction>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="inm-20220630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact" toRefs="ix_0_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inm:CustomerOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inm:CustomerOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inm:RightOfUseAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inm:RightOfUseAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:IPRDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:IPRDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:IPRDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:CannabinoidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inm:BayMedicaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inm:PurchasePriceConsiderationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inm:PurchasePriceConsiderationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-02</xbrli:startDate>
    <xbrli:endDate>2021-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inm:ATMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ8btGW5qMQVqzLsfi3GzVuMY7sD/FFw7U4o2i8MgAqSMg6pxwpeBm32Q4Yx+CEjQMnrWZzgc+HrjKz4FGA65QOvsgEC/wMtHrdik6IbyDDLXxJdt3/VqavjFzajJqD6rwRbNxWB/9EPBc1wENO3701leuZtdXSpohHx25mAouKCHQxfXoc5q0CB/s8eMhbBXgs6kLNzvlp10tFysH8r6qkJ1UCQPsQ3R4=] CSR-->
  <xbrli:period>
    <xbrli:instant>2022-04-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inm:ATMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-22</xbrli:startDate>
    <xbrli:endDate>2022-04-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-06</xbrli:startDate>
    <xbrli:endDate>2022-06-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-06</xbrli:startDate>
    <xbrli:endDate>2022-06-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inm:BayMedicaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inm:BayMedicaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-16</xbrli:startDate>
    <xbrli:endDate>2020-11-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-11-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-12</xbrli:startDate>
    <xbrli:endDate>2021-02-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-21</xbrli:startDate>
    <xbrli:endDate>2022-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-02</xbrli:startDate>
    <xbrli:endDate>2021-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-06</xbrli:startDate>
    <xbrli:endDate>2022-06-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsInvestmentOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsInvestmentOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-06</xbrli:startDate>
    <xbrli:endDate>2022-06-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:GrossProceedsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:AllocatedToAdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:ShareIssuanceCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:GrossProceedsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:AllocatedToAdditionalPaidinCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:ShareIssuanceCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inm:SharePurchaseWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inm:SharePurchaseWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inm:SharePurchaseWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-03-01</xbrli:startDate>
    <xbrli:endDate>2017-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-01</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-25</xbrli:startDate>
    <xbrli:endDate>2021-07-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inm:BayMedicaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="inm:TypeOfCurrencyAxis">inm:USDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-11</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-01</xbrli:startDate>
    <xbrli:endDate>2022-09-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:InvestmentOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="cadPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:CAD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>f10k2022ex21-1_inmedpharma.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SUBSIDIARIES OF INMED PHARMACEUTICALS INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Subsidiary</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Jurisdiction</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Biogen Sciences Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">BC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Sweetnam Consulting Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">BC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">InMed Pharmaceuticals Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">BayMedica, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>f10k2022ex23-1_inmedpharma.htm
<DESCRIPTION>CONSENT OF KPMG LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">Consent of Independent Registered
Public Accounting Firm</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We consent to incorporation by reference in the registration
statements (Nos. 333-253925, 333-257858 and 333-265731) on Form S-1, (Nos. 333-262533 and 333-264187) on Form S-3 and (Nos. 333-253912
and 333-260323) on Form S-8 of our report dated September 23, 2022, with respect to the consolidated financial statements of InMed Pharmaceuticals
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">/s/ KPMG LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Chartered Professional Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Vancouver, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">September 23, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>f10k2022ex31-1_inmedpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Eric A. Adams, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of InMed Pharmaceuticals Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any
change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that
has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 23, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Eric A. Adams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 34%"> <FONT STYLE="font-size: 10pt">Eric A. Adams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: &nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>f10k2022ex31-2_inmedpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Brenda Edwards, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of InMed Pharmaceuticals Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any
change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that
has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 23, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Brenda Edwards</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 34%"> <FONT STYLE="font-size: 10pt">Brenda Edwards</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>f10k2022ex32-1_inmedpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Eric A. Adams, the President and Chief Executive Officer
of InMed Pharmaceuticals Inc. (the &ldquo;Company&rdquo;), hereby certify that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The Annual Report on Form
10-K for the year ended June 30, 2022 (the &ldquo;Report&rdquo;) of the Company fully complies with the requirements of Section 13(a)
or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 23, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Eric A. Adams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">Eric A. Adams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: &nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>f10k2022ex32-2_inmedpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Brenda Edwards, the Chief Financial Officer of InMed Pharmaceuticals
Inc. (the &ldquo;Company&rdquo;), hereby certify that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The Annual Report on Form
10-K for the year ended June 30, 2022 (the &ldquo;Report&rdquo;) of the Company fully complies with the requirements of Section 13(a)
or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 23, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Brenda Edwards</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Brenda Edwards</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>inm-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Sep 23 19:20:26 UTC 2022 -->
<xs:schema xmlns:inm="http://www.Inmedpharmaceuticalsinc.com/20220630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.Inmedpharmaceuticalsinc.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="inm-20220630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="inm-20220630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="inm-20220630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="inm-20220630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" id="inm_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals" id="inm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" id="inm_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals" id="inm_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" id="inm_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" id="inm_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern" id="inm_r_NatureofBusinessandGoingConcern">
        <link:definition>007 - Disclosure - Nature of Business and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies" id="inm_r_SignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration" id="inm_r_CustomerConcentration">
        <link:definition>009 - Disclosure - Customer Concentration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/Inventories" id="inm_r_Inventories">
        <link:definition>010 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet" id="inm_r_PropertyEquipmentandRouAssetsNet">
        <link:definition>011 - Disclosure - Property, Equipment and Rou Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill" id="inm_r_ImpairmentofIntangibleAssetsandGoodwill">
        <link:definition>012 - Disclosure - Impairment of Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets" id="inm_r_IntangibleAssets">
        <link:definition>013 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/Acquisition" id="inm_r_Acquisition">
        <link:definition>014 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities" id="inm_r_AccountsPayableandAccruedLiabilities">
        <link:definition>015 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves" id="inm_r_ShareCapitalandReserves">
        <link:definition>016 - Disclosure - Share Capital and Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments" id="inm_r_ShareBasedPayments">
        <link:definition>017 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations" id="inm_r_LeaseObligations">
        <link:definition>018 - Disclosure - Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare" id="inm_r_BasicandDilutedLossPerShare">
        <link:definition>019 - Disclosure - Basic and Diluted Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes" id="inm_r_IncomeTaxes">
        <link:definition>020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation" id="inm_r_SegmentInformation">
        <link:definition>021 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions" id="inm_r_NonCashTransactions">
        <link:definition>022 - Disclosure - Non-Cash Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies" id="inm_r_CommitmentsandContingencies">
        <link:definition>023 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement" id="inm_r_FinancialRiskManagement">
        <link:definition>024 - Disclosure - Financial Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions" id="inm_r_RelatedPartyTransactions">
        <link:definition>025 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents" id="inm_r_SubsequentEvents">
        <link:definition>026 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" id="inm_r_AccountingPoliciesByPolicy">
        <link:definition>027 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables" id="inm_r_InventoriesTables">
        <link:definition>028 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables" id="inm_r_PropertyEquipmentandRouAssetsNetTables">
        <link:definition>029 - Disclosure - Property, Equipment and Rou Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables" id="inm_r_ImpairmentofIntangibleAssetsandGoodwillTables">
        <link:definition>030 - Disclosure - Impairment of Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables" id="inm_r_IntangibleAssetsTables">
        <link:definition>031 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables" id="inm_r_AcquisitionTables">
        <link:definition>032 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables" id="inm_r_AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables" id="inm_r_ShareCapitalandReservesTables">
        <link:definition>034 - Disclosure - Share Capital and Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables" id="inm_r_ShareBasedPaymentsTables">
        <link:definition>035 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables" id="inm_r_LeaseObligationsTables">
        <link:definition>036 - Disclosure - Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables" id="inm_r_BasicandDilutedLossPerShareTables">
        <link:definition>037 - Disclosure - Basic and Diluted Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables" id="inm_r_IncomeTaxesTables">
        <link:definition>038 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables" id="inm_r_SegmentInformationTables">
        <link:definition>039 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables" id="inm_r_FinancialRiskManagementTables">
        <link:definition>040 - Disclosure - Financial Risk Management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails" id="inm_r_NatureofBusinessandGoingConcernDetails">
        <link:definition>041 - Disclosure - Nature of Business and Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails" id="inm_r_SignificantAccountingPoliciesDetails">
        <link:definition>042 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" id="inm_r_CustomerConcentrationDetails">
        <link:definition>043 - Disclosure - Customer Concentration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails" id="inm_r_InventoriesDetails">
        <link:definition>044 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable" id="inm_r_ScheduleofinventoriesTable">
        <link:definition>045 - Disclosure - Inventories (Details) - Schedule of inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable" id="inm_r_ScheduleofpropertyequipmentandrightofuseassetsTable">
        <link:definition>046 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of property, equipment and right of use assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails" id="inm_r_ImpairmentofIntangibleAssetsandGoodwillDetails">
        <link:definition>047 - Disclosure - Impairment of Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" id="inm_r_ScheduleofintangibleassetsTable">
        <link:definition>048 - Disclosure - Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" id="inm_r_IntangibleAssetsDetails">
        <link:definition>049 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0" id="inm_r_ScheduleofintangibleassetsTable0">
        <link:definition>050 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" id="inm_r_ScheduleofamortizationexpenseTable">
        <link:definition>051 - Disclosure - Intangible Assets (Details) - Schedule of amortization expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails" id="inm_r_AcquisitionDetails">
        <link:definition>052 - Disclosure - Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable" id="inm_r_ScheduleoftotalconsiderationTable">
        <link:definition>053 - Disclosure - Acquisition (Details) - Schedule of total consideration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable" id="inm_r_ScheduleoffairvalueofassetsacquiredandliabilitiesTable">
        <link:definition>054 - Disclosure - Acquisition (Details) - Schedule of fair value of assets acquired and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable" id="inm_r_ScheduleofproformaconsolidatedresultsTable">
        <link:definition>055 - Disclosure - Acquisition (Details) - Schedule of pro forma consolidated results</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" id="inm_r_ScheduleofaccountspayableandaccruedliabilitiesTable">
        <link:definition>056 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" id="inm_r_ShareCapitalandReservesDetails">
        <link:definition>057 - Disclosure - Share Capital and Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ8btGW5qMQVqzLsfi3GzVuMY7sD/FFw7U4o2i8MgAqSMg6pxwpeBm32Q4Yx+CEjQMnrWZzgc+HrjKz4FGA65QOvsgEC/wMtHrdik6IbyDDLXxJdt3/VqavjFzajJqD6rwRbNxWB/9EPBc1wENO3701leuZtdXSpohHx25mAouKCHQxfXoc5q0CB/s8eMhbBXgs6kLNzvlp14ZT1GmWnw9ZoaSAkJvTzQg=] CSR-->
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable" id="inm_r_ScheduleofprivateplacementofferingTable">
        <link:definition>058 - Disclosure - Share Capital and Reserves (Details) - Schedule of private placement offering</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable" id="inm_r_ScheduleofchangesinsharepurchasewarrantsTable">
        <link:definition>059 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable" id="inm_r_ScheduleofchangesinagentswarrantsTable">
        <link:definition>060 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" id="inm_r_ShareBasedPaymentsDetails">
        <link:definition>061 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable" id="inm_r_ScheduleofoutstandingoptionsTable">
        <link:definition>062 - Disclosure - Share-Based Payments (Details) - Schedule of outstanding options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" id="inm_r_LeaseObligationsDetails">
        <link:definition>063 - Disclosure - Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable" id="inm_r_ScheduleofminimumleasepaymentsTable">
        <link:definition>064 - Disclosure - Lease Obligations (Details) - Schedule of minimum lease payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable" id="inm_r_ScheduleofweightedaveragenumberofcommonsharesTable">
        <link:definition>065 - Disclosure - Basic and Diluted Loss Per Share (Details) - Schedule of weighted average number of common shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails" id="inm_r_IncomeTaxesDetails">
        <link:definition>066 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable" id="inm_r_ScheduleofareconciliationofincometaxesTable">
        <link:definition>067 - Disclosure - Income Taxes (Details) - Schedule of a reconciliation of income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="inm_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>068 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" id="inm_r_ScheduleofreportablesegmentsTable">
        <link:definition>069 - Disclosure - Segment Information (Details) - Schedule of reportable segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails" id="inm_r_NonCashTransactionsDetails">
        <link:definition>070 - Disclosure - Non-Cash Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" id="inm_r_CommitmentsandContingenciesDetails">
        <link:definition>071 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" id="inm_r_FinancialRiskManagementDetails">
        <link:definition>072 - Disclosure - Financial Risk Management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable" id="inm_r_ScheduleoffairvalueandcarryingvaluesofthecompanyTable">
        <link:definition>073 - Disclosure - Financial Risk Management (Details) - Schedule of fair value and carrying values of the company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails" id="inm_r_RelatedPartyTransactionsDetails">
        <link:definition>074 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" id="inm_r_SubsequentEventsDetails">
        <link:definition>075 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfInventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfInventoriesAbstract"/>
  <xs:element name="ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfAmortizationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfAmortizationExpenseAbstract"/>
  <xs:element name="AcquisitionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AcquisitionAbstract"/>
  <xs:element name="ScheduleOfTotalConsiderationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfTotalConsiderationAbstract"/>
  <xs:element name="ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfProFormaConsolidatedResultsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfProFormaConsolidatedResultsAbstract"/>
  <xs:element name="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
  <xs:element name="ShareCapitalAndReservesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareCapitalAndReservesAbstract"/>
  <xs:element name="ScheduleOfPrivatePlacementOfferingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfPrivatePlacementOfferingAbstract"/>
  <xs:element name="ScheduleOfChangesInSharePurchaseWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract"/>
  <xs:element name="ScheduleOfChangesInAgentsWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfChangesInAgentsWarrantsAbstract"/>
  <xs:element name="ScheduleOfOutstandingOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfOutstandingOptionsAbstract"/>
  <xs:element name="ScheduleOfMinimumLeasePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfMinimumLeasePaymentsAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract"/>
  <xs:element name="ScheduleOfAReconciliationOfIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfReportableSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfReportableSegmentsAbstract"/>
  <xs:element name="NonCashTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_NonCashTransactionsAbstract"/>
  <xs:element name="FinancialRiskManagementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialRiskManagementAbstract"/>
  <xs:element name="ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract2"/>
  <xs:element name="CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract10"/>
  <xs:element name="GoodwillAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_GoodwillAbstract"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract11"/>
  <xs:element name="IndefiniteLivedIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_IndefiniteLivedIntangibleAssetsAbstract"/>
  <xs:element name="IprDAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_IprDAbstract"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract12"/>
  <xs:element name="DefiniteLivedIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_DefiniteLivedIntangibleAssetsAbstract"/>
  <xs:element name="TrademarkAndIntellectualPropertyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_TrademarkAndIntellectualPropertyAbstract"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract13"/>
  <xs:element name="DefiniteLivedIntangibleAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_DefiniteLivedIntangibleAssetsAbstract0"/>
  <xs:element name="PatentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_PatentsAbstract"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract15"/>
  <xs:element name="PurchasePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_PurchasePriceAbstract"/>
  <xs:element name="AllocationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AllocationAbstract"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract16"/>
  <xs:element name="AssetsAcquiredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AssetsAcquiredAbstract"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract17"/>
  <xs:element name="LiabilitiesAssumedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_LiabilitiesAssumedAbstract"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_UnlabeledAbstract18"/>
  <xs:element name="June302022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_June302022Abstract"/>
  <xs:element name="IncreaseReductionInIncomeTaxesResultingFromAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
  <xs:element name="FinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialAssetsAbstract"/>
  <xs:element name="FinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialLiabilitiesAbstract"/>
  <xs:element name="FinancialAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialAssetsAbstract0"/>
  <xs:element name="FinancialLiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialLiabilitiesAbstract0"/>
  <xs:element name="AcquisitionConsiderationPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_AcquisitionConsiderationPayable"/>
  <xs:element name="WarrantModificationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_WarrantModificationExpense"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuedForPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares"/>
  <xs:element name="ShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareIssuanceCosts"/>
  <xs:element name="LossAndComprehensiveIncomelossesForThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_LossAndComprehensiveIncomelossesForThePeriod"/>
  <xs:element name="ATMOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_ATMOfferingNetOfIssuanceCosts"/>
  <xs:element name="ATMOfferingNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ATMOfferingNetOfIssuanceCostsShares"/>
  <xs:element name="RegisteredDirectAndPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_RegisteredDirectAndPrivatePlacement"/>
  <xs:element name="RegisteredDirectAndPrivatePlacementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_RegisteredDirectAndPrivatePlacementShares"/>
  <xs:element name="AgentsWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_AgentsWarrants"/>
  <xs:element name="AgentsInvestmentOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_AgentsInvestmentOptions"/>
  <xs:element name="ExerciseOfPrefundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_ExerciseOfPrefundedWarrants"/>
  <xs:element name="ExerciseOfPrefundedWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ExerciseOfPrefundedWarrantsinShares"/>
  <xs:element name="ExerciseOfWarrantsin" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ExerciseOfWarrantsin"/>
  <xs:element name="ExerciseOfWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ExerciseOfWarrantsinShares"/>
  <xs:element name="AcquisitionOfBayMedica" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_AcquisitionOfBayMedica"/>
  <xs:element name="AcquisitionOfBayMedicainShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AcquisitionOfBayMedicainShares"/>
  <xs:element name="LossAndComprehensivelossesForThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_LossAndComprehensivelossesForThePeriod"/>
  <xs:element name="InterestIncomeaccruedReceivedOnShorttermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_InterestIncomeaccruedReceivedOnShorttermInvestments"/>
  <xs:element name="UnrealizedGainOnDerivativeWarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_UnrealizedGainOnDerivativeWarrantsLiability"/>
  <xs:element name="UnrealizedGainOnForeignExchange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_UnrealizedGainOnForeignExchange"/>
  <xs:element name="FinanceExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_FinanceExpense"/>
  <xs:element name="WarrantModificationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_WarrantModificationExpenses"/>
  <xs:element name="CashAcquiredFromAcqusition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_CashAcquiredFromAcqusition"/>
  <xs:element name="NatureofBusinessandGoingConcernTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_NatureofBusinessandGoingConcernTable"/>
  <xs:element name="NatureofBusinessandGoingConcernLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_NatureofBusinessandGoingConcernLineItems"/>
  <xs:element name="AcquisitionTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AcquisitionTextBlock"/>
  <xs:element name="ShareCapitalAndReservesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareCapitalAndReservesTextBlock"/>
  <xs:element name="NonCashTransactionsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_NonCashTransactionsTextBlock"/>
  <xs:element name="FinancialRiskManagementTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialRiskManagementTextBlock"/>
  <xs:element name="COVID19ImpactsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_COVID19ImpactsPolicyTextBlock"/>
  <xs:element name="InProcessRDPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_InProcessRDPolicyTextBlock"/>
  <xs:element name="FinancialAssetsAndLiabilitiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock"/>
  <xs:element name="PatentsAndIntellectualPropertyCostsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock"/>
  <xs:element name="ScheduleOfPrivatePlacementOfferingTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock"/>
  <xs:element name="ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock"/>
  <xs:element name="ScheduleOfChangesInAgentsWarrantsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock"/>
  <xs:element name="ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock"/>
  <xs:element name="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable"/>
  <xs:element name="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems"/>
  <xs:element name="FiniteLivedIntangibleAssetNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_FiniteLivedIntangibleAssetNet"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash"/>
  <xs:element name="BusinessCombinationPostclosingAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_BusinessCombinationPostclosingAdjustments"/>
  <xs:element name="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable"/>
  <xs:element name="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities"/>
  <xs:element name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_AccruedResearchAndDevelopment"/>
  <xs:element name="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable"/>
  <xs:element name="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems"/>
  <xs:element name="TotalCommonShareValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_TotalCommonShareValue"/>
  <xs:element name="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable"/>
  <xs:element name="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems"/>
  <xs:element name="ShareCapitalOfNumberOfBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareCapitalOfNumberOfBalance"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance"/>
  <xs:element name="AggregateIntrinsicValueAtBeginning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_AggregateIntrinsicValueAtBeginning"/>
  <xs:element name="ShareBasedPaymentNumberOfGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentNumberOfGranted"/>
  <xs:element name="WeightedAverageSharePriceGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_WeightedAverageSharePriceGranted"/>
  <xs:element name="AggregateIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_AggregateIntrinsicValueGranted"/>
  <xs:element name="ShareBasedPaymentNumberOfExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentNumberOfExercised"/>
  <xs:element name="ShareBasedPaymentsWeightedAverageSharePriceExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised"/>
  <xs:element name="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable"/>
  <xs:element name="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems"/>
  <xs:element name="ShareBasedPaymentNumberOfBalanceAtBeginning" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentNumberOfBalanceAtBeginning"/>
  <xs:element name="ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning"/>
  <xs:element name="ShareBasedPaymentAggregateIntrinsicValueAtBeginning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning"/>
  <xs:element name="ShareBasedPaymentSharesNumberOfGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentSharesNumberOfGranted"/>
  <xs:element name="ShareBasedPaymentWeightedAverageSharePriceGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentWeightedAverageSharePriceGranted"/>
  <xs:element name="ShareBasedPaymentAggregateIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentAggregateIntrinsicValueGranted"/>
  <xs:element name="ShareBasedPaymentNumberOfBalanceAtEnding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentNumberOfBalanceAtEnding"/>
  <xs:element name="ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding"/>
  <xs:element name="ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding"/>
  <xs:element name="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers"/>
  <xs:element name="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted"/>
  <xs:element name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited"/>
  <xs:element name="ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice"/>
  <xs:element name="NumberOfVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_NumberOfVestedAndExercisable"/>
  <xs:element name="WeightedAverageExercisePriceVestedAndExercisable" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_WeightedAverageExercisePriceVestedAndExercisable"/>
  <xs:element name="NumberOfUnvested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_NumberOfUnvested"/>
  <xs:element name="WeightedAverageExercisePriceUnvested" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_WeightedAverageExercisePriceUnvested"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentDueYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_LesseeOperatingLeaseLiabilityPaymentDue"/>
  <xs:element name="DeferredTaxAssetsPropertyAndEquipmentsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_DeferredTaxAssetsPropertyAndEquipmentsNet"/>
  <xs:element name="DeferredTaxAssetsFinancingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_DeferredTaxAssetsFinancingCost"/>
  <xs:element name="LeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_LeaseLiabilities"/>
  <xs:element name="DeferredTaxAssetsAndLiabilitiesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_DeferredTaxAssetsAndLiabilitiesGross"/>
  <xs:element name="DeferredTaxAssetsIntangibleAssetsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_DeferredTaxAssetsIntangibleAssetsNet"/>
  <xs:element name="DeferredTaxAssetsLeaseObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_DeferredTaxAssetsLeaseObligations"/>
  <xs:element name="DeferredTaxAssetLiabilitiesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_DeferredTaxAssetLiabilitiesNet"/>
  <xs:element name="OtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_OtherOperatingExpenses"/>
  <xs:element name="CashAndCashEquivalent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_CashAndCashEquivalent"/>
  <xs:element name="CustomerConcentrationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_CustomerConcentrationDetailsTable"/>
  <xs:element name="CustomerConcentrationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_CustomerConcentrationDetailsLineItems"/>
  <xs:element name="ConcentrationRiskPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ConcentrationRiskPercentage"/>
  <xs:element name="ImpairmentofIntangibleAssetsandGoodwillDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable"/>
  <xs:element name="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems"/>
  <xs:element name="ImpairmentOfIntangibleAssetExcludingGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
  <xs:element name="ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
  <xs:element name="AcquisitionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_AcquisitionDetailsTable"/>
  <xs:element name="AcquisitionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AcquisitionDetailsLineItems"/>
  <xs:element name="ShareCapitalandReservesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_ShareCapitalandReservesDetailsTable"/>
  <xs:element name="ShareCapitalandReservesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareCapitalandReservesDetailsLineItems"/>
  <xs:element name="PrefundWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_PrefundWarrants"/>
  <xs:element name="TransactionCostsAllocatedToAdditionalPaidinCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_TransactionCostsAllocatedToAdditionalPaidinCapital"/>
  <xs:element name="ExercisedCommonSharesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ExercisedCommonSharesDescription"/>
  <xs:element name="CommonSharesNetIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_CommonSharesNetIssuance"/>
  <xs:element name="PrefundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_PrefundedWarrants"/>
  <xs:element name="CommonSharesConsultingServices" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_CommonSharesConsultingServices"/>
  <xs:element name="IPOWarrantIssue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_IPOWarrantIssue"/>
  <xs:element name="WarrantExpiryDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_WarrantExpiryDate"/>
  <xs:element name="WarrantsModificationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_WarrantsModificationExpense"/>
  <xs:element name="WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_WarrantsIssued"/>
  <xs:element name="IssuanceOfCommonSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_IssuanceOfCommonSharesIssued"/>
  <xs:element name="WarrantsIssuanceTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_WarrantsIssuanceTerm"/>
  <xs:element name="ShareBasedPaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_ShareBasedPaymentsDetailsTable"/>
  <xs:element name="ShareBasedPaymentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedPaymentsDetailsLineItems"/>
  <xs:element name="IssuedAndOutstandingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_IssuedAndOutstandingPercentage"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
  <xs:element name="WeightedAverageForfeitureRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_WeightedAverageForfeitureRate"/>
  <xs:element name="LeaseObligationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_LeaseObligationsDetailsTable"/>
  <xs:element name="LeaseObligationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_LeaseObligationsDetailsLineItems"/>
  <xs:element name="OtherVariableLeaseCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_OtherVariableLeaseCost"/>
  <xs:element name="RecognizedTaxBenefits" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_RecognizedTaxBenefits"/>
  <xs:element name="NonCashTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_NonCashTransactionsDetailsTable"/>
  <xs:element name="NonCashTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_NonCashTransactionsDetailsLineItems"/>
  <xs:element name="EstimatedFairValueCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_EstimatedFairValueCommonShares"/>
  <xs:element name="CostOfServicesDirectsMaterials" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_CostOfServicesDirectsMaterials"/>
  <xs:element name="ExpenditureBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_ExpenditureBalance"/>
  <xs:element name="GuaranteedInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_GuaranteedInvestment"/>
  <xs:element name="WarrantsToPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_WarrantsToPurchase"/>
  <xs:element name="CommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_CommonShares"/>
  <xs:element name="TypeOfCurrencyDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_TypeOfCurrencyDomain"/>
  <xs:element name="FinancialRiskManagementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_FinancialRiskManagementDetailsTable"/>
  <xs:element name="FinancialRiskManagementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_FinancialRiskManagementDetailsLineItems"/>
  <xs:element name="ForeignCurrencyRiskPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ForeignCurrencyRiskPercentage"/>
  <xs:element name="ShortTermInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_ShortTermInvestment"/>
  <xs:element name="workingCapitalSurplus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="inm_workingCapitalSurplus"/>
  <xs:element name="LegalService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="inm_LegalService"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="inm_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_SubsequentEventsDetailsLineItems"/>
  <xs:element name="TypeOfCurrencyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="inm_TypeOfCurrencyAxis"/>
  <xs:element name="ATMMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ATMMember"/>
  <xs:element name="AgentsInvestmentOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AgentsInvestmentOptionsMember"/>
  <xs:element name="AgentsWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AgentsWarrantsMember"/>
  <xs:element name="AllocatedToAdditionalPaidinCapitalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_AllocatedToAdditionalPaidinCapitalMember"/>
  <xs:element name="BayMedicaAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_BayMedicaAgreementMember"/>
  <xs:element name="BayMedicaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_BayMedicaIncMember"/>
  <xs:element name="BayMedicaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_BayMedicaMember"/>
  <xs:element name="CannabinoidMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_CannabinoidMember"/>
  <xs:element name="CustomerOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_CustomerOneMember"/>
  <xs:element name="GrossProceedsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_GrossProceedsMember"/>
  <xs:element name="IPRDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_IPRDMember"/>
  <xs:element name="InMedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_InMedMember"/>
  <xs:element name="InvestmentOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_InvestmentOptionsMember"/>
  <xs:element name="PreferredInvestmentOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_PreferredInvestmentOptionsMember"/>
  <xs:element name="PrefundedWarrantsIssuedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_PrefundedWarrantsIssuedMember"/>
  <xs:element name="PurchasePriceConsiderationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_PurchasePriceConsiderationMember"/>
  <xs:element name="RightOfUseAssetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_RightOfUseAssetMember"/>
  <xs:element name="ShareIssuanceCostsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_ShareIssuanceCostsMember"/>
  <xs:element name="SharePurchaseWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_SharePurchaseWarrantsMember"/>
  <xs:element name="SharesIssuedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_SharesIssuedMember"/>
  <xs:element name="USDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_USDMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="inm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>inm-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Sep 23 19:20:26 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedBalanceSheet" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedIncomeStatement" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedCashFlow" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofamortizationexpenseTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleoffairvalueandcarryingvaluesofthecompanyTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionConsiderationPayable" xlink:href="inm-20220630.xsd#inm_AcquisitionConsiderationPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="inm_AcquisitionConsiderationPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="5" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="inm_WarrantModificationExpense" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ8btGW5qMQVqzLsfi3GzVuMY7sD/FFw7U4o2i8MgAqSMg6pxwpeBm32Q4Yx+CEjQMnrWZzgc+HrjKz4FGA65QOvsgEC/wMtHrdik6IbyDDLXxJdt3/VqavjFzajJqD6rwRbNxWB/9EPBc1wENO3701leuZtdXSpohHx25mAouKCHQxfXoc5q0CB/s8eMhbBXgs6kLNzvlp1wl2bBxSuHrbtRH51QZ5KOM=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" xlink:href="inm-20220630.xsd#inm_InterestIncomeaccruedReceivedOnShorttermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="inm_FinanceExpense" xlink:href="inm-20220630.xsd#inm_FinanceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inm_FinanceExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantModificationExpenses" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inm_WarrantModificationExpenses" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="inm_UnrealizedGainOnDerivativeWarrantsLiability" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnDerivativeWarrantsLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inm_UnrealizedGainOnDerivativeWarrantsLiability" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="inm_UnrealizedGainOnForeignExchange" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnForeignExchange"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inm_UnrealizedGainOnForeignExchange" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="inm_CashAcquiredFromAcqusition" xlink:href="inm-20220630.xsd#inm_CashAcquiredFromAcqusition"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inm_CashAcquiredFromAcqusition" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_StockIssued1" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable">
    <loc xlink:type="locator" xlink:label="inm_FiniteLivedIntangibleAssetNet" xlink:href="inm-20220630.xsd#inm_FiniteLivedIntangibleAssetNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="inm_FiniteLivedIntangibleAssetNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="inm_FiniteLivedIntangibleAssetNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="inm_FiniteLivedIntangibleAssetNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="inm_FiniteLivedIntangibleAssetNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="inm_FiniteLivedIntangibleAssetNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>inm-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Sep 23 19:20:26 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedBalanceSheet" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedIncomeStatement" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareholdersEquityType2or3" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedCashFlow" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NatureofBusinessandGoingConcern" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SignificantAccountingPolicies" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CustomerConcentration" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_Inventories" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_PropertyEquipmentandRouAssetsNet" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ImpairmentofIntangibleAssetsandGoodwill" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IntangibleAssets" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_Acquisition" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/Acquisition"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AccountsPayableandAccruedLiabilities" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareCapitalandReserves" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareBasedPayments" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_LeaseObligations" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_BasicandDilutedLossPerShare" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IncomeTaxes" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SegmentInformation" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NonCashTransactions" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CommitmentsandContingencies" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_FinancialRiskManagement" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_RelatedPartyTransactions" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SubsequentEvents" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AccountingPoliciesByPolicy" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_InventoriesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_PropertyEquipmentandRouAssetsNetTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ImpairmentofIntangibleAssetsandGoodwillTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IntangibleAssetsTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AcquisitionTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareCapitalandReservesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareBasedPaymentsTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_LeaseObligationsTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_BasicandDilutedLossPerShareTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IncomeTaxesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SegmentInformationTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_FinancialRiskManagementTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofinventoriesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofpropertyequipmentandrightofuseassetsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofintangibleassetsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofintangibleassetsTable0" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofamortizationexpenseTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleoftotalconsiderationTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleoffairvalueofassetsacquiredandliabilitiesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofproformaconsolidatedresultsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofaccountspayableandaccruedliabilitiesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofprivateplacementofferingTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofchangesinsharepurchasewarrantsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofchangesinagentswarrantsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofoutstandingoptionsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofminimumleasepaymentsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofweightedaveragenumberofcommonsharesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofareconciliationofincometaxesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofreportablesegmentsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleoffairvalueandcarryingvaluesofthecompanyTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NatureofBusinessandGoingConcernDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SignificantAccountingPoliciesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CustomerConcentrationDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_InventoriesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ImpairmentofIntangibleAssetsandGoodwillDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IntangibleAssetsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AcquisitionDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareCapitalandReservesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareBasedPaymentsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_LeaseObligationsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IncomeTaxesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NonCashTransactionsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CommitmentsandContingenciesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_FinancialRiskManagementDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_RelatedPartyTransactionsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SubsequentEventsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#DocumentAndEntityInformation" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionConsiderationPayable" xlink:href="inm-20220630.xsd#inm_AcquisitionConsiderationPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="inm_AcquisitionConsiderationPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="inm_WarrantModificationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:href="inm-20220630.xsd#inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" xlink:href="inm-20220630.xsd#inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ATMOfferingNetOfIssuanceCosts" xlink:href="inm-20220630.xsd#inm_ATMOfferingNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_ATMOfferingNetOfIssuanceCosts" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ATMOfferingNetOfIssuanceCostsShares" xlink:href="inm-20220630.xsd#inm_ATMOfferingNetOfIssuanceCostsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_ATMOfferingNetOfIssuanceCostsShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_RegisteredDirectAndPrivatePlacement" xlink:href="inm-20220630.xsd#inm_RegisteredDirectAndPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_RegisteredDirectAndPrivatePlacement" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_RegisteredDirectAndPrivatePlacementShares" xlink:href="inm-20220630.xsd#inm_RegisteredDirectAndPrivatePlacementShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_RegisteredDirectAndPrivatePlacementShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareIssuanceCosts" xlink:href="inm-20220630.xsd#inm_ShareIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_ShareIssuanceCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsWarrants" xlink:href="inm-20220630.xsd#inm_AgentsWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_AgentsWarrants" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsInvestmentOptions" xlink:href="inm-20220630.xsd#inm_AgentsInvestmentOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_AgentsInvestmentOptions" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfPrefundedWarrants" xlink:href="inm-20220630.xsd#inm_ExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_ExerciseOfPrefundedWarrants" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfPrefundedWarrantsinShares" xlink:href="inm-20220630.xsd#inm_ExerciseOfPrefundedWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_ExerciseOfPrefundedWarrantsinShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfWarrantsin" xlink:href="inm-20220630.xsd#inm_ExerciseOfWarrantsin"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_ExerciseOfWarrantsin" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfWarrantsinShares" xlink:href="inm-20220630.xsd#inm_ExerciseOfWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_ExerciseOfWarrantsinShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionOfBayMedica" xlink:href="inm-20220630.xsd#inm_AcquisitionOfBayMedica"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_AcquisitionOfBayMedica" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionOfBayMedicainShares" xlink:href="inm-20220630.xsd#inm_AcquisitionOfBayMedicainShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_AcquisitionOfBayMedicainShares" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_WarrantModificationExpense" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_LossAndComprehensivelossesForThePeriod" xlink:href="inm-20220630.xsd#inm_LossAndComprehensivelossesForThePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_LossAndComprehensivelossesForThePeriod" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_LossAndComprehensiveIncomelossesForThePeriod" xlink:href="inm-20220630.xsd#inm_LossAndComprehensiveIncomelossesForThePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inm_LossAndComprehensiveIncomelossesForThePeriod" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" xlink:href="inm-20220630.xsd#inm_InterestIncomeaccruedReceivedOnShorttermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_UnrealizedGainOnDerivativeWarrantsLiability" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnDerivativeWarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inm_UnrealizedGainOnDerivativeWarrantsLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_UnrealizedGainOnForeignExchange" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnForeignExchange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inm_UnrealizedGainOnForeignExchange" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_FinanceExpense" xlink:href="inm-20220630.xsd#inm_FinanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inm_FinanceExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantModificationExpenses" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inm_WarrantModificationExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_CashAcquiredFromAcqusition" xlink:href="inm-20220630.xsd#inm_CashAcquiredFromAcqusition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inm_CashAcquiredFromAcqusition" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_StockIssued1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern">
    <loc xlink:type="locator" xlink:label="inm_NatureofBusinessandGoingConcernLineItems" xlink:href="inm-20220630.xsd#inm_NatureofBusinessandGoingConcernLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_NatureofBusinessandGoingConcernTable" xlink:href="inm-20220630.xsd#inm_NatureofBusinessandGoingConcernTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_NatureofBusinessandGoingConcernLineItems" xlink:to="inm_NatureofBusinessandGoingConcernTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NatureofBusinessandGoingConcernLineItems" xlink:to="us-gaap_NatureOfOperations" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/Inventories">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/Acquisition">
    <loc xlink:type="locator" xlink:label="inm_AcquisitionAbstract" xlink:href="inm-20220630.xsd#inm_AcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionTextBlock" xlink:href="inm-20220630.xsd#inm_AcquisitionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionAbstract" xlink:to="inm_AcquisitionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves">
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalAndReservesAbstract" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalAndReservesTextBlock" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalAndReservesAbstract" xlink:to="inm_ShareCapitalAndReservesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions">
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsAbstract" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsTextBlock" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsAbstract" xlink:to="inm_NonCashTransactionsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement">
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementAbstract" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementTextBlock" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementAbstract" xlink:to="inm_FinancialRiskManagementTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_COVID19ImpactsPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_COVID19ImpactsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inm_COVID19ImpactsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_InProcessRDPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_InProcessRDPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inm_InProcessRDPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_FinancialAssetsAndLiabilitiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesVendorAllowancesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesVendorAllowancesPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesVendorAllowancesPolicy" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables">
    <loc xlink:type="locator" xlink:label="inm_AcquisitionAbstract" xlink:href="inm-20220630.xsd#inm_AcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables">
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalAndReservesAbstract" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfPrivatePlacementOfferingTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalAndReservesAbstract" xlink:to="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalAndReservesAbstract" xlink:to="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalAndReservesAbstract" xlink:to="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables">
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementAbstract" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfInventoriesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_RightOfUseAssetMember" xlink:href="inm-20220630.xsd#inm_RightOfUseAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inm_RightOfUseAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_GoodwillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_IPRDMember" xlink:href="inm-20220630.xsd#inm_IPRDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="inm_IPRDMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_GoodwillFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfIntangibleAssetsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfAmortizationExpenseAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_FiniteLivedIntangibleAssetNet" xlink:href="inm-20220630.xsd#inm_FiniteLivedIntangibleAssetNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAmortizationExpenseAbstract" xlink:to="inm_FiniteLivedIntangibleAssetNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_PurchasePriceConsiderationMember" xlink:href="inm-20220630.xsd#inm_PurchasePriceConsiderationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inm_PurchasePriceConsiderationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationPostclosingAdjustments" xlink:href="inm-20220630.xsd#inm_BusinessCombinationPostclosingAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inm_BusinessCombinationPostclosingAdjustments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_PurchasePriceConsiderationMember" xlink:href="inm-20220630.xsd#inm_PurchasePriceConsiderationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inm_PurchasePriceConsiderationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_LiabilitiesAssumedAbstract" xlink:href="inm-20220630.xsd#inm_LiabilitiesAssumedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="inm_LiabilitiesAssumedAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LiabilitiesAssumedAbstract" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfProFormaConsolidatedResultsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfProFormaConsolidatedResultsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfProFormaConsolidatedResultsAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfProFormaConsolidatedResultsAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ8btGW5qMQVqzLsfi3GzVuMY7sD/FFw7U4o2i8MgAqSMg6pxwpeBm32Q4Yx+CEjQMnrWZzgc+HrjKz4FGA65QOvsgEC/wMtHrdik6IbyDDLXxJdt3/VqavjFzajJqD6rwRbNxWB/9EPBc1wENO3701leuZtdXSpohHx25mAouKCHQxfXoc5q0CB/s8eMhbBXgs6kLNzvlp11lUQ25XpzQ14mQ+UNjgRM0=] CSR-->
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AccruedResearchAndDevelopment" xlink:href="inm-20220630.xsd#inm_AccruedResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="inm_AccruedResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable">
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_SharesIssuedMember" xlink:href="inm-20220630.xsd#inm_SharesIssuedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inm_SharesIssuedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_PrefundedWarrantsIssuedMember" xlink:href="inm-20220630.xsd#inm_PrefundedWarrantsIssuedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inm_PrefundedWarrantsIssuedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_GrossProceedsMember" xlink:href="inm-20220630.xsd#inm_GrossProceedsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inm_GrossProceedsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AllocatedToAdditionalPaidinCapitalMember" xlink:href="inm-20220630.xsd#inm_AllocatedToAdditionalPaidinCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inm_AllocatedToAdditionalPaidinCapitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareIssuanceCostsMember" xlink:href="inm-20220630.xsd#inm_ShareIssuanceCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inm_ShareIssuanceCostsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="us-gaap_SharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_TotalCommonShareValue" xlink:href="inm-20220630.xsd#inm_TotalCommonShareValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="inm_TotalCommonShareValue" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable">
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_SharePurchaseWarrantsMember" xlink:href="inm-20220630.xsd#inm_SharePurchaseWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="inm_SharePurchaseWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalOfNumberOfBalance" xlink:href="inm-20220630.xsd#inm_ShareCapitalOfNumberOfBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_ShareCapitalOfNumberOfBalance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AggregateIntrinsicValueAtBeginning" xlink:href="inm-20220630.xsd#inm_AggregateIntrinsicValueAtBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_AggregateIntrinsicValueAtBeginning" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_ShareBasedPaymentNumberOfGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageSharePriceGranted" xlink:href="inm-20220630.xsd#inm_WeightedAverageSharePriceGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_WeightedAverageSharePriceGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AggregateIntrinsicValueGranted" xlink:href="inm-20220630.xsd#inm_AggregateIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_AggregateIntrinsicValueGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfExercised" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_ShareBasedPaymentNumberOfExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsWeightedAverageSharePriceExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable">
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsWarrantsMember" xlink:href="inm-20220630.xsd#inm_AgentsWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inm_AgentsWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfBalanceAtBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentNumberOfBalanceAtBeginning" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentSharesNumberOfGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentSharesNumberOfGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentSharesNumberOfGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfBalanceAtEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentNumberOfBalanceAtEnding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfOutstandingOptionsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfOutstandingOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:href="inm-20220630.xsd#inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="inm-20220630.xsd#inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_June302022Abstract" xlink:href="inm-20220630.xsd#inm_June302022Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="inm_June302022Abstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_NumberOfVestedAndExercisable" xlink:href="inm-20220630.xsd#inm_NumberOfVestedAndExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_June302022Abstract" xlink:to="inm_NumberOfVestedAndExercisable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageExercisePriceVestedAndExercisable" xlink:href="inm-20220630.xsd#inm_WeightedAverageExercisePriceVestedAndExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_June302022Abstract" xlink:to="inm_WeightedAverageExercisePriceVestedAndExercisable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_NumberOfUnvested" xlink:href="inm-20220630.xsd#inm_NumberOfUnvested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_June302022Abstract" xlink:to="inm_NumberOfUnvested" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageExercisePriceUnvested" xlink:href="inm-20220630.xsd#inm_WeightedAverageExercisePriceUnvested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_June302022Abstract" xlink:to="inm_WeightedAverageExercisePriceUnvested" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDue" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="inm-20220630.xsd#inm_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsPropertyAndEquipmentsNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsPropertyAndEquipmentsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_DeferredTaxAssetsPropertyAndEquipmentsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsFinancingCost" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsFinancingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_DeferredTaxAssetsFinancingCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_LeaseLiabilities" xlink:href="inm-20220630.xsd#inm_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_LeaseLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsAndLiabilitiesGross" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsAndLiabilitiesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_DeferredTaxAssetsAndLiabilitiesGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsIntangibleAssetsNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_DeferredTaxAssetsIntangibleAssetsNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsLeaseObligations" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_DeferredTaxAssetsLeaseObligations" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetLiabilitiesNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_DeferredTaxAssetLiabilitiesNet" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_InMedMember" xlink:href="inm-20220630.xsd#inm_InMedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inm_InMedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BayMedicaMember" xlink:href="inm-20220630.xsd#inm_BayMedicaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inm_BayMedicaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_OtherOperatingExpenses" xlink:href="inm-20220630.xsd#inm_OtherOperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="inm_OtherOperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShortTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CumulativeEarningsDeficit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_CashAndCashEquivalent" xlink:href="inm-20220630.xsd#inm_CashAndCashEquivalent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="inm_CashAndCashEquivalent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails">
    <loc xlink:type="locator" xlink:label="inm_CustomerConcentrationDetailsLineItems" xlink:href="inm-20220630.xsd#inm_CustomerConcentrationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_CustomerConcentrationDetailsTable" xlink:href="inm-20220630.xsd#inm_CustomerConcentrationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_CustomerConcentrationDetailsLineItems" xlink:to="inm_CustomerConcentrationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_CustomerConcentrationDetailsTable" xlink:to="srt_MajorCustomersAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_CustomerConcentrationDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_CustomerOneMember" xlink:href="inm-20220630.xsd#inm_CustomerOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inm_CustomerOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCustomer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_CustomerConcentrationDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskCustomer" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ConcentrationRiskPercentage" xlink:href="inm-20220630.xsd#inm_ConcentrationRiskPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_CustomerConcentrationDetailsLineItems" xlink:to="inm_ConcentrationRiskPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails">
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_IPRDMember" xlink:href="inm-20220630.xsd#inm_IPRDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="inm_IPRDMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="us-gaap_GoodwillGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:href="inm-20220630.xsd#inm_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="inm_ImpairmentOfIntangibleAssetExcludingGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:href="inm-20220630.xsd#inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="us-gaap_ImpairmentChargeOnReclassifiedAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails">
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsLineItems" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsTable" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="inm_AcquisitionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_AcquisitionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_AcquisitionDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_AcquisitionDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_CannabinoidMember" xlink:href="inm-20220630.xsd#inm_CannabinoidMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="inm_CannabinoidMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BayMedicaMember" xlink:href="inm-20220630.xsd#inm_BayMedicaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inm_BayMedicaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_Revenues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="us-gaap_LegalFees" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails">
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_ShareCapitalandReservesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_PreferredInvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_PreferredInvestmentOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inm_PreferredInvestmentOptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsInvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_AgentsInvestmentOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inm_AgentsInvestmentOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BayMedicaAgreementMember" xlink:href="inm-20220630.xsd#inm_BayMedicaAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inm_BayMedicaAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ATMMember" xlink:href="inm-20220630.xsd#inm_ATMMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="inm_ATMMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_PrefundWarrants" xlink:href="inm-20220630.xsd#inm_PrefundWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_PrefundWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_TransactionCostsAllocatedToAdditionalPaidinCapital" xlink:href="inm-20220630.xsd#inm_TransactionCostsAllocatedToAdditionalPaidinCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_TransactionCostsAllocatedToAdditionalPaidinCapital" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ExercisedCommonSharesDescription" xlink:href="inm-20220630.xsd#inm_ExercisedCommonSharesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_ExercisedCommonSharesDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_CommonSharesNetIssuance" xlink:href="inm-20220630.xsd#inm_CommonSharesNetIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_CommonSharesNetIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_PrefundedWarrants" xlink:href="inm-20220630.xsd#inm_PrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_PrefundedWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_CommonSharesConsultingServices" xlink:href="inm-20220630.xsd#inm_CommonSharesConsultingServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_CommonSharesConsultingServices" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_IPOWarrantIssue" xlink:href="inm-20220630.xsd#inm_IPOWarrantIssue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_IPOWarrantIssue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantExpiryDate" xlink:href="inm-20220630.xsd#inm_WarrantExpiryDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_WarrantExpiryDate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantsModificationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_WarrantsModificationExpense" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsIssued" xlink:href="inm-20220630.xsd#inm_WarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_WarrantsIssued" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_IssuanceOfCommonSharesIssued" xlink:href="inm-20220630.xsd#inm_IssuanceOfCommonSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_IssuanceOfCommonSharesIssued" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsIssuanceTerm" xlink:href="inm-20220630.xsd#inm_WarrantsIssuanceTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_WarrantsIssuanceTerm" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentsDetailsTable" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="inm_ShareBasedPaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_ShareBasedPaymentsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_IssuedAndOutstandingPercentage" xlink:href="inm-20220630.xsd#inm_IssuedAndOutstandingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="inm_IssuedAndOutstandingPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageForfeitureRate" xlink:href="inm-20220630.xsd#inm_WeightedAverageForfeitureRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="inm_WeightedAverageForfeitureRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails">
    <loc xlink:type="locator" xlink:label="inm_LeaseObligationsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_LeaseObligationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_LeaseObligationsDetailsTable" xlink:href="inm-20220630.xsd#inm_LeaseObligationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="inm_LeaseObligationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_LeaseObligationsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="us-gaap_VariableLeaseCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_OtherVariableLeaseCost" xlink:href="inm-20220630.xsd#inm_OtherVariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="inm_OtherVariableLeaseCost" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_RecognizedTaxBenefits" xlink:href="inm-20220630.xsd#inm_RecognizedTaxBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="inm_RecognizedTaxBenefits" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails">
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsDetailsTable" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="inm_NonCashTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_NonCashTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_BayMedicaIncMember" xlink:href="inm-20220630.xsd#inm_BayMedicaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inm_BayMedicaIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_EstimatedFairValueCommonShares" xlink:href="inm-20220630.xsd#inm_EstimatedFairValueCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="inm_EstimatedFairValueCommonShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_LoansReceivableFairValueDisclosure" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredUnitsIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_PreferredUnitsIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_CostOfServicesDirectsMaterials" xlink:href="inm-20220630.xsd#inm_CostOfServicesDirectsMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inm_CostOfServicesDirectsMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ExpenditureBalance" xlink:href="inm-20220630.xsd#inm_ExpenditureBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inm_ExpenditureBalance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostDirectMaterial"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CostDirectMaterial" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_GuaranteedInvestment" xlink:href="inm-20220630.xsd#inm_GuaranteedInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inm_GuaranteedInvestment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsToPurchase" xlink:href="inm-20220630.xsd#inm_WarrantsToPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inm_WarrantsToPurchase" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_CommonShares" xlink:href="inm-20220630.xsd#inm_CommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inm_CommonShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails">
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementDetailsLineItems" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementDetailsTable" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="inm_FinancialRiskManagementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_TypeOfCurrencyAxis" xlink:href="inm-20220630.xsd#inm_TypeOfCurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_FinancialRiskManagementDetailsTable" xlink:to="inm_TypeOfCurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_TypeOfCurrencyDomain" xlink:href="inm-20220630.xsd#inm_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="inm_TypeOfCurrencyAxis" xlink:to="inm_TypeOfCurrencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_TypeOfCurrencyDomain_0" xlink:href="inm-20220630.xsd#inm_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="inm_TypeOfCurrencyAxis" xlink:to="inm_TypeOfCurrencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_USDMember" xlink:href="inm-20220630.xsd#inm_USDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_TypeOfCurrencyDomain" xlink:to="inm_USDMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ForeignCurrencyRiskPercentage" xlink:href="inm-20220630.xsd#inm_ForeignCurrencyRiskPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="inm_ForeignCurrencyRiskPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesGainLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_Cash" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherMinorityInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMinorityInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_OtherMinorityInterests" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_OtherShortTermInvestments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_ShortTermInvestment" xlink:href="inm-20220630.xsd#inm_ShortTermInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="inm_ShortTermInvestment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_workingCapitalSurplus" xlink:href="inm-20220630.xsd#inm_workingCapitalSurplus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="inm_workingCapitalSurplus" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="inm_LegalService" xlink:href="inm-20220630.xsd#inm_LegalService"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="inm_LegalService" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="inm_SubsequentEventsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="inm_SubsequentEventsDetailsTable" xlink:href="inm-20220630.xsd#inm_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="inm_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inm_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="inm_InvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_InvestmentOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="inm_InvestmentOptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>inm-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Sep 23 19:20:26 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss before taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Total cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Total cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Total cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_GoodwillFairValueDisclosure_lbl" xml:lang="en-US">Balance as of beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillFairValueDisclosure" xlink:to="us-gaap_GoodwillFairValueDisclosure_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_GoodwillFairValueDisclosure_lbl0" xml:lang="en-US">Balance as of ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillFairValueDisclosure" xlink:to="us-gaap_GoodwillFairValueDisclosure_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FiniteLivedIntangibleAssetNet" xlink:href="inm-20220630.xsd#inm_FiniteLivedIntangibleAssetNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="inm_FiniteLivedIntangibleAssetNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FiniteLivedIntangibleAssetNet" xlink:to="inm_FiniteLivedIntangibleAssetNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalAndReservesAbstract" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalAndReservesAbstract_lbl" xml:lang="en-US">Share Capital And Reserves [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalAndReservesAbstract" xlink:to="inm_ShareCapitalAndReservesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalOfNumberOfBalance" xlink:href="inm-20220630.xsd#inm_ShareCapitalOfNumberOfBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="inm_ShareCapitalOfNumberOfBalance_lbl" xml:lang="en-US">Number of Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalOfNumberOfBalance" xlink:to="inm_ShareCapitalOfNumberOfBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="inm_ShareCapitalOfNumberOfBalance_lbl0" xml:lang="en-US">Number of Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalOfNumberOfBalance" xlink:to="inm_ShareCapitalOfNumberOfBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl" xml:lang="en-US">Weighted Average Share Price, Beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl0" xml:lang="en-US">Weighted Average Share Price, Ending balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_AggregateIntrinsicValueAtBeginning" xlink:href="inm-20220630.xsd#inm_AggregateIntrinsicValueAtBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="inm_AggregateIntrinsicValueAtBeginning_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AggregateIntrinsicValueAtBeginning" xlink:to="inm_AggregateIntrinsicValueAtBeginning_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="inm_AggregateIntrinsicValueAtBeginning_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AggregateIntrinsicValueAtBeginning" xlink:to="inm_AggregateIntrinsicValueAtBeginning_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:href="inm-20220630.xsd#inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl" xml:lang="en-US">Number of Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl0" xml:lang="en-US">Number of Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsAbstract" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NonCashTransactionsAbstract_lbl" xml:lang="en-US">Non-Cash Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NonCashTransactionsAbstract" xlink:to="inm_NonCashTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementAbstract" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialRiskManagementAbstract_lbl" xml:lang="en-US">Financial Risk Management [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialRiskManagementAbstract" xlink:to="inm_FinancialRiskManagementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaids and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract" xlink:to="inm_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Property, equipment and ROU assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract0" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract0" xlink:to="inm_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts payable and accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionConsiderationPayable" xlink:href="inm-20220630.xsd#inm_AcquisitionConsiderationPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AcquisitionConsiderationPayable_lbl" xml:lang="en-US">Acquisition consideration payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionConsiderationPayable" xlink:to="inm_AcquisitionConsiderationPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract1" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract1" xlink:to="inm_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract2" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract2" xlink:to="inm_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract" xlink:href="inm-20220630.xsd#inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract_lbl" xml:lang="en-US">Common shares, no par value, unlimited authorized shares:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract" xlink:to="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common shares, no par value, unlimited authorized shares 650,667 (June 30, 2021 - 322,028) issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract3" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract3" xlink:to="inm_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development and patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Amortization and depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract4" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract4" xlink:to="inm_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Finance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Unrealized gain on derivative warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract5" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract5" xlink:to="inm_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other Comprehensive Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfOtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign currency translation gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract6" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract6" xlink:to="inm_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per share for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share for the year Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share for the year Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US">Weighted average outstanding common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average outstanding common shares Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Weighted average outstanding common shares Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Public offering (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:href="inm-20220630.xsd#inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl" xml:lang="en-US">Private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" xlink:href="inm-20220630.xsd#inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares_lbl" xml:lang="en-US">Private placement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Reclassification of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareIssuanceCosts" xlink:href="inm-20220630.xsd#inm_ShareIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareIssuanceCosts_lbl" xml:lang="en-US">Share issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareIssuanceCosts" xlink:to="inm_ShareIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LossAndComprehensiveIncomelossesForThePeriod" xlink:href="inm-20220630.xsd#inm_LossAndComprehensiveIncomelossesForThePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LossAndComprehensiveIncomelossesForThePeriod_lbl" xml:lang="en-US">Loss and comprehensive income for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LossAndComprehensiveIncomelossesForThePeriod" xlink:to="inm_LossAndComprehensiveIncomelossesForThePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ATMOfferingNetOfIssuanceCosts" xlink:href="inm-20220630.xsd#inm_ATMOfferingNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ATMOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">ATM offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMOfferingNetOfIssuanceCosts" xlink:to="inm_ATMOfferingNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ATMOfferingNetOfIssuanceCostsShares" xlink:href="inm-20220630.xsd#inm_ATMOfferingNetOfIssuanceCostsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ATMOfferingNetOfIssuanceCostsShares_lbl" xml:lang="en-US">ATM offering, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMOfferingNetOfIssuanceCostsShares" xlink:to="inm_ATMOfferingNetOfIssuanceCostsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_RegisteredDirectAndPrivatePlacement" xlink:href="inm-20220630.xsd#inm_RegisteredDirectAndPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_RegisteredDirectAndPrivatePlacement_lbl" xml:lang="en-US">Registered direct and private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RegisteredDirectAndPrivatePlacement" xlink:to="inm_RegisteredDirectAndPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_RegisteredDirectAndPrivatePlacementShares" xlink:href="inm-20220630.xsd#inm_RegisteredDirectAndPrivatePlacementShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_RegisteredDirectAndPrivatePlacementShares_lbl" xml:lang="en-US">Registered direct and private placement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RegisteredDirectAndPrivatePlacementShares" xlink:to="inm_RegisteredDirectAndPrivatePlacementShares_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsWarrants" xlink:href="inm-20220630.xsd#inm_AgentsWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AgentsWarrants_lbl" xml:lang="en-US">Agents&apos; warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsWarrants" xlink:to="inm_AgentsWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsInvestmentOptions" xlink:href="inm-20220630.xsd#inm_AgentsInvestmentOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AgentsInvestmentOptions_lbl" xml:lang="en-US">Agents&apos; investment options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsInvestmentOptions" xlink:to="inm_AgentsInvestmentOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfPrefundedWarrants" xlink:href="inm-20220630.xsd#inm_ExerciseOfPrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfPrefundedWarrants" xlink:to="inm_ExerciseOfPrefundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfPrefundedWarrantsinShares" xlink:href="inm-20220630.xsd#inm_ExerciseOfPrefundedWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ExerciseOfPrefundedWarrantsinShares_lbl" xml:lang="en-US">Exercise of pre-funded warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfPrefundedWarrantsinShares" xlink:to="inm_ExerciseOfPrefundedWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfWarrantsin" xlink:href="inm-20220630.xsd#inm_ExerciseOfWarrantsin"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ExerciseOfWarrantsin_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfWarrantsin" xlink:to="inm_ExerciseOfWarrantsin_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ExerciseOfWarrantsinShares" xlink:href="inm-20220630.xsd#inm_ExerciseOfWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ExerciseOfWarrantsinShares_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfWarrantsinShares" xlink:to="inm_ExerciseOfWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionOfBayMedica" xlink:href="inm-20220630.xsd#inm_AcquisitionOfBayMedica"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AcquisitionOfBayMedica_lbl" xml:lang="en-US">Acquisition of BayMedica</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionOfBayMedica" xlink:to="inm_AcquisitionOfBayMedica_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionOfBayMedicainShares" xlink:href="inm-20220630.xsd#inm_AcquisitionOfBayMedicainShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AcquisitionOfBayMedicainShares_lbl" xml:lang="en-US">Acquisition of BayMedica (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionOfBayMedicainShares" xlink:to="inm_AcquisitionOfBayMedicainShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for consulting services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for consulting services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WarrantModificationExpense_lbl" xml:lang="en-US">Warrant modification expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantModificationExpense" xlink:to="inm_WarrantModificationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="inm_WarrantModificationExpense_lbl0" xml:lang="en-US">Warrant modification expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantModificationExpense" xlink:to="inm_WarrantModificationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_LossAndComprehensivelossesForThePeriod" xlink:href="inm-20220630.xsd#inm_LossAndComprehensivelossesForThePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LossAndComprehensivelossesForThePeriod_lbl" xml:lang="en-US">Loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LossAndComprehensivelossesForThePeriod" xlink:to="inm_LossAndComprehensivelossesForThePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Cash provided by (used in):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract7" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract7" xlink:to="inm_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Items not requiring cash:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Amortization and depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Amortization of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" xlink:href="inm-20220630.xsd#inm_InterestIncomeaccruedReceivedOnShorttermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_InterestIncomeaccruedReceivedOnShorttermInvestments_lbl" xml:lang="en-US">Interest income received on short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" xlink:to="inm_InterestIncomeaccruedReceivedOnShorttermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Impairment of intangible assets and goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinanceExpense" xlink:href="inm-20220630.xsd#inm_FinanceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_FinanceExpense_lbl" xml:lang="en-US">Finance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinanceExpense" xlink:to="inm_FinanceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantModificationExpenses" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WarrantModificationExpenses_lbl" xml:lang="en-US">Warrant modification expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantModificationExpenses" xlink:to="inm_WarrantModificationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract8" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract8" xlink:to="inm_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CashAcquiredFromAcqusition" xlink:href="inm-20220630.xsd#inm_CashAcquiredFromAcqusition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CashAcquiredFromAcqusition_lbl" xml:lang="en-US">Cash acquired from acquisition of BayMedica</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CashAcquiredFromAcqusition" xlink:to="inm_CashAcquiredFromAcqusition_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract9" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract9" xlink:to="inm_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Shares issued for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effects of foreign exchange on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of intangible assets and goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnrealizedGainOnDerivativeWarrantsLiability" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnDerivativeWarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="inm_UnrealizedGainOnDerivativeWarrantsLiability_lbl" xml:lang="en-US">Unrealized gain on derivative warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnrealizedGainOnDerivativeWarrantsLiability" xlink:to="inm_UnrealizedGainOnDerivativeWarrantsLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnrealizedGainOnForeignExchange" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnForeignExchange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="inm_UnrealizedGainOnForeignExchange_lbl" xml:lang="en-US">Unrealized foreign exchange loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnrealizedGainOnForeignExchange" xlink:to="inm_UnrealizedGainOnForeignExchange_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaids and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Acquisition consideration payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xml:lang="en-US">Loan receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl0" xml:lang="en-US">Loans receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income - Foreign Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF BUSINESS AND GOING CONCERN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CUSTOMER CONCENTRATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, EQUIPMENT AND ROU ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, equipment and right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, equipment and ROU assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:to="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract10" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract10" xlink:to="inm_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_GoodwillAbstract" xlink:href="inm-20220630.xsd#inm_GoodwillAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_GoodwillAbstract_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_GoodwillAbstract" xlink:to="inm_GoodwillAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Acquired at October 13, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract11" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract11" xlink:to="inm_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_IndefiniteLivedIntangibleAssetsAbstract" xlink:href="inm-20220630.xsd#inm_IndefiniteLivedIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_IndefiniteLivedIntangibleAssetsAbstract_lbl" xml:lang="en-US">Indefinite lived intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IndefiniteLivedIntangibleAssetsAbstract" xlink:to="inm_IndefiniteLivedIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_IprDAbstract" xlink:href="inm-20220630.xsd#inm_IprDAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_IprDAbstract_lbl" xml:lang="en-US">IPR&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IprDAbstract" xlink:to="inm_IprDAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract12" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract12" xlink:to="inm_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DefiniteLivedIntangibleAssetsAbstract" xlink:href="inm-20220630.xsd#inm_DefiniteLivedIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DefiniteLivedIntangibleAssetsAbstract_lbl" xml:lang="en-US">Definite lived intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DefiniteLivedIntangibleAssetsAbstract" xlink:to="inm_DefiniteLivedIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_TrademarkAndIntellectualPropertyAbstract" xlink:href="inm-20220630.xsd#inm_TrademarkAndIntellectualPropertyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_TrademarkAndIntellectualPropertyAbstract_lbl" xml:lang="en-US">Trademark and Intellectual Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TrademarkAndIntellectualPropertyAbstract" xlink:to="inm_TrademarkAndIntellectualPropertyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract13" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract13" xlink:to="inm_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DefiniteLivedIntangibleAssetsAbstract0" xlink:href="inm-20220630.xsd#inm_DefiniteLivedIntangibleAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DefiniteLivedIntangibleAssetsAbstract0_lbl" xml:lang="en-US">Definite lived intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DefiniteLivedIntangibleAssetsAbstract0" xlink:to="inm_DefiniteLivedIntangibleAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PatentsAbstract" xlink:href="inm-20220630.xsd#inm_PatentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PatentsAbstract_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PatentsAbstract" xlink:to="inm_PatentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract14" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract14" xlink:to="inm_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases" xlink:to="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract15" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract15" xlink:to="inm_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionTextBlock" xlink:href="inm-20220630.xsd#inm_AcquisitionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AcquisitionTextBlock_lbl" xml:lang="en-US">ACQUISITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionTextBlock" xlink:to="inm_AcquisitionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US">Schedule of total consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US">Estimated fair value of common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash_lbl" xml:lang="en-US">cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationPostclosingAdjustments" xlink:href="inm-20220630.xsd#inm_BusinessCombinationPostclosingAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BusinessCombinationPostclosingAdjustments_lbl" xml:lang="en-US">Less:Post-closing adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationPostclosingAdjustments" xlink:to="inm_BusinessCombinationPostclosingAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Estimated fair value of consideration transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of assets acquired and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PurchasePriceAbstract" xlink:href="inm-20220630.xsd#inm_PurchasePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PurchasePriceAbstract_lbl" xml:lang="en-US">Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PurchasePriceAbstract" xlink:to="inm_PurchasePriceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AllocationAbstract" xlink:href="inm-20220630.xsd#inm_AllocationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AllocationAbstract_lbl" xml:lang="en-US">Allocation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AllocationAbstract" xlink:to="inm_AllocationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract16" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract16_lbl" xml:lang="en-US">($)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract16" xlink:to="inm_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AssetsAcquiredAbstract" xlink:href="inm-20220630.xsd#inm_AssetsAcquiredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AssetsAcquiredAbstract_lbl" xml:lang="en-US">Assets acquired:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AssetsAcquiredAbstract" xlink:to="inm_AssetsAcquiredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment_lbl" xml:lang="en-US">IPR&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark_lbl" xml:lang="en-US">Trademark</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract17" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract17" xlink:to="inm_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LiabilitiesAssumedAbstract" xlink:href="inm-20220630.xsd#inm_LiabilitiesAssumedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LiabilitiesAssumedAbstract_lbl" xml:lang="en-US">Liabilities assumed:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LiabilitiesAssumedAbstract" xlink:to="inm_LiabilitiesAssumedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities_lbl" xml:lang="en-US">Other short-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xml:lang="en-US">Total liabilities acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Estimated fair value of net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Schedule of pro forma consolidated results</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrentAndNoncurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableTradeCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AccruedResearchAndDevelopment" xlink:href="inm-20220630.xsd#inm_AccruedResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AccruedResearchAndDevelopment" xlink:to="inm_AccruedResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xml:lang="en-US">Employee compensation, benefits and related accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalAndReservesTextBlock" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareCapitalAndReservesTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL AND RESERVES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalAndReservesTextBlock" xlink:to="inm_ShareCapitalAndReservesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfPrivatePlacementOfferingTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock_lbl" xml:lang="en-US">Schedule of private placement offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock" xlink:to="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Issue Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_TotalCommonShareValue" xlink:href="inm-20220630.xsd#inm_TotalCommonShareValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_TotalCommonShareValue_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TotalCommonShareValue" xlink:to="inm_TotalCommonShareValue_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in share purchase warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" xlink:to="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentNumberOfGranted_lbl" xml:lang="en-US">Number of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfGranted" xlink:to="inm_ShareBasedPaymentNumberOfGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageSharePriceGranted" xlink:href="inm-20220630.xsd#inm_WeightedAverageSharePriceGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WeightedAverageSharePriceGranted_lbl" xml:lang="en-US">Weighted Average Share Price, Granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageSharePriceGranted" xlink:to="inm_WeightedAverageSharePriceGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AggregateIntrinsicValueGranted" xlink:href="inm-20220630.xsd#inm_AggregateIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AggregateIntrinsicValueGranted" xlink:to="inm_AggregateIntrinsicValueGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfExercised" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentNumberOfExercised_lbl" xml:lang="en-US">Number of Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfExercised" xlink:to="inm_ShareBasedPaymentNumberOfExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsWeightedAverageSharePriceExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised_lbl" xml:lang="en-US">Weighted Average Share Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised" xlink:to="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Intrinsic value of warrants exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in agents warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock" xlink:to="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfBalanceAtBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtBeginning_lbl" xml:lang="en-US">Number of Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfBalanceAtBeginning" xlink:to="inm_ShareBasedPaymentNumberOfBalanceAtBeginning_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning_lbl" xml:lang="en-US">Weighted Average Share Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentSharesNumberOfGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentSharesNumberOfGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentSharesNumberOfGranted_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentSharesNumberOfGranted" xlink:to="inm_ShareBasedPaymentSharesNumberOfGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceGranted_lbl" xml:lang="en-US">Weighted Average Share Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentWeightedAverageSharePriceGranted" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentAggregateIntrinsicValueGranted" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfBalanceAtEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtEnding_lbl" xml:lang="en-US">Number of Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfBalanceAtEnding" xlink:to="inm_ShareBasedPaymentNumberOfBalanceAtEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding_lbl" xml:lang="en-US">Weighted Average Share Price, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED PAYMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="inm-20220630.xsd#inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired/Forfeited (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_UnlabeledAbstract18" xlink:href="inm-20220630.xsd#inm_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract18" xlink:to="inm_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_June302022Abstract" xlink:href="inm-20220630.xsd#inm_June302022Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_June302022Abstract_lbl" xml:lang="en-US">June 30, 2022:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_June302022Abstract" xlink:to="inm_June302022Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NumberOfVestedAndExercisable" xlink:href="inm-20220630.xsd#inm_NumberOfVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_NumberOfVestedAndExercisable_lbl" xml:lang="en-US">Number of Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NumberOfVestedAndExercisable" xlink:to="inm_NumberOfVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageExercisePriceVestedAndExercisable" xlink:href="inm-20220630.xsd#inm_WeightedAverageExercisePriceVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WeightedAverageExercisePriceVestedAndExercisable_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and exercisable (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageExercisePriceVestedAndExercisable" xlink:to="inm_WeightedAverageExercisePriceVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NumberOfUnvested" xlink:href="inm-20220630.xsd#inm_NumberOfUnvested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_NumberOfUnvested_lbl" xml:lang="en-US">Number of Unvested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NumberOfUnvested" xlink:to="inm_NumberOfUnvested_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageExercisePriceUnvested" xlink:href="inm-20220630.xsd#inm_WeightedAverageExercisePriceUnvested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Weighted Average Exercise Price, Unvested (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageExercisePriceUnvested" xlink:to="inm_WeightedAverageExercisePriceUnvested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASE OBLIGATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths_lbl" xml:lang="en-US">Less than one year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive_lbl" xml:lang="en-US">One to five years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive_lbl" xml:lang="en-US">More than five years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDue_lbl" xml:lang="en-US">Total undiscounted lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">BASIC AND DILUTED LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average number of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" xlink:to="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares - basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of a reconciliation of income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax expense (recovery) at the statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="inm-20220630.xsd#inm_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl" xml:lang="en-US">Increase (reduction) in income taxes resulting from:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Share issuance cost capitalized in equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense (recovery)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Non-capital losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsPropertyAndEquipmentsNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsPropertyAndEquipmentsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DeferredTaxAssetsPropertyAndEquipmentsNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsPropertyAndEquipmentsNet" xlink:to="inm_DeferredTaxAssetsPropertyAndEquipmentsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsFinancingCost" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsFinancingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DeferredTaxAssetsFinancingCost_lbl" xml:lang="en-US">Financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsFinancingCost" xlink:to="inm_DeferredTaxAssetsFinancingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsAndLiabilitiesGross" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsAndLiabilitiesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DeferredTaxAssetsAndLiabilitiesGross_lbl" xml:lang="en-US">Deferred tax assets and liabilities, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsAndLiabilitiesGross" xlink:to="inm_DeferredTaxAssetsAndLiabilitiesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsIntangibleAssetsNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DeferredTaxAssetsIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsIntangibleAssetsNet" xlink:to="inm_DeferredTaxAssetsIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetsLeaseObligations" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DeferredTaxAssetsLeaseObligations_lbl" xml:lang="en-US">Lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsLeaseObligations" xlink:to="inm_DeferredTaxAssetsLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_DeferredTaxAssetLiabilitiesNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_DeferredTaxAssetLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetLiabilitiesNet" xlink:to="inm_DeferredTaxAssetLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of reportable segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_OtherOperatingExpenses" xlink:href="inm-20220630.xsd#inm_OtherOperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_OtherOperatingExpenses_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_OtherOperatingExpenses" xlink:to="inm_OtherOperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Unrestricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsTextBlock" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_NonCashTransactionsTextBlock_lbl" xml:lang="en-US">NON-CASH TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NonCashTransactionsTextBlock" xlink:to="inm_NonCashTransactionsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementTextBlock" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_FinancialRiskManagementTextBlock_lbl" xml:lang="en-US">FINANCIAL RISK MANAGEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialRiskManagementTextBlock" xlink:to="inm_FinancialRiskManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US">Schedule of fair value and carrying values of the company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialAssetsAbstract" xlink:href="inm-20220630.xsd#inm_FinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_FinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialAssetsAbstract" xlink:to="inm_FinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_FinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_FinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialLiabilitiesAbstract" xlink:to="inm_FinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialAssetsAbstract0" xlink:href="inm-20220630.xsd#inm_FinancialAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_FinancialAssetsAbstract0_lbl" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialAssetsAbstract0" xlink:to="inm_FinancialAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialLiabilitiesAbstract0" xlink:href="inm-20220630.xsd#inm_FinancialLiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_FinancialLiabilitiesAbstract0_lbl" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialLiabilitiesAbstract0" xlink:to="inm_FinancialLiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Expired/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LeaseLiabilities" xlink:href="inm-20220630.xsd#inm_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="inm_LeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LeaseLiabilities" xlink:to="inm_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets and liabilities, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_RightOfUseAssetMember" xlink:href="inm-20220630.xsd#inm_RightOfUseAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_RightOfUseAssetMember_lbl" xml:lang="en-US">Right of Use Asset (leases) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RightOfUseAssetMember" xlink:to="inm_RightOfUseAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_IPRDMember" xlink:href="inm-20220630.xsd#inm_IPRDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_IPRDMember_lbl" xml:lang="en-US">IPR&amp;D [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IPRDMember" xlink:to="inm_IPRDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademark and Intellectual Property [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PurchasePriceConsiderationMember" xlink:href="inm-20220630.xsd#inm_PurchasePriceConsiderationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PurchasePriceConsiderationMember_lbl" xml:lang="en-US">Purchase Price Consideration [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PurchasePriceConsiderationMember" xlink:to="inm_PurchasePriceConsiderationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_SharesIssuedMember" xlink:href="inm-20220630.xsd#inm_SharesIssuedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_SharesIssuedMember_lbl" xml:lang="en-US">Shares Issued [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesIssuedMember" xlink:to="inm_SharesIssuedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PrefundedWarrantsIssuedMember" xlink:href="inm-20220630.xsd#inm_PrefundedWarrantsIssuedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PrefundedWarrantsIssuedMember_lbl" xml:lang="en-US">Pre-funded Warrants Issued [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PrefundedWarrantsIssuedMember" xlink:to="inm_PrefundedWarrantsIssuedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_GrossProceedsMember" xlink:href="inm-20220630.xsd#inm_GrossProceedsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_GrossProceedsMember_lbl" xml:lang="en-US">Gross Proceeds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_GrossProceedsMember" xlink:to="inm_GrossProceedsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AllocatedToAdditionalPaidinCapitalMember" xlink:href="inm-20220630.xsd#inm_AllocatedToAdditionalPaidinCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AllocatedToAdditionalPaidinCapitalMember_lbl" xml:lang="en-US">Allocated to Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AllocatedToAdditionalPaidinCapitalMember" xlink:to="inm_AllocatedToAdditionalPaidinCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareIssuanceCostsMember" xlink:href="inm-20220630.xsd#inm_ShareIssuanceCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareIssuanceCostsMember_lbl" xml:lang="en-US">Share issuance costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareIssuanceCostsMember" xlink:to="inm_ShareIssuanceCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_SharePurchaseWarrantsMember" xlink:href="inm-20220630.xsd#inm_SharePurchaseWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_SharePurchaseWarrantsMember_lbl" xml:lang="en-US">Share Purchase Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharePurchaseWarrantsMember" xlink:to="inm_SharePurchaseWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="inm_SharePurchaseWarrantsMember_lbl0" xml:lang="en-US">Share purchase warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharePurchaseWarrantsMember" xlink:to="inm_SharePurchaseWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsWarrantsMember" xlink:href="inm-20220630.xsd#inm_AgentsWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AgentsWarrantsMember_lbl" xml:lang="en-US">Agents&apos; Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsWarrantsMember" xlink:to="inm_AgentsWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_InMedMember" xlink:href="inm-20220630.xsd#inm_InMedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_InMedMember_lbl" xml:lang="en-US">InMed [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InMedMember" xlink:to="inm_InMedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BayMedicaMember" xlink:href="inm-20220630.xsd#inm_BayMedicaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BayMedicaMember_lbl" xml:lang="en-US">BayMedica [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BayMedicaMember" xlink:to="inm_BayMedicaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_TypeOfCurrencyAxis" xlink:href="inm-20220630.xsd#inm_TypeOfCurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_TypeOfCurrencyAxis_lbl" xml:lang="en-US">Type Of Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TypeOfCurrencyAxis" xlink:to="inm_TypeOfCurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CashAndCashEquivalent" xlink:href="inm-20220630.xsd#inm_CashAndCashEquivalent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CashAndCashEquivalent_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CashAndCashEquivalent" xlink:to="inm_CashAndCashEquivalent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Private placement (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl" xml:lang="en-US">Deferred financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Straight-line method percentage per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xml:lang="en-US">Income tax positions, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCustomer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl" xml:lang="en-US">Net sales description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCustomer" xlink:to="us-gaap_ConcentrationRiskCustomer_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ConcentrationRiskPercentage" xlink:href="inm-20220630.xsd#inm_ConcentrationRiskPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ConcentrationRiskPercentage_lbl" xml:lang="en-US">Concentration percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ConcentrationRiskPercentage" xlink:to="inm_ConcentrationRiskPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Inventory expensed to cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillGross_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:href="inm-20220630.xsd#inm_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl" xml:lang="en-US">Definite lived intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:to="inm_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:href="inm-20220630.xsd#inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US">Impairment charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:to="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets_lbl" xml:lang="en-US">Impairment charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:to="us-gaap_ImpairmentChargeOnReclassifiedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Acquired in-process research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Straight-line basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl0" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Weighted average estimated remaining useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense on intangible assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xml:lang="en-US">Description of business acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Acquisition percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US">Intangible assets estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PrefundWarrants" xlink:href="inm-20220630.xsd#inm_PrefundWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PrefundWarrants_lbl" xml:lang="en-US">Pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PrefundWarrants" xlink:to="inm_PrefundWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Gross proceeds from warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Transaction costs allocated to common shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_TransactionCostsAllocatedToAdditionalPaidinCapital" xlink:href="inm-20220630.xsd#inm_TransactionCostsAllocatedToAdditionalPaidinCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_TransactionCostsAllocatedToAdditionalPaidinCapital_lbl" xml:lang="en-US">Transaction costs allocated to additional paid-in capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TransactionCostsAllocatedToAdditionalPaidinCapital" xlink:to="inm_TransactionCostsAllocatedToAdditionalPaidinCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ExercisedCommonSharesDescription" xlink:href="inm-20220630.xsd#inm_ExercisedCommonSharesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ExercisedCommonSharesDescription_lbl" xml:lang="en-US">Exercised common shares description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExercisedCommonSharesDescription" xlink:to="inm_ExercisedCommonSharesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CommonSharesNetIssuance" xlink:href="inm-20220630.xsd#inm_CommonSharesNetIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CommonSharesNetIssuance_lbl" xml:lang="en-US">Net issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesNetIssuance" xlink:to="inm_CommonSharesNetIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PrefundedWarrants" xlink:href="inm-20220630.xsd#inm_PrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PrefundedWarrants_lbl" xml:lang="en-US">Pre-funded warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PrefundedWarrants" xlink:to="inm_PrefundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CommonSharesConsultingServices" xlink:href="inm-20220630.xsd#inm_CommonSharesConsultingServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CommonSharesConsultingServices_lbl" xml:lang="en-US">Common shares consulting services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesConsultingServices" xlink:to="inm_CommonSharesConsultingServices_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_IPOWarrantIssue" xlink:href="inm-20220630.xsd#inm_IPOWarrantIssue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_IPOWarrantIssue_lbl" xml:lang="en-US">Warrant issue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IPOWarrantIssue" xlink:to="inm_IPOWarrantIssue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantExpiryDate" xlink:href="inm-20220630.xsd#inm_WarrantExpiryDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WarrantExpiryDate_lbl" xml:lang="en-US">Warrant expiry date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantExpiryDate" xlink:to="inm_WarrantExpiryDate_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantsModificationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WarrantsModificationExpense_lbl" xml:lang="en-US">Warrants modification expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsModificationExpense" xlink:to="inm_WarrantsModificationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants expiry term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsIssued" xlink:href="inm-20220630.xsd#inm_WarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WarrantsIssued_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsIssued" xlink:to="inm_WarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_IssuanceOfCommonSharesIssued" xlink:href="inm-20220630.xsd#inm_IssuanceOfCommonSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_IssuanceOfCommonSharesIssued_lbl" xml:lang="en-US">Issuance of common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IssuanceOfCommonSharesIssued" xlink:to="inm_IssuanceOfCommonSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrants to re-price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsIssuanceTerm" xlink:href="inm-20220630.xsd#inm_WarrantsIssuanceTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WarrantsIssuanceTerm_lbl" xml:lang="en-US">Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsIssuanceTerm" xlink:to="inm_WarrantsIssuanceTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_IssuedAndOutstandingPercentage" xlink:href="inm-20220630.xsd#inm_IssuedAndOutstandingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_IssuedAndOutstandingPercentage_lbl" xml:lang="en-US">Issued and outstanding, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IssuedAndOutstandingPercentage" xlink:to="inm_IssuedAndOutstandingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl" xml:lang="en-US">Options shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value at grant date of options granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Weighted average risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Weighted average volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Weighted average dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WeightedAverageForfeitureRate" xlink:href="inm-20220630.xsd#inm_WeightedAverageForfeitureRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WeightedAverageForfeitureRate_lbl" xml:lang="en-US">Weighted average forfeiture rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageForfeitureRate" xlink:to="inm_WeightedAverageForfeitureRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment transactions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unvested options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Weighted-average vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable operating costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_OtherVariableLeaseCost" xlink:href="inm-20220630.xsd#inm_OtherVariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_OtherVariableLeaseCost_lbl" xml:lang="en-US">Estimated variable operating costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_OtherVariableLeaseCost" xlink:to="inm_OtherVariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income statutory corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Non-capital loss carry-forwards (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_RecognizedTaxBenefits" xlink:href="inm-20220630.xsd#inm_RecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_RecognizedTaxBenefits_lbl" xml:lang="en-US">Recognized tax benefits percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RecognizedTaxBenefits" xlink:to="inm_RecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants issued to placement agent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitIssued_lbl" xml:lang="en-US">Common shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_EstimatedFairValueCommonShares" xlink:href="inm-20220630.xsd#inm_EstimatedFairValueCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_EstimatedFairValueCommonShares_lbl" xml:lang="en-US">Estimated fair value common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_EstimatedFairValueCommonShares" xlink:to="inm_EstimatedFairValueCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableFairValueDisclosure_lbl" xml:lang="en-US">Loan receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableFairValueDisclosure" xlink:to="us-gaap_LoansReceivableFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredUnitsIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredUnitsIssued_lbl" xml:lang="en-US">Preferred shares issued options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredUnitsIssued" xlink:to="us-gaap_PreferredUnitsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Fair value investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Exercised warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Issuance of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US">Unpaid financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CostOfServicesDirectsMaterials" xlink:href="inm-20220630.xsd#inm_CostOfServicesDirectsMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CostOfServicesDirectsMaterials_lbl" xml:lang="en-US">Materials cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CostOfServicesDirectsMaterials" xlink:to="inm_CostOfServicesDirectsMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Expenditure amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ExpenditureBalance" xlink:href="inm-20220630.xsd#inm_ExpenditureBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ExpenditureBalance_lbl" xml:lang="en-US">Balance of expenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExpenditureBalance" xlink:to="inm_ExpenditureBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostDirectMaterial"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostDirectMaterial_lbl" xml:lang="en-US">Materials and equipment cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDirectMaterial" xlink:to="us-gaap_CostDirectMaterial_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_GuaranteedInvestment" xlink:href="inm-20220630.xsd#inm_GuaranteedInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_GuaranteedInvestment_lbl" xml:lang="en-US">Guaranteed investment face value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_GuaranteedInvestment" xlink:to="inm_GuaranteedInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_WarrantsToPurchase" xlink:href="inm-20220630.xsd#inm_WarrantsToPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_WarrantsToPurchase_lbl" xml:lang="en-US">Warrants to purchase (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsToPurchase" xlink:to="inm_WarrantsToPurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CommonShares" xlink:href="inm-20220630.xsd#inm_CommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CommonShares_lbl" xml:lang="en-US">Common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonShares" xlink:to="inm_CommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Issuance date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Agreement payments paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ForeignCurrencyRiskPercentage" xlink:href="inm-20220630.xsd#inm_ForeignCurrencyRiskPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ForeignCurrencyRiskPercentage_lbl" xml:lang="en-US">Foreign currency risk, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ForeignCurrencyRiskPercentage" xlink:to="inm_ForeignCurrencyRiskPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesGainLoss_lbl" xml:lang="en-US">Effect on gain or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xml:lang="en-US">Foreign exchange gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents subject to floating interest rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherMinorityInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMinorityInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherMinorityInterests_lbl" xml:lang="en-US">Non-interest bearing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherMinorityInterests" xlink:to="us-gaap_OtherMinorityInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermInvestments_lbl" xml:lang="en-US">Guaranteed investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShortTermInvestment" xlink:href="inm-20220630.xsd#inm_ShortTermInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ShortTermInvestment_lbl" xml:lang="en-US">Cash and cash equivalents and short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShortTermInvestment" xlink:to="inm_ShortTermInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_workingCapitalSurplus" xlink:href="inm-20220630.xsd#inm_workingCapitalSurplus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_workingCapitalSurplus_lbl" xml:lang="en-US">Working capital surplus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_workingCapitalSurplus" xlink:to="inm_workingCapitalSurplus_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LegalService" xlink:href="inm-20220630.xsd#inm_LegalService"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_LegalService_lbl" xml:lang="en-US">Legal services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LegalService" xlink:to="inm_LegalService_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Exercisable term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_COVID19ImpactsPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_COVID19ImpactsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_COVID19ImpactsPolicyTextBlock_lbl" xml:lang="en-US">COVID-19 Impacts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_COVID19ImpactsPolicyTextBlock" xlink:to="inm_COVID19ImpactsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ8btGW5qMQVqzLsfi3GzVuMY7sD/FFw7U4o2i8MgAqSMg6pxwpeBm32Q4Yx+CEjQMnrWZzgc+HrjKz4FGA65QOvsgEC/wMtHrdik6IbyDDLXxJdt3/VqavjFzajJqD6rwRbNxWB/9EPBc1wENO3701leuZtdXSpohHx25mAouKCHQxfXoc5q0CB/s8eMhbBXgs6kLNzvlp1x1qmhR83+VsbcT9fShbTEg=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_InProcessRDPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_InProcessRDPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_InProcessRDPolicyTextBlock_lbl" xml:lang="en-US">In-Process R&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InProcessRDPolicyTextBlock" xlink:to="inm_InProcessRDPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_FinancialAssetsAndLiabilitiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Financial Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:to="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesVendorAllowancesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesVendorAllowancesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesVendorAllowancesPolicy_lbl" xml:lang="en-US">Cost of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesVendorAllowancesPolicy" xlink:to="us-gaap_CostOfSalesVendorAllowancesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock_lbl" xml:lang="en-US">Patents and Intellectual Property Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock" xlink:to="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CustomerOneMember" xlink:href="inm-20220630.xsd#inm_CustomerOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CustomerOneMember" xlink:to="inm_CustomerOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CannabinoidMember" xlink:href="inm-20220630.xsd#inm_CannabinoidMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_CannabinoidMember_lbl" xml:lang="en-US">Cannabinoid [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CannabinoidMember" xlink:to="inm_CannabinoidMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ATMMember" xlink:href="inm-20220630.xsd#inm_ATMMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_ATMMember_lbl" xml:lang="en-US">ATM [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMMember" xlink:to="inm_ATMMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BayMedicaAgreementMember" xlink:href="inm-20220630.xsd#inm_BayMedicaAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BayMedicaAgreementMember_lbl" xml:lang="en-US">BayMedica Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BayMedicaAgreementMember" xlink:to="inm_BayMedicaAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_PreferredInvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_PreferredInvestmentOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_PreferredInvestmentOptionsMember_lbl" xml:lang="en-US">Preferred Investment Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PreferredInvestmentOptionsMember" xlink:to="inm_PreferredInvestmentOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AgentsInvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_AgentsInvestmentOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_AgentsInvestmentOptionsMember_lbl" xml:lang="en-US">Agents&#8217; Investment Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsInvestmentOptionsMember" xlink:to="inm_AgentsInvestmentOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_BayMedicaIncMember" xlink:href="inm-20220630.xsd#inm_BayMedicaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_BayMedicaIncMember_lbl" xml:lang="en-US">BayMedica&#8217;s [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BayMedicaIncMember" xlink:to="inm_BayMedicaIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="inm_BayMedicaIncMember_lbl0" xml:lang="en-US">BayMedica Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BayMedicaIncMember" xlink:to="inm_BayMedicaIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_USDMember" xlink:href="inm-20220630.xsd#inm_USDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_USDMember_lbl" xml:lang="en-US">U.S. Dollar [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_USDMember" xlink:to="inm_USDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_InvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_InvestmentOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="inm_InvestmentOptionsMember_lbl" xml:lang="en-US">Investment Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InvestmentOptionsMember" xlink:to="inm_InvestmentOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NatureofBusinessandGoingConcernTable" xlink:href="inm-20220630.xsd#inm_NatureofBusinessandGoingConcernTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NatureofBusinessandGoingConcernTable_lbl" xml:lang="en-US">Nature of Business and Going Concern [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NatureofBusinessandGoingConcernTable" xlink:to="inm_NatureofBusinessandGoingConcernTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NatureofBusinessandGoingConcernLineItems" xlink:href="inm-20220630.xsd#inm_NatureofBusinessandGoingConcernLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NatureofBusinessandGoingConcernLineItems_lbl" xml:lang="en-US">Corporate Information and Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NatureofBusinessandGoingConcernLineItems" xlink:to="inm_NatureofBusinessandGoingConcernLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable_lbl" xml:lang="en-US">Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" xlink:to="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems_lbl" xml:lang="en-US">Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable_lbl" xml:lang="en-US">Acquisition (Details) - Schedule of fair value of assets acquired and liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" xlink:to="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems_lbl" xml:lang="en-US">Acquisition (Details) - Schedule of fair value of assets acquired and liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable_lbl" xml:lang="en-US">Share Capital and Reserves (Details) - Schedule of private placement offering [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems_lbl" xml:lang="en-US">Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable_lbl" xml:lang="en-US">Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems_lbl" xml:lang="en-US">Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable_lbl" xml:lang="en-US">Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems_lbl" xml:lang="en-US">Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CustomerConcentrationDetailsTable" xlink:href="inm-20220630.xsd#inm_CustomerConcentrationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CustomerConcentrationDetailsTable_lbl" xml:lang="en-US">Customer Concentration (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CustomerConcentrationDetailsTable" xlink:to="inm_CustomerConcentrationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_CustomerConcentrationDetailsLineItems" xlink:href="inm-20220630.xsd#inm_CustomerConcentrationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CustomerConcentrationDetailsLineItems_lbl" xml:lang="en-US">Customer Concentration (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CustomerConcentrationDetailsLineItems" xlink:to="inm_CustomerConcentrationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable_lbl" xml:lang="en-US">Impairment of Intangible Assets and Goodwill (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable" xlink:to="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems_lbl" xml:lang="en-US">Impairment of Intangible Assets and Goodwill (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsTable" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionDetailsTable_lbl" xml:lang="en-US">Acquisition (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionDetailsTable" xlink:to="inm_AcquisitionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionDetailsLineItems" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionDetailsLineItems_lbl" xml:lang="en-US">Acquisition (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionDetailsLineItems" xlink:to="inm_AcquisitionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsTable_lbl" xml:lang="en-US">Share Capital and Reserves (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsTable" xlink:to="inm_ShareCapitalandReservesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareCapitalandReservesDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalandReservesDetailsLineItems_lbl" xml:lang="en-US">Share Capital and Reserves (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalandReservesDetailsLineItems" xlink:to="inm_ShareCapitalandReservesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentsDetailsTable" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentsDetailsTable_lbl" xml:lang="en-US">Share-Based Payments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentsDetailsTable" xlink:to="inm_ShareBasedPaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_ShareBasedPaymentsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentsDetailsLineItems" xlink:to="inm_ShareBasedPaymentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LeaseObligationsDetailsTable" xlink:href="inm-20220630.xsd#inm_LeaseObligationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LeaseObligationsDetailsTable_lbl" xml:lang="en-US">Lease Obligations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LeaseObligationsDetailsTable" xlink:to="inm_LeaseObligationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_LeaseObligationsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_LeaseObligationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LeaseObligationsDetailsLineItems_lbl" xml:lang="en-US">Lease Obligations (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LeaseObligationsDetailsLineItems" xlink:to="inm_LeaseObligationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsDetailsTable" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NonCashTransactionsDetailsTable_lbl" xml:lang="en-US">Non-Cash Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NonCashTransactionsDetailsTable" xlink:to="inm_NonCashTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_NonCashTransactionsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NonCashTransactionsDetailsLineItems_lbl" xml:lang="en-US">Non-Cash Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NonCashTransactionsDetailsLineItems" xlink:to="inm_NonCashTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_TypeOfCurrencyDomain" xlink:href="inm-20220630.xsd#inm_TypeOfCurrencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_TypeOfCurrencyDomain_lbl" xml:lang="en-US">TypeOfCurrency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TypeOfCurrencyDomain" xlink:to="inm_TypeOfCurrencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementDetailsTable" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialRiskManagementDetailsTable_lbl" xml:lang="en-US">Financial Risk Management (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialRiskManagementDetailsTable" xlink:to="inm_FinancialRiskManagementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_FinancialRiskManagementDetailsLineItems" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialRiskManagementDetailsLineItems_lbl" xml:lang="en-US">Financial Risk Management (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialRiskManagementDetailsLineItems" xlink:to="inm_FinancialRiskManagementDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_SubsequentEventsDetailsTable" xlink:href="inm-20220630.xsd#inm_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SubsequentEventsDetailsTable" xlink:to="inm_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="inm_SubsequentEventsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SubsequentEventsDetailsLineItems" xlink:to="inm_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ATMOfferingNetOfIssuanceCosts_lbl0" xml:lang="en-US">Amount of ATM offering, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMOfferingNetOfIssuanceCosts" xlink:to="inm_ATMOfferingNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ATMOfferingNetOfIssuanceCostsShares_lbl0" xml:lang="en-US">ATM offering, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMOfferingNetOfIssuanceCostsShares" xlink:to="inm_ATMOfferingNetOfIssuanceCostsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_AccruedResearchAndDevelopment_lbl0" xml:lang="en-US">The amount of accrued research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AccruedResearchAndDevelopment" xlink:to="inm_AccruedResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_AcquisitionConsiderationPayable_lbl0" xml:lang="en-US">Amount of acquisition consideration payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionConsiderationPayable" xlink:to="inm_AcquisitionConsiderationPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_AcquisitionOfBayMedica_lbl0" xml:lang="en-US">Acquisition of baymedica.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionOfBayMedica" xlink:to="inm_AcquisitionOfBayMedica_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_AcquisitionOfBayMedicainShares_lbl0" xml:lang="en-US">Number of shares acquisition of baymedica.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionOfBayMedicainShares" xlink:to="inm_AcquisitionOfBayMedicainShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_AgentsInvestmentOptions_lbl0" xml:lang="en-US">Amount of agents&apos; investment options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsInvestmentOptions" xlink:to="inm_AgentsInvestmentOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_AgentsWarrants_lbl0" xml:lang="en-US">The value of agents&#8217; warrants.&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsWarrants" xlink:to="inm_AgentsWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_AggregateIntrinsicValueGranted_lbl0" xml:lang="en-US">Aggregate Intrinsic Value granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AggregateIntrinsicValueGranted" xlink:to="inm_AggregateIntrinsicValueGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_BusinessCombinationPostclosingAdjustments_lbl0" xml:lang="en-US">This amount of Post-closing adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationPostclosingAdjustments" xlink:to="inm_BusinessCombinationPostclosingAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents_lbl0" xml:lang="en-US">This amount of patents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark_lbl0" xml:lang="en-US">Amount of trademark.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_CashAcquiredFromAcqusition_lbl0" xml:lang="en-US">Cash acquired from acqusition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CashAcquiredFromAcqusition" xlink:to="inm_CashAcquiredFromAcqusition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_CashAndCashEquivalent_lbl0" xml:lang="en-US">Cash and cash equivalent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CashAndCashEquivalent" xlink:to="inm_CashAndCashEquivalent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_CommonShares_lbl0" xml:lang="en-US">Common shares or common stock is a class of stock issued by corporations that represent ownership in the corporation for shareholders. The hope is that the company will grow and prosper, driving up the price of their shares. Being a common shareholder is a way for investors to benefit from the growth of a company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonShares" xlink:to="inm_CommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_CommonSharesConsultingServices_lbl0" xml:lang="en-US">Common shares consulting services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesConsultingServices" xlink:to="inm_CommonSharesConsultingServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_CommonSharesNetIssuance_lbl0" xml:lang="en-US">Common shares net issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesNetIssuance" xlink:to="inm_CommonSharesNetIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ConcentrationRiskPercentage_lbl0" xml:lang="en-US">For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the &quot;benchmark&quot; (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ConcentrationRiskPercentage" xlink:to="inm_ConcentrationRiskPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_CostOfServicesDirectsMaterials_lbl0" xml:lang="en-US">Cost of materials used in services rendered by an entity during the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CostOfServicesDirectsMaterials" xlink:to="inm_CostOfServicesDirectsMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_DeferredTaxAssetLiabilitiesNet_lbl0" xml:lang="en-US">Net deferred tax asset, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetLiabilitiesNet" xlink:to="inm_DeferredTaxAssetLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_DeferredTaxAssetsAndLiabilitiesGross_lbl0" xml:lang="en-US">Deferred tax assets and liabilities, gross.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsAndLiabilitiesGross" xlink:to="inm_DeferredTaxAssetsAndLiabilitiesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_DeferredTaxAssetsFinancingCost_lbl0" xml:lang="en-US">Financing costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsFinancingCost" xlink:to="inm_DeferredTaxAssetsFinancingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_DeferredTaxAssetsIntangibleAssetsNet_lbl0" xml:lang="en-US">Intangible assets, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsIntangibleAssetsNet" xlink:to="inm_DeferredTaxAssetsIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_DeferredTaxAssetsLeaseObligations_lbl0" xml:lang="en-US">Lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsLeaseObligations" xlink:to="inm_DeferredTaxAssetsLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_DeferredTaxAssetsPropertyAndEquipmentsNet_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsPropertyAndEquipmentsNet" xlink:to="inm_DeferredTaxAssetsPropertyAndEquipmentsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_EstimatedFairValueCommonShares_lbl0" xml:lang="en-US">Estimated fair value common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_EstimatedFairValueCommonShares" xlink:to="inm_EstimatedFairValueCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ExerciseOfPrefundedWarrants_lbl0" xml:lang="en-US">Exercise of pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfPrefundedWarrants" xlink:to="inm_ExerciseOfPrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ExerciseOfPrefundedWarrantsinShares_lbl0" xml:lang="en-US">Number of shares exercise of pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfPrefundedWarrantsinShares" xlink:to="inm_ExerciseOfPrefundedWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ExerciseOfWarrantsin_lbl0" xml:lang="en-US">Exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfWarrantsin" xlink:to="inm_ExerciseOfWarrantsin_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ExerciseOfWarrantsinShares_lbl0" xml:lang="en-US">Exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfWarrantsinShares" xlink:to="inm_ExerciseOfWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ExercisedCommonSharesDescription_lbl0" xml:lang="en-US">Exercised common shares description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExercisedCommonSharesDescription" xlink:to="inm_ExercisedCommonSharesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ExpenditureBalance_lbl0" xml:lang="en-US">The balance of expenditure is the balance of spending against the amount of available funds. While this may seem to be a relatively simple process, balancing expenditures can be complex when credit accounts, payables and receivables become involved.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExpenditureBalance" xlink:to="inm_ExpenditureBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_FinanceExpense_lbl0" xml:lang="en-US">The amount of finance expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinanceExpense" xlink:to="inm_FinanceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock_lbl0" xml:lang="en-US">Financial Assets and Liabilities Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:to="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ForeignCurrencyRiskPercentage_lbl0" xml:lang="en-US">Foreign currency risk, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ForeignCurrencyRiskPercentage" xlink:to="inm_ForeignCurrencyRiskPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_GuaranteedInvestment_lbl0" xml:lang="en-US">Guaranteed investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_GuaranteedInvestment" xlink:to="inm_GuaranteedInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl0" xml:lang="en-US">The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:to="inm_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl0" xml:lang="en-US">Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:to="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_InProcessRDPolicyTextBlock_lbl0" xml:lang="en-US">In-Process R&amp;D policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InProcessRDPolicyTextBlock" xlink:to="inm_InProcessRDPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_InterestIncomeaccruedReceivedOnShorttermInvestments_lbl0" xml:lang="en-US">Interest income (accrued) received on short-term investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" xlink:to="inm_InterestIncomeaccruedReceivedOnShorttermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_IssuanceOfCommonSharesIssued_lbl0" xml:lang="en-US">Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IssuanceOfCommonSharesIssued" xlink:to="inm_IssuanceOfCommonSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_IssuedAndOutstandingPercentage_lbl0" xml:lang="en-US">Issued and outstanding, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IssuedAndOutstandingPercentage" xlink:to="inm_IssuedAndOutstandingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LeaseLiabilities" xlink:to="inm_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LegalService_lbl0" xml:lang="en-US">The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LegalService" xlink:to="inm_LegalService_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDue_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LossAndComprehensiveIncomelossesForThePeriod_lbl0" xml:lang="en-US">Loss and comprehensive income (loss) for the period.&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LossAndComprehensiveIncomelossesForThePeriod" xlink:to="inm_LossAndComprehensiveIncomelossesForThePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_LossAndComprehensivelossesForThePeriod_lbl0" xml:lang="en-US">Loss for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LossAndComprehensivelossesForThePeriod" xlink:to="inm_LossAndComprehensivelossesForThePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_NumberOfUnvested_lbl0" xml:lang="en-US">Number of unvested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NumberOfUnvested" xlink:to="inm_NumberOfUnvested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_NumberOfVestedAndExercisable_lbl0" xml:lang="en-US">Number of Vested and exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NumberOfVestedAndExercisable" xlink:to="inm_NumberOfVestedAndExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_OtherOperatingExpenses_lbl0" xml:lang="en-US">Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_OtherOperatingExpenses" xlink:to="inm_OtherOperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_OtherVariableLeaseCost_lbl0" xml:lang="en-US">Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_OtherVariableLeaseCost" xlink:to="inm_OtherVariableLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock_lbl0" xml:lang="en-US">Patents and Intellectual Property Costs Policy [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock" xlink:to="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_PrefundWarrants_lbl0" xml:lang="en-US">The number of shares pre-fund warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PrefundWarrants" xlink:to="inm_PrefundWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_RecognizedTaxBenefits_lbl0" xml:lang="en-US">Recognized tax benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RecognizedTaxBenefits" xlink:to="inm_RecognizedTaxBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_RegisteredDirectAndPrivatePlacement_lbl0" xml:lang="en-US">Amount of registered direct and private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RegisteredDirectAndPrivatePlacement" xlink:to="inm_RegisteredDirectAndPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_RegisteredDirectAndPrivatePlacementShares_lbl0" xml:lang="en-US">Registered direct and private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RegisteredDirectAndPrivatePlacementShares" xlink:to="inm_RegisteredDirectAndPrivatePlacementShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock_lbl0" xml:lang="en-US">Schedule of changes in agents warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock" xlink:to="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of an entity&apos;s basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" xlink:to="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl0" xml:lang="en-US">Gross number of share options (or share units) granted during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl1" xml:lang="en-US">Weighted Average Share Price, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited_lbl0" xml:lang="en-US">Weighted Average Exercise Price, expired/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted_lbl0" xml:lang="en-US">Weighted Average Exercise Price, granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedPaymentNumberOfExercised_lbl0" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfExercised" xlink:to="inm_ShareBasedPaymentNumberOfExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedPaymentNumberOfGranted_lbl0" xml:lang="en-US">Number of granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfGranted" xlink:to="inm_ShareBasedPaymentNumberOfGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding_lbl0" xml:lang="en-US">Weighted Average Share Price, Ending Balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised_lbl0" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised" xlink:to="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShareIssuanceCosts_lbl0" xml:lang="en-US">Share issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareIssuanceCosts" xlink:to="inm_ShareIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_ShortTermInvestment_lbl0" xml:lang="en-US">Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShortTermInvestment" xlink:to="inm_ShortTermInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl0" xml:lang="en-US">Stock Issued During Period Value Issued For Private Placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares_lbl0" xml:lang="en-US">Stock Issued During Period Value Issued For Private Placement Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_TotalCommonShareValue_lbl0" xml:lang="en-US">Amount of total share value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TotalCommonShareValue" xlink:to="inm_TotalCommonShareValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_TransactionCostsAllocatedToAdditionalPaidinCapital_lbl0" xml:lang="en-US">Transaction costs allocated to additional paid-in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TransactionCostsAllocatedToAdditionalPaidinCapital" xlink:to="inm_TransactionCostsAllocatedToAdditionalPaidinCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_UnrealizedGainOnDerivativeWarrantsLiability_lbl0" xml:lang="en-US">Amount of unrealized gain on derivative warrants liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnrealizedGainOnDerivativeWarrantsLiability" xlink:to="inm_UnrealizedGainOnDerivativeWarrantsLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_UnrealizedGainOnForeignExchange_lbl0" xml:lang="en-US">Amount Of Unrealized gain on foreign exchange.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnrealizedGainOnForeignExchange" xlink:to="inm_UnrealizedGainOnForeignExchange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WarrantModificationExpense_lbl1" xml:lang="en-US">The amount of warrant modification expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantModificationExpense" xlink:to="inm_WarrantModificationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WarrantModificationExpenses_lbl0" xml:lang="en-US">Amount of warrant modification expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantModificationExpenses" xlink:to="inm_WarrantModificationExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WarrantsIssued_lbl0" xml:lang="en-US">Number of warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsIssued" xlink:to="inm_WarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WarrantsToPurchase_lbl0" xml:lang="en-US">Warrants are a derivative that give the right, but not the obligation, to buy or sell a security&#8212;most commonly an equity&#8212;at a certain price before expiration. The price at which the underlying security can be bought or sold is referred to as the exercise price or strike price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsToPurchase" xlink:to="inm_WarrantsToPurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WeightedAverageExercisePriceUnvested_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Unvested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageExercisePriceUnvested" xlink:to="inm_WeightedAverageExercisePriceUnvested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WeightedAverageExercisePriceVestedAndExercisable_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Vested and exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageExercisePriceVestedAndExercisable" xlink:to="inm_WeightedAverageExercisePriceVestedAndExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WeightedAverageForfeitureRate_lbl0" xml:lang="en-US">Weighted Average Forfeiture Rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageForfeitureRate" xlink:to="inm_WeightedAverageForfeitureRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_WeightedAverageSharePriceGranted_lbl0" xml:lang="en-US">Weighted Average Share Price granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageSharePriceGranted" xlink:to="inm_WeightedAverageSharePriceGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="inm_workingCapitalSurplus_lbl0" xml:lang="en-US">Working capital surplus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_workingCapitalSurplus" xlink:to="inm_workingCapitalSurplus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AggregateIntrinsicValueGranted_lbl1" xml:lang="en-US">Aggregate Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AggregateIntrinsicValueGranted" xlink:to="inm_AggregateIntrinsicValueGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ExerciseOfPrefundedWarrantsinShares_lbl1" xml:lang="en-US">Exercise Of Prefunded Warrantsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfPrefundedWarrantsinShares" xlink:to="inm_ExerciseOfPrefundedWarrantsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths_lbl1" xml:lang="en-US">Lessee Operating Lease Liability Payment Due Next Twelve Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CustomerOneMember_lbl0" xml:lang="en-US">Customer One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CustomerOneMember" xlink:to="inm_CustomerOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillFairValueDisclosure_lbl1" xml:lang="en-US">Goodwill, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillFairValueDisclosure" xlink:to="us-gaap_GoodwillFairValueDisclosure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LossAndComprehensiveIncomelossesForThePeriod_lbl1" xml:lang="en-US">Loss And Comprehensive Incomelosses For The Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LossAndComprehensiveIncomelossesForThePeriod" xlink:to="inm_LossAndComprehensiveIncomelossesForThePeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_SharePurchaseWarrantsMember_lbl1" xml:lang="en-US">Share Purchase Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharePurchaseWarrantsMember" xlink:to="inm_SharePurchaseWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfChangesInAgentsWarrantsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInAgentsWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfChangesInAgentsWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Changes In Agents Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfChangesInAgentsWarrantsAbstract" xlink:to="inm_ScheduleOfChangesInAgentsWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentSharesNumberOfGranted_lbl0" xml:lang="en-US">Share Based Payment Shares Number Of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentSharesNumberOfGranted" xlink:to="inm_ShareBasedPaymentSharesNumberOfGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive_lbl1" xml:lang="en-US">Lessee Operating Lease Liability Payment Due After Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_EstimatedFairValueCommonShares_lbl1" xml:lang="en-US">Estimated Fair Value Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_EstimatedFairValueCommonShares" xlink:to="inm_EstimatedFairValueCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_TypeOfCurrencyAxis_lbl0" xml:lang="en-US">Type Of Currency Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TypeOfCurrencyAxis" xlink:to="inm_TypeOfCurrencyAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AgentsWarrants_lbl1" xml:lang="en-US">Agents Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsWarrants" xlink:to="inm_AgentsWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitIssued_lbl0" xml:lang="en-US">Common Unit, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WarrantExpiryDate_lbl0" xml:lang="en-US">Warrant Expiry Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantExpiryDate" xlink:to="inm_WarrantExpiryDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ExercisedCommonSharesDescription_lbl1" xml:lang="en-US">Exercised Common Shares Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExercisedCommonSharesDescription" xlink:to="inm_ExercisedCommonSharesDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_COVID19ImpactsPolicyTextBlock_lbl0" xml:lang="en-US">COVID19 Impacts Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_COVID19ImpactsPolicyTextBlock" xlink:to="inm_COVID19ImpactsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DeferredTaxAssetLiabilitiesNet_lbl1" xml:lang="en-US">Deferred Tax Asset Liabilities Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetLiabilitiesNet" xlink:to="inm_DeferredTaxAssetLiabilitiesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Property Equipment And Right Of Use Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract" xlink:to="inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AggregateIntrinsicValueAtBeginning_lbl1" xml:lang="en-US">Aggregate Intrinsic Value At Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AggregateIntrinsicValueAtBeginning" xlink:to="inm_AggregateIntrinsicValueAtBeginning_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding_lbl0" xml:lang="en-US">Share Based Payment Aggregate Intrinsic Value Balance At Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl0" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_RegisteredDirectAndPrivatePlacement_lbl1" xml:lang="en-US">Registered Direct And Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RegisteredDirectAndPrivatePlacement" xlink:to="inm_RegisteredDirectAndPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PrefundedWarrants_lbl0" xml:lang="en-US">Prefunded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PrefundedWarrants" xlink:to="inm_PrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Private Placement Offering Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock" xlink:to="inm_ScheduleOfPrivatePlacementOfferingTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_lbl0" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:to="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl0" xml:lang="en-US">Capital Expenditure, Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentNumberOfExercised_lbl1" xml:lang="en-US">Share Based Payment Number Of Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfExercised" xlink:to="inm_ShareBasedPaymentNumberOfExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ATMMember_lbl0" xml:lang="en-US">ATMMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMMember" xlink:to="inm_ATMMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract18" xlink:to="inm_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract16" xlink:to="inm_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract17" xlink:to="inm_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0" xml:lang="en-US">Increase Reduction In Income Taxes Resulting From Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="inm_IncreaseReductionInIncomeTaxesResultingFromAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ForeignCurrencyRiskPercentage_lbl1" xml:lang="en-US">Foreign Currency Risk Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ForeignCurrencyRiskPercentage" xlink:to="inm_ForeignCurrencyRiskPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CashAndCashEquivalent_lbl1" xml:lang="en-US">Cash And Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CashAndCashEquivalent" xlink:to="inm_CashAndCashEquivalent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock_lbl1" xml:lang="en-US">Financial Assets And Liabilities Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:to="inm_FinancialAssetsAndLiabilitiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ATMOfferingNetOfIssuanceCostsShares_lbl1" xml:lang="en-US">ATMOffering Net Of Issuance Costs Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMOfferingNetOfIssuanceCostsShares" xlink:to="inm_ATMOfferingNetOfIssuanceCostsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl0" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CostOfServicesDirectsMaterials_lbl1" xml:lang="en-US">Cost Of Services Directs Materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CostOfServicesDirectsMaterials" xlink:to="inm_CostOfServicesDirectsMaterials_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PrefundWarrants_lbl1" xml:lang="en-US">Prefund Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PrefundWarrants" xlink:to="inm_PrefundWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl0" xml:lang="en-US">Investment Owned, at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareIssuanceCostsMember_lbl0" xml:lang="en-US">Share Issuance Costs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareIssuanceCostsMember" xlink:to="inm_ShareIssuanceCostsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredUnitsIssued_lbl0" xml:lang="en-US">Preferred Units, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredUnitsIssued" xlink:to="us-gaap_PreferredUnitsIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfMinimumLeasePaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Minimum Lease Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="inm_ScheduleOfMinimumLeasePaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LossAndComprehensivelossesForThePeriod_lbl1" xml:lang="en-US">Loss And Comprehensivelosses For The Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LossAndComprehensivelossesForThePeriod" xlink:to="inm_LossAndComprehensivelossesForThePeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_USDMember_lbl0" xml:lang="en-US">USDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_USDMember" xlink:to="inm_USDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl0" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialLiabilitiesAbstract" xlink:to="inm_FinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Changes In Share Purchase Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract" xlink:to="inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WarrantsToPurchase_lbl1" xml:lang="en-US">Warrants To Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsToPurchase" xlink:to="inm_WarrantsToPurchase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NumberOfVestedAndExercisable_lbl1" xml:lang="en-US">Number Of Vested And Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NumberOfVestedAndExercisable" xlink:to="inm_NumberOfVestedAndExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Shares Based Payments Awards Option Outstandings Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash_lbl0" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WeightedAverageForfeitureRate_lbl1" xml:lang="en-US">Weighted Average Forfeiture Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageForfeitureRate" xlink:to="inm_WeightedAverageForfeitureRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NumberOfUnvested_lbl1" xml:lang="en-US">Number Of Unvested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NumberOfUnvested" xlink:to="inm_NumberOfUnvested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceGranted_lbl0" xml:lang="en-US">Share Based Payment Weighted Average Share Price Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentWeightedAverageSharePriceGranted" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ExerciseOfWarrantsin_lbl1" xml:lang="en-US">Exercise Of Warrantsin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfWarrantsin" xlink:to="inm_ExerciseOfWarrantsin_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl0" xml:lang="en-US">Cumulative Earnings (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_IssuedAndOutstandingPercentage_lbl1" xml:lang="en-US">Issued And Outstanding Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IssuedAndOutstandingPercentage" xlink:to="inm_IssuedAndOutstandingPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnrealizedGainOnDerivativeWarrantsLiability_lbl1" xml:lang="en-US">Unrealized Gain On Derivative Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnrealizedGainOnDerivativeWarrantsLiability" xlink:to="inm_UnrealizedGainOnDerivativeWarrantsLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WarrantModificationExpense_lbl2" xml:lang="en-US">Warrant Modification Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantModificationExpense" xlink:to="inm_WarrantModificationExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl0" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_IndefiniteLivedIntangibleAssetsAbstract_lbl0" xml:lang="en-US">Indefinite Lived Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IndefiniteLivedIntangibleAssetsAbstract" xlink:to="inm_IndefiniteLivedIntangibleAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherMinorityInterests_lbl0" xml:lang="en-US">Other Noncontrolling Interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherMinorityInterests" xlink:to="us-gaap_OtherMinorityInterests_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfAmortizationExpenseAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Amortization Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfAmortizationExpenseAbstract" xlink:to="inm_ScheduleOfAmortizationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Acquired-in-Place Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases" xlink:to="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract10" xlink:to="inm_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract11" xlink:to="inm_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract14" xlink:to="inm_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialRiskManagementTextBlock_lbl0" xml:lang="en-US">Financial Risk Management Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialRiskManagementTextBlock" xlink:to="inm_FinancialRiskManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract15" xlink:to="inm_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract12" xlink:to="inm_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract13" xlink:to="inm_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract_lbl0" xml:lang="en-US">Common Shares No Par Value Unlimited Authorized Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract" xlink:to="inm_CommonSharesNoParValueUnlimitedAuthorizedSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl0" xml:lang="en-US">Goodwill and Intangible Asset Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning_lbl0" xml:lang="en-US">Share Based Payment Weighted Average Share Price Balance At Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning_lbl0" xml:lang="en-US">Share Based Payment Aggregate Intrinsic Value At Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FiniteLivedIntangibleAssetNet_lbl0" xml:lang="en-US">Finite Lived Intangible Asset Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FiniteLivedIntangibleAssetNet" xlink:to="inm_FiniteLivedIntangibleAssetNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive_lbl1" xml:lang="en-US">Lessee Operating Lease Liability Payment Due Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl0" xml:lang="en-US">Trademarks [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WarrantsIssuanceTerm_lbl0" xml:lang="en-US">Warrants Issuance Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsIssuanceTerm" xlink:to="inm_WarrantsIssuanceTerm_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract2" xlink:to="inm_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DefiniteLivedIntangibleAssetsAbstract_lbl0" xml:lang="en-US">Definite Lived Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DefiniteLivedIntangibleAssetsAbstract" xlink:to="inm_DefiniteLivedIntangibleAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract1" xlink:to="inm_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract4" xlink:to="inm_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillGross_lbl0" xml:lang="en-US">Goodwill, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract3" xlink:to="inm_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WeightedAverageSharePriceGranted_lbl1" xml:lang="en-US">Weighted Average Share Price Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageSharePriceGranted" xlink:to="inm_WeightedAverageSharePriceGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_June302022Abstract_lbl0" xml:lang="en-US">June302022 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_June302022Abstract" xlink:to="inm_June302022Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract0" xlink:to="inm_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract9" xlink:to="inm_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CommonSharesNetIssuance_lbl1" xml:lang="en-US">Common Shares Net Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesNetIssuance" xlink:to="inm_CommonSharesNetIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract6" xlink:to="inm_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract5" xlink:to="inm_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract8" xlink:to="inm_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract7" xlink:to="inm_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Changes In Agents Warrants Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock" xlink:to="inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Changes In Share Purchase Warrants Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" xlink:to="inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinanceExpense_lbl1" xml:lang="en-US">Finance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinanceExpense" xlink:to="inm_FinanceExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_InProcessRDPolicyTextBlock_lbl1" xml:lang="en-US">In Process RDPolicy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InProcessRDPolicyTextBlock" xlink:to="inm_InProcessRDPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock_lbl1" xml:lang="en-US">Patents And Intellectual Property Costs Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock" xlink:to="inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WarrantsIssued_lbl1" xml:lang="en-US">Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsIssued" xlink:to="inm_WarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LeaseLiabilities_lbl1" xml:lang="en-US">Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LeaseLiabilities" xlink:to="inm_LeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trademark</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl0" xml:lang="en-US">Deferred Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesGainLoss_lbl0" xml:lang="en-US">Debt Securities, Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnlabeledAbstract" xlink:to="inm_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl1" xml:lang="en-US">Stock Issued During Period Value Issued For Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtEnding_lbl0" xml:lang="en-US">Share Based Payment Number Of Balance At Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfBalanceAtEnding" xlink:to="inm_ShareBasedPaymentNumberOfBalanceAtEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl0" xml:lang="en-US">Repayments of Long-Term Capital Lease Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PurchasePriceConsiderationMember_lbl0" xml:lang="en-US">Purchase Price Consideration Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PurchasePriceConsiderationMember" xlink:to="inm_PurchasePriceConsiderationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Expired Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" xlink:to="inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of Assets Acquired And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract" xlink:to="inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WarrantsModificationExpense_lbl0" xml:lang="en-US">Warrants Modification Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantsModificationExpense" xlink:to="inm_WarrantsModificationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AccruedResearchAndDevelopment_lbl1" xml:lang="en-US">Accrued Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AccruedResearchAndDevelopment" xlink:to="inm_AccruedResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PrefundedWarrantsIssuedMember_lbl0" xml:lang="en-US">Prefunded Warrants Issued Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PrefundedWarrantsIssuedMember" xlink:to="inm_PrefundedWarrantsIssuedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl1" xml:lang="en-US">Impairment Of Intangible Asset Indefinitelived Excluding Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:to="inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_NonCashTransactionsTextBlock_lbl0" xml:lang="en-US">Non Cash Transactions Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_NonCashTransactionsTextBlock" xlink:to="inm_NonCashTransactionsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_InterestIncomeaccruedReceivedOnShorttermInvestments_lbl1" xml:lang="en-US">Interest Incomeaccrued Received On Shortterm Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InterestIncomeaccruedReceivedOnShorttermInvestments" xlink:to="inm_InterestIncomeaccruedReceivedOnShorttermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract_lbl0" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfOtherComprehensiveIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WeightedAverageExercisePriceVestedAndExercisable_lbl1" xml:lang="en-US">Weighted Average Exercise Price Vested And Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageExercisePriceVestedAndExercisable" xlink:to="inm_WeightedAverageExercisePriceVestedAndExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl0" xml:lang="en-US">Finite-Lived Patents, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DefiniteLivedIntangibleAssetsAbstract0_lbl0" xml:lang="en-US">Definite Lived Intangible Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DefiniteLivedIntangibleAssetsAbstract0" xlink:to="inm_DefiniteLivedIntangibleAssetsAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_GuaranteedInvestment_lbl1" xml:lang="en-US">Guaranteed Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_GuaranteedInvestment" xlink:to="inm_GuaranteedInvestment_lbl1"/>
    <loc xlink:type="locator" xlink:label="inm_AcquisitionAbstract" xlink:href="inm-20220630.xsd#inm_AcquisitionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionAbstract_lbl" xml:lang="en-US">Acquisition Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionAbstract" xlink:to="inm_AcquisitionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CannabinoidMember_lbl0" xml:lang="en-US">Cannabinoid Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CannabinoidMember" xlink:to="inm_CannabinoidMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ExpenditureBalance_lbl1" xml:lang="en-US">Expenditure Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExpenditureBalance" xlink:to="inm_ExpenditureBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableFairValueDisclosure_lbl0" xml:lang="en-US">Loans Receivable, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableFairValueDisclosure" xlink:to="us-gaap_LoansReceivableFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl0" xml:lang="en-US">Concentration Risk, Customer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCustomer" xlink:to="us-gaap_ConcentrationRiskCustomer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionOfBayMedicainShares_lbl1" xml:lang="en-US">Acquisition Of Bay Medicain Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionOfBayMedicainShares" xlink:to="inm_AcquisitionOfBayMedicainShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl0" xml:lang="en-US">Common Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionTextBlock_lbl0" xml:lang="en-US">Acquisition Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionTextBlock" xlink:to="inm_AcquisitionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PurchasePriceAbstract_lbl0" xml:lang="en-US">Purchase Price Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PurchasePriceAbstract" xlink:to="inm_PurchasePriceAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_OtherVariableLeaseCost_lbl1" xml:lang="en-US">Other Variable Lease Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_OtherVariableLeaseCost" xlink:to="inm_OtherVariableLeaseCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_TransactionCostsAllocatedToAdditionalPaidinCapital_lbl1" xml:lang="en-US">Transaction Costs Allocated To Additional Paidin Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TransactionCostsAllocatedToAdditionalPaidinCapital" xlink:to="inm_TransactionCostsAllocatedToAdditionalPaidinCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl0" xml:lang="en-US">Payments of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DeferredTaxAssetsPropertyAndEquipmentsNet_lbl1" xml:lang="en-US">Deferred Tax Assets Property And Equipments Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsPropertyAndEquipmentsNet" xlink:to="inm_DeferredTaxAssetsPropertyAndEquipmentsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WarrantModificationExpenses_lbl1" xml:lang="en-US">Warrant Modification Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WarrantModificationExpenses" xlink:to="inm_WarrantModificationExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AllocatedToAdditionalPaidinCapitalMember_lbl0" xml:lang="en-US">Allocated To Additional Paidin Capital Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AllocatedToAdditionalPaidinCapitalMember" xlink:to="inm_AllocatedToAdditionalPaidinCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_InvestmentOptionsMember_lbl0" xml:lang="en-US">Investment Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InvestmentOptionsMember" xlink:to="inm_InvestmentOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DeferredTaxAssetsAndLiabilitiesGross_lbl1" xml:lang="en-US">Deferred Tax Assets And Liabilities Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsAndLiabilitiesGross" xlink:to="inm_DeferredTaxAssetsAndLiabilitiesGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermInvestments_lbl0" xml:lang="en-US">Other Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfIntangibleAssetsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfIntangibleAssetsAbstract" xlink:to="inm_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionOfBayMedica_lbl1" xml:lang="en-US">Acquisition Of Bay Medica</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionOfBayMedica" xlink:to="inm_AcquisitionOfBayMedica_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule Of AReconciliation Of Income Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_RecognizedTaxBenefits_lbl1" xml:lang="en-US">Recognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RecognizedTaxBenefits" xlink:to="inm_RecognizedTaxBenefits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl0" xml:lang="en-US">Income Tax Examination, Likelihood of Unfavorable Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentAggregateIntrinsicValueGranted_lbl0" xml:lang="en-US">Share Based Payment Aggregate Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentAggregateIntrinsicValueGranted" xlink:to="inm_ShareBasedPaymentAggregateIntrinsicValueGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LiabilitiesAssumedAbstract_lbl0" xml:lang="en-US">Liabilities Assumed Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LiabilitiesAssumedAbstract" xlink:to="inm_LiabilitiesAssumedAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AllocationAbstract_lbl0" xml:lang="en-US">Allocation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AllocationAbstract" xlink:to="inm_AllocationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Number Of Common Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:to="inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ExerciseOfPrefundedWarrants_lbl1" xml:lang="en-US">Exercise Of Prefunded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfPrefundedWarrants" xlink:to="inm_ExerciseOfPrefundedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PatentsAbstract_lbl0" xml:lang="en-US">Patents Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PatentsAbstract" xlink:to="inm_PatentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AcquisitionConsiderationPayable_lbl1" xml:lang="en-US">Acquisition Consideration Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AcquisitionConsiderationPayable" xlink:to="inm_AcquisitionConsiderationPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BusinessCombinationPostclosingAdjustments_lbl1" xml:lang="en-US">Business Combination Postclosing Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationPostclosingAdjustments" xlink:to="inm_BusinessCombinationPostclosingAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl0" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalAndReservesTextBlock_lbl0" xml:lang="en-US">Share Capital And Reserves Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalAndReservesTextBlock" xlink:to="inm_ShareCapitalAndReservesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AssetsAcquiredAbstract_lbl0" xml:lang="en-US">Assets Acquired Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AssetsAcquiredAbstract" xlink:to="inm_AssetsAcquiredAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl1" xml:lang="en-US">Impairment Of Intangible Asset Excluding Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:to="inm_ImpairmentOfIntangibleAssetExcludingGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl0" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CommonShares_lbl1" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonShares" xlink:to="inm_CommonShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl0" xml:lang="en-US">Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AgentsInvestmentOptions_lbl1" xml:lang="en-US">Agents Investment Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsInvestmentOptions" xlink:to="inm_AgentsInvestmentOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BayMedicaAgreementMember_lbl0" xml:lang="en-US">Bay Medica Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BayMedicaAgreementMember" xlink:to="inm_BayMedicaAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl0" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfPrivatePlacementOfferingAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfPrivatePlacementOfferingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfPrivatePlacementOfferingAbstract_lbl" xml:lang="en-US">Schedule Of Private Placement Offering Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfPrivatePlacementOfferingAbstract" xlink:to="inm_ScheduleOfPrivatePlacementOfferingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value And Carrying Values Of The Company Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract" xlink:to="inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_GrossProceedsMember_lbl0" xml:lang="en-US">Gross Proceeds Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_GrossProceedsMember" xlink:to="inm_GrossProceedsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareIssuanceCosts_lbl1" xml:lang="en-US">Share Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareIssuanceCosts" xlink:to="inm_ShareIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets_lbl0" xml:lang="en-US">Impairment Charge on Reclassified Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:to="us-gaap_ImpairmentChargeOnReclassifiedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment_lbl0" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In-process Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ConcentrationRiskPercentage_lbl1" xml:lang="en-US">Concentration Risk Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ConcentrationRiskPercentage" xlink:to="inm_ConcentrationRiskPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised_lbl1" xml:lang="en-US">Share Based Payments Weighted Average Share Price Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised" xlink:to="inm_ShareBasedPaymentsWeightedAverageSharePriceExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_TotalCommonShareValue_lbl1" xml:lang="en-US">Total Common Share Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TotalCommonShareValue" xlink:to="inm_TotalCommonShareValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfProFormaConsolidatedResultsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfProFormaConsolidatedResultsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfProFormaConsolidatedResultsAbstract_lbl" xml:lang="en-US">Schedule Of Pro Forma Consolidated Results Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfProFormaConsolidatedResultsAbstract" xlink:to="inm_ScheduleOfProFormaConsolidatedResultsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ATMOfferingNetOfIssuanceCosts_lbl1" xml:lang="en-US">ATMOffering Net Of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ATMOfferingNetOfIssuanceCosts" xlink:to="inm_ATMOfferingNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Share Price Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" xlink:to="inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_lbl2"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Accounts Payable And Accrued Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CashAcquiredFromAcqusition_lbl1" xml:lang="en-US">Cash Acquired From Acqusition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CashAcquiredFromAcqusition" xlink:to="inm_CashAcquiredFromAcqusition_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_RegisteredDirectAndPrivatePlacementShares_lbl1" xml:lang="en-US">Registered Direct And Private Placement Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RegisteredDirectAndPrivatePlacementShares" xlink:to="inm_RegisteredDirectAndPrivatePlacementShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl0" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_IssuanceOfCommonSharesIssued_lbl1" xml:lang="en-US">Issuance Of Common Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IssuanceOfCommonSharesIssued" xlink:to="inm_IssuanceOfCommonSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_SharesIssuedMember_lbl0" xml:lang="en-US">Shares Issued Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesIssuedMember" xlink:to="inm_SharesIssuedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding_lbl1" xml:lang="en-US">Share Based Payment Weighted Average Share Price Balance At Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" xlink:to="inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfReportableSegmentsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfReportableSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfReportableSegmentsAbstract_lbl" xml:lang="en-US">Schedule Of Reportable Segments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfReportableSegmentsAbstract" xlink:to="inm_ScheduleOfReportableSegmentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DeferredTaxAssetsIntangibleAssetsNet_lbl1" xml:lang="en-US">Deferred Tax Assets Intangible Assets Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsIntangibleAssetsNet" xlink:to="inm_DeferredTaxAssetsIntangibleAssetsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BayMedicaIncMember_lbl1" xml:lang="en-US">Bay Medica Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BayMedicaIncMember" xlink:to="inm_BayMedicaIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares_lbl1" xml:lang="en-US">Stock Issued During Period Value Issued For Private Placement Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" xlink:to="inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_RightOfUseAssetMember_lbl0" xml:lang="en-US">Right Of Use Asset Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_RightOfUseAssetMember" xlink:to="inm_RightOfUseAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Earnings Per Shares Basic And Diluted Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" xlink:to="inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_workingCapitalSurplus_lbl1" xml:lang="en-US">working Capital Surplus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_workingCapitalSurplus" xlink:to="inm_workingCapitalSurplus_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentNumberOfGranted_lbl1" xml:lang="en-US">Share Based Payment Number Of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfGranted" xlink:to="inm_ShareBasedPaymentNumberOfGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl0" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareBasedPaymentNumberOfBalanceAtBeginning_lbl0" xml:lang="en-US">Share Based Payment Number Of Balance At Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareBasedPaymentNumberOfBalanceAtBeginning" xlink:to="inm_ShareBasedPaymentNumberOfBalanceAtBeginning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Realized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfOutstandingOptionsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfOutstandingOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfOutstandingOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfOutstandingOptionsAbstract" xlink:to="inm_ScheduleOfOutstandingOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_OtherOperatingExpenses_lbl1" xml:lang="en-US">Other Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_OtherOperatingExpenses" xlink:to="inm_OtherOperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LegalService_lbl1" xml:lang="en-US">Legal Service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LegalService" xlink:to="inm_LegalService_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl0" xml:lang="en-US">Goodwill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ExerciseOfWarrantsinShares_lbl1" xml:lang="en-US">Exercise Of Warrantsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ExerciseOfWarrantsinShares" xlink:to="inm_ExerciseOfWarrantsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialAssetsAbstract0_lbl0" xml:lang="en-US">Financial Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialAssetsAbstract0" xlink:to="inm_FinancialAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostDirectMaterial_lbl0" xml:lang="en-US">Cost, Direct Material</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDirectMaterial" xlink:to="us-gaap_CostDirectMaterial_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_WeightedAverageExercisePriceUnvested_lbl1" xml:lang="en-US">Weighted Average Exercise Price Unvested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_WeightedAverageExercisePriceUnvested" xlink:to="inm_WeightedAverageExercisePriceUnvested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_LesseeOperatingLeaseLiabilityPaymentDue_lbl1" xml:lang="en-US">Lessee Operating Lease Liability Payment Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="inm_LesseeOperatingLeaseLiabilityPaymentDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_IprDAbstract_lbl0" xml:lang="en-US">Ipr DAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IprDAbstract" xlink:to="inm_IprDAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialLiabilitiesAbstract0_lbl0" xml:lang="en-US">Financial Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialLiabilitiesAbstract0" xlink:to="inm_FinancialLiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AgentsInvestmentOptionsMember_lbl0" xml:lang="en-US">Agents Investment Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsInvestmentOptionsMember" xlink:to="inm_AgentsInvestmentOptionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfInventoriesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfInventoriesAbstract_lbl" xml:lang="en-US">Schedule Of Inventories Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfInventoriesAbstract" xlink:to="inm_ScheduleOfInventoriesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_FinancialAssetsAbstract_lbl0" xml:lang="en-US">Financial Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_FinancialAssetsAbstract" xlink:to="inm_FinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_TrademarkAndIntellectualPropertyAbstract_lbl0" xml:lang="en-US">Trademark And Intellectual Property Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_TrademarkAndIntellectualPropertyAbstract" xlink:to="inm_TrademarkAndIntellectualPropertyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl0" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl1" xml:lang="en-US">Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_UnrealizedGainOnForeignExchange_lbl1" xml:lang="en-US">Unrealized Gain On Foreign Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_UnrealizedGainOnForeignExchange" xlink:to="inm_UnrealizedGainOnForeignExchange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_IPRDMember_lbl0" xml:lang="en-US">IPRDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IPRDMember" xlink:to="inm_IPRDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_CommonSharesConsultingServices_lbl1" xml:lang="en-US">Common Shares Consulting Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_CommonSharesConsultingServices" xlink:to="inm_CommonSharesConsultingServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BayMedicaMember_lbl0" xml:lang="en-US">Bay Medica Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BayMedicaMember" xlink:to="inm_BayMedicaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl0" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl0" xml:lang="en-US">Common Stock, Shares Authorized, Unlimited [Fixed List]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DeferredTaxAssetsFinancingCost_lbl1" xml:lang="en-US">Deferred Tax Assets Financing Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsFinancingCost" xlink:to="inm_DeferredTaxAssetsFinancingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_PreferredInvestmentOptionsMember_lbl0" xml:lang="en-US">Preferred Investment Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_PreferredInvestmentOptionsMember" xlink:to="inm_PreferredInvestmentOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_InMedMember_lbl0" xml:lang="en-US">In Med Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_InMedMember" xlink:to="inm_InMedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableTradeCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl1" xml:lang="en-US">Payments to Acquire Loans Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShortTermInvestment_lbl1" xml:lang="en-US">Short Term Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShortTermInvestment" xlink:to="inm_ShortTermInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_AgentsWarrantsMember_lbl0" xml:lang="en-US">Agents Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_AgentsWarrantsMember" xlink:to="inm_AgentsWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesVendorAllowancesPolicy_lbl0" xml:lang="en-US">Cost of Sales, Vendor Allowances, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesVendorAllowancesPolicy" xlink:to="us-gaap_CostOfSalesVendorAllowancesPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_GoodwillAbstract_lbl0" xml:lang="en-US">Goodwill Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_GoodwillAbstract" xlink:to="inm_GoodwillAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0" xml:lang="en-US">Property, Plant and Equipment, Salvage Value, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ShareCapitalOfNumberOfBalance_lbl1" xml:lang="en-US">Share Capital Of Number Of Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ShareCapitalOfNumberOfBalance" xlink:to="inm_ShareCapitalOfNumberOfBalance_lbl1"/>
    <loc xlink:type="locator" xlink:label="inm_ScheduleOfTotalConsiderationAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfTotalConsiderationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_ScheduleOfTotalConsiderationAbstract_lbl" xml:lang="en-US">Schedule Of Total Consideration Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_ScheduleOfTotalConsiderationAbstract" xlink:to="inm_ScheduleOfTotalConsiderationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl0" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities_lbl0" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other Shortterm Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" xlink:to="inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_IPOWarrantIssue_lbl0" xml:lang="en-US">IPOWarrant Issue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_IPOWarrantIssue" xlink:to="inm_IPOWarrantIssue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="inm_DeferredTaxAssetsLeaseObligations_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inm_DeferredTaxAssetsLeaseObligations" xlink:to="inm_DeferredTaxAssetsLeaseObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl0" xml:lang="en-US">Variable Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>inm-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Sep 23 19:20:26 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedBalanceSheet" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedIncomeStatement" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareholdersEquityType2or3" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ConsolidatedCashFlow" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NatureofBusinessandGoingConcern" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SignificantAccountingPolicies" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CustomerConcentration" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_Inventories" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_PropertyEquipmentandRouAssetsNet" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ImpairmentofIntangibleAssetsandGoodwill" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IntangibleAssets" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_Acquisition" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/Acquisition"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AccountsPayableandAccruedLiabilities" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareCapitalandReserves" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareBasedPayments" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_LeaseObligations" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_BasicandDilutedLossPerShare" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IncomeTaxes" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SegmentInformation" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NonCashTransactions" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CommitmentsandContingencies" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_FinancialRiskManagement" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_RelatedPartyTransactions" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SubsequentEvents" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AccountingPoliciesByPolicy" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_InventoriesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_PropertyEquipmentandRouAssetsNetTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ImpairmentofIntangibleAssetsandGoodwillTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IntangibleAssetsTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AcquisitionTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareCapitalandReservesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareBasedPaymentsTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_LeaseObligationsTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_BasicandDilutedLossPerShareTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IncomeTaxesTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SegmentInformationTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_FinancialRiskManagementTables" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofinventoriesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofpropertyequipmentandrightofuseassetsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofintangibleassetsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofintangibleassetsTable0" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofamortizationexpenseTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleoftotalconsiderationTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleoffairvalueofassetsacquiredandliabilitiesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofproformaconsolidatedresultsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofaccountspayableandaccruedliabilitiesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofprivateplacementofferingTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofchangesinsharepurchasewarrantsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofchangesinagentswarrantsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofoutstandingoptionsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofminimumleasepaymentsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofweightedaveragenumberofcommonsharesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofareconciliationofincometaxesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleofreportablesegmentsTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ScheduleoffairvalueandcarryingvaluesofthecompanyTable" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NatureofBusinessandGoingConcernDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SignificantAccountingPoliciesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CustomerConcentrationDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_InventoriesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ImpairmentofIntangibleAssetsandGoodwillDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IntangibleAssetsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_AcquisitionDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareCapitalandReservesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_ShareBasedPaymentsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_LeaseObligationsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_IncomeTaxesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_NonCashTransactionsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_CommitmentsandContingenciesDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_FinancialRiskManagementDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_RelatedPartyTransactionsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#inm_r_SubsequentEventsDetails" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="inm-20220630.xsd#DocumentAndEntityInformation" roleURI="http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionConsiderationPayable" xlink:href="inm-20220630.xsd#inm_AcquisitionConsiderationPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="AcquisitionConsiderationPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="WarrantModificationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuedForPrivatePlacement" xlink:href="inm-20220630.xsd#inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuedForPrivatePlacement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" xlink:href="inm-20220630.xsd#inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATMOfferingNetOfIssuanceCosts" xlink:href="inm-20220630.xsd#inm_ATMOfferingNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ATMOfferingNetOfIssuanceCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATMOfferingNetOfIssuanceCostsShares" xlink:href="inm-20220630.xsd#inm_ATMOfferingNetOfIssuanceCostsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ATMOfferingNetOfIssuanceCostsShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegisteredDirectAndPrivatePlacement" xlink:href="inm-20220630.xsd#inm_RegisteredDirectAndPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="RegisteredDirectAndPrivatePlacement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegisteredDirectAndPrivatePlacementShares" xlink:href="inm-20220630.xsd#inm_RegisteredDirectAndPrivatePlacementShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="RegisteredDirectAndPrivatePlacementShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuanceCosts" xlink:href="inm-20220630.xsd#inm_ShareIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ShareIssuanceCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgentsWarrants" xlink:href="inm-20220630.xsd#inm_AgentsWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AgentsWarrants" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgentsInvestmentOptions" xlink:href="inm-20220630.xsd#inm_AgentsInvestmentOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AgentsInvestmentOptions" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrants" xlink:href="inm-20220630.xsd#inm_ExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfPrefundedWarrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfPrefundedWarrantsinShares" xlink:href="inm-20220630.xsd#inm_ExerciseOfPrefundedWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfPrefundedWarrantsinShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrantsin" xlink:href="inm-20220630.xsd#inm_ExerciseOfWarrantsin"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfWarrantsin" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrantsinShares" xlink:href="inm-20220630.xsd#inm_ExerciseOfWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfWarrantsinShares" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionOfBayMedica" xlink:href="inm-20220630.xsd#inm_AcquisitionOfBayMedica"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AcquisitionOfBayMedica" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionOfBayMedicainShares" xlink:href="inm-20220630.xsd#inm_AcquisitionOfBayMedicainShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AcquisitionOfBayMedicainShares" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="WarrantModificationExpense" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossAndComprehensivelossesForThePeriod" xlink:href="inm-20220630.xsd#inm_LossAndComprehensivelossesForThePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="LossAndComprehensivelossesForThePeriod" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossAndComprehensiveIncomelossesForThePeriod" xlink:href="inm-20220630.xsd#inm_LossAndComprehensiveIncomelossesForThePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="LossAndComprehensiveIncomelossesForThePeriod" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="InterestIncomeaccruedReceivedOnShorttermInvestments" xlink:href="inm-20220630.xsd#inm_InterestIncomeaccruedReceivedOnShorttermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="InterestIncomeaccruedReceivedOnShorttermInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrealizedGainOnDerivativeWarrantsLiability" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnDerivativeWarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="UnrealizedGainOnDerivativeWarrantsLiability" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="UnrealizedGainOnForeignExchange" xlink:href="inm-20220630.xsd#inm_UnrealizedGainOnForeignExchange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="UnrealizedGainOnForeignExchange" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpense" xlink:href="inm-20220630.xsd#inm_FinanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FinanceExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantModificationExpenses" xlink:href="inm-20220630.xsd#inm_WarrantModificationExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="WarrantModificationExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAcquiredFromAcqusition" xlink:href="inm-20220630.xsd#inm_CashAcquiredFromAcqusition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="CashAcquiredFromAcqusition" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_StockIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureofBusinessandGoingConcernTable" xlink:href="inm-20220630.xsd#inm_NatureofBusinessandGoingConcernTable"/>
    <loc xlink:type="locator" xlink:label="NatureofBusinessandGoingConcernLineItems" xlink:href="inm-20220630.xsd#inm_NatureofBusinessandGoingConcernLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureofBusinessandGoingConcernTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureofBusinessandGoingConcernTable" xlink:to="NatureofBusinessandGoingConcernLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureofBusinessandGoingConcernLineItems" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/Inventories">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/Acquisition">
    <loc xlink:type="locator" xlink:label="AcquisitionAbstract" xlink:href="inm-20220630.xsd#inm_AcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="AcquisitionTextBlock" xlink:href="inm-20220630.xsd#inm_AcquisitionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionAbstract" xlink:to="AcquisitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves">
    <loc xlink:type="locator" xlink:label="ShareCapitalAndReservesAbstract" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalAndReservesTextBlock" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalAndReservesAbstract" xlink:to="ShareCapitalAndReservesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions">
    <loc xlink:type="locator" xlink:label="NonCashTransactionsAbstract" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="NonCashTransactionsTextBlock" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsAbstract" xlink:to="NonCashTransactionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement">
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementAbstract" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementTextBlock" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementAbstract" xlink:to="FinancialRiskManagementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="COVID19ImpactsPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_COVID19ImpactsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="COVID19ImpactsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InProcessRDPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_InProcessRDPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InProcessRDPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsAndLiabilitiesPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_FinancialAssetsAndLiabilitiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FinancialAssetsAndLiabilitiesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesVendorAllowancesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesVendorAllowancesPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesVendorAllowancesPolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentsAndIntellectualPropertyCostsPolicyTextBlock" xlink:href="inm-20220630.xsd#inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PatentsAndIntellectualPropertyCostsPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables">
    <loc xlink:type="locator" xlink:label="AcquisitionAbstract" xlink:href="inm-20220630.xsd#inm_AcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables">
    <loc xlink:type="locator" xlink:label="ShareCapitalAndReservesAbstract" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPrivatePlacementOfferingTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfPrivatePlacementOfferingTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalAndReservesAbstract" xlink:to="ScheduleOfPrivatePlacementOfferingTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalAndReservesAbstract" xlink:to="ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInAgentsWarrantsTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalAndReservesAbstract" xlink:to="ScheduleOfChangesInAgentsWarrantsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" xlink:href="inm-20220630.xsd#inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables">
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementAbstract" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoriesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetMember" xlink:href="inm-20220630.xsd#inm_RightOfUseAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="RightOfUseAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable"/>
    <loc xlink:type="locator" xlink:label="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_GoodwillMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IPRDMember" xlink:href="inm-20220630.xsd#inm_IPRDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="IPRDMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TrademarksMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable" xlink:to="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_GoodwillFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillFairValueDisclosure_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems" xlink:to="us-gaap_GoodwillFairValueDisclosure_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmortizationExpenseAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedIntangibleAssetNet" xlink:href="inm-20220630.xsd#inm_FiniteLivedIntangibleAssetNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTotalConsiderationAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfTotalConsiderationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTotalConsiderationAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PurchasePriceConsiderationMember" xlink:href="inm-20220630.xsd#inm_PurchasePriceConsiderationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="PurchasePriceConsiderationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationPostclosingAdjustments" xlink:href="inm-20220630.xsd#inm_BusinessCombinationPostclosingAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="BusinessCombinationPostclosingAdjustments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract" xlink:to="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PurchasePriceConsiderationMember" xlink:href="inm-20220630.xsd#inm_PurchasePriceConsiderationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="PurchasePriceConsiderationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable" xlink:to="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilitiesAssumedAbstract" xlink:href="inm-20220630.xsd#inm_LiabilitiesAssumedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems" xlink:to="LiabilitiesAssumedAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" xlink:href="inm-20220630.xsd#inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAssumedAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAssumedAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProFormaConsolidatedResultsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfProFormaConsolidatedResultsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProFormaConsolidatedResultsAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZ8btGW5qMQVqzLsfi3GzVuMY7sD/FFw7U4o2i8MgAqSMg6pxwpeBm32Q4Yx+CEjQMnrWZzgc+HrjKz4FGA65QOvsgEC/wMtHrdik6IbyDDLXxJdt3/VqavjFzajJqD6rwRbNxWB/9EPBc1wENO3701leuZtdXSpohHx25mAouKCHQxfXoc5q0CB/s8eMhbBXgs6kLNzvlp1wTvDSKAUrRPKUrZhycILqQ=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProFormaConsolidatedResultsAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopment" xlink:href="inm-20220630.xsd#inm_AccruedResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="AccruedResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrivatePlacementOfferingAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfPrivatePlacementOfferingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrivatePlacementOfferingAbstract" xlink:to="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedMember" xlink:href="inm-20220630.xsd#inm_SharesIssuedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SharesIssuedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsIssuedMember" xlink:href="inm-20220630.xsd#inm_PrefundedWarrantsIssuedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrefundedWarrantsIssuedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceedsMember" xlink:href="inm-20220630.xsd#inm_GrossProceedsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="GrossProceedsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllocatedToAdditionalPaidinCapitalMember" xlink:href="inm-20220630.xsd#inm_AllocatedToAdditionalPaidinCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="AllocatedToAdditionalPaidinCapitalMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuanceCostsMember" xlink:href="inm-20220630.xsd#inm_ShareIssuanceCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="ShareIssuanceCostsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable" xlink:to="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalCommonShareValue" xlink:href="inm-20220630.xsd#inm_TotalCommonShareValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems" xlink:to="TotalCommonShareValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInSharePurchaseWarrantsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInSharePurchaseWarrantsAbstract" xlink:to="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SharePurchaseWarrantsMember" xlink:href="inm-20220630.xsd#inm_SharePurchaseWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="SharePurchaseWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable" xlink:to="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalOfNumberOfBalance" xlink:href="inm-20220630.xsd#inm_ShareCapitalOfNumberOfBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="ShareCapitalOfNumberOfBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueAtBeginning" xlink:href="inm-20220630.xsd#inm_AggregateIntrinsicValueAtBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="AggregateIntrinsicValueAtBeginning" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentNumberOfGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="ShareBasedPaymentNumberOfGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharePriceGranted" xlink:href="inm-20220630.xsd#inm_WeightedAverageSharePriceGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="WeightedAverageSharePriceGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueGranted" xlink:href="inm-20220630.xsd#inm_AggregateIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="AggregateIntrinsicValueGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentNumberOfExercised" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="ShareBasedPaymentNumberOfExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsWeightedAverageSharePriceExercised" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsWeightedAverageSharePriceExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="ShareBasedPaymentsWeightedAverageSharePriceExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalOfNumberOfBalance_0" xlink:href="inm-20220630.xsd#inm_ShareCapitalOfNumberOfBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="ShareCapitalOfNumberOfBalance_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_0" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueAtBeginning_0" xlink:href="inm-20220630.xsd#inm_AggregateIntrinsicValueAtBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems" xlink:to="AggregateIntrinsicValueAtBeginning_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInAgentsWarrantsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfChangesInAgentsWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInAgentsWarrantsAbstract" xlink:to="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AgentsWarrantsMember" xlink:href="inm-20220630.xsd#inm_AgentsWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="AgentsWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable" xlink:to="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentNumberOfBalanceAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfBalanceAtBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentNumberOfBalanceAtBeginning" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAggregateIntrinsicValueAtBeginning" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentAggregateIntrinsicValueAtBeginning" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentSharesNumberOfGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentSharesNumberOfGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentSharesNumberOfGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentWeightedAverageSharePriceGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentWeightedAverageSharePriceGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAggregateIntrinsicValueGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentAggregateIntrinsicValueGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentNumberOfBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentNumberOfBalanceAtEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentNumberOfBalanceAtEnding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems" xlink:to="ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingOptionsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfOutstandingOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:href="inm-20220630.xsd#inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="inm-20220630.xsd#inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_0" xlink:href="inm-20220630.xsd#inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June302022Abstract" xlink:href="inm-20220630.xsd#inm_June302022Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsAbstract" xlink:to="June302022Abstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfVestedAndExercisable" xlink:href="inm-20220630.xsd#inm_NumberOfVestedAndExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="June302022Abstract" xlink:to="NumberOfVestedAndExercisable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceVestedAndExercisable" xlink:href="inm-20220630.xsd#inm_WeightedAverageExercisePriceVestedAndExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="June302022Abstract" xlink:to="WeightedAverageExercisePriceVestedAndExercisable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfUnvested" xlink:href="inm-20220630.xsd#inm_NumberOfUnvested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="June302022Abstract" xlink:to="NumberOfUnvested" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceUnvested" xlink:href="inm-20220630.xsd#inm_WeightedAverageExercisePriceUnvested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="June302022Abstract" xlink:to="WeightedAverageExercisePriceUnvested" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumLeasePaymentsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentDueYearFive" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentDueYearFive" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="inm-20220630.xsd#inm_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumLeasePaymentsAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageNumberOfCommonSharesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:href="inm-20220630.xsd#inm_IncreaseReductionInIncomeTaxesResultingFromAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="IncreaseReductionInIncomeTaxesResultingFromAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseReductionInIncomeTaxesResultingFromAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsPropertyAndEquipmentsNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsPropertyAndEquipmentsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsPropertyAndEquipmentsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsFinancingCost" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsFinancingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsFinancingCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilities" xlink:href="inm-20220630.xsd#inm_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="LeaseLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAndLiabilitiesGross" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsAndLiabilitiesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAndLiabilitiesGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsIntangibleAssetsNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsIntangibleAssetsNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseObligations" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetsLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLeaseObligations" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetLiabilitiesNet" xlink:href="inm-20220630.xsd#inm_DeferredTaxAssetLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetLiabilitiesNet" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReportableSegmentsAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfReportableSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReportableSegmentsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InMedMember" xlink:href="inm-20220630.xsd#inm_InMedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="InMedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BayMedicaMember" xlink:href="inm-20220630.xsd#inm_BayMedicaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="BayMedicaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherOperatingExpenses" xlink:href="inm-20220630.xsd#inm_OtherOperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="OtherOperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract" xlink:href="inm-20220630.xsd#inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CumulativeEarningsDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalent" xlink:href="inm-20220630.xsd#inm_CashAndCashEquivalent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="CustomerConcentrationDetailsTable" xlink:href="inm-20220630.xsd#inm_CustomerConcentrationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CustomerConcentrationDetailsLineItems" xlink:href="inm-20220630.xsd#inm_CustomerConcentrationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="CustomerConcentrationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CustomerConcentrationDetailsTable" xlink:to="srt_MajorCustomersAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerOneMember" xlink:href="inm-20220630.xsd#inm_CustomerOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CustomerConcentrationDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CustomerConcentrationDetailsTable" xlink:to="CustomerConcentrationDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCustomer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CustomerConcentrationDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskCustomer" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskPercentage" xlink:href="inm-20220630.xsd#inm_ConcentrationRiskPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CustomerConcentrationDetailsLineItems" xlink:to="ConcentrationRiskPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ImpairmentofIntangibleAssetsandGoodwillDetailsTable" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ImpairmentofIntangibleAssetsandGoodwillDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IPRDMember" xlink:href="inm-20220630.xsd#inm_IPRDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="IPRDMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsTable" xlink:to="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="us-gaap_GoodwillGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfIntangibleAssetExcludingGoodwill" xlink:href="inm-20220630.xsd#inm_ImpairmentOfIntangibleAssetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="ImpairmentOfIntangibleAssetExcludingGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:href="inm-20220630.xsd#inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentChargeOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentChargeOnReclassifiedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="us-gaap_ImpairmentChargeOnReclassifiedAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails">
    <loc xlink:type="locator" xlink:label="AcquisitionAbstract" xlink:href="inm-20220630.xsd#inm_AcquisitionAbstract"/>
    <loc xlink:type="locator" xlink:label="AcquisitionDetailsTable" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AcquisitionDetailsLineItems" xlink:href="inm-20220630.xsd#inm_AcquisitionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionAbstract" xlink:to="AcquisitionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BayMedicaMember" xlink:href="inm-20220630.xsd#inm_BayMedicaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BayMedicaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CannabinoidMember" xlink:href="inm-20220630.xsd#inm_CannabinoidMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="CannabinoidMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsTable" xlink:to="AcquisitionDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_Revenues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AcquisitionDetailsLineItems" xlink:to="us-gaap_LegalFees" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails">
    <loc xlink:type="locator" xlink:label="ShareCapitalAndReservesAbstract" xlink:href="inm-20220630.xsd#inm_ShareCapitalAndReservesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsTable" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalandReservesDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ShareCapitalandReservesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalAndReservesAbstract" xlink:to="ShareCapitalandReservesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMMember" xlink:href="inm-20220630.xsd#inm_ATMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ATMMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BayMedicaAgreementMember" xlink:href="inm-20220630.xsd#inm_BayMedicaAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="BayMedicaAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredInvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_PreferredInvestmentOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PreferredInvestmentOptionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgentsInvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_AgentsInvestmentOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="AgentsInvestmentOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsTable" xlink:to="ShareCapitalandReservesDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundWarrants" xlink:href="inm-20220630.xsd#inm_PrefundWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="PrefundWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionCostsAllocatedToAdditionalPaidinCapital" xlink:href="inm-20220630.xsd#inm_TransactionCostsAllocatedToAdditionalPaidinCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="TransactionCostsAllocatedToAdditionalPaidinCapital" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisedCommonSharesDescription" xlink:href="inm-20220630.xsd#inm_ExercisedCommonSharesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="ExercisedCommonSharesDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesNetIssuance" xlink:href="inm-20220630.xsd#inm_CommonSharesNetIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="CommonSharesNetIssuance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrants" xlink:href="inm-20220630.xsd#inm_PrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="PrefundedWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesConsultingServices" xlink:href="inm-20220630.xsd#inm_CommonSharesConsultingServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="CommonSharesConsultingServices" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IPOWarrantIssue" xlink:href="inm-20220630.xsd#inm_IPOWarrantIssue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="IPOWarrantIssue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExpiryDate" xlink:href="inm-20220630.xsd#inm_WarrantExpiryDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="WarrantExpiryDate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsModificationExpense" xlink:href="inm-20220630.xsd#inm_WarrantsModificationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="WarrantsModificationExpense" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssued" xlink:href="inm-20220630.xsd#inm_WarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="WarrantsIssued" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonSharesIssued" xlink:href="inm-20220630.xsd#inm_IssuanceOfCommonSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="IssuanceOfCommonSharesIssued" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuanceTerm" xlink:href="inm-20220630.xsd#inm_WarrantsIssuanceTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareCapitalandReservesDetailsLineItems" xlink:to="WarrantsIssuanceTerm" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsTable" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_ShareBasedPaymentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ShareBasedPaymentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingPercentage" xlink:href="inm-20220630.xsd#inm_IssuedAndOutstandingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="IssuedAndOutstandingPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:href="inm-20220630.xsd#inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageForfeitureRate" xlink:href="inm-20220630.xsd#inm_WeightedAverageForfeitureRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="WeightedAverageForfeitureRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeaseObligationsDetailsTable" xlink:href="inm-20220630.xsd#inm_LeaseObligationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeaseObligationsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_LeaseObligationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeaseObligationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsTable" xlink:to="LeaseObligationsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsLineItems" xlink:to="us-gaap_VariableLeaseCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherVariableLeaseCost" xlink:href="inm-20220630.xsd#inm_OtherVariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseObligationsDetailsLineItems" xlink:to="OtherVariableLeaseCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedTaxBenefits" xlink:href="inm-20220630.xsd#inm_RecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="RecognizedTaxBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails">
    <loc xlink:type="locator" xlink:label="NonCashTransactionsAbstract" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="NonCashTransactionsDetailsTable" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NonCashTransactionsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_NonCashTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsAbstract" xlink:to="NonCashTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BayMedicaIncMember" xlink:href="inm-20220630.xsd#inm_BayMedicaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BayMedicaIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsTable" xlink:to="NonCashTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedFairValueCommonShares" xlink:href="inm-20220630.xsd#inm_EstimatedFairValueCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="EstimatedFairValueCommonShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_LoansReceivableFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredUnitsIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_PreferredUnitsIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashTransactionsDetailsLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CostOfServicesDirectsMaterials" xlink:href="inm-20220630.xsd#inm_CostOfServicesDirectsMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CostOfServicesDirectsMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenditureBalance" xlink:href="inm-20220630.xsd#inm_ExpenditureBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ExpenditureBalance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostDirectMaterial"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CostDirectMaterial" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GuaranteedInvestment" xlink:href="inm-20220630.xsd#inm_GuaranteedInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="GuaranteedInvestment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchase" xlink:href="inm-20220630.xsd#inm_WarrantsToPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="WarrantsToPurchase" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonShares" xlink:href="inm-20220630.xsd#inm_CommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommonShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails">
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementAbstract" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementDetailsTable" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialRiskManagementDetailsLineItems" xlink:href="inm-20220630.xsd#inm_FinancialRiskManagementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementAbstract" xlink:to="FinancialRiskManagementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyAxis" xlink:href="inm-20220630.xsd#inm_TypeOfCurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsTable" xlink:to="TypeOfCurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyDomain" xlink:href="inm-20220630.xsd#inm_TypeOfCurrencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="TypeOfCurrencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="USDMember" xlink:href="inm-20220630.xsd#inm_USDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="USDMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsTable" xlink:to="FinancialRiskManagementDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyRiskPercentage" xlink:href="inm-20220630.xsd#inm_ForeignCurrencyRiskPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="ForeignCurrencyRiskPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesGainLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_Cash" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherMinorityInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMinorityInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_OtherMinorityInterests" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_OtherShortTermInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermInvestment" xlink:href="inm-20220630.xsd#inm_ShortTermInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="ShortTermInvestment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="workingCapitalSurplus" xlink:href="inm-20220630.xsd#inm_workingCapitalSurplus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialRiskManagementDetailsLineItems" xlink:to="workingCapitalSurplus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="LegalService" xlink:href="inm-20220630.xsd#inm_LegalService"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="LegalService" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="inm-20220630.xsd#inm_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="inm-20220630.xsd#inm_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentOptionsMember" xlink:href="inm-20220630.xsd#inm_InvestmentOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="InvestmentOptionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="inm-20220630.xsd#inm_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #R AH# 2(  A$! Q$!_\0
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M'^$'@63X%^%M?E\,^$;JSM]-N=;O=4O4NM1F6XMY6:YECB1&?<H$:[0">:_
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MI1E*@TI1>THMQ2:>FJ=M3_7"HK_) '_!9+_@J@P4K^W/\<SNQ@?VAII8Y&0
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M@[<[6^4_,"*T7A;GDOAQ6!;]:B_'HO-Z:"_XB-DEK^RQG_@M'^M]17^1^?\
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MA!24G-+WE\3CKNNMG>[=]5P7@#]B'X::]\/-%^/7[2O[5/AO]EGP#\;?C?\
M$3X:?L_Z6GP\\0?$G6_&M[X4\67ND^(/$NHZ=H%Q:0^"_ .C:I=66DS:A.UR
M\;)(B6JQQJ&ZNR_X)ECP7<_M=W/[3O[2/@[]G[PU^Q?XZ^''@WQ[XH'@_7/'
MUOX]T7XEV\VH^#=>^'&FZ/);7NJW6KZ8;/4]'TN=8=UE=R&XNHY(F6N>^&?[
M97[/>J_!;X>_ _\ ;#_9E\;_ !O\.? GXM?$+XI_ /Q#\,OBDOPXUO1+3XF>
M)D\7>)OAGXYCETW4K7Q!X+N]=M[6\6:R%KK$1^TJEQMD 'U=X._;,^"_QY_9
M\_X*;_%?]LGP';^.1\>/CK^S#=:=\!_ /Q$3P!X\T;PUX;AU32-$O/A7JEY;
MW\UU;_#?1[6STZ]N=3LKNWO!<SO+$KE2JJXCB.A3<:<:RA5Y:2E>#2;7(W%+
MWK/7H[:/1))ZQADU6S3A--N4TO=YH2G!OEYG'7E<M*G*DUOU/$K3_@E+>3_'
M+QK\-=0_:?\ AUHGP<T?]DF/]MSP5^T;JWAG7AX6\;_ J2:U69[WPE&S:WH7
MB*P:2YMKO1=US/'J5LD!;RYE<=II/_!*+X/>)-3_ &?8/#O_  4+^'FJV/[9
MWAG4[_\ 8_2X^$WC2PUWXC>*-#DN['6O#/Q(T<2M!\,M-BU>R32K#7KNZU :
MA<W4!6W"ABOG_C#_ (*56'B;QG\89]%^"+^%/A)KG[#U[^PE\#?AU'XL.HZG
M\*_ J2V5U8>+?$.NW-KO\6^(+J]MY]0\0,L5LE]<W!6'RHHU4^9?#O\ ;QT[
MP)X@_P"":>MR_"FZU0?\$^SXA;4K<>(([1_BT-<\5W/B8Q6<YMW_ .$8BM3.
MMN%D%WODC67@':/0I8;B><\)>K4BE3J7=3V4H<RIR<;IRDFY.,5;E<5*3MRK
M6/-3J9'4;BJ5.+3:?11]R5G?DT]]QCHVK7W7OQ]J_9K_ ."17Q$^-W@#PMX^
M^)'Q%\1_!Y?B?\4O&OP;^$FG^%O@IXX^,MOJOC#X?ZU+X6UO6OB'KWA1([#P
M!X.?Q-&=&T_6-467,:W-Q)$J1?-R7AO_ ()K>&- \ ^+O'W[5W[6/A/]E\>
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MM;KX9?M;?$+]IN7Q4^I0O#KFG^.K[3KU/!*Z:D,;64^FC3Q ^J)*T%RDI+0
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M\,1>-;K5=6U7PWI_B>P\(7,8GM_$^I?#ZYU0>,;#2&MWCN/.N-)0O;2)<(3
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M5A"')+R$$HC.H((%68UC:#SH+D3PR*A,\,JO#L<B/S;<JQ$ZM(P90"C+#EV
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M)\KO=-QU5VG9O2APWS2]I43G2?PM233NDU=*2:=N9]KJ^EK/^7;X4?#[Q/\
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M+GP]I66K:M;7KN82\/,XE-5'FV'YD[Q?)5?+;9+3;RM:[;MJ[_YCOB;]I?\
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M_+_\,_''XK^ -$\->'O GQ3\;>$-!\&^.$^)?A/2= \23:?9^&/B$EDNG?\
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M0>I/IBDWQGGS(QG_ *:)_C7^JK_Q#U_\$C/^C1O"G_@[\3?_ "VH_P"(>O\
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MTD6-R'F1,9#J1_$._P#G%?ZJ7_$/7_P2,_Z-&\*?^#OQ-_\ +:G)_P &]O\
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MUX8 $CGTR.G%.H **** "BBB@ HHHH **** "BBFHZR E#N 9E)P1\RDJPY
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M7VD3ZGX<\-^'WN;O2+SP_I=C<ZKJ=S:?:4C24I"G3:9^WS\7?&-I\,-"\"_
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M)\7>'[[SIO#7C?P#X<O/"6GS6%A<*UG-I6I^&]0FT[6-%N<66H)'YS;)RS2
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M444 (0#C(!P<C(S@CH1Z$>M+110 4QXTD 5U5P&5@& (W*<J<'N#R*?10
M     8 '  '0 =@**** "BBB@!KHLBE'4,IQE2,@X((R/8@$>XIU%% !111_
M7I0 @ 4 *  .@   ^@'%+110 A /! (R#@C/(.0>>X/(]#2T44 -V*',@4;R
MH0MCDJI)"D^@+$CZFG444 %%%% !1110 4444 %%%% !1110 4444 %)@9!P
M,@$ XY /4 ]<' S]*6B@ HHHH ;L7?YFT;]NS=CYMN=VW/IGG'K3J** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4ROA^R>"+0[:ZTE?[119;K6VB9KO3KN0L1!!%*T4<$\<,BRA)V:1#Y2OV%%
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M]//!\0'O+28"2QTW1S"DD6H3D17L,\<L"F/+5XY^T/\ MJ_\,]_M,?#[X?\
MB'3=0UCX5^(/@-\3/BMX@NO!_A+7?&/BFPN_ &KZ=;SW0BT*"Z6#0X=*OKB\
MNY)(RY>Q<(RA7#GPA_82LOAC\:/&'Q$UCQC%XC^'NK_"C0_ /A?X:V^CSZ>O
MA'Q'?:/I6E_%/QG8Z_%>R:Q]M^)%QIQO-32"YA:#SPJ,KP"63I];_8JT!?'N
MB>)? FK#P=X=\._L^_%3X%Z7X;DEU77!"GQ)G^WG78K[5+^[O4^PW[O-);27
M<K2JNU&3?E "[XQ_X* _L[>#Y](8:KXI\4:->>!_"/Q*U[Q/X-\(:YXD\.^
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M'W]O6^D1-_;]OK3^+WGD\G65N=(MY-NF1Z,D%Y>QFWMX_+:%;261@P#>?_\
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MNFD71<7[31*UOY155E:1T1ORDUG]ES]JSXR_$O\ :M3XC>$?ASX.\7ZU\/\
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ME?ASM=VT5W9;V5W97ZV5C]5C?E5][*_K97_&YXU\4_CS\,_@W?\ A?2_'?B
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M-[75HO"]GX-_:#U^V\2)J^G_ -GV4\S:]X4UFTCN;[3);9;3Q)9/)837]O\
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M425].=_M$UI=11*R12S0^C_ 70_V@M'DG^ OQ5N9_&/@CP%\#/"'A?4OCUK
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M/=.D#R;V KX1^(G_  3A\:>.=&\&Z;IWC7PQI+>%?@M^S7\*)S)I=Q''-<_
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M/!D6N_#CPGK<ICT^]U&:2-;G42&22*[/VB9+5MD4DD"P[2&2\VMK^)_VK?\
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MT+PDYCWV>L:S*]W9ZQJ^G7!S'<VUA-;-9174!DB>;[5&&1H07V?V;/!OQ?\
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MAW1M2.HP&WBF^RZ58B[NI+AY)%7Z2^ ?[)FN?##XJ_#_ ,57NF>"8O!OA_\
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M1I]S>W,FG07D%KIR"^NIH8,L//\ X(>#-7\4_M=_MM?$A]'O/#WA:YT+X7_
MKPPU]I4ME!K;>#O"]Y=ZSKNF+*JQ7>D6U]KPTRU:-!#(EIOB+PRH:^9OAO\
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M=Q-;RRV\5A'#=02R6EUY\7YL:K_P34^-6M?"KX%?#Z'6_ WAG5/AS\)OVL_
M&O:[9AC9MJ?QHU6_O_"]]:P6JQ7DNEZD8[8^*-/=Y-EIJMS;(V;0K)ZA\2?V
M4?CS^T?HW[/FGZ]X!\ _L_O\*;#XH>%-9N?#GB&PUC4[G2_%OP6N?ACI?B+P
MPWAZWL8](CL-3O6NK:P>ZO;B/1%^R#R99<@ ^]-%_; _9C\0:'XS\3:9\;/
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M/5K*T^&U[J%W)KFL:W%H]WH=RVJFYBT[3+:&T\^RT"-;&;RV3=* ?31_:9\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *JQ,QNKI2255+<@$G )$F2!T&<#..N!GI1136S]/U1,MX
M?XG_ .DR+5%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #- G@# 2(  A$! Q$!_\0
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M<'/']?;-=!X:\2W_ (4U6/5-*GD,S.@OK:4?NI+52-R/VVL/4'G'&.A[/S_
M#UEOC[XA5Y8IO#EE#=6\S0W$;77&4)!W'(P 1[]/2E_X7_KO_0OZ9_X&?_7I
MOC'PQI_C?2SX^\(11?:CM&M:>N V(^9G ! #'&X\#*@'U%>$RL#EDC$44\N6
M4X),T1*E<\\9!X&![8/*4+]?P ]X_P"%_P"N_P#0OZ9_X&?_ %Z1OV@-<"DG
M0--  .2+O<0/9<\GT'?I7@IC60%"JD-U#< XYP<=L@9KS#XZ_%K0/@'\#OC)
M\>?%4UG#I7PG^'OBSQ_?S2%1'<W&G:)=W5E9$LDB!99XHT'[M^3PK'BG[/S_
M  _X('V7+\=_$UF52\T&P266+SH-TC(!$1D$G=@ CJ><<]JC'Q[\02[2-$TI
MB3A0;L?,<CC[Q[D U_'%^Q3_ ,%+_$O[/7P8_;9F^(?Q@O/VI?&GA?X>?"/]
MJ3X>VOB/4->5?#WB?XYZQ9>&O$GP?O+S7=)@OK#PW\+_ !5KVCP:O+I9%K;V
M3NT;J #7HGP__;E_:-_91_:7_;*^*/[1J?!WQ-X*?]H/]F+P#^T1<?#[QCK?
MB'X8_!WPIXL^$.K:YH/B;X1-)(L6@+<>*[;3X_&WAZYD5UDO9KF0K&^Y3V?G
M^'_! _K>_P"%]>)(SM;0-*49&3]L("]B?O8XQGZ#TH_X7[KO_0'TH^WVSK[?
M>[U_*]XF_P""R_QI\&:5^SYX@NOAE\)KVQ\>)\)]<^*_PVTFR\57_BWP?\)/
MC9\2-2\+_#'Q#KOBJ]U!M$\&3ZMX=DL]>T^S)9M59HXXEDW@'U&V_P""L7QN
M\.?$"3Q#\2O@_P#"1_V:W_:5_:2_9JMF\!:KXBD^,DWB'X%^!-6^(=CK-UI%
MU$;"RT_5;.W32'TVW#S133#4T4JBBCV?G^ '])I^/^NX/_%/Z9T/_+Y_]>HQ
M^T!KQ( \.Z42>G^EC_XJOYI_&?\ P5$_:R\$?LY?LS?%+4/A5\"?$WC[]NSQ
M:L/[-GA_X=7'BCXB1^!O#VF^']0\0ZGIWQ7\/0ZJ9/&'B:>"2QM-*GLM0TRV
MGO)YYI+8#3I47YP_;/\ ^"C/[4?QN_94^/?PUTCX/^#/V=O%O@?]C;PM\=OV
MG8/B'XOU3P]\1O#UQXV^(UIX3T31O@3>Z9J$ T^\N$LFOK\7>JW,5O;7C:.Z
M2-*$<Y//\ /ZYO\ AH#71_S+VE?^!?\ ]E4W_"_M=_Z &F#W^V9Q_P"/5\I_
M#4R3_#'X3RR233RS?"_X;7E[>W4JW>H2O+X&T1B954#!9S\[$;LDDY-=E@=@
M,]N._P"5'L_/\/\ @@?5_@;XP+XBU!]*UV"#3)YAFRF@<[9,$8&6R0&S@'W
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MCR000#P+7/@7^SFGP0\)_LM^*/#?@.Q^ [+I>C^$/@]KGBBRTC3;Z+PCK/\
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M_0+74M+N+&XU^T^SK)<)<:5%</<P&U1I_.2-4P&8U_*3\%OVBF_88^&WQ]^
MOP_\5> ?&6K:=K/PVM/"'_!13]FRS,LOQ%LOBAXLU5K+P9^TUJOC6#7/!W@O
MXC^$;M3!JWB6[M+E[&SC+7UJAG7# _JD\4>//!'@I-(N/'GC?P?X./B/5+'2
MO"DWBKQ3:Z#)XK\3S7(@C\/>%A,R+>7[(%6"S7+W,@**"QJEHWPN^'?A[XG>
M,?C1H7A.STSXO>/_  SHGA/QYXWTP_\ $U\2^&?#%W/J.@V.I17+BW>ZL;H
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MOAVS_;#_ &L?!W[:7P1_8IL?C<?BOX4^--[\'OVE?AE^T?<^'-$M;&^_8_\
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MQHFJ:+<7GBSQ!<6SN]YX,T$VNO:D&D\1&[N8E+$ _K8\,ZSX.NUNO#7A76]
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M7'4EJD_X5'X_;_F"(W_7348UQ],=??\ #WKV3R=7/\5X<<8-Q+QGH!DG'/\
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M]=6M_M/VDQ-D$/,Y4G*D9!X(VCG/09]*5W;WH58OLZ%3[[VL5S+^>C\JU/\
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M/.1^T5^T,O!_:"^,?4\OX[UUB?J5^4^G'%(?VB/VACT_:!^,_?E?'VM =".
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M%/1^V>NVROV/8/\ AH?]H8?\W _&?_@?CS7&/YJ ,=< \]<\$4?\-$?M#?\
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M_P!!.*_\&O\ S/7O^&A_VBC][X_?&2,=,Q>/];RW&,'(/'?]/H?\-#_M#_\
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M/,$T<T%Q'+$P2X66T826[K(2"#%(B.G.5*_)@U_8S_P3N_;&T;XW_L?/XO\
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M-)D'/F,BA&DSO90%)*C%"RQ+NVM;KO9'?;,B[GC4)&[8^\T:#;&QRR+A5(
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MPI-K4$,09KV>)X(9[N!9GD>1#\BJ!OZI^WC\/M8^/WPJ_:7L?A/\3O\ A.O
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MQAXWUV77_$]_:^,M:MK.;5-1"H)K.S2<11V^6&512I.=P.,#]4@#_$<^G?\
MITZ'@_6JGR  !%  5< #&U3N5<%>BG)4< $Y%70QE;#-SI3E0G_/=Z]O@N^_
MX>1A7P='&4G2JQ4MM6K^NFCUV?DS\B#_ ,$2O^"?0)!\ ^+<C@_\5]J?4?\
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M^[Z*T6;X]I/Z]B==?XDO_D@_L/*O^?4?_)3X0_X=A?L%?]&Z^'/_  9^(?\
MYHJ/^'8?[!7_ $;KX<_\&?B'_P":*ON^BH>=XY-KZ[BM';XW_P#)!_8>5?\
M/J/_ )*?!\G_  3$_8),+J/V=/#88,HW?VIXASR5/;Q#D<'U_I74:O\ \$M_
MV![?2=/N%_9Q\++Y@ +)J7B$.QP,F0CQ "><XY/'OU^QC]V7@?<!Z#J"<'ZC
ML>H[5VGB%B?#VDG/)12?<\#)]3BN:6=X_F?^VXK=_P#+R7_R?YDO(\MZ8=->
M<E]ZTT_R/S>;_@F'^P:AP/V<_#9'4$ZKX@[_ %\0G_/84#_@F'^P61EOV=?#
M8/H-4\0G^7B$?YQ^'WAN;^\?S-)DGJ<U:SC'M)K'8K7^_+_Y,/[#RW_H'_\
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MA/''^S?X8C$)"%4U?Q#MR>3A?^$AQV SC(]N^:/^"8G[!AX;]G/PT!CMJGB
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M=[]_[9]_Y^O"_P#$4%^PMV^&_P"T%CM_Q2&G>V/^8S[#\J_DG^*?_!/'X_\
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M9O,,<K^Y+1VZ>?EY']I7_$2M^P2./^%=?M&\>OA7P_G\?^)K1_Q$K?L$]?\
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M/9ONOQ*F!Z#\A1@>@_(5=;RD&6 "Y R$#'YC@8&.>32.L"X7<=S\@&,K[GG
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ME"EC+U9QIQM;FEMO^!YF:J4L.Z<4W)OY*RZGP#^P=\9/ G[._P"UU\(?C/\
M$R;5;7P%X(O?&Z:_>Z=ID>I3_;M?\*:YIMM):VS@G[.&OX]Q48+=2#BOUL^
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M<!@J=_\ :Z36VG-LMM]K[O<T]IBO^?,^OV?_ +4_;+3_ /@I/^P]X4^)>O\
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M'+4_D?WH^>J*^A?^&0?VM_\ HUWX_P#_ (:WQ?\ _*VC_AD']K?_ *-=^/\
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MU1I8H@I'D\"_@>@_(4UL!7P/0?D*,#T'Y"K&!Z#\A1@>@_(4I2Y7:P%?:O\
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M*1\K%2PZ9*#"GCI@<<=1P<BE;YOO!3T_A4<K]T\ ?,.S?>[YSS116<H-MM6
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M"G[1=G^ %'RT_NBCRE/"J >Q_P GTJ]LM_5_\_A04A RI;<.F>G\J/:+L_P
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M?PJ+?:=C)^7_ -:HE+FMI:P'1:"H6.<  #>..W>N@K T/_4S'N6R3[C-;]2
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M_P#!4HY_X*#?M('G_D8/#)R>^=$B/7O[U\"MU/U/\Z^_?^"I4;_\/ _VD"H
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M'3/2HO-@_OG_ +Y2@!FY/[[?]\BFOM(^\6YS@J,5+YL']\_]\I2&2!A@L?\
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MU!S0!395\S;@8YXYQW_PK9O%#6%KD9P?_916>(PT@;'&>>ON:UKE0;"#(Z.
M/^^3_@* ,-%52,?*,\XYZ>U3;D_OM_WR*4!%.3P!R3UQ^!.*=YL']\_]\I0
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M  X0_8RC^9O$WQHD4C*@^++$<<^ED">F",]??-?M^8V))]3GN>OX4[;@ '/
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M?T'^% $/E/Z?H?\ "CRG]/T/^%3;V]?T'^%&]O7]!_A0! 0590>HQ_,FK]P
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+]_6K5 !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #@ @(# 2(  A$! Q$!_\0
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MYBF)8T9VS@J""*'@< M523>B2Y:>[:2Z/=M6]0^LU/Y7_P"!2_R/JS_AN_\
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M<VDMI>Q7@D\C[%+97<5]]H\QH3:_89(%NUO%N$>W>T:%;E)U*/$O!)]0R_\
MY]+_ ,!@'UFI_*__  *7^1]3?\-W_MQ_]'G?M4?^'W^)/_S1T?\ #=_[<?\
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M0:=3 **** "BBB@ HHHH **** "BBB@ HHHI77W@%%,+@$C!X[\8_GG]*<2
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M[+2M)TO]H+]IRQTS2].MH;+3]-L;?X^?$&.WLK"SMTCM[2TMXP(X+>"..&)
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M.RU&W&O?%'Q(]KJ$EY>V=QJOQH@FMOB9)=6DTK07,'BB&XF6XMIE:*T:026
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M_#;6/&]QX>NM3L9_B-H?PDOO$&N>"?!VLR1:A''9Z-I_B#Q+=W6M&WT^:_\
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MP'\0]4^*_@VQCO\ 4)ET/QYK<WB:ZU;6A<-=.^H3O-XO\2E+6[FFTY8[UH1
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MPO\ &K]HS2OBQHW@_P"'W@'7?V@?#/AGX-I\-]+U6*72?@]=^*O!NG:WXO\
M%VI:G'XLMO'^K^)_# UZ^LHK0:!INB2VFCQZ??,)-6G^5OA_^W+^TMH?P\\0
MZ1XJ\07FH?$/QCX6_9/O/A5K'QO^%FG?#K4M,US]HCQ3;_#SQ;X]M/#GA;4)
M-(\<?"'PCK=Y8W7AJ,W^D>*=0\37$GA_488]+N=/OW_3.Z_8]^ FK^/_ !3\
M0I_!.HIKGBF]UF\\36&E^,_%=CX/\1^(-:TBY\/ZYXOUCP!IVLVG@V3QU<Z3
M))8S>*+S2I-9NR#--<M<LLIH>'/V)/V>_#'A?Q3X+3X>W_B31?&_@_1? 6N)
MX^\3^+/B+>CP5X<9[CP[X5TS6?%^O:KJ7AS0O#MW)#?Z/;:'<Z<^G:U:VVIV
M@^TVD,T34X)6<(OSY4WOWW?S)E3;;:DXKLF[+T73^F>:>)?&WQP_9?\ '7PC
M;XV_&BU^+'P1\=S_ !*\(^*_$VH?#OP]X&U[PKXMLO!MWX]\"7<TWA^X.G7%
MKKP\'^-_#%FAM[)&GU'P[:3275[.LS]KX.^+WQ&\-?L7ZK^TC\5["#4_&EA\
M*_B!\<SX7M+(:##9Z&;#5/%W@[P08V$[VLFB^%1H6C:IJQ<M+J:ZAJ9@$=QB
MMN;]C#X#:Y\*M9^"7B/P5XD\5> /$WB7P[XH\1#QKX^\:^*?$&L:WX3U72=5
M\.WUSXPUG6[CQ1&^BW&BV<5I#;W]O MG')8;9K.YFBE]2\(_!RS\-^(OB[K6
MJ:CJGBJW^+NN:?=7_A_6%QX3\.^&=$\*Z=X/T;P?H'AT/-80:/'HUG=3:_N2
M-M?OM4O4D@:/RPN:=FGYWV\^VWR-&KQ:VNK;^5M]_GN?G[\0_B!^UO\ #C]G
M#PK\6-8^.LWB_P 5_%O6?@%#!I/PX^!?A>YOO!4OQ0U_0&\1:1\)(+_5[B#Q
M;I<6@ZM<:58OXON+N\BO+6UUN344:>2QKF?AK^TO^T=\7[CX1? &R\>)\//B
M=XH^(O[1FB^/OB9KOPST73?B5X7\%_ E?#6H>&O#NJ_"J]OKSPMH/Q:\>Z9X
MY\-:OKAMKO6?#5GX6AGUK2B9M2CAL?KZR_8*_9RT[0=8\(6_@KQ4?#VH7&AS
MZ9%'\3?B6+GP,_AG7K;Q+X8TOX:W<OBE[CP!H6@:S:PZA:6_A>XTV&.6*VA2
MW:UM8[=>CU#]BS]GV[\'V/@B;P5JL%OIGB_4_B)9>+K'QGXXM_BC9>/==M5L
M]>\70_%.TUM/'4^L:M8*NE:M<3ZV_P#:6D+;Z:T7V:TAMDU<XR5N5+SY4OR_
MK3[\?9RB[\S:72]]_P"M_P 3YG\>?M"?M"?!K4?C=\&O%7BCPUXW^*^J^!_@
M[??LO^*K;PC9^%;7Q)XH^)7BF+X/:_!J?A==0O;>Z;P;X\.G^,[VV:X(_L?5
M+U-T=G:P.(/@W^V?J?B7]M36O@YJOQ,\%^(OAWXBN?&?PE\":+IND6]GXQLO
MB]\ -/TRZ^(7B;7M8@G>WFT#XD2W?BN#0=%V$Z;-X+A&G75W%J<R1?7T7[,7
MP9&H_!777^&QFUS]G8^)1\(]8OM9UF[U7PH_BW3I](\03B^O+V]N?$$]Y8SS
M7<-[XA?4)UUMAJD0MM2_TP3:C^S;\-6^'7@_X=>'O"[>']+^&6MOXP^&4J3:
MG=7GA+QQ:IKLMCXIBNFNQJ&N745_XCU:YOM/UG46M-;:\GM[LO;2,U1.VEK=
M=K?H7#=GTXL@9F4@@@\ ]<8_R?H1[4R7[R?1O_0XZ\M^#O@!/A?\/_!'P_MM
M7\0>(+7P;X=LM!_M_P 47MUJ?B'7)((=\NK:U?W3,]S>ZE,7OI'W$V33?V:!
MMBS7J4OWD^C8^N^.L/\ EXWTY5K]YH?(G[&O_(O?M ?]GA?M/?\ JS]5K["K
MX]_8UX\/?M 9X_XS"_:>Z\=?B?JM?85:RW?]=$ 4444@"BBH)9!$'ED9(X88
MWD>1F "JJY9CG "J 223CCK0!*YPC'.,*QSD+C )SN/ ^IX'4\5\_>-?C)#I
M?G:5X;DCU._3,=QJI .GV#=H@4 ^V7:<$O%_HYQG:0>..^)/Q3GU>6?0O#ER
MT&DIOCO]10DRZJZG9);0%2&BMEVDK,AVS+C#%2*\,4'A5'?Y5'KTP .YZ #D
M]!5P5[W7WH"WJ%_/K5S<76MS2ZU/>)):WRWSY@OM/NMT-_;R6\F(Q8264D\<
MMLJ+#."(Y496(/\ $#^TM\(+K_@FO_P4<ET^SCGL?@OX^U*3Q+X/G2.1+*Z^
M&'Q)NV@U;1OE)1+GX>:T;N*YB),L%K:6<S/NGF:7^W-61U=RR81 _F,4(55&
M\[C*1"(BH)D:=TB5 6+9 K\=_P#@L%^S+H_[7'[*/B3QA\.OLOB7XM?LTS7O
MC?P_/HT=S,VN>$]0TU;GXA^#K"_$+6>J0WGATQ>(;9M*GO8(M1T=(TD62653
M[F1X^67XU.\G&K91BKN--K1R45I&[>^EWK<X,PPT<3AJU/D3ERZ/E3>SV=KW
M^\^5RRN?,1HY$E"RQRPX\J:*10\4\>WC9/&R3+CC#TE?)G[%7Q>3XM? G0)+
MR_%WXA\!1+X.UOS"%FN+72K>-_#=Y*I/F"2ZT>6U5I7^:::WGY8QOM^M"NTE
M2,%25(ZX*G!'X$8K]<I25:E3J.TN>$9-NSUE%/5ZZZ]?S/S.<9T9RI7DG"4H
M6U3]UM/1J_3702BBBKY8_P L?N1G=]W]["BBBFDHZQ23\M!J4EM)KYL/J ?8
M@$?D>*:RY.XD X"O*W+K&2.%)R268*@4Y&&/'%._H"3[ #)/T Y/M6OH&@:M
MXIU[1?#>@VSW6MZYJ5GI^EPJ-R-=73*T<D^ VVUC@WW$\A 6.!&E9@JDU?MY
M4HSJ.HX\E.4M9\KDE]G5J][;;!'FE."LYN<U#E2<I6?6R3=M=[6\SZR_8S^%
M%UXK^(<'Q)OQ=Z=HWP[G6ZTJ[M;F:S;5/%$ZR)!IT<]O)%<26>G6R37^H1+*
M8FF6V6:-T8*?WM\#_&V=/L^E>+RVUV6"'7XXLXD<[4&JP*H.^4$,)H5547F0
M=Z^/_AI\.])^%W@GP]X&TA1(NDVY%Y=&,K/J6L7CR2:CJ,I899]0NA/+&N25
MB_=#Y$"CNLD\Y//?U'3\1@ ?0#M7XUG^9PS3&XF2II+G45[EDN2*INVBW<;W
M6_6[/U#*\#+!X:C&51RCRWY'.Z7,W/2-W;=[H_1ZVN8[B%+B*:&:%U5T>W=9
M49'&5970E6!!!4KP1R*M5\3_  _^).H>#9HK2]DFU#P_*Y$UL0#)IV]@HDMQ
MRTD2#!\L<*BD "OL73;^UU2UMM0L+B*YM+J,2P7$.=DD?("D,25<$_,.JL"&
M'%>$E96[:;6V.Y[OU9IT444 %>0^(O@OX$\3>(;WQ3?IXEL->U"'3[;4+WP]
MXY\7>&O[1BTJ*X@TZ._MM UG3K2X-K#=3QQO- \@$AR[,JLOKU%.[6S: \/'
MP"\"9YOOB+CW^+OQ+/Z?\)1S0?@!X!/6^^(?_AVOB7_\U%>X44U.2VDU\R'3
MIR=Y0BWW<4SP_P#X9_\  (Z7_P 1!_W5OXE__-15.?\ 9N^&-U=V=_<'QS/?
M:>+@6%Y)\4_B.]S9B[@%K="VG/B;S(1<0 13!& D4 MEN:]\HJE6JQ^&I->D
MFOR)]C1_Y]4__ %_D>'?\,_^ /\ G^^(G/\ U5OXE_\ S4T#]G_P IR+_P"(
M@/3_ )*Y\3/_ )J:]QHH=6J]ZDW;^\RU""VC%>B/$#\ O G&+_XBG_NKGQ+'
M_NT<UGW_ .S?\,]4M9['4QXZU"RNHVANK2\^*WQ'N;:YB<("D\$OB=HY5&Q"
M@=6V,H9-K<U[_13]O6M;VM2W;F8G2IO>$'ZQ3/#!^S_X"4 +>?$-0  H'Q<^
M)0"@=  /%& !V P . ,5+_PH+P'_ -!#XB?^':^)?_S45[=11[>M_P _:G_@
M;%[&E_S[A_X"O\CQ ? 'P$.E_P#$/_P[7Q*_^:BE_P"%!> L@_VA\1"1TS\6
MOB61]Y6P0?%&""47((((&"""0?;J*F52I)IRG.36S<F[?>5&,8IJ,5%/=)))
M^MCPBV_9P^$-I;6]I!X;E$-K!%;PB77-9N)!%#&L<?F3SWLL\S[%&^::2261
MLO([NS,2O=Z*KV];_G[4_P# Y?YB]G#^2'_@,?\ (^+O@R"/VROVT<]]#_9G
MQ_P'P1XJS_,5]HU^>,FO?%?X1_M1?M!^-]*_9T^*/Q:\'?%;PW\%W\.>(?AU
MK/PL2WM=0\%:#KNBZ_I.L6?C3X@^$;^TN[>YO87BEA@NK>5#M#@G(]-3]ICX
MM,<-^Q#^TJ@QG)UC]GDC/IQ\<,UD6?8-%?(7_#2OQ7_Z,F_:3_\ !O\ L]__
M #\*/^&E?BO_ -&3?M)_^#?]GO\ ^?A0!]>T5\A?\-*_%?\ Z,F_:3_\&_[/
M?_S\*/\ AI7XK_\ 1DW[2?\ X-_V>_\ Y^% 'U[17R%_PTK\5_\ HR;]I/\
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MT+3D@T\R Z@4U\->*_'\_P!K\?;M \&1W>I6^F?#W1[^26/QCX7U;2+*&/\
MX6T;W3X;J>^BDGNM07P5I<VG6&F3726>LWM_=6>&]3TW3]+TBQLM&TK2=*TS
M0;*UCL+/0K.P@M]$L=+PRMI5MI4(^R0Z=Y4D\$MC#'Y1@E$ EN #(;.T!B02
MV<_,W#$$EL%02J[2S#<O,@VF4LZAJ6IC*=*I[6FKRLEO_P ,!_'[\4/@^?\
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M'_PK^*J^'_A+IFE:%JEM9/\ "F2TT)K[0I?"/B:[_M/XD6VDMXE2"^U)O/G
M/Z,/*3T_0?X4>4GI^@_PK\S_ !#^U=\?O#O["'A/]H:^^%^C^%?CEXAT7X&V
M%MX(^(6LI<^#O^$D^+/B[P-X//B77=0\!W6HW.F:"I\6R:^- MR=5L$2UT6_
M%A<"[E@^5O%O_!4;XN> _CA\7_@W/H_PF^(-W\(O@G\>];UN]T*P\7^#OL/Q
MJ^ ?PW\*^-=6TN]L=<U[5/$.H> O%%[XBDT[3KVQ\.V=G86_V.33/%_BV^@O
M88P#]V?*3T_0?X4>4GI^@_PK\1]#_P""@'[6J?M,_"7]G'Q3\,/A!>:GJNF?
M!34_B7JN@:[/X5M]<TCXV6?B#7=0\5_!G_A./&%MKVO:3\&-+LM*TCQ#I:^%
M/$E[XYUH:F+.]\'S"WLE]*^)W[>OB[X;_$O]J[3M=\7? _P1X'_9HT2&&Q\)
M>-?^$JUOX[?$?5-;\!>#O%FA_$_P]X3\,:AIT5Y\'[34_%W_  CERVE:9>23
M3Z%KEUJ_B+PZEA=SQ 'ZW>4G^0/\*3R5]3^2_P#Q-?@;H'_!2[]J7XB_!;1_
M'/@3PC\!K?Q1H_A7]MSQ?X^NM9O?&%_X7UW2OV-==\!VT=M\/X?"NL:S;V%]
M\3=*\97*I)J'B3Q%;Z!/;V][8WGB**WG@C]Q3]NSXVVGQ<U[5/$&A?#?2?V<
M[+XH^(/A-;0QKXXU'XKZ?=Z3^R/+^TW'X]U!M,231]1T6PGTS4_!]UX2TG2F
MUG68;NQUO3]1-W:S:;* ?KS*I1@JG ;@$H&VX21B6 4$@E5'RY(&<BB,%HT9
MBA8J"3'@IGOM)4$CTR ?6OYJ8_\ @I;\;_C1IGPL\56OC[X'?!^]\$_M<6/P
M^D^)GBC7=3\.? GQ9X&\>?LM^*/BAHC?$7P_;>*-=U6V?3]3>PM++2;OQEHM
MU-KD.C:AJMCH-REUHJ?1/@S]N[]HCQU8^%=;\$^%/">@_$;XT67[$WAZTT#X
MD>(_'&M_#7P9?_&V/X\)K_BG2M(TU-)U.:QGB^'6G:UI7V*>PNO%6C:AI,^J
MW$$C+=N#5NJNC]T-H[]._"]/RJ.<[4!A"L^X<,/E*X);+*K;, 9#, N0%SEA
M7X.:I_P5*^,=OIOP]U%_#_P5\-ZII_@;PMXL\;>"O$.L^+E\3_M#>(]3^/?C
M7X#>(O 7[*EBKK<7.J:1>>#)?$SQ:O9^,;[3O^$J\,:-JMGI]O%/XC'@/QD_
M;S^-^J_!?2OASX:\;>$OAC,^F_#7Q9<^*/B!XY\37WQL^+$GC+]LK5?AC<^#
MO@5?Q75K_:]_X)\-^'X8/&27&G:^A@\06FB,NF:8RZV0?N?R_=8_I@B99!PQ
M/"N"8U3*/G:=N"RD[2"&P1CD<U-M'H/R'^%?C,/^"C/Q(TSP?^VAK&K:7\(;
MCQG^SW\0O!^@^'/#OAO4=5UGP%X4^'?C_P")=Q\,O#?Q0^+'Q2T?5]<LM5TW
M0+*TNO'WQ$\-:7I'@;Q7X)L=!U70=6TA;2ZM?%38W@K_ (*'_&3QAXI\"_#6
MY\4?LK^%;V\^)?Q@\+WW[1&N:_XC@_9[^,NA?"75/AE#'I'P,DN?$5I]J^(/
MC"#XCS:?]AN?&&OZ5H6I>!_$\NDOX@A0Q1A.G38_;811D [%R0#G SGUI?*3
MT_0?X5^+/PX_X*3>,-2T[X7_ !'^)'B7]G7PWX ^)7Q^O_A=XK\)Q>*M4L/&
M_P"S+X?M_#'QAGT73OCWJ.LZI'INF^/]<\6_#?1]%MH+W2_"=K>W?B"[T32K
M#6;R'1[NY]:_8^_;#^/7[4?CSX=7#Z%\)/#WPGO_ -F#X/?''QQ/9'QAJGC3
M5/$OQEU/XD:7H6C^"V-W#X?T[PEI*>!+?5;S6=9_M+4=4@UA;6TA5;8WE 'Z
MF>4GI^@_PH\I/3]!_A7X P?\% /VE?"_A/2]8\)Z7X'\1^#/!G@._P#B]\4)
M_B'JOC/6?B!KNCZI^V7XQ^ :>%O!FJVXM;'3I[;P_8#5].N]9M;V"RFTBUTB
M.W:PO6O(?WOTRY:ZBDD8N?FC 8D-&P,*.#%(,+,/FR\T:+"[DB'<BAV +_E)
MZ?H/\*/*3T_0?X5)1D<\].OM]: (_*3T_0?X5%-:13! ^[".K@#;ABIY5@5.
M59=R,O=68<'!%FB@".*)8E*J2<D$DXY(54R H55&$'RJJKG) &34E%% !4<K
M*D;.[!%4$L[$!47&&=BQ "H"68DC !YIYZ'M]*\M^+6OMHO@K4/(D=+S5U&E
MVPC8JZBY63S77&2 84=&Y'$F.M-*[2[L#Y;\?>))/%OB6_U%L_88'ET_2HR3
MM2SM9##]H )($UQ*DDC2+M#1F,!!C)X]5;Y=JM(,J-L2[G+?=6'&0 \A_>;R
M0JJ#D=Z3C"#:%*HB[1T5%1510?0 'N3U)Y.:X?XC:WJ>A^$=0?0=,O=7\1:K
M<6_A[P]IVEWNF6.IMJ>N_P#$K_M.TGU5X;5$T&VO)-;O&(U&<V6FW#0:8[0^
M<-P.5T_[)\4?'9UF==(U'P-\+/$;Z?X8 M=:M=9E^-OAZ6ZL]6UAI96M=.U3
M0_"FG74^D>'TL8KV.X\32ZMJQD^TZ/;RK[$3NY;Y@69P"3M$C'_6J@(1)-I*
M;D4;E)W[V^:L;P]H%MX7T#1O#5IJ%[J]MH6E6&D1ZKJ,YN+_ %86$:)_:>H3
M[4%Q?WTZO>W-T8U>6XGEEX,K[MF@ H.%4N2, XQT)/UY_EQ^/!7?> ? %QXV
MU M,[VNB:>Z-J-VH/F2D@.ME9D?<NG&UV?!Q&1QV,N23M9@9OA+P?KWBJ\":
M1:Q^3 ^V]O+]2FEVT4H"2H_F1R+=W-Q&R+):!"DL,<8?:N[=X;^S7_P2)_9/
M_9P\1_$O6[/2M9^($?Q+^)&M_$B+PQXUOH;CP#X(N_$$EO++HG@SPO;116TF
MF;H6>2?5Y=3W206T")"$.[]6=)TC3=(TZVT_3[..UM+= (H0@!ZEO,E_O3.2
M7D9N2Y/08 T!!"N[;&HW=0!@=0<8Z 9 .!@9YQ3ABL11YOJ]6=/FNI)2:33O
M=7B[JZ=C.I!5TE6A3FH_!>-[6^&]UTT^[0YO0O"GAGPQ:0:=X7T+1O#VGVT8
MB@L=%TVPTRV2-5PJB.T@BP%'0*0#W!'%;H3:26>0YZ9E8]STW9 QGJH!]\<5
M8\J/D;%YZ\5P/Q \8:=X'L=$O+R2*%=6\3Z)HGS\DP7]VL=[(HSUM[/SI\CD
M%!P:YYN<T^91D^[G4;^^Z?Z#C%QBXJ%)7_EC9?E]QU6H:7I.K6[V>JZ;I^J6
MDJLDEKJ5K!?P2(P"LLD5TDL;*1U!7D9X-?$/QG_X)^_L[_%A-1NM/\*1_#OQ
M/<PN8_$/@=4TU#,XZZGX>_Y NI6A;DK':039)Q< YS]VVZI)$K[?O;CSR1\Q
MX^@Z#VJ7R8N/W:\'<,@'!_'^73VK>AB\5A)*IA:CHU%HY*I4M:Z=M-]5U373
MS6-;#4\13E3K4Z;3VLM;];W2TM\S\E/A3^R+JG[,.CZX-0O[3Q==^(-026]\
M8:=836WDZ7""-)TN2T(>2QA23,][+YTL;R8?"C@>D#&SG!;/RNC;XY%[E6P,
M%>!@]<GTK]';J""6WFBF@6XAD1DE@=0R2HW#*ZMPRD=0>H%?'OQ.^'C^%W.K
MZ+#)=:!<3SR21+Q+IEPQRR@C'^@S?,;91G:4/)!JZN+K8B;JXB7M*KW:>_5[
M]WJ5A\/2PU-4Z4>5;OS??[CR.E))"C/W-^WA3MWC' 8%<AOGW$%F_P!5(7@
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MNIM/ /UT2SBTV=KM2TAN ENR!!D<DKY?)$<8(7=RFXEY;F2>0HT>A;OYRNX
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M7&LSJV1@XA10HSG)&'P!@8QW[>ZUX?\  2Y6;PE?1$@RP:U.)<   S6UK,O
MXYWD\?2O<*QE\3_KH 5\8?M5^ 9;NUT_X@:>FZ71PFGZ\%R96L)W LYXX4B<
M2+%<,//9F7RX@6+87CZHU'Q=X<T>Y^R:OX@T?3+DD!8-0O;>SD8D C8)Y8P^
M58'Y>QJ22;1O$.GWEBMS8ZQ97MK+;W45I<VUTTMO<1M&Z'[/(5C!5SY<ASL8
MAP<\U(/8^+OV:?BN;&ZM_AMXCO$^R3R.?#,\Q9GMKK!GETV[NY'(DCG&/L6X
M+F=A$J=#7GO[3:3+\5KWS%(#:%HSHPN5N'*>3<1S3>2P06KQR.8=BLZL(P^5
M+8'&_$SX?:O\+/%$<<<CC3)+B34O#&M1M)Y!5)3<0))<2KN?4+"X54DBF.PP
MC,>0W/0_&S7$\7V'P[^(,/FI+KWAB?2]77]QNBUKP[<B.]@D\E=RO+-,DXC8
M;1$ZH,@D'=)1:DM-[?EU[JZ_R,>:7?\ (^I_@WX@TWP=\!=*\2:W,J:9;+J-
M]L^U&ZNIW>_N?LMM;9$:K=3S+Y<=HN[;C(8[R%^*=;U7Q/\ &+Q]#(S^=K&O
M7L&G:9!-&XM-/TZ&5FA.R+>+.*",A=3G4$[@0V>E=W\6?$$NG>%/AO\ #*U.
M8=$T*UUW7DMD +:UJ2O=V-J54 K-!YJSJO\ $+@9XQ7T!^SA\*+CPY9GQYK\
M#6^K:U:E-(L6C9&TK3) 6N)KWS2(UNK]LNP(&$*XX)-2VX>]%V<FTW9/3?JF
MO.^A<9-O5]/U/I#PAX9LO"/A[1O#]DA2WTJV2VC#!'9Y>LLV\*#F1B3GC"XS
MR*ZNN2O?&'AW3B#?>(M M6[1SZOIL!..V'N7DQGCY%))R%4FMC3-3M=5B6ZL
M;R&_LY QBN;;YHGP1UDP%..=A0889/:LVW)W;N_E^A9Q7Q<MA<^ ==!4,;>*
M*[0D9VO;SQL&'H<$C/8$U\0 ;0%]"PS_ 'L.WS$<X)/)Y//<U]S_ !3N$MO
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MRPALKCQ+KYT^RT==:UEXBSWNI#2M+TW3!=2NQ%CI]G:QA(+6%%[.B@ HHHH
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MG/=Z8RR2W=P([Z&>990J_6WQ/\8^*;V<:#X"^&1\97P4"?7O$&A";P]:S,2
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M#[$)P/+/G3R2]"3\[L[,[D*6DED=Y9/E \R1R,[B3++(J2B-DP&4,[;BL?!
M!; RJKQ\^=@; .3C'P->_P#!17X6V'CV]\#S^ _BX=,L=:F\(GXIKX-A3X77
MWCZ+X,V'Q]M_ FG:S+K2:M-XAU/X9WIU2U:71X=)L]4AET'5-4M-0C"R^'_M
M%?\ !1/58OAYX8E_9K^'WBGQ5\1_'MW^Q?>:=_;WA32]1T7PGX(_;'UO4;?P
MGXEO=)N_&_A6'Q%JNE:=H.KVVJZ7;:[%:Z3JKV3373VADN2 ?KFNXJI#'! /
M*\\C/.<'/U IQ&0!D\8[]<>IZU^:-K_P4[^#::I\5/!EQX6^(EQ\0_A-J?P^
M\.KX)T[2/#NL>(/B;KWQ-\8ZG\.?!6F^ 8= \6:SIL.JZYXST35;270_%.J:
M%JFC:?:/J>I6T6GJ]U'#X?\ ^"C7F?%?XG_#WXB_L]_%CX5:+X&U#]EOPSI?
MBKQ+%X6O9=1\:_M0ZPWAGP_X=U?0-'\47E[IDFA>()8$OY[2748)=-L]6NXY
MA)%8PWH!^F>W&<'!)R3DGGV!X ^F.G2C;SDDDXQD$CC/3 X_'K7YW^)/^"D_
MP9\/:NNF_P#"(_%+4;'3Q^T%J7CGQ-9^%(O^$8^%O@S]F/Q1'X.^+'C_ ,?Z
MK/JD*V'AC3]<N+.'04TJ+5M>\3QWB#2-%FGAFA'J/[(_[:GPL_;)\.>,-?\
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M>%UOI_C+XFT32+7_ (2G7-.O/+@T'2_#_C*Y$DWA%I[HW-M>+9V\L^I"XB2
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M1;RQU"R\27&D:I_PCFFVWPQ\0R:&XOI].UK0YM80:K9( >W>/OV/_P!D/1/
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MO5UDT7Q+++\']8N=8\"7*Q75L-:&HC1H9-2BLK6'PWPM^T1^VK>?!_Q_XC\
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M:?\ :97AFDAF@PA9Q.SJQ6>/>8Y(@\FRZB=85F#37%NI#BVF;)-;= !1110
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M0O&&F64WA9[GQ##H-_<6=M9ZY#)XDL=)=XK"\BL9##P7@G]@B;X5Z]\#M?\
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M=VQP/^6<<0P@(.=B1KO?)+LQ ->D>"?AGK/B^59YTETG0_,C:;4)@R3W*?\
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M$NL3W31:5XO\,:?X2UZ"ZFD5I)[N\TC3K:*/53$-0L@MQ%:3):S_ &4?:-%
M'QE!^Q!\";+7++Q!I_@J32;[1[W1]5T6VT;7+BTT;3=9T>[@N[75[33#$+6V
MU +;MIMQ);V\-G<:5<RQ+IT5S//<KB:1_P $_OV;/#;Q2:-\,H62"'7+6&VN
M-?NKFW_LWQ)XE?QEK&G7%E=POI]Y%)XA6._LVOH+V[AO$MG&I00PL:^Z** /
M@G2_^">/[/.F2ZC/9>&?$.GOK>O77B+7;>#QQK4]IK-W=PPP&TU07)F;5M+M
M!;VMU8Z=?AH8+^V4RR7=FL,"=):?L,_ :UT*Q\-/X3U6]TO3I-%GL/MWB[6;
MF>WE\/RZ1):-++]HBENFU6+1+*V\1I=27,6L6PN-.D,&F:A>V[?:5% 'CWP5
M^#'@_P" O@W3_AO\.M*BT3P/HIOWT?2P[2R6K:A>M>S(),C='YDDA9Y \TC$
M*62.&,2>PT44 %%%% $4[M'#(ZC+*A*C /('&<D *#RQSPN3VK\]_C%^U_XK
M\"_M.Z-\!],F^#?A'P]I/P@M_C;XT\5_&#7O$&C:EXQT*\\3ZOX<D\(_!G2-
M%@F.O^)?#B:'=ZEXCN9CJ!@;4="TVVT66:]EN(OT,9592K ,K A@1D$'@@CT
M(KD]9\ >!?$>I:'K/B+P7X4U_6/"]S+>>&=6UOP]I.K:GX<NYEC6:YT&_P!0
MM+B[T>>58HA)+ITMM(XC3<QVC !^*'PE_P""IGQM^.-G>>'OAQX ^"5[XVU?
MX_?!OX3^!?$^OZUXNT#X>7_A/XT?";QW\5=(\5:OI$<VK^-;?5M)L/ D]LGA
MZXCT;5M<36K&273/#\]M>6\7167_  4D^-_B;3/ GCK2_A+\(;/P)I_@+]G+
MQK\9+75/&7BF7QC'J?QI_:)\<?L[:KI'PN2VT=-%G3PWK/@@>,=(U#Q5-;R:
MIIMT-$EM;>^62=/UZT+X3_"WPO&(?#'PV\!^&XEU'^V5B\/^$= T6-=8Q=*-
M75--T^U5=51;Z^$>I "]C%[>!)U%U/YFO%X&\$P6YLX/!_A>&T:*Q@-K%H&E
M1VQ@TO4)]6TR#R$M!%Y.G:M=7.J6,6SR[34KFXO[=8[J:25@#^?/XU_\%//B
M+XMTG]I?P7X!U/P!X3B^%>I_"'QI\,_BSHGB77O".G2>'5_:^L_@/XI\+?$[
M^W99M<TNUN[KP]K,>M^)7T+P];/I%U>QZ5I6J6$EAK=]Z)J?_!2WXIVJ>*_&
MW_""^#O$'B;X4^"OVM-+2+PA\3-1/P(^*NO_  :^)OPP\&:#XL\/3OH&J:]-
MH&MOXR:QEUJ2ZN#X7U31_$6C1+JT;0W4?[6I\(/A+'/XCN8_A=\.H[CQC</=
M^+KA/!/AI9_%-W),+B2Y\1RKI@DURXDN%6=YM3:ZD:8"5F+@-5JP^%_PTTO2
M[31-,^'O@C3]%T_3;K1K#1[+PIH5KI5AH]]<I>7ND6.G06"6=GI=Y>1I>76G
M6T,5G<7BBZFA>X_>4 ?C]XQ_X*1_'/PKJ6L?"S7/"?[-WA/XK>$?B+\>?"?B
M;X@>./'/B[0/@'J&E_!KX?>$/B1::/X:O9+9?%47C_QSH'CFRM++2M4D6'36
M\,>*M8MX=9M(K6T?Q/XG_P#!2GXLMX>^)[>"K+P=\.-3\>_"V\\?Z9JWQ\^(
MFI^']!^%/V3]CGP'\8#X$\,?V/X?M+C2?B3JVN?$".#0=,N[G5%>7PYKNOSV
MLLX&DVW[W^(/AC\-?%MD^F^*OAYX&\3:=)KMKXHDL/$'A/0-9LI/$UE&L-EX
MB>UU'3[F!M=M(D2*UU=HSJ%O&BI%<(J@"37?AQ\/O%$;Q>)/ O@WQ#%+J=GK
M<L6N^%]$U>.36M.LFTW3]7D34+&X5]4L-.9K"ROV!N[6R9K6":.!C&0#\:/B
M?^U/\5]!_9[_ &&=2T'4=:\"^*=1^(O[)%EXH^,_QVU>V\+_  7^)\'Q,^$'
MB/4=?L]1\7:+K%]K.K6;ZJ+2_P!=L;K2_"QNM8TNTM(+_P NY$U<G9_\%=_%
M#ZA^S$__  K[X;W&J?%O5O#/A_XE>%QXC\064^DR>-/B)XX^%_A;Q_\ #SQE
MKW]F:!>?#/Q/J?@6;Q/H$<.E>(?$E[X9G-_KEKX>LH+74;_]Q=<^'G@/Q/HJ
M^&_$O@OPGXA\.)%'"GAW7/#NDZMH"110FWA1=%O[6XTP+#;LUO%BUS% SP(5
MB=D-*X^%/PQN[SP_J-U\.? 5SJ/A+3HM(\*7]QX.\/3WOAG28 HATOP]=2Z>
M\^BZ;"$016.FR6UK$$18XE55  /PI_X>]?']M+\%:#I/P4^%GB[XN:IJ'Q3N
MO'/AO1O$=UI'@SPF_P .)? 4D/PCTGXB>)_%&E>"O&'Q \16'CFWU+1_'?AO
MQ)J7@FZT2W75I='M+A+[1[/T_P ,?MI?%[XX?MW? ;X?VNN?#OX>_#NW^)7[
M7_P[U+X0Z3XUU'5/C!?7_P (/ .E6NG:M\9?"42II-IHUUKUU-XN\'3Z5<1R
M6.DG29_MFI?VU,UI^N\GP2^#4VCZ;X=F^$GPPE\/:/J[^(-(T&3P!X5?1M*U
MZ1F>36]-TQM*:RL=7DD9I)-2MH(KUW9F:<DDG7C^&?PZ@\1ZAXQMO ?@ZU\8
M:MY7]J^+;;PUH]MXHU(00?981?\ B*"TBUB[$5J3:()[V0+:DVPQ S1D _GD
M\)_MK?MI_P!B_"_XIZMXJ^!/Q \2>%OAW_P43\:_%'PE9:OXL\&^"+S1?V>?
M'^@1:1H/B/0M-T^[O[7XI6'A>TN]-TR]N+>WTO3+;4;/4M:M)9KT%OHF\_X*
MI_%Z]^*?QKT;P9^S]H.H?"WX0^!?B!JUQJ.O>,=*T3Q>NK>$?V?8/CEHGBV\
MLY_$"WNH?#SQ+?WMOX+^R^'_  AJ&KV%N&\5MJEQ;&XTVS_92V^&OPZLVU1[
M7P%X+MGUR76IM:>V\+:';MK$WB2."+Q%+JABL5.H2Z_%:VT>MR7?G-JJ6UNE
M\9U@B"17'PM^&5UKDOB>Z^'7@2Y\2SZ"?"LWB&X\(^'Y]<F\,&%[<^&Y=6ET
M]M0DT#[/));_ -CO<'3O(D>+[-Y;%2 ?DJ?^"DGQ<\(_'[]FOX"_$+PK\%]5
M\4_%F;X:Z5\4=+^'-_XW>?X<:I\:/#7BKQ7X N-$U7Q>ND1^,(+>P\."VU#3
M="T35;B] O-5U"\\(0?8;*[\U^%?_!2KXI_':U\(V&O6'PDM;;QE)^R?X]T^
M_P#V?OB-K6N77@&V^*_[2.A?"#7?A%\8+_5=$N;:U\93VET=<CT&TATN;6=,
M7Q!X>*VS:='K=U^UNJ_##X:WVK6GBR\^'_@RX\5Z/I?]D:-XID\+:-+XFT;2
MPLD<=AI&O"Q;6-+LH5FD\J#3[J&*W#LT4:D5P_P<^ ?P=^#'@O1OAW\/? 7A
MW1?#VD6VBI$G]BZ?-JFIS^&([=-"UKQ+JSV45]KOB+3_ "8I+77]8:XU1;I'
MEMKI75I& /R*\+_\%4OVA_%_@#XV_$'P]^SE\.M#T;PRT-YX'N?&OQ,T'09_
M#=I;?%?5? ?B32?B=H$_B]=>U7Q?I7AS3+_QW8^']$L_"+ZZEK/X7TF2XUMK
M6*;]G_@_XWTWXL_"CX=_$O3-4L-8T[Q_X+\+^,++5M%L=8T;3-1MM?T6QU2*
M\T_3-?BM]?T^PNTN1+;V&N00ZG;VKQVVH1"Y27,E]\%_@]J0\4C4/A1\-+X>
M.KN"_P#&XO? ?A:['C&_M)EN;6]\5"?2I!XAN[:X59[>YU;[9-#,JRQNK@-7
MHUM;P6D$-K:PQ6]M;QI#!;P1I#!!#&H2*&&*,*D444:K''&BA(T540!5  !*
MHVJ%!R%  )P. ,=  !^  ]!2T44 %%%% !1110 4444 %%%% !1110 4444
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M5]=:)X#\*: 4_L_0[*.3(/VBYC:YO'([O+(K #L#P",9Y-=N%4  * %&%
M4>P' QVQTJ.:7=@>+>$?@OH.BM%>:V1KFHQ[702Q[;""3D[HH2"9'!Q\[L5!
M'W.37LRPQH%5$551=BJJA55?[JJ!A1VX ..]2  9QW.?QHI;[@(JA0%'  P.
M2>![DDGZDYI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !O ,0# 2(  A$! Q$!_\0
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MCR$&U7DD=@B)& 6R><X/H/;J0.,@U^:_[87_  5$_9X_90U[3?@ZI\5_'_\
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M97<FI/-;PZ=]GN)?MLTJQV_F,2  =9135;<,X([$'@@CJ#3J "BBB@ HHHH
M**** "BBB@ HHHH **** /Q<_P""L?Q-^/MIXI_8+_9:^"GQL\0_LZP_MO\
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M4-/F.^, ]<_X(&RBT_X)<?L\VTD<BNWC#]I5MK1LAWK^TM\7BZ!7"G<GS#.
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M'GP[\9_&3X@Z=\,[.WO_ -G[]I6+X?>'M2\37?A?X[? 2\E@\%ZO<:_#I?\
M9J^-O#,&@>+=/N;U]1-Y=2JQ?#_85_X)]:7^V-X _9X_X*%?\%%_B9K/[:WQ
ML^)OPY\ _&SX8_"_QK8P:%^RG^S:GCK0].\7:9HOPK^ MG+=^&]3\1>'X[^.
MSE\>^/5\3>(+N6W6>U:P:($_IO\ \%)AG_@GQ^W#C@G]DO\ :"&?I\+?$_4^
MV>,>_M6+_P $MN/^";7[!*]Q^R!^SP/^^?A9X8!_7I0!]R06%M!%:Q10PPQV
MD44$$,$:1V\,$"A(;>&)%2..&$!?*CC1%B"JB*J +5W:/3U_#/IZ<\_6EHH
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M:WMF,?VF6 2(S?FK^U#^U3^W=\1OB?\ $O\ 9U_8B^"6C_!#0_A;(MI\8O\
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7,;'  +J&( Z %LD#O@<9)/4DDH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? FX# 2(  A$! Q$!_\0
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MKYN!<37T5M*) ES)%%#+MB.X%4?[&\)_"?X9_P#!/W_@J)\(]!^'_B'XKO\
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M8&68EB<#DDDGJ233J_B4_K\**** "BBB@ HHHH **** "BBB@ HHHH ****
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MXKO?B)X<\1^)/#=K?P:[XL\9+8#P+_;(M3%JUWX=.H'4[G3+E=05F>0*^?\
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M8UVR^'.J>%+9)[O3/%T.JZ/#:^(+;8SZC#<VT+VLTD+Z==+%YRL_>:5^U?\
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M\I>TCKHM-SS,YR^GFF68S U81J*O1:C":3A*<;R@IJSO!R7+))7<922UM?\
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MYCB ;!W 5:I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGQ&\'>/=3\'WDUCXFT[PYK,&I3Z;=6TSVL]LYA.UF%ZOV1;E=UH9@Z&4,K
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M\>F0$R?>&G?MS?M&:'_P3]^(G[0_BWPM\,-:^)?A3QE:^#O#7B#PAXFA\0^
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M\4:Q\'_#UO?>,?A2WAZ73K.\TCQ;X@\;0:UX=TR6Z:\DO- TW4=0\/6MU?\
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M (/:5-KNC_#KX7>,]+BNK?5([>TM&3PUKFGG4)/'&C&?6-.M(#;3H.G^%?\
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MX+W7M"LM6TW4@^G6?V^:'3((4TMY[BT5$KP+X>?MW?%OXU_MV?#?1_#7QD\
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MOXI\9R:W>65OHFNJT::7;K>R+;+/J%Q)7*ZC_P %#?VX/"WQ _9F^%E_X/\
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M'@+5M2UC7OAJ-,:TTW3(KR!;?4I+."V>VN9)+!)Q9FUFBN #U3XN_P#!-/\
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MA:]X$T6^CN/V6I]&N=&\#6=IJFD0?LV^'[K3IWT^9(UD&H^(M3N%U-+R Q/
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M^S5^U=^U!8_M'^-?$^L'0I?@=\9_VI_A_P##V[^%7B,:Y<?$7P)XC\:?L_\
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MHUQ/"]\/$.FWMQH-PVI11 :SX?GLKZ.PFU&U&9+N*YM0#C]>_;J_X)_?#?\
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M8= *_82ORG/:*H9UFU&+O&EF.,@M+:+$5':WE=KSM?J?L.2595\GRNK/XJF
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MOI?BC1?B0ZS:EXMTK7[*>T%S(@T.+2HTP0#O]6_;8_8)UGQ9H'PNM_$/P_\
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MW8_9>&<11Q/#^45*$N>"P5&FY-6?/3CR3CY\LHM)V5TT[:A1117@GNA1110
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M/^NYX+ANM,_8T\,Z5JVGS6>K6?[.VGVFIVSQA7M=2_X5A$][&2V,2H9Y4._
M4B0-NV;7_P NK_@G-\*X/C3^WC^R/\-SI4VLVFL_&WPC)JEC:H)9O[ TV;^V
M[C4BCK)"+:UCMD>Y:9&C!<YVYX_U(_VROB#'\'OV0_VCOB%-+' /!OP8^)>K
M6FY457;3_"FKR6%F @4*;KRH;-'0"2,RK(N'08\GQGJRQ>><,97A[SQ=:KAL
M5+$8CEQ,K5,5A(?5HTX<JA#E5502MRS:E&,G!(_6O"FCAZ/#^>8M47@U"I4H
MU,1.7M:LE[*HY2O+5Q7-%Z.UI7=DFC_(N5+'4?'-]::[,VGZ+J/Q!O;3Q#>Q
M!O.TO2+SQ08M4O8HV(8O9VDD\J*3DM'@G)-?OK^U?^R7^PAX'_9+USQ9X-C\
M)Z%XCTGPO9ZAX'\8:+XAAO\ 7_&FN[(1;6%Y"+R9=1CU&5]NH"*",Z>2>556
M4_B1\"_@;\6/VI/'EEX ^&'AV#Q-XZUR/4==UE9[N*UTK3M-N+JXNY]6U:[
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M/LEO!_Q[^7(9/,!RS*<5_I*_\$:F:'_@E[^Q5&P0J_P7T"(QR!@[)%%?!0H
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M<12Z[:Z%>VVDR2+(RV7F)Y[@'Z\T444 %%%(S*JLS,%5069F("JH&2S$X
M)))P!R: %HJE9ZEIVHV[7>GW]E?6J23Q/<V=U!<VZ2VTLD-S&TT$CQK);S12
MQ3H6#12QR1R!61@+@(8!E(*D @@@@@C(((X((Y!'!% "T4R22.&.2661(HHD
M:2661E2..-%+/)([$*B(H+,S$*J@DD $U#]JB-RML&3>1)E78QNQ18W/D(R
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MGPU@MEO;^#4[7Q$TEMH@OM2LK6\T[1)-7U&&33M,36Y])^UZ@T>G6ZSW>]0
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M:OX6\2>$8TOKW5;K5=6D%Y.@L$MX61(_SF^"'[8/[5_P6\%?$OPA\(?&.O\
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MHETWC)[[P5?ZE)I-L+Z!X5TM%NTS-8\,_M[?MX>,/VA_"WAG4KCX<_!S3D\
M_#_5)_ /Q+T?5[*#Q_HOB+X2W'B?Q/XUT:_M_#6H21:KX;\<RPV;V-OJ.GD:
M? ;.YTER '^_M$_X*2_"NW^+NI_#KQ9X8M/!?@[P_<_%NV_X6/>7T+:4^E>
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MVT\<5E<73R6<TY5U_</8-_F98':5P';802#N,>=A?C <KO"Y7.#BGT ?C/\
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M6=&4,,LN2;I*.(]HU.25KTXPC*-M)-GDT]S+/(9IHH /->=@GF1J&9"K-E)
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MCN1%%/))'OGG-Q<;H;6VM9,2SW#G]T@=F8 9KSB61G,AWNQED\UV8_-NW;L
MC "]L8SMQ@YYKU/X)_&/Q=\!?BOX#^,'@22RMO%7P_UF35M)-Y&)+*:.XA6W
MO-.O5??NL+B ,KKR5+%CN4;*]+BI<4X;@K-,9POA<NK<7PR2O5RS"8ZHO[-E
MG;P==N&(FH_O,-/$^SA44(QE6I2G"-G-6_.J4,CJ\34::Q^(P/#5+/:U2G76
M$E4Q7]E8JNH5'*CS<T)/#5*BE3YVXW=I'N7[5G["7Q\_8RE\)3?&6PT671/&
MD4[:+XI\+7_]J:$=0LTW7&B2W!5)QJ9!\]-L!MA!&^9LD./H?_@BO\<+_P"
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MRQF2PG1=+%.FZ=>7+5@USTW*3BK)7;D]6WJDS_9:(;*[2H4$[P5)+#:0 I#
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M6! N(PQ5UD#R%I93(BE%D:60O([JA*!V8L$^7..*L44 %%%% !1110 4444
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MWE25+X[M_$?!?]H/_@L;\9_ ?[4OQX^$WQ7^,5[\./A3;_M0>*=7UCXA>'_
M[>#?$OCCX-_&?^T/ _PQ_9]_LP0ZK<>'-8^&D>LZ%XDU#68)9#J-I ;#R(XU
MB?\ ?#Y(_MC!!Z$'KT/H<'\CP?0\4M?R"?%C_@H[^T/\</V(/VPO^"COP5_:
ME;]G_P"!-C\5?@;X;_9MTK6_#V@6HUK2/"X\,K\:M)TK5=?6)&E\7^+M2O;2
M>\M/[2/]GZ->QV\T!,LLG]7_ ,+?$]KXT^&W@+Q99:QI^OP>(/"'A[5/[:TJ
MZ@O=/U*:ZTNVDNKJTNK:6>":)[HS?-'-*H8,N]B": .\HHHH **** "BBB@
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MHTJWD!=K5+NX^UVUHY?/F6T4T*O'*F-L3$LJQL6RQ(%>%_MW_M%?#GX ^#?
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M_2+>QBAFO;34-.OM2AL[V+4;2S%E=++%<%1%(Z_'J?\ !(?Q/<Z=X5A\0?M
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M->>)9PC?8;*VM5N)[.W$C(AU;46)ATUV;9YC*I1C7NO_  4U^!5I^S3^WO\
MM/?"739$OM-TCXJ>(M=T2/*EVTGQ4R:M;0%E2-1Y%UJ=](=L:KY0@  ,9)^$
MK6:[MI[6\TZ\N;"YMI[:YL;ZWN9+"YL;VQXCNK:ZA>*47B@C]]#)&695P4X)
M^USK#YEQ7X>RCD&9?ZMYIFN5XNE@<?17ME@L1BL%B*.&QKA://+"UJU'$^RT
MYW14&US:?(X26!R3B=RQU&&(PF!QU%XG"U5&U>%+$TY5L,[W7)5A3J46]4HU
M&TVE<_>3_@IQ_P $MO@I^R%\$]%^+GPK\9^*;6ZA\1Z;X3U?PSXRO;2[N/%4
MNH!(KB\T806MD\+:=N-Y<L8[B-K<; R\N?Q^_9_\+7/BGX^? +PY8I))J>O_
M !E^&^GPQJ-V^1O%>DK.J(%)R(CE?O$-S\W2L+QS\9_BM\7#I,/Q3^)?CCQ[
M;:3MM="F\4ZW+?QZ0J(()E@@4K &GA00O/-#),T8PLH.6K] ?^"-OPIE^.G_
M  4[_90\+11&;3O#OCL?$C5@B@A-/\+VIUF1Y'*2*D0>.S"AD!#A_+?S&3;^
M/>"W"?B5X9^"^/R/QBXZH^)/%E+.LZQ5/C2&$C@<9A<EJ4,7]2P=.DO>J^T_
M=TZM/F7LXRD[RM9_;\89UP[Q7QMDKX0X?CPIETXTO;T</!>RJUI3@HP4HMJ4
M92Y8\UU9/96L?ZING6\=II]C:1$F*VL[6WB+$%C'# D:%B  2549( !/.!TJ
MTRJZE'571AAE8!E8>A4@@CV(I"@)C(+*(R2%4X5LHR;64#E0&R!QA@I[4^OP
M>4G*4I/>4G*]]7S-R;Z6=Y/\_3^@H1Y80@W?EA"+?1\L(QO\^6_SL5[>V2V5
MDC:0H6=PCL&"-)++-(5.T-\[RMD,S *JJH4 YL444B@HHHH *0@$8.<<=..A
MSCZ'H1W&12T'_#]#_7H?:C^NWXAOH]F?F9\5O^"4/[(_Q:^*[_%[Q+X+O3K]
M_J2ZMXBT[3M8N;30/$U]YQN9KG7-,DBO&NY9I%#2,)LRS2L2JCD?7/Q9\8>!
M_P!FGX!>-_'E]X;#^ OA3X$NM0N?"VAVL4BS>']$M@B:)IUE<_Z*L#0226D<
M,^+8)(TDS)'N8>\@8 &2< #)ZG'<^Y[UY#\?OA)9_'KX,?$CX-:CK-UX>T[X
MD^%M0\)ZAK5E:PWMWI]AJJI#>S6UK</';S3FU\V.-9V\H,X:174%&]G->).(
ML\PF68#.,]S?,LNR:C['*\OQ>/KUL)@H6BN6A3G.48>[%0NOLI1UC[I\[DO"
M?#G#V)S'&9-E.$P&)S6M]8QU6A3495JNK;O;W5)MR<8M1YFY<J=K?D_^SG\?
M_P#@F=#\-/BOXYU/]GGX'?LK_P!F>-/"F@_$72]:\&?#M]#UKQ?KGAW3?'&A
M-I.M^#;*\T'Q4=+L+BUUFXET*2:/P[J"&YN7L=72Y,/W/KW[0?[%?BCQQ;:-
MXB\5_"GQ'XUA^%E]X@N=0U/2].U46'PG\6Z!#>:NE[X@>PO[;1]"\3:&RO+H
M-SJ5K%K,:+%+:W.$W?G_ .+?^"+O@58]#MOAIX\\->#?#WP]\86'C[P3\,=5
M\&OKOPUTSQ!XC^&\7PP^+8U+2X]>MM1>P\::-#%>Z?':O8S:/JL,<L<TL3S(
MWH.K_P#!)Q;CP_\ 'OX5Z!\4?#?@_P" W[2?P]TG0O'W@71/AT(]<\+>,?#?
MA_2]%T/5/AWXOF\0OJ.E>%Y);2>YU/0[\7-V8_(M[#4+57E*^,?1'5Q_$[_@
MD7X37PG\?+!/V8-.U#[5JWPX\'^/;?P9X<;Q+;7/AZQMSJWA#1$LM'.K:;9Z
M#H=VEW>V%MIZ:79Z&EQ+*D=I%<M7.:#K?_!'C4_$?QZ^%VF_#?\ 9TTVU^&^
MD?#KXA_&BUE^%FB:5X#UC3?'L3WWPY\21W]MH$7AKQG=:N+?=:V]E->7=H9H
MUGLX7O(Q-XYXG_X)>?'71=2^ 6E_!_Q-\"_!^I:#<_&"U^,7Q:B^%4=^-=T#
MQ_\ #B'P#9F/P5K.KWSOXKU#3K!Y=5UZPUFQBMM2>R"026=S<QGUL_\ !*_5
M?#FGWGA[P#\<W\->'/[%_9V;PS8ZQX%TO7DTKXF?LZQS+H7BR_ U>QCUCP[X
MM-[J$>L>#Y;:..!&M/L]Y%]CB- 'UII'[;?[%G@KP[\,--T?XZ?"W0_"_CM=
M<L?A?HFG&'38FTCP.DT'B33M-T.SM;8:3I/@M+*2#6[N[AMH=&D,,5ZL?VBW
M,GM.D?M(?";Q'\*?^%Z:#XNL[SX3P6FH:C/XK-I?BWNK#3IKJWFFTZV6W-_<
MF1[226P,=H\6I6[PRVLC1SP/)\0_";_@FE8>#_'>I_%;Q_XWT'XC_$3Q5X4^
M+^E?$"UU+X>Z=!\.]:UGXT:DFJZ\V@^%9II[?P_X=T\V.F:='IFE207VJ6@O
M9/$&HZA=RI)71^#OV%OB;X:_8WUW]FK2OVF->TGQ'JOB6ZUSP_XZ\.:']DTG
MP+H=UK'V\_#GPIHLFIOJ%OX&TZT>XT.PLWUD7R:6([5;J"+,: 'O5E^W9^R9
M<GX<0Q_'KX>WES\6-)\1^(/ <=KJRB;7/#_@]WB\5ZT;=@7L-.\.W,5Q;:K<
M7IBCMI(&61@X=$WM%_:_^ ?C'X2_$'XT_#[X@Z%XZ\#_  MLO%-]XUN] NO/
MNM*7PC97=]J-G-:NL<EM>WMO:K-HWV[[+::E:7%O>P71M)4F/Y[_  7_ ."/
M7A7X;_#OQGX'\3?%"'Q;<>-?@?\ $;X.:E?67@NRT=]+3XG^.]5^(&OZEHUU
M)J6H:A8V@U&[L],33UE$E[I4$OV^\GNO)EC^A?V:OV&3^SW\!/BE\'[O5?!-
M_P"(/BCH.I>%=0\<^#O"=QX;EUB ^!6^'OA_6/&.EZEKNI1:YXALM!CM/M<U
MI+96MV+(0M#NCBG< N?L[_\ !2O]G?XT^"OA!XB\3>-_"?PU\4?'/1K7Q3X#
M^'VKZX+C6XO#>MW%VGA)O$%R+:"TT?7/$MM:33V>C7K6]Q)+#/;6?VQHFD;Z
M-\5?M6_LY^$?#EQXI\0_&OX?:#X?M_#"^-7UV_UNU;3?^$437I/#<VMQRK*$
MGL(]=@?19YXG9;;49;>";$DT*2?G9J'_  2C!U6WT'1_C++-\#O%,7P9U+XO
M^%KWP3H5WXZ\6^(/V?\ 3+73?!=_X.\91-:KX*378[?SO$EG!IVIVAO(E?2(
MM,2\OQ<<SIG_  2:\0ZW<:C8^,OVC$\1> ]#\'Z-X$^%?@^S^%VAQCPOX0T_
MXY6WQFNK/Q)J=QK$UOXGUN6YLI?#T;36=A9065XTEW97%Q;+,P!]D?$W_@I;
M^R!\-?@E>?'6?XN^&];\*-IOBVYT"#2YYY=3\0ZGX+B1_$&B6FFBW.H6][ID
MD]M#?M=VL,-H\X$TBE'"^A:W^VG\ OAY\,?A9\3/C+\0?#_PLLOB_H5CX@\(
MZ7XCN\:A=V][8V>IS6UO%9K=/>OI.GWB7NJ7,*"&VL8+N_E\JUM9Y(_B/XO_
M /!+76?%_BGQQXU^%7QF\-> /$_C\?&_0?$-IJ_PPT3Q3H.E^!?CA%8_VII>
MC:'=7LFGV_B70[BS,VE^(9+00NKK%<:;-Y4<JZ/[3W[$WQT\=ZA^R!X6^"7C
M_P "^%-'^!7P]^)/P\^(/CSQ_P"#]*\8B?0O&GP_LO UM'H_AB:&W-MX@OD,
MUZNJ6M_8P:<?D,,\$TD# 'V"_P"W7^RK;ZUX\T>?XY^ I)?AEHFA>)O'$EKJ
M N+7P[HOC&WMKOP8^HZA"9+);SQ%;3K/I-A!+-?7MO+;R_9HO- /E7QT_P""
MGO[*7P:^#.E_&&#XG>%_&5KXNTT7GP_\/>&]0;5-;\73Q>)M)\*:E:VEM8Q7
M"6\VE:MK=C:W45Y+;L+Q;JR9HY8'(^>!_P $@_ 47[-_Q!_9]TKXERK<>)_B
M3\-?BSX?\82^'XY+[3];^'?A_2]&L=,\1QP:G'<^(O#ES?V6IWZV,.HZ8UI_
M:/V>S>UAMH$3FO$O_!(G7+WP>WAOP/\ %+X=?#%O'O@+3/AM\;K/PS\*GN?#
MNM^'[+XB6OQ&O-5^'^FZKXANI?!WBK6=42^@U?54F=-1%^M]=PS:C96MTH!^
MB,/[;?[,D?B'Q'X-U?XO^#-(\7^#O#FH^)O%FC7VJ1VRZ%8Z)80:CX@AO-3F
M":5]N\.6TZ-X@M(KV232&65;T1"&1EX70/\ @H_^QMX[O=.T7X>?M _#KQ1X
MGU:+6WTCPW!JQM[_ %2[T;29M7336ENHX;?3)=3LHWO]*FO74:I86]Q<:9'=
MQ)))'\8^(_\ @D1<Z[/XP\+W_P ;K%?@T%^,/B;X<>'V^']DGC'PMXY^,FBS
MZ)K\_B7QR-6.H^,?"NG6KM+8:-JD9D<W,L&H7.H6T<4*>H>,?^"5_@WQ@GB1
MK/Q[8^')/$_CCX*^,+FYT'P!X>M[FT'P:^#=]\)[6TL;Q9!<V\OB"34+C6-0
MD\U[>V\J*TL[6(^:Y /I[PW^WA^S-XG\0^%/AW%\6_!.E?%CQ98Z'<VG@*[U
MBVO+ZUOM<T?_ (2&RTFYO;"2;36N+S2(;NYLVBO&>[@MIY;6&66)K:K=Q^WE
M^RC;>$_'7C*?XS>$;/1_AOK]AX2\8OJ-U/I]UHGBO6K=KCPYH5SIUW;Q:D]W
MXC"2IHGD6DJZA)$T5N7E*H?D3P[_ ,$K-'\*:8]K8_%JXAUP_$[X+?$>Q\6+
MX*TO^UM*/P7^&[>!K'3[>\EN)9(1JVHW'_"172FYB@ENK6%(8[<!POG_ ,)O
M^"1&N>&M:UWQ1\3_ -H2;XEZ[K_Q%^ WCZ]O;OPBDT>HCX%:CJ]_IEEJT>H:
MI<0ZE-KYOK1-0O+F*4VT5LT&GQVR,'(!]#^.O^"KG[*F@7>NZ!X)\42?$OQ9
MI_P.N/C]HNG^&[>=]&\1>";+Q+I_A:_BM/$!B>RM]<LM5O9(+G1;@)J$#V5T
M)H$$;$?5WPY_:C^"7Q2TSP)<^$OB#X;O]4^(-AK%YH.AI?AM2G;PK<K8>,K?
M[,J&8-X6U/.EZK(R+%;7TEK#(R_:X"_YV2_\$HM2TN^\6?\ "(?'-?#N@_$'
MX>_%OP'XVL%\$64DTEO\1?BQ??%C3]1\/S/?M:Z)-H5]=)HD\<=JUK?:7#%(
M;>.[B$TG;_LA?L)WWP1_;0_:E^.^H6B6OP_URS\'>&?@+X<E2S-IX:EO_#>D
M7/QN\6:!9P<Z*/B/XSTVUU*^C8W$LR0A&NVD^V"8 ][C_P""A?[,>C-HME\2
M?BAX0^''B+7]8UW2=)\,:MK=KJ.HW<&B^)'\*R:W(^EM<)I^DR:Y!+I\=QJ"
MVRFXEMT?898/.^XXY$EC26)UDBD19(Y$8,CHZAD=&!(964AE8$@@@@X-?CSJ
M'_!*?P[?1_%^74?B@LDOQ$^'?CCP!9ZC>>"](OKGPE<>,?BT/B?%JVGWEZQ$
MRZ8_D:*C 0/9Q+-*'EN(3++^M>@6ATW2=(T>&0O'HVF:9I\DSQLC3&UL$@"&
M&6>6XMI-BP7!\V28A9!&9)'#NH!O4444 %%%%  <X.,9QQGIGMGKQ^%?C+_P
M56\=>-?AQXL_8E\2Z-\9X/@-;Q?&GQBOB3XF7V@:MXF\'Z5I7_"KO$=[%I7B
M30=/GA2ZL;C6+'3X[?5-9\JPMYY808C<2*H_9DG )P3@$X'4X[#W/:OECX]_
MM"_"KX,O\.?#?Q5T^[\2R_&3QP_@+P'X8L_#,WBV^U?Q.UE>W[V,ME'936L<
M0TZ*7[.;F..Z9KA--:-KHE) #\9= _X*4?M>^(+KX6WFM6OACP-X]DTCX#1Z
M'^S]?^!?$$OB/]J+3?BMX\N_#OC+Q]X0O(H;J[\+P>%M&TBWU>'2&LGFTB"^
MOO[82V^T6P6MJW_!0']OCP#\,O%/Q3U+0/#GQ-N/'GP[^)_B7P)X8T+X<ZWI
M$?P<U+P'\?-1^&5M+XCO[FZFEU*1? "S>)M8TFXBM-2EFLC- HM;E GW/X0_
MX*B_ #Q+X2U'XA:K\&/C!X<\3Z)\6/B5\'_"O@ZY^',NL^.O%-K\*+B=_'/C
M'P-8Z:LSR>#-'TOS-3UC4(WLULA+#8ZD$U#-K%J>*O\ @JK^Q+X9UK3O#,&I
M^*_&UEK^E>#88]1\'_#75/$OAFZE^,NGZQXA\ ^&9KVPTPVMUJGC*'3[^WL-
M'A\]VNK@VNH0B[EEV@'H'[#'[2OC;XC> -!T+X^^.OA9KGQ4\5:QXRO?AE<^
M ]0A\SXD_#3PY=6D8\6-HEM+<PV-[I;W;6/B*"RN+BTT^\MY;<S2/"9I_P ]
M=?\ VI/^"CVN>//&R^#O&/PR\'^#+SQE^UWX=\-Z3J?P8\0:E?\ AG3_ -GK
M1;'Q/X G.H_VA$NJ:K\0K5M3CU)Y[+[/>EX&T6!A;2S2_;UG^V?^Q+X=O/V?
MOBI%X:/AFS^,%C=?#OP%X_/@=M$TKP ^I>)8-'U'P)XHN0D-AX$U2Y\6VTUA
MJEFBPL]UIY%U*Z&%7X7XF_\ !47X.>&K'X?^(_AO\/?%_P 0_ .O_M"6_P $
M]0\1Z7X&U2Z;Q'#<6WBG2M9\2?"N"*&2[\>PZ=KGA+4/#^IWMDJ6;6[I?_;K
MBW,<<X!\8Z9_P56_:"\9_'&X\.?#O3FGAN_V=O'?BO6/AUXN^%^N6<G@?XG>
M'?@S8?$3P_<Z=<V<J:]X@\&ZOKMS-I5MJU[:::FKF&XTFRA:^B^TQ]WK7[4G
M_!1+X>^&O%WBR\\3^"/B)%\._P!C7X1?'G5='TWX0:]I]QXE^)WQ4O?(\06N
MG7,=S/$/ ?PZT7SM5FTBQ2\\63W,*B[@07$,1^T_VA?VV?AC\%OV(=8_;H^&
M&@^%_%WA>ZL?#MQI(\16[^'HK&SUKQ!8>$]:GUN;3-*O]=FM_#CI+=:O86ME
M?:C+#I=Y]B^VM);02>O?LK?M.VOQJ_9GM/C?\3-/\&_#34(O#=WKWC#2])UF
M+7O#NC>$8A>W6@>*4::"UU6WT3Q/X6@MM>TZPUNSLM533IX(KG3[:;]S0!^1
M&N?\%)?VR/AOX)UW5_ .G>#/VH?#%W\7XO@#\'?C%H7@37;;2?B?\3/B)X%@
MU[X=ZAK^F:3J1N_#7@+PQX^NV\*>+->FE6WG@U335M;K3IK.;[=^A'_!.G]M
M?QE^U;H>MZK\5;32_A[XLNI%\,>%_AG?Z3?:'XQN-4^%]O+X:^,OC)M.O[F2
M34/!MS\2EU&Q\*:U!!:6=WI-I:(/,D=)I^K^'O\ P46_9 \4WWAWP-H5QJO@
MZ77;_P -'PUI>K^!Y?#%E+HWC"VU35/ /C:PBEMDM(_#7BO^PI&T'688FC^U
MO9"3R9)(V&1:_MU_L6+\5/!GB@#6=*UOXF^"?$47PV^*VH>#-0TG0?&?A/PK
M-KGB+7-"\,:QJ<-NS1Z@WAR76;;35M[6]UM;BVNX(?WDLA /S2TG]M7]J7X8
M^$M9\+^,_P!I2PLM6U']J;]IW0]>^*WQ*^%9UFS^#/ACP+'JWB#X)?"&\T'0
M19G4I_'L,.GZ%I.LWTUE)J447]F07USX@GF>?TW2/V^?VX[F:W^+WB?2? GA
M'X=^$+S]G'0?%/P:NO 7BF3Q=XD3XP^&-4O_ !1XLM?%:AK?3[#3;[1H]<LS
M;V-U:^']!?6++6))+V(2VGU7)_P4U_91UJSL_'OB6V&B?![Q3\.)OB?HUSX\
M^'FIZ9XI\=6^E^,+#PQX>UO2/#&K:6M]?O=ZQ>6]OX;MKJ%=4NGNENK&-3A:
M]=\ ?M^_LG?M!ZI\.O 7P]O]<\::Q\9-+\7Z?#X?L_"U_;_V9H/@G4KCP[XV
MT_QHUS%%;:(FD7TT]@^FW,B7\_VMH]-0R7!5@#\G_P!FS_@J)^TAX^L;[XQ_
M%CQ/X-TOX0/\:_@YH?B/P;J?@@:7XL^&_P +M7UG7-/\=_$-CHFM:Q>77P_F
M:PT)]!\3ZOI47VR'4KJ5K:UC9'M]RW_X*=_MC>/OB=\%O#_P\T/X6>&_#WC>
M^U+Q+9:U\1-(U7PC9?%OPWI_Q;?P>O@S3;G6EMM0T/Q!:_#R"?Q-;7=E8:BN
MOZI=07%A;Z;ITL<,7[3_  ,_8I_9E_9ON/$%S\(/A9HGAB7Q-I*>'=3,DEYJ
MZGPQ#J$NI6GA>W75[B]$/AZQN91]DTP;H8HX+>/YA"M?0MWX0\+7R64=UX>T
M:9-,!_LM)-.M&32Y"I03Z;&8C'872*Q6.ZM4BGC4E4D"D@@'YA?\%,OC%XHN
M/V,?&'Q$_9C@OOC+X[\'?%+P-;^&?!G@#7;BVD\;>+/#VJPW>I^!3X@T=95T
MZWE$ODZ]=^9<6=G]EO++4A&D-W&OQ+J7[=OQ[AF\.>)=,\4Z5H5M\1]$^#WA
MSXI?&G5OA9XW@\)_LYZKXLU74[+Q=;ZWX2N+JXTA-5T*XTVV\.Q:E<RV,1N;
M.TUC4S+I5WI<"?T'^$O O@_P)H%IX6\(>'=+T#P_8S7=S:Z786J1VT=U?333
MWMT0VYI+F[FN9WN+B1GEE,KAW*G%;-WHVD:A!>6M_I6FWMMJ((U"WN[&UN8+
MX%40B\AFB>.Y!2*)")E?Y8T7HB@ '\O'P/\ VLOVWO!GP0T+5/!GC7P[XMT7
MP'X.\1?%OQQJ?BSX9>+]5USX[ZKJG[14?PR;0/")O;BQN_#VGKX1U:RNM/TR
M#3KO4-.U"#2?L.DR: 467V_PK^WO^W_\0OB!^TE?>&O#7P8\.Z'\';;XE^?\
M%/&,=Y%\0?#^@_#[6["^TW4K=8KZU7Q WB3P<^MSR^('LXM(M;NSL[2*PNG@
MN(IOZ(TM;:.**&.W@2&$((8DAC6*$1NDD8BC50D822.-T" !71&7#*I'+ZWX
M"\(^(H/$<&K:#IMPWBO0[GPWKMY'96MKJ=]HEW;W%M/I\NK6L,.IM;M'=W&R
M-[MUA>5VA$9=L@'Y^_LE?M8R?M;?L[^)_B7J%[H_AG4_'O@WQ?\ %/X8_#6&
MWELOB'X;^!GB./Q)IO@/4_&.F3LM]#K-S=Z9>VE[/8V]I$CV>E1F&W>_MFN?
MRJ^&?[:G[3G[,GP_O?B1J'@OQK\2OA[X'T;X6^&O&OA^;1/%OBSXD:[XF^*2
M>)EL=7T9;V_:XEUG0_$MAX;TGQHDMG<7$>FZG:B]2UFMH)F_HW\!?!GX:?#!
MH'\">%-.\.O!X>T+PHDMFA><^'?#6G6^EZ)I#7%P9KC[%86MK!Y<"2JCSI]H
ME$DS,Y]"FT^RN%:*:V@D@E,IGMI(()+>Y,Q1G-Q%)&PE)>-')/+.H+[L# !_
M/'X>_;W_ ."@\7Q^\<> O''ASX.Z%-\-_ FHZIK_ ,/+FQUS2=5\6:</A)??
M$=?'GPZ749WUG7IM%\3"Q\%:EI%G;7EA'Y-W&]R+^>WK]6OV*?BKXX\<?"#P
M3IWQN^(WA#QI^T%=>%=.\<_$C1/#/AZ3P5/X.M?&P_MWPYI.H>#+_4;_ %?1
MXK*PO8]*L9M0\FYU"&SCFN($NUNGD^M+GPSX=O=3AUJ]T'1[S5[:&:VM=4N]
M.M+K4+6VN0@N;>TO)X9)[6WN?+0W$,$D<4[*&E5V&:RM)\ >#=!UCQ#XBT/P
M[I6D^(/%<ME-XAUNQM(8]4U5M-B2"P2ZO'1Y6@LX4$5K;*5M[="WDQ(S%B =
MA3(T,<:H9'E*C!DE*F1N<Y8JJ*3VX4#':GT4 -6-%9W5$5Y"ID95 :0JH52[
M 98JH"J6)PH ' Q3J** "BBB@ HHHH **** "OY7O^#J[]FR^^(O[(7PU_:%
MT&Q2XU3]G_Q]&-<=-HGF\)^-!#I$T!/ELS1VFJ&TO@2ZQPQ)=EE=I4V_U0U^
M(_\ P</7JV7_  2D_:)D9@J.?",,@/\ $D_B.RMT7 (+9N)H P!R%+/P%)'T
MO!V+J8+B?)*U*:@WCZ%*<FW&,:5>2I57)K:,82YF]4E%MII'@<44*&(R#-(8
MF*E3CAI5>65N64Z34Z<7=/24O=?DVUJC^"+_ ()T_"[X$_$WXU'1OC;/I&HP
MV7AJ._\ "WA[Q'>_V;X>\5:Y),#/:7%R6BCLDB4E%MY)-UP22L@S@9/_  4-
M\"?!SX=?'F3PY\"KG3YM%N?#5K?Z[I.BW,=YHVB>(5EQ/865T-ZM!&@PL DD
MDR#B0YX^%HY)H7BE,Q@<I"JR1RS6"27(C#.UJ+<M<^9!#\\9@.Y)0K[9#A27
M -U-.JQW4TRRQ3N)EO+?4'E(&U[B"_VW4<3'YH;ELK*Q$@4]#_:D8U:>-A&O
M*E1EB*D5@J=3$8>.(S"E.<8^VP&&^L/$8B@DVY5%0BE!.36A_$_^J^._UEJ\
M6SS+,<7D-'#SP\LMITISR?!XB<)1A_M/,J:DJC@XQY8OFCI)(^JOV"?@M>_M
M"?ML_LO?!VQMOMD?C+XQ>%Y;L$D+/X?T*[M]?UJ3!1A$(K/3+ZW,CJR>;-;Y
M4@$/_KQ6=K%96EK90(D<%I;P6L,<:A$2*WB6*-$0<(BHBJJCA0 !P*_@/_X-
M7OV8]'^(W[4OQ7_:8UJ*WN8?@7X<MO"_A2RD3SFM_$7C%+NVO]0MQSY36]C!
M;LC@@B0W,FXJ70?W[L<*3SP"> 2?R )/T )/0 GBOYB\9<T^M\4RP*E)PRJD
MZ,TU[JJR?O<EF[Q4(+WK)N]EU1_4_A1EZPW#KQCBHSQ];GO:S<*<4KRNKW<I
M:ZM73?5'^:5_P<D?"O4?AS_P5*\?>))[=(]*^*7P[\%>-=(\M-IF6"V&A:EY
M4@^4O%=V9EF09(C=$^7;Q^<_["/@7X/?$7]H/P_X6^--W8KX4_LO59K.PU6Z
M%AINJZ]#%YFE:3<W+;/*AO+DK!.V]"49L2(/F']<'_!UU^S1IOBK]G_X2_M4
MZ7Y$'B?X0>,HOA]K\ZQ+]KU?PYXTBADAAA107)L=0V3IF0K#^]01EY-S?PIF
MXEC<H_G"_AC:YB.GPW%S=MYB >=916>;FY$8 \T0X>!AD9.,?LGAYG=#,>"\
MH<*].:P?/A<:Y5*5.&!G1C**EC*E>K2IT:57EC[*I*;4VTM[L_&/$SAC&8OB
M#-LNP2Q4,3FD*[PKP<)SKPA7I3OB:<(*,OW/M)3;BXM<CU6E_P!+?^"E'PC^
M 7PU^*GAVT^#,.E65SJ.@W4OC+PMX5U&/4M$T:^MYEATR2TNE:5(I)T^>>!I
M)7D;@,A//[:_\&F_[,4GB'XT?M!_M8ZE:.VB^"/#FF?"_P (33(JA]6\1F+5
M-3N(596.V/3+&&)61U:-MR/Q@-_(Y'<SW!G>=[B1K@L9YKF6Z,IF\P3H;IKJ
M1KF.[615\F.58PG"D,>:_NS_ .#1[Q)!<?LV?M->%&9%OM*^+VDZE+;Q_*L5
MK?Z$YM]L99BJB5KB)#N(\F*&,9,19I\4XXS"\$XZ-+DARRPE6HU6I3C6PF+G
M"'M<-.A6K0K1Y9IR:E%)2;UMKU>#>1SRC,\)DV98^MG%7+Z+C[?&1:Q*K4DY
MPG.$[RM&<5=MMKEBW=M6_KHHHHK^03^K0HHHH **** "BBB@ KY7_;@U/XF:
M+^R+^T1J_P &O$FK>#_BIIOPK\4WO@+Q7H>BP>(]6\-^)K>Q:33-<L=!N8I[
M?5Y=*G47QTZ:WN8[N.!X&MK@/Y+_ %17G_Q6^(?A#X2_#;QM\3/B!J+Z1X(\
M#>'-3\2^+-42TGOSI^@:5;M<ZI>/:6UO=33PV]HDLMPB6\I\A9&*[02 #^>;
MX7?'+]J7PM\:=6^-OA/XW6'QC^'ES\-OV&M"\2^%]:\*:Q]M^*U_XW\*ZE_P
MFOB/PM>0VZV'@O45U2VFBU"\MK"\M+F]6[&I+9O92O#]<?\ !/+]L7]J[]I7
MQG\5KKXR:-\.]&\&66E>(9+;P)9[[+XE_"OQ/X=\5>)=+&B:UI/EW"ZYHNH:
M-;:%=IK%[)87*W=Y9)!93PW,ET_LWC/_ (*2?L@?"3P[X&N?%FD>-_"ECXC\
M :!X_30]'^&.JSV?AGP)XHO(M!T;5?$HT:T&F:7ITFIZQ:Z=:"655,^IAK-9
M(WEDK;U7_@H!^R#X2^%T7QSO-.\4Z+X2U[Q_>?##QKK$?PUUG3=?\*>*;)+/
M2=4M_B=%]DM]2TEM-DO-(L;NXUF262%;RSNHV:VB:XB /RO^'?\ P58^.VH:
M%\2_$GB+XC>&O'>BW.B^/[SQ'_PI_P"%.K:G?_LI^+=&^+K?#SPIX7UY=5OC
M;>-(M5TZWBGO=U[:O8/<W6K/*MJ(D3<^&O\ P4(_;V^+_@'P[XNT:Y\%^&$^
M'OPK\=>/O&;_ /"I/$>N2?&+4- ^.5E\-_#NGZ$ZW<>G^&X-:\)3C5I4MCJ<
MT.H7=K>6LU_: PU]R_LD?M'^&=;^*NO_ +,?@;X0^!?!7P]TSQG\;M-T^\\,
MR1WEO=67@[5XKV>[OK*:&:+5K;Q3>^('9+B2Y411VR0Q":.:/[/[%J__  4*
M_9+^'5[\:?"7B"?7/ VH?L_^%-)\1^+-#F\":C!<3^$?$&N0>%])OO NEZ;!
M)<^)-,N_$\^GZ/#%HMLMN;N[MYQMMUGN8 #\\]3_ &]/VMO%NC_'N^\'>,_
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MU.XT21+:3Q5?QJ)M.:&[BBU"_P#-NKG^GA]"TIMX2QLX%EBDBE6&RLE64/\
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MY6ZQ_P $F/@CXT^%/CWX6?%#XA_%KXB)XR\*> /A[I?C?5/$,6F>.O 7P_\
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M3QE\/O$:&..-94$7B5;$S,^&81I:W$J.IPKMY-P^&@B4_P 67_!(GXL?LO\
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M: _BC3/!GB<ZA?Z&L<<UQ=VDMNOEW-M;R#RY+J%I99+0-\J3B-L':*_U:?\
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M5_*Q_204444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8#_@G!^V?X?_ &*OCIKOCWQKX9O_ !)X)\<>$3X1\6Q^' L^MZ9 +E;BWO\
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MRK?PZ4<+*6(5;5-6@J7.W9*\;/JU]?\ _!33]NC0?VW?BM\/]9\ ^$]5\,^
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M13U^&W[J4445^0G[V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^@^BBBOP8_;0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Y 78# 2(  A$! Q$!_\0
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M5O\ H(K]>JZ_]O?>?4W_  W1^W#_ -'K_M??^)*?&/\ ^;+C\*/^&Z/VX?\
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M/J>!_P"@6C_X!_\ :![:M_T$5^O5?_)'U-_PW1^W%S_QFO\ M?<_]7*?&/\
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M7O;XG_PYY;RG .3DZ,VWN_>[W>TK'^=W_P 0>_[>G_1T_P"R#]/LOQDS^?\
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M^7)ZI].?\,_K5OB?.I;XFF]M\%3Z*W;16Z*R\B?[(R]N_L9W;3>L]_\ P/\
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M/D?YW)_X,]?V\CG=^U-^R 2X(8_9/C&"<E20V/" # A55B09&"(3)O16I?\
MB#U_;QW;A^U+^R &P 6%K\9<LH& KL?")=P!P%9MF,[E<G-?Z(OER<\I^O'Z
M?SS2>7)ZK]>?\,?I0N)LYC>V)IJZ_P"@*'?S3$LIP"VHU%_V]/O_ (S_ #NS
M_P &>O[>#;B?VI/V0"3@\VOQD!9@=PD?;X17=('PXD!1@P)S\S90_P#!GK^W
MEDG_ (:E_8_^9]^W[%\82 =S-CYO!YX(*H><;4&S8Q9F_P!$;RY/5/IS_AG]
M:/+D]4_7_"F^)LY;;>)IW:Y6_J5._+HTMNZ]?,?]DX"]_8U+W>MY]5_C/\[L
M_P#!GQ^WH2?^,I_V0>3G/V7XRXYYZ?\ "(YQV'I1_P 0>_[>G_1T_P"R"/K:
M_&3GZ8\(\?C7^B)Y<F.J?7G/\L?I1Y<GJGZ_X4?ZS9R[?[5'16_W2*_)B_LG
M +_ES/[Y;]?M?UY'^=W_ ,0>_P"WI_T=/^R#]/LOQDR/<_\ %(\CZ<T?\0>_
M[>G_ $=/^R#]?LGQEQ^7_"(YK_1$\N3U3]?\*3RY/5?KS_AC]*7^LV<_]!4?
M_"1?+K_76X_[)P'_ #YG_P"3?+[7]=;G^=Y_Q![_ +>G_1T_[(/'_3K\9.?I
M_P 4CQ^-'_$'O^WH?^;IOV0C["U^,F1]?^*1K_1$\N3U3]>?KQ_+%.5'!).P
M],=>/TIKB;.;_P"\Q?IAHQ_\F;:6NNJ?Z!_9. _Y\S^^2]?M?U^!^,W_  0[
M_P""=?Q9_P""8/[*'BS]G/XP^._AW\1/$^M_''QI\5+?7_AG'XDB\/PZ5XH\
M/>$-+MM+E_X2C3],U!M2M;CPY=RW!CMC;B&XMMDC-O)_9ZD&>^W\,]:6O'JU
M:M>K5KUI*56K-SG)*S;:W?2_HDO(]"E3C2A&G#F4(JT8R^RNR\NUV^NH4445
M!H%%%% !1110 4444 %%%% $4S^7%(_(VH3D9SD#CISC/7'.,XK\%OC;^U/\
M2O#>M_M._&WQ1\>/C!\/[7]F3]J/1_A)IOP0^%NF? ?5="\+?"&STCP'J]O\
M2?B_\._BGJW@WQU\7+#XY1:[JC:'+X%\9V.NZ38ZUHEK\-M&O=;\/ZQ=7?[U
M31B:-XB2H<;21C.,\XR".>GJ,\$'!'D7B3]G[X(>,O&GA[XD^,/A'\,_%OQ%
M\(M:OX5\>^)_ 7A37?&/AQK&5Y[%M%\1ZGI-QJVG-87$DD^GFVND_L^:226R
M%O-(\A /R;^&7_!2SQ9X=\/_ !(T;XAIH/B_Q-X-^,WP^T'0KJ[\3:5H>O>+
M/#WQY_;V^.G[..E:'H^@6FGV\FI:A\+_  ;\/-/.E0:=;SW7B?48OL&M&PNO
M.OI=?P]_P4<^/'BS1_A);Z)X=_9(T_Q;^TVUEXK^"L?B#]H#Q!)HWPU^'UQX
M(^(/CZ[T_P#:2ATWP<^J:+X^FTSX>76@>'8?"(N="UKQ=<>+M.C%I:_#/5[C
M5OIO]M?6_P!G+]E_X?Z!\<_$GP!^&OQ&^)EAXO@\%? [2KWPWX T'6;CXB>.
M=5U'QB;6U^)'B#1IK?X8^&+/4-+\0?%?XB>/7=AX8T;PUXF\;?9=2UNW6&]_
MGI_9+_X+0?L8?M)?$GX@_"CQ1\&/V'?B;\*/%WC[P]XE^.4?PH^!_C/P/?>'
M[G5/%^D^$=&^/6L:-\:_"AT3]I/P%X6\=>)]%LO'7CBQMOAW\1O!6D^)T^($
M7PYU3PZOB:;30#]%Q_P6P\2V>G:Q\1M>^!NEZ5\,1\"=4^)O@;1;7Q=JFO\
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MA*"2XN(/"O@+PKH/A#P]#>WDPFO;^/2?#]C86:WEXX3[7<>29KGRH?.=S$A
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MM\.Y]>6[^'6N^&-!^SZ+%I[W-WJM2/\ :F_X+6V^B_"F'Q%^RY!:^-=0^/\
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M8:AK,=QJTD!_X1R>2;3M8N?L]M=6LH$9'YZ:)XI_;O\ AG'\2/AKX"\':_\
M\(?X,LM%TOX9:UXM\.^+OBKXF6UU/QM\,K&W\83>,_%UPT_Q O\ 5=(\3_$K
M5==T'4/$NK?\(A;^&8(9;7PU!H<<>J_I)^TM\>)?@1X?\':K#X>L_%=WXZ^)
MGAOX8Z58ZIXRTSP%HUEJWB6RUJ]L]2UKQ+JME?VUCI5O)HWD7(%O).7N8Q!'
M*Q\F3X3US_@J/HTMK:1>"OA3=ZS=Z]\%_$/Q$T@ZSXSL=+71O&6C_"'7OC+;
M^ _$FG6VCSW+6%[X8T&=X_$6@3ZD9X+BPOEL;6WU.VN(6>I@H8^K1C"EEN&Q
M5+VKKP^LSBO?M&FW[LKJ+45:^MV]%8P+C]HC]MF\\0?'O2OAEHG_  MJ'X::
MY\8_!-I,_P *[?0=(TF[\!WWPZL_!_B33_$NEW;6OCCQGJT>L^,[G5/AS;6$
MPCAT&RN4TN-(K>UUGK]&^+/[=]^O@:[UC02FDV^G_"^[\4:-'\(KRT_X3:T\
M6?M%:]X#\13:G=:PVE:MX$U#2_@S!HWQ U;3[?2;*YT>Y==2NM)TBQGDTJ+(
M\*_\% O&GAZ]\=MXQ^$7AO5]$37=>U#0+[X:>*M*8V3^&/@!\-_CIX\L;R";
M3?-\3'3_  YK_B'6;7QB9+&YU5=.LM"DTHRL=4GK:K_P5@\'P^"M?\8Z+\)]
M;U6WT;4=2MIM'U#Q=I6AWU]:Z=HWBCQZM_I-Q<Z-/;7,M_\ !C2/"OQ5L5NY
M]/ TGX@:!93W4%S!=3S!V?4\:XJ,,EPM62MS5(5:?M7=6]Z\XQ2;NU9)\WR:
MRK_XJ_M\ZU<>'[B7X4ZEKNLZ1XKM]6DTN_\ ASK?@C2O"GCV'PG\:U?X;:?J
M%CK\*?$+X96=QI?PVN8?B5J3WVD7-_XACMY+B:YO[6#0OJS]A35OC-XAU#X^
M^(/C!=?$6^?5_%GPXN?"MW\0/ =_\,8Y+1?A!X-M_%$/A;P+=W5W!H6BV/C2
M'7M.G^QO&NHZE9W6I7,;W5U+<W'5? W]J:R^-7Q(\8?#33_ FLZ'K/PYTF;4
MO'=YJ.K6MQ%H3ZSJMDWPSM8K:"VC%ZOQ*\%3MX[LYXC'!IVGVAL;E)[AHY1]
MIPP10'$2*@V <#G /3GG\SZ>@P/3^OZ]#S\5.K23PU7+L-A)\L9.=.7-5DG)
M27.TW&]ET=N5K5O4F8X4G!..<#&3@YXR0/PR,],U^$'[</Q)_;4\-?MK:MJ_
MP,^-&B> /@_\%?V4O#?Q7E^'7C#7/#X\,_&[XE1ZE\?I]7^#6A^"[G1EU?QE
MXY\>6^D?">Q&H1>/_ EQX TF6QU718O$%]XE>TC_ '?95=2K#*L,$9(_(@@@
M^A!!!Y!S7-ZEX5\'ZG<BYU?PUX<U&[$847.I:+IU[<>6@8(@GN;:63:H9PB;
M^ 6"KC-(\\_F\U[_ (**_P#!1SP?XL^(7AV+X;_ #QOIOASX >"?%=AXXT/P
M[K%O'XF^(?BGPO\ #S7?%7B+PMX<LO'^J6FN7_PY\1>)?B+X0NO@+<>-K/QM
MXE@^&UC=Z3?R:EXCD23I/&?_  4=_;:/B;6_A_\ #[PW\.];A>[T:+PQ\6_$
M_P (=<\/^$+[P/XCM/V7[#P[XYU70I?BM9OI_B>WU;QE^TCK?BGX5R:];ZYX
M8T_X=Z?9:^^D1:?+=ZS_ $&_\(1\.% C'@SP:HDE:4)_PC6C!6F R\A7["!Y
MH7EF8;P 23@'%@?#_P  .@QX)\'M&PR /#>BE2"H3('V+'**JG_9 !X&* /Y
MU+[_ (*._MW:-XPU;PY:^"/AEXEMM ^.OCKPAHOC+2OASJR>$_C#X7T/Q7\+
M=+\!^&=.N+[XI:=JWPG\.>*? ?B+XD^+_%G[2'C'2KKX=:)XR\!3^%_"EOXF
M\.W6FZSJ?U!^R#^UY^U[\2?C[\%_A_\ &>T^&M_X0^*7P1^(_P 2_%8^&OP\
MU30[WX3>.]%\>:MIOACP-XR\0ZK\0M;L"\W@+3]%N+2/P_!K'B;5=7OM4O\
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MD)^SKXF\#?&3X2_"7XD_%?Q'\1/C;XKU&S^(?PRFATOQ?XR\0>'M+FOY=?\
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M(D;PW>'Q#XYU.W5E&1JFLZ#IT&DM=HQVM'9W.H1<9%TXQ7H&F?\ !NI^U?\
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MW>KZA'9VB 10I=:G?7=],5^::ZN9IG^9SCM#=6X(!FC&>F6'/*CKTY++M_O
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M_!*O]N_X(P7NI^.OV4/&UYI-@CR7>O\ @&TT7XEZ3%;QD;KAO^$+O=7U)(&
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M.? WASPWX)^&&M?"7Q%XH^%J>!?#FJV>C>(M8\37GC._NOY<?^"A_P#P1O\
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MI.EZ)JZ?#K3K^\D\%^-/&DVBZ>VI74%OJ6GO^S#?\$L_^">15E_X8Z^ S9!
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MT6SU+QYX7F\4Z7I'BKQ3X-\&:7\+?"7Q"\2Z58W_ (_T7Q+:I+ITWZH?&/\
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MT;R2?M2?'E7D<J?V;M);!;N/B)H* XQM& N1A1\Q)QT%?U0_MS?\F9_M9?\
M9NGQ@_\ 4"UZOY7O^#:'_DZ;X]?]FWZ9_P"K&T&OV3@VG#_B%/BC>$).,<JY
M93C&<X\L\(UR5)QG4CO+X9QW;UNS^??$"=2'C7X/4XU*L:=6EGBJTU5JJG4]
MG3Q3I\]/VG)+E=VG*+>NK9_:*+6,'.6_3U!]/7)_'\U%M&.<>V3DG'Y_TJQ1
M7XW9_P U3_P;4_\ DS^@5""VA%7_ +J*_P!EBQ@KZXZ_RS_A3&M$/1F3J/E
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M//X=:_9N#?\ DU/BE_ARK\9X0_GGQ"_Y/=X-?]>L_P#_ $WB5^;2];+=I/\
MM/HHR!U.**_&3^A;KNOO7^84444!==U]Z_S"@]#BBB@+KNOO7^92-K%("&B3
M!#*0R @H_P!Y"IW*58<$8Q@XQC(K\>/VJ_\ @BW^RC^T1XENOB7X+T:3]GKX
MPIJB:RGC7X;Z/HEWX5U[58)A<0W/C7X4:W:3^"_$\;S@-J!CMM'N]33?'>75
MR)'W?LI17?EN:YIDV(CB<IQ^)RZLOBEA*CHJHKWY:L8M0G!O5QE!J^NC/%SW
MAW(N)L'/ 9]EF#S3"3M^[QE*-:5.2^&="M)JK0J1=K5(2;:7*TT?R,C_ ((R
M?M8_"3XN^&?&>B_ K]B/]H_0]&U:XOM3N]/U7XA? /4?%=D]G=VPTWQ%X2MM
M<N_ NGP7!EB-S%IFEZKIV0[V^FQR^7/%^,O_  4&_P""7'[</PL^ _Q^T7XA
MZ1X%^!EG^T+XJ^$FL>#=8T?XE:WK7P2.@?"C4_B=J_B/]EKQY\3M5;4?^%4:
M%XKO_'/A3XE?#V_^*>M6GPZ\9Z]\*QH.N^)M.\16'AB)_P#1_P #T'Y"JMW9
M6]["]O<QI+!(C12P2HDL$\3C:T5Q!*KQ3Q$=8Y%9#SD$$@_09MQOGF=X26$S
M*>'Q"J1P\:E=TZL<1-8>3E#F:Q#HW<FG)K#IOE2VT/G<@\.N'N&<QCF.4SQU
M*4%C5##U:]"KAXK'4,-AJB5\+"O:G2PM-4[5E9N3ES:'^;+^P-_P2A_;D^+'
M[,GPL^%WPQN_#GQ#U?X2>/OC+XWUSQ[IOQ+^Q?"3X?\ ASXLZ/\ #_3='_9S
M^'/Q=M%N?#OQ:U*;7_!FL?&7XB:=\.;W7OA_\.]4U'P] VO/XS\5>)+2#[D/
M_!![_@J,>NE^!<=#_P 9"S=._ LQVK^[&WTVWM1 ENJP16PV06\,<<-M#"$"
M+#%!$J1Q1I@%5C55!SA>:T*]+AOQ*XAX6RQ95EU')JN'5:K7Y\?E=/%UW4K-
M.5ZDJL%R))*,.5Q5FW?FE?S>+O";A?C3-O[8S;$Y[1Q7U:EA53RS-ZF"PZI4
M7-Q?LHTJC=1N<G*?,GJDDN5'\#7B3_@D;_P4'_9N@D^-OQ#TF/1O#'@_PA\7
M-(_X6)\/?'&M_%SQ1\"_%OQ#^$OC+X?_  ^_:*LO 6A:??>)=2L/@MXM\1V/
MB3Q!K'A73M1\4>"O#\^I^/M#L+F]\*H$_//_ ((C_L'_ +5_@7]I#5?"H\>^
M#/%MUX]^(_P/U;2?"_P:^*WA[XX:+H&I_";X^?#_ .+&O?M8_$+Q)X#UC7_#
M'PSTSP3\/?#7C;P5X1O/'&IZ)\2?B'K_ ,5E\ Z!X;OM'U/Q<UA_ITW$"W"A
M#++$1N^:%PD@+(RY5]I967.Y2I!R.<J2#E:1X;T;03<?V-IMAI:WES)>WRZ;
MI]CIXO[V50DEY??8K>W^V7;JJ[[FX\R=B.9-I*U\WQ%Q%F'%&9U,VS*.$AB:
ME.E2E# X2C@<*HT8\D7##4%&E&37Q.*U>UEH?5\)\+9=P;DM#(<JJXZM@L/5
MK5:<\RQ=3'8QRKS<Y*>*K-U9Q3?NJ3:ZMMGY5ZA\)_VAOAS\4OVG?".C?LL>
M"OVB/#G[4?[1_P /?C/H'Q;\>>+? L/PW\(>&++P[\*/#6I^'OC3X9UZ[D^)
M$^H_!.3X<W_B?X1VO@'PWXMT[6;S4] @MKSPA?P:]=Q?G%IO_!-O]L[QUX:G
M^&&I:1\0?!L&C^!/V]_!1UOXQ?%'X->)?@W9V?[1GB7Q3KW@VV^!VB_"JUNO
MB[X>E\=33>&M%^).I>.[V6#3_AYJ7CC1ETZ_UJ[TQD_J.HKPCZ0^%?V?I_B_
MXR^)6H>+O'/[(/AS]F#2/#?PC\+_  XL_$&K^(/AMXL^*WB#5-/UFYU&?P-X
M7O/A7J&L:+:_ 3P5%YD_AN;7M2TW6=;UW5WN[+P?X<L[.Z.H%?=5% !113'.
MU"=VW&,M@' R,]>.G3- 'AW[17QP\)_LZ?";QK\8/&LI_L/P9HCWT=A&Z+>:
M]K-S*++0?#>F!\[M2U_5I;73[<!9/*626[90EJS#^1[X,?##XS_\%0_VM=>U
MKQEJMY;V>K7<7BKXK^*[!#<6/P]^'\$TMKHW@KPI'<[X8+Z>VB70/!VGO$Y=
M_MOB*^6;R+V2Y^]?^"['Q]N+OQ3\*/V>-,OVAT?P_I,GQ9\;Q02G%YJVHO=Z
M1X,L9XRRQL=/TZU\0:G%NSNN-0LRH!4,/U$_X)@_LT6/[.?[+G@Z#4[ 1?$3
MXI6-C\3_ (@W,BCSTN_$%E&_A_P_)(%!\GPSX=:RTX0,<+?R:I-M!N6  /M'
MX3_"GP)\&/ ?ASX<_#3P[I_A7P;X8LDLM*T>PCPN H$][>W#YGU'5KZ<-=:A
MJUT\MW?W#O-+*=_/I=( %  X X Y.!Z<_P"12T %%%% !1110!^<W_!03]@W
MPQ^V#\/;W4--ATO0OC?X0TZZF^&OC(I';27^ T[>!?%=R(U^V>&-;N L<$\Y
MEF\.:E)'JU@0GV^UOOPD_P""8G[6OB/]E7X[7W[/OQ5DO- ^&_Q'\7MX1\2Z
M-KN^VD^%OQ>BO'T.SU1EN#Y=A::IJ$:>&_%P016\L;Z9X@63_B72SW/]=UQ%
MYT$D73>NTXZXR,X]\9QZ'FOY:O\ @MU^S)9>!/B3X._:*\,6 L=)^+ZW/A;X
M@"S00VUO\0=!T])M'\0;E0>1>>)O#=O);W%RQ:5M0\-)<&1Y[LF@#^I='#$K
MCE2P/(/W2!S@G!.<X/..]25\._\ !.GXZW7[0_[)/PJ\=:Q<&Z\6Z3I4W@#Q
MQ,Y<S3>*? TPT.[O9V=W9YM7L8-/UJ1V.YVU$L<@BJ'[8'[=W@+]CG4O"-CX
MZ\)>-/$H\7:'XW\613^%]1^'VG0Z5X9^'@T!_%%Y<#QWXT\'-JVHQ1:]:RZ3
MX=\.-K'B#6"EQ%I^E74BF.FHRD[1BY/LFEIWU:,JU:EAZ<JM>:ITHVYYM-J/
M,U&-U%-N\FEHG;=Z:GWC5:XB>0)L<)AB7!Z2 J5VMP00>,@@@@<@X KXR\>?
MMW_L]>"O#WB75(_&H\2Z_P"%-)\'ZYK?@#0HL^.+*P\8:UX2TF%&TC4DT^-]
M2T#_ (370+[Q;H,5S)KGANSNT&KZ?9R3VRRW/&_[<W[./A&]\"V]Q\1M(OM+
M\:B*Z?Q3I&H6,OA[PII.H>!?&'COP_K?BF[N)HI+:S\2Z9X+UBRT*PL+?4-<
MOM8^Q62:6&N$W5[&HU\,HM]4M5;SM9[='9F4L9AH2<)UH0:A&;YY1BE&5N6[
M;25U*.]DN9)V>AC?%W_@G#^PY\>M7_M[XL_LM_!SQ;X@:6:677/^$5MM U2[
MDE'S/J&H^&#HMYJ,A XGO99Y%(W*=W(\!\<?\$8OV!/$/A\V?@[X)Z?\(?'.
MCPZ9/\-OBU\/-;\3+X]^$/B+PW?1ZSX/\2^ G\2:MKWAVVG\,:]!%J$&@:CH
M5]X6U6WDO]*UC2+S2]5U*UNOJCQY^VW^S/X L/&LFM?%O0?[6\ GPU%XIT72
MK'6M<U[3+CQ9K^A>&=+@&AZ7IMSJ5W/#KGB31=+UR&SM[B;PQ>ZE:V_B.+2Y
MY4A;B+S]OCX%Z=_PKJRN?%5OJGB?XF_$'3/ .A^$M U/1]9U;3%UCXB:]\-K
M3Q1K\]G<_P!FZ7H%OK/AC6[F\%W=Q:NEKI>KQQ:5/<:/J<=KI%8NR4JU5I.R
M7O?#T33LG]UK'-;)X5/:J&7JLU=UE2I5JB6[_>+9WUY;WN[VU/QT^ G_  ;>
M_"WX:?&SQ+\0?$UU\ M&\,>+;U#\0_\ A1OPI^(?@CQC\8?#3ZI#K>N?#V\A
M\<?&#XC>!/@/\._'^I6MM'\3O#?P.\+Z3=^+/#K:AX)TC7/"'@O5M2T&Y_:7
MXU?L6:9\8OBC9_%O3?CI\=O@KXH'PEN_@CKX^#.O^"]#MO%'P[OO$EQXIFTR
MZG\4> ?%VJ^']3M]3N[H:=XB\':EX>UK3X94^RW<<]K;3Q_0/PK^-?PL^->G
MZMJ?PK\>>'O'5CH&I_V1K5QH-TUP-.OY+6&^MH[F.6*&9(;^PN;;4=*O!&UE
MJ^FW$&HZ9<WEC-'.WJ@S@9.3ZBL&FG:2<6NCW^X]"$XSC&4=8RCS)JS5NUTV
MK^C:\SX3U7_@GM\"KOQ)\(_$_AT>*_AW?_ GX'^(O@!\+8O /B*32++P[X,U
MGPS>>%- UJ6UO+/41J?COX8Z5K?B\_#'Q3?2S3^&K_QKXIU![>^N-6GK4^%/
M[ ?[./P(\=?#7X@?!/P-IGPJUGX<_"35_@I<Q^"++1]!L?B9X)U1_"]W:R_%
MJ&QT:*?QUXG\.ZQX4M==\.^*+^[BUBQU36?%,LUU=1^(;Z,_;-%!9%!%Y,,<
M6=WEH$!Y/"\ 9/)P,#)R3C))))J6J]TSK"YC)#C!4 9)PRY&.X(X."#@G##J
M/DG3OVK]+U#XA'P>O@OQ#;>%)?%'C'P38_$Z^UWP39Z7J/B7P!!.WBR/3/"-
MUK\/CC4M%TF\M;G1Y/$%CH%W;RZNB1);-:S17+95*]&BXJK4C3YW9<U[:=W:
MQE4K4:3BJM2-/G;2YKVTMU^9]?45\E0_MI?L_7%UHZVOC>ZN-.U=_&Z7.N#P
MYK]OHGAP_#O2+#6?$G_"4WM[IUM_PCY6QU33Y[%;N$C4!>VHMMXE4ULVO[6W
MP"OX].FMOB;H\4>JWMAIMB;NVU2R+:GJ6K:EH5OIERMUI\3V5\NK:5?6=Y!=
M)$VG>5#<72QVUW;RRY_7<'_T%X7_ ,**7_R1BL=@G_S%X;YXBE_\D?3E%?,N
MG_M7? W4=<A\.6WQ$MAK%Q;>&KZ&SN]&UZQ,EEXQU'3-+\.W0EO-+MX4L[G4
M];T?3I[J258+&YU6QAU!XFF4U[=X+\8:#X\\/Z9XK\+ZB=5\/ZS;RW&E:CY$
M]LE];P74]H]S#%<PV\_DF>"413&$1W,/DW$+/%)&[:4Z]&M?V52%2V[A)27R
M<;IHVIUZ-:_LJD*G+NX24EZIQ;31YQ^T]X&U#XG?LX_'CX<Z3N_M;QU\(/B+
MX4TD(BR.^J:]X3U;3=.C1&(#-)>7$,:@GJP/:OXR_P#@AQ\6_ ?[,'[3.C^(
MOC-XBTCPOX;_ &DO ?C'X+:3XHU6X_L[2_!?Q4^'7C#P[J[>%O&6I7ABL='E
MUZSGCEL+J^FCM8#=Z5:320232F'^YZ\,@MW,2AGW1X!(7 \Q,L&/ *#+ XR"
M..<5_/1^V-_P1UU3QC\7-<^-G[+T'PSNM)^(/C71?&WQT_9<^,VEO-\)/B%K
MNE:C#=W?B_P-JEE9W=U\//&NM6KZC!?7<5LEG/<:G>23W+Z7=ZEH][^D<&\1
M9;A,JXEX6SFO+!8#B6AAHQQ<(PE/V^&<Y2HKFE'E4H0P\DYV@Y0E&4H*2D?C
MWB;PQG6+SW@_C7A_"/,<PX0KUJ57 RERWPV9XK!S6*HP?O8MT%0QD*^&P_-B
M*;KX3&TX3GAHP?[_ %OJ=C=117%O=VLT$\:2PS0WEM+#+%(-R21S)*T;HZD,
MC(2K(5=6*L#4_P!MM<X-Q!D#G_2+;&?KYHY_SBOX=OB]_P $AO\ @I7XP^)7
MC/Q%\._V9M#^#O@W5=<N[GP[\./ _P"TWI^K^$/#.G-*YBMM#OM<\6VU^+.<
M-]H^Q"STW3].DD>TTG2M-L(XK2/S3_AS!_P5CS@?#6]Q_P!G#>%<>G4^,,_G
M]:]C">&7"6)H8>O/Q3R#"2Q%!5W0KT:#JT')I>RJNGGLJ?M%>[4&XV3:?0\3
M$^+G&>&Q6*P]+P:XRQ,,-6E16*HQM0Q"C?\ >T55P%.KR2W7/%2LU=7O;^]3
M[;:X_P"/F#Z_:+;/Y>9_2@WMKQ_I,'X7%L?S_>''Z5_!5_PYA_X*Q<9^&E^/
MK^T+X9YY/]SQ?B@?\$8/^"LC9Q\-;X\ Y_X:%\+CKTP?^$O Y_&NE^%7!Z_Y
MNYPV_*.%YF_11SG7Y?H8?\1DXVO;_B#'&'-_)SQ]I?MR?V;:ZZKVNBUOT/[U
M?MMKG_CY@^GVBVQ^?F_UH%[:\_Z3!^-Q;#\OW@S^M?P6'_@B_P#\%9!D_P#"
MM+X?]W#>%L#IT'_"8&F_\.8?^"L?_1-;[_Q(7PM_3Q?0O"O@]_\ -V^'%_CP
MOLW_ . SSI-KS6GS0_\ B,?''_1E.-O_ "G_ /,?WG]ZOVVUX_TF#K_S\6V?
MQ_>\#\OK1]MM<_\ 'S!]/M%MC\_-_K7\%?\ PY@_X*Q\9^&=][?\9"^&N?\
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M%;3O^"O.FKJ9"M'^VGXWA<SDH6N+KQ/XIBLA\P'S+)=0&('&XR+MSD9_LLH
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MMIS6T*PM(E&%&%&,+U'']/\ /:E-M$3G!_!F'\CC\,58HK-8?#I65"BE>_\
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M]3?#J>DZM;2VE[;.=I*%H92T$T92:VG59X'CF2.1/XW?B_\ #7XU_P#!+O\
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M#]/8D\N-4W%BHY9OO,Q)+,?=F))]S3Z_+_\ X8D_;1_Z2V_M-?\ AA_V.O\
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M(MK)$FQ4 /YQ_CO_ ,%0OVA-?\>?M'_"3X7_ !.^%O@G1O"=EXFU[PQ\3?\
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M^%H]/UKQ]:OJWBSPC:#Q/)8:[\/=)/@CQ7KL/Q ?Q):^"+R#0KJ[?3= O9/
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M']HPP6_AS3]2M9[3]*(/O7__ &$)_P#TC@JQ8?ZN?_KC/_Z675 'Y9Q?"?\
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C_,I*/D_,60[=Q(&""!9JK:])_P#KL/\ T3#5J@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #< @(# 2(  A$! Q$!_\0
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M&O?#:#Q^=:'Q$^,G@7X-ZI%X)^)WQ;TC7M.\-#P#X:TW4?&-KX@NO!7@6^U
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M-P'_ #X_\IT__D1?6<5_T$+_ ,"9^G'_  ^@_P""I?\ T>7\1O\ PG?AQ_\
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M^M^/_B'-*?"7@'P;X!\*,FMZUJ5_:6[ZMJ]^9[*QT72%2XGG=Y'CB]?^+_\
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M*LJL#D$ @BBNQY/DZ;B\'-25KJZNK[7][JC#Z_B]5[75;ZO_ "/WA_XB0O\
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M:1(PPABB1/!R<_D!^0Q7[U_\0W'_  4T_P"@9\!/_#K2?_*&C_B&X_X*:?\
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M_P &M(T[XV?$C6OC/J?AGP_>?$OP]I>A_&OQ5X83PUXI^(6G7>A^-+'69_\
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MZ!_P2N_X*3R<']A?]HLXYY\(VB_^A:QR/Y=^M9JGEBJ*2Q>&:7>LNK;?RO\
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MC'[1G_A'6O\ \MZZGC,&VY/&8:[LG^]731'(L-73D_93LW=>Z_/R/@>H9_\
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MXM?'^U_:'^%7QG\<Z9X#\0VFI^%[?0]0\-ZC>26&9M(DLXI+F&=;?4!<VT@
M2Y6%A<(@8D?@I^U_\.OB1XO_ ."G?_!6G_@H1\!++6+O]H#_ ()8>.?V-?B/
MX)T73+N<6/C7X3>%?AM+;_M!?#^ZL(MZ7%UKGP\&J7=K$P4B*TN4C5KF>)U\
MN>5UL+]5A5QE'$1K8:K4^M4X*,)UH1LJ*A:*C-5?W;6W,K_"[GJX;-(8WZPJ
M=&="=&MATHU-7[.JHS>_>%VI;I:K5:_W*_$7XE^"?A/X!\9?%#XA>(=/\*^
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MS6ER/%#>);CQNO@6TMS=^,9B=-TTZ0+Z\NFBAT0F]%K"4D:X9^3^E]?S1_\
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MXZ'Q%^/.K:']DUJPN[+P797]U86VASRZ=I-AJ=TT$4-SX:\0R6:+-=B0S?\
M!)/5?@;^V5\"?VQO^",WQ9UW4O%GPZTS5O%OQ!_92\9:]H6I^'/$LGP[O-;:
M;2]9TC0/$^GVFJZ/X@^'>OR:3XM2QEMI-]KK>OQM+/:R742<M+AMT\OPF/Q5
M9\T,-@<7FF%A:-;#X/')T?K5"]W7JX2LOK&(PT8V6'E&\DFY+H>>5/KF)H1I
MJ5*TJ&#J)*U;$I<_/>^M/E]Q+X7-7N?UP_&K]I_X)?L[?"?7_CE\9_'VC>!?
MA/X7T_3-3UOQKJ4XN=)M[/6I[6VTI[0Z:M[<ZL^HS7<*V$.F6]U+=H)9H5:*
M)GKG/!G[8?P!\?W?PSL?#GCV!K_XR>$M-\<_#2PU33M4T2\\4>&-8%TVDZC;
M6NK65I/;-J<5E/<6-I>QV]W<6YBE6';,F?X_?V*_@W^T_P#MW?M"> _^"9/[
M77B_2-=_9R_X)1^,]<UKXFVFFW]U+J?QIN-#\32:'\*?#7BB:21VU+1=+A6>
MRTR%A"]EX:E>.[:>]%M*G[A_MI_#36?B)^V=\./A]X*NH/#'B&/X.RZIX)GL
M(S:V>FZ_X.DU?6]$LM,%L8TLPL6EVMK"+81H$$D"@12.*_+?&+.L5X8Y-DU?
M 4Z6?YOF/$>599]7I/\ V>IE6;5Y2PM:'LHNI#.L1@J%>KA\#KAVYTU4:DVE
M$L]KRPLL92PTE3I8JEAU!QYI8QI*-=4?Y;55.$6KNZ>FEC]N-5\8Z'X>TC4]
M<\07D.CZ3HEG<W^JZA>S1Q6UG9649FNKN60D?N880'=E#8D86X!G!0>(3?M=
M_ 2W^&^G_%ZX\>V4/PWU76&\/V'BEK:]-I<:PDDR/8^0ELURCQ^1*SN\00!>
M&)S7Y8^,OCG\2/VQ_!^C? JUTW5/ >J>%O"OB#Q/^U%J;P) E@W@J*[2W\-6
M(!?>GB#5K1=1O;:81E'NFBD6:.#=7B.N[5_X)B^!WS.BO\=YV5$7;L,VK:ML
M@C0$JJAD1"V"VQG#DHSU^(YOXWYG!X[$Y)E3GD^%X6Q>:8/,LTPTJ5?,,[R^
M>64LSP,L!3G2J?4<JGF45B,3AYKVV(HU</3J1]UE8O/I^VJT\-1<*4,+*NL3
M.$JU/VRIQE]74(M2G.,I>S<(R4Y3C*,7>S/V)L/V_OV3]6O['2M.^+NEW.H:
MC>6MC:VR:;K"N]S>S+;VT1>33TB7S))(\$R8"NI.!G'6?$/]K_\ 9_\ A/XE
MNO!_Q#^(EEX9\265O8WEQI5S9ZA=3I::C$9[6Y5K*UN$>)H0)'8'Y P!&<@?
M,_PHT7]J.>Z\ GQ3\%OV6+;X?.=#&IZO8N\OBNVTE=-MV&HV*3VDEO)J:JL#
MA'=OW[R$?(J&O*;K3M*U[_@J9K.G>(-*TW5[.7X0Y>PU:ULK[3A<+H-O):,8
M;U)75]S2(B[!@@; 0:]FOX@<90RG)<13J9-0S'B+/LBRK +-LDQV!PU*.:9?
MFV)G*C@,/G.-S7,Z7M\'07MZ4L.Z-.?/-<DG;>.98OZMAIN,74KU\-1DZF!Q
M>$IQ]M/EE)U*]:5.'*M4F_>?NIIM6_0CX:?M2? [XOWDFF_#CXB>'O%&IP(9
M9M,M[Z*UU58MC.KIIM\+>\G+!2=D,;NB8D=0A!K</QX^'"_$^V^#<OB!8/B1
M=:2==3PT\,QF73/*EG^T?:EB-HP\F(OL67=\RK]XXK\J_P#@H)H'PX\!>(?@
MAXD^%EKH7AGX['Q_I]GH&F^#8+;2]5O- EDM7O$U>UTQ$=(A,8HH+FYA/VB&
MZGMF"Q"*0=I?-=-_P5(TEWA0WZ_ 1Y7MG>81QZFOA@SO''$LA&#? QXR?E)
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M/U$L(GP=R-!.K1\#/[IV4J<%MY<(@'"_-R<X!_ER/[(_[3C?L^>+?#,GP/\
M'?\ PD4G[>6@?$NVTC^S+%KV\\"Q:?=^;XOMK=[XVLNEPSRK;RRR.TZ*=ZVP
ME&VOZB-7E9;6=(%9YWMK@1^6"6$@0^4FY"K1O+)A87+J@E"[L@''Y&>$_P!G
M']KCX>_V9\2= \7ZQJWB[1_AQKES)\,(?$J2>%/$?C:7QCX:U!=&\87/CR?Q
M&'U/Q?H;:E%K>N>&)/#EOHYT'25TZX>6.2*[]7*LVKY8\1##J,I5Y4Y-3OR\
MU-24'JU%-*I-)N[2G)+1ROY&:Y11S-4)UI2A&@W=T_B=W>SY4V^B7_#'4?\
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M^+FLZ+I'A>ZUWX8_&#6_ $4>D>'+!-*M;2V71+6.YMS)"C1ZDJ730WDJEB#
M(46O\!O^"+_[#'[/WQ.LOC;H'AWXE^-_BWX=2[3P;X\^,_Q5\4?%#6/!NIRV
M\]K!KGA:'Q+(^EV&MV4=U.NF:E<6%XVG/*TMD\$WSU^MHV#@!5!0;5XQR=H
M'3DD  #DD#@G!E1X0H=O+W(-C.=A*?,PVLQ.1@@Y'3.<5[E//<X=#"TJV.QG
MLX89PIP]O4M2IV=-4(I)<M)4I.*IWY>1N/+RNS3RS!<TJD:%)NHE&I>G%^TD
MK/GG?64]+<S]Y]SX1_9!_P""?_[.?[$.A?$/1/@SH>NW5W\6/&M[\0OB+XG^
M(_B$^/?&/B;Q#?B19I;[Q)J=E;RK:VYFG<6>QF#33.$,LKN:_P 0/^"?'[.O
MQ"_:Q^%7[;-SIGBOP[\>_@WI!T3PUX@\&>(KGPQH&L:"@U('0_&7AV#3VMO$
M6G2QZQJ,#I+/$TL=RJ&7$%MY/WPTEN@)=HD&X.=Q11N<%@QY^\P!(;J<'FE+
MPGDA#N)'.PY(Y(Z\D>E2\RQ+J>U=>NZK@Z;J.I-S<'3]BX.3;;@Z7[KELX\G
MNVL:+!4%&G%4::C2ES4DH02IRUU@M%%ZO6+3U/A'X#_L$_L^?L]?M"?M!_M1
M_#2#Q=:?%/\ :BOEO/BW/K7BN76/#T\XOS?)_P (YHK6B+I'EW9W>7!-(&7:
M)I"$4'H?B'X4^!>B?M$^!/BEXNU&[TGXIZ)X(\92^&)'U'4DT>'PCX:TN_U+
MQ7=RZ=;V%U8W%SI]C?W%T);J[M+F\MA<-I<=V^FW<*_9PDB)W#:2<C<"N<#
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MBW$XMX)9RC/Y:EMBE0QQ[DX 'WF/)"@D D8/COQ2_:'^"_P/L?"VI_&;XG>
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M=HOB*(^)=*TF'7KW5)+GLM?_ &,?@K8^ ?$Q^*?C[XI>+]+L?A*OPP\6>/\
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M\3OA'<?!GQK=ZM(L=NUGH#> +NZCM%FG5M*U>./5K>1I[:,KP%]_P3A_9O\
M%_PZF\(>.]6^+_Q,'B3Q[\*/B1>_$'QC\0[_ %'X@ZO<_".PCTWX>Z WBC2]
M-TRU7P%;^&[S4O#.JZ+8Z?'9^(="\3^(K/6[V_NM>O+JZ .=\;?\%,/V<O#V
MB_$70?A3JEKXV^*?@3P;?>-;/X?7NCWWA#3->N=,?PK<^-]"AU*XTL6S>+_"
M.F>,])U/QIX>M(DO=$^U26E\TDT%T4_4;3[6TL[2""RMK>UMTC3RX;>&.")
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M"9/A3+\5_A9X)\4^(/C;\&_"?Q/^'7P[_9T\9V7C^Y\2^)/C!\<]$^%WP?\
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MQ.+A]:=+"8^IE55PA&47BX5O8MQ;UNIV36FOV;7:_347/(#+@YP1D\<X]/\
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M\2?"'CW7/B;??'..X\!:%X!_X9DO?AYKWP[T_P"!MH@M[_Q]8?&;4M?UJ_\
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M!WP,OC_XMW%E_P )9X?UKXL:T=7\/VMO\7?B#\)O&GB'X;1Z)X!U*'QYX4\
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M;K')=V%I.TD" 'I,^?)DQDD*2, $\<]#QV_#J.:\IURY?2/$\GB)K!KM]&\
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M_P 69?%VL>:U];+J_P /9+W4)%\ F6Q?[0L=M;W5HT4IS:7$EA'!<(UM+(I
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M<2V_Q TP11%XAX0U>5H([O48U+IJ5@,K8VL3Z!)(^T)'+=7*:A&TA%O$\1G
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M=75](O==-]//R/C^*<_QN3SP,</"C.&(ISDX58N2C*&MW9J^ZMVUW3/]$?\
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MO!GO17*\%AKOW'N_M/OZGJ_ZR9K_ ,_*7_@#/WBKQ3]HKX _"W]J3X+?$'X
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MBF]VEJ>6:EX#\&1^-9_BA?VJ6OB2T\/W?ANXURYU*>WM$\/N\-Q<I<6DLB6
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M99])2%#E84TZ62S2((D#% *[&MB0HHHH **** "BBB@ HHHH **** "BBB@
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ML66D^WF-Y(I9VF8/&Y!3/-9/B+7=4\0^==:I<"9K:TN%M45%CAM81$X$,,2
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MAOQ'X?URR@U'2=;T#6[22PU?1]3LKE)(+O3]2LYI;:[MIE:.:)RK+T(^(?\
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) ()?_P D?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %J K8# 2(  A$! Q$!_\0
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M8YNUZB3W;YM/.Y^S?_#_ +_X*??]%@\,_P#A&:=_C1_P_P"_^"GW_18/#/\
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M^-?C/_GM_P#KHJZ>6Y79WH1WTO37X>Z+ZUB?^?S_ / G_F?LQ_P_[_X*??\
M18/#/_A&:=_C1_P_[_X*??\ 18/#/_A&:=_C7XST5I_9N5?] \/_  7_ /:C
M^M8K_G\__ G_ )G[,?\ #_O_ (*??]%@\,_^$9IW^-'_  _[_P""GW_18/#/
M_A&:=_C7XST4?V;E7_0/3_\ !?\ ]J'UK%?\_G_X$_\ ,_9C_A_W_P %/O\
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M\:/^'_?_  4^_P"BP>&?_",T[_&OQGHH_LW*O^@>'_@O_P"U#ZUBO^?S_P#
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M)_,_17P;_P %2_VLO GB;X;^*] U3X?7MI\,/@NW[/6D>$?$'A33;_P)XO\
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M',RW&NWHLK2V&M0:P-8N$OGN1(]]!N2X,BDYRO'W_!4_]I3XB_$OX5?%Z_\
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MG^$OQ4:)/M=IOMHH_BBRLCNTZK=/)-\RNGE[8N=K=1\B_;[3_G^M/_ FQ_\
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M9_\ /_9_^!-E_P#)?^<?3/\ I&_\.U?^"?/_ $9[\%/_  0WG_RQH_X=J_\
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MV?\ S_V?_@39?_)?X_\ U^*3[?:?\_\ 9_\ @39?_)=?Z1W_  [5_P""?/\
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M/$_A"^T#7UL=*GB_M'2)[E+F\LG(N?DCN98XF;A@OEC@]D\^@_L)^OKZ_/\
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M2UDZ6BG;[_\ ,_S<AJ-BB>6=1L51HYD;?>VHDD>:<3RS-.;F68S-Q"Q#JIA
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M )_[/_P)LO?_ *>_\Y^N/]([_AVK_P $^?\ HSWX*?\ @AO/_EC1_P .U?\
M@GS_ -&>_!3_ ,$-Y_\ +&E_;\?Y/R_S#^R'_.?YN/V^T_Y_[/\ \";+_P"2
M_P#.#[9/M]I_S_VG_@39?_)?^<_7'^D=_P .U?\ @GS_ -&>_!3_ ,$-Y_\
M+&C_ (=J_P#!/G_HSWX*?7^P;S_Y8X_2G_;\?Y/R_P P_LA_SG^;C]OM/^?^
MS_\  FR_^2Z/M]I_S_VG_@39?_)?X?\ UN:_TCO^':O_  3Y_P"C/?@I_P""
M&\_^6-'_  [5_P""?/\ T9[\%/\ P0WG_P L:/[?C_)^7^8?V0_Y_P"OO/\
M-Q^WVG_/_9_^!-EZ_P#7W^/T]^*/M]I_S_V?_@39?_)=?Z1W_#M7_@GS_P!&
M>_!3_P $-Y_\L:/^':O_  3Y_P"C/?@I_P""&\_^6-+^WX_R?E_F']D/^?\
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M_B:/['U7_H'7G_@/)_\ $U4^VW/_ #_7?_@QDH^VW/\ S_7?_@QDHOY+[O\
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M,^^-O'T[4[^Q]5_Z!UY_X#R?_$U!]OU'MJ%WCM_I<Y_7'-1F]NLG-]=Y[_\
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MR?\ Q-5/MMS_ ,_UW_X,9*/MMS_S_7?_ (,9*+^2^[_@BMYO[_\ @%LZ1J8
MS8W>\LH$?V>4MY?/F3'"X$<6%WGKEUP#S4<NDZLA=!97D;M$QB)A,8F#QOL*
M2O%(\1#;65HHS.6VJJX)J#[=>!9C'?W2M]F?>?MLTC_9Q+ TX0+DY\L'/?T]
M#^?G[:O[;6L_LR>-?@OX4T(^"M5L?%NJ2>,/C+9>.?$4&GZCHOP:L=:T/0+B
M^\+QWL\#1ZTE[KEEJ]C< E9+33=1B0%PV"_E'[O^"%O-_?\ \ POVVOV-OV@
M?VI?&GAU?!WQ T;X1^ _!'PR\:6^@GQ-X!L?B'?>(_B-XG6SCBU&_@U'5-*7
MPTVDQ6\W]GZO:;]4LQ*US%;2.NP^63?!;_@H+_9_QD^'Y^!OA'Q4/VD/A!\*
MOAGXE^+^O?$K2D\,^!=1\+^'+_PEXIU_5/!E[Y-YJY^RW,.HZ)"EO/>"XVQ.
MZ#[VSK?[=7QAL_VW];^ GAKQ!\)?%W@FV^)_A/P@OP9T?3-6@^-VO>!O%7AN
M#66^.4'BAD.EKX<T/3[Q9;R&&8R2V%O<3^7MRP^NOVTOCYXA_9Q^!GBCQQX7
MNO#VH?$?5/$>@^#/A>GC_6)-.\(:[XE\67B6EA<ZM/<^4MM96\4?V^61@&DM
MK5S%DL,IMM6M'7^Z_P#/SZA;S?W_ / /H?P7X*N_!_@SPAX)M8]5U>S\->&-
M!\/V-Z]A>O\ VF=-LHK:ZU)[@1L8C<7<3".&8I:):E1YN!BMXZ;J017_ +.O
M2IB64D6[DKO. C#'WCU'8CO7YD+^U%^TY\<G_9RT[]F7Q9\$?!6K_%SX.>+_
M (F?$AOB#I6J^/-&_P"$S\(ZBWAW7?!/AZ73 XL- L=5B8VUZY2*,21RNP16
M(^NOV:OC=JOQ\^!_A3XF:MI5UX=\47L^K>'/%NB66KF_L-*\1>&M2ETG4DM[
MNV:2VGMC>0,UK/ [130,KQLR\U"@NOYL+>;^_P#X!]"'1M6!P=.O 1_T[R?_
M !-)_8^J_P#0.O/_  'D_P#B:K->WNX^;?78DS\X_M"0?/\ Q<?7--^VW/\
MS_7?_@QDJRK^2^[_ ();_L?5?^@=>?\ @/)_\32'2-5'_,-O3]+>0_\ LM5?
MMMS_ ,_UW_X,9*<M[/SNOKOV_P")C+_2I<4W?77S):OU:]'I^1LZ-IFHQZI:
MF6QO(P5N0I:VF(+?9I.!A3SCGG XZUD#3=09P$L+QQ^^Y%M*!_K<]U%:&D7L
MO]IVG^E74O%SA3?SN!_HTOS84$CL,UCFYNR0RWUVB_O,I]KG0?ZS^\5 &#R,
M]>E4O=5DE;SU?YA;S?W_ / +@TK5"0/[.O>?^G>3_"G_ -CZK_T#KS_P'D_^
M)J@+JZ!!^W77!'_,1DJ3[;<_\_UW_P"#&2G?R7W?\$+>;^__ (!;_L?5?^@=
M>?\ @/)_\31_8^J_] Z\_P# >3_XFJGVVY_Y_KO_ ,&,E'VVY_Y_KO\ \&,E
M%_)?=_P0MYO[_P#@%O\ L?5?^@=>?^ \G_Q-']CZK_T#KS_P'D_^)JI]MN?^
M?Z[_ /!C)1]MN?\ G^N__!C)1?R7W?\ !"WF_O\ ^ 6_['U7_H'7G_@/)_\
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MG_Q-']CZK_T#KS_P'D_^)JI]MN?^?Z[_ /!C)1]MN?\ G^N__!C)1?R7W?\
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M@W=FA4GP=K>B:?I@\4>'"2)YXI+B./S0K5X3\.OV)OBKH7Q$_9[^(7B/XW>
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M D'*^HH;3;) I?7+!0S*@R!DNPW*N!E@67D9 R*_%WX&_M8?M4:UX6^&$'Q
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MMC VGB2\5>;BPM+"XED^R_\ 'TUZL,U@1*JD>,7W["?P_?6O _C#0?CC\8_
M7C'PAX<T7PG>>,/#OBVUO=<^(WA+1;TW?AG1OB1#>P75IXAM=#M-L,5]&5U*
MVL5%N6^4BOSPUO\ ;8_;K\!:=KGCKQA;_LV:UX3\/^!_@U\8-<\/>#?#WC-/
M%6N>$?BEXMB\-+\/K'5A>"*/7/#,<T=]::E<H]CK%N)K$1KNYMW'_!1'X_\
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MEZ?>EDBC4HJ#\KO&O[:'QT^,DW[-OCOQ2WA1?!%A\+M2^*_C;P?\,?VA]?\
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M3=<DUF[\4^)H-)/PW\2ZYXMU719(IK3P_IL7B?POJ,VIVUM#?"2&8LWZL_\
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M$CL<Y% ')IX'\ 2V<$+^"_#2V$5CJ&B+;W&BV$N=!UZ6.VUO2+*TCMX19IK
M98[B *=]B9GY534X\%^#+74=/U9?!W@B#Q!I,FG7&CZZ/#MBMWI5Q#;&RTQ-
M-D:WE"'P_9_\2R%@% L'D(.S(/3.S2/YDC,\@<2!W)9PZH8U?<V3O$;,@;.0
MC%0=I(H5W7[K,N05.UB/E(P1P>A!((Z$''2@#R75/V?/V?\ 7-3L=7UKX&_"
M?6-6T2.^.EWVN?#_ ,*:EJ5C_;%R\NIKH^H2:<TD-QJM\\ES<2?\LU<LV!@U
MRE[^S'^R3IGA_6-/U3]G3X :=X3:Y?Q%K]MJGPJ\)77AJ/4$YDU?48'TW%_K
MB!MR7>2$<AAR :^@2JX^Z/E#[>!QO7:^/3<ORMC[PX.17D_QXM]?O?@7\6K/
MPM:W.H>))/ NMIX=L;.WBO+J;5C"AM(K*SG5X)[EI!^YAD0QR/A6!!- &A#\
M#O@OXAO/!WC:'X0^ -;U#P)I-E;?##Q7?>#-'U+4?!6B11$:))X3\1'3FN_#
MZ*/GT^WMG5(YDB"X*@U3\-?L\?#?PWX U?X2)\/[;Q5X(\=:]K_B7Q=I'B?3
MH/&>D>-]4UZ^?5M9E\1V%TLC'4I=2D<2(1N#L>]?EEXO^'_[3ESXG\9_%.RU
MW]H'3-?^%W@;]D6V^$O@;1-3NM*\$^(O$^M1:!;?%TZAH%A/!I>LW6F64VJO
MK^E7=M+;:%<1&2U2*5<CYR^(OPS^.GPY\!_&;P5\+/$?[4GA'2KC]L?Q)K/Q
MY\2:M:_$#XL:U_PJ'74U;6?"&H_"1=(\7>&];N?#[ZY=6MMJJ^$=<L7TBR18
M[TLL8  /WJN_V=/@WKW@U_AI??L^?#36?ASI5_:WUW\-6^'GA^3P?9:U;QC^
MSYK?PQ)IC6=G=VD*IF>,"YRFYB6!KE;_ .!'[.6E:YX-U_7/@K\&[/7HHH?#
M'PW\1ZOX)T:#58FB:6&#P;X3OFTX3VFD0V,VH+'"3N5_, &W;C^>WXC_ !5^
M(>D_%O\ 8]^$7Q/_ &J?BE::%!HW@"[E^)TA\8_!/Q)9:AJ_Q%,<=OXG^%K^
M(=>UKQE<:YIL,'ABZO\ 7=4O);*QO8;XSEW>5OO74_ W[1UC\(-8\<:=-\:?
M$WQ6\0_M(?%>Y73/$%W'>'PQX%\.Z!JVG_#N_P##>A:J]W'X>LM1GN;>?3;Z
MQ,5QJLQWSNY- 'ZUS> /",:Q0:CX#\,"WFM]-TZ"._T/3[JRO=&\,W#7EGX<
MOQ>Z<$?2=$NU76+!_P#5&Z@38<XKRCQ7^RC\"/$W@?XK^"X_A5X3\"Z+\;+*
M>R^)&N^!O#6@^&_$'B6*[NTGF'BV^TS3EFN#=P(&_LZ<B.Y')4AJ^$?V9K[Q
MU^S;\4?A1X9^-'C3XY>)M(_:*^"GA>+6HOBK=ZIXLN+7]J>Y\2B*+1-#L!/.
MOA_0;/PC+?2>(=-A$&G),MO(\9;!KQ?XT6WCG]EOXI?MW?M$>%;_ /:&E\6^
M"?%WPV^.NC:)JWBC6-0^"WQ)^%L%A'8>,_AWX4L=3N;K1]/\12:A(4L[6.V6
M^6Y1(X"(\@ '[%^%/@1\)_ N@Q:'X!^"G@CPGX<T6*6Z.G^%_!.AZ?I9O=1M
MEM-5U&6R73!;-=:I 9+6\U,?OKJR^60E*J>%_P!G_P""G@2WDN/!'P.^&/A+
M2II[J0P^$_A[H6GZ;=7-UYFGW7VR<Z8([^[U.S4Q7$JLP42/TYK\"H/$WQW_
M .%OZM\/]5^('[5_BCX[:;8?LU^._A1IG@S4=1B^#WAG5_B9H.E^*_'N@_&"
M2.;^S=/@M='OGL[NVURWN].CL(PNF6]O?9>OH;X":/\ M7Q?\%!=6N/C1\</
MB?HUS:_$?Q_#JGPL@^%/CVZ^$.O_  RGD">"+#1/B(_C)_AWHEM+H8T^[L)=
M/\$PZ]<7*7$5_J<-W]HDE /UBLU_9S\&VFG^(K:Z^#/A2PTS4]3\(Z/KBGPO
MI+IK5W;1V.L^!I+B*WBFCFM-.MK#0[RWCD$ITT1(PV.0?+-6_9Y_9CMOA[\6
M?@OJ5QHOA?0_V@Q:>+OB)HMIKME8WNKV<NKZ.^FG3K&X81V'AZSNK'3=+TCS
M4%K?6]XR89)"#^=6J?LQ^,/B1^V+\;_$WCOX2:WI?[,/Q]TKXC?"#X8^'+N&
MWO3\*?CYIGA^R6\_:2;1[2-;#3-)^(SZ;I6E0:FT"W&E2:1'?0S)-JUR\E+X
M>?#'XZ_%#X&?$WXG?&#X6^*M$^,&F>(/@7^S]H>AZE8I+KVK_"KX)>*K&UN/
MB;:&57D_L;Q+>73W%[&&"SV]I;2S!_L\95=?P _8+X;_  H^">@>%K#PA\)/
MAY\,-.\$Z?JYNY-+\&^&/#EOH]MXA\,V3"ZU34;72]/877C-+B&U::] )\[)
MZ4_PY\ _@UX=U*[\5>&?@?\ #/P]?:CJR>)M;\2Z#\/=#L;^[N[&\CO[;4-3
MN6TL!/$MUJ*+J%RK,LK7%K"Y7+"ORM\6Z#\1? _[-_AJQ\1:'\>O#?POO?VL
M/'\OQT/[/\5W9_%^Z\ ZC;S-H%SHMCIK0^(;31+G6XM+6XOM!GMS):R3YW*S
M Y%[>?&.Y_:6TJTT"7]JL>-D^)/PT;X%S3W&M?\ #/,W[*=Q91/XFN_BW'<7
M;6?_  GS:+#JL>O_ /"1177BRPU-+:>"\4E" #]1]&^&O[-.H^-/"7B/0/AY
M\"]1^)OA+^U'\&WMIX=\.7WB[2HDU/.LR>'IK"P>>!=)U6999&VEH9V<D@BL
M_P"&G[''P%^%TWB-?"_P/\.:YXB\2:YXOU[QGXT\3>%M$UCQ9XGD\8:S+XB\
M01>(/$EUIK7MSX2EOY&33=$=@(E15B&U17Y'>,OAE\<?"=IXLU[PY\*_B&M[
M<Z?\?K)M1\.1:UX:UK1O#.L^/[.YG\3:;+H.J6FO7<&A:,)]>TN+2+RTO?%M
MO!]FMC8M(6K\YM1^,_Q[T;Q'X ^#OQL^/'QT\&?#ZT\27EW\./B-K-_XQ^#/
MBV+PQJGB)4T'Q!>^#-6\1>)/%GCZTEO6AT6/3M?UN^?3HW+S")6*A@?UTS?#
MGPA?WD^OW/@'PYJ.H:@]O87&MWOAG3_[0U:*PT]-*A$\[Z;^_MXM)BBTW2E0
MLL.FQ00  )BHC\/?!>BZKIMW;^!/"^E:UITMD--OK3P]I]OKMH[Z/!I5J;"\
M2UMS:VD/A^"VTC4XF8BZ@BCA497%?S;0^&_V[-0U?QW8ZC^T-^TAIWQ8U3Q9
M;^&?'W@O1_A3XVTGP]!X%NO&9@N/$/A#X@:YXRU7P1I\^G>$?*OHY?"_AS39
MB9F'WT&/VZ_9/\(^-_AW-^T'\,/$=_X\UWP%X$^,\-G\%]<^)6M7OB?Q%JO@
M/5_!7A[Q%-=6_B75)Y[[Q#I+^(M2U2:"_N"38WCSZ3 RP64<:@'ONI?#?X;^
M(?!D_P .=:\">"-5^'>I?:+37/ VK^'-/D\%7MHMS-?PP7.@7,$MM?S0WIN[
MQ[.XB,5Y<S1LW8'A_!/[/7P4^'WC.P\>> _!.C?#S4++P7J'@[PSI/A6QL?"
MWA_PEX5O;R&YO['P[X/T>T@L=)U+Q'>VUM?7LT(C>.XM8'D^7(/M> TCL1EF
M.YB>2S?(=S$\ELJIR<G('/ J7<P8L&8,2Q+9.XE\!R3URP #'.6P,YH ^??@
M[^RO\!/@)H5_X>^'/PI\*:?<:G:ZK8>)O$VHZ#IL?BCQI;ZOK%WK-W;>,-:@
MC9]<@NKK5[J$)=;XMCE9E*Y%=7JOP,^!FK>*=$\::M\%_AC?^.-'M5TCP]XH
MU'P7X>N?$>GZ=;+]BM=#L]173]EEIEI8S7-C&&(4+,H QQ7J:HB#:B*J_,,*
MH488Y88  ^8\MZGDYIX)"L@)"/G>@X5LD,=R]&RRACD') /4"@#QVP_9T_9Y
MTW2;;PS9? OX/Z=H-OXAE\4:=HECX#\/#2+/QM(S27'BW3X?[.Q9S3DD27
M1I2S$\UUTOPX\$3Z=?:,O@S0-/M]1U.VOY9=.T+2].9?$,=K)9:1XA@N[*.,
MCQ%H43M'HVL )]ERN"N,#M0[C.&89B\DX8\P_P#/(\\Q?],_N^U1A$7HBCY2
MG"@?(3N*\#[I/)7H3SC- 'CVE_ +X*Z9\*-!^"^J?#CPOXR^&'@]+?4;#PI\
M0=+T[Q2TWB&/49KRUOKI=0M)VN-9M=5FGU'5KMI&\Z[FDE!VL,7_ /AG_P"
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M268Y))(!R23D ]132 2SD N2"6(^8DNF26ZDG R2><#/2@#VOX7_ /(,U/\
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MM[2*Z\V.VB54A5 *UWOKZ2!+62]O'MDD:5('NIVB61_O,(VD*X)R=N-H8E@
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M+0 4444 % =4=!(ZI%*WD3$Y!$4P,;LN ?GC5C*H(PQ3!(S11C.%)PC';(0
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M%%% !1110 4444 %%%% !1110 4444 %%%% !0>A_P" _P#H:T4'H?\ @/\
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M CB"_,]Q,'F*-%@Q"*%20LDA+;I,?*,<\4VB@!H"J6$0>.$L9%A=@Y25^9Y
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M#,HK1)T4< WY X!"GD=CTHSHW_3_ /D?\* ,ZBM'.C?]/_Y'_"C.C?\ 3_\
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MD\'KCGGOS0!F>:G]^'\WH\U/[\/YO6I_;4O_ #XZ/_WY;_XJC^VI?^?'1_\
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M\.JI<WFJ6A@EFE%D^GG6E.GI)!]OBU'3;6.+8 L\86NB;]M#]F:/5-6T._\
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M\3EB!Q\Q.PEO4[5R><#I0!E>:G]^'\WH\U/[\/YO6I_;4O\ SXZ/_P!^6_\
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MPMGF\,_$!;SQ-X5;PQ::1K>K2Z7K.GI8:5%+<ZK>;@+O49Y T7EA<CYSL_\
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M7FK^,/%4>K'PW:Z3I/@JPOYO%?A1+R\ :'5=:TVVTJPA/GW,Z7"XH^X#X?\
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M92$"OM#@1@,Z(IBCB+@[A$D#RQ&,?*_F%FY510!_-G\;_P#@EK\4_A9X'O\
M6?A7\,_A=\2/%'AGQY!XC^'WQ!\%:]X\@_:0L])U3QK'XKN+K4;:72]5\%,+
M9C),7M)O$$EV;>R66WB,)C/Z ?L@?LR^+%\#_#3XG?$/X>>&?@WXGM?V</B3
M\()/A_JFG&_URTU7Q;XWM=;?QI?ZK?:/IRZ1>Z]%#-/J_P!DM;:2<S.J-"C;
M:_5$22H,02R6^V&.&-8G*1QK"X:(A$VDLBY13N P<XS2O([-)(&9)Y&+/*&+
M^8N1MCE27S%DC0 @*<#YB3VP ?E5X-_X)V:UX8\"^/O#TGCCP+-XF\7?$/\
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M1110 4444 %!Z'_@/_H:T4'H?^ _^AK0![5\+_\ D&:G_P!A _\ H%%'PO\
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M4?\ 'V21NX/7GKC\ZK_:M&_Z!'_DY)_\55>[1SI_A]@CE1IL^6"L5'^EG&6
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MH *#T/\ P'_T-:*#T/\ P'_T-: /:OA?_P @S4_^P@?_ $"BCX7_ /(,U/\
M["!_] HK&?Q/Y?D!S'Q&_P"0RG_7HG_HZ6O/>P^I_DM>B?$;_D,P_P#7"/\
M]&35YZ_4?3^IHA\2^?Y ,HHHK8 HHHH **** #^G3VZ?X#\A1_\ J_#THHH
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M76-2#!O-B+@$+)-:V3^4#@L4XR-P&&'0X&0:R]JGJJG\!_A1M7^ZOY#_  H
MUWUK5&PSWS3/T#+9V2(J^@('Z9Y[ "F?VSJO_/TW_?BRK,VKC&!CKC QGUQT
MI-B?W5_[Y'^% &I_;&JG@7))/ !@L\$GUV_-CUQSZ<UH6&J:A/%J%O//"?\
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M&6F4KD@T1^)?/\F!\7:U_P %$O@IH?Q5UKX;:U\-?BCX>\.>$O'D'PK\1?M
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MQ3H5O?W,D,_BNRLOM&DWUO+:WD*2VSA897(V_K^M?-@?K?:?MA?LOWOC'2?
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M!]"_\!IO_CM8J_=7Z#^5+0!L_P!LQ?\ 0'T+_P !IO\ X[1_;,7_ $!]"_\
M :;_ ..UC44 ;/\ ;,7_ $!]"_\  :;_ ..T?VS%_P! ?0O_  &F_P#CM8U%
M &S_ &S%_P! ?0O_  &F_P#CM']LQ?\ 0'T+_P !IO\ X[6-10!L_P!LQ?\
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M$I8M%&T#2,D)QY0=XYR'?;R[-M<DY=%)Q7R9\#_@/<_"+XG?'OQ)9P^&-(\
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MMXDUSX/ZMXU\=64-[H_@;3/$*(_E7FG:5=1O=:WK#+:/*L^^3S!'M^EOC!X
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M'J2S<\GMT%-HH **** "BBB@ HHHH **** "BBB@ H/0_P# ?_0UHH/0_P#
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M%?#VA:_KT7B[6-#TG2](U;Q*--_LF7Q8FEV%OI\%U-:*673G5+=)!$A*C)4
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "@]#_P !_P#0UHH/0_\  ?\
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MOHOBNQU&>XL]5BO[AM(@DAF%@5_>W9<, <;TR: -HD D$@$!202 0&&Y2<]
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M44WP#+IYT[4C86DB1?VD0R23$MN,9().[(('!'3!'UHK-QNV]?P\O,#F_B&
M=<7(!Q91XR,X_?RU\&_MV^"/$OQ'_8X_:$\#^#M#U7Q'XE\0^%='ATS1_#<E
MO;^*+K[%XQ\.ZE=?V%/=*]H+Q;6SF:**X1TDN!!N4H&!^\_B%_R'%_Z\H_\
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M-*$4YS@2,S@DDAB2#3XY98GDECEE269=DLJR.)'7(;#2 [SD@$G=DXP3C(H
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MVJM-HDZW%O#=!H 60&LWP?\ L4?$#X?^'O@U\/;/X2_"_P -W5Y^T]IGQO\
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M^+G_ ,"9O_BJ9]JN?^?FZ_\  F7_ .*H D_LC6/^@?>?]\PT?V1K'_0/O/\
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MJN?^?FZ_\"9?_BJ )/[(UC_H'WG_ 'S#1_9&L?\ 0/O/^^8:C^U7/_/S=?\
M@3+_ /%4?:KG_GYNO_ F7_XJ@"3^R-8_Z!]Y_P!\PT?V1K'_ $#[S_OF&H_M
M5S_S\W7_ ($R_P#Q5'VJY_Y^;K_P)E_^*H D_LC6/^@?>?\ ?,-']D:Q_P!
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M/^'\+N&LO#5]?&!KXZBUYJC6]A90PWD>)M_ZHHJA1A1W[#U-/P!T&*.:7?\
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M:[_SUL_^_I_^)H_X5MKO_/6S_P"_I_\ B:]UP/0?D*,#T'Y"CGEW_! >%?\
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5>_6BNSE1& +*I.>I4'L?444@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ JH# 2(  A$! Q$!_\0
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MXT8]C1[-!S,^@?\ A<?A3^]>?]^/_KT?\+C\*_WKS_OQ_P#7KY^Z<TJJ78(
M69S@ #DGMBCV:#F9] ?\+C\*_P!Z\_[\?_7H_P"%Q^%?[UY_WX_^O7@,L4D$
MSQ31M'*IPRLOS _2F9^G^'UH]F@YF?0/_"X_"O\ >O/^_'_UZ/\ A<?A7^]>
M?]^/_KU\_=\8H_"CV:#F9] _\+C\*_WKS_OQ_P#7H_X7'X5_O7G_ 'X_^O7S
M_P#C0%+,% +,>@7DD^E'LT',SZ _X7'X5_O7G_?C_P"O1_PN/PI_>O/^_'_U
MZ^?R"C%65E8=0PP11[_E1[.(<S/H#_A<?A7^]>?]^/\ Z]'_  N/PK_>O/\
MOQ_]>O 8()KF01VT3RN06"HN3@=3]*8/I1[-!S,^@?\ A<?A3^]>?]^/_KT?
M\+C\*_WKS_OQ_P#7KY^I\,$UQ*(X(GFDZA$7)/K1[-!S,]^_X7'X5_O7G_?C
M_P"O1_PN/PK_ 'KS_OQ_]>OG[H<9Z<$D=Z/K1[.(<S/H'_A<?A7^]>?]^/\
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M\*_WKS_OQ_\ 7KY^HH]F@YF?0/\ PN/PK_>O/^_'_P!>C_A<?A7^]>?]^/\
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MYHYH **.:.: "BCFCF@ HHYHYI,#5\,?\C9I'_7VG\Z^JZ^5/#'_ "-FD?\
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M*YT[=]I;R6"H5ZC=C!/L*.=ARH\V_P"%&2_]!U?^_'_UZ/\ A1DH_P"8ZO\
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MM% "8I:** "BBB@!DO\ JF_W37-5TLO^J;_=-<U51)D%%%%62%%%% !1110
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MZD=+TBVN0;?4+>WNK[:#$I<C*8)ST(YH'Q9T>;4[^RM;*\F-NLK(R8Q,8^7
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MP!0N"0>/S[4 9\.@Z1;0W$4&FVL<=R<SHL0 D^OK4K6-G)-%+);QNT(*Q,R
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M3WCL3]CT<P;ED0Q [B_<@Y'6LU_$GBJ+6-#L[>[CL+9;.T,4<D;$718#S!@
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M>BD%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% $<G^I?Z&N;KI)?]4_\ NFN;JH$L****T)"BBBD 4444 %%%% !1110
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M7VC0Z?&\IANIKB7@-N 4*!DC.>]>GID/CG&.* ):*** "BBB@ HHHH ****
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MNG2JL,#R2DA4O&=CO">N.G'>O8GT^UD4*UO"1C&#&I&/RIATNS_=8MH (O\
M5 0K^[_W>./PH \DC\0W^M_$'1A?7D:F#5IXUTU82'ME"$*S-W!_K4-]K.H>
M'O&NOZ["UU<6S7?]G/ &+!':-?*8 \ !B>E>RBRMQ*9A#%YIZR>6-Q^IH-G
M<YBC()!(*#DCH3ZGWH \2MFU'2] U;PXTU]?7]YJRP.L,A,NW8'EV$D =QU
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)/O6K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS*)")#[8(_+TJM)\-M5F\6S:O//93PLLZ 2!\NDB8",H.,#VY->K44 >2/\
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M&Q]ZN<]>>U &C+X\TZY\':EXATK-TMBIWPM\C!AC@YZ=<_2H_#GC1=0MK/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "P 78# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBCK0 4
M54O-0MK H;F3RU<D!MI(SUP3VJ2UNHKNW2>%]T;C()&/;H>E $]%&1ZT9'K0
M 449'K1D>M !11D>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%&1ZT
M9'K0 449'K1D>M !11D>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%
M&1ZT9'K0 449'K1D>M !11D>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M&1Z
MT %%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%%% ' _$=QMT<*KRNEX#Y:2J,
MY&!D$'.><'H".2*[U>E<%\27@B@TII7CCWW00N[E1P,C. 2>1QTY(ZC(KO5S
MM&>M %'4-)@U*2-IWE 0,-JM@'/J/7T/:K%I:I:6RP1EBJYY<Y)).22?4DFJ
MFKZJNEI$[PO(K[AE2!@A2W?UQBI=,OEU#3X;M4:,2+G8W53G!!_*@"UY4?\
M<7\J/*C_ +B_E1YR?WJ/.3^]0 >5'_<7\J/*C_N+^5'G)_>H\Y/[U !Y4?\
M<7\J/*C_ +B_E1YR?WJ/.3^]0 >5'_<7\J/*C_N+^5'G)_>H\Y/[U !Y4?\
M<7\J/*C_ +B_E1YR?WJ/.3^]0 >5'_<7\J/*C_N+^5'G)_>H\Y/[U !Y4?\
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MQVS^-=$)D_O4P'A0HP!@>U%"L&&0<BB@#A?B-+<00Z3/:QM(\5T7P)E3.%Z
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M'ZT 245'^^_V/UH_??['ZT 245'^^_V/UH_>YYV?K0!\O^*?^1NUC_K\D_\
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M_NT /S1FF>3'_=H\F/\ NT /S1FF>3'_ ':/)C_NT /S1FF>3'_=H\F/^[0
M_-&:9Y,?]VCR8_[M #\T9IGDQ_W:/)C_ +M #\T<4SR8_P"[2>3'G[M 'R_X
MI_Y&[6/^OR3_ -"KK_@S_P C==_]>9_]"%<AXI_Y&W6/^OR3_P!"KKO@T WB
MV[!_Y\S_ .A+7HU/X'R/-I_Q5ZGNU&:C\F/^[2^3'_=KSCTBO>?ZZS_Z[_\
MLK5;S5&\B02V?R_\MQ_Z"U6O)C_NT 29HS3/)C_NT>3'_=H ?FD)IODQ_P!V
MD\F/^[0!PWQ=_P"1#E_Z^(OYUX%7OGQ;15\"2X&/])B_G7@=>AA/@9Y^)^,^
MEO 7_(B:-_U[+729KF? <:-X%T;*Y_T9:Z+R8_[M<$OB9W0^%$F:IV'WKO\
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MF+D*MY>$^6/WSLWF'>,!SAG_ -D'[L8^\W)JSIF[^V;4$2$B<E]S<ABAY?\
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M\G#MG(3KCDXKQ_XFD?\ "PM3Y'_+/_T 5T822<SFQ/P#OAAS\0M._P!V3_T
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L1:N447?<+(JIIUI%()(X(T8#&Y1@XJ?RE]#^9I]%+<=A H P.E%+10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $" 30# 2(  A$! Q$!_\0
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M^'QDMJ+N00[E!3/'2N@>]EB(9YCM'.,US&KJ%^(8&,C<O7_=KJM"TPZKJ^9
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MMS%Y[94R#;$A[)GK]3UKA/"R-)KNHJ%W9C?.>WS=:V)O%FD3RF1KB?/O%_\
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M0.&>"X!Q*!V/M6;<S"TTU;961Y=[2-L&%&XYP!V KD6\;Z8Y^>>=B.A,7/\
M.G/XYTLQ)&DDJJ!ALP9+?7F@/:+L_N+]S<M' 5'S,_RJ#5.5/+TVX ;/[B3/
MO\M9:^(=%#[WN;AGSU\K@#T S2W/B72&M;A8Y9RSQ,B@Q=R,>M,B<^:+23^X
M^N-,_P"059_]<$_]!%%&F?\ (*L_^N"?^@BBD;EEN@KS_0?MR_$C4M\E^UD[
M28\V)E42C^$DD@J%(*E0!R,\UWTSI%$TDC*J("S,QP !U)->;>&KG2;OXF7-
MU93K*\JW&)%NDF:3#+DD Y1.1M]<4 3_ !=B231].WQH^+DX#J&_A/K7E26-
MNQ"_9;<L>PB7BO6OBN<:1IW_ %\'_P!!->9Q92-5C($TIPCG^'N3^%!#IQD[
MM%?^SK0RBV2VM?/()=FB!6(8[X'7T%74TG2D0*;6&3"_>:( D^^!4L48C C3
MA??J3ZGUJ4  '(!]Z!>QI]AD.BZ4PQ)9V_3@A!R?RK-N]+AM7:2*Q@FAQDH8
MQN'N..?I6H,!@3QQZU,/WI"HIP5SC.<?2@/8T^QS4MM9@1O'#;M&XR"(AT_*
MN<T"[>_UR^MIX;=XH@VQ?)4?Q8]*ZRYLP-7*P?NTFAWL@'!<'DCTKCO"2X\4
MZFK?[73_ 'J ]E#L=E;:9;2OC[) <<G]VO\ A6SI_A.+5?-\BQMU@A;$LWE
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MX]L5PG@[+>,-4]RV?^^Z[ZXE@WR3IN 0%%R<'<>3^'2O/O!K[/%FIMC/+?\
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M]'F'_(00?\!;_"N:UO\ LW59X9$U:W01@C#*W//TH'[6/])G41 -;HDC@!E
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MQ^ZHSS^M-BTC2=W[_3+=,],;O\:N1G+/*< $_+GGBIK:W-P274GW[T![*/\
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M-;FH_$>TO8VAAO+2"+H'WKYA'U'"C\S7/G6])$;8U"VW'@8?&!0'M8=SC]3
M7XBVH7& 8L?]\UZ+!<M')'*APZ' !/Y5Y[?PQ7'BJ/4H[^R\E2IR9QG@>E=1
M#K.G(K"74+7GJ!*.: ]K#N>@"47L<<T;C:W4#H#W!H.H7+0[%$JR9*\'Y0/7
M/K7$6GBBVT^<R6VIVK*>&C>0;7'OZ'WK6C\::,R9DOX >R%\A: ]K#N:LEQ>
MW/[EPS-DC<Q_/%3VFEM+((W?]V.ISQ^=9/\ PFN@1#":A"YQ_$W&:S=2\9VU
MZGD1:C;10$<CS1D^WT]J ]K#N3ZQ<0-J=S-:D"/"Q(<\87@FO./&S W>GX[
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MXL<'\1_*O+_B"F-0T[)R2&_F*+C]E'^K_P"9MP:'I,FT-I=L"P]#5C_A'=&
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M:-6F\R_E3JL/[L?AW_.GZ'(R^(IE:3#"S#+@=@ZG'XU4N5D%S,&(W;VS]<T
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IR?6C)]:** N&3ZT9/K110,,GUHR?6BB@389/K2]J**3*@+1112-#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #1 7<# 2(  A$! Q$!_\0
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MG1M'J?SI:* $VCU/YT;1ZG\Z6B@!-H]3^=&T>I_.EHH 3:/4_G1M'J?SI:*
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MW+V+&X:0@2,J&6#RG."1DC..?48K4/0XZUS7@F\O+O2;@W[7#S1W4D>^88+
M'@CD\4 =-15:_DN(K.1[5-\PQM7&<\U8.0.!F@!:*K7-R]O&K"$NS,%"[@.M
M4Y=9>W3=/9LG#$8D5LX&::3>PG)+<U:*QTUUC,B/:%%9PF[S >IQG%<=-\9M
M(ANY+<Z;?$I(8RPVXR#CUS5*G)]"74BNIZ314<<GF1)(%.&4-U]:?D_W?UJ"
MQ:*3)_N_K1D_W?UH 6BDR?[OZT9/]W]: %HI,G^[^M)D_P!T_G0 ZBHY9?*B
M>0HS!1G ZFE20NBL$(! (SUH ?13<G^Z?SI<G^[^M "T4F3_ '?UHR?[OZT
M+129/]W]:,G^[^M "T4F3_=_6C)_N_K0 M%-R?[I_.C)_NG\Z '44W)_N_K2
MY/\ =_6@!:*3)_N_K1D_W?UH 6BDR?[OZT9/]W]: %HI,G^[^M&3_=_6@!:*
M3)_N_K1D_P!W]: %J.>"*Y@>">-9(G&UD89##T-/R?[OZT9/]W]: *D6E:?!
M;K!%90)"N=J+& !GKQ4C6%FZ;&M867T,8J?)_N_K1D_W?UH A-C:'&;:'CI\
M@XH^Q6OE+%]FA\M>BE!@<Y_GS4V3_=_6C)_N_K0!"+*U50HMH@H[;!3!IMB
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MU08_)Z[*3C47P,G+_P#H0KC?B5SX;E)&#]J@_D]=<.AR2ZF1\&S_ ,5?<_\
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MO*%RN< Y(.#GWJI)LF+2/FSQ8,>*]:_Z^Y?YFOH_PV#_ ,(QI?/_ "Z1=O\
M9%?-_BTY\5ZU_P!?<O\ ,U](^&_^18TO_KUC_P#0173B?@B<^'^.1J4445QG
M607IG6SE:V4-,%RBLV 3Z9[5ROPY(.AW7S.76[=65F9MN,# W<UV)Z&N4^'[
M,WAZ0O+YK_:9=[G=G.[H=P!S0!U=%8UUXA@LVO!+$V+89!R/G/3'MS6O&XDB
M20=& (_&@"KJ/W8/^NR_R-8^L_ZA#WP_\JU]0(*6_7F9>WUK(UHXMT^C_P J
MUI[HQJ=2N=N^'^]YZ?\ H0KYZO?^0M=?]?3_ /H9KZ&).8?EX\].?^!"OGF]
M_P"0M=?]?3_^AFNRG\3.2IT/JNT_X\X/^N:_RJ:H+1@+. <_ZM>WM4NX8SS^
M5>>]ST%L.IK2(K*K.H9N@)ZU -0LC+Y0NX/,_N^8,TDQ#7=M\H/+=1[=J0RU
M14,\[0Q;UC+G(&.E2Y&<<_E0 M99Q]MN\]-Z_P#H K3+;>Q_ 5EYS?7F ?\
M6+P?]T54=R)[&-+C^TY,],O_ .A"N-^)6/\ A&9=O3[5!C/T>NRD.-4DP,G+
M\?\  A7'?$LG_A&I<C!^U0<?@]=<.ARRZF1\&O\ D;[G_KT/_H0KW:O"?@T?
M^*ON?^O0_P#H0KW4'(SS^-98G^(;8;^&9]__ ,?]I_NR?R%96K]L?W!_Z,6M
M6^8&^M!S]V3M["LK5N3S_<'3_KHM1 J95N=NT8_NR?\ HMJ^?M'_ .0OIO\
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M->(>._\ D=-0^D7_ *+6O;_AQ_R3[1_^N/\ 4U5?^%$SP_\ $9U-9-M]Z?\
MZ[OGWYK6K)M_OS^OGOC\ZY8G5,QH<F>3!Q\@_P#0FKS_ .*/_(/T_P#Z^Y/_
M $6M>@1;?/DW?W1C'^\U>?\ Q1_Y!^G_ /7W)_Z+6NRGNCDGLRW\$?\ C_UG
M_KG'_,U[)7C?P1_X_M9_ZYQ_S->R5SXC^(SHH?PT9]R?^)B!W,/_ +-61?\
M-X,<?-%_)ZU[G']H<XSY/_LU9.H#_2ESTW1=/^!T4]T$S$\2_P#("U/)S_H$
M_P#(5Y'X(_Y'?1/^OE?Y&O6_$F/[!U/;T^PS_P A7DG@?_D=]$_Z^5_D:ZX_
M#(Y9?%$^G:J:E_QZ?\#7^=6ZJ:E_QZ?\#7^=>>MSO>QF:I_Q[#UWG_T%JS)
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M\4C4HHHKC.P**** *6J2W<5H&LU+2%P#M7<0/7'?M5N,N8U+@!R!N [&G44
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M!I+O]TH5")L%<'(/3US[<TV[\ :5J%Y-<WTUW.\CLRJ9<+&#U4#T/?UKJJ*
M$10B*HSA1@9I:** "L*;PG837%U-YEPANI5EE57&UB#G&".F:W:* .9N_ ^F
MWMO#;2SW7V5#(6A63 ?>VX@^P/8>M:VCZ-::'9-:V?F>6SF0^8Y8ECU))^E:
M%% !1110 V1%EC:-AE6!4CV-<U>^!M,U VZ3S7?V>WB6..%)=H!4DAN.XS73
MT4 4]+TVVT?38;"T4K;P@A 3D@$D_P!:N444 %%%% &#>^%+.[DNY4N+JWEO
M)(WG>*0@ML!  ].&(XJ30?"VF^'#,;!9090%;S'W8 S@#TZG\ZVJ* "BBB@
MK-U#1+74;ZVO)C()K97$15L ;A@G'>M*B@#F-/\  NE6%_%?^9=SW<;!_,EE
MSN8# )'3@$X],FNGHHH **** *M_I\&I6P@N Q0.L@VG!!4Y'/X5@W'@/2[F
MUMK.2>\-G A40^=PV6SSZX]*ZBB@"CI.DVNBV(L[,.(@Q;YV+$D\DDGWJ]11
M0 4444 %%%% !1110 4444 %%%% !36^^GXT44 .%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $( 6 # 2(  A$! Q$!_\0
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MI&N[Y99T+%1'YA61U&!T7@"KNB:O+J@NTN+)[.XM9O)EB>17YVJP(*\$884
M:U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%)D49H 6BC-&: "BC-&: "BC-&: "BC-&: "BC-&10 44@(-+0 444
M4 %-V+W&?PIU% ";0*PM!_Y#'B/_ *_E_P#1,=;U8.@_\ACQ%_U_+_Z)CH W
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Y?Q%8VVI>)-!M+R(36["Y9HV)VDA%P2/;)JU_P (7X<_Z!-O^O\ C2:I
M_P CAX?_ -RZ_P#0%JUJ%OK<MQNL+^R@@VCY)K5I&S]0X_E0!6_X0SPY_P!
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M38!PR_0@_C570?\ D,^(_P#K^7_T3'0!O444A. 30 M%8H\4::=3^P>9)O\
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M.!&9);?]^B#JVT'<H_WE+#\: .@'2EK \(ZL=3T2,2R>9<6^(I'_ +_ */\
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M]Q/X5N8[&_E:71Y&"6MY(<M;D](I3Z=E<_0\X)Z@'- "T444 %%%% !1110
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M(C@A[RRL<(OXG],GM6D3BN:M_P#B>^*'NS\UAI+-#!Z27)&)'_X"#L'N6]*
M-+0=+.DZ4D$DGFW+L9;F;_GK*QRS?GP/0 "J7A'_ (\-0_["=U_Z--= .*Y_
MPE_QXW__ &$KK_T:: -NXMXKJWD@GC26*12KQN,JP/4$5S<,\OA2:.SO97ET
M5V"6UW(<FU)X$<I/5>RN?H>QKJ:BG@BN89(9HTDBD4HZ.,AE/4$>E $@.:6N
M6AFE\)S);7<C2:&[!+>Y<Y:S)/$<A[IV5STZ'L:Z@'B@!:Y^?Q9#;ZI_9S:5
MJSSG<5*6N5=5(!8'/3+#\ZZ"L"Y_Y'O3O^P?<?\ H<5 &\#D9I:!10 4444
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M]CU&PF\V5YWM9K<I&C.=Q$;*<A<GN#5W_A(;^SXU70;R%>\UIBYC^OR_./\
MOF@#H:*S-.\0:5JK;+*_@FD'6,-AQ]5/(_*G:CKNF:3Q?W]O Q^ZC/\ .WT4
M<G\!0!HTUW55))  Y)-<_P#\)'>7O_()T*\G7M-=?Z-']?F^8_@M176CZYK5
MI-;:KJL5I;3HT<D&G1?,5(P1YCY/?LHH K^"==TG5KG7H]/U&WNG749)&6)P
M2%(4 _3(//3BNOKR?X4_#:V\):WK.H#4)+J2.9[&,%-@"#:V3SR>GY>]>L4
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M]AR&9<';G@'UK:&CZQJ0SJNK?9X3_P NNF9C&/0RGYC^&VK'AS3I[6R>ZOE
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MQZ<$CZ&ND2-(T5$4*BC:JJ,  =A6#XU_Y%>;_KO;_P#HY*Z"@ HHHH ****
M"BBB@ HHHH **** "N;N?#FI3ZTNIIXAN(G17CCC%M$55&*DKR,G[HYKI**
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M]!"T_P"_R_XT 7**I_VMIW_/_:8_Z[+_ (T?VMIO_00M/^_R_P"- %RBJ?\
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M0HR1W4*S*K=5!&<&@"+_ (1S0_\ H#:=_P" J?X4?\(YH?\ T!M._P# 5/\
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MIUX9DM98I"S[H@I8MD8VG<<=^!GK0!OKX;T0* =&T[('_/JG^%+_ ,(YH?\
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MP6\F)4W8]<"J^BZQ%K5DUS'#-"4E>&2&90'C=#AE."1^1K2H **** "BBB@
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AWKR^9->2(!@8"1(NU$]^Y)]36Q110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $! 4@# 2(  A$! Q$!_\0
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M44 5+[3;74X/)O(A+%G.TDC^5)I^EV>EPF&R@$,9YV@DCT[FKE% !2,H8$$
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MLXO"MXUX7V?*46-E#%PZE<;OE^]C.>,9S6;X!T][./497CDB\V50D9N(90B
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M["$?_H+5L#I6/KO^LTC_ +"$?_H+5L#I0 4444 %%%% !1110 4444 %%%%
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M8]?OS:%',S$1;@W&W'R?[U '245B?V'>_P#0Q:C_ -\Q?_$4?V'??]#%J/\
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M,GVKST\KAMN,YZY_"GP:[876HQ6<$PD,UO\ :89$(*2H&VG:PZD$C/U%<J?
M$IU6:X\ZT-L]X+CRC$>%\Y)-N.G\&/J:MZ3X:O--UO3P5C-K:F]G,J  %IY,
MK&!U&!DGMTH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? <0# 2(  A$! Q$!_\0
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M@Z^U&PD1+F+;L9EW 98#I]#7C/\ PMKQA_S^V_\ X#K7K/Q2_P"2=:G]$_\
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M6SXP_P"?VW_\!UH_X6SXP_Y_;?\ \!UI\7P_C_MZ^T^>[NFAMY(U6>&-0"'
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M"1'PY<ZE%=722P6XN0MQ$J"1">,#.X<="1@TOBBTMC\1-,MEMXUADCM T:J
MI# 9X%-*(:B?\+:\7_\ /];?]^%I?^%L^,/^?VW_ / =:Z/4/#FD3:WJ.HV%
ME$+&.UNK:: +\L%Q&/E8>F1R*YN[\ I8^'C>7&IJE^+-;ORVVA&!'W!SNW8]
ML4KQ[!J+_P +9\8?\_MO_P" ZT?\+9\8?\_MO_X#K4TG@32%U:WT=-;N6U.>
MT^T+$;<!1E-RINSU/-51X(M[:S%WJ.H2P+!8"]O42(%XMS;411GDG'>G[H:D
MG_"V?&'_ #^V_P#X#K1_PMGQA_S^V_\ X#K4%YX*@@LKN_AU"26S735U&U9X
MPK."VW:XSQ]14UMX&M9;RVA;492TVG17JPHJ^;*S]50,0#C&<GK1[H:B_P#"
MV?%^/^/VW_[\+1_PMKQ>>E[;?]^%JCX;BT73_$]W;:RZ)''&\=L][&0B2_PM
M*O8>U:=[X'O;^YO#BVBU&*2 _9[)/W$L$G F7GCW%'NAJ1?\+9\8?\_MO_X#
MK1_PMGQA_P _MO\ ^ ZTVX\%:>EEJEQ:ZE=79LII(MEO$K,FP?>=<YP3D @&
MKUYX-TC4M4T2PTJ2:VDN--%Y<%T&TQ@<MR?O$\8Z4>Z&I3_X6SXP_P"?VW_\
M!UH_X6SXP_Y_;?\ \!UIX\!6)U Q#5V%O]A>[?A7DBV$95@I(Y'/!IL?@G2K
MIK-+36+HRZA9O=VBR6P P@)(?!XY';-+W0U&GXM>+QUOK8?]L%H_X6WXN'_+
M];<_],%J+P#:V<ZZ]-=I99MK$R1R7<>^.-MP&XBM2QDTI?"'B35'E@:X\^*W
M^T6%FIB"'_GFK] ><GK0^5/8-2C_ ,+:\7G_ )?;?_P'6C_A;/C#_G]M_P#P
M'6MS7/#-GK&K6FE6$KVUEI^EQW4H$*!BK#C#9^9R>NXX%8,_@BQLYK^YN-7)
MTNRMDG>2%%>7<YP(R =N0>^:/=[!J._X6SXP_P"?VW_\!UH_X6SXP_Y_;?\
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M.'Q!?Q:G=:A*MO=3W>3-]J@$BN?7'\JV="\;W5AXBO-:U"2:6Y>T:WACA4!
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M;$3W-A?1W1N)+=K)@OF1L@!8DYP>"*ZVQO(=2T^WOK?<8+B-95WK@A3V(]:
M(O[/?_GJGY&D_LYS_P M4_6KU% &DBD1H,]% HIR_=7Z44 ,N?\ CW>L._TY
M-039)/<P@J5/D2[=ZD<@\5N7/_'NU<'XT\1WNA3:7#9SZ?;?:VE#SWX/EIM0
ML.G<XQ0!J#PMI:7,5Q'#+&(W21(DD(C+(NT-M[G'%11^$M)2V-N5G>/9Y<?F
M2Y,(W;_D...>>]<"?&U_%)?ZVH2"ZN["Q$=O+EHT=RP) )  ..IQ5_3OB-J5
MY)H#SQV%O!?QD3!<O(TN6& ,Y"_+D'D4 =E=>&+"^ %S+>R-Y?E2.9R&E7=N
M 8@<X/IBEN/#.G7$DCN;A6>;S\)+@*Y7:2HQQE>M<&/B!XG%F;QHM(,0L1?[
M K!O+$OEE <_>/7/:M?0O'=[JOQ#?03%;FP<3"-U7;(C1XSD$Y(YZ\4 =/%X
M;TR&U:W2.01D0J1O)XBY0?AU/K0/#6G+!/;;9A#(V1&)!B,[MV4XR#NYYS7)
M7GC_ %&VBUJY!TP+9W+6L-D^[SHL2*OG2?[&#N_*H8_''B"XD2QM&TB:X$]Q
M%]M",8)EBB$FY!W_ +I[9H [%_#.GR1X9KGSB[NUP)3YDA9=K9;'0CC%20>'
M["">QE43$6( MHWDRL9 QD#&<X]^:Y"Q^(%]?2F8KI\$,5A'<FS?<9[MF0L?
M*]@1BJ.F_$+Q)?:5YS6FF)//<VT=N^_<JB4D$, 201ZF@#NT\-Z:C3$1R9G2
M6.3]YU64Y?Z>WI5>+PQ TD[W4A+-.LMN8?E:(*@0#)SDX'.:Y2R\6:[>^(-%
MCEO+"V@9[VWN8]A"3R0MCY2>A/4#ZU4U+XC:_IOA73M68::]Q?B6=(1&0HBC
MZ@DG&[Z4 >A+H5F;B25/M ,R!)8Q)A)<+M!8>N#BH$\+Z:J+@W6]$C6.;S?W
MD83)7:<=1DCZ5PU[XHUG;XF>YOX/)MQ9RVUFF4D19 A^4]<<D?6E/Q*U86US
M<K'IL@-K<S+:QAO,M#$VT"?V;\* .\3PWIJ(ZA'^>&2&1BY)97(+$^I) YJ6
M[T6TO$MP[3Q-;QF*.2&3:X0C!7/<$5SEEXKU6/3?$#:A!:S7NDM%M^RJ0KB1
M PX//RYY]:CN_%FK6$-NTT=H3-.8-^ ,+QB8JI.$&2"/<4 =3:Z-8V4DK00;
M?-A2W9,_+L4$* /H>35)?"FDJC*WVF12B1#?-G:B/O51Z &L>7Q=?V[7$I6U
MN8XY[B 6L(Q(!&N0Y/H3^A%/MO$FJS-;03_9;<W,N([R10$"^7N*E0<9SD<G
MI0!MWGAZQO;_ .V3><LK/'(RK+A&=/N,R]R/K5#0/"SZ/),KW*-!+$8GCB!'
MFL3GS&ST.">G'-9\FOZI8S:@'NX+G.H1VT06(8A1HPV[KR.H';)JKK'B#4KO
M2)X9VMK"2**!I4)^><O(1\A!XX7H,]: .HB\.:9#;FW2*0)F%L&3H8N$_P#K
MU=GTZVN+XWDJ%IC;M;$Y('EMR1C^M8VN>(Y-,URWLX&C?]]$DT;1]!(V =V>
M#[ ?6L#2+W5+)[29M1CDCN)KZ2=#&,SM&3M&2>#QQB@#I(/".EV\+)%]I7)C
M8-YOS*8_N8.,<9/;FK]KI%M::C)?J9I+IT\KS)GW$)G=M''3/KFN7@\4:W<6
M=O*L-JAN[B".*61.$\S.Y2H))QCJ<9K6UJ_OM/UG2UCNT6!H+AIHO+'[]D (
M /8GL* +%IX7TJQN+6:WAE#6KR21?O"1F3K^'/'I31X5TM;<0HDZQ& 6[*)>
M'0,6&?7!)Q]:Q9?%FHPVBR"6PE::"&X5U&([??(%*/CJ0#G/7@U!=>*;JVO&
MD>&VN)K99XDN$)". T8W  XP-_/^[0!U[Z5:.FH(R,1?_P#'QAOO?+MX].*I
MWGAJQNM[8DCGV*J2 Y"E$*J<=\ _C69J_B:XT<P1K>6EY<+M:811 *Z%PO7/
M'7MFFV&J3Z=X3^T1NK2OJ<D EG.5C#2D;F]AZ4 6=%\*+I2QI/)&T4,D4L$$
M.0B2("/,.>YSTZ5I_P!AV)TX:>JRK )3.A#_ #J^=VX'US7*:=KM] ES MY9
M!S<7<[7,OS1OL( 103QFI;[Q3=-97/VN&***>Q,EO$?FWD("P=@<H0>Q[=Z
M-W_A%=.6/"&Z1_WA>5)L22>9RX9NX)Y_E3YO#.EW#*9X7DBBB:*.%GRD:E=I
M"C&>GO60/$NHPN9BELUFER]JL(!W_+#O#;OJ,8]#3M#UZ]UC1]5O+A[:2&.
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MGFR/- [%!&?*V@@!B2"W/)Z\U&?#VM0Z=%%"DPW6UN+I&E+F9U<[QR>25QW
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M L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM+<W3HJGYK?RP8\=\DG&?:G6FO:W=-90;K9#=3B-;AD4_*8BQPJD@$$8Y[4
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M110 4444 :B_=7Z44+]U?I10 RY_X]VK.K1N?^/=JSJ "BBB@ HHHH ****
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M.&&)G>*&.-G.79%P6/J<=:?10 SR8MN/*CQ@C&T8YZTB6\$2JL=O"BK]T*@
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MH+>[ANVG6%]S02F*52,%&'8_I4] !1110 4444 %%%% !1110 4444 %%%%
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M<2VTL@FU. PW:R';'%C!0KGCG)_&NTH_+\J .(@TWQ!!:QQ#3VE>VL9(,RS
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MFN416;<TD=LJMT !4YRK#'7/X5HZ9I\MI?:E>3$;[N5=N&R0B(%7)]>I/UH
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MRAMTFNVG";U#NAQ$'.$W?+GIQQWJY_;5U>7$EA>0_8%NK5O)P269_+W-AP<
MJ>Q[<YH Z?\ #\Z,^O/UK.\/W<E]X=TZ[F_ULL"ESZGIG]*T: #)HHHH ***
M* #V[>E'I[444 %%%% !1110 =*.^:** "BBB@ HHHH **** "BBB@ HHHH
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I4?8?^FA_*@"G15S[#_TT/Y4GV'_IH?RH LK]U?I13E&U0.N!12 __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ". 1X# 2(  A$! Q$!_\0
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MK[:;;WEI#<RQ/!-]D>>2*W3!?:P .WMD5[KIQ3L<W/)ZG2?\)YX:_P"@F/\
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M^_K_ .-;=E9P:?:16EK&(X(EVH@.=HJQ12;;W!)+8K7]E#J-C-9W*EH)E*.
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y ;4# 2(  A$! Q$!_\0
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MH_X7G??] &W_ ._Y_P *\IP<9P<>N.*3(]11R1#F9ZO_ ,+SOO\ H V__?\
M/^%'_"\[[_H V_\ W_/^%>3Y![BES1R1#F9ZO_PO.^_Z -O_ -_S_A1_PO.^
M_P"@#;_]_P _X5Y0/FQCG/3%&0.I HY(AS,]7_X7G??] &W_ ._Y_P */^%Y
MWW_0!M_^_P"?\*\IVMY?F!24SMW8XSZ9]:3(]11R1#F9ZO\ \+SOO^@#;_\
M?\_X4?\ "\[[_H V_P#W_/\ A7E*JSYV MM&YMHS@>I]J3(]:.2(<S/5_P#A
M>=]_T ;?_O\ G_"C_A>=]_T ;?\ [_G_  KRCMFBCDB',SU?_A>=]_T ;?\
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MMU;LF\31[2YC!+ 98'! ]Z +.+#_ * VF_\ @.O^%'^@?] ?3?\ P'7_  J
MRQ $F1  ,DEAP*:]S;QH6::/: "<-G / /':@"S_ *!_T!M-_P# =?\ "C%A
M_P! ;3?_  '7_"LM]<TR,RAKM<QD!L(QR<XXXYY]*L/?V:([FX0[$#L%R3M/
M0@#G^= %S%A_T!M-_P# =?\ "C_0/^@-IO\ X#K_ (5F?VWII4M]J7:-H+!3
M@;AD<XZFKL<B2H'C8,C="* )O] _Z VF_P#@.O\ A1_H'_0&TW_P'7_"HZ*
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MC-KO6/S%B="X8'+ -T"X .>M.L]4U.ZO$C:U1(B^'<Q./+ #'9SU/ ^8<<T
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M8/H: $HI<'T-&#Z&@!**7!]#1@^AH 2G1_ZV/_>'\Z;@^AIT8)E3@_>';WH
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M?44VG#[C?44 )N/K1D^M)@^E% "Y/K1D^M)10 N3ZT9/K244 +D^M&3ZTE%
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M)8R-Y)"R#)VXYY^7!P._% '445R,FLZ_))]FAMV,GE!PRVK*S*2WS$D_NS@
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M?M=NL4<\DD>T.&4.^[=U WCISQ@T /M/!NG6JR$M)*9&#DNJ\$>V/S]:SYO
M<27=M<V5Z5>)UWBX0.&0'...I^M6]/\ #=Y9ZK#=-=P-''([;<NS;6[<GDY_
MB].*Z7K0!A0^$=)CMKBVDA\Z&:02890"I!+#YAR>3U-;H "@ 8 & **.U #L
M91<],FN9D\17,.8EB62=;J6-E>-QP&^11@?>(Y!Z<5TQ_P!6OU-)N;&,G'3K
M0!RS^)M2$-XR:.^^W0GYBP!(8+UQSSD_05:M]6U*YTZXN#;10O&L>SRLON9B
M-Q'J,5O[F]3^?2C)/4F@#C9=5UV13':2R-.\@66(6X7[,V\@*&;@@@9R<U?O
M]:N+.:X@GE$8CM1(\L,)9U? ^X,$,"?7&*Z/<W')XHR1T)% '-Z7JFHRWD\4
MK?;BMLLB+  BJV!D$D=2<D<XI^K:IJ5M+9/% T;.K[K-<2.Q_A.0,%1UX(KH
M2S$8+$_6@$@8!P/:@#C%UK68%2Z+M>66=A9;?;(1N W8QZD@?0UV77MCZTNY
MLYW'/UI* "G#[C?44VG#[C?44 8FIW&I6NI&6VE>2$0;A;&,;"Y<*,L!NZ$G
M'M67<>)]4CN+F);:*,6UPJ^<R2%67Y@=P )'(&"/6M#5/$PTO5EL?LC2@PF3
M>KX(."0,>AV]>V:@?Q5<"XM;46D<4[SI'(&GSM!< [.!O.#D],4 0_\ "4:D
M+B=)--BMTC5#OE=B5W8RS*!DKR>G/K2W?B>_1REM8-*\.XS*JM@X+!1DC@$
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M10 4444 %%%% !1VHH[4 *?]6/J:2E/^K'U-)0 4444 %%%% !1110 4444
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MBA; )8 $DDG@8]C7TYKG_( U'_KUD_\ 037S5H-IXAN[&./2Y-L"NS)EU&'
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ML#0T:*RI?$6GQPW<J.\R6L0E<HN 06VC!/!Y[]*?)KVFV]NLMS=)!GJK\D<
MXX^HH TJ*IG5;$7(MQ<(TS0&X5%.=T?J*K6GB+3[M(27:!YV*Q)(.6(]QD'J
M.] &K15.SU6ROI#%!,&D499<'C\>A_ ]ZN4 %%%% $A_U$?^\W]*CZ=?2I#_
M *B//3<W]*YR1=;4&*&*= +F1O,WH0P8Y0\_P@9R.M &_0.3P,GTKG73Q08K
MI0\08*?)8;3N.X#@?3)Y[G%6(;?5Y-/G%S.\DK+&(\A4Z$%B<=#^- &W@D#
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M3><SB=3*ZG!5<!1C@98DC/H,U;2#6I;.[$LLF3%B&-V0,?F).XC^+;@9''-
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "A -$# 2(  A$! Q$!_\0
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M110 4444 %%%% !1110!4U-[F+3;F2S7=<K$QB7&<MC@8KA_[8\=_P#0-_\
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MWMZUO]B1Y858)!I\MLY0.PW'>[9&1[$9'K0!Z%?7T&G6KW-P7$:XSL0N22<
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M EQ/%;6\D\TJ1Q1J7=W. JCJ2?2LO15TVXN+W5M.G,WV]T>7.1@J@4?*0"O
M!Y^M<1XLU[5=5\F"QMI&TB]CV1(T+*]RQSP>-R$_*8VQM."6/&*[3P_X=31I
M+NZDN&N+V]97GF:-4W8!QPHQGDDGN3Z8  -RLC76TN[LVT;4KV.#^THWA1#*
M$>08PVS/4\TFO>(]/\/0H][-M:0,44*6.!C<Q Z(N1ENV17"6EE?>.)K.'54
M,]E%BYGFEAV@,2 \"$85XF'0J2?E!)YQ0!ZA&@2)4&<*,#-.XJ&UMH;*SBM[
M>/RX8E"H@).T>E<#XR\:.B_9-,8_9I5>-[ZWE ;>N=R1/]T2+@'#?>SM ZD
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M3Z*H"@=@*UL9HH *Q=5\,:;K-PD]Y%(SJGE/LE9!+'G/EN!]Y<\X/]36U10
MBC 'K39(UE1HW4,C JRL,@@]13Z* ,;1_#5EHMP\T#7$C&,0Q^?*9/*B!)$:
MYZ*"?<^_%;!Z<4M% 'GT_AK4M7U=K;4H+C"7;W*ZJ+A3Y2#/E"!3G8W0,I7!
MVYR3C';Z?80:990V5K&([>%0L:YS@59VBEH :Z[D*XR",8KG=)\*?V;-$)[Y
M[VUM8_+LX)8U A 8,"<?>88 #8! ]R37244 &*XSQ-HNJ:EJLZK9QZA975NM
MO&LT^V*VRW[PO'D;\K@AAD@KQCK79TF* ,[1-#M="LC;6QED+-N>:=]\DAP
M"Q[X4 #T %:5%% %6]L+;4(EBNX$FC5UD4,/NLIR&'H015D#UI:* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! 4X# 2(  A$! Q$!_\0
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MH?#MK:W9N;62>W=F8N(W&'#-NVD8Z DXQSR: -D4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "] 3@# 2(  A$! Q$!_\0
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M *ZW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI;6TD\I81QJ6;:I8X'H!R:X/PIXLO]=UH+<7\"02&4QV:Z9-&VU2=I\YSM/
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M:R+C5A#/XA_LUKF%IWV.)HN9 ZQX&<9$9^3C;COFI?%TWBIOAFQOK6S\IK&
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MH6?^?63_ -#KZ0KYP_:4_P"1AT+_ *]9/_0Z /+_  /_ ,CYX?\ ^O\ @_\
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M@NE6*W(N!96PF!!$@B&[(!53GV!('L:FN;2"]MI+:ZACG@D&'BD0,K#W!ZT
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "- +H# 2(  A$! Q$!_\0
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M2\3WUI>66@RVUQ'(LVJV<B;6Y92P(..O0T =<.E% HH "<4W>-V.]*W:N/\
M"GA[6-+U_6=1U2Y65;R3]R@D+;%W,>_L5'X4 =C1129'K0 M%%% !111F@ H
MHHH **** "BBB@ HHHH **** "@]*Y;Q%XLFT/5;6QAT>XO6G02;HR0 N[#=
MCR../]H?6NH/W: .3N/A[I,]_>7JSW4,]S)YP:-E'EN3EB..<_[6<9.,9JIX
MB\.Z1IB>'YK73[=+B'4[*%)_+'F;%(4 MU/ Q6=K%OXF_M/56L_[4EM))E=F
M1O+=$Z".##89>C$X!Z^M6=87Q$MMX:&I/8F$7]B)MH;SC+D;LG.W[V>@H ]
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MN@7=Q<7$FGHL]P!YLD;%&8ABV<@C!R3SU.:H>*;"TM+;0A;VT4?EZK9QH50
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M>Y9MC-P\>UL@Q..J\8_+ !/IGAJ8^*SXCEBBM5G7>UB27(D:-09"<X63@H<
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1#% "T444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "T 50# 2(  A$! Q$!_\0
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MW;7$;0O&8 "&2+.[?G)R1W]:ZR@ HHHH **** "BBB@ HHHH **** "BBB@
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MTW_ME_Z :K>"?^0K<_\ 7#_V859\0?\ (H:;_P!LO_0#5;P3_P A6Y_ZX?\
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M]/\ T<U>8?$S_DIGB/\ Z_I/YUZAKO\ R:MI/^^G_HYJ .#^"W_)6-%^LO\
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MA=W)Q[8H TOB;_R;UX:^EG_Z*-<[^SA_R.FI_P#8//\ Z,6O1/$7P\\3>(O
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M[1!/I:N9C*JLR0&9D7!Y"CKDA1[;LU0U%_$-W>:5.N@!A9RB=S]L1=Y,3*0
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M>I?"KP[JWA3P<NBZK;QQS0RNXDBF#JX8Y_#% #O&W_(5MO\ KA_[,:M>$O\
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M2V@MKF:/18],N&D"R",L1+\H((+ $XW8/'4&@#EKRTNK3XHQ7$P^SV\]PAC
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MRV[G#\OOQV QTK;\*)I,NK7]YIVH:E<3,J+*+K 61,L$=0%&1PP!^M)XSO\
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MX\=W-C?7ER\&)<1W<4<4O!^4;4!RH!R"6!YZ5L?$:[U.RT:WETR>[A;SL2-
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MGH?E*@ _>Y/7.<USUE81+XS1A%?BX&IR,]HSOY<<0WLDV=NT@L['&?X\=0:
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M#<),T,K%5G53RA8 XSP<X/3!X)IW_"4>'L_\AS3?_ M/\:/^$H\/?]!S3?\
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MM'L[9?&,!CCO/M0OIS-:-,Y%NB^9Y<A!7;@[W[_\M!C.#7;CQ1X>'37-,_\
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MO /[0DDBDV29:)E#%1[@A#^E=-0 4444 %%%% !1110 4444 %%%% !1110
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(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O 4(# 2(  A$! Q$!_\0
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MRN/*:7('W^.>F:S1X$L_[(N+";5]<G6:=9O/DOF\U"HP K#H.3D>]=OYL?\
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MUJT$-Q'C=&Q&1D9I=1\=Z)I26SWFJ01K=1^;"=P^=.F: -*5)RJ[%7<#SN)
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M3U*YL9T6*RDN$92<HI))]!CI^/K6I28H YTZYJN%<Z-(JL<!6)W;L9(P!ZY
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M% &[1110 4444 %%%% !116<NL1-K<FE"WN1*D0E,A3]WM)P.<^H(_"@#/\
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M)41@SG&,'K@B@#TNO+[/_D88?^OL?^AUZA7E]G_R,,/_ %]C_P!#H M^+O\
MD8)O^N:?RJSXD_Y!>B_]</Z+5;Q=_P C!-_US3^56?$G_(+T7_KA_P"RK0 E
MO_R(5W_U\_U6I/!/_(4N?^N/_LU1V_\ R(-W_P!?/]5IW@QMFHW;]0MOG]:
M.ZSVI:XK1O$DD_B*Y5XKDPWLB"'?.&6+ Q@+C@'DGD\UV@Z4 +1110 4444
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MMOV30H898[B179H%1L$YV@J>5'3\*@M?"_@T>,[FTBT"S6>*W1AM@3:I!)W
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MX=!_X2"R^4_?/;V->B7EI#>V[P7";XF^\NXC/XCFN6L?#?ADZU=I$@>5<;8
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MO3/6J_A:Z6\T&"5+>.W!) BC8D+@^I[T -TV/?XBOKHV5Q;$CRRS2*4E /4
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M&S&<  <$]>M2>*[R.RMK-Y+6&X)N %$K$!3C[W'M]: -6[<PZ9*WDO<[(_\
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image_024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? *4# 2(  A$! Q$!_\0
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M1/;I$JOK,_,:@9&%QT^M '74444 %%%% !1110 4444 %%%% !1110 4444
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=ZQ4KG'K@D?C0!9HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>image_025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G 4P# 2(  A$! Q$!_\0
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M1Y8@T5M(\L)V2;  .NXJ@#@G&[MQ7>:-YW]AV'VC?Y_V:/S-_P![=M&<^^:
M(//UW_H'Z?\ ^!S_ /QJCS]=_P"@?I__ ('/_P#&JU*J/JEA'<26[WL"S1!2
M\9D&Y=QPN1[GI0!6\_7?^@?I_P#X'/\ _&J//UW_ *!^G_\ @<__ ,:JQ/JV
MG6L[03WUO%*L9E9'D (0 DL?08!/X5"GB'1I$C=-5LRLBNR'SU^8(,N1S_".
M3Z4 -\_7?^@?I_\ X'/_ /&J//UW_H'Z?_X'/_\ &JF?6--CO(;1[^W6XF :
M*)I &<'H0.^<''K5W(]: ,SS]=_Z!^G_ /@<_P#\:H\_7?\ H'Z?_P"!S_\
MQJM":XBMX))I7VQQH78XS@ 9)J*2_MHK>.=Y,1R% IVGDL0%XZ\YH J>?KO_
M $#]/_\  Y__ (U1Y^N_] _3_P#P.?\ ^-5I[E]10"#TH SHY=9:5!-96*1$
MC<R7;L0/8&,9/XUH@8&*6B@ HHHH **** "BBB@ HHHH *AN8C-;RQ!MI="N
M?3(IEW>I9Q>8T,\@W;=L,1D;ZX'.*I?\)!#_ ,^&J?\ @#)_A0!SDG@6:>T@
MMIKZ-XHX;6(JR,0?*CD0\9Z$N#_P&JMM\/;FWN+)FU/?% ZLT2ED^;;%EP>2
M&)C8]LACSUSUO_"00_\ /AJG_@#)_A1_PD$/_/AJG_@#)_A0!S>J^%;_ %'Q
M4MPMPXMEAA87<I!D1EE9RL>,8XP,D=#U-4X?AW>K]HSJ<*++8?8RD:,%9@5/
MG-SR[;3G\.:[#_A((?\ GPU3_P  9/\ "C_A((?^?#5/_ &3_"@#GK/P2^G7
MNMW$,ELPU"VEAC58BK0Y9RJ@^F'P?H*R]0\%WUSHC7J0HNH&R@B%MM&X;()(
MVCW9Q@EP?3Y:[7_A((?^?#5/_ &3_"C_ (2"'_GPU3_P!D_PH OVD1@M(86;
M<8XU4MZX&*K:[IBZSH5]IK2M$+J%HO,49*Y&,X[_ $J'_A((?^?#5/\ P!D_
MPI\FMQ1B,FRU%MZ[AMLY#CKP>.#QTH YO6/"6HZY<6%Q/=VD,D$1BD$*OM(\
MR-PP&<-CR_NMQR/2F:7X&FTS5)KN*_4Q3VD\3PB,C$TC9,@.>/E"@CU&:Z3_
M (2"'_GPU3_P!D_PH_X2"'_GPU3_ , 9/\* .(U#P7J=[X:BGB'D:C%8VL*P
M ?.AB5UD53NQ\V_].:1/#&KG0)XQ9>2+>TFBLXD*^8[RRY>0KG"ML ^7./F(
MKN/^$@A_Y\-4_P# &3_"C_A((?\ GPU3_P  9/\ "@#G_!NB7NGZA')/8_98
M(K$P+EAF1C.[Y(!.#@@D= 6P.E=J1U-9/_"00_\ /AJG_@#)_A3I-=A4[39:
MD> <BRD(Y&?2@#)U/Q<;"/5;B/3VFMM-E2":4SA,R-MX P?E&]<G\@:RI_B+
M8R+'#=:3(T5Q#N^=U9&D\TQ^7R.IVLPR!D#H#6E=P:'?37$MQH^J,USM,V+6
M=0Y7&UB!@;A@8;KQUJ.2P\.30F&30+]T+I(=UG,275RX8GJ3N9CGJ<G.: -"
M[\306.NRZ?<(PB18AYJ@L6D<2,%QV 6,G/OBL.\^)UC:K?NEC/((((I[7YPI
MNPZ*Y !^Z55@3GM3]6TW3]8UA+^>'657=$TD*V,@$AC$@'(&1D2$'Z5*=)\+
MLB*WAR^81JRINLYB5#1B,@$_[ "_04 ;^A:LVLPW3M#Y+6]RT) ;.0 &!_%6
M%:X&!7+Z/<6ND1W*QVNK2&XN'G8FPD&,X  XZ  #\*TSKL(16^PZEAB>!929
M&/48H U:XW7/!TNIZS_:ME>?8[H%-K*6()'#,1G&<!<8].<UN?\ "00_\^&J
M?^ ,G^%'_"00_P#/AJG_ ( R?X4 95[X;NIY-?2&YMQ;ZQ#M8R1L7B?RO+&,
M'!7@'VY]:P+GX;7-S8R(VIQQW925H90C/Y4CA 3N8[F!5&!![-@< 5VG_"00
M_P#/AJG_ ( R?X4?\)!#_P ^&J?^ ,G^% &'J7@V>^U2WOHK]8F@@MHE0JQ4
MF-V)8C."<-E?[K &LJ/X:S?8H89;]&>)2-[;F!;,7S@<;21&<]>6Z]:['_A(
M(?\ GPU3_P  9/\ "C_A((?^?#5/_ &3_"@#E+OP'J,\=A!#JT,4-HLBKB(A
MOF,G /7;M=1C(^[W[/3P%<1NDB:E&LGF,\K!&S(/,C=0>>P1A_P*NH_X2"'_
M )\-4_\  &3_  H_X2"'_GPU3_P!D_PH X#5O NHV=M9V]I%]OBVQF2*,;5>
M5(PN7)8$!SR6&2,=Z]3CSCD8]JR_^$@A_P"?#5/_  !D_P */^$@A_Y\-4_\
M 9/\* -:BLVWUF*XG2%;._0L?O2VCHH^I(P*T5.X9H 6BBB@ HHHH **** "
MBBB@!,#.<<TM%% !1110!EZ[>RV&G>;%*D):2.,RR#*Q!G"ES] :=H5Y-?Z1
M;W-PRM(X.608#88@,!Z$ '\:OO&L@(89!&"".#2H@08'0# 'I0 ZBBB@ I,
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M*:V.^UGD$#_?9D4%2.>G7@#UK+MO$VH-J*6_V^TGCCG1$=(P/MJLX5BF&XV
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MIE:X@#0J&E!<9C!Z%O0?6I8GCEB62)U>-QE64Y!'J#0 ^BBB@ HHHH ****
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>image_026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "@ 1P# 2(  A$! Q$!_\0
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MPD?P"#"PBOEAE>V6!G4.QXE\S 8OG8<E2N>G3'2@#HQIFHD_\AZ[_P"_$/\
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M[_[\0_\ Q%']EZC_ -!^[_[\0_\ Q%:NY?[P_.C<O]X?G0!E?V7J/_0?N_\
MOQ#_ /$4U].OXU+/XANE51DDPP  ?]\5K[E_O#\ZANX8[NTFMW?"RQM&2#R
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M9_X1W1/^@/8?^ R?X5<M;9+2W2"+=Y<:[5#.6('U/)J:@#-_X1W1/^@/8?\
M@,G^%'_".Z)_T![#_P !D_PK2HH S?\ A'=$_P"@/8?^ R?X4?\ ".Z)_P!
M>P_\!D_PK2HH S?^$=T3_H#V'_@,G^%'_".Z)_T![#_P&3_"M*B@#-_X1W1/
M^@/8?^ R?X4?\([HG_0'L/\ P&3_  K2HH S#X>T0#_D#Z?_ . R?X5AQ2>'
MI;6:?_A';=0BH\0:VB_?*[;4*^F2,<XQ77$9!%9(\.Z8D4L(MSLEQN D?H,X
M YX )) & #R,&@#$DN/#\**\_AJ&-2LF<VT1(=#ADP#ZX&>G(YJ6W&BSWEM;
M'PO;QM-(\3$PPGRW0$L" <D8 Y&1\PK37PUI2NQ^SOEHC"P,\A#*22<@M@G)
M)R><\YJW9Z79V4B-##AT5E#LS,WS'+9))))(&2>>* (_^$=T3_H#V'_@,G^%
M+_PCNB?] >P_\!D_PK2HH S?^$=T3_H#V'_@,G^%(?#VB $_V/8'_MV3_"M.
MD/(Q0!Q\\_AZ"T@N3X<M\2,P9#:IOC"R",D@ Y^8C %;%KH_AZ]MH[B#2M/>
M*095OLJC]",BG6GAZPM&E,2R,LA4[9)6?:0V_@DDCYCD\]:TK>WBM8%AA0)&
MN<*/<YH I?\ ".Z)_P! >P_\!D_PH_X1W1/^@/8?^ R?X5I44 9O_".Z)_T!
M[#_P&3_"C_A'=$_Z ]A_X#)_A6E10!F_\([HG_0'L/\ P&3_  H_X1W1/^@/
M8?\ @,G^%:5% &;_ ,([HG_0'L/_  &3_"D/AS1#_P P>P_\!D_PK3HH :B+
M&BHBA548  P *=110 4C9*G'6EI"<#- & K:GI]_>,RW,\$T[/'D*RJOEC &
M.5^88YSU^M:&E2WLL<OVU2&60JI*;,@8YQD\9SCVQ20:HMUJ4]B+6Z1X "TC
MH ASTP<\YY[=JT: "BBB@ HHHH **** "BBB@ HHHH **** "L/Q-:7UY9PI
M8),9A(&#12A,8Z;OF''TR1Z&MRL_5-7@TE8VF2:0ON(6)-Q"J,LV/0"@#'BT
M_4C)K22)>)#=H1$RSJ7C;YN4^;C.1@_+Z$#&:U-!@N[?2HHKQ-DJEA@MDE<G
M;NY;G&,X)&:2^U^UT]L7"3;/(><2+&2K!1N(!]<<U;L+Z/4+2*YB4B.097)!
M/Z$C]: +5%%% !4%[&\ME<1Q_?>-E7G')!Q4]1SS"""29@2L:%B!UP!F@#/T
M&VO[2Q\B_F:9H]JQNVW)78N<[>.&W#Z8K4JEIFJ6FKVBW5G*LL3#J#]T]<'W
MY%7: "BBB@ HHHH **** "BBB@ HHHH *#THI#T- &=?:);7WF&0NIE*ERKD
M9V@@?S-0P:!'!<),+JY8I)O56?Y?N[<$8Y&#_+TJHVJW5IJ5Z]R+UUC;$5O%
M;@QM'@$.'(^]G=QN]L=ZLV_B*">]CM!;W2R.<$M'\J'!ZGMT_44 ;0&!12 Y
M -+0 4444 %%%% !1110 4444 %%%% !6?J>D6^JB,3F53'D!HI"A*L,,I([
M$=:T*P_$UQJ%M;VTEA)(&67YXHXRS3#!^4':P7G') 'N* )SH4)OOM:W5XLG
ME&%0)OE53GH,<'I^0]*M:?I\6FVP@A+%=S.6=LLS,<DD^I)K"U6_ULZBL=C%
M+#9FWE_TCRU<+)M."R_>X(X !SGO6KH4]W<:5#)=K*)<L"9!@N 2 V-JX!'.
M" : -.BBB@ IDT2SPO$XRCJ5;GL>*?4-W,T%I/,H!:.-G /<@9H 99V,-BKK
M"" Y!.3GHH4?HHJS7(IXBUJ_2-].L%5&VY:XMY1D-L&1TX&YC]%[=:7^V-;N
MH[F)K)X&%NSJ5B<,C *0=Q^5LDL,#D;>: .MHKDFU77V*S6,$<D-RWF*9HV.
MQ26"@;2.RACG^_6QHE_/>QSBZ26.=)3E'B90JGE0"0 W'<9]Z -6BBB@ HHH
MH **** "BBB@ I&^Z:6@\B@#/@U2VGOYK&-;CSH1E]T#JHSTPQ&#^!J]MR,$
MFLV\T<7,DLT=S)!-(5.]><;0P&/P8TNBV%WI]K)%>7ANI&D+"0YSMXP#F@#2
M V@ 4M%% !1110 4444 %%%% !1110 4444 %(5S2T4 9UOJEG<7TME'(QGC
MSD%&"G! .UB,-@D X/&:T!TK-M-$AM-0DNUFF;<7*1,1LC+D,Y'&>2.Y..U:
M8X% !1110 5'-(L,,DK_ '$4LW&> *DJ.>%;B"2%B0LBE#CK@C% $%C>6NHV
MJ7-I,DT+#AD8$#VX[^U6=O'4U4T[3(=,C>.#(5RI(P.H55[#T45=H ;L I0N
M*6B@ HHHH **** "BBB@ HHHH *0]#2TAZ&@#E+WQ)>VVMSQ"WE&GQLD?GFW
M8J&#*9#N]-K-VXV'K2#Q#=^9;RW$P@MV225,6Y)N0)& 4>GR!3[[L]!7027]
MG'=M;-<QK.JHS1EOF 9MJG'N>!4;:I8++%&UVFZ9F5%!SN(.T_D>.>] ":?J
M\-^Z1JK+(T9DZY7@XX;HWX5I4Q8U4*0 ,# P.E/H **** "BBB@ HHHH ***
M* "BBB@ K.UR\DL-&N[J&5(I(HBRLZ[AGMP.N>E:-5KVZALH'N;B01Q(/F8@
M\?E0!R+^)M3SJDBS0K!! 98Y?*WHIR-B\')9@3P0,$=Q79P2K/;QRJP974,"
M.A!K._M_2_+FD%]&4A(#L,D G& #CD\C@5HP31W$$<T3J\<BAE93D,#T(H D
MHHHH *BNIOL]K-/C=Y:,^,XS@9J6D8*RD, 5(P0>F* .2'B^YNU1M,LHKA6*
MAG>1U'S; ,?*<C+G)]%-*/$U[=+=11VA@D2V,B]6=" IRP*XP=Q ^AKJ-T42
M@&157' ) '3_  J.XN;>W@EEEE 2-=[\YP/7 H YR7Q%JB,KV]G'<0SL6B9V
M9-J$LJ]%.<[-Q_WA5B'4M2U>T==/N(+>[BNAYJ3(?EASTQZD=ZVH+FT*O''*
MBB%C&R_="D $C\ 14-SJ]A9PB6YNXTC,WD!B>/,SC;]<T 4_#^HZA>(\=_"J
MNH#HZD_.I9@,C P1MZ#/45N57M+F"\A6:WE$B'(R/7TJQ0 4444 %%%% !11
M10 4A&1BEI#P* .>N?"OVC4I-074KE+EWWCH47&TJ-OH"BGWY]:<OAN: !K;
M4Y(IGB>.=_*4^9N=GR/[IW,W3L?;-5;SQ:UKKDUGL06L;)'Y[HX4/N7S,MC;
M@*V>O53GBHY/%MS&\#"WBD@G258V0DEI/,9(0/\ 9;;U]QVH TDT2[2.%5U)
MX]B;2L:87KG SSCG')-,DTN_EMXK..Z:VBAC\LOG<9N,9X.1_P#7JAIOBN>>
M%9;UK2-Q'&#:1Y\UV9%;>N6^YDD#([=>U:EQXBT^V4%I68D+M5%)+%C@#VY]
M: +>DV=Y96S1WM[]KD+E@Y7! ]*OUFWFMV-C/Y,\Q$@(W*%)V@]S[=/SJW:W
M<%Y )H) Z$D9 QR#@T 3T444 %%%% !1110 4444 %4]3M)[ZQEM[>[:UD<8
M\Y5W%1GGCW&1[9JV>AKGK_7Y;.76(Q/IX:RMDGC$DF#SNSOYXZ#&/4>M $8\
M);)_M$-XL$R[#'Y, 5-R_P 3+GYCC([8!K>L+--/L(+1&9EA0(&;J?>N5;Q?
M<'^U&1K-$M8S)$9&!5@-O+,'R,[OE! SV)YK1L?$#WGB:XTXA! BYB9,,7PJ
MG<2&X4[N/EP<=>U '0T444 %0W<)N+.>%2 9(V0$]LC%35%<3"WMI9B"1&A<
M@=\#- ',1>"DE2,ZE=I=R*4/-NH48V9 '/!\L#Z$U-!X.AMWF(NV8/ 8A^[
M;D*#ENI'RC [<U$WC1)=GV"S%X&958I<H I;8!SSWD _ T?\)<;E+E+>#RY$
MMS*A=PQ! 4G<G4#YN#WP: )9?!UK>+ ]ZZRSH,NQC5@S%F9B,]B6_("K]AH:
MVD3P7$J7<'F>;&DL0RC>N>_-9<WBJZ@D_=V'VJ.5B8BLH3"995SGKDHQSZ$5
M9BUB_P!3LB^E?9&N$NMDD<K\I%GJ0#D-B@"[I&A6^CO*UN?]: 'PH&X@L=QQ
MU)W=?85JUS%AJ>I:Q:"/R?)GCE20R+, &BWL,XP>?D(VGUZUTRYQS0 M%%%
M!1110 4444 %(W0TM!Z4 4WNK-/-$D]N%C8))N=?E9L8!]"<C@]<U7;5](0
M-J5BF',8'GH,,/X>O4>E9=_X/%]?W%S]LV)<2"62+R\AF7;Y9)S_  X;\QZ5
M-9>%Q:2!OM;2CSXYOG3)&W=\H/\ =^;@=N?7@ VY+6"=")8HY%88(= 01Z<]
MJ5[6!SEXHV/')4'ITK'CTS5XXF']HH&\PL#@MQCW]3VQ@=J)+75SI\MM;W)2
MZ,C-]IEP5(;. O4\9'&!TZT :2Z99@-OA65FZM-^\8]QRV35B*".%=L:*BYS
MA0 ,]S5'2[?4X"PO[F*9-@"[1R#DYR<#/&*TJ "BBB@ HHHH **** "BBB@
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MC)&:L6\,$,*1VZ(D2\*L8 4?0#B@"6BBB@ J.>9;>"29\[8T+''H!FI*1E#
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93_"@#3!R,T4B(L:*B*%51@*!@ 4M '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>image_027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( .(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@!"<
M'% .:YCQNNI26%I%I4=^9WG ,UHY @7N[*""^.R]">O%4])@\40W&K"+!9YP
M\4VIAL$%FRJJCD;0NS!&.IR.* .THK&\+ZK<ZSH,-[=I$EPTDL;B'.S*2,F1
MGGG;FMF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH "<4W>OJ/SI)%WQ
MLA.-P(S6?%I"PRI)YQ.P@XV]: +8OK4S^0+B(S;RGE[QNW;=V,>N.?I2QWEO
M*4$<R.7+!=K Y*G#?D>#7-:YX)M];U&YO?MUQ;/-&JXBP '!&7]<E0%(]!51
M?A[!"H$.IW* 9+*5RKL6+$N,\^A^@H [.&>*X3?"ZR)DC<I!&0<$?@014E<O
MX?\ ",6@:K->IJ-S,)4*>4YP@);<3@?YY/K73Y'K0 M%%% !1110 4444 %%
M8OB369M#LXKF*VCN-\JQ^6TNQG)X"H,$LY/ 'XDXK.TKQI!>27GVFUDMXXMK
M1L@:8NC.Z#(4$J<QMQR,8YH F\"?\BK#_P!?-U_Z/DKI:YCP ZR^$+>1<[7N
M+EAD$'!GD['I73T %%%% !5>&]M[B26."XAEDA.V14<,4/HP'0_6K%<MX:@B
MB\3^+C'$B,U]$6*J!G]Q&>?7DG\Z -C3=<L=6GO8+.1GDLIO(N T;+L?TR0,
M_AZUHUSWAC/V[Q'S_P Q5O\ T5%70T %%%% !1110 4444 %%%% %/58KFXT
MF\ALY/+N9('2%\XVN5(4Y[8.*\E\.^"OBG8^(M.NM6\5+<Z?%.KW$/VQVWH.
MHP5YKV&Y:1+:5HAND"$H.N3CBN9LM2\2R7ENES8[(6<"1O*Q@=^] $7B;0-<
MU?54N;"_AMX(K=H5A9G!?S 0[$C@8&W'!Z=JS;30_&DKPWDFJ+#-"'2.*1P0
M07'W@%QM*KP.2#SGFMG7I==35'%A]K\D6Q, MXHV1IL-GS"W('W,8]^M<]IU
MWX_+V1GAF:$R*LYDC16"F1,MT'1=X(QT.1TH D-CX_\ ,6U74E:3R6S<Y41+
MUQ_#DMTY_P#UUTWA^RURTEG;6-1CNUD52@7^!MS9QP.-NS\0:H3ZMXAMS=Q0
M:5-<RK>N$>1,(8?X I!&>>"3TSDYJYX?U'7[V^N(]7TF.R@B'[J17W>:<XXY
MXZ$_1E]Z .CHHHH **** $;(&17,MXLF6]\EM&NUCW;=QFA$G7KY._?C\,^U
M=,QP*\?&E?\ "5^.+V.Z@T^W D#RO%=0RRAS'@%&\O<1M7[N?E//:@#U*^TC
M3]6\DW]I'<&!]\1<<HV,9'H<5+::;8V$D\EI:0P/</OE:- "[>I_SWIUS>6]
MC$)+F>.%"RH&D< %B< <]R:;:ZC:7LUQ#;7$<LENVR54.2C>A]^* ,3P)SX5
MBS_S\W7_ */DKI:YKP)_R*L7_7S=?^CY*Z6@ HHHH #7,VA^RRZA<P@+-+&\
MLK8^^ZJ "?H !^%=,>AKF(_]5=_]>\O\J /*O@EXZU_Q'XQU*SU&ZCD@FA>\
M=5B5<RY1,Y Z8 XKUSPSJ.I:A-K2ZA+;N+34'MH?)B*?(%4_-DG)^;]*^??V
M>'$?CJ_D(R%TV0X^CI7N7@V^62]UB,(P-U=O>H3_  J51<'WXH [ '-8?BS5
MKW1-$-[816\LHGBB*W!8+AW"9XYX+ _G5K1CJQMI/[86U%QYK[/LV=OEY^7.
M>^.M9_C&WDO]$^Q0[?->>&0%C@825';GZ*: +6O:Q-H>G172V;W;//% 8XY%
M3!=@H.6[9(_.M.6XAMU4SS1Q!C@%V R?3FN!^)?C71]"TK3HK]YD>ZNH9X@L
M1;Y(ID9\^AQ5GQ/>Z;XA\.^'-0C5);6YU.RGB\Y!G87'.#TX- '=44BD,H((
M(/0BEH **** *]].]M8W$\:&1XHF=4'\1 R!7!:5\0-;O]4LK6?PW)!%<2JC
MRD2?(#WY6O1",T8H Y;7M;U'3]4:WMEC5%MC+$K6TDIN7PWRAEX7;M4\]=U<
M]IGC;Q)<R62S:6LD$TB1R3);NNW=(@SC.,8+ ^A ]Z]*V^YHQZ\T <%=>,-;
MLM2E271Y&LXYIU#QIDR*CD#_ '>!R3UZBI]'\9W^J3W!72\6S1R&WF0EEWHO
M()P,@D<'CTQ7:21++&T;@,C##*1D$>E-AMXK>%(8$6.)!A410 ![ 4 <+I?C
M?53;1FZTR2],A&R:"%X0WR*64*V>58D$Y PI/48K5\/>+Y]=U%+5M&N[5&MO
M/,LOW0<XVC(&1[__ *ZZG;[F@#% !12T4 (1FO-K#[+!\49K.&"R@6&7;%'$
MMM$V#$&)V[/,/)/(8?3BO2B0.IKSN*XF/Q%GO)9)/[/$@\N=C,8=GE#HX(BQ
MNSU&<_A0!UGB/08]?L88&,:R0W,5Q'(Z;BA1PQQZ$@$9]ZS+3P8$EU$7%[*M
MO=3B5(K*22#:=S,6)#$[CNP<8!VCBNJW#UI<T <O\/XUA\'VT2EBJ3W*@LQ8
MD"=QR3R3[UT5Q=V]J%-Q/%"&.U3(X7)]!GO7$Z'<ZE;^#+4:7):QW#7MR6:Y
MC9UV"X?< %(.?2N-^.7C&]T63P]#;6UI+%(WVW%S%O(DC92N.>G)SZT >VYI
M:\TUG4KC5]'\-7L[E)3;Q:@?*9D!DQG! /*\]#4WC7QC?:)<Z*EO)+&&1;FY
M$:H1-'W0;@=ISW'8F@#T4]#7,)_JKO\ Z]Y?Y5T%I/\ :K.&XVE1+&K@'MD9
MQ7/Q_P"JN_\ KWE_E0!X#^S]_P CGJ?_ &"Y?_0DKV/PG<QV=U>74N?+AM&D
M?:,G ()KQS]G[_D<]3_[!<O_ *$E>L:/_P >6L_]@R7^5 &K\/=>AU-]5MQ>
M7US+]JDGC-TQ;9 S8103TX[5T.M?>@_'^E><_"#_ )"VH_\ 7LG_ *$:]&UK
M[T'X_P!* /"OVA_^/?PO_P!<Y_YI76V0!\#^$R0#_P 2J/K]!7)?M#_\>_A?
M_KG/_-*ZZR_Y$;PG_P!@J/\ D* /0(]9MM(TC1DGCG;[68X(_)B+X8CC=CH/
M>M[K7G7B/Q4^@V'A^"&[EMW81RW&VW60/;CAP">C?2N_M)TNK6*XCSY<J+(N
MX8.",B@"4')Z&DD8)&S'H 2:YK187B\4:Y<M).T-RT1ME>9F4*$^?"DX7YLU
MB^%O'UCXB\0Z]ID>M07@0DV44=NR-Y04%B2>N&.WMT]Z -'PA=I)J>M+]INY
MOM%T9[<3R,X2+:HP ?N_,6X^E=/::A9WQE%I=07!A;9)Y4@?8WH<=#[5PGA2
M1HKN[D0@,EH[ ^XQ67\*]7O+G7-1MY#"([E7O90D2J6E9E!.1V]J /6****
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MO?\ KR?^E8'PD_Y&:X_Z\C_Z$M=!X7_U][_UY/\ TKG_ (2?\C-<_P#7D?\
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MR%]1_P"O9/\ T(UZ-K7WH/Q_I0!X5^T/_P >_A?_ *YS_P TKKK+_D1O"?\
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MZ'T-25QOA_P?>Z6^H&34&A,[*$DM,!G"L[;WW C<=^#U^Z.: *_AW_D5;/\
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MH.,]%&>@J'2/ [&">PN[[4XK.PE^S:>NZ,?Z.$4CG;SSN&3Z4 <C\1^NA_\
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>image_028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "N .\# 2(  A$! Q$!_\0
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M _\ =X4]>_%6WUS1X0V_4[)=D@B.9E&U\<+]<5@VOP\TN$R-<37$S%Y?+&[
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MNV1J$7<<G &.33[>Z@NX_,MYHY4R1NC8,,@X(R*AO[9[S3KJUBDV/+"\8?\
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>image_029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "' .T# 2(  A$! Q$!_\0
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M@, %4<@]/>NG%G%C[O3I\Q_Q]A0!9H/2JJV,2C&WC.?O'K^?L*#80'/R=?\
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MNO1=J@>E #J**9*6$3E!E@.![T /HK*%SJ6/^/?_ ,=J75&O%TF22T.+E )
MNW._!!*X]P"/QH T**X236_$SSI!!8F,321R))+$?W<;L#@@>B\'OG)S36\2
M>(W@#)I4B3>8I$7E.6D&?F ;&%'&.>><B@#O:*R?#]_=ZCIPGO;<02EB H!
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M#_Z&*]:_:3_Y&?1?^O-O_0S7DOAS_D:-)_Z_8?\ T,5U'B'W8**!10 4444
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M*^?5^Z*^@OV>O^1?UK_K[3_T"ON<]_W%^J.:E\11\1?\C)J?_7R_\ZTO /\
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M/^1HTG_K]A_]#%>J?!'W8**!10 4444 %(>O2EHH 3%&!2T4 )M'I1M%+10
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MVSF!M9O*F$<MI+G[S<D&,K@\9)XZAN,KQ%+J?B;5?[,L9S;3VUQ(GV0NPW(
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>image_030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ") /$# 2(  A$! Q$!_\0
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M!549+,< #U-.IDL231-'(BNC##*PR"/0B@"I#K&FW$J10ZA9R.YPJI.I+?0
M\U>KCO#VC:9!XN\1/%IMG&\%Q!Y3) H*9@7[N!QU[5V- !1110 5G:IISZ@D
M:QW$L!1BQ*,1N!4K@X(]<_A4NJ7PTS39[TQF185+LH.#BFZ5J<>K:=#>PJR)
M*"0K#!&#@B@#E;O2;S3M9\--/JUQ=@ZE(2CJ "3!)@^N1@]./F/%=Q7/>(O^
M0QX9_P"PBW_I/+70T %%%% '.:WXEN]%O(8?["O;J.>5((9HI8@KR,"0N&8$
M=#R1BMRSFEN+.*6>V>VE9<M#(RLR'T)4D'\#6%XN^]H'_88@_D]=)0 4444
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M/%W_ ".FO?\ 81G_ /0S7O<.?[V_\+_0RK?"5-%_Y#^F?]?</_H8KZO^)?\
MR3;Q#_UYO7RAHO\ R'],_P"ON'_T,5]7_$O_ ))MXA_Z\GK?B#_>Z?HOS%2^
M%GR%7J7P#_Y*!/\ ]@^3_P!#2O+:]2^ ?_)0)_\ L'R?^AI7MYU_N$_E^:,Z
M?Q'5?M%?\@_P]_UVF_\ 05KP0U[W^T5_R#_#W_7:;_T%:\$K#A[_ '/YO]!U
M?B/I;X!_\D\E_P"PA+_Z"E>I5Y;\ _\ DGDO_80E_P#04KU*OC\9_O-3U?YF
M\=D%%%%<Q04444 4-6UG3=$L_M6J7L-G;[@GFS/M7<>@S^%>>7'B+X?R>,[6
MY^WZ UO]BF\R3$9'F&2,C)Q][ /ZT?'H?\6\3_K_ (OY-7S3DU[.690L=2=3
MGM9VV,YU.5V/M71]?TC7HI)-(U"WO8XCM=H'#!3C.#6F.E>,?L\?\@#6_P#K
M[3_T 5[-D5YF(H^QK2I7O9V+B[JXM%)N'K2UB,**** .!^,W_)+=6^L7_HQ:
M^5.]?5?QF_Y);JWUB_\ 1BU\J=Z^OX9_A3]5^1SUMT>R?L\?\A_7/^O6/_T,
MT[]HC_D.:%_U[2_^A"F_L\?\A_7/^O6/_P!#-._:(_Y#FA?]>TO_ *$*X_\
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A"T[3M8M[V.6\U$W$6&WQ] #G@].>*W<444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>image_031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? +$# 2(  A$! Q$!_\0
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MK'X:ZM)&Y1W$<:E3@\NH/Z9KR_X(^-);379- O[AW@OOF@:1B=LH'3G^\/U
M]:I1NKDN5G8^A:**R_$>N6WAOP_>ZM=$>7;1E@N?OMT51]3@5)1J45\M> _$
M>HZA\6=,OKR[E=[J[;S%WG;EP1C'ISP*^I:J4>447<****D84444 <[XS\86
M?@K1DU*]MYYTDE$*I#C.X@GG)X'!J[X:UQ/$GAVSUB.!H$ND+"-FR5P2.OX5
MY_\ 'W_D1[/_ *_T_P#0'KIOA;_R330_^N+?^AM567+<F^MCKZ***DH****
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DM,SPN)(UFN9'17 QN"DXSCO1=!9FO1114C"BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>image_032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? +$# 2(  A$! Q$!_\0
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MK'X:ZM)&Y1W$<:E3@\NH/Z9KR_X(^-);379- O[AW@OOF@:1B=LH'3G^\/U
M]:I1NKDN5G8^A:**R_$>N6WAOP_>ZM=$>7;1E@N?OMT51]3@5)1J45\M> _$
M>HZA\6=,OKR[E=[J[;S%WG;EP1C'ISP*^I:J4>447<****D84444 <[XS\86
M?@K1DU*]MYYTDE$*I#C.X@GG)X'!J[X:UQ/$GAVSUB.!H$ND+"-FR5P2.OX5
MY_\ 'W_D1[/_ *_T_P#0'KIOA;_R330_^N+?^AM567+<F^MCKZ***DH****
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DM,SPN)(UFN9'17 QN"DXSCO1=!9FO1114C"BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103093360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INMED
PHARMACEUTICALS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001728328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1428279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 310 &#8211; 815 W Hastings<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Vancouver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">B.C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V6C 1B4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">669-7207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Vancouver, Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289101688464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,176,866<span></span>
</td>
<td class="nump">$ 7,363,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">44,804<span></span>
</td>
<td class="nump">46,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">88,027<span></span>
</td>
<td class="nump">11,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">2,490,854<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other assets</a></td>
<td class="nump">797,225<span></span>
</td>
<td class="nump">956,762<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,597,776<span></span>
</td>
<td class="nump">8,378,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Property, equipment and ROU assets, net</a></td>
<td class="nump">904,252<span></span>
</td>
<td class="nump">326,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,108,915<span></span>
</td>
<td class="nump">1,061,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">176,637<span></span>
</td>
<td class="nump">14,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">12,787,580<span></span>
</td>
<td class="nump">9,781,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,415,265<span></span>
</td>
<td class="nump">2,134,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease obligations</a></td>
<td class="nump">404,276<span></span>
</td>
<td class="nump">80,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionConsiderationPayable', window );">Acquisition consideration payable</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,319,541<span></span>
</td>
<td class="nump">2,215,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations</a></td>
<td class="nump">389,498<span></span>
</td>
<td class="nump">189,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">3,709,039<span></span>
</td>
<td class="nump">2,404,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited authorized shares 650,667 (June 30, 2021 - 322,028) issued and outstanding</a></td>
<td class="nump">70,718,461<span></span>
</td>
<td class="nump">60,587,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">31,684,098<span></span>
</td>
<td class="nump">21,513,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(93,452,587)<span></span>
</td>
<td class="num">(74,852,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">128,569<span></span>
</td>
<td class="nump">128,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
<td class="nump">9,078,541<span></span>
</td>
<td class="nump">7,376,567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
<td class="nump">$ 12,787,580<span></span>
</td>
<td class="nump">$ 9,781,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition consideration payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103036512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock, shares authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">650,667<span></span>
</td>
<td class="nump">322,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">650,667<span></span>
</td>
<td class="nump">322,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289101952064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 1,089,435<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">545,889<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">543,546<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development and patents</a></td>
<td class="nump">7,282,615<span></span>
</td>
<td class="nump">5,338,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,867,030<span></span>
</td>
<td class="nump">4,479,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Amortization and depreciation</a></td>
<td class="nump">185,657<span></span>
</td>
<td class="nump">120,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairment of intangible assets and goodwill</a></td>
<td class="nump">3,472,593<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,807,895<span></span>
</td>
<td class="nump">9,938,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest and other income</a></td>
<td class="nump">96,090<span></span>
</td>
<td class="nump">16,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Finance expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(360,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain on derivative warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">242,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantModificationExpense', window );">Warrant modification expense</a></td>
<td class="num">(1,314,307)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss</a></td>
<td class="num">(117,551)<span></span>
</td>
<td class="num">(163,101)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">(18,600,117)<span></span>
</td>
<td class="num">(10,203,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Other Comprehensive Gain</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign currency translation gain</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">430,443<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss for the year</a></td>
<td class="num">$ (18,600,117)<span></span>
</td>
<td class="num">$ (9,772,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share for the year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share for the year Basic (in Dollars per share)</a></td>
<td class="num">$ (33.17)<span></span>
</td>
<td class="num">$ (37.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average outstanding common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average outstanding common shares Basic (in Shares)</a></td>
<td class="nump">560,829<span></span>
</td>
<td class="nump">268,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantModificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant modification expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantModificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103037840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share for the year Diluted</a></td>
<td class="num">$ (33.17)<span></span>
</td>
<td class="num">$ (37.96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted average outstanding common shares Diluted</a></td>
<td class="nump">560,829<span></span>
</td>
<td class="nump">268,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103824624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income - Foreign Exchange</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 53,065,240<span></span>
</td>
<td class="nump">$ 17,764,333<span></span>
</td>
<td class="num">$ (64,649,381)<span></span>
</td>
<td class="num">$ (301,874)<span></span>
</td>
<td class="nump">$ 5,878,318<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2020</a></td>
<td class="nump">208,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Public offering</a></td>
<td class="nump">$ 6,052,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,052,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering (in Shares)</a></td>
<td class="nump">71,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement', window );">Private placement</a></td>
<td class="nump">$ 2,917,157<span></span>
</td>
<td class="nump">1,545,343<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,462,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares', window );">Private placement (in Shares)</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Reclassification of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,763,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,763,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(1,446,980)<span></span>
</td>
<td class="num">(170,798)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,617,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantModificationExpense', window );">Warrant modification expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LossAndComprehensiveIncomelossesForThePeriod', window );">Loss and comprehensive income for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,203,089)<span></span>
</td>
<td class="nump">430,443<span></span>
</td>
<td class="num">(9,772,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">610,193<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">610,193<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 60,587,417<span></span>
</td>
<td class="nump">21,513,051<span></span>
</td>
<td class="num">(74,852,470)<span></span>
</td>
<td class="nump">128,569<span></span>
</td>
<td class="nump">7,376,567<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="nump">322,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement', window );">Private placement</a></td>
<td class="nump">$ 1,459,051<span></span>
</td>
<td class="nump">10,540,635<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,999,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares', window );">Private placement (in Shares)</a></td>
<td class="nump">35,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ATMOfferingNetOfIssuanceCosts', window );">ATM offering, net of issuance costs</a></td>
<td class="nump">$ 146,533<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">146,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ATMOfferingNetOfIssuanceCostsShares', window );">ATM offering, net of issuance costs (in Shares)</a></td>
<td class="nump">10,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_RegisteredDirectAndPrivatePlacement', window );">Registered direct and private placement</a></td>
<td class="nump">$ 754,072<span></span>
</td>
<td class="nump">4,245,508<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,999,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_RegisteredDirectAndPrivatePlacementShares', window );">Registered direct and private placement (in Shares)</a></td>
<td class="nump">65,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">$ (375,220)<span></span>
</td>
<td class="num">(2,506,795)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,882,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AgentsWarrants', window );">Agents' warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">739,920<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">739,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AgentsInvestmentOptions', window );">Agents' investment options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">192,492<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">192,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ExerciseOfPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">$ 4,283,969<span></span>
</td>
<td class="num">(4,283,654)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ExerciseOfPrefundedWarrantsinShares', window );">Exercise of pre-funded warrants (in Shares)</a></td>
<td class="nump">125,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ExerciseOfWarrantsin', window );">Exercise of warrants</a></td>
<td class="nump">$ 769,260<span></span>
</td>
<td class="num">(769,260)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ExerciseOfWarrantsinShares', window );">Exercise of warrants (in Shares)</a></td>
<td class="nump">6,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionOfBayMedica', window );">Acquisition of BayMedica</a></td>
<td class="nump">$ 3,013,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,013,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionOfBayMedicainShares', window );">Acquisition of BayMedica (in Shares)</a></td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for consulting services</a></td>
<td class="nump">$ 79,879<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for consulting services (in Shares)</a></td>
<td class="nump">3,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantModificationExpense', window );">Warrant modification expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,314,307<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,314,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LossAndComprehensivelossesForThePeriod', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,600,117)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,600,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">697,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">697,894<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 70,718,461<span></span>
</td>
<td class="nump">$ 31,684,098<span></span>
</td>
<td class="num">$ (93,452,587)<span></span>
</td>
<td class="nump">$ 128,569<span></span>
</td>
<td class="nump">$ 9,078,541<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="nump">650,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ATMOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of ATM offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ATMOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ATMOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ATM offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ATMOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionOfBayMedica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition of baymedica.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionOfBayMedica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionOfBayMedicainShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares acquisition of baymedica.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionOfBayMedicainShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AgentsInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of agents' investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AgentsInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AgentsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of agents&#8217; warrants.

..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AgentsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ExerciseOfPrefundedWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ExerciseOfPrefundedWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ExerciseOfWarrantsin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ExerciseOfWarrantsin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ExerciseOfWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ExerciseOfWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LossAndComprehensiveIncomelossesForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss and comprehensive income (loss) for the period.

..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LossAndComprehensiveIncomelossesForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LossAndComprehensivelossesForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LossAndComprehensivelossesForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_RegisteredDirectAndPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of registered direct and private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_RegisteredDirectAndPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_RegisteredDirectAndPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered direct and private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_RegisteredDirectAndPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Issued For Private Placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Issued For Private Placement Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantModificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant modification expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantModificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289188084800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">$ (18,600,117)<span></span>
</td>
<td class="num">$ (10,203,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not requiring cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Amortization and depreciation</a></td>
<td class="nump">185,657<span></span>
</td>
<td class="nump">120,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">697,894<span></span>
</td>
<td class="nump">610,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
<td class="nump">79,879<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">326,133<span></span>
</td>
<td class="nump">107,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of assets</a></td>
<td class="nump">11,355<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_InterestIncomeaccruedReceivedOnShorttermInvestments', window );">Interest income received on short-term investments</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_UnrealizedGainOnDerivativeWarrantsLiability', window );">Unrealized gain on derivative warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(242,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_UnrealizedGainOnForeignExchange', window );">Unrealized foreign exchange loss</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible assets and goodwill</a></td>
<td class="nump">3,472,593<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on lease obligations</a></td>
<td class="num">(341,862)<span></span>
</td>
<td class="num">(93,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FinanceExpense', window );">Finance expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">360,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantModificationExpenses', window );">Warrant modification expense</a></td>
<td class="nump">1,314,307<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,003,732)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaids and other assets</a></td>
<td class="nump">190,661<span></span>
</td>
<td class="num">(823,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(61,432)<span></span>
</td>
<td class="num">(14,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(40,008)<span></span>
</td>
<td class="nump">40,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(811,599)<span></span>
</td>
<td class="nump">346,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(5,142)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Total cash used in operating activities</a></td>
<td class="num">(15,583,758)<span></span>
</td>
<td class="num">(9,790,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CashAcquiredFromAcqusition', window );">Cash acquired from acquisition of BayMedica</a></td>
<td class="nump">91,566<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Acquisition consideration payable</a></td>
<td class="num">(300,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(39,108)<span></span>
</td>
<td class="num">(1,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLoansReceivable', window );">Loan receivable</a></td>
<td class="num">(425,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Total cash used in investing activities</a></td>
<td class="num">(672,999)<span></span>
</td>
<td class="num">(1,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issued for cash</a></td>
<td class="nump">17,146,114<span></span>
</td>
<td class="nump">12,472,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issuance costs</a></td>
<td class="num">(1,784,791)<span></span>
</td>
<td class="num">(1,617,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="num">(290,826)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Total cash provided by financing activities</a></td>
<td class="nump">15,070,497<span></span>
</td>
<td class="nump">10,854,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effects of foreign exchange on cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">494,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash during the period</a></td>
<td class="num">(1,186,260)<span></span>
</td>
<td class="nump">1,557,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents beginning of the period</a></td>
<td class="nump">7,363,126<span></span>
</td>
<td class="nump">5,805,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents end of the period</a></td>
<td class="nump">$ 6,176,866<span></span>
</td>
<td class="nump">$ 7,363,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_CashAcquiredFromAcqusition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired from acqusition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_CashAcquiredFromAcqusition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_FinanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_FinanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_InterestIncomeaccruedReceivedOnShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income (accrued) received on short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_InterestIncomeaccruedReceivedOnShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_UnrealizedGainOnDerivativeWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on derivative warrants liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_UnrealizedGainOnDerivativeWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_UnrealizedGainOnForeignExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Unrealized gain on foreign exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_UnrealizedGainOnForeignExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantModificationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of warrant modification expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantModificationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of loan receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105876960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_NatureofBusinessandGoingConcernLineItems', window );"><strong>Corporate Information and Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF BUSINESS AND GOING CONCERN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>1.
NATURE OF BUSINESS AND GOING CONCERN</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">InMed
Pharmaceuticals Inc. (&#8220;InMed&#8221; or the &#8220;Company&#8221;) was incorporated in the Province of British Columbia on May 19,
1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline
of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high
unmet medical needs. The Company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids
for various market sectors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s shares are listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the trading symbol &#8220;INM&#8221;. InMed&#8217;s
corporate office and principal place of business is located at #310 &#8211; 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Update (&#8220;ASU&#8221;) 2014-15,
Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated
whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability
to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Through
June 30, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred
recurring losses and negative cash flows from operations since its inception, including net losses of $18.6 million and $10.2 million
for the years ended June 30, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of $93.5 million as of
June 30, 2022 (June 30, 2021 - $74.9 million). The Company expects to continue to generate operating losses for the foreseeable future.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of the issuance date of these consolidated
financial statements, the Company expects its cash and cash equivalents of $6.2 million as of June 30, 2022, combined with the approximate
$5.4 million of net proceeds from a private placement which closed on September 13, 2022 (see Note 20), will be sufficient to fund its
operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal
2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory
as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to
raise additional capital to finance its operations. As a result of the recurring losses and requirement for cash in fiscal 2023 or the
beginning of fiscal 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within
one year after the date that the consolidated financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including
collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing
on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s existing
stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its
commitments, realize its assets and discharge its liabilities in the normal course. These consolidated financial statements do not reflect
adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going
concern and such adjustments could be material.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_NatureofBusinessandGoingConcernLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_NatureofBusinessandGoingConcernLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289196220256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>2.
SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United
States (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;)
for financial information.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the
reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported.
It also requires management to exercise judgment in applying the Company&#8217;s accounting policies. In the future, actual experience
may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions
and estimates are significant to these consolidated financial statements are the estimated fair values of the assets acquired and liabilities
assumed in acquisitions, the estimate of useful life of intangible assets, the application of the going concern assumption, the impairment
assessment for long-lived assets, and determining the fair value of share-based payments and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>COVID-19
Impacts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 11, 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. The full extent to which the COVID-19
pandemic may directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses,
research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain,
such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to
contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating
to the preparation of these consolidated financial statements. While there was no material impact to the Company&#8217;s consolidated
financial statements as of and for the year ended June 30, 2022, the Company&#8217;s future assessment of the magnitude and duration
of COVID-19, as well as other factors, could result in a material impact to the Company&#8217;s consolidated financial statements in
future reporting periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Consolidation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical
Ltd., BayMedica, LLC, Biogen Sciences Inc., and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either
directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain
benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany
transactions are eliminated in preparing these consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Foreign
Currency</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -20.55pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
functional currency of the Company and its subsidiaries is the U.S. Dollar. These consolidated financial statements are presented in
U.S. Dollars. References to &#8220;$&#8221; and &#8220;US$&#8221; are to United States (&#8220;U.S.&#8221;) dollars and references to
&#8220;C$&#8221; are to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Business
Combinations</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Business
combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair
values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as
goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair
values at the date of acquisition. If the Company&#8217;s interest in the fair value of the acquiree&#8217;s net identifiable assets
exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in
connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments
with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an
insignificant risk of change in value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Short-term
Investments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve
months. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change
in value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Accounts
Receivable</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Accounts
receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company&#8217;s
best estimate of the amount of probable credit losses in existing accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition
and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected
to affect future collections experience. Expected credit losses on our accounts receivable were immaterial as at June 30, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Inventories</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Inventories
are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value.
Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing
costs and production and labor costs related to manufacturing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. At June 30, 2022,
no amounts had been charged to the valuation allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Deferred
Financing Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity
financings as deferred financing costs until such financings are consummated. After consummation of the equity financing, these costs
are recorded as a reduction to shareholders&#8217; equity generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred financing costs will be expensed immediately as a charge to operating expenses in the consolidated statements
of operations and comprehensive loss. As of June 30, 2022, $<span style="-sec-ix-hidden: hidden-fact-78">Nil</span> (2021 - $112,074) of deferred financing costs were capitalized and recorded
as prepaids and other assets on the consolidated balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Property, Equipment and ROU Assets,
Net </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment
and leasehold improvements are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of
equipment and leasehold improvements comprises their purchase price. The useful lives of equipment and leasehold improvements are reviewed
at least once per year. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated
useful lives as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Computer equipment &#8211; 30% per annum</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Leasehold
                                            improvements &#8211; lesser of initial lease term or useful life</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment
and leasehold improvements, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The right-of-use assets are initially
measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less
any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the right-of-use asset or the
lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits.
The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition,
the right-of-use assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability
(see Note 2 Lease (i)).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Intangible
Assets, Net </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property
is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment
losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>In-Process
R&amp;D</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In-process
R&amp;D (&#8220;IPR&amp;D&#8221;) is classified as an indefinite-lived intangible asset and is not amortized. IPR&amp;D becomes definite-lived
upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent
to the acquisition of IPR&amp;D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual
basis or more frequently if an indicator of impairment is present.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Impairment
of Long-Lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the
asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted
cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount
by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale
are reported at the lower of the carrying amount or fair value, less costs to sell. As of June 30, 2022, the Company determined that
the long-lived assets of BayMedica were impaired (see Note 6) and no assets were held-for-sale.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Goodwill</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company tests goodwill for potential
impairment annually on June 30, or more frequently if an event or other circumstance indicates that the Company may not be able to recover
the carrying amount of the net assets of the reporting unit. The Company&#8217;s operations consist of two operating and reportable segments,
InMed Pharmaceuticals (the &#8220;InMed&#8221; segment) and BayMedica (the &#8220;BayMedica&#8221; segment). In evaluating goodwill for
impairment, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. If a Company bypasses the qualitative assessment, or if the Company concludes that it is more likely
than not that the fair value of a reporting unit is less than its carrying value, then the Company performs a quantitative impairment
test by comparing the fair value of a reporting unit with its carrying amount (See Note 6) and records an impairment charge if the carrying
value exceeds the fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Assets and Liabilities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and
subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are
or elected to be carried at fair value through profit or loss or where changes in fair value are recognized in the consolidated statements
of operations and comprehensive loss in other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments are subsequently recorded at cost plus accrued interest, which approximates fair value. Accounts receivable are reported
at outstanding amounts, net of provisions for uncollectable amounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
Liabilities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities, including accounts payable and accrued liabilities, are initially recognized at fair value net of any transaction costs
directly attributable to the issuance of the instrument and subsequently carried at amortized cost using the effective interest rate
method. This ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried
in the consolidated balance sheet. Interest expense in this context includes initial transaction costs and premiums payable on redemption,
as well as any interest or coupon payable while the liability is outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Assets and Liabilities (cont&#8217;d)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">To
determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of
financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three
levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                               1 &#8211;</span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;Unadjusted
                                            quoted prices in active markets for identical instruments.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> Level 2 &#8211;</span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;Inputs
                                            other than quoted prices included within Level 1 that are observable for the asset or liability,
                                            either directly or indirectly. Level 2 inputs include quoted prices for similar assets or
                                            liabilities in active markets, quoted prices for identical or similar assets or liabilities
                                            in markets that are not active, inputs other than quoted prices that are observable for the
                                            asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived
                                            principally from or corroborated by observable market data by correlation or other means
                                            (market corroborated inputs).</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                               3 &#8211;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;Inputs
                                            are unobservable and reflect the Company&#8217;s assumptions as to what market participants
                                            would use in pricing the asset or liability. The Company develops these inputs based on the
                                            best information available. Assets and liabilities are classified based on the lowest level
                                            of input that is significant to the fair value measurements. Changes in the observability
                                            of valuation inputs may result in a reclassification of levels for certain securities within
                                            the fair value hierarchy.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities,
approximate their carrying values as at June 30, 2022 and 2021 due to their immediate or short-term maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company records a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset
and liability method. Under this method, it recognizes deferred income tax assets and liabilities for the expected future tax consequences
of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets and liabilities
are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities
are expected to be realized or settled. The Company recognizes the deferred income tax effects of a change in tax rates in the period
of the enactment. The Company records a valuation allowance to reduce its deferred tax assets to the net amount that management believes
is more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions are more likely
than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than fifty percent likely
of being realized. The Company records interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Revenue
Recognition</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products
and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers
in exchange for those products and services. ASC 606, <i>Revenue from Contracts with Customers</i> defines a five-step process to recognize
revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations
in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract,
and recognizing revenue when or as the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Revenue consists of manufacturing and
distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when
control over the products have been transferred to the customer and the Company has a present right to payment. Sales and other taxes
that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return,
for claims of damaged or non-compliant products, exist with the Company&#8217;s customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense,
when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Revenues
within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance
of when control is transferred to the customer. The time between invoicing and when payment is due is not significant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cost
of Sales</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Cost
of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing
costs. Cost of sales also includes production and labor costs for the Company&#8217;s manufacturing business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Shipping
and Handling</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company records freight billed to customers within Net sales. Shipping and handling costs associated with inbound freight and goods shipped
to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating
expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Earnings
(Loss) Per Share</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Basic
earnings (loss) per common share (&#8220;EPS&#8221;) is computed by dividing the net income or loss applicable to common shares of the
Company by the weighted average number of common shares outstanding for the relevant period. Diluted earnings (loss) per common share
(&#8220;Diluted EPS&#8221;) is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average
number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive
instruments were converted. If the conversion of outstanding stock options and warrants into common share is anti-dilutive, then diluted
EPS is not presented separately from EPS.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Share-based
Payments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
fair value, at the grant date, of equity-classified share awards is charged to income or loss over the period for which the benefits
of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards
are measured separately and expensed over the related tranche&#8217;s vesting period. The corresponding accrued entitlement is recorded
in additional paid-in capital. The amount recognized as an expense is adjusted to reflect the number of share options that vest. The
fair value of awards is calculated using the Black-Scholes option pricing model which considers the exercise price, current market price
of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Starting
July 1, 2018, the Company accounts for non-employee awards under the guidance provided under ASU 2018-07 and uses an expected term to
value non-employee options on an award-by-award basis.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
expected term of the Company&#8217;s employee stock options is determined using the simplified method and the Company estimates the forfeitures
on the grant date for options issued. The expected term of the Company&#8217;s non-employee stock options is the contractual term of
the options granted and the Company estimates the forfeitures on the grant date for options issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company conducts research and development programs and incurs costs related to these activities, including research and development personnel
compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the
periods in which they are incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Patents
and Intellectual Property Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty
surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third
parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the
patent.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
reporting </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s operations consist of two operating and reportable segments, the InMed segment and the BayMedica segment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry (See Note 15).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">At
inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date,
discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental
borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized
cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in
an index or rate, if there is a change in the Company&#8217;s estimate of the amount expected to be payable under a residual value guarantee,
or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability
is re-measured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit
or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component
and its associated non-lease components as a single lease component for all of its asset classes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement
of the right-of-use asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize
right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated
with these leases is recognized as an expense on a straight- line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fair
                                            Value Measurement</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
June 2022, FASB issued ASU 2022-03, <i>Fair Value Measurement (Topic 82):</i> Fair Value Measurement of Equity Securities Subject to
Contractual Sale Restrictions. The amendments in this ASU clarify the guidance in ASC 820 on the fair value measurement of an equity
security that is subject to a contractual sale restriction and require specific disclosures related to such an equity security. This
standard is effective for fiscal years beginning after December 15, 2023. The Company does not expect the standard to have a significant
impact on the consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105063280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Customer Concentration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CUSTOMER CONCENTRATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2.4pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>3.
CUSTOMER CONCENTRATION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company had three customers during the year ended June 30, 2022, which individually generated 10% or more of the Company&#8217;s net
sales. These customers accounted for 48% of the Company&#8217;s sales for the year ended June 30, 2022. As of June 30, 2022, these customers
represented 0% of the Company&#8217;s outstanding accounts receivable.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289108091200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>4.
INVENTORIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Inventories
consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
 2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
 2021</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">292,577</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,724,851</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">473,426</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,490,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, inventory expensed to cost of goods sold was $545,889 (2021 - $<span style="-sec-ix-hidden: hidden-fact-83">Nil</span>).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104999168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Rou Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, EQUIPMENT AND ROU ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><b>5. PROPERTY,
EQUIPMENT AND ROU ASSETS, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Property, equipment and ROU assets
consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>June 30,<br/>
2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>June 30,<br/>
2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">$</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">$</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-size: 10pt">Right of Use Assets (leases)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,167,436</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">439,321</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">212,877</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">66,888</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Leasehold Improvements</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">40,409</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">42,986</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Property and equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,420,722</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">549,195</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Less: accumulated depreciation and amortization</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(516,470</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(222,600</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Property, equipment and ROU assets, net</span></td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">904,252</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">326,595</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expense on property, equipment
and leasehold improvements for the year ended June 30, 2022, was $26,426 (2021 - $21,143). Amortization expense related to the right-of-use
assets for the year ended June 30, 2022, was $289,594 (2021 - $76,165) and was recorded in general and administrative expenses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289192737200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>6.
IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, the Company recorded goodwill of $2,023,039, definite lived intangible assets of $216,000, IPR&amp;D of
$1,249,000 and patents of $1,191,000 in connection with the acquisition of BayMedica, as described in Note 8.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company performs an annual impairment
test at the reporting unit level as of June 30 of each fiscal year. As of June 30, 2022, the Company qualitatively assessed whether it
is more likely than not that the respective fair value of the Company&#8217;s BayMedica reporting unit was less than its carrying amount,
including goodwill. For a variety of reasons, performance of the BayMedica segment has not materialized as expected. Contributing factors
include but are not limited to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"/><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">market
                                            demand for launched compounds has not materialized as quickly as the Company anticipated;</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">recent
                                            overarching recessionary pressures have contributed to hesitation within the health and wellness
                                            (H&amp;W) sector to invest in, and launch, new rare cannabinoid products;</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">in
                                            this nascent market, BayMedica&#8217;s perceived competitive advantages of certified, high purity and
                                            reliability and consistency of supply have not resonated with the industry&#8217;s current
                                            product manufacturers; and</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">additional
                                            downward pricing pressure for cannabinoids in the H&amp;W sector.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
a result of this sustained decline in performance compared to expectations and continuing market uncertainties, the Company determined
that as of June 30, 2022, it was more likely than not that the carrying value of these acquired intangibles exceeded their estimated
fair value. Accordingly, the Company performed an impairment analysis as of that date using the income method, the relieve from royalty
method and the multi-period excess earnings method. This analysis required significant judgments, including the estimation of future revenues,
royalties, licensing fees, costs, the probability of success in various phases of its development programs, potential post launch cash
flows and discount rates. The Company recorded a goodwill and intangible asset impairment charge for the excess of the reporting unit&#8217;s
carrying value over its fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table provides the Company&#8217;s
goodwill, indefinite and definite lived intangible assets as of June 30, 2022 and 2021. There was no impairment of InMed long lived intangible
assets as of June 30, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,023,039</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,023,039</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Indefinite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,249,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,249,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Definite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademark and Intellectual Property</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">216,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(786,637</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(200,554</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">965,229</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Definite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(47,314</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,143,686</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,108,915</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For goodwill, the Company recognized
an impairment charge of $2 million and $<span style="-sec-ix-hidden: hidden-fact-90">Nil</span> during the years ended June 30, 2022 and 2021, respectively. For the identified indefinite
lived assets, the Company recognized an impairment charge of $1.2 million and $<span style="-sec-ix-hidden: hidden-fact-91">Nil</span> during the years ended June 30, 2022 and 2021, respectively.
For identified definite lived intangible assets, the Company recognized an impairment charge of $0.2 million and $<span style="-sec-ix-hidden: hidden-fact-92">Nil</span> during the years
ended June 30, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105819344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>7.
INTANGIBLE ASSETS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intellectual property</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(818,505</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(674,723</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,108,915</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,061,697</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated
useful life of 18 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 13 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Amortization
expense on intangible assets for the year ended June 30, 2022 was $159,228 (2021 - $99,723). The Company expects amortization expense
to be incurred over the next five years as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">807,385</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105063280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionAbstract', window );"><strong>Acquisition Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionTextBlock', window );">ACQUISITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>8.
ACQUISITION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On October 13, 2021, the Company completed
the acquisition of BayMedica, a private company based in the U.S. that specializes in the manufacturing and commercialization of rare
cannabinoids. The Company acquired 100% of BayMedica in exchange for i) 82,000 common shares issued to BayMedica&#8217;s equity and convertible
debt holders, subject to a six-month contractual hold period and ii) $1 million to be held in escrow, subject to reduction for certain
post-closing adjustments or satisfaction of indemnification claims under the definitive agreement (the &#8220;BayMedica Agreement&#8221;)
in the six- and twelve-month periods following the closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Total
consideration for the acquisition of BayMedica is summarized as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Purchase
                                            Price<br/>
                                            Consideration<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Estimated fair value of common shares issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,013,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:Post-closing adjustments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(199,543</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Estimated fair value of consideration transferred</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,813,957</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
82,000 common shares were valued at $36.75, being the closing price of the Company&#8217;s common shares on Nasdaq on October 13, 2021.
The cash component is subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims and therefore
is subject to further changes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the acquisition, the Company has a $425,000 loan receivable from BayMedica and BayMedica has an equal loan payable to the Company.
As a result of the acquisition of BayMedica, the loan receivable and payable is effectively settled between the parties.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the acquisition method of accounting, the purchase price of BayMedica has been allocated to the acquired assets and assumed
liabilities based on their estimated acquisition date fair values. The fair value estimates were based on income, estimates and other
analyses. The excess of the total consideration over the estimated fair value of the amounts initially assigned to the identifiable assets
acquired and liabilities assumed has been recorded as goodwill, which is not deductible for income taxes purposes. The goodwill balance
represents the assembled workforce acquired, the combined company&#8217;s expectations of the strategic opportunities available as a
result of the acquisition, and other synergies that will be derived from the acquisition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the final fair value of assets acquired and liabilities assumed as of the acquisition date:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Purchase Price</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Allocation</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>($)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets acquired:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">91,566</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">487,122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">131,674</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">133,911</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,249,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Trademark</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">216,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,023,039</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total assets acquired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,559,412</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Liabilities assumed:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,024,487</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other short-term liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">598,245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long-term debt</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,723</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities acquired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,745,455</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Estimated
    fair value of net assets acquired</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,813,957</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; ">Tangible
assets and liabilities were valued at their respective carrying amounts as management believes that these amounts approximated their
acquisition-date fair values.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Purchase Price allocation includes certain identifiable intangible assets with an estimated fair value of approximately $2,656,000. These
intangible assets include trade secrets, product formulation knowledge, patents and trademarks. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
IPR&amp;D are related identifiable intangible assets associated with cannabinoid manufacturing processes and includes knowhow and trade
secrets. The multi-period excess earnings method was used to determine the fair value of these assets as at the date of acquisition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; ">The
acquired trademark represents the trade name ProDiol&#174;. The fair value of the trademark was determined using the relief from
royalty method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Acquired
patents consist of patents related to the development of cannabinoid analogs, the fair value of which was determined using the income
approach. This intangible asset is being amortized over an estimated useful life of 18 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Following the acquisition date, the
operating results of BayMedica have been included in the consolidated financial statements. For the period from the October 13, 2021 acquisition
date through June 30, 2022, sales attributable to BayMedica were $1.1 million and operating losses attributable to BayMedica were $5.2
million. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $0.2 million
for the year ended June 30, 2022 and were included in general and administrative expenses in the consolidated statements of operations
and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the pro forma consolidated results of the Company assuming the BayMedica acquisition had been completed on July
1, 2020:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year Ended June
    30</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365,755</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,904,013</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,260,014</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,705,494</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105901280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>9.
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Accounts
payable and accrued liabilities consist of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,166,068</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">775,129</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">839,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,901</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee compensation, benefits and related accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">880,207</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">270,439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169,641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,415,265</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,134,878</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289188081312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalAndReservesAbstract', window );"><strong>Share Capital And Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalAndReservesTextBlock', window );">SHARE CAPITAL AND RESERVES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>10.
SHARE CAPITAL AND RESERVES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 7, 2022, the Company effected a one-for-25 reverse stock split of its issued and outstanding common shares. Accordingly, all
common share, stock option, per common share and warrant amounts for all periods presented in the consolidated financial statements and
notes thereto have been adjusted retrospectively to reflect this reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company&#8217;s authorized share structure consisted of: (i) an unlimited number of common shares without par value;
and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as at June 30, 2022
and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company may issue preferred shares and may, at the time of issuance, determine the rights, preference and limitations pertaining to these
shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding
up of the Company before any payment is made to the holders of common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Common Shares</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, the Company completed the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">July
2021 Private Placement Offering:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Transaction
    Description</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Issue
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Shares Issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74.325</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,645,970</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants
    Issued</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">125,853</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74.3226</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,353,716</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,999,686</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allocated to Additional
    Paid-in Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,540,635</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,459,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Share Issuance Costs</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(247,336</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
July 2, 2021, the Company closed a private placement of its common shares and issued an aggregate of 35,600 common shares and 125,853
pre-funded warrants, for gross proceeds of $11,999,686. The pre-funded warrants were determined to be common stock equivalents. Each
common share and each pre-funded warrant were sold in the offering with a warrant to purchase a common share. Transaction costs were
allocated proportionally between common shares and warrants with $247,336 allocated to common shares and the balance of $1,786,831 allocated
to additional paid-in capital and recorded as a component of shareholders&#8217; equity in the consolidated balance sheet. The 125,853
pre-funded warrants were fully exercised for 125,853 common shares during the year ended June 30, 2022, resulting in a $4,283,654 reclassification
from additional paid-in capital to common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">June
2022 Registered Direct and Private Placement Offerings:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Transaction
    Description</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Issue
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Shares Issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,002</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.450</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,394,286</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants
    Issued</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$'</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.4474</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,605,294</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,999,580</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allocated to Additional
    Paid-in Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,245,508</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">754,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Share Issuance Costs</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(127,884</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
April 22, 2022, the Company issued 10,759 common shares under an at-the-market offering (&#8220;ATM&#8221;) for proceeds of $146,533,
net of issuance costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
June 6, 2022, the Company closed a registered direct offering and concurrent private placement of its common shares. In the registered
direct offering, the Company issued an aggregate of 65,002 common shares and 98,169 pre-funded warrants, for gross proceeds of $3,500,002.
In the concurrent private placement, the Company issued an aggregate of 69,930 pre-funded warrants for gross proceeds of $1,499,999.
The pre-funded warrants were determined to be common stock equivalents. Each common stock and each pre-funded warrant were sold in the
offerings with a preferred investment option to purchase a common share. Transaction costs were allocated proportionally between common
shares and warrants with $127,884 allocated to common shares and the balance of $719,964 allocated to additional paid-in capital and
recorded as a component of shareholders&#8217; equity in the consolidated balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2022, in accordance with the BayMedica Agreement, the Company issued 82,000 common shares to BayMedica&#8217;s
historical equity and convertible debt holders (See Note 8). In addition, the Company issued 78,312 common shares for consulting services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Share Purchase
                                            Warrants</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
November 16, 2020, 71,200 warrants were issued with an exercise price of $127.75 per share, were immediately exercisable upon issuance,
and expire 6 years following the date of issuance. On June 6, 2022, the Company amended the warrants to re-price them to $18.50 per share
with an expiry date of June 6, 2029. Accordingly, the Company has calculated the incremental fair value from the modification to be $119,555
and is recognized as a warrant modification expense in the statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
February 12, 2021, 27,720 warrants were issued with an exercise price of $121.25 per share, were exercisable 6 months following issuance,
and expire 5.5 years following the date of issuance. On March 21, 2022, the Company amended the warrants to re-price them to $11.25 per
share with an expiry date of March 31, 2023. Between March 21, 2022 and June 30, 2022, 15,606 of the warrants were exercised on a cashless
basis resulting in the issuance of 6,293 common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
July 2, 2021, 161,453 warrants were issued with an exercise price of $71.20 per share, were immediately exercisable upon issuance, and
expire 5 years following the date of issuance. The pre-funded and common warrants did not meet the criteria to be classified as a liability
award and therefore were treated as an equity award and recorded as a component of shareholders&#8217; equity in the consolidated balance
sheet. On June 6, 2022, the Company amended the warrants to re-price them to $18.50 per share with an expiry date of June 6, 2029. Accordingly,
the Company has calculated the incremental fair value from the modification to be $1,194,752 and is recognized as a warrant modification
expense in the statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of changes in share purchase warrants from July 1, 2021 to June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average <br/>Share Price</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Aggregate
    Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">98,920</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">75,47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,453</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,606</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.25</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">125,611</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30,
    2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">244,767</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41.99</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
total intrinsic value of warrants exercised during the year ended June 30, 2022 was $125,611 (2021 - $<span style="-sec-ix-hidden: hidden-fact-103">Nil</span>).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">d)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Agents&#8217;
                                            Warrants</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
July 2, 2021, 12,109 warrants were issued for services with an exercise price of $92.9075 per share, were immediately exercisable upon
issuance, and expire 5 years following the date of issuance. The agents&#8217; warrants did not meet the criteria to be classified as
a liability award and therefore were treated as an equity award and recorded as a component of shareholders&#8217; equity in the consolidated
balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of changes in agents&#8217; warrants from July 1, 2021 to June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average <br/>Share Price</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Aggregate
    Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,109</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92.9075</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30,
    2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,109</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92.9075</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">e)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Preferred Investment
                                            Options</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
June 6, 2022, 233,100 preferred investment options were issued with an exercise price of $19.75 per share, were immediately exercisable
upon issuance, and expire 6.5 years following the date of issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">f)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Agents&#8217;
                                            Investment Options</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
June 6, 2022, 15,152 preferred investment options were issued for services with an exercise price of $26.8125 per share, were exercisable
4 months upon issuance, and expire 5 years following the date of issuance.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalAndReservesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalAndReservesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED PAYMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. SHARE-BASED PAYMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Option Plan Details</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 24, 2017, and as amended on November 20, 2020, the Company&#8217;s shareholders approved: (i) the adoption of a new stock option
plan (the &#8220;Plan&#8221;) pursuant to which the Board of Directors may, from time to time, in its discretion and in accordance with
regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase
common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (20%) of the issued and
outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the new
stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company&#8217;s
previous stock option plan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As at June 30, 2022, there were 18,163
(June 30, 2021 &#8211; 19,735) options available for future allocation pursuant to the terms of the Plan. The option price under each
option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board
of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Stock
options granted prior to May 2021 were granted with Canadian dollar exercise prices (United States dollar amounts for weighted average
exercise prices and aggregate intrinsic value are calculated using prevailing rates as at June 30, 2022). Commencing in May 2021, stock
options are granted with United States dollar exercise prices.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of changes in outstanding options from July 1, 2021 to June 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price<br/>
$</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,472</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215.35</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,160</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34.20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,029</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">122.38</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,603</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">128.59</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">June 30, 2022:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,182</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228.87</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,421</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39.35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Fair Value
                                            of Options Issued During the Period</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Weighted
                                            Average Fair Value at Grant Date of Options Granted:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
weighted average fair value at grant date of options granted during the year ended June 30, 2022, was $21.04 per option (year ended June
30, 2021 - $49.03). Assumptions used for options granted during the year ended June 30, 2022 included a weighted average risk-free interest
rate of 1.17% (year ended June 30, 2021 &#8211; 0.27%), weighted average expected life of 3.1 years calculated using the Simplified Method
for directors, officers and employees and the contractual life for consultants, weighted average volatility factor of 97.15% (year ended
June 30, 2021 &#8211; 105.88%), weighted average dividend yield of 0% (year ended June 30, 2021 &#8211; 0%) and a 5% forfeiture rate
(year ended June 30, 2021 &#8211; 5%).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ii)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Expenses
                                            Arising from Share-based Payment Transactions:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Total
expenses arising from share-based payment transactions recognized during the year ended June 30, 2022, were $697,894 (2021 - $610,193).
$419,075 was allocated to general and administrative expenses (2021 - $405,801) and the remaining $278,819 was allocated to research
and development expenses (2021 - $204,392). Unrecognized compensation cost at June 30, 2022 related to unvested options was $292,959
which will be recognized over a weighted-average vesting period of 1.0 years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105011088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">LEASE OBLIGATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. LEASE OBLIGATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In conjunction with the acquisition
of BayMedica (Note 8), the Company acquired an operating lease for a corporate office with a remaining term of 1.8 years as at June 30,
2022. On the date of acquisition of BayMedica, the Company recognized right-of-use assets of $728,115 and a lease liability of $825,427,
utilizing the remaining term on acquisition and a 4.0% discount rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company is committed to minimum lease payments as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Maturity Analysis</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2022</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431,169</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">One to five years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">396,665</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">More than five years </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-<span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">827,834</span></td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Excludes estimated variable operating costs of $92,964 and $60,916 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104900640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>13.
BASIC AND DILUTED LOSS PER SHARE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Basic
loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding
during the period. The pre-funded warrants were determined to be common stock equivalents and have been included in the weighted average
number of shares outstanding for calculation of the basic earnings per share number. As the outstanding stock options and warrants are
anti-dilutive, they are excluded from the weighted average number of common shares in the table below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year Ended</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,600,117</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted loss per share</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(33.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(37.96</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of common shares
    - basic and diluted</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">560,829</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">268,793</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104985760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
INCOME TAXES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax
rate of 27.0% (June 30, 2021 &#8211; 27.0%) to the tax expense:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss before taxes</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,600,117</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense (recovery) at the statutory
    rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,710,669</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,754,834</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation
    allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,112,045</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,109,545</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(220,491</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">613,269</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">99,490</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign exchange differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">591,263</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,074,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share issuance cost
    capitalized in equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(582,548</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(390,685</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">197,131</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,484</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense (recovery)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Deferred
tax assets and liabilities are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-capital losses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,003,766</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,742,381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,004</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">702,479</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">434,399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">193,549</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">553,392</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">248,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,994</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,108</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,753,434</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,228,892</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(181,845</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,546</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease obligations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55,260</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(77,612</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(71,806</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(259,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,681,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,969,435</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,681,628</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,969,435</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A
full valuation allowance has been applied against the net deferred tax assets because it is not more likely than not that future taxable
income will be available against which the Company can utilize the benefits therefrom.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company has non-capital loss carry-forwards of approximately $62,921,785 (June 30, 2021 - $50,897,706) available
to offset future taxable income in Canada and the United States. These non-capital loss carryforwards begin to expire in 2026.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company recognizes tax benefits
from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities,
based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from any such position
would be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.
It is the Company&#8217;s policy to recognize interest and penalties accrued on any uncertain tax benefits as a component of income tax
expense. There were no uncertain tax positions as of June 30, 2022 or 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company files income tax returns
in the U.S. federal jurisdiction, various state jurisdictions, and Canada. With few exceptions, the Company is no longer subject to U.S.
federal and state tax examinations for fiscal years prior to 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is subject to taxation
at the federal, state, and local levels in the United States and Canada.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>15. SEGMENT INFORMATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">As of the closing of the BayMedica
acquisition, the Company aligned into two operating and reportable segments, the InMed segment and the BayMedica segment. The Company
reports segment information based on the management approach which designates the internal reporting used by the Chief Operating Decision
Maker (&#8220;CODM&#8221;), which is the Company&#8217;s Chief Executive Officer, for making decisions and assessing performance as the
source of the Company&#8217;s reportable segments. The CODM allocates resources and assesses the performance of each operating segment
based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss)
before interest and taxes. The Company has determined its reportable segments to be InMed and BayMedica based on the information used
by the CODM. Other than cash, cash equivalents and short-term investments (&#8220;Unrestricted cash&#8221;) balances, the CODM does not
regularly review asset information by reportable segment and therefore, the Company does not report asset information by reportable segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents information about the Company&#8217;s reportable segments for the year ended June 30, 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year
    Ended June 30,</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>InMed</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BayMedica</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>InMed</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BayMedica</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,089,435</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,089,435</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,410,753</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,278,799</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,689,552</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,203,089</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,203,089</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,410,753</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,189,364</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,600,117</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unrestricted cash</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,984,622</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,244</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104991872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Cash Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_NonCashTransactionsAbstract', window );"><strong>Non-Cash Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_NonCashTransactionsTextBlock', window );">NON-CASH TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. NON-CASH TRANSACTIONS</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Investing and financing activities that
do not have a direct impact on cash flows are excluded from the statements of cash flows. During the year ended June 30, 2022, the following
transactions were excluded from the statement of cash flows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 2, 2021, the Company issued warrants to its placement agent. The fair value of these warrants was $739,920 and was included in share issuance costs related to the July 2021 private placement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 13, 2021, the Company issued 82,000 common shares to BayMedica&#8217;s equity and convertible debt holders, pursuant to the BayMedica Agreement. The estimated fair value of these common shares was $3,013,500 and was included in the total consideration for the acquisition of BayMedica (see Note 8). On acquisition of BayMedica, the loan receivable from BayMedica of $425,000 was settled (see Note 8).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2022, the Company issued 3,132 common shares for consulting services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">iv)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 6, 2022, the Company issued 15,152 preferred investment options to its placement agent. The fair value of these investment options was $192,491 and was included in share issuance costs related to the June 2022 registered direct and private placement offerings.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">v)</span></td><td><span style="font-family: Times New Roman, Times, Serif">15,606 warrants were exercised on a cashless basis resulting in the issuance of 6,293 common shares.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">vi)</span></td><td><span style="font-family: Times New Roman, Times, Serif">As at June 30, 2022, the Company has unpaid financing costs of $26,587.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">During
the year ended June 30, 2021, the following transaction was excluded from the statement of cash flows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As at June 30, 2021, the Company has unpaid financing costs of $164,812.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_NonCashTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_NonCashTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_NonCashTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_NonCashTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>17.
COMMITMENTS AND CONTINGENCIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of agreements with various contract research organizations, as at June 30, 2022, the Company is committed for contract research
services and materials at a cost of approximately $2,910,529. A total of $2,149,619 of these expenditures are expected to occur in the
twelve months following June 30, 2022 and the balance of $760,910 in the following twelve month period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of agreements with various vendors, as at June 30, 2022, the Company is committed for contract materials and equipment at
a cost of approximately $634,092, expected to occur in the twelve months following June 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia (&#8220;UBC&#8221;),
the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of
certain drug products that are covered by the agreement. To date, no payments have been required to be made.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of a December 13, 2018 Collaborative Research Agreement with UBC in which the Company owns all rights, title and interests
in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon
filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of a November 1, 2018 Contribution Agreement with National Research Council Canada, as represented by its Industrial Research
Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual
property developed in part with NRC-IRAP contributions, may become repayable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments include guaranteed investment certificates with a face value of $44,676 (June 30, 2021 - $46,391) that are pledged as security
for a corporate credit card.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are
common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently
holds commercial general liability insurance. This insurance limits the Company&#8217;s liability and may enable the Company to recover
a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and it
believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities
relating to these obligations for any period presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to a technology licensing agreement, the Company is committed to issue, subject to regulatory approval, up to 700 warrants to purchase
700 common shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of
the common shares prior to each milestone achievement and the warrants will be exercisable for a period of three years for issuance date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company entered into a patent license agreement with a third party (the &#8220;Licensor&#8221;) in an agreement dated February 15, 2021.
The Company is required to make future royalty payments to Licensor based on net sales of licensed products, with minimum payments required
starting in 2021. In December 2021, the Company amended the License Agreement including the deferral of the 2021 minimum payments to
2022. As at June 30, 2022, the Company has paid $300,000 for the minimum payments under the agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of
business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility
that a material loss may be incurred.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104929536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FinancialRiskManagementTextBlock', window );">FINANCIAL RISK MANAGEMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>18.
FINANCIAL RISK MANAGEMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
fair values of short-term investments, accounts receivable, and accounts payable and accrued liabilities approximate their carrying values
because of the short-term nature of these instruments. Cash and cash equivalents are measured at fair value using Level 1 inputs. The
Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the fair values and carrying values of the Company&#8217;s financial instruments at June 30, 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,
    2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Level
    1</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Level
    2</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total financial assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">132,831</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,309,697</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2021</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,462</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,462</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,919</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,919</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,381</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,421,507</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Market Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Market
risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices.
Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk.
The Company does not currently have significant commodity price risk or equity price risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><i>Foreign
Currency Risk</i>:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Foreign
currency risk is the risk that the future cash flows or fair value of the Company&#8217;s financial instruments that are denominated
in a currency that is not the Company&#8217;s functional currency (U.S. dollar) will fluctuate due to changes in foreign exchange rates.
Portions of the Company&#8217;s cash and cash equivalents and accounts payable and accrued liabilities are denominated in Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Accordingly,
the Company is exposed to fluctuations in exchange rates, primarily against the Canadian dollar.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company has a net excess of Canadian dollar denominated cash and cash equivalents in excess of Canadian dollar
denominated accounts payable and accrued liabilities of C$2,052,109 which is equivalent to US$1,592,436 at the June 30, 2022 exchange
rate. The Canadian dollar financial assets generally result from holding Canadian dollar cash to settle anticipated near-term accounts
payable and accrued liabilities denominated in Canadian dollars. The Canadian dollar financial liabilities generally result from purchases
of supplies and services from suppliers in Canada.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Each
change of 1% in the Canadian dollar in relation to the U.S. dollar results in a gain or loss, with a corresponding effect on cash flows,
of $15,924 based on the June 30, 2022 net Canadian dollar assets (liabilities) position. During the year ended June 30, 2022, the Company
recorded foreign exchange loss of $107,433 (2021 &#8211; gain of $80,713) related to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><i>Interest
Rate Risk:</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Interest
rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at June 30, 2022, holdings
of cash and cash equivalents of $5,087,615 (June 30, 2021 - $7,053,329) are subject to floating interest rates. The balance of the Company&#8217;s
cash holdings of $1,089,251 (June 30, 2021 - $309,796) are non-interest bearing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">As
at June 30, 2022, the Company held variable rate guaranteed investment certificates, with one-year terms, of $44,676 (June 30, 2021 -
$46,391).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s current policy is to invest excess cash in guaranteed investment certificates or interest-bearing accounts of major Canadian
chartered banks or credit unions with comparable credit ratings. The Company regularly monitors compliance to its cash management policy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Credit Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Credit
risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual
obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash and cash equivalents,
short-term investments and loan receivable. Cash and cash equivalents and short-term investments are maintained with financial institutions
of reputable credit and may be redeemed upon demand. In the normal course of business, the Company does not provide third party loans.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash
and cash equivalents and short-term investments with high-credit quality financial institutions and management considers this risk to
be minimal for all cash and cash equivalents and short-term investments assets based on changes that are reasonably possible at each
reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Liquidity
                                            Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Liquidity
risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company&#8217;s policy is
to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without
incurring unacceptable losses or risking damage to the Company&#8217;s reputation. A key risk in managing liquidity is the degree of
uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at June 30, 2022,
the Company has cash and cash equivalents and short-term investments of $6,221,670 (June 30, 2021 - $7,409,588), current liabilities
of $3,181,316 (June 30, 2021 - $2,215,361) and a working capital surplus of $6,416,460 (June 30, 2021 - $6,162,908).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_FinancialRiskManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_FinancialRiskManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289106393440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>19.
RELATED PARTY TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright
Canada LLP (&#8220;NRF&#8221;). From February 11, 2022 to June 30, 2022, NRF rendered legal services in the amount of $345,935 (2021
- $<span style="-sec-ix-hidden: hidden-fact-133">Nil</span>) to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented
the amount of consideration established and agreed to by NRF.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104999168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>20.
SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
July 2022, 69,930 of the June 2022 pre-funded warrants were exercised resulting in the issuance of 69,930 common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 7, 2022, the Company consolidated all of its issued and outstanding share capital on the basis of one post-consolidation share
for each twenty-five pre-consolidation common shares of the Company in order to regain compliance with all of Nasdaq&#8217;s continued
listing requirements. Accordingly, all common share, stock option, per common share and warrant amounts for all periods presented in the
consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 7, 2022, 22,920 of the June 2022 pre-funded warrants were exercised resulting in the issuance of 22,920 common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
September 13, 2022, the Company closed a $6.0 million private placement. Under the terms of the private placement, an aggregate of 691,245
common shares, or common share equivalents, and investment options to purchase up to an aggregate of 1,382,490 common shares, at an effective
purchase price of $8.68 per common share and associated investment options. The warrants have an exercise price of $8.44 per share, are
exercisable immediately and have a term of seven years. After deducting the placement agent fees, the Company received net proceeds of
approximately $5.4 million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102051616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United
States (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;)
for financial information.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the
reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported.
It also requires management to exercise judgment in applying the Company&#8217;s accounting policies. In the future, actual experience
may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions
and estimates are significant to these consolidated financial statements are the estimated fair values of the assets acquired and liabilities
assumed in acquisitions, the estimate of useful life of intangible assets, the application of the going concern assumption, the impairment
assessment for long-lived assets, and determining the fair value of share-based payments and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_COVID19ImpactsPolicyTextBlock', window );">COVID-19 Impacts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>COVID-19
Impacts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">On
March 11, 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. The full extent to which the COVID-19
pandemic may directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses,
research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain,
such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to
contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating
to the preparation of these consolidated financial statements. While there was no material impact to the Company&#8217;s consolidated
financial statements as of and for the year ended June 30, 2022, the Company&#8217;s future assessment of the magnitude and duration
of COVID-19, as well as other factors, could result in a material impact to the Company&#8217;s consolidated financial statements in
future reporting periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Basis
of Consolidation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical
Ltd., BayMedica, LLC, Biogen Sciences Inc., and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either
directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain
benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany
transactions are eliminated in preparing these consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Foreign
Currency</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -20.55pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
functional currency of the Company and its subsidiaries is the U.S. Dollar. These consolidated financial statements are presented in
U.S. Dollars. References to &#8220;$&#8221; and &#8220;US$&#8221; are to United States (&#8220;U.S.&#8221;) dollars and references to
&#8220;C$&#8221; are to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Business
Combinations</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Business
combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair
values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as
goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair
values at the date of acquisition. If the Company&#8217;s interest in the fair value of the acquiree&#8217;s net identifiable assets
exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in
connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments
with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an
insignificant risk of change in value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term Investments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Short-term
Investments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve
months. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change
in value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Accounts
Receivable</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Accounts
receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company&#8217;s
best estimate of the amount of probable credit losses in existing accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition
and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected
to affect future collections experience. Expected credit losses on our accounts receivable were immaterial as at June 30, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Inventories</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Inventories
are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value.
Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing
costs and production and labor costs related to manufacturing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. At June 30, 2022,
no amounts had been charged to the valuation allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Deferred
Financing Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity
financings as deferred financing costs until such financings are consummated. After consummation of the equity financing, these costs
are recorded as a reduction to shareholders&#8217; equity generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred financing costs will be expensed immediately as a charge to operating expenses in the consolidated statements
of operations and comprehensive loss. As of June 30, 2022, $<span style="-sec-ix-hidden: hidden-fact-78">Nil</span> (2021 - $112,074) of deferred financing costs were capitalized and recorded
as prepaids and other assets on the consolidated balance sheet.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Property, Equipment and ROU Assets,
Net </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment
and leasehold improvements are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of
equipment and leasehold improvements comprises their purchase price. The useful lives of equipment and leasehold improvements are reviewed
at least once per year. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated
useful lives as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Computer equipment &#8211; 30% per annum</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Leasehold
                                            improvements &#8211; lesser of initial lease term or useful life</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Equipment
and leasehold improvements, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The right-of-use assets are initially
measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less
any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the right-of-use asset or the
lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits.
The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition,
the right-of-use assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability
(see Note 2 Lease (i)).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Intangible
Assets, Net </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property
is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment
losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_InProcessRDPolicyTextBlock', window );">In-Process R&amp;D</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>In-Process
R&amp;D</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In-process
R&amp;D (&#8220;IPR&amp;D&#8221;) is classified as an indefinite-lived intangible asset and is not amortized. IPR&amp;D becomes definite-lived
upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent
to the acquisition of IPR&amp;D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual
basis or more frequently if an indicator of impairment is present.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Impairment
of Long-Lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the
asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted
cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount
by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale
are reported at the lower of the carrying amount or fair value, less costs to sell. As of June 30, 2022, the Company determined that
the long-lived assets of BayMedica were impaired (see Note 6) and no assets were held-for-sale.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Goodwill</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company tests goodwill for potential
impairment annually on June 30, or more frequently if an event or other circumstance indicates that the Company may not be able to recover
the carrying amount of the net assets of the reporting unit. The Company&#8217;s operations consist of two operating and reportable segments,
InMed Pharmaceuticals (the &#8220;InMed&#8221; segment) and BayMedica (the &#8220;BayMedica&#8221; segment). In evaluating goodwill for
impairment, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. If a Company bypasses the qualitative assessment, or if the Company concludes that it is more likely
than not that the fair value of a reporting unit is less than its carrying value, then the Company performs a quantitative impairment
test by comparing the fair value of a reporting unit with its carrying amount (See Note 6) and records an impairment charge if the carrying
value exceeds the fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FinancialAssetsAndLiabilitiesPolicyTextBlock', window );">Financial Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Assets and Liabilities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and
subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are
or elected to be carried at fair value through profit or loss or where changes in fair value are recognized in the consolidated statements
of operations and comprehensive loss in other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Short-term
investments are subsequently recorded at cost plus accrued interest, which approximates fair value. Accounts receivable are reported
at outstanding amounts, net of provisions for uncollectable amounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
Liabilities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Financial
liabilities, including accounts payable and accrued liabilities, are initially recognized at fair value net of any transaction costs
directly attributable to the issuance of the instrument and subsequently carried at amortized cost using the effective interest rate
method. This ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried
in the consolidated balance sheet. Interest expense in this context includes initial transaction costs and premiums payable on redemption,
as well as any interest or coupon payable while the liability is outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financial
Assets and Liabilities (cont&#8217;d)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">To
determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of
financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three
levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                               1 &#8211;</span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;Unadjusted
                                            quoted prices in active markets for identical instruments.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> Level 2 &#8211;</span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;Inputs
                                            other than quoted prices included within Level 1 that are observable for the asset or liability,
                                            either directly or indirectly. Level 2 inputs include quoted prices for similar assets or
                                            liabilities in active markets, quoted prices for identical or similar assets or liabilities
                                            in markets that are not active, inputs other than quoted prices that are observable for the
                                            asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived
                                            principally from or corroborated by observable market data by correlation or other means
                                            (market corroborated inputs).</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Level
                               3 &#8211;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;Inputs
                                            are unobservable and reflect the Company&#8217;s assumptions as to what market participants
                                            would use in pricing the asset or liability. The Company develops these inputs based on the
                                            best information available. Assets and liabilities are classified based on the lowest level
                                            of input that is significant to the fair value measurements. Changes in the observability
                                            of valuation inputs may result in a reclassification of levels for certain securities within
                                            the fair value hierarchy.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities,
approximate their carrying values as at June 30, 2022 and 2021 due to their immediate or short-term maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company records a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset
and liability method. Under this method, it recognizes deferred income tax assets and liabilities for the expected future tax consequences
of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets and liabilities
are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities
are expected to be realized or settled. The Company recognizes the deferred income tax effects of a change in tax rates in the period
of the enactment. The Company records a valuation allowance to reduce its deferred tax assets to the net amount that management believes
is more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions are more likely
than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than fifty percent likely
of being realized. The Company records interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Revenue
Recognition</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products
and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers
in exchange for those products and services. ASC 606, <i>Revenue from Contracts with Customers</i> defines a five-step process to recognize
revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations
in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract,
and recognizing revenue when or as the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Revenue consists of manufacturing and
distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when
control over the products have been transferred to the customer and the Company has a present right to payment. Sales and other taxes
that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return,
for claims of damaged or non-compliant products, exist with the Company&#8217;s customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense,
when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Revenues
within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance
of when control is transferred to the customer. The time between invoicing and when payment is due is not significant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesVendorAllowancesPolicy', window );">Cost of Sales</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cost
of Sales</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Cost
of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing
costs. Cost of sales also includes production and labor costs for the Company&#8217;s manufacturing business.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Shipping
and Handling</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company records freight billed to customers within Net sales. Shipping and handling costs associated with inbound freight and goods shipped
to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating
expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Earnings
(Loss) Per Share</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Basic
earnings (loss) per common share (&#8220;EPS&#8221;) is computed by dividing the net income or loss applicable to common shares of the
Company by the weighted average number of common shares outstanding for the relevant period. Diluted earnings (loss) per common share
(&#8220;Diluted EPS&#8221;) is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average
number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive
instruments were converted. If the conversion of outstanding stock options and warrants into common share is anti-dilutive, then diluted
EPS is not presented separately from EPS.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Share-based
Payments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
fair value, at the grant date, of equity-classified share awards is charged to income or loss over the period for which the benefits
of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards
are measured separately and expensed over the related tranche&#8217;s vesting period. The corresponding accrued entitlement is recorded
in additional paid-in capital. The amount recognized as an expense is adjusted to reflect the number of share options that vest. The
fair value of awards is calculated using the Black-Scholes option pricing model which considers the exercise price, current market price
of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Starting
July 1, 2018, the Company accounts for non-employee awards under the guidance provided under ASU 2018-07 and uses an expected term to
value non-employee options on an award-by-award basis.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
expected term of the Company&#8217;s employee stock options is determined using the simplified method and the Company estimates the forfeitures
on the grant date for options issued. The expected term of the Company&#8217;s non-employee stock options is the contractual term of
the options granted and the Company estimates the forfeitures on the grant date for options issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company conducts research and development programs and incurs costs related to these activities, including research and development personnel
compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the
periods in which they are incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock', window );">Patents and Intellectual Property Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Patents
and Intellectual Property Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty
surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third
parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the
patent.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
reporting </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s operations consist of two operating and reportable segments, the InMed segment and the BayMedica segment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry (See Note 15).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">At
inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date,
discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental
borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized
cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in
an index or rate, if there is a change in the Company&#8217;s estimate of the amount expected to be payable under a residual value guarantee,
or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability
is re-measured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit
or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component
and its associated non-lease components as a single lease component for all of its asset classes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement
of the right-of-use asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize
right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated
with these leases is recognized as an expense on a straight- line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recent
Accounting Pronouncements Not Yet Adopted</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fair
                                            Value Measurement</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">In
June 2022, FASB issued ASU 2022-03, <i>Fair Value Measurement (Topic 82):</i> Fair Value Measurement of Equity Securities Subject to
Contractual Sale Restrictions. The amendments in this ASU clarify the guidance in ASC 820 on the fair value measurement of an equity
security that is subject to a contractual sale restriction and require specific disclosures related to such an equity security. This
standard is effective for fiscal years beginning after December 15, 2023. The Company does not expect the standard to have a significant
impact on the consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_COVID19ImpactsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_COVID19ImpactsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_FinancialAssetsAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Assets and Liabilities Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_FinancialAssetsAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_InProcessRDPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-Process R&amp;D policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_InProcessRDPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patents and Intellectual Property Costs Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesVendorAllowancesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for allowances received from a vendor. The disclosure differentiates between those allowances that are recorded as a reduction in the price of the vendors' products or services (that is, the entity's inventory) and which ultimately will be recorded as a reduction in the entity's cost of sales and those that are not.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesVendorAllowancesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
 2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
 2021</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">292,577</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in process</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,724,851</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">473,426</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,490,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104871040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Rou Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, equipment and right of use assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>June 30,<br/>
2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>June 30,<br/>
2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">$</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">$</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-size: 10pt">Right of Use Assets (leases)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">1,167,436</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">439,321</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">212,877</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">66,888</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Leasehold Improvements</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">40,409</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">42,986</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Property and equipment</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,420,722</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">549,195</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt"><span style="font-size: 10pt">Less: accumulated depreciation and amortization</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(516,470</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(222,600</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Property, equipment and ROU assets, net</span></td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">904,252</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">326,595</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104858880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,023,039</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,023,039</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Indefinite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,249,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,249,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Definite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademark and Intellectual Property</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">216,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(786,637</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(200,554</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">965,229</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Definite lived intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at July 1, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Acquired at October 13, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(47,314</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at June 30, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,143,686</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,108,915</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105067552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intellectual property</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(818,505</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(674,723</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,108,915</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,061,697</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,477</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">807,385</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289106104944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionAbstract', window );"><strong>Acquisition Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of total consideration</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Purchase
                                            Price<br/>
                                            Consideration<br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Estimated fair value of common shares issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,013,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less:Post-closing adjustments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(199,543</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Estimated fair value of consideration transferred</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,813,957</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of fair value of assets acquired and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Purchase Price</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Allocation</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>($)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Assets acquired:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">91,566</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">487,122</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">131,674</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">133,911</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,249,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Trademark</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">216,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,023,039</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total assets acquired</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,559,412</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Liabilities assumed:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,024,487</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other short-term liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">598,245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long-term debt</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">122,723</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities acquired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,745,455</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: none; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Estimated
    fair value of net assets acquired</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,813,957</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of pro forma consolidated results</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year Ended June
    30</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365,755</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,904,013</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: none; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,260,014</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,705,494</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289108068304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,166,068</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">775,129</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">839,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,901</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee compensation, benefits and related accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,120</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">880,207</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">270,439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169,641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,415,265</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,134,878</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289106332560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalAndReservesAbstract', window );"><strong>Share Capital And Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfPrivatePlacementOfferingTableTextBlock', window );">Schedule of private placement offering</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Transaction
    Description</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Issue
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Shares Issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,600</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74.325</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,645,970</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants
    Issued</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">125,853</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74.3226</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,353,716</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,999,686</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allocated to Additional
    Paid-in Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,540,635</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,459,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Share Issuance Costs</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(247,336</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Transaction
    Description</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Issue
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">Shares Issued</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,002</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.450</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,394,286</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pre-funded Warrants
    Issued</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$'</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.4474</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,605,294</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross Proceeds</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,999,580</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allocated to Additional
    Paid-in Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,245,508</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">754,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Share Issuance Costs</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(127,884</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock', window );">Schedule of changes in share purchase warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average <br/>Share Price</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Aggregate
    Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">98,920</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">75,47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">161,453</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,606</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.25</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">125,611</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30,
    2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">244,767</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41.99</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock', window );">Schedule of changes in agents warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average <br/>Share Price</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Aggregate
    Intrinsic Value</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,109</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92.9075</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30,
    2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,109</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92.9075</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of changes in agents warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfPrivatePlacementOfferingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfPrivatePlacementOfferingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104991872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of outstanding options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price<br/>
$</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2021</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,472</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215.35</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,160</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34.20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,029</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">122.38</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,603</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">128.59</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">June 30, 2022:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,182</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228.87</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,421</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39.35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105072544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of minimum lease payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Maturity Analysis</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June
    30,<br/>
    2022</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">431,169</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">One to five years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">396,665</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">More than five years </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-<span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">827,834</span></td><td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102083728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock', window );">Schedule of weighted average number of common shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year Ended</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,600,117</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basic and diluted loss per share</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(33.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(37.96</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of common shares
    - basic and diluted</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">560,829</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">268,793</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105073152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of a reconciliation of income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss before taxes</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,600,117</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense (recovery) at the statutory
    rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,710,669</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,754,834</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (reduction) in income taxes resulting
    from:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in valuation
    allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,112,045</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,109,545</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(220,491</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">613,269</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">99,490</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign exchange differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">591,263</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,074,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share issuance cost
    capitalized in equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(582,548</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(390,685</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">197,131</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,484</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax expense (recovery)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-capital losses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,003,766</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,742,381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,004</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">702,479</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">434,399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">193,549</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">553,392</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">248,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,994</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,108</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,753,434</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,228,892</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(181,845</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,546</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease obligations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55,260</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(77,612</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(71,806</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(259,457</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,681,628</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,969,435</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,681,628</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,969,435</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105833376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of reportable segments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Year
    Ended June 30,</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>InMed</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BayMedica</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>InMed</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BayMedica</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif">Sales</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,089,435</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,089,435</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,410,753</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,278,799</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,689,552</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,203,089</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,203,089</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,410,753</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,189,364</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18,600,117</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,203,089</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unrestricted cash</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,984,622</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">192,244</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289108067248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of fair value and carrying values of the company</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>June 30,
    2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Level
    1</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Level
    2</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,804</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,027</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total financial assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,176,866</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">132,831</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,309,697</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2021</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term investments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,462</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,462</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,919</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,919</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,363,126</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,381</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,421,507</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and
    accrued Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,134,878</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289098940240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Going Concern (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses</a></td>
<td class="nump">$ 18.6<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeEarningsDeficit', window );">Accumulated deficit</a></td>
<td class="nump">93.5<span></span>
</td>
<td class="nump">$ 74.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CashAndCashEquivalent', window );">Cash and cash equivalents</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_CashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_CashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEarningsDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative earnings (deficits) for relevant time periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEarningsDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102057984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 112,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Straight-line method percentage per annum</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax positions, description</a></td>
<td class="text">Recognized income tax positions are measured at the largest amount that is greater than fifty percent likely
of being realized.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lease term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121825205&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289098606480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Customer Concentration (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CustomerConcentrationDetailsLineItems', window );"><strong>Customer Concentration (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCustomer', window );">Net sales description</a></td>
<td class="text">The
Company had three customers during the year ended June 30, 2022, which individually generated 10% or more of the Company&#8217;s net
sales.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inm_CustomerOneMember', window );">Customer One [Member] | Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CustomerConcentrationDetailsLineItems', window );"><strong>Customer Concentration (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ConcentrationRiskPercentage', window );">Concentration percentage</a></td>
<td class="nump">48.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inm_CustomerOneMember', window );">Customer One [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CustomerConcentrationDetailsLineItems', window );"><strong>Customer Concentration (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ConcentrationRiskPercentage', window );">Concentration percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ConcentrationRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ConcentrationRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_CustomerConcentrationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_CustomerConcentrationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes "Information about Major Customers" that may be disclosed elsewhere (for instance, segment disclosures).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inm_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inm_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289104962176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Inventory expensed to cost of goods sold</a></td>
<td class="nump">$ 545,889<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289098646192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - Schedule of inventories - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfInventoriesAbstract', window );"><strong>Schedule Of Inventories Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">$ 292,577<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">1,724,851<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">473,426<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 2,490,854<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102558128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Rou Assets, Net (Details) - Schedule of property, equipment and right of use assets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,420,722<span></span>
</td>
<td class="nump">$ 549,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(516,470)<span></span>
</td>
<td class="num">(222,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and ROU assets, net</a></td>
<td class="nump">904,252<span></span>
</td>
<td class="nump">326,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inm_RightOfUseAssetMember', window );">Right of Use Asset (leases) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,167,436<span></span>
</td>
<td class="nump">439,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">212,877<span></span>
</td>
<td class="nump">66,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 40,409<span></span>
</td>
<td class="nump">$ 42,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inm_RightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inm_RightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102871968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">$ 2,023,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentOfIntangibleAssetExcludingGoodwill', window );">Definite lived intangible assets</a></td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill', window );">Impairment charge</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentChargeOnReclassifiedAssets', window );">Impairment charge</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Acquired in-process research and development expense</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_IPRDMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentOfIntangibleAssetExcludingGoodwill', window );">Definite lived intangible assets</a></td>
<td class="nump">1,249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentOfIntangibleAssetExcludingGoodwill', window );">Definite lived intangible assets</a></td>
<td class="nump">$ 1,191,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ImpairmentOfIntangibleAssetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ImpairmentOfIntangibleAssetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentChargeOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -URI https://asc.fasb.org/extlink&amp;oid=29634951&amp;loc=d3e1756-110224<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2459-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentChargeOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_IPRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_IPRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102504464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 2,108,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Acquired at October 13, 2022</a></td>
<td class="nump">2,023,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment losses</a></td>
<td class="num">(2,023,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_IPRDMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Acquired at October 13, 2022</a></td>
<td class="nump">1,249,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment losses</a></td>
<td class="num">(1,249,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademark and Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of beginning</a></td>
<td class="nump">1,736,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Acquired at October 13, 2022</a></td>
<td class="nump">216,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="num">(786,637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment losses</a></td>
<td class="num">(200,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of ending</a></td>
<td class="nump">965,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems', window );"><strong>Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Acquired at October 13, 2022</a></td>
<td class="nump">1,191,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="num">(47,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Balance as of ending</a></td>
<td class="nump">$ 1,143,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_IPRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_IPRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289106286704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Straight-line basis</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average estimated remaining useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense on intangible assets (in Dollars)</a></td>
<td class="nump">$ 159,228<span></span>
</td>
<td class="nump">$ 99,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103052208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of intangible assets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfIntangibleAssetsAbstract', window );"><strong>Schedule Of Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intellectual property</a></td>
<td class="nump">$ 1,736,420<span></span>
</td>
<td class="nump">$ 1,736,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">1,191,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases', window );">Intangible assets</a></td>
<td class="nump">2,927,420<span></span>
</td>
<td class="nump">1,736,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets', window );">Less: accumulated depreciation</a></td>
<td class="num">(818,505)<span></span>
</td>
<td class="num">(674,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 2,108,915<span></span>
</td>
<td class="nump">$ 1,061,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land or leased assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to existing tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102262112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of amortization expense<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfAmortizationExpenseAbstract', window );"><strong>Schedule Of Amortization Expense Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2022</a></td>
<td class="nump">$ 161,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2023</a></td>
<td class="nump">161,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2024</a></td>
<td class="nump">161,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2025</a></td>
<td class="nump">161,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">2026</a></td>
<td class="nump">161,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FiniteLivedIntangibleAssetNet', window );">Total</a></td>
<td class="nump">$ 807,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_FiniteLivedIntangibleAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_FiniteLivedIntangibleAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102372576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 13, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionDetailsLineItems', window );"><strong>Acquisition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLoansReceivable', window );">Loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,600,117)<span></span>
</td>
<td class="num">$ (10,203,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089,435<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_CannabinoidMember', window );">Cannabinoid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionDetailsLineItems', window );"><strong>Acquisition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inm_BayMedicaMember', window );">BayMedica [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionDetailsLineItems', window );"><strong>Acquisition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionDetailsLineItems', window );"><strong>Acquisition (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Description of business acquisition</a></td>
<td class="text">The Company acquired 100% of BayMedica in exchange for i) 82,000 common shares issued to BayMedica&#8217;s equity and convertible
debt holders, subject to a six-month contractual hold period and ii) $1 million to be held in escrow, subject to reduction for certain
post-closing adjustments or satisfaction of indemnification claims under the definitive agreement (the &#8220;BayMedica Agreement&#8221;)
in the six- and twelve-month periods following the closing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Acquisition percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of loan receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_CannabinoidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=inm_CannabinoidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inm_BayMedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inm_BayMedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289106368624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details) - Schedule of total consideration - Purchase Price Consideration [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Estimated fair value of common shares issued</a></td>
<td class="nump">$ 3,013,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash', window );">cash</a></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_BusinessCombinationPostclosingAdjustments', window );">Less:Post-closing adjustments</a></td>
<td class="num">(199,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Estimated fair value of consideration transferred</a></td>
<td class="nump">$ 3,813,957<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_BusinessCombinationPostclosingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount of Post-closing adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_BusinessCombinationPostclosingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inm_PurchasePriceConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inm_PurchasePriceConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102377248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition (Details) - Schedule of fair value of assets acquired and liabilities - Purchase Price Consideration [Member]<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems', window );"><strong>Acquisition (Details) - Schedule of fair value of assets acquired and liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 91,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">36,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">487,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and deposits</a></td>
<td class="nump">131,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">133,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="nump">1,249,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents', window );">Patents</a></td>
<td class="nump">1,191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark', window );">Trademark</a></td>
<td class="nump">216,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Goodwill</a></td>
<td class="nump">2,023,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">5,559,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LiabilitiesAssumedAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,024,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities', window );">Other short-term liabilities</a></td>
<td class="nump">598,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Long-term debt</a></td>
<td class="nump">122,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Total liabilities acquired</a></td>
<td class="nump">1,745,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Estimated fair value of net assets acquired</a></td>
<td class="nump">$ 3,813,957<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount of patents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of trademark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inm_PurchasePriceConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inm_PurchasePriceConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289105910032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Details) - Schedule of pro forma consolidated results - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfProFormaConsolidatedResultsAbstract', window );"><strong>Schedule Of Pro Forma Consolidated Results Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,365,755<span></span>
</td>
<td class="nump">$ 1,904,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,260,014)<span></span>
</td>
<td class="num">$ (10,705,494)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfProFormaConsolidatedResultsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfProFormaConsolidatedResultsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103966512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Schedule Of Accounts Payable And Accrued Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade payables</a></td>
<td class="nump">$ 1,166,068<span></span>
</td>
<td class="nump">$ 775,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AccruedResearchAndDevelopment', window );">Accrued research and development expenses</a></td>
<td class="nump">839,638<span></span>
</td>
<td class="nump">309,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee compensation, benefits and related accruals</a></td>
<td class="nump">139,120<span></span>
</td>
<td class="nump">880,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued general and administrative expenses</a></td>
<td class="nump">270,439<span></span>
</td>
<td class="nump">169,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 2,415,265<span></span>
</td>
<td class="nump">$ 2,134,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289097505184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Reserves (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 06, 2022</div></th>
<th class="th"><div>Apr. 22, 2022</div></th>
<th class="th"><div>Mar. 21, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsLineItems', window );"><strong>Share Capital and Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common shares issued</a></td>
<td class="nump">65,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_PrefundWarrants', window );">Pre-funded warrants</a></td>
<td class="nump">98,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from warrants (in Dollars)</a></td>
<td class="nump">$ 3,500,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,999,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs allocated to common shares (in Dollars)</a></td>
<td class="nump">127,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TransactionCostsAllocatedToAdditionalPaidinCapital', window );">Transaction costs allocated to additional paid-in capital (in Dollars)</a></td>
<td class="nump">$ 719,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,786,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ExercisedCommonSharesDescription', window );">Exercised common shares description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 125,853
pre-funded warrants were fully exercised for 125,853 common shares during the year ended June 30, 2022, resulting in a $4,283,654 reclassification
from additional paid-in capital to common shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,667<span></span>
</td>
<td class="nump">322,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_IPOWarrantIssue', window );">Warrant issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,453<span></span>
</td>
<td class="nump">27,720<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 71.2<span></span>
</td>
<td class="nump">$ 121.25<span></span>
</td>
<td class="nump">$ 127.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantExpiryDate', window );">Warrant expiry date</a></td>
<td class="text">Jun.  06,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantsModificationExpense', window );">Warrants modification expense (in Dollars)</a></td>
<td class="nump">$ 119,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,194,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_IssuanceOfCommonSharesIssued', window );">Issuance of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrants to re-price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of warrants exercised (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,611<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsLineItems', window );"><strong>Share Capital and Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.9075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantsIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inm_PreferredInvestmentOptionsMember', window );">Preferred Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsLineItems', window );"><strong>Share Capital and Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 19.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Expire term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantsIssued', window );">Warrants issued</a></td>
<td class="nump">233,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inm_AgentsInvestmentOptionsMember', window );">Agents&#8217; Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsLineItems', window );"><strong>Share Capital and Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 26.8125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Expire term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantsIssued', window );">Warrants issued</a></td>
<td class="nump">15,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantsIssuanceTerm', window );">Options exercisable</a></td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsLineItems', window );"><strong>Share Capital and Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from warrants (in Dollars)</a></td>
<td class="nump">$ 1,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_PrefundedWarrants', window );">Pre-funded warrants (in Dollars)</a></td>
<td class="nump">$ 69,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inm_BayMedicaAgreementMember', window );">BayMedica Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsLineItems', window );"><strong>Share Capital and Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CommonSharesConsultingServices', window );">Common shares consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=inm_ATMMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsLineItems', window );"><strong>Share Capital and Reserves (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CommonSharesNetIssuance', window );">Net issuance costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_CommonSharesConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares consulting services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_CommonSharesConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_CommonSharesNetIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares net issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_CommonSharesNetIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ExercisedCommonSharesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercised common shares description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ExercisedCommonSharesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_IPOWarrantIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_IPOWarrantIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_IssuanceOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_IssuanceOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_PrefundWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares pre-fund warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_PrefundWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_PrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_PrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalandReservesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalandReservesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_TransactionCostsAllocatedToAdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs allocated to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_TransactionCostsAllocatedToAdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantsIssuanceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantsIssuanceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantsModificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantsModificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inm_PreferredInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inm_PreferredInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inm_AgentsInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inm_AgentsInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inm_BayMedicaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inm_BayMedicaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inm_ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inm_ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102872656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Reserves (Details) - Schedule of private placement offering - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TotalCommonShareValue', window );">Total</a></td>
<td class="nump">$ 754,072<span></span>
</td>
<td class="nump">$ 1,459,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inm_SharesIssuedMember', window );">Shares Issued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number (in Shares)</a></td>
<td class="nump">65,002<span></span>
</td>
<td class="nump">35,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 21.45<span></span>
</td>
<td class="nump">$ 74.325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TotalCommonShareValue', window );">Total</a></td>
<td class="nump">$ 1,394,286<span></span>
</td>
<td class="nump">$ 2,645,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inm_PrefundedWarrantsIssuedMember', window );">Pre-funded Warrants Issued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number (in Shares)</a></td>
<td class="nump">168,099<span></span>
</td>
<td class="nump">125,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 21.4474<span></span>
</td>
<td class="nump">$ 74.3226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TotalCommonShareValue', window );">Total</a></td>
<td class="nump">$ 3,605,294<span></span>
</td>
<td class="nump">$ 9,353,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inm_GrossProceedsMember', window );">Gross Proceeds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TotalCommonShareValue', window );">Total</a></td>
<td class="nump">4,999,580<span></span>
</td>
<td class="nump">11,999,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inm_AllocatedToAdditionalPaidinCapitalMember', window );">Allocated to Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TotalCommonShareValue', window );">Total</a></td>
<td class="num">(4,245,508)<span></span>
</td>
<td class="num">(10,540,635)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inm_ShareIssuanceCostsMember', window );">Share issuance costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TotalCommonShareValue', window );">Total</a></td>
<td class="num">$ (127,884)<span></span>
</td>
<td class="num">$ (247,336)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_TotalCommonShareValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total share value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_TotalCommonShareValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inm_SharesIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inm_SharesIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inm_PrefundedWarrantsIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inm_PrefundedWarrantsIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inm_GrossProceedsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inm_GrossProceedsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inm_AllocatedToAdditionalPaidinCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inm_AllocatedToAdditionalPaidinCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inm_ShareIssuanceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inm_ShareIssuanceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103810576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentNumberOfExercised', window );">Number of Exercised</a></td>
<td class="num">(15,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentsWeightedAverageSharePriceExercised', window );">Weighted Average Share Price, Exercised</a></td>
<td class="nump">11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercised (in Dollars)</a></td>
<td class="nump">$ 125,611<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=inm_SharePurchaseWarrantsMember', window );">Share purchase warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalOfNumberOfBalance', window );">Number of Beginning balance</a></td>
<td class="nump">98,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance', window );">Weighted Average Share Price, Beginning balance (in Dollars per share)</a></td>
<td class="nump">$ 7,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AggregateIntrinsicValueAtBeginning', window );">Aggregate Intrinsic Value, Beginning balance (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentNumberOfGranted', window );">Number of Granted</a></td>
<td class="nump">161,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WeightedAverageSharePriceGranted', window );">Weighted Average Share Price, Granted (in Dollars per share)</a></td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AggregateIntrinsicValueGranted', window );">Aggregate Intrinsic Value, Granted (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalOfNumberOfBalance', window );">Number of Ending balance</a></td>
<td class="nump">244,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance', window );">Weighted Average Share Price, Ending balance (in Dollars per share)</a></td>
<td class="nump">$ 41.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_AggregateIntrinsicValueAtBeginning', window );">Aggregate Intrinsic Value, Ending balance (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AggregateIntrinsicValueAtBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AggregateIntrinsicValueAtBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_AggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_AggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price, Beginning balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentNumberOfExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentNumberOfExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentNumberOfGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentNumberOfGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentsWeightedAverageSharePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentsWeightedAverageSharePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalOfNumberOfBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalOfNumberOfBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WeightedAverageSharePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WeightedAverageSharePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inm_SharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inm_SharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102058400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital and Reserves (Details) - Schedule of changes in agents warrants - Agents' Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems', window );"><strong>Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentNumberOfBalanceAtBeginning', window );">Number of Beginning Balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning', window );">Weighted Average Share Price, Beginning Balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning', window );">Aggregate Intrinsic Value, Beginning Balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentSharesNumberOfGranted', window );">Granted | shares</a></td>
<td class="nump">12,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentWeightedAverageSharePriceGranted', window );">Weighted Average Share Price, Granted | $ / shares</a></td>
<td class="nump">$ 92.9075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentAggregateIntrinsicValueGranted', window );">Aggregate Intrinsic Value, Granted | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentNumberOfBalanceAtEnding', window );">Number of Ending Balance | shares</a></td>
<td class="nump">12,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding', window );">Weighted Average Share Price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 92.9075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding', window );">Aggregate Intrinsic Value, Ending Balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentNumberOfBalanceAtBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentNumberOfBalanceAtBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentNumberOfBalanceAtEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentNumberOfBalanceAtEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentSharesNumberOfGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentSharesNumberOfGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price, Ending Balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentWeightedAverageSharePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentWeightedAverageSharePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inm_AgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inm_AgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102302480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2017</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share-Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_IssuedAndOutstandingPercentage', window );">Issued and outstanding, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross', window );">Options shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,163<span></span>
</td>
<td class="nump">19,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value at grant date of options granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.04<span></span>
</td>
<td class="nump">$ 49.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.17%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.15%<span></span>
</td>
<td class="nump">105.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Weighted average dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WeightedAverageForfeitureRate', window );">Weighted average forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment transactions (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,894<span></span>
</td>
<td class="nump">$ 610,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unvested options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Weighted-average vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share-Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment transactions (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,075<span></span>
</td>
<td class="nump">405,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share-Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment transactions (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,819<span></span>
</td>
<td class="nump">$ 204,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_IssuedAndOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_IssuedAndOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedPaymentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedPaymentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WeightedAverageForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Forfeiture Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WeightedAverageForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289098994320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - Schedule of outstanding options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfOutstandingOptionsAbstract', window );"><strong>Schedule Of Outstanding Options Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Number of Beginning balance</a></td>
<td class="nump">36,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 215.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Granted</a></td>
<td class="nump">31,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted', window );">Weighted Average Exercise Price, Granted (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 34.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Expired/Forfeited</a></td>
<td class="num">(12,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited', window );">Weighted Average Exercise Price, Expired/Forfeited (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 122.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Number of Ending balance</a></td>
<td class="nump">55,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending balance</a></td>
<td class="nump">128.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_June302022Abstract', window );"><strong>June 30, 2022:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_NumberOfVestedAndExercisable', window );">Number of Vested and exercisable</a></td>
<td class="nump">26,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WeightedAverageExercisePriceVestedAndExercisable', window );">Weighted Average Exercise Price, Vested and exercisable (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 228.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_NumberOfUnvested', window );">Number of Unvested</a></td>
<td class="nump">29,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WeightedAverageExercisePriceUnvested', window );">Weighted Average Exercise Price, Unvested (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 39.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_June302022Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_June302022Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_NumberOfUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_NumberOfUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_NumberOfVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_NumberOfVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfOutstandingOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfOutstandingOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, expired/Forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WeightedAverageExercisePriceVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WeightedAverageExercisePriceVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102362560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LeaseObligationsDetailsLineItems', window );"><strong>Lease Obligations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LeaseObligationsDetailsLineItems', window );"><strong>Lease Obligations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_OtherVariableLeaseCost', window );">Estimated variable operating costs</a></td>
<td class="nump">$ 60,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LeaseObligationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LeaseObligationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_OtherVariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_OtherVariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289101936096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligations (Details) - Schedule of minimum lease payments<br></strong></div></th>
<th class="th" colspan="2">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfMinimumLeasePaymentsAbstract', window );"><strong>Schedule Of Minimum Lease Payments Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths', window );">Less than one year</a></td>
<td class="nump">$ 431,169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive', window );">One to five years</a></td>
<td class="nump">396,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive', window );">More than five years</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LesseeOperatingLeaseLiabilityPaymentDue', window );">Total undiscounted lease liabilities</a></td>
<td class="nump">$ 827,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Excludes estimated variable operating costs of $92,964 and $60,916 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LesseeOperatingLeaseLiabilityPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LesseeOperatingLeaseLiabilityPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfMinimumLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfMinimumLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103033840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Loss Per Share (Details) - Schedule of weighted average number of common shares - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract', window );"><strong>Schedule Of Weighted Average Number Of Common Shares Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">$ (18,600,117)<span></span>
</td>
<td class="num">$ (10,203,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted loss per share</a></td>
<td class="num">$ (33.17)<span></span>
</td>
<td class="num">$ (37.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares - basic and diluted</a></td>
<td class="nump">560,829<span></span>
</td>
<td class="nump">268,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289098630272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income statutory corporate tax rate</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Non-capital loss carry-forwards (in Dollars)</a></td>
<td class="nump">$ 62,921,785<span></span>
</td>
<td class="nump">$ 50,897,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_RecognizedTaxBenefits', window );">Recognized tax benefits percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_RecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_RecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102528784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of a reconciliation of income taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract', window );"><strong>Schedule Of AReconciliation Of Income Taxes Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss before taxes</a></td>
<td class="num">$ (18,600,117)<span></span>
</td>
<td class="num">$ (10,203,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (recovery) at the statutory rate</a></td>
<td class="num">(4,710,669)<span></span>
</td>
<td class="num">(2,754,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_IncreaseReductionInIncomeTaxesResultingFromAbstract', window );"><strong>Increase (reduction) in income taxes resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">4,112,045<span></span>
</td>
<td class="nump">4,109,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(220,491)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Permanent differences</a></td>
<td class="nump">613,269<span></span>
</td>
<td class="nump">99,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign exchange differences</a></td>
<td class="nump">591,263<span></span>
</td>
<td class="num">(1,074,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share issuance cost capitalized in equity</a></td>
<td class="num">(582,548)<span></span>
</td>
<td class="num">(390,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Other</a></td>
<td class="nump">197,131<span></span>
</td>
<td class="nump">10,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (recovery)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_IncreaseReductionInIncomeTaxesResultingFromAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_IncreaseReductionInIncomeTaxesResultingFromAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102503760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Schedule Of Deferred Tax Assets And Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Non-capital losses</a></td>
<td class="nump">$ 17,003,766<span></span>
</td>
<td class="nump">$ 13,742,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_DeferredTaxAssetsPropertyAndEquipmentsNet', window );">Property and equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_DeferredTaxAssetsFinancingCost', window );">Financing costs</a></td>
<td class="nump">702,479<span></span>
</td>
<td class="nump">434,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">193,549<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="nump">553,392<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">248,254<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">51,994<span></span>
</td>
<td class="nump">51,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_DeferredTaxAssetsAndLiabilitiesGross', window );">Deferred tax assets and liabilities, gross</a></td>
<td class="nump">18,753,434<span></span>
</td>
<td class="nump">14,228,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_DeferredTaxAssetsIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(181,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="num">(16,546)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_DeferredTaxAssetsLeaseObligations', window );">Lease obligations</a></td>
<td class="num">(55,260)<span></span>
</td>
<td class="num">(77,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets and liabilities, net</a></td>
<td class="num">(71,806)<span></span>
</td>
<td class="num">(259,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">18,681,628<span></span>
</td>
<td class="nump">13,969,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(18,681,628)<span></span>
</td>
<td class="num">(13,969,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_DeferredTaxAssetLiabilitiesNet', window );">Net deferred tax asset, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_DeferredTaxAssetLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net deferred tax asset, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_DeferredTaxAssetLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_DeferredTaxAssetsAndLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and liabilities, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_DeferredTaxAssetsAndLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_DeferredTaxAssetsFinancingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_DeferredTaxAssetsFinancingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_DeferredTaxAssetsIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_DeferredTaxAssetsIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_DeferredTaxAssetsLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_DeferredTaxAssetsLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_DeferredTaxAssetsPropertyAndEquipmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_DeferredTaxAssetsPropertyAndEquipmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102302624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - Schedule of reportable segments - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 1,089,435<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_OtherOperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">19,689,552<span></span>
</td>
<td class="nump">10,203,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,600,117)<span></span>
</td>
<td class="num">(10,203,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Unrestricted cash</a></td>
<td class="nump">6,176,866<span></span>
</td>
<td class="nump">7,363,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inm_InMedMember', window );">InMed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_OtherOperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">13,410,753<span></span>
</td>
<td class="nump">10,203,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,410,753)<span></span>
</td>
<td class="num">(10,203,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Unrestricted cash</a></td>
<td class="nump">5,984,622<span></span>
</td>
<td class="nump">7,363,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inm_BayMedicaMember', window );">BayMedica [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,089,435<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_OtherOperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">6,278,799<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,189,364)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Unrestricted cash</a></td>
<td class="nump">$ 192,244<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_OtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_OtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inm_InMedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inm_InMedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inm_BayMedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inm_BayMedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289097513792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-Cash Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 06, 2022</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Oct. 13, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_NonCashTransactionsDetailsLineItems', window );"><strong>Non-Cash Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants issued to placement agent</a></td>
<td class="nump">$ 739,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredUnitsIssued', window );">Preferred shares issued options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Exercised warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Issuance of common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Unpaid financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inm_BayMedicaIncMember', window );">BayMedica Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_NonCashTransactionsDetailsLineItems', window );"><strong>Non-Cash Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_EstimatedFairValueCommonShares', window );">Estimated fair value common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,013,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableFairValueDisclosure', window );">Loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_EstimatedFairValueCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_EstimatedFairValueCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_NonCashTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_NonCashTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of preferred units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inm_BayMedicaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inm_BayMedicaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102429376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CostOfServicesDirectsMaterials', window );">Materials cost</a></td>
<td class="nump">$ 2,910,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Expenditure amount</a></td>
<td class="nump">2,149,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ExpenditureBalance', window );">Balance of expenditure</a></td>
<td class="nump">760,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Materials and equipment cost</a></td>
<td class="nump">634,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_GuaranteedInvestment', window );">Guaranteed investment face value</a></td>
<td class="nump">$ 44,676<span></span>
</td>
<td class="nump">$ 46,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_WarrantsToPurchase', window );">Warrants to purchase (in Shares)</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_CommonShares', window );">Common shares (in Shares)</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Issuance date</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Agreement payments paid</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_CommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares or common stock is a class of stock issued by corporations that represent ownership in the corporation for shareholders. The hope is that the company will grow and prosper, driving up the price of their shares. Being a common shareholder is a way for investors to benefit from the growth of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_CommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_CostOfServicesDirectsMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of materials used in services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_CostOfServicesDirectsMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ExpenditureBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The balance of expenditure is the balance of spending against the amount of available funds. While this may seem to be a relatively simple process, balancing expenditures can be complex when credit accounts, payables and receivables become involved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ExpenditureBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_GuaranteedInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranteed investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_GuaranteedInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_WarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants are a derivative that give the right, but not the obligation, to buy or sell a security&#8212;most commonly an equity&#8212;at a certain price before expiration. The price at which the underlying security can be bought or sold is referred to as the exercise price or strike price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_WarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102332096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Risk Management (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FinancialRiskManagementDetailsLineItems', window );"><strong>Financial Risk Management (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 1,592,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,052,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">107,433<span></span>
</td>
<td class="nump">$ 80,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents subject to floating interest rates</a></td>
<td class="nump">5,087,615<span></span>
</td>
<td class="nump">7,053,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherMinorityInterests', window );">Non-interest bearing</a></td>
<td class="nump">1,089,251<span></span>
</td>
<td class="nump">309,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Guaranteed investment</a></td>
<td class="nump">44,676<span></span>
</td>
<td class="nump">46,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ShortTermInvestment', window );">Cash and cash equivalents and short-term investments</a></td>
<td class="nump">6,221,670<span></span>
</td>
<td class="nump">7,409,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">3,181,316<span></span>
</td>
<td class="nump">2,215,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_workingCapitalSurplus', window );">Working capital surplus</a></td>
<td class="nump">$ 6,416,460<span></span>
</td>
<td class="nump">$ 6,162,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_TypeOfCurrencyAxis=inm_USDMember', window );">U.S. Dollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_FinancialRiskManagementDetailsLineItems', window );"><strong>Financial Risk Management (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_ForeignCurrencyRiskPercentage', window );">Foreign currency risk, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesGainLoss', window );">Effect on gain or loss</a></td>
<td class="nump">$ 15,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_FinancialRiskManagementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_FinancialRiskManagementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ForeignCurrencyRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ForeignCurrencyRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_ShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_ShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_workingCapitalSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital surplus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_workingCapitalSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherMinorityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of equity interests owned by noncontrolling shareholders, partners, or other equity holders in one or more of the entities consolidated into the reporting entity's financial statements other than joint ventures, limited partnerships, operating partnerships or interests held by preferred unit holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherMinorityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_TypeOfCurrencyAxis=inm_USDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_TypeOfCurrencyAxis=inm_USDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289103989968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Risk Management (Details) - Schedule of fair value and carrying values of the company - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,176,866<span></span>
</td>
<td class="nump">$ 7,363,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">44,804<span></span>
</td>
<td class="nump">46,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">88,027<span></span>
</td>
<td class="nump">11,919<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">6,309,697<span></span>
</td>
<td class="nump">7,421,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued Liabilities</a></td>
<td class="nump">2,415,265<span></span>
</td>
<td class="nump">2,134,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">2,415,265<span></span>
</td>
<td class="nump">2,134,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">6,176,866<span></span>
</td>
<td class="nump">7,363,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">6,176,866<span></span>
</td>
<td class="nump">7,363,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">44,804<span></span>
</td>
<td class="nump">46,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">88,027<span></span>
</td>
<td class="nump">11,919<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">132,831<span></span>
</td>
<td class="nump">58,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued Liabilities</a></td>
<td class="nump">2,415,265<span></span>
</td>
<td class="nump">2,134,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">$ 2,415,265<span></span>
</td>
<td class="nump">$ 2,134,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289106316992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_LegalService', window );">Legal services</a></td>
<td class="nump">$ 345,935<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_LegalService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_LegalService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140289102485904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 13, 2022</div></th>
<th class="th"><div>Sep. 07, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,920<span></span>
</td>
<td class="nump">69,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,920<span></span>
</td>
<td class="nump">69,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement (in Dollars)</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="nump">$ 8.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 8.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Exercisable term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars)</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common shares</a></td>
<td class="nump">691,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=inm_InvestmentOptionsMember', window );">Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inm_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common shares</a></td>
<td class="nump">1,382,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inm_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inm_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=inm_InvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=inm_InvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>f10k2022_inmedpharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:inm="http://www.Inmedpharmaceuticalsinc.com/20220630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inm-20220630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2022-09-23</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inm:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inm:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inm:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inm:RightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">inm:CannabinoidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inm:BayMedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inm:PurchasePriceConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inm:PurchasePriceConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inm:ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-22</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inm:ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-22</startDate>
            <endDate>2022-04-22</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2022-06-06</startDate>
            <endDate>2022-06-06</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2022-06-06</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-06</startDate>
            <endDate>2022-06-06</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inm:BayMedicaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inm:BayMedicaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-06</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:PreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-06</startDate>
            <endDate>2022-06-06</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-06</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-06</startDate>
            <endDate>2022-06-06</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:GrossProceedsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:AllocatedToAdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:ShareIssuanceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:PrefundedWarrantsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:GrossProceedsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:AllocatedToAdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:ShareIssuanceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inm:SharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inm:SharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inm:SharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:AgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-24</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:InMedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inm:BayMedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2021-06-25</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inm:BayMedicaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inm:TypeOfCurrencyAxis">inm:USDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-07</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-13</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">inm:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cadPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-39685</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">INMED PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">98-1428279</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">Suite 310 &#x2013; 815 W Hastings</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Vancouver</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">B.C</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c0">V6C 1B4</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(604)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">669-7207</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">INM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">908761</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">Vancouver, Canada</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">6176866</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">7363126</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="0" unitRef="usd">44804</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c4" decimals="0" unitRef="usd">46462</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">88027</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" unitRef="usd">11919</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">2490854</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" unitRef="usd">797225</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" unitRef="usd">956762</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">9597776</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" unitRef="usd">8378269</us-gaap:AssetsCurrent>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="0" unitRef="usd">904252</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c4" decimals="0" unitRef="usd">326595</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" unitRef="usd">2108915</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="0" unitRef="usd">1061697</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="0" unitRef="usd">176637</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="0" unitRef="usd">14655</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">12787580</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" unitRef="usd">9781216</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">2415265</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">2134878</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">404276</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" unitRef="usd">80483</us-gaap:OperatingLeaseLiabilityCurrent>
    <inm:AcquisitionConsiderationPayable contextRef="c3" decimals="0" unitRef="usd">500000</inm:AcquisitionConsiderationPayable>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">3319541</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">2215361</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" unitRef="usd">389498</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" unitRef="usd">189288</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">3709039</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" unitRef="usd">2404649</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">650667</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">650667</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="INF" unitRef="shares">322028</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="INF" unitRef="shares">322028</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">70718461</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" unitRef="usd">60587417</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">31684098</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="0" unitRef="usd">21513051</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-93452587</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" unitRef="usd">-74852470</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" unitRef="usd">128569</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="0" unitRef="usd">128569</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">9078541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">7376567</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">12787580</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" unitRef="usd">9781216</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">1089435</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">545889</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">543546</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">7282615</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">5338084</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">6867030</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">4479333</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="0" unitRef="usd">185657</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c5" decimals="0" unitRef="usd">120866</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges contextRef="c0" decimals="0" unitRef="usd">-3472593</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">17807895</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">9938283</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" unitRef="usd">96090</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c5" decimals="0" unitRef="usd">16017</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestIncomeExpenseNet contextRef="c5" decimals="0" unitRef="usd">-360350</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c5" decimals="0" unitRef="usd">242628</us-gaap:UnrealizedGainLossOnDerivatives>
    <inm:WarrantModificationExpense contextRef="c0" decimals="0" unitRef="usd">1314307</inm:WarrantModificationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c0" decimals="0" unitRef="usd">-117551</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c5" decimals="0" unitRef="usd">-163101</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-18600117</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-10203089</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c5" decimals="0" unitRef="usd">430443</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" unitRef="usd">-18600117</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c5" decimals="0" unitRef="usd">-9772646</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-33.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-37.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="0" unitRef="shares">560829</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c5" decimals="0" unitRef="shares">268793</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">208828</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">53065240</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">17764333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">-64649381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" unitRef="usd">-301874</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" unitRef="usd">5878318</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c11" decimals="INF" unitRef="shares">71200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c11" decimals="0" unitRef="usd">6052000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c5" decimals="0" unitRef="usd">6052000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares contextRef="c11" decimals="INF" unitRef="shares">42000</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement contextRef="c11" decimals="0" unitRef="usd">2917157</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement contextRef="c12" decimals="0" unitRef="usd">1545343</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement contextRef="c5" decimals="0" unitRef="usd">4462500</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c12" decimals="0" unitRef="usd">1763980</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="0" unitRef="usd">1763980</us-gaap:StockIssuedDuringPeriodValueOther>
    <inm:ShareIssuanceCosts contextRef="c11" decimals="0" unitRef="usd">-1446980</inm:ShareIssuanceCosts>
    <inm:ShareIssuanceCosts contextRef="c12" decimals="0" unitRef="usd">-170798</inm:ShareIssuanceCosts>
    <inm:ShareIssuanceCosts contextRef="c5" decimals="0" unitRef="usd">-1617778</inm:ShareIssuanceCosts>
    <inm:LossAndComprehensiveIncomelossesForThePeriod contextRef="c13" decimals="0" unitRef="usd">-10203089</inm:LossAndComprehensiveIncomelossesForThePeriod>
    <inm:LossAndComprehensiveIncomelossesForThePeriod contextRef="c14" decimals="0" unitRef="usd">430443</inm:LossAndComprehensiveIncomelossesForThePeriod>
    <inm:LossAndComprehensiveIncomelossesForThePeriod contextRef="c5" decimals="0" unitRef="usd">-9772646</inm:LossAndComprehensiveIncomelossesForThePeriod>
    <us-gaap:ShareBasedCompensation contextRef="c12" decimals="0" unitRef="usd">610193</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">610193</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="INF" unitRef="shares">322028</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">60587417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" unitRef="usd">21513051</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">-74852470</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">128569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">7376567</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="INF" unitRef="shares">322028</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">60587417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" unitRef="usd">21513051</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">-74852470</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">128569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">7376567</us-gaap:StockholdersEquity>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares contextRef="c19" decimals="INF" unitRef="shares">35600</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement contextRef="c19" decimals="0" unitRef="usd">1459051</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement contextRef="c20" decimals="0" unitRef="usd">10540635</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement contextRef="c0" decimals="0" unitRef="usd">11999686</inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement>
    <inm:ATMOfferingNetOfIssuanceCostsShares contextRef="c19" decimals="INF" unitRef="shares">10759</inm:ATMOfferingNetOfIssuanceCostsShares>
    <inm:ATMOfferingNetOfIssuanceCosts contextRef="c19" decimals="0" unitRef="usd">146533</inm:ATMOfferingNetOfIssuanceCosts>
    <inm:ATMOfferingNetOfIssuanceCosts contextRef="c0" decimals="0" unitRef="usd">146533</inm:ATMOfferingNetOfIssuanceCosts>
    <inm:RegisteredDirectAndPrivatePlacementShares contextRef="c19" decimals="INF" unitRef="shares">65002</inm:RegisteredDirectAndPrivatePlacementShares>
    <inm:RegisteredDirectAndPrivatePlacement contextRef="c19" decimals="0" unitRef="usd">754072</inm:RegisteredDirectAndPrivatePlacement>
    <inm:RegisteredDirectAndPrivatePlacement contextRef="c20" decimals="0" unitRef="usd">4245508</inm:RegisteredDirectAndPrivatePlacement>
    <inm:RegisteredDirectAndPrivatePlacement contextRef="c0" decimals="0" unitRef="usd">4999580</inm:RegisteredDirectAndPrivatePlacement>
    <inm:ShareIssuanceCosts contextRef="c19" decimals="0" unitRef="usd">-375220</inm:ShareIssuanceCosts>
    <inm:ShareIssuanceCosts contextRef="c20" decimals="0" unitRef="usd">-2506795</inm:ShareIssuanceCosts>
    <inm:ShareIssuanceCosts contextRef="c0" decimals="0" unitRef="usd">-2882015</inm:ShareIssuanceCosts>
    <inm:AgentsWarrants contextRef="c20" decimals="0" unitRef="usd">739920</inm:AgentsWarrants>
    <inm:AgentsWarrants contextRef="c0" decimals="0" unitRef="usd">739920</inm:AgentsWarrants>
    <inm:AgentsInvestmentOptions contextRef="c20" decimals="0" unitRef="usd">192492</inm:AgentsInvestmentOptions>
    <inm:AgentsInvestmentOptions contextRef="c0" decimals="0" unitRef="usd">192492</inm:AgentsInvestmentOptions>
    <inm:ExerciseOfPrefundedWarrantsinShares contextRef="c19" decimals="INF" unitRef="shares">125853</inm:ExerciseOfPrefundedWarrantsinShares>
    <inm:ExerciseOfPrefundedWarrants contextRef="c19" decimals="0" unitRef="usd">4283969</inm:ExerciseOfPrefundedWarrants>
    <inm:ExerciseOfPrefundedWarrants contextRef="c20" decimals="0" unitRef="usd">-4283654</inm:ExerciseOfPrefundedWarrants>
    <inm:ExerciseOfPrefundedWarrants contextRef="c0" decimals="0" unitRef="usd">315</inm:ExerciseOfPrefundedWarrants>
    <inm:ExerciseOfWarrantsinShares contextRef="c19" decimals="INF" unitRef="shares">6293</inm:ExerciseOfWarrantsinShares>
    <inm:ExerciseOfWarrantsin contextRef="c19" decimals="0" unitRef="usd">769260</inm:ExerciseOfWarrantsin>
    <inm:ExerciseOfWarrantsin contextRef="c20" decimals="0" unitRef="usd">-769260</inm:ExerciseOfWarrantsin>
    <inm:AcquisitionOfBayMedicainShares contextRef="c19" decimals="INF" unitRef="shares">82000</inm:AcquisitionOfBayMedicainShares>
    <inm:AcquisitionOfBayMedica contextRef="c19" decimals="0" unitRef="usd">3013500</inm:AcquisitionOfBayMedica>
    <inm:AcquisitionOfBayMedica contextRef="c0" decimals="0" unitRef="usd">3013500</inm:AcquisitionOfBayMedica>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c19" decimals="INF" unitRef="shares">3132</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c19" decimals="0" unitRef="usd">79879</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="0" unitRef="usd">79879</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <inm:WarrantModificationExpense contextRef="c20" decimals="0" unitRef="usd">1314307</inm:WarrantModificationExpense>
    <inm:WarrantModificationExpense contextRef="c0" decimals="0" unitRef="usd">1314307</inm:WarrantModificationExpense>
    <inm:LossAndComprehensivelossesForThePeriod contextRef="c21" decimals="0" unitRef="usd">-18600117</inm:LossAndComprehensivelossesForThePeriod>
    <inm:LossAndComprehensivelossesForThePeriod contextRef="c0" decimals="0" unitRef="usd">-18600117</inm:LossAndComprehensivelossesForThePeriod>
    <us-gaap:ShareBasedCompensation contextRef="c20" decimals="0" unitRef="usd">697894</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">697894</us-gaap:ShareBasedCompensation>
    <us-gaap:SharesOutstanding contextRef="c23" decimals="INF" unitRef="shares">650667</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" unitRef="usd">70718461</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" unitRef="usd">31684098</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="0" unitRef="usd">-93452587</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" unitRef="usd">128569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">9078541</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-18600117</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-10203089</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">185657</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="0" unitRef="usd">120866</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">697894</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">610193</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" decimals="0" unitRef="usd">79879</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="0" unitRef="usd">326133</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c5" decimals="0" unitRef="usd">107828</us-gaap:OperatingLeaseExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c0" decimals="0" unitRef="usd">-11355</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c5" decimals="0" unitRef="usd">-555</us-gaap:GainLossOnDispositionOfAssets>
    <inm:InterestIncomeaccruedReceivedOnShorttermInvestments contextRef="c0" decimals="0" unitRef="usd">-115</inm:InterestIncomeaccruedReceivedOnShorttermInvestments>
    <inm:InterestIncomeaccruedReceivedOnShorttermInvestments contextRef="c5" decimals="0" unitRef="usd">131</inm:InterestIncomeaccruedReceivedOnShorttermInvestments>
    <inm:UnrealizedGainOnDerivativeWarrantsLiability contextRef="c5" decimals="0" unitRef="usd">242628</inm:UnrealizedGainOnDerivativeWarrantsLiability>
    <inm:UnrealizedGainOnForeignExchange contextRef="c0" decimals="0" unitRef="usd">-1770</inm:UnrealizedGainOnForeignExchange>
    <inm:UnrealizedGainOnForeignExchange contextRef="c5" decimals="0" unitRef="usd">445</inm:UnrealizedGainOnForeignExchange>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c0" decimals="0" unitRef="usd">3472593</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c0" decimals="0" unitRef="usd">341862</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c5" decimals="0" unitRef="usd">93951</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <inm:FinanceExpense contextRef="c5" decimals="0" unitRef="usd">360350</inm:FinanceExpense>
    <inm:WarrantModificationExpenses contextRef="c0" decimals="0" unitRef="usd">1314307</inm:WarrantModificationExpenses>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">2003732</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c0" decimals="0" unitRef="usd">-190661</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c5" decimals="0" unitRef="usd">823172</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="0" unitRef="usd">61432</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c5" decimals="0" unitRef="usd">14161</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">40008</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" unitRef="usd">-40198</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">-811599</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" unitRef="usd">346685</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="0" unitRef="usd">-5142</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-15583758</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">-9790640</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <inm:CashAcquiredFromAcqusition contextRef="c0" decimals="0" unitRef="usd">91566</inm:CashAcquiredFromAcqusition>
    <us-gaap:StockIssued1 contextRef="c0" decimals="0" unitRef="usd">300457</us-gaap:StockIssued1>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">39108</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="usd">1725</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireLoansReceivable contextRef="c0" decimals="0" unitRef="usd">425000</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-672999</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-1725</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" unitRef="usd">17146114</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c5" decimals="0" unitRef="usd">12472500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c0" decimals="0" unitRef="usd">1784791</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c5" decimals="0" unitRef="usd">1617778</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfDebt contextRef="c0" decimals="0" unitRef="usd">290826</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">15070497</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">10854722</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="0" unitRef="usd">494960</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-1186260</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">1557317</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">7363126</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c10" decimals="0" unitRef="usd">5805809</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">6176866</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">7363126</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;1.
NATURE OF BUSINESS AND GOING CONCERN&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;InMed
Pharmaceuticals Inc. (&#x201c;InMed&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the Province of British Columbia on May 19,
1981 under the &lt;i&gt;Business Corporations Act&lt;/i&gt; of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline
of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high
unmet medical needs. The Company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids
for various market sectors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s shares are listed on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the trading symbol &#x201c;INM&#x201d;. InMed&#x2019;s
corporate office and principal place of business is located at #310 &#x2013; 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15,
Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated
whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability
to continue as a going concern within one year after the date that the consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -3.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Through
June 30, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred
recurring losses and negative cash flows from operations since its inception, including net losses of $18.6 million and $10.2 million
for the years ended June 30, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of $93.5 million as of
June 30, 2022 (June 30, 2021 - $74.9 million). The Company expects to continue to generate operating losses for the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of the issuance date of these consolidated
financial statements, the Company expects its cash and cash equivalents of $6.2 million as of June 30, 2022, combined with the approximate
$5.4 million of net proceeds from a private placement which closed on September 13, 2022 (see Note 20), will be sufficient to fund its
operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal
2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory
as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to
raise additional capital to finance its operations. As a result of the recurring losses and requirement for cash in fiscal 2023 or the
beginning of fiscal 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within
one year after the date that the consolidated financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including
collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing
on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s existing
stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its
commitments, realize its assets and discharge its liabilities in the normal course. These consolidated financial statements do not reflect
adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going
concern and such adjustments could be material.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-5" unitRef="usd">18600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="-5" unitRef="usd">10200000</us-gaap:ProfitLoss>
    <us-gaap:CumulativeEarningsDeficit contextRef="c3" decimals="-5" unitRef="usd">93500000</us-gaap:CumulativeEarningsDeficit>
    <us-gaap:CumulativeEarningsDeficit contextRef="c4" decimals="-5" unitRef="usd">74900000</us-gaap:CumulativeEarningsDeficit>
    <inm:CashAndCashEquivalent contextRef="c3" decimals="-5" unitRef="usd">6200000</inm:CashAndCashEquivalent>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c0" decimals="-5" unitRef="usd">5400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2.
SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United
States (&#x201c;US GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;)
for financial information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the
reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported.
It also requires management to exercise judgment in applying the Company&#x2019;s accounting policies. In the future, actual experience
may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions
and estimates are significant to these consolidated financial statements are the estimated fair values of the assets acquired and liabilities
assumed in acquisitions, the estimate of useful life of intangible assets, the application of the going concern assumption, the impairment
assessment for long-lived assets, and determining the fair value of share-based payments and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;COVID-19
Impacts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 11, 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. The full extent to which the COVID-19
pandemic may directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses,
research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain,
such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to
contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating
to the preparation of these consolidated financial statements. While there was no material impact to the Company&#x2019;s consolidated
financial statements as of and for the year ended June 30, 2022, the Company&#x2019;s future assessment of the magnitude and duration
of COVID-19, as well as other factors, could result in a material impact to the Company&#x2019;s consolidated financial statements in
future reporting periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Basis
of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical
Ltd., BayMedica, LLC, Biogen Sciences Inc., and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either
directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain
benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany
transactions are eliminated in preparing these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -20.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
functional currency of the Company and its subsidiaries is the U.S. Dollar. These consolidated financial statements are presented in
U.S. Dollars. References to &#x201c;$&#x201d; and &#x201c;US$&#x201d; are to United States (&#x201c;U.S.&#x201d;) dollars and references to
&#x201c;C$&#x201d; are to Canadian dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Business
Combinations&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Business
combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair
values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as
goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair
values at the date of acquisition. If the Company&#x2019;s interest in the fair value of the acquiree&#x2019;s net identifiable assets
exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in
connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments
with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an
insignificant risk of change in value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Short-term
Investments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve
months. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change
in value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company&#x2019;s
best estimate of the amount of probable credit losses in existing accounts receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition
and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected
to affect future collections experience. Expected credit losses on our accounts receivable were immaterial as at June 30, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories
are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value.
Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing
costs and production and labor costs related to manufacturing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. At June 30, 2022,
no amounts had been charged to the valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Deferred
Financing Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity
financings as deferred financing costs until such financings are consummated. After consummation of the equity financing, these costs
are recorded as a reduction to shareholders&#x2019; equity generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred financing costs will be expensed immediately as a charge to operating expenses in the consolidated statements
of operations and comprehensive loss. As of June 30, 2022, $&lt;span style="-sec-ix-hidden: hidden-fact-78"&gt;Nil&lt;/span&gt; (2021 - $112,074) of deferred financing costs were capitalized and recorded
as prepaids and other assets on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property, Equipment and ROU Assets,
Net &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equipment
and leasehold improvements are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of
equipment and leasehold improvements comprises their purchase price. The useful lives of equipment and leasehold improvements are reviewed
at least once per year. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated
useful lives as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment &#x2013; 30% per annum&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold
                                            improvements &#x2013; lesser of initial lease term or useful life&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equipment
and leasehold improvements, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The right-of-use assets are initially
measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less
any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the right-of-use asset or the
lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits.
The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition,
the right-of-use assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability
(see Note 2 Lease (i)).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets, Net &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property
is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment
losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;In-Process
R&amp;amp;D&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In-process
R&amp;amp;D (&#x201c;IPR&amp;amp;D&#x201d;) is classified as an indefinite-lived intangible asset and is not amortized. IPR&amp;amp;D becomes definite-lived
upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent
to the acquisition of IPR&amp;amp;D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual
basis or more frequently if an indicator of impairment is present.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the
asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted
cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount
by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale
are reported at the lower of the carrying amount or fair value, less costs to sell. As of June 30, 2022, the Company determined that
the long-lived assets of BayMedica were impaired (see Note 6) and no assets were held-for-sale.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company tests goodwill for potential
impairment annually on June 30, or more frequently if an event or other circumstance indicates that the Company may not be able to recover
the carrying amount of the net assets of the reporting unit. The Company&#x2019;s operations consist of two operating and reportable segments,
InMed Pharmaceuticals (the &#x201c;InMed&#x201d; segment) and BayMedica (the &#x201c;BayMedica&#x201d; segment). In evaluating goodwill for
impairment, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. If a Company bypasses the qualitative assessment, or if the Company concludes that it is more likely
than not that the fair value of a reporting unit is less than its carrying value, then the Company performs a quantitative impairment
test by comparing the fair value of a reporting unit with its carrying amount (See Note 6) and records an impairment charge if the carrying
value exceeds the fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Financial
Assets and Liabilities &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and
subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are
or elected to be carried at fair value through profit or loss or where changes in fair value are recognized in the consolidated statements
of operations and comprehensive loss in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
investments are subsequently recorded at cost plus accrued interest, which approximates fair value. Accounts receivable are reported
at outstanding amounts, net of provisions for uncollectable amounts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
liabilities, including accounts payable and accrued liabilities, are initially recognized at fair value net of any transaction costs
directly attributable to the issuance of the instrument and subsequently carried at amortized cost using the effective interest rate
method. This ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried
in the consolidated balance sheet. Interest expense in this context includes initial transaction costs and premiums payable on redemption,
as well as any interest or coupon payable while the liability is outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Financial
Assets and Liabilities (cont&#x2019;d)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;To
determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of
financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three
levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                               1 &#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;Unadjusted
                                            quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt; Level 2 &#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;Inputs
                                            other than quoted prices included within Level 1 that are observable for the asset or liability,
                                            either directly or indirectly. Level 2 inputs include quoted prices for similar assets or
                                            liabilities in active markets, quoted prices for identical or similar assets or liabilities
                                            in markets that are not active, inputs other than quoted prices that are observable for the
                                            asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived
                                            principally from or corroborated by observable market data by correlation or other means
                                            (market corroborated inputs).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                               3 &#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;Inputs
                                            are unobservable and reflect the Company&#x2019;s assumptions as to what market participants
                                            would use in pricing the asset or liability. The Company develops these inputs based on the
                                            best information available. Assets and liabilities are classified based on the lowest level
                                            of input that is significant to the fair value measurements. Changes in the observability
                                            of valuation inputs may result in a reclassification of levels for certain securities within
                                            the fair value hierarchy.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities,
approximate their carrying values as at June 30, 2022 and 2021 due to their immediate or short-term maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company records a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset
and liability method. Under this method, it recognizes deferred income tax assets and liabilities for the expected future tax consequences
of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets and liabilities
are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities
are expected to be realized or settled. The Company recognizes the deferred income tax effects of a change in tax rates in the period
of the enactment. The Company records a valuation allowance to reduce its deferred tax assets to the net amount that management believes
is more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions are more likely
than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than fifty percent likely
of being realized. The Company records interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products
and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers
in exchange for those products and services. ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; defines a five-step process to recognize
revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations
in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract,
and recognizing revenue when or as the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Revenue consists of manufacturing and
distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when
control over the products have been transferred to the customer and the Company has a present right to payment. Sales and other taxes
that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return,
for claims of damaged or non-compliant products, exist with the Company&#x2019;s customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense,
when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues
within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance
of when control is transferred to the customer. The time between invoicing and when payment is due is not significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cost
of Sales&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost
of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing
costs. Cost of sales also includes production and labor costs for the Company&#x2019;s manufacturing business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Shipping
and Handling&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company records freight billed to customers within Net sales. Shipping and handling costs associated with inbound freight and goods shipped
to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating
expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Earnings
(Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
earnings (loss) per common share (&#x201c;EPS&#x201d;) is computed by dividing the net income or loss applicable to common shares of the
Company by the weighted average number of common shares outstanding for the relevant period. Diluted earnings (loss) per common share
(&#x201c;Diluted EPS&#x201d;) is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average
number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive
instruments were converted. If the conversion of outstanding stock options and warrants into common share is anti-dilutive, then diluted
EPS is not presented separately from EPS.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Share-based
Payments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value, at the grant date, of equity-classified share awards is charged to income or loss over the period for which the benefits
of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards
are measured separately and expensed over the related tranche&#x2019;s vesting period. The corresponding accrued entitlement is recorded
in additional paid-in capital. The amount recognized as an expense is adjusted to reflect the number of share options that vest. The
fair value of awards is calculated using the Black-Scholes option pricing model which considers the exercise price, current market price
of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Starting
July 1, 2018, the Company accounts for non-employee awards under the guidance provided under ASU 2018-07 and uses an expected term to
value non-employee options on an award-by-award basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
expected term of the Company&#x2019;s employee stock options is determined using the simplified method and the Company estimates the forfeitures
on the grant date for options issued. The expected term of the Company&#x2019;s non-employee stock options is the contractual term of
the options granted and the Company estimates the forfeitures on the grant date for options issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company conducts research and development programs and incurs costs related to these activities, including research and development personnel
compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the
periods in which they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Patents
and Intellectual Property Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty
surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third
parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the
patent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Segment
reporting &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s operations consist of two operating and reportable segments, the InMed segment and the BayMedica segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry (See Note 15).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date,
discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#x2019;s incremental
borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized
cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in
an index or rate, if there is a change in the Company&#x2019;s estimate of the amount expected to be payable under a residual value guarantee,
or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability
is re-measured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit
or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component
and its associated non-lease components as a single lease component for all of its asset classes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement
of the right-of-use asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize
right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated
with these leases is recognized as an expense on a straight- line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
                                            Value Measurement&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
June 2022, FASB issued ASU 2022-03, &lt;i&gt;Fair Value Measurement (Topic 82):&lt;/i&gt; Fair Value Measurement of Equity Securities Subject to
Contractual Sale Restrictions. The amendments in this ASU clarify the guidance in ASC 820 on the fair value measurement of an equity
security that is subject to a contractual sale restriction and require specific disclosures related to such an equity security. This
standard is effective for fiscal years beginning after December 15, 2023. The Company does not expect the standard to have a significant
impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
consolidated financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United
States (&#x201c;US GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;)
for financial information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the
reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported.
It also requires management to exercise judgment in applying the Company&#x2019;s accounting policies. In the future, actual experience
may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions
and estimates are significant to these consolidated financial statements are the estimated fair values of the assets acquired and liabilities
assumed in acquisitions, the estimate of useful life of intangible assets, the application of the going concern assumption, the impairment
assessment for long-lived assets, and determining the fair value of share-based payments and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <inm:COVID19ImpactsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;COVID-19
Impacts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 11, 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. The full extent to which the COVID-19
pandemic may directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses,
research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain,
such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to
contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating
to the preparation of these consolidated financial statements. While there was no material impact to the Company&#x2019;s consolidated
financial statements as of and for the year ended June 30, 2022, the Company&#x2019;s future assessment of the magnitude and duration
of COVID-19, as well as other factors, could result in a material impact to the Company&#x2019;s consolidated financial statements in
future reporting periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</inm:COVID19ImpactsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Basis
of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
consolidated financial statements include the accounts of the Company and its subsidiaries, including subsidiaries: InMed Pharmaceutical
Ltd., BayMedica, LLC, Biogen Sciences Inc., and Sweetnam Consulting Inc. A subsidiary is an entity that the Company controls, either
directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain
benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany
transactions are eliminated in preparing these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Foreign
Currency&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify; text-indent: -20.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
functional currency of the Company and its subsidiaries is the U.S. Dollar. These consolidated financial statements are presented in
U.S. Dollars. References to &#x201c;$&#x201d; and &#x201c;US$&#x201d; are to United States (&#x201c;U.S.&#x201d;) dollars and references to
&#x201c;C$&#x201d; are to Canadian dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Business
Combinations&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.85pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Business
combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair
values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as
goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair
values at the date of acquisition. If the Company&#x2019;s interest in the fair value of the acquiree&#x2019;s net identifiable assets
exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in
connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
and cash equivalents include cash-on-hand, demand deposits with financial institutions and other short-term, highly liquid investments
with original maturities of three months or less when acquired that are readily convertible to known amounts of cash and subject to an
insignificant risk of change in value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Short-term
Investments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
investments include fixed and variable rate guaranteed investment certificates, with terms greater than three months and less than twelve
months. Guaranteed investment certificates are convertible to known amounts of cash and are subject to an insignificant risk of change
in value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Accounts
Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company&#x2019;s
best estimate of the amount of probable credit losses in existing accounts receivable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition
and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected
to affect future collections experience. Expected credit losses on our accounts receivable were immaterial as at June 30, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories
are initially valued at weighted average cost and subsequently valued at the lower of weighted average cost and net realizable value.
Costs included in inventories are the purchase price of goods and cost of services rendered, freight costs, warehousing costs, purchasing
costs and production and labor costs related to manufacturing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
determining any valuation allowances, the Company reviews inventory for obsolete, redundant, and slow-moving goods. At June 30, 2022,
no amounts had been charged to the valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Deferred
Financing Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity
financings as deferred financing costs until such financings are consummated. After consummation of the equity financing, these costs
are recorded as a reduction to shareholders&#x2019; equity generated as a result of the offering. Should the in-process equity financing
be abandoned, the deferred financing costs will be expensed immediately as a charge to operating expenses in the consolidated statements
of operations and comprehensive loss. As of June 30, 2022, $&lt;span style="-sec-ix-hidden: hidden-fact-78"&gt;Nil&lt;/span&gt; (2021 - $112,074) of deferred financing costs were capitalized and recorded
as prepaids and other assets on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts contextRef="c4" decimals="0" unitRef="usd">112074</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property, Equipment and ROU Assets,
Net &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equipment
and leasehold improvements are recorded at cost, less accumulated depreciation and accumulated impairment losses. The initial cost of
equipment and leasehold improvements comprises their purchase price. The useful lives of equipment and leasehold improvements are reviewed
at least once per year. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated
useful lives as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer equipment &#x2013; 30% per annum&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold
                                            improvements &#x2013; lesser of initial lease term or useful life&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equipment
and leasehold improvements, acquired or disposed of during the year, are depreciated proportionately for the period they are in use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The right-of-use assets are initially
measured based on the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, less
any lease incentives received. The assets are amortized to the earlier of the end of the useful life of the right-of-use asset or the
lease term using the straight-line method as this most closely reflects the expected pattern of consumption of the future economic benefits.
The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. In addition,
the right-of-use assets are periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability
(see Note 2 Lease (i)).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="c3" decimals="2" unitRef="pure">0.30</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets, Net &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
assets are comprised of acquired intellectual property, which consists of certain patents and technical know-how. The intellectual property
is recorded at cost and is amortized on a straight-line basis over an estimated useful life of 18 years net of any accumulated impairment
losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c0">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inm:InProcessRDPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;In-Process
R&amp;amp;D&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In-process
R&amp;amp;D (&#x201c;IPR&amp;amp;D&#x201d;) is classified as an indefinite-lived intangible asset and is not amortized. IPR&amp;amp;D becomes definite-lived
upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent
to the acquisition of IPR&amp;amp;D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual
basis or more frequently if an indicator of impairment is present.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</inm:InProcessRDPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the
asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted
cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured as the amount
by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale
are reported at the lower of the carrying amount or fair value, less costs to sell. As of June 30, 2022, the Company determined that
the long-lived assets of BayMedica were impaired (see Note 6) and no assets were held-for-sale.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company tests goodwill for potential
impairment annually on June 30, or more frequently if an event or other circumstance indicates that the Company may not be able to recover
the carrying amount of the net assets of the reporting unit. The Company&#x2019;s operations consist of two operating and reportable segments,
InMed Pharmaceuticals (the &#x201c;InMed&#x201d; segment) and BayMedica (the &#x201c;BayMedica&#x201d; segment). In evaluating goodwill for
impairment, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting
unit is less than its carrying amount. If a Company bypasses the qualitative assessment, or if the Company concludes that it is more likely
than not that the fair value of a reporting unit is less than its carrying value, then the Company performs a quantitative impairment
test by comparing the fair value of a reporting unit with its carrying amount (See Note 6) and records an impairment charge if the carrying
value exceeds the fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" unitRef="pure">2</us-gaap:NumberOfOperatingSegments>
    <inm:FinancialAssetsAndLiabilitiesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Financial
Assets and Liabilities &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
assets are initially recognized at fair value, plus transaction costs that are directly attributable to their acquisition or issue and
subsequently carried at amortized cost, using the effective interest rate method, less any impairment losses. No financial assets are
or elected to be carried at fair value through profit or loss or where changes in fair value are recognized in the consolidated statements
of operations and comprehensive loss in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
investments are subsequently recorded at cost plus accrued interest, which approximates fair value. Accounts receivable are reported
at outstanding amounts, net of provisions for uncollectable amounts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
liabilities, including accounts payable and accrued liabilities, are initially recognized at fair value net of any transaction costs
directly attributable to the issuance of the instrument and subsequently carried at amortized cost using the effective interest rate
method. This ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried
in the consolidated balance sheet. Interest expense in this context includes initial transaction costs and premiums payable on redemption,
as well as any interest or coupon payable while the liability is outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Financial
Assets and Liabilities (cont&#x2019;d)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;To
determine the fair value of financial instruments, the Company uses the fair value hierarchy for inputs used to measure fair value of
financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three
levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                               1 &#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;Unadjusted
                                            quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt; Level 2 &#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;Inputs
                                            other than quoted prices included within Level 1 that are observable for the asset or liability,
                                            either directly or indirectly. Level 2 inputs include quoted prices for similar assets or
                                            liabilities in active markets, quoted prices for identical or similar assets or liabilities
                                            in markets that are not active, inputs other than quoted prices that are observable for the
                                            asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived
                                            principally from or corroborated by observable market data by correlation or other means
                                            (market corroborated inputs).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                               3 &#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;Inputs
                                            are unobservable and reflect the Company&#x2019;s assumptions as to what market participants
                                            would use in pricing the asset or liability. The Company develops these inputs based on the
                                            best information available. Assets and liabilities are classified based on the lowest level
                                            of input that is significant to the fair value measurements. Changes in the observability
                                            of valuation inputs may result in a reclassification of levels for certain securities within
                                            the fair value hierarchy.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carrying value of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable and accrued liabilities,
approximate their carrying values as at June 30, 2022 and 2021 due to their immediate or short-term maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</inm:FinancialAssetsAndLiabilitiesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company records a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset
and liability method. Under this method, it recognizes deferred income tax assets and liabilities for the expected future tax consequences
of temporary differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets and liabilities
are measured using the enacted tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities
are expected to be realized or settled. The Company recognizes the deferred income tax effects of a change in tax rates in the period
of the enactment. The Company records a valuation allowance to reduce its deferred tax assets to the net amount that management believes
is more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions are more likely
than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than fifty percent likely
of being realized. The Company records interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="c0">Recognized income tax positions are measured at the largest amount that is greater than fifty percent likely
of being realized.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products
and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers
in exchange for those products and services. ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; defines a five-step process to recognize
revenue that requires judgment and estimates, including identifying the contract with the customer, identifying the performance obligations
in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract,
and recognizing revenue when or as the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Revenue consists of manufacturing and
distribution sales of bulk rare cannabinoids, which are generally recognized at a point in time. The Company recognizes revenue when
control over the products have been transferred to the customer and the Company has a present right to payment. Sales and other taxes
that are required to be remitted to regulatory authorities are recorded as liabilities and excluded from sales. Limited rights of return,
for claims of damaged or non-compliant products, exist with the Company&#x2019;s customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has elected the practical expedient that allows it to recognize the incremental costs of obtaining a contract as an expense,
when incurred, if the amortization period of the asset that the Company otherwise would have recognized is one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues
within the scope of ASC 606 do not include material amounts of variable consideration. Customer payments are generally due in advance
of when control is transferred to the customer. The time between invoicing and when payment is due is not significant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesVendorAllowancesPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cost
of Sales&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost
of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing
costs. Cost of sales also includes production and labor costs for the Company&#x2019;s manufacturing business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesVendorAllowancesPolicy>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Shipping
and Handling&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company records freight billed to customers within Net sales. Shipping and handling costs associated with inbound freight and goods shipped
to customers are recorded in cost of sales. Other shipping and handling costs, such as for quality assurance, are recorded in operating
expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Earnings
(Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
earnings (loss) per common share (&#x201c;EPS&#x201d;) is computed by dividing the net income or loss applicable to common shares of the
Company by the weighted average number of common shares outstanding for the relevant period. Diluted earnings (loss) per common share
(&#x201c;Diluted EPS&#x201d;) is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average
number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive
instruments were converted. If the conversion of outstanding stock options and warrants into common share is anti-dilutive, then diluted
EPS is not presented separately from EPS.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Share-based
Payments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value, at the grant date, of equity-classified share awards is charged to income or loss over the period for which the benefits
of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards
are measured separately and expensed over the related tranche&#x2019;s vesting period. The corresponding accrued entitlement is recorded
in additional paid-in capital. The amount recognized as an expense is adjusted to reflect the number of share options that vest. The
fair value of awards is calculated using the Black-Scholes option pricing model which considers the exercise price, current market price
of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Starting
July 1, 2018, the Company accounts for non-employee awards under the guidance provided under ASU 2018-07 and uses an expected term to
value non-employee options on an award-by-award basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
expected term of the Company&#x2019;s employee stock options is determined using the simplified method and the Company estimates the forfeitures
on the grant date for options issued. The expected term of the Company&#x2019;s non-employee stock options is the contractual term of
the options granted and the Company estimates the forfeitures on the grant date for options issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company conducts research and development programs and incurs costs related to these activities, including research and development personnel
compensation, services provided by contract research organizations and lab supplies. Research and development costs are expensed in the
periods in which they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <inm:PatentsAndIntellectualPropertyCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Patents
and Intellectual Property Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
costs of filing for patents and of prosecuting and maintaining intellectual property rights are expensed as incurred due to the uncertainty
surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third
parties for approved products or where there are alternative future uses are capitalized and amortized over the remaining life of the
patent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</inm:PatentsAndIntellectualPropertyCostsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Segment
reporting &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s operations consist of two operating and reportable segments, the InMed segment and the BayMedica segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry (See Note 15).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
inception of a contract, the Company assesses whether a contract is, or contains, a lease based on whether the contract conveys the right
to control the use of an identified asset for a period of time in exchange for consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
lease liability is initially measured as the present value of future lease payments excluding payments made at the commencement date,
discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#x2019;s incremental
borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. The lease liability is measured at amortized
cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in
an index or rate, if there is a change in the Company&#x2019;s estimate of the amount expected to be payable under a residual value guarantee,
or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option. When the lease liability
is re-measured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit
or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has lease arrangements that include both lease and non-lease components. The Company accounts for each separate lease component
and its associated non-lease components as a single lease component for all of its asset classes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has elected to apply the practical expedient to exclude initial direct costs such as annual operating costs from the measurement
of the right-of-use asset at the date of initial application. The Company has elected to apply the practical expedient not to recognize
right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. The lease payments associated
with these leases is recognized as an expense on a straight- line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="c3">P12Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
                                            Value Measurement&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
June 2022, FASB issued ASU 2022-03, &lt;i&gt;Fair Value Measurement (Topic 82):&lt;/i&gt; Fair Value Measurement of Equity Securities Subject to
Contractual Sale Restrictions. The amendments in this ASU clarify the guidance in ASC 820 on the fair value measurement of an equity
security that is subject to a contractual sale restriction and require specific disclosures related to such an equity security. This
standard is effective for fiscal years beginning after December 15, 2023. The Company does not expect the standard to have a significant
impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2.4pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;3.
CUSTOMER CONCENTRATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company had three customers during the year ended June 30, 2022, which individually generated 10% or more of the Company&#x2019;s net
sales. These customers accounted for 48% of the Company&#x2019;s sales for the year ended June 30, 2022. As of June 30, 2022, these customers
represented 0% of the Company&#x2019;s outstanding accounts receivable.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskCustomer contextRef="c0">The
Company had three customers during the year ended June 30, 2022, which individually generated 10% or more of the Company&#x2019;s net
sales.</us-gaap:ConcentrationRiskCustomer>
    <inm:ConcentrationRiskPercentage contextRef="c27" decimals="2" unitRef="pure">0.48</inm:ConcentrationRiskPercentage>
    <inm:ConcentrationRiskPercentage contextRef="c28" decimals="2" unitRef="pure">0</inm:ConcentrationRiskPercentage>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;4.
INVENTORIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories
consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;292,577&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,724,851&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;473,426&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,490,854&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended June 30, 2022, inventory expensed to cost of goods sold was $545,889 (2021 - $&lt;span style="-sec-ix-hidden: hidden-fact-83"&gt;Nil&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;292,577&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,724,851&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;473,426&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,490,854&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="c3" decimals="0" unitRef="usd">292577</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="0" unitRef="usd">1724851</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" unitRef="usd">473426</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">2490854</us-gaap:InventoryNet>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" unitRef="usd">545889</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;b&gt;5. PROPERTY,
EQUIPMENT AND ROU ASSETS, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Property, equipment and ROU assets
consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-size: 10pt"&gt;Right of Use Assets (leases)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,167,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;439,321&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;212,877&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;66,888&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,409&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;42,986&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,420,722&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;549,195&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(516,470&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(222,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Property, equipment and ROU assets, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;904,252&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;326,595&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Depreciation expense on property, equipment
and leasehold improvements for the year ended June 30, 2022, was $26,426 (2021 - $21,143). Amortization expense related to the right-of-use
assets for the year ended June 30, 2022, was $289,594 (2021 - $76,165) and was recorded in general and administrative expenses.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-size: 10pt"&gt;Right of Use Assets (leases)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,167,436&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;439,321&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;212,877&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;66,888&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,409&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;42,986&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,420,722&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;549,195&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(516,470&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(222,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Property, equipment and ROU assets, net&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;904,252&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;326,595&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"/&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c29" decimals="0" unitRef="usd">1167436</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c30" decimals="0" unitRef="usd">439321</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c31" decimals="0" unitRef="usd">212877</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c32" decimals="0" unitRef="usd">66888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c33" decimals="0" unitRef="usd">40409</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c34" decimals="0" unitRef="usd">42986</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">1420722</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" unitRef="usd">549195</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">516470</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">222600</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">904252</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" unitRef="usd">326595</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;6.
IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended June 30, 2022, the Company recorded goodwill of $2,023,039, definite lived intangible assets of $216,000, IPR&amp;amp;D of
$1,249,000 and patents of $1,191,000 in connection with the acquisition of BayMedica, as described in Note 8.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company performs an annual impairment
test at the reporting unit level as of June 30 of each fiscal year. As of June 30, 2022, the Company qualitatively assessed whether it
is more likely than not that the respective fair value of the Company&#x2019;s BayMedica reporting unit was less than its carrying amount,
including goodwill. For a variety of reasons, performance of the BayMedica segment has not materialized as expected. Contributing factors
include but are not limited to:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"/&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;market
                                            demand for launched compounds has not materialized as quickly as the Company anticipated;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;recent
                                            overarching recessionary pressures have contributed to hesitation within the health and wellness
                                            (H&amp;amp;W) sector to invest in, and launch, new rare cannabinoid products;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;in
                                            this nascent market, BayMedica&#x2019;s perceived competitive advantages of certified, high purity and
                                            reliability and consistency of supply have not resonated with the industry&#x2019;s current
                                            product manufacturers; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;additional
                                            downward pricing pressure for cannabinoids in the H&amp;amp;W sector.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
a result of this sustained decline in performance compared to expectations and continuing market uncertainties, the Company determined
that as of June 30, 2022, it was more likely than not that the carrying value of these acquired intangibles exceeded their estimated
fair value. Accordingly, the Company performed an impairment analysis as of that date using the income method, the relieve from royalty
method and the multi-period excess earnings method. This analysis required significant judgments, including the estimation of future revenues,
royalties, licensing fees, costs, the probability of success in various phases of its development programs, potential post launch cash
flows and discount rates. The Company recorded a goodwill and intangible asset impairment charge for the excess of the reporting unit&#x2019;s
carrying value over its fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following table provides the Company&#x2019;s
goodwill, indefinite and definite lived intangible assets as of June 30, 2022 and 2021. There was no impairment of InMed long lived intangible
assets as of June 30, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,023,039&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,023,039&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Indefinite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,249,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,249,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Definite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademark and Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(786,637&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(200,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;965,229&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Definite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,191,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(47,314&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,143,686&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,108,915&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;For goodwill, the Company recognized
an impairment charge of $2 million and $&lt;span style="-sec-ix-hidden: hidden-fact-90"&gt;Nil&lt;/span&gt; during the years ended June 30, 2022 and 2021, respectively. For the identified indefinite
lived assets, the Company recognized an impairment charge of $1.2 million and $&lt;span style="-sec-ix-hidden: hidden-fact-91"&gt;Nil&lt;/span&gt; during the years ended June 30, 2022 and 2021, respectively.
For identified definite lived intangible assets, the Company recognized an impairment charge of $0.2 million and $&lt;span style="-sec-ix-hidden: hidden-fact-92"&gt;Nil&lt;/span&gt; during the years
ended June 30, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillGross contextRef="c3" decimals="0" unitRef="usd">2023039</us-gaap:GoodwillGross>
    <inm:ImpairmentOfIntangibleAssetExcludingGoodwill contextRef="c0" decimals="0" unitRef="usd">216000</inm:ImpairmentOfIntangibleAssetExcludingGoodwill>
    <inm:ImpairmentOfIntangibleAssetExcludingGoodwill contextRef="c35" decimals="0" unitRef="usd">1249000</inm:ImpairmentOfIntangibleAssetExcludingGoodwill>
    <inm:ImpairmentOfIntangibleAssetExcludingGoodwill contextRef="c36" decimals="0" unitRef="usd">1191000</inm:ImpairmentOfIntangibleAssetExcludingGoodwill>
    <us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,023,039&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,023,039&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Indefinite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,249,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,249,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Definite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademark and Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(786,637&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(200,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;965,229&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Definite lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired at October 13, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,191,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(47,314&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,143,686&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,108,915&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c38" decimals="0" unitRef="usd">2023039</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillImpairmentLoss contextRef="c38" decimals="0" unitRef="usd">2023039</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c35" decimals="0" unitRef="usd">1249000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillImpairmentLoss contextRef="c35" decimals="0" unitRef="usd">1249000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillFairValueDisclosure contextRef="c42" decimals="0" unitRef="usd">1736420</us-gaap:GoodwillFairValueDisclosure>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c43" decimals="0" unitRef="usd">216000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c44" decimals="0" unitRef="usd">-786637</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:GoodwillImpairmentLoss contextRef="c43" decimals="0" unitRef="usd">200554</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillFairValueDisclosure contextRef="c44" decimals="0" unitRef="usd">965229</us-gaap:GoodwillFairValueDisclosure>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c36" decimals="0" unitRef="usd">1191000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c46" decimals="0" unitRef="usd">-47314</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:GoodwillFairValueDisclosure contextRef="c46" decimals="0" unitRef="usd">1143686</us-gaap:GoodwillFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">2108915</us-gaap:FiniteLivedIntangibleAssetsNet>
    <inm:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill contextRef="c0" decimals="0" unitRef="usd">2</inm:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentChargeOnReclassifiedAssets contextRef="c0" decimals="1" unitRef="usd">1.2</us-gaap:ImpairmentChargeOnReclassifiedAssets>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c0" decimals="1" unitRef="usd">0.2</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;7.
INTANGIBLE ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,191,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,927,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(818,505&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(674,723&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: none; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,108,915&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,061,697&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired
intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired
patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated
useful life of 18 years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
at June 30, 2022, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 13 years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization
expense on intangible assets for the year ended June 30, 2022 was $159,228 (2021 - $99,723). The Company expects amortization expense
to be incurred over the next five years as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;807,385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,191,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,927,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,736,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(818,505&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(674,723&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: none; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,108,915&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,061,697&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" unitRef="usd">1736420</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c4" decimals="0" unitRef="usd">1736420</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedPatentsGross contextRef="c3" decimals="0" unitRef="usd">1191000</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedIntangibleAssetAcquiredInPlaceLeases contextRef="c3" decimals="0" unitRef="usd">2927420</us-gaap:FiniteLivedIntangibleAssetAcquiredInPlaceLeases>
    <us-gaap:FiniteLivedIntangibleAssetAcquiredInPlaceLeases contextRef="c4" decimals="0" unitRef="usd">1736420</us-gaap:FiniteLivedIntangibleAssetAcquiredInPlaceLeases>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets contextRef="c3" decimals="0" unitRef="usd">818505</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets contextRef="c4" decimals="0" unitRef="usd">674723</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">2108915</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c4" decimals="0" unitRef="usd">1061697</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c0">P18Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c0">P18Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c0">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">159228</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" unitRef="usd">99723</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,477&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;807,385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="c3" decimals="0" unitRef="usd">161477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="c3" decimals="0" unitRef="usd">161477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="c3" decimals="0" unitRef="usd">161477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="c3" decimals="0" unitRef="usd">161477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="c3" decimals="0" unitRef="usd">161477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <inm:FiniteLivedIntangibleAssetNet contextRef="c3" decimals="0" unitRef="usd">807385</inm:FiniteLivedIntangibleAssetNet>
    <inm:AcquisitionTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;8.
ACQUISITION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On October 13, 2021, the Company completed
the acquisition of BayMedica, a private company based in the U.S. that specializes in the manufacturing and commercialization of rare
cannabinoids. The Company acquired 100% of BayMedica in exchange for i) 82,000 common shares issued to BayMedica&#x2019;s equity and convertible
debt holders, subject to a six-month contractual hold period and ii) $1 million to be held in escrow, subject to reduction for certain
post-closing adjustments or satisfaction of indemnification claims under the definitive agreement (the &#x201c;BayMedica Agreement&#x201d;)
in the six- and twelve-month periods following the closing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
consideration for the acquisition of BayMedica is summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Purchase
                                            Price&lt;br/&gt;
                                            Consideration&lt;br/&gt; ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated fair value of common shares issued&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,013,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:Post-closing adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(199,543&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,813,957&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
82,000 common shares were valued at $36.75, being the closing price of the Company&#x2019;s common shares on Nasdaq on October 13, 2021.
The cash component is subject to reduction for certain post-closing adjustments or satisfaction of indemnification claims and therefore
is subject to further changes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prior
to the acquisition, the Company has a $425,000 loan receivable from BayMedica and BayMedica has an equal loan payable to the Company.
As a result of the acquisition of BayMedica, the loan receivable and payable is effectively settled between the parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
accordance with the acquisition method of accounting, the purchase price of BayMedica has been allocated to the acquired assets and assumed
liabilities based on their estimated acquisition date fair values. The fair value estimates were based on income, estimates and other
analyses. The excess of the total consideration over the estimated fair value of the amounts initially assigned to the identifiable assets
acquired and liabilities assumed has been recorded as goodwill, which is not deductible for income taxes purposes. The goodwill balance
represents the assembled workforce acquired, the combined company&#x2019;s expectations of the strategic opportunities available as a
result of the acquisition, and other synergies that will be derived from the acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the final fair value of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Purchase Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Allocation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;91,566&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;487,122&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid expenses and deposits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;131,674&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133,911&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,249,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,191,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademark&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: none; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,023,039&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,559,412&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,024,487&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other short-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;598,245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122,723&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,745,455&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: none; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated
    fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,813,957&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;Tangible
assets and liabilities were valued at their respective carrying amounts as management believes that these amounts approximated their
acquisition-date fair values.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Purchase Price allocation includes certain identifiable intangible assets with an estimated fair value of approximately $2,656,000. These
intangible assets include trade secrets, product formulation knowledge, patents and trademarks. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired
IPR&amp;amp;D are related identifiable intangible assets associated with cannabinoid manufacturing processes and includes knowhow and trade
secrets. The multi-period excess earnings method was used to determine the fair value of these assets as at the date of acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
acquired trademark represents the trade name ProDiol&#xae;. The fair value of the trademark was determined using the relief from
royalty method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Acquired
patents consist of patents related to the development of cannabinoid analogs, the fair value of which was determined using the income
approach. This intangible asset is being amortized over an estimated useful life of 18 years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Following the acquisition date, the
operating results of BayMedica have been included in the consolidated financial statements. For the period from the October 13, 2021 acquisition
date through June 30, 2022, sales attributable to BayMedica were $1.1 million and operating losses attributable to BayMedica were $5.2
million. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $0.2 million
for the year ended June 30, 2022 and were included in general and administrative expenses in the consolidated statements of operations
and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the pro forma consolidated results of the Company assuming the BayMedica acquisition had been completed on July
1, 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended June
    30&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,365,755&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,904,013&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,260,014&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,705,494&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</inm:AcquisitionTextBlock>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="c47">The Company acquired 100% of BayMedica in exchange for i) 82,000 common shares issued to BayMedica&#x2019;s equity and convertible
debt holders, subject to a six-month contractual hold period and ii) $1 million to be held in escrow, subject to reduction for certain
post-closing adjustments or satisfaction of indemnification claims under the definitive agreement (the &#x201c;BayMedica Agreement&#x201d;)
in the six- and twelve-month periods following the closing.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c48" decimals="2" unitRef="pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Purchase
                                            Price&lt;br/&gt;
                                            Consideration&lt;br/&gt; ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated fair value of common shares issued&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,013,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:Post-closing adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(199,543&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,813,957&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c51" decimals="0" unitRef="usd">3013500</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash contextRef="c51" decimals="0" unitRef="usd">1000000</inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash>
    <inm:BusinessCombinationPostclosingAdjustments contextRef="c51" decimals="0" unitRef="usd">-199543</inm:BusinessCombinationPostclosingAdjustments>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c51" decimals="0" unitRef="usd">3813957</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">82000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:TemporaryEquityRedemptionPricePerShare contextRef="c3" decimals="2" unitRef="usdPershares">36.75</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:PaymentsToAcquireLoansReceivable contextRef="c0" decimals="0" unitRef="usd">425000</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Purchase Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Allocation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;91,566&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;487,122&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid expenses and deposits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;131,674&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;133,911&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,249,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,191,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademark&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;216,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: none; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,023,039&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,559,412&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,024,487&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other short-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;598,245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122,723&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,745,455&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: none; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated
    fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,813,957&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c52" decimals="0" unitRef="usd">91566</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c52" decimals="0" unitRef="usd">36100</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c52" decimals="0" unitRef="usd">487122</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c52" decimals="0" unitRef="usd">131674</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c52" decimals="0" unitRef="usd">133911</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment contextRef="c52" decimals="0" unitRef="usd">1249000</inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment>
    <inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents contextRef="c52" decimals="0" unitRef="usd">1191000</inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents>
    <inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark contextRef="c52" decimals="0" unitRef="usd">216000</inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c52" decimals="0" unitRef="usd">2023039</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c52" decimals="0" unitRef="usd">5559412</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c52" decimals="0" unitRef="usd">1024487</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities contextRef="c52" decimals="0" unitRef="usd">598245</inm:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c52" decimals="0" unitRef="usd">122723</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c52" decimals="0" unitRef="usd">1745455</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c52" decimals="0" unitRef="usd">3813957</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c3" decimals="0" unitRef="usd">2656000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c49">P18Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:OperatingIncomeLoss contextRef="c50" decimals="-5" unitRef="usd">1100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Revenues contextRef="c50" decimals="-5" unitRef="usd">5200000</us-gaap:Revenues>
    <us-gaap:LegalFees contextRef="c0" decimals="-5" unitRef="usd">200000</us-gaap:LegalFees>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended June
    30&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,365,755&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,904,013&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: none; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,260,014&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,705,494&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c0" decimals="0" unitRef="usd">1365755</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c5" decimals="0" unitRef="usd">1904013</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-19260014</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-10705494</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;9.
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts
payable and accrued liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,166,068&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;775,129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;839,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Employee compensation, benefits and related accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;880,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;270,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169,641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,415,265&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,134,878&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,166,068&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;775,129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;839,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Employee compensation, benefits and related accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,120&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;880,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;270,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169,641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,415,265&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,134,878&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">1166068</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">775129</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <inm:AccruedResearchAndDevelopment contextRef="c3" decimals="0" unitRef="usd">839638</inm:AccruedResearchAndDevelopment>
    <inm:AccruedResearchAndDevelopment contextRef="c4" decimals="0" unitRef="usd">309901</inm:AccruedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="c3" decimals="0" unitRef="usd">139120</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="c4" decimals="0" unitRef="usd">880207</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c3" decimals="0" unitRef="usd">270439</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c4" decimals="0" unitRef="usd">169641</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">2415265</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">2134878</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <inm:ShareCapitalAndReservesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;10.
SHARE CAPITAL AND RESERVES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 7, 2022, the Company effected a one-for-25 reverse stock split of its issued and outstanding common shares. Accordingly, all
common share, stock option, per common share and warrant amounts for all periods presented in the consolidated financial statements and
notes thereto have been adjusted retrospectively to reflect this reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
at June 30, 2022, the Company&#x2019;s authorized share structure consisted of: (i) an unlimited number of common shares without par value;
and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as at June 30, 2022
and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company may issue preferred shares and may, at the time of issuance, determine the rights, preference and limitations pertaining to these
shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding
up of the Company before any payment is made to the holders of common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended June 30, 2022, the Company completed the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;July
2021 Private Placement Offering:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transaction
    Description&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issue
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74.325&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,645,970&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-funded Warrants
    Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,853&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74.3226&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,353,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,999,686&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated to Additional
    Paid-in Capital&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,540,635&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,459,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(247,336&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
July 2, 2021, the Company closed a private placement of its common shares and issued an aggregate of 35,600 common shares and 125,853
pre-funded warrants, for gross proceeds of $11,999,686. The pre-funded warrants were determined to be common stock equivalents. Each
common share and each pre-funded warrant were sold in the offering with a warrant to purchase a common share. Transaction costs were
allocated proportionally between common shares and warrants with $247,336 allocated to common shares and the balance of $1,786,831 allocated
to additional paid-in capital and recorded as a component of shareholders&#x2019; equity in the consolidated balance sheet. The 125,853
pre-funded warrants were fully exercised for 125,853 common shares during the year ended June 30, 2022, resulting in a $4,283,654 reclassification
from additional paid-in capital to common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
2022 Registered Direct and Private Placement Offerings:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transaction
    Description&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issue
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,002&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.450&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,394,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-funded Warrants
    Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168,099&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$'&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.4474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,605,294&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,999,580&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated to Additional
    Paid-in Capital&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,245,508&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;754,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(127,884&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
April 22, 2022, the Company issued 10,759 common shares under an at-the-market offering (&#x201c;ATM&#x201d;) for proceeds of $146,533,
net of issuance costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 6, 2022, the Company closed a registered direct offering and concurrent private placement of its common shares. In the registered
direct offering, the Company issued an aggregate of 65,002 common shares and 98,169 pre-funded warrants, for gross proceeds of $3,500,002.
In the concurrent private placement, the Company issued an aggregate of 69,930 pre-funded warrants for gross proceeds of $1,499,999.
The pre-funded warrants were determined to be common stock equivalents. Each common stock and each pre-funded warrant were sold in the
offerings with a preferred investment option to purchase a common share. Transaction costs were allocated proportionally between common
shares and warrants with $127,884 allocated to common shares and the balance of $719,964 allocated to additional paid-in capital and
recorded as a component of shareholders&#x2019; equity in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended June 30, 2022, in accordance with the BayMedica Agreement, the Company issued 82,000 common shares to BayMedica&#x2019;s
historical equity and convertible debt holders (See Note 8). In addition, the Company issued 78,312 common shares for consulting services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share Purchase
                                            Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
November 16, 2020, 71,200 warrants were issued with an exercise price of $127.75 per share, were immediately exercisable upon issuance,
and expire 6 years following the date of issuance. On June 6, 2022, the Company amended the warrants to re-price them to $18.50 per share
with an expiry date of June 6, 2029. Accordingly, the Company has calculated the incremental fair value from the modification to be $119,555
and is recognized as a warrant modification expense in the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
February 12, 2021, 27,720 warrants were issued with an exercise price of $121.25 per share, were exercisable 6 months following issuance,
and expire 5.5 years following the date of issuance. On March 21, 2022, the Company amended the warrants to re-price them to $11.25 per
share with an expiry date of March 31, 2023. Between March 21, 2022 and June 30, 2022, 15,606 of the warrants were exercised on a cashless
basis resulting in the issuance of 6,293 common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
July 2, 2021, 161,453 warrants were issued with an exercise price of $71.20 per share, were immediately exercisable upon issuance, and
expire 5 years following the date of issuance. The pre-funded and common warrants did not meet the criteria to be classified as a liability
award and therefore were treated as an equity award and recorded as a component of shareholders&#x2019; equity in the consolidated balance
sheet. On June 6, 2022, the Company amended the warrants to re-price them to $18.50 per share with an expiry date of June 6, 2029. Accordingly,
the Company has calculated the incremental fair value from the modification to be $1,194,752 and is recognized as a warrant modification
expense in the statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following is a summary of changes in share purchase warrants from July 1, 2021 to June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average &lt;br/&gt;Share Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;98,920&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif"&gt;75,47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,453&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,606&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30,
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;244,767&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
total intrinsic value of warrants exercised during the year ended June 30, 2022 was $125,611 (2021 - $&lt;span style="-sec-ix-hidden: hidden-fact-103"&gt;Nil&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Agents&#x2019;
                                            Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
July 2, 2021, 12,109 warrants were issued for services with an exercise price of $92.9075 per share, were immediately exercisable upon
issuance, and expire 5 years following the date of issuance. The agents&#x2019; warrants did not meet the criteria to be classified as
a liability award and therefore were treated as an equity award and recorded as a component of shareholders&#x2019; equity in the consolidated
balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following is a summary of changes in agents&#x2019; warrants from July 1, 2021 to June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average &lt;br/&gt;Share Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif"&gt;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,109&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92.9075&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30,
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,109&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92.9075&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Preferred Investment
                                            Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 6, 2022, 233,100 preferred investment options were issued with an exercise price of $19.75 per share, were immediately exercisable
upon issuance, and expire 6.5 years following the date of issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;f)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Agents&#x2019;
                                            Investment Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
June 6, 2022, 15,152 preferred investment options were issued for services with an exercise price of $26.8125 per share, were exercisable
4 months upon issuance, and expire 5 years following the date of issuance.&lt;/span&gt;&lt;/p&gt;</inm:ShareCapitalAndReservesTextBlock>
    <inm:ScheduleOfPrivatePlacementOfferingTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transaction
    Description&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issue
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,600&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74.325&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,645,970&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-funded Warrants
    Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,853&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74.3226&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,353,716&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,999,686&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated to Additional
    Paid-in Capital&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,540,635&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,459,051&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(247,336&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transaction
    Description&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issue
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,002&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.450&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,394,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pre-funded Warrants
    Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168,099&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$'&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.4474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,605,294&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,999,580&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Allocated to Additional
    Paid-in Capital&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,245,508&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;754,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(127,884&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</inm:ScheduleOfPrivatePlacementOfferingTableTextBlock>
    <us-gaap:SharesIssued contextRef="c74" decimals="INF" unitRef="shares">35600</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="c74" decimals="3" unitRef="usdPershares">74.325</us-gaap:SharesIssuedPricePerShare>
    <inm:TotalCommonShareValue contextRef="c75" decimals="0" unitRef="usd">2645970</inm:TotalCommonShareValue>
    <us-gaap:SharesIssued contextRef="c76" decimals="INF" unitRef="shares">125853</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="c76" decimals="4" unitRef="usdPershares">74.3226</us-gaap:SharesIssuedPricePerShare>
    <inm:TotalCommonShareValue contextRef="c77" decimals="0" unitRef="usd">9353716</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c78" decimals="0" unitRef="usd">11999686</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c79" decimals="0" unitRef="usd">-10540635</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c5" decimals="0" unitRef="usd">1459051</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c80" decimals="0" unitRef="usd">-247336</inm:TotalCommonShareValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c53" decimals="0" unitRef="shares">35600</us-gaap:StockIssuedDuringPeriodSharesOther>
    <inm:PrefundWarrants contextRef="c54" decimals="0" unitRef="shares">125853</inm:PrefundWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c53" decimals="0" unitRef="usd">11999686</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c53" decimals="0" unitRef="usd">247336</us-gaap:PaymentsOfStockIssuanceCosts>
    <inm:TransactionCostsAllocatedToAdditionalPaidinCapital contextRef="c53" decimals="0" unitRef="usd">1786831</inm:TransactionCostsAllocatedToAdditionalPaidinCapital>
    <inm:ExercisedCommonSharesDescription contextRef="c0">The 125,853
pre-funded warrants were fully exercised for 125,853 common shares during the year ended June 30, 2022, resulting in a $4,283,654 reclassification
from additional paid-in capital to common shares.</inm:ExercisedCommonSharesDescription>
    <us-gaap:SharesIssued contextRef="c81" decimals="INF" unitRef="shares">65002</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="c81" decimals="3" unitRef="usdPershares">21.45</us-gaap:SharesIssuedPricePerShare>
    <inm:TotalCommonShareValue contextRef="c82" decimals="0" unitRef="usd">1394286</inm:TotalCommonShareValue>
    <us-gaap:SharesIssued contextRef="c83" decimals="INF" unitRef="shares">168099</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="c83" decimals="4" unitRef="usdPershares">21.4474</us-gaap:SharesIssuedPricePerShare>
    <inm:TotalCommonShareValue contextRef="c84" decimals="0" unitRef="usd">3605294</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c85" decimals="0" unitRef="usd">4999580</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c86" decimals="0" unitRef="usd">-4245508</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c0" decimals="0" unitRef="usd">754072</inm:TotalCommonShareValue>
    <inm:TotalCommonShareValue contextRef="c87" decimals="0" unitRef="usd">-127884</inm:TotalCommonShareValue>
    <us-gaap:SharesIssued contextRef="c55" decimals="0" unitRef="shares">10759</us-gaap:SharesIssued>
    <inm:CommonSharesNetIssuance contextRef="c56" decimals="0" unitRef="usd">146533</inm:CommonSharesNetIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c57" decimals="0" unitRef="shares">65002</us-gaap:StockIssuedDuringPeriodSharesOther>
    <inm:PrefundWarrants contextRef="c58" decimals="0" unitRef="shares">98169</inm:PrefundWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c57" decimals="0" unitRef="usd">3500002</us-gaap:ProceedsFromIssuanceOfWarrants>
    <inm:PrefundedWarrants contextRef="c59" decimals="0" unitRef="usd">69930</inm:PrefundedWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c59" decimals="0" unitRef="usd">1499999</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c57" decimals="0" unitRef="usd">127884</us-gaap:PaymentsOfStockIssuanceCosts>
    <inm:TransactionCostsAllocatedToAdditionalPaidinCapital contextRef="c57" decimals="0" unitRef="usd">719964</inm:TransactionCostsAllocatedToAdditionalPaidinCapital>
    <us-gaap:CommonStockSharesIssued contextRef="c60" decimals="0" unitRef="shares">82000</us-gaap:CommonStockSharesIssued>
    <inm:CommonSharesConsultingServices contextRef="c61" decimals="0" unitRef="shares">78312</inm:CommonSharesConsultingServices>
    <inm:IPOWarrantIssue contextRef="c62" decimals="0" unitRef="shares">71200</inm:IPOWarrantIssue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c63" decimals="2" unitRef="usdPershares">127.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c62">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c58" decimals="2" unitRef="usdPershares">18.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inm:WarrantExpiryDate contextRef="c57">2029-06-06</inm:WarrantExpiryDate>
    <inm:WarrantsModificationExpense contextRef="c57" decimals="0" unitRef="usd">119555</inm:WarrantsModificationExpense>
    <inm:IPOWarrantIssue contextRef="c64" decimals="0" unitRef="shares">27720</inm:IPOWarrantIssue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c65" decimals="2" unitRef="usdPershares">121.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c64">P6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c65">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c66" decimals="2" unitRef="usdPershares">11.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inm:WarrantExpiryDate contextRef="c67">2023-03-31</inm:WarrantExpiryDate>
    <inm:WarrantsIssued contextRef="c66" decimals="0" unitRef="shares">15606</inm:WarrantsIssued>
    <inm:IssuanceOfCommonSharesIssued contextRef="c67" decimals="0" unitRef="shares">6293</inm:IssuanceOfCommonSharesIssued>
    <inm:IPOWarrantIssue contextRef="c53" decimals="0" unitRef="shares">161453</inm:IPOWarrantIssue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c54" decimals="2" unitRef="usdPershares">71.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c53">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c53" decimals="2" unitRef="usdPershares">18.5</us-gaap:WarrantExercisePriceDecrease>
    <inm:WarrantsModificationExpense contextRef="c53" decimals="0" unitRef="usd">1194752</inm:WarrantsModificationExpense>
    <inm:ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average &lt;br/&gt;Share Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;98,920&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif"&gt;75,47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;161,453&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,606&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,611&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30,
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;244,767&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;41.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</inm:ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock>
    <inm:ShareCapitalOfNumberOfBalance contextRef="c88" decimals="INF" unitRef="shares">98920</inm:ShareCapitalOfNumberOfBalance>
    <inm:ShareBasedPaymentNumberOfGranted contextRef="c89" decimals="INF" unitRef="shares">161453</inm:ShareBasedPaymentNumberOfGranted>
    <inm:WeightedAverageSharePriceGranted contextRef="c89" decimals="2" unitRef="usdPershares">18.5</inm:WeightedAverageSharePriceGranted>
    <inm:ShareBasedPaymentNumberOfExercised contextRef="c0" decimals="INF" unitRef="shares">-15606</inm:ShareBasedPaymentNumberOfExercised>
    <inm:ShareBasedPaymentsWeightedAverageSharePriceExercised contextRef="c0" decimals="2" unitRef="shares">11.25</inm:ShareBasedPaymentsWeightedAverageSharePriceExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c3" decimals="0" unitRef="usd">125611</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <inm:ShareCapitalOfNumberOfBalance contextRef="c90" decimals="INF" unitRef="shares">244767</inm:ShareCapitalOfNumberOfBalance>
    <inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance contextRef="c90" decimals="2" unitRef="usdPershares">41.99</inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c3" decimals="0" unitRef="usd">125611</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <inm:WarrantsIssued contextRef="c68" decimals="0" unitRef="shares">12109</inm:WarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c68" decimals="4" unitRef="usdPershares">92.9075</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c69">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <inm:ScheduleOfChangesInAgentsWarrantsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average &lt;br/&gt;Share Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif"&gt;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;&#x202f;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,109&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92.9075&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30,
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,109&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;92.9075&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</inm:ScheduleOfChangesInAgentsWarrantsTableTextBlock>
    <inm:ShareBasedPaymentSharesNumberOfGranted contextRef="c92" decimals="INF" unitRef="shares">12109</inm:ShareBasedPaymentSharesNumberOfGranted>
    <inm:ShareBasedPaymentWeightedAverageSharePriceGranted contextRef="c92" decimals="4" unitRef="usdPershares">92.9075</inm:ShareBasedPaymentWeightedAverageSharePriceGranted>
    <inm:ShareBasedPaymentNumberOfBalanceAtEnding contextRef="c91" decimals="INF" unitRef="shares">12109</inm:ShareBasedPaymentNumberOfBalanceAtEnding>
    <inm:ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding contextRef="c91" decimals="4" unitRef="usdPershares">92.9075</inm:ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding>
    <inm:WarrantsIssued contextRef="c70" decimals="0" unitRef="shares">233100</inm:WarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c70" decimals="2" unitRef="usdPershares">19.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c71">P6Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <inm:WarrantsIssued contextRef="c72" decimals="0" unitRef="shares">15152</inm:WarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c72" decimals="4" unitRef="usdPershares">26.8125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inm:WarrantsIssuanceTerm contextRef="c73">P4M</inm:WarrantsIssuanceTerm>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c73">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;11. SHARE-BASED PAYMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Option Plan Details&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
March 24, 2017, and as amended on November 20, 2020, the Company&#x2019;s shareholders approved: (i) the adoption of a new stock option
plan (the &#x201c;Plan&#x201d;) pursuant to which the Board of Directors may, from time to time, in its discretion and in accordance with
regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase
common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (20%) of the issued and
outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the new
stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company&#x2019;s
previous stock option plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As at June 30, 2022, there were 18,163
(June 30, 2021 &#x2013; 19,735) options available for future allocation pursuant to the terms of the Plan. The option price under each
option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board
of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
options granted prior to May 2021 were granted with Canadian dollar exercise prices (United States dollar amounts for weighted average
exercise prices and aggregate intrinsic value are calculated using prevailing rates as at June 30, 2022). Commencing in May 2021, stock
options are granted with United States dollar exercise prices.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following is a summary of changes in outstanding options from July 1, 2021 to June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;br/&gt;
$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,472&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;215.35&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,029&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122.38&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,603&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and exercisable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,182&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;228.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair Value
                                            of Options Issued During the Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -21.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;i)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
                                            Average Fair Value at Grant Date of Options Granted:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
weighted average fair value at grant date of options granted during the year ended June 30, 2022, was $21.04 per option (year ended June
30, 2021 - $49.03). Assumptions used for options granted during the year ended June 30, 2022 included a weighted average risk-free interest
rate of 1.17% (year ended June 30, 2021 &#x2013; 0.27%), weighted average expected life of 3.1 years calculated using the Simplified Method
for directors, officers and employees and the contractual life for consultants, weighted average volatility factor of 97.15% (year ended
June 30, 2021 &#x2013; 105.88%), weighted average dividend yield of 0% (year ended June 30, 2021 &#x2013; 0%) and a 5% forfeiture rate
(year ended June 30, 2021 &#x2013; 5%).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ii)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expenses
                                            Arising from Share-based Payment Transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
expenses arising from share-based payment transactions recognized during the year ended June 30, 2022, were $697,894 (2021 - $610,193).
$419,075 was allocated to general and administrative expenses (2021 - $405,801) and the remaining $278,819 was allocated to research
and development expenses (2021 - $204,392). Unrecognized compensation cost at June 30, 2022 related to unvested options was $292,959
which will be recognized over a weighted-average vesting period of 1.0 years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <inm:IssuedAndOutstandingPercentage contextRef="c93" decimals="2" unitRef="pure">0.20</inm:IssuedAndOutstandingPercentage>
    <inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross contextRef="c3" decimals="0" unitRef="shares">18163</inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross>
    <inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross contextRef="c4" decimals="0" unitRef="shares">19735</inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;br/&gt;
$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,472&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;215.35&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(12,029&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122.38&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55,603&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and exercisable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,182&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;228.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers contextRef="c4" decimals="0" unitRef="shares">36472</inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="cadPershares">215.35</inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c0" decimals="0" unitRef="shares">31160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <inm:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted contextRef="c0" decimals="2" unitRef="cadPershares">34.2</inm:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c0" decimals="0" unitRef="shares">12029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <inm:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited contextRef="c0" decimals="2" unitRef="cadPershares">122.38</inm:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited>
    <inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers contextRef="c3" decimals="0" unitRef="shares">55603</inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <inm:ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="shares">128.59</inm:ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice>
    <inm:NumberOfVestedAndExercisable contextRef="c0" decimals="0" unitRef="shares">26182</inm:NumberOfVestedAndExercisable>
    <inm:WeightedAverageExercisePriceVestedAndExercisable contextRef="c0" decimals="2" unitRef="cadPershares">228.87</inm:WeightedAverageExercisePriceVestedAndExercisable>
    <inm:NumberOfUnvested contextRef="c0" decimals="0" unitRef="shares">29421</inm:NumberOfUnvested>
    <inm:WeightedAverageExercisePriceUnvested contextRef="c0" decimals="2" unitRef="cadPershares">39.35</inm:WeightedAverageExercisePriceUnvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c3" decimals="2" unitRef="usdPershares">21.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c4" decimals="2" unitRef="usdPershares">49.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" unitRef="pure">0.0117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="4" unitRef="pure">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c0" decimals="4" unitRef="pure">0.9715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c5" decimals="4" unitRef="pure">1.0588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <inm:WeightedAverageForfeitureRate contextRef="c0" decimals="2" unitRef="pure">0.05</inm:WeightedAverageForfeitureRate>
    <inm:WeightedAverageForfeitureRate contextRef="c5" decimals="2" unitRef="pure">0.05</inm:WeightedAverageForfeitureRate>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" unitRef="usd">697894</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="0" unitRef="usd">610193</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c94" decimals="0" unitRef="usd">419075</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c95" decimals="0" unitRef="usd">405801</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c96" decimals="0" unitRef="usd">278819</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c97" decimals="0" unitRef="usd">204392</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c3" decimals="0" unitRef="usd">292959</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c0">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;12. LEASE OBLIGATIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In conjunction with the acquisition
of BayMedica (Note 8), the Company acquired an operating lease for a corporate office with a remaining term of 1.8 years as at June 30,
2022. On the date of acquisition of BayMedica, the Company recognized right-of-use assets of $728,115 and a lease liability of $825,427,
utilizing the remaining term on acquisition and a 4.0% discount rate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;The Company is committed to minimum lease payments as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity Analysis&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431,169&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;396,665&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;More than five years &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total undiscounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;827,834&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -1.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Excludes estimated variable operating costs of $92,964 and $60,916 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c3">P1Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" unitRef="usd">728115</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" unitRef="usd">825427</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c3" decimals="3" unitRef="pure">0.04</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity Analysis&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;431,169&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;396,665&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;More than five years &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total undiscounted lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;827,834&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -1.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <inm:LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths contextRef="c3" decimals="0" unitRef="usd">431169</inm:LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths>
    <inm:LesseeOperatingLeaseLiabilityPaymentDueYearFive contextRef="c3" decimals="0" unitRef="usd">396665</inm:LesseeOperatingLeaseLiabilityPaymentDueYearFive>
    <inm:LesseeOperatingLeaseLiabilityPaymentDue contextRef="c3" decimals="0" id="ix_0_fact" unitRef="usd">827834</inm:LesseeOperatingLeaseLiabilityPaymentDue>
    <us-gaap:VariableLeaseCost contextRef="c98" decimals="0" unitRef="usd">92964</us-gaap:VariableLeaseCost>
    <inm:OtherVariableLeaseCost contextRef="c99" decimals="0" unitRef="usd">60916</inm:OtherVariableLeaseCost>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;13.
BASIC AND DILUTED LOSS PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding
during the period. The pre-funded warrants were determined to be common stock equivalents and have been included in the weighted average
number of shares outstanding for calculation of the basic earnings per share number. As the outstanding stock options and warrants are
anti-dilutive, they are excluded from the weighted average number of common shares in the table below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,600,117&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(33.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(37.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number of common shares
    - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;560,829&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;268,793&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,600,117&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(33.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(37.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number of common shares
    - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;560,829&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;268,793&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-18600117</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-10203089</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-33.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-37.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">560829</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">268793</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax
rate of 27.0% (June 30, 2021 &#x2013; 27.0%) to the tax expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,600,117&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax expense (recovery) at the statutory
    rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,710,669&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,754,834&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase (reduction) in income taxes resulting
    from:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,112,045&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,109,545&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(220,491&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;613,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99,490&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;591,263&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share issuance cost
    capitalized in equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(582,548&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(390,685&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;197,131&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,484&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax expense (recovery)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
tax assets and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-capital losses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,003,766&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,742,381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,004&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financing costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;702,479&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;434,399&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;193,549&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;553,392&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248,254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,994&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,108&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,753,434&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,228,892&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(181,845&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,546&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(55,260&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(77,612&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71,806&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(259,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,681,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,969,435&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,681,628&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13,969,435&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
full valuation allowance has been applied against the net deferred tax assets because it is not more likely than not that future taxable
income will be available against which the Company can utilize the benefits therefrom.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
at June 30, 2022, the Company has non-capital loss carry-forwards of approximately $62,921,785 (June 30, 2021 - $50,897,706) available
to offset future taxable income in Canada and the United States. These non-capital loss carryforwards begin to expire in 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company recognizes tax benefits
from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities,
based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from any such position
would be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.
It is the Company&#x2019;s policy to recognize interest and penalties accrued on any uncertain tax benefits as a component of income tax
expense. There were no uncertain tax positions as of June 30, 2022 or 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company files income tax returns
in the U.S. federal jurisdiction, various state jurisdictions, and Canada. With few exceptions, the Company is no longer subject to U.S.
federal and state tax examinations for fiscal years prior to 2019.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company is subject to taxation
at the federal, state, and local levels in the United States and Canada.&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" unitRef="pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="3" unitRef="pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,600,117&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax expense (recovery) at the statutory
    rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,710,669&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,754,834&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase (reduction) in income taxes resulting
    from:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,112,045&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,109,545&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(220,491&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;613,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99,490&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;591,263&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,074,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share issuance cost
    capitalized in equity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(582,548&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(390,685&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;197,131&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,484&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax expense (recovery)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-18600117</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-10203089</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" unitRef="usd">-4710669</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="0" unitRef="usd">-2754834</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" unitRef="usd">4112045</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" unitRef="usd">4109545</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="0" unitRef="usd">-220491</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c0" decimals="0" unitRef="usd">613269</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c5" decimals="0" unitRef="usd">99490</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="0" unitRef="usd">591263</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c5" decimals="0" unitRef="usd">-1074000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c0" decimals="0" unitRef="usd">-582548</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c5" decimals="0" unitRef="usd">-390685</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="c0" decimals="0" unitRef="usd">197131</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="c5" decimals="0" unitRef="usd">10484</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-capital losses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,003,766&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,742,381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,004&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financing costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;702,479&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;434,399&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;193,549&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;553,392&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248,254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,994&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,108&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,753,434&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,228,892&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(181,845&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,546&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(55,260&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(77,612&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(71,806&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(259,457&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,681,628&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,969,435&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,681,628&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13,969,435&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">17003766</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c4" decimals="0" unitRef="usd">13742381</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <inm:DeferredTaxAssetsPropertyAndEquipmentsNet contextRef="c4" decimals="0" unitRef="usd">1004</inm:DeferredTaxAssetsPropertyAndEquipmentsNet>
    <inm:DeferredTaxAssetsFinancingCost contextRef="c3" decimals="0" unitRef="usd">702479</inm:DeferredTaxAssetsFinancingCost>
    <inm:DeferredTaxAssetsFinancingCost contextRef="c4" decimals="0" unitRef="usd">434399</inm:DeferredTaxAssetsFinancingCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c3" decimals="0" unitRef="usd">193549</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c3" decimals="0" unitRef="usd">553392</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c3" decimals="0" unitRef="usd">248254</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <inm:LeaseLiabilities contextRef="c3" decimals="0" unitRef="usd">-51994</inm:LeaseLiabilities>
    <inm:LeaseLiabilities contextRef="c4" decimals="0" unitRef="usd">-51108</inm:LeaseLiabilities>
    <inm:DeferredTaxAssetsAndLiabilitiesGross contextRef="c3" decimals="0" unitRef="usd">18753434</inm:DeferredTaxAssetsAndLiabilitiesGross>
    <inm:DeferredTaxAssetsAndLiabilitiesGross contextRef="c4" decimals="0" unitRef="usd">14228892</inm:DeferredTaxAssetsAndLiabilitiesGross>
    <inm:DeferredTaxAssetsIntangibleAssetsNet contextRef="c4" decimals="0" unitRef="usd">-181845</inm:DeferredTaxAssetsIntangibleAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">16546</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <inm:DeferredTaxAssetsLeaseObligations contextRef="c3" decimals="0" unitRef="usd">-55260</inm:DeferredTaxAssetsLeaseObligations>
    <inm:DeferredTaxAssetsLeaseObligations contextRef="c4" decimals="0" unitRef="usd">-77612</inm:DeferredTaxAssetsLeaseObligations>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c3" decimals="0" unitRef="usd">71806</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c4" decimals="0" unitRef="usd">259457</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="0" unitRef="usd">18681628</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="0" unitRef="usd">13969435</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">18681628</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" unitRef="usd">13969435</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">62921785</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="0" unitRef="usd">50897706</us-gaap:OperatingLossCarryforwards>
    <inm:RecognizedTaxBenefits contextRef="c0" decimals="2" unitRef="pure">0.50</inm:RecognizedTaxBenefits>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;15. SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;As of the closing of the BayMedica
acquisition, the Company aligned into two operating and reportable segments, the InMed segment and the BayMedica segment. The Company
reports segment information based on the management approach which designates the internal reporting used by the Chief Operating Decision
Maker (&#x201c;CODM&#x201d;), which is the Company&#x2019;s Chief Executive Officer, for making decisions and assessing performance as the
source of the Company&#x2019;s reportable segments. The CODM allocates resources and assesses the performance of each operating segment
based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss)
before interest and taxes. The Company has determined its reportable segments to be InMed and BayMedica based on the information used
by the CODM. Other than cash, cash equivalents and short-term investments (&#x201c;Unrestricted cash&#x201d;) balances, the CODM does not
regularly review asset information by reportable segment and therefore, the Company does not report asset information by reportable segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
InMed segment is largely organized around the research and development of cannabinoid-based pharmaceuticals products and the BayMedica
segment is largely organized around developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health
and wellness industry.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents information about the Company&#x2019;s reportable segments for the year ended June 30, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    Ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;InMed&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;BayMedica&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;InMed&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;BayMedica&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,089,435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,089,435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,410,753&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,278,799&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,689,552&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13,410,753&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,189,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,600,117&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrestricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,984,622&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,244&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    Ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;InMed&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;BayMedica&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;InMed&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;BayMedica&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,089,435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,089,435&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,410,753&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,278,799&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,689,552&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(13,410,753&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,189,364&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(18,600,117&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,203,089&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrestricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,984,622&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192,244&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c101" decimals="0" unitRef="usd">1089435</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">1089435</us-gaap:Revenues>
    <inm:OtherOperatingExpenses contextRef="c100" decimals="0" unitRef="usd">13410753</inm:OtherOperatingExpenses>
    <inm:OtherOperatingExpenses contextRef="c101" decimals="0" unitRef="usd">6278799</inm:OtherOperatingExpenses>
    <inm:OtherOperatingExpenses contextRef="c0" decimals="0" unitRef="usd">19689552</inm:OtherOperatingExpenses>
    <inm:OtherOperatingExpenses contextRef="c102" decimals="0" unitRef="usd">10203089</inm:OtherOperatingExpenses>
    <inm:OtherOperatingExpenses contextRef="c5" decimals="0" unitRef="usd">10203089</inm:OtherOperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c100" decimals="0" unitRef="usd">-13410753</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c101" decimals="0" unitRef="usd">-5189364</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-18600117</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c102" decimals="0" unitRef="usd">-10203089</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-10203089</us-gaap:OperatingIncomeLoss>
    <us-gaap:RestrictedCashNoncurrent contextRef="c104" decimals="0" unitRef="usd">5984622</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c105" decimals="0" unitRef="usd">192244</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="0" unitRef="usd">6176866</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c106" decimals="0" unitRef="usd">7363126</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c4" decimals="0" unitRef="usd">7363126</us-gaap:RestrictedCashNoncurrent>
    <inm:NonCashTransactionsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;16. NON-CASH TRANSACTIONS&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Investing and financing activities that
do not have a direct impact on cash flows are excluded from the statements of cash flows. During the year ended June 30, 2022, the following
transactions were excluded from the statement of cash flows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 2, 2021, the Company issued warrants to its placement agent. The fair value of these warrants was $739,920 and was included in share issuance costs related to the July 2021 private placement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 13, 2021, the Company issued 82,000 common shares to BayMedica&#x2019;s equity and convertible debt holders, pursuant to the BayMedica Agreement. The estimated fair value of these common shares was $3,013,500 and was included in the total consideration for the acquisition of BayMedica (see Note 8). On acquisition of BayMedica, the loan receivable from BayMedica of $425,000 was settled (see Note 8).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;iii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 1, 2022, the Company issued 3,132 common shares for consulting services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;iv)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On June 6, 2022, the Company issued 15,152 preferred investment options to its placement agent. The fair value of these investment options was $192,491 and was included in share issuance costs related to the June 2022 registered direct and private placement offerings.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;v)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,606 warrants were exercised on a cashless basis resulting in the issuance of 6,293 common shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;vi)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As at June 30, 2022, the Company has unpaid financing costs of $26,587.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
the year ended June 30, 2021, the following transaction was excluded from the statement of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As at June 30, 2021, the Company has unpaid financing costs of $164,812.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</inm:NonCashTransactionsTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c108" decimals="0" unitRef="usd">739920</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CommonUnitIssued contextRef="c109" decimals="0" unitRef="shares">82000</us-gaap:CommonUnitIssued>
    <inm:EstimatedFairValueCommonShares contextRef="c109" decimals="0" unitRef="usd">3013500</inm:EstimatedFairValueCommonShares>
    <us-gaap:LoansReceivableFairValueDisclosure contextRef="c109" decimals="0" unitRef="usd">425000</us-gaap:LoansReceivableFairValueDisclosure>
    <us-gaap:CommonUnitIssued contextRef="c110" decimals="0" unitRef="shares">3132</us-gaap:CommonUnitIssued>
    <us-gaap:PreferredUnitsIssued contextRef="c58" decimals="0" unitRef="shares">15152</us-gaap:PreferredUnitsIssued>
    <us-gaap:InvestmentOwnedAtFairValue contextRef="c3" decimals="0" unitRef="usd">192491</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c3" decimals="0" unitRef="shares">15606</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c3" decimals="0" unitRef="shares">6293</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">26587</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">164812</us-gaap:DeferredCostsCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;17.
COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the terms of agreements with various contract research organizations, as at June 30, 2022, the Company is committed for contract research
services and materials at a cost of approximately $2,910,529. A total of $2,149,619 of these expenditures are expected to occur in the
twelve months following June 30, 2022 and the balance of $760,910 in the following twelve month period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the terms of agreements with various vendors, as at June 30, 2022, the Company is committed for contract materials and equipment at
a cost of approximately $634,092, expected to occur in the twelve months following June 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia (&#x201c;UBC&#x201d;),
the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of
certain drug products that are covered by the agreement. To date, no payments have been required to be made.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the terms of a December 13, 2018 Collaborative Research Agreement with UBC in which the Company owns all rights, title and interests
in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon
filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the terms of a November 1, 2018 Contribution Agreement with National Research Council Canada, as represented by its Industrial Research
Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual
property developed in part with NRC-IRAP contributions, may become repayable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term
investments include guaranteed investment certificates with a face value of $44,676 (June 30, 2021 - $46,391) that are pledged as security
for a corporate credit card.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are
common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently
holds commercial general liability insurance. This insurance limits the Company&#x2019;s liability and may enable the Company to recover
a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and it
believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities
relating to these obligations for any period presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to a technology licensing agreement, the Company is committed to issue, subject to regulatory approval, up to 700 warrants to purchase
700 common shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of
the common shares prior to each milestone achievement and the warrants will be exercisable for a period of three years for issuance date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company entered into a patent license agreement with a third party (the &#x201c;Licensor&#x201d;) in an agreement dated February 15, 2021.
The Company is required to make future royalty payments to Licensor based on net sales of licensed products, with minimum payments required
starting in 2021. In December 2021, the Company amended the License Agreement including the deferral of the 2021 minimum payments to
2022. As at June 30, 2022, the Company has paid $300,000 for the minimum payments under the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;From
time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of
business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility
that a material loss may be incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <inm:CostOfServicesDirectsMaterials contextRef="c3" decimals="0" unitRef="usd">2910529</inm:CostOfServicesDirectsMaterials>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c0" decimals="0" unitRef="usd">2149619</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <inm:ExpenditureBalance contextRef="c0" decimals="0" unitRef="usd">760910</inm:ExpenditureBalance>
    <us-gaap:CostDirectMaterial contextRef="c0" decimals="0" unitRef="usd">634092</us-gaap:CostDirectMaterial>
    <inm:GuaranteedInvestment contextRef="c3" decimals="0" unitRef="usd">44676</inm:GuaranteedInvestment>
    <inm:GuaranteedInvestment contextRef="c4" decimals="0" unitRef="usd">46391</inm:GuaranteedInvestment>
    <inm:WarrantsToPurchase contextRef="c0" decimals="0" unitRef="shares">700</inm:WarrantsToPurchase>
    <inm:CommonShares contextRef="c0" decimals="0" unitRef="shares">700</inm:CommonShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">300000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <inm:FinancialRiskManagementTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;18.
FINANCIAL RISK MANAGEMENT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair values of short-term investments, accounts receivable, and accounts payable and accrued liabilities approximate their carrying values
because of the short-term nature of these instruments. Cash and cash equivalents are measured at fair value using Level 1 inputs. The
Company measured its derivative warrant liabilities at fair value on a recurring basis using level 3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the fair values and carrying values of the Company&#x2019;s financial instruments at June 30, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
    1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
    2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,804&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,804&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;132,831&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,309,697&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable and
    accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,462&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,462&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;58,381&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,421,507&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable and
    accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Market Risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Market
risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices.
Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk.
The Company does not currently have significant commodity price risk or equity price risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Foreign
Currency Risk&lt;/i&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign
currency risk is the risk that the future cash flows or fair value of the Company&#x2019;s financial instruments that are denominated
in a currency that is not the Company&#x2019;s functional currency (U.S. dollar) will fluctuate due to changes in foreign exchange rates.
Portions of the Company&#x2019;s cash and cash equivalents and accounts payable and accrued liabilities are denominated in Canadian dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accordingly,
the Company is exposed to fluctuations in exchange rates, primarily against the Canadian dollar.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
at June 30, 2022, the Company has a net excess of Canadian dollar denominated cash and cash equivalents in excess of Canadian dollar
denominated accounts payable and accrued liabilities of C$2,052,109 which is equivalent to US$1,592,436 at the June 30, 2022 exchange
rate. The Canadian dollar financial assets generally result from holding Canadian dollar cash to settle anticipated near-term accounts
payable and accrued liabilities denominated in Canadian dollars. The Canadian dollar financial liabilities generally result from purchases
of supplies and services from suppliers in Canada.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Each
change of 1% in the Canadian dollar in relation to the U.S. dollar results in a gain or loss, with a corresponding effect on cash flows,
of $15,924 based on the June 30, 2022 net Canadian dollar assets (liabilities) position. During the year ended June 30, 2022, the Company
recorded foreign exchange loss of $107,433 (2021 &#x2013; gain of $80,713) related to Canadian dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Interest
Rate Risk:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at June 30, 2022, holdings
of cash and cash equivalents of $5,087,615 (June 30, 2021 - $7,053,329) are subject to floating interest rates. The balance of the Company&#x2019;s
cash holdings of $1,089,251 (June 30, 2021 - $309,796) are non-interest bearing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
at June 30, 2022, the Company held variable rate guaranteed investment certificates, with one-year terms, of $44,676 (June 30, 2021 -
$46,391).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s current policy is to invest excess cash in guaranteed investment certificates or interest-bearing accounts of major Canadian
chartered banks or credit unions with comparable credit ratings. The Company regularly monitors compliance to its cash management policy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Credit Risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Credit
risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual
obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash and cash equivalents,
short-term investments and loan receivable. Cash and cash equivalents and short-term investments are maintained with financial institutions
of reputable credit and may be redeemed upon demand. In the normal course of business, the Company does not provide third party loans.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash
and cash equivalents and short-term investments with high-credit quality financial institutions and management considers this risk to
be minimal for all cash and cash equivalents and short-term investments assets based on changes that are reasonably possible at each
reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liquidity
                                            Risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Liquidity
risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company&#x2019;s policy is
to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without
incurring unacceptable losses or risking damage to the Company&#x2019;s reputation. A key risk in managing liquidity is the degree of
uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at June 30, 2022,
the Company has cash and cash equivalents and short-term investments of $6,221,670 (June 30, 2021 - $7,409,588), current liabilities
of $3,181,316 (June 30, 2021 - $2,215,361) and a working capital surplus of $6,416,460 (June 30, 2021 - $6,162,908).&lt;/span&gt;&lt;/p&gt;</inm:FinancialRiskManagementTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;June 30,
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
    1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
    2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,804&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,804&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,176,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;132,831&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,309,697&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable and
    accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,415,265&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,462&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,462&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,363,126&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;58,381&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,421,507&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable and
    accrued Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,134,878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c112" decimals="0" unitRef="usd">6176866</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">6176866</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c113" decimals="0" unitRef="usd">44804</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="0" unitRef="usd">44804</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c113" decimals="0" unitRef="usd">88027</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">88027</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c112" decimals="0" unitRef="usd">6176866</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c113" decimals="0" unitRef="usd">132831</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c3" decimals="0" unitRef="usd">6309697</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c113" decimals="0" unitRef="usd">2415265</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">2415265</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c113" decimals="0" unitRef="usd">2415265</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c3" decimals="0" unitRef="usd">2415265</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c114" decimals="0" unitRef="usd">7363126</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">7363126</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c115" decimals="0" unitRef="usd">46462</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c4" decimals="0" unitRef="usd">46462</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c115" decimals="0" unitRef="usd">11919</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" unitRef="usd">11919</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c114" decimals="0" unitRef="usd">7363126</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c115" decimals="0" unitRef="usd">58381</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c4" decimals="0" unitRef="usd">7421507</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c115" decimals="0" unitRef="usd">2134878</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">2134878</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c115" decimals="0" unitRef="usd">2134878</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c4" decimals="0" unitRef="usd">2134878</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c3" decimals="0" unitRef="cad">2052109</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c3" decimals="0" unitRef="usd">1592436</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <inm:ForeignCurrencyRiskPercentage contextRef="c111" decimals="2" unitRef="pure">0.01</inm:ForeignCurrencyRiskPercentage>
    <us-gaap:DebtSecuritiesGainLoss contextRef="c111" decimals="0" unitRef="usd">15924</us-gaap:DebtSecuritiesGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="c0" decimals="0" unitRef="usd">107433</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="c5" decimals="0" unitRef="usd">80713</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:Cash contextRef="c3" decimals="0" unitRef="usd">5087615</us-gaap:Cash>
    <us-gaap:Cash contextRef="c4" decimals="0" unitRef="usd">7053329</us-gaap:Cash>
    <us-gaap:OtherMinorityInterests contextRef="c3" decimals="0" unitRef="usd">1089251</us-gaap:OtherMinorityInterests>
    <us-gaap:OtherMinorityInterests contextRef="c4" decimals="0" unitRef="usd">309796</us-gaap:OtherMinorityInterests>
    <us-gaap:OtherShortTermInvestments contextRef="c3" decimals="0" unitRef="usd">44676</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c4" decimals="0" unitRef="usd">46391</us-gaap:OtherShortTermInvestments>
    <inm:ShortTermInvestment contextRef="c3" decimals="0" unitRef="usd">6221670</inm:ShortTermInvestment>
    <inm:ShortTermInvestment contextRef="c4" decimals="0" unitRef="usd">7409588</inm:ShortTermInvestment>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">3181316</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">2215361</us-gaap:OtherLiabilitiesCurrent>
    <inm:workingCapitalSurplus contextRef="c3" decimals="0" unitRef="usd">6416460</inm:workingCapitalSurplus>
    <inm:workingCapitalSurplus contextRef="c4" decimals="0" unitRef="usd">6162908</inm:workingCapitalSurplus>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;19.
RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright
Canada LLP (&#x201c;NRF&#x201d;). From February 11, 2022 to June 30, 2022, NRF rendered legal services in the amount of $345,935 (2021
- $&lt;span style="-sec-ix-hidden: hidden-fact-133"&gt;Nil&lt;/span&gt;) to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented
the amount of consideration established and agreed to by NRF.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <inm:LegalService contextRef="c116" decimals="0" unitRef="usd">345935</inm:LegalService>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;20.
SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -21.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
July 2022, 69,930 of the June 2022 pre-funded warrants were exercised resulting in the issuance of 69,930 common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 7, 2022, the Company consolidated all of its issued and outstanding share capital on the basis of one post-consolidation share
for each twenty-five pre-consolidation common shares of the Company in order to regain compliance with all of Nasdaq&#x2019;s continued
listing requirements. Accordingly, all common share, stock option, per common share and warrant amounts for all periods presented in the
consolidated financial statements and notes thereto have been adjusted retrospectively to reflect this reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 7, 2022, 22,920 of the June 2022 pre-funded warrants were exercised resulting in the issuance of 22,920 common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: -1.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 13, 2022, the Company closed a $6.0 million private placement. Under the terms of the private placement, an aggregate of 691,245
common shares, or common share equivalents, and investment options to purchase up to an aggregate of 1,382,490 common shares, at an effective
purchase price of $8.68 per common share and associated investment options. The warrants have an exercise price of $8.44 per share, are
exercisable immediately and have a term of seven years. After deducting the placement agent fees, the Company received net proceeds of
approximately $5.4 million.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c117" decimals="0" unitRef="shares">69930</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c117" decimals="0" unitRef="shares">69930</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c118" decimals="0" unitRef="shares">22920</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c118" decimals="0" unitRef="shares">22920</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c119" decimals="-5" unitRef="usd">6000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SharesIssued contextRef="c120" decimals="0" unitRef="shares">691245</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="c121" decimals="0" unitRef="shares">1382490</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="c122" decimals="2" unitRef="usdPershares">8.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockOptionExercisePriceDecrease contextRef="c119" decimals="2" unitRef="usdPershares">8.44</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:DebtInstrumentTerm contextRef="c119">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c119" decimals="-5" unitRef="usd">5400000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <dei:AuditorFirmId contextRef="c0">85</dei:AuditorFirmId>
    <us-gaap:InventoryNet
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AcquisitionConsiderationPayable
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="c0" id="hidden-fact-2">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="c5" id="hidden-fact-3">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockNoParValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c5"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="c5"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="c0"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:WarrantModificationExpense
      contextRef="c5"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="c0"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-14"
      unitRef="usdPershares">-33.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-15"
      unitRef="usdPershares">-37.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c5"
      decimals="0"
      id="hidden-fact-16"
      unitRef="shares">268793</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c0"
      decimals="0"
      id="hidden-fact-17"
      unitRef="shares">560829</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c12"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c13"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c14"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement
      contextRef="c13"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement
      contextRef="c14"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c11"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c13"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c14"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareIssuanceCosts
      contextRef="c13"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareIssuanceCosts
      contextRef="c14"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:LossAndComprehensiveIncomelossesForThePeriod
      contextRef="c11"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:LossAndComprehensiveIncomelossesForThePeriod
      contextRef="c12"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c11"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c13"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c14"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement
      contextRef="c21"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:StockIssuedDuringPeriodValueIssuedForPrivatePlacement
      contextRef="c22"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ATMOfferingNetOfIssuanceCosts
      contextRef="c20"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ATMOfferingNetOfIssuanceCosts
      contextRef="c21"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ATMOfferingNetOfIssuanceCosts
      contextRef="c22"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:RegisteredDirectAndPrivatePlacement
      contextRef="c21"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:RegisteredDirectAndPrivatePlacement
      contextRef="c22"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareIssuanceCosts
      contextRef="c21"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareIssuanceCosts
      contextRef="c22"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AgentsWarrants
      contextRef="c19"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AgentsWarrants
      contextRef="c21"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AgentsWarrants
      contextRef="c22"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AgentsInvestmentOptions
      contextRef="c19"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AgentsInvestmentOptions
      contextRef="c21"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AgentsInvestmentOptions
      contextRef="c22"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ExerciseOfPrefundedWarrants
      contextRef="c21"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ExerciseOfPrefundedWarrants
      contextRef="c22"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ExerciseOfWarrantsin
      contextRef="c21"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ExerciseOfWarrantsin
      contextRef="c22"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ExerciseOfWarrantsin
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AcquisitionOfBayMedica
      contextRef="c20"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AcquisitionOfBayMedica
      contextRef="c21"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AcquisitionOfBayMedica
      contextRef="c22"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c21"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c22"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:WarrantModificationExpense
      contextRef="c19"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:WarrantModificationExpense
      contextRef="c21"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:WarrantModificationExpense
      contextRef="c22"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:LossAndComprehensivelossesForThePeriod
      contextRef="c19"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:LossAndComprehensivelossesForThePeriod
      contextRef="c20"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:LossAndComprehensivelossesForThePeriod
      contextRef="c22"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c19"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c21"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c22"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c5"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:UnrealizedGainOnDerivativeWarrantsLiability
      contextRef="c0"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="c5"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:FinanceExpense
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:WarrantModificationExpenses
      contextRef="c5"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c5"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c5"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:CashAcquiredFromAcqusition
      contextRef="c5"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="c5"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c0"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="c3"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="c4"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="c4"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryFinishedGoods
      contextRef="c4"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c4"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c5"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillFairValueDisclosure
      contextRef="c37"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillFairValueDisclosure
      contextRef="c39"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillFairValueDisclosure
      contextRef="c40"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillFairValueDisclosure
      contextRef="c41"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillFairValueDisclosure
      contextRef="c45"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c36"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill
      contextRef="c5"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentChargeOnReclassifiedAssets
      contextRef="c5"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c5"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="c4"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance
      contextRef="c88"
      decimals="0"
      id="hidden-fact-94"
      unitRef="usdPershares">7547</inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance>
    <inm:AggregateIntrinsicValueAtBeginning
      contextRef="c88"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AggregateIntrinsicValueGranted
      contextRef="c89"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:AggregateIntrinsicValueAtBeginning
      contextRef="c90"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareBasedPaymentNumberOfBalanceAtBeginning
      contextRef="c91"
      id="hidden-fact-98"
      unitRef="shares"
      xsi:nil="true"/>
    <inm:ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning
      contextRef="c91"
      id="hidden-fact-99"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <inm:ShareBasedPaymentAggregateIntrinsicValueAtBeginning
      contextRef="c91"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareBasedPaymentAggregateIntrinsicValueGranted
      contextRef="c92"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding
      contextRef="c91"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c4"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive
      contextRef="c3"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c5"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:DeferredTaxAssetsPropertyAndEquipmentsNet
      contextRef="c3"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="c4"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="c4"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="c4"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:DeferredTaxAssetsIntangibleAssetsNet
      contextRef="c3"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c4"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:DeferredTaxAssetLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:DeferredTaxAssetLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c100"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c102"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c103"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:OtherOperatingExpenses
      contextRef="c103"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="c103"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="c107"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c113"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c112"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c112"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="c112"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c112"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c115"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c114"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c114"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="c114"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c114"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <inm:LegalService
      contextRef="c5"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001728328</dei:EntityCentralIndexKey>
    <dei:EntityPublicFloat contextRef="c2" decimals="0" unitRef="usd">0</dei:EntityPublicFloat>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Excludes estimated variable operating costs of $92,964 and $60,916 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>122
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #5\-U4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  U?#=5E5'+6N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>*'%@K";-I66G#08K;.QF;+4UC?]@:R1]^R5>FS*V!]C1TL^?
M/H%:%83R$5^B#QC)8+H;;>^24&'-CD1! "1U1"M3.27<U-S[:"5-SWB (-5)
M'A!X5=V#19):DH096(2%R+I6*Z$B2O+Q@M=JP8?/V&>85H ]6G24H"YK8-T\
M,9S'OH4;8(811IN^"Z@78J[^B<T=8)?DF,R2&H:A')J<FW:HX?WYZ36O6QB7
M2#J%TZ]D!)T#KMEU\ENSV>X>6<<KSHMJ5?!F5Z]$TPC^\#&[_O"["5NOS=[\
M8^.K8-?"K[OHO@!02P,$%     @ -7PW59E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MP,*FQ#2)E8@-"F*#.AV60\-0=/ES3MU?9VB^QF)/Z%O"8XZC](I4P0.%FXX
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M+PMI!Z@*]?D1QRAQ"=<]IH @BF)&V< QM5R*QLET>TQ@Y5H3/V"H!2B$&Q"
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M&L7^>E?_T[1^B/?QO$W;TSIJM8Y>KA6'F#949$RLN@2/GB?X:5JG8'_GG5R
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M)7_RPX+^(*A= 'V?*V4W$[=!^T]*_P!02P,$%     @ -7PW51M+3S":"
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MUN7SLK7Y?BME\2C*TFE\.%[$84*B;+B*_7:\/C?A'MK82\?E'7LZUJ$U*CF
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M7Y:EZYO.-FM]XVI;6N._?][!)/CH\U(&?,T#7AP9\/Q"_^*:;N/UFZ8RU7"
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MN">+A67\UEO8)# )#=A0?![7NBT^&VWB1+B PH/=W?&"NTW1Z6*U LN(*U=
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MI+6H_X2 <&.*;4%&(?J3$@81;%(%IRS:=I_P7L6U%)8DK%FC&"TS8A!'^'!
M&>>50\J0"\D?[C%HQ66"C4C&>C2[7&:S@K94C#DD5M8'M!WUCS"A%08KR2W
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MDT:&4=J4U ]*%*+A9"(4U6=@2LD7_,1IEMS$Y!#S0E^E8(S*I,)91IIAY&3
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M7 S+UG:B,W(D'EL/BQYVJTUA7=[?-CZ' 9O,21)M&;$94AK(+,A5(WW$]M;
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M%!AG? #NKQR$3?(#)XC?[7_U/U!+ P04    "  U?#=5[P;X1[,"   3!@
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MTQ EKBI+$!R((0^ )9!&U+2I+76&%FHWH9M6UA+AC3W KBL*"%!LW5G0>@"
M6:@&7$696>HEMT0 W ;OK!T2PF&+(<<:]ANB&YXI>R/*$X<IH0YA,.< "O,2
MD&8BI3I,F[=CG>B""X*3ZS .7G9K&A#(%:&IJ4?R$8N0Z*5PN[4A$PC+@G1%
M(=GYOF+2I.[+):)-Y>W:X)KR:7?J->5>*@35>JQ!.4&<24J0+-I4%U"34D.
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MAPV6N!5T4!R01LDMMJUP200()&(AQ''HLW#<E=]1EN:RZ3NCNRO<(7(B])T
M&X?^H#^!:$1$!E&O.Y*_&AKS!]'09Z,A65%_X,?C&,Z=I^!$&@K4NUH W<RI
M2J,2G;?3V*21EN_AC4!_X'HG2@,2MY0:7HV''NA&])J%554M-!ME2;9J,Z?_
M!&H70-^W2MGCPA7H_CSS;U!+ P04    "  U?#=5U3QA-[4*  #X(0  &0
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M$#\.1_YP1B?0UZ*C <9)6EF/,(G"@'#03K7(6G]5VQ?;"J\[QRSV9^BT]87
MS;AST17:S0\O=7VV2VR N:/3=<NZG,.Z^()C5[E!Y[:="[UTORF@3NE@KR_>
MN[>[GRUNZ]OZR_+Z-P],FTL<Z1BQ%C -@\FXAS;C?D>H/UA5NKO[7%FK<O>X
M$ASC&BW ]PNE;/N!'.Q^S+GY#U!+ P04    "  U?#=5<&OVU:0#  "$!P
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M[1QH/E?46NW +7"\>.?_ %!+ P04    "  U?#=5%(%-%G<#  #%!P  &0
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M+W=O<FMS:&5E=',O<VAE970R,2YX;6R%5VMOVS84_:Y?07C=D "*K:=EI4F
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M'#(MYZT8XNB1\SR%98(%I$]HG5H"-\EF89)G>/J#[Z5=N%N6QV%99O031[,
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M&\*$#;W22^=&(2N:,XIAXI],50CN!VE2H@X%&JA*55C,Q7*)[2<U@1O*\LF
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M T,&^+W0N(&[ 2VPN_7-_@502P,$%     @ -GPW54!W/P3P(0  M7   !D
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M=&)<6)0IBQ;2;2&])<%?+_$2TRWJN(*"V2\@ C;\W!HR"4!N\JP&.>Z_ZG\
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MC%,R?<R08]'[.6 HA=L$=1M-\V!U^9@U-%I.,=T=H.U\I115&:6AU^B:1B<
M'@=$8R0I?77!^V!R44$O+,L%N[0 !\X#=5(F*ZJX6C^;TF*=Q"=AA&O'=< .
MLT/<*TLHP/FM>L:;$4]+>@GAI!E$N -[BIU_X\23#6^:NMOW=C;6@CKRSL(+
M9E]-;DW)Q]IE:$)#U])(2FX4MR9958(Y*4;6&CR[\D08G)([4)IK4FI,Z A&
M:/CQ&54D-3P1O9H7W$>/J2LY1/@@[G$.>YSC'J>U3&PVN)CN-OA%ZMRCZN01
M'08>7J]QL#5(25]2)S:%YD&52!IK8&Q%JB*A3VIBTB?X-2>J4DT2%(D[;H!*
MM$8F9231'FI":O%41PZR_O-=<1U8GEZG9"BI)]D5\<OH[;LT6</M)@B+T'&&
MNR)G:JQES.DS7-N[#_B$[TF1%UERHHBESX=/A^^0MR_FT2=3/:L2!LV.",D6
M0?\!;+,XKW)K0FT"Z!I.!!H!8I)EM8O\+.UGC)BH&(C\"(SJ'_\L$EHAH?']
M6$5$DS/@&&G0+&"Y.NRS8+-2/&,K)LG8(%C"7G,.M@BO([S5OX&W_@+>HG1(
M7:<X@(C@' MF^?[ <1J/>>(5X\E"2R*F:[2?_0@33M(>4TZ?W0P4$/O^[(3&
M8RHI1]M7I>K86$4\)K75,G9,+*<[)GX.A;?+.([R+G;>C&FQ:9 G&N+\.FI\
M'7WT0/Q@+,V26D^0EM34[,O.I9V,PQZ8F&5OV\:NNM8K+<Z-];SEAAI;J$5*
M]8I3R"/+:\>PC?.6,<L1&L5C\Q U '"^PV<XJY' ?@%"D_9^!@HH+%"6J?^3
M8))(:;L%T[[94CG"MJ%/"/Z5+M3H,"9O^41L[#3ZWR:[$898DY%$^(D&"FDU
MB-0^BIB)QQ#7-IU$[TA<'[!G>]CUO33&IR?F<J0$FSHVF)*MNQ8M7A$/<2SL
M8];1.MHM=>]5H3!>>H<--A4%=UR^D[ZVM+LYU(?WV2'S;7E^B[UW'G80T@S
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MH$7/L=_'36YD;L.5D+QFW4B6/Y/'4$+]4!U?J!>]TO&[K9-B@UIA:]8=.18
M;*%_\<GUD;9+KKG&0D7_W7 ONNQ, '[<'E]$T!M(2SI[U9<[>WWSQ[6$AO,
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M, R]YRL(KQ@V(*L=Q6G:+C'0="O6 06*=EL/PPZ*S<1"9<F3Y+K[^U%RXF9
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M,LV:@OQ[>O.LO:-ZPZ5!@JW!%5\.^@'2S5/1=*RJ?'E>*0O%WC>W\+HR[2:
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M_7&*?23[^TL_T:*S=X:ET'@#L<,-7OE &@/<7PFA#Q-SP/$2.?L&4$L#!!0
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M&E.?Y+1$X=P7(6L'[!HN(62L$PW.5&#0Z[7[0421@T[ONO7*-VP]HG& =#J
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ML''%1LEBCZBH=T#4Y9(\T%$JRY*J75LW^I"'HZ\<]O =F6J2V*$4H$U!QZ;
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MP7@'W-]H[5X7/L$TJE=_ 5!+ P04    "  V?#=5N\.\5=X"  #[!P  &0
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MLV(9!:WN<.0O=Q 8U@2&>]7\(HY%P;6"6XR1+LF,86,'-'K9,XFG=0RGA^V
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M6- NP9ZO$&D?N NZD9W]!5!+ P04    "  V?#=5$H?)U'@"  !B!P  &0
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M:W*4F5FY44*_I=I.3>;Y%E.ATZP 7X$Y4YBMZ3(C8"HE41)@EH)?.$_W-,O
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M&M,CMK$;^L' <R)[NV_F];H#G8-6Y^"DSCG5D&O5IZP&#O=7=,>NXQPK.[E
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MW_,BM\*$.5EJ[RU$EO*MHH3!0B"YK2HL?LZ \OW$&3HO-Q[)IE3FAINE-=[
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MF#P"#O2V^=I3&@U6)Q6K$V=>GW'B88:+.4DE/E9M^5TY%?;%=++S !W1,3Y
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M (8/N6V ]V=2FJ<3VT&U.SOY#U!+ P04    "  V?#=59A _([L"  ",!@
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M+TJ2;!Z5O#(L,_[1X;7XG#3MGAK&=ARCHTQIB88J$PGSCG= ,VQ=[^H2F3-
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M"*R3-K].FZ_ME+_WJC7 19R!LFD&AV.)X;;:U',MJ]_,IU:VZUG6<"L'-<%
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M[@B."%,&\OJ&4O%RHFY0[VPOO@%02P,$%     @ -GPW5:24S$GW P  LQ(
M !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULS9A=;]LV%(;_"J$-0PJT
MEBC;LIW9!A*GVUHL0Q"C[<6P"T8ZEH5*I$92=O;O2U**+#LRG6CNL!OK\WP\
MQX='+SC=,OY5K $D>LQ2*F;.6LK\TG5%N(:,B![+@:HG*\8S(M4ECUV1<R"1
M,<I2U_>\P,U(0IWYU-R[X_,I*V2:4+CC2!191O@_UY"R[<S!SM.-^R1>2WW#
MG4]S$L,2Y*?\CJLKM_82)1E0D3"*.*QFSA6^7."1-C!O?$Y@*QKG2*,\,/95
M7WR(9HZG,X(40JE=$'78P +25'M2>?Q=.77JF-JP>?[D_1<#KV >B( %2[\D
MD5S/G+&#(EB1(I7W;/L;5$!#[2]DJ3"_:%N]ZSDH+(1D666L,L@26A[)8U6(
MA@$.CACXE8%_:# X8M"O#/H&M,S,8-T02>93SK:(Z[>5-WUB:F.L%4U"]=^X
ME%P]392=G"_7A -:D#R1)$6$1N@>!/ -"'1Q Y(DJ7B#WJ&E:I^H2 &Q%0K7
MA,;J>4*1,-9YP=4] 6A+."=4"F7P:7F#+GY\,W6E2E*'<L,JH>LR(?](0MA'
MMXS*M4#O:031O@-7T=6(_A/BM6_U^+&@/=3WWB+?\_V6A!8O-\>6=/IUQ?O&
M7_\_K?B?OZLPZ(.$3/S55O0RIT%[3GI67(J<A#!SU# PV3CSGW[ @?=S6\'.
MY&RO?(.Z? .;]_D?1?8 7%?E_2/P,!&'/5+REDZ&QHD>99OY.SP,O&#J;IHD
MUE@=288UR=!*\L6,&(C0U0:X&IFH[(P[GH3PUDY7.L;]!A[&/7]X0&>-WY$N
MJ.D"*]U5''.(B51-225/U-P/T6>2%DTT=*$Z^H:E*>&B=524(8(FIC\,,#[@
MM&;2SHDLB*,:<61%7!Y;B[>@>[1U'5H]OG8=GLG9'ORXAA__#\?8^)SE.Y.S
MO?)-ZO)-7CC&KB%.*$UHK.1(2F@(;=R39^-L,I[XWL$ZL(;L"(2]G9+P_L4\
M>X;97/PH5[4P/=&N&+QG<V T'(P.Z.WI=<5O""G<=>!9V=N)K;%>--*JHG1P
M=+HH_JXH_@O;_%>]P-N_9I6/9G?C  ^&_<,_V!JK*\M.MV&KKCG1WQ7?:[JZ
M##=N8H][A]]P>U)=H7=J"]OEEJ6K6XC;.3N(K/9>_AYJ#>_D&K;KM8;RI-&)
M>5VY:K:T/QB,@F<SZWM(-+S3:-@NTDY(T#W,UW1V&774H!_@WF1R"-]!MYV&
MWZDW;)=O-H5ZE+R=MX,0:^_PLRHZM[$MD &/S6Z)0"$KJ"QW".J[]8[,E=F'
M<'>OE]LYMX2K3YA *:R4J=<;J;[EY0Y)>2%9;C89'IB4+#.G:R 1</V">KYB
M3#Y=Z #U/M7\&U!+ P04    "  V?#=5ZM@06QH#  "A"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,2YX;6R]5EE/VT 0_BLC%[4@ 3YR$9I82J '5:D0
M$?" ^K#8$WN%O9ONKA,J]<=W=^TXJ3 6A]07>Z_YYOMF]IC1BHM[F2(J>,@S
M)L=.JM3BV'5EE&).Y"%?(-,S<RYRHG17)*Y<""2Q-<HS-_"\OIL3RIQP9,<N
M1#CBA<HHPPL!LLAS(GY/,>.KL>,[ZX%+FJ3*#+CA:$$2G*&Z6EP(W7-KE)CF
MR"3E# 3.Q\[$/Y[Z@3&P*ZXIKN16&XR4.\[O3><L'CN>88091LI $/U;X@EF
MF4'2/'Y5H$[MTQANM]?HGZUX+>:.2#SAV0V-53IVCAR(<4Z*3%WRU5>L!/4,
M7L0S:;^PJM9Z#D2%5#ROC#6#G++R3QZJ0&P9=)\R""H#&PBW=&19GA)%PI'@
M*Q!FM48S#2O56FMRE)FLS)30LU3;J7"6$H%P0A94D0P(B^$2)8HE2M@]145H
M)O?@ &9Z-\1%AL#G$*6$)7J>ZI@FR)2$%1&"F,8!3.S(![A9#]V>8WZ'XN?(
M59JN<>I&%;5I22UX@IH?P#EG*I7PB<48_PO@:IVUV& M=AJT(GXKV"%TO'T(
MO"" J]DI[.[LP0ZX($T89/5K\=2IP]JQGCK_):RWWS4\G"G,96,<2R[=9B[F
M7!_+!8EP[.B#:UDXX?MW?M_[V**T6ROMMJ&'/PJ37B-@B@EEC+($IB0C+$+X
MTQC0DG,K:C-G:*';J^GV6NG>V&.*,4R6*'2<H<S4A: 1[C=*V&R/)AFMWEXN
MHU_+Z+?*F"2)P(0HO2N8$E1?DA%<DZQX2D,3]58/+Z<^J*D/6JE_,7M:)Z!M
M<Y0(/8M@WI6EO@Q\;SAREPV.CVK'1V](_896>\)+'[Z_Q6T8' Z]0:^9W;!F
M-WQM1K>H-3%JQ7UY'GUO\W1XSSSZ^H)^[KFO,)^96W_K'?/?D-U'!-N37/EZ
M?I;]8,,S>&V>'Y-LY-:*_X)\NUM50XXBL;61A(@73)4%1#U:UU^3LNK8+"^+
MMW,B]*4C(<.Y-O4.!SJ]HJR'RH[B"UN#W'&E*QK;3'4-B<(LT/-SSM6Z8QS4
M56GX%U!+ P04    "  V?#=5A;)X-@@%  "&&0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6RUF6%OHS88Q[^*Q:;I3KHFF) 0NC126^ZV3JM6M>KN
MQ6DOW. D5@$SVTF:;[_'0$A('??8T3<M$#]__/RP_?PQDPT7SW))J4(O:9+)
M"V>I5'[>[\O9DJ9$]GA.,_AESD5*%)R*15_F@I*X"$J3ON>ZHWY*6.9,)\6U
M.S&=\)5*6$;O!)*K-"5B>T43OKEPL+.[<,\62Z4O]*>3G"SH U6/^9V LWZM
M$K.49I+Q# DZOW N\7GDN3J@:/$WHQMY<(QT*D^</^N3F_C"<76/:$)G2DL0
M^+>FUS1)M!+TX]]*U*GOJ0,/CW?J7XKD(9DG(NDU3[ZR6"TOG+&#8CHGJT3=
M\\WOM$IHJ/5F/)'%7[2IVKH.FJVDXFD5##U(65;^)R\5B(, T#$'>%6 =Q3@
M#4X$#*J P?$=_!,!?A7@%V3*5 H.$5%D.A%\@X1N#6KZH(!91$/Z+-//_4$)
M^)5!G)H^+(F@9U= +D9W9 M/5$GT(:**L$1^1&?H\2%"'W[^..DKN)N.Z<\J
MY:M2V3NAC-$MS]12HL]93&-#_/4;\9Y%H ]IUKEZNURO/*OB+1$]Y/F?D.?B
MP-0A>_@?JZR'!JX.]SQ#>/3]X=B2S:!^<H-";_#_GMRW/Z$]NE$TE?^8'EXI
M[IO%]6IS+G,RHQ<.+">2BC5UIK_\A$?NKR9P78I%'8DUH/HU5-^F/KV1<@4\
M218C6"2E@@.6+3ZAG(H9 (:5T,2RU,1N(:I7VO74[<$061\RLMZX+:..Q!J,
MAC6CH9717[E>L262>@#"D&,9*L:B-"X25JVVXZP4&QYPQF,\&C1)1X9683 8
MUJT:68_JK$?6K+\6%42/C345, [0G#"!UB1944046@B2*10311&?(UXA*JY"
MC&84\20A0NJA5*(SXK)VHBVN4BPX .'AGNL?X7K=R@][[L",*ZAQ!>UP"2:?
MS^:"4L0 "71>(0&T3 RLRFT9E&+8;\Q-%^L"T*!@;N=Z@9G#N.8P;L>!ON1@
M>>!"PN;&[*UZ;;.W=VZ ME0/28Q276G1" ;P5IK6FXXZU4 8U@C#=@C7/"&*
M)4QM3PXAJV);B*%I:(0!'AX-(4,[F&[#\=@\A+"[]VAN.P(Q6[.80I':,IJ8
MO-657;$M@4JM6>&.LK>W:69^X$YQRU67BSEE:B7HR6=OEVR=.C85=_?XV;_9
MK G VP/PK !*E_=4N+R\='E(05619%:6F(/28C;I5OW6-$JUT4&6HS 8A\<U
MQ=0.NS@\457PWO1BJ_V;/F9K*!T 8U=BW\R_4Z-;J1WFY85>. R/\W\/$XOW
M+A;;;>QNVIS52R9  R.KS0?CY@6C2W]Z_4;_<%%X3(6FJVXTP>VM+;9[V]]H
M!L"2X@7@,H;W;29AMNFM"?09"G<FP?!^NZ7I$Q7&MRJ[?&N*7:I%7:DUT>[]
M,QZ]Y_LJ[M09=ZH6=:76)+NWVMCNM7^\1G3JN"NUPS72QZ$;O"J9P:OW-!_<
MDHM/U(B]Y<9V6WL/?21BMBQF<437-.%Y >7[IG"G!KQ3M:@KM2;8O1''X;M.
MX4Y=>:=J45=JS8W)O</W[ [_AZ>P7;\MVTJM87."\1@?VQQ3.]<?A-[1%.X?
M;%"G5"R*C7Z)9GR5J7+_MKY:?TRX++;0CZY?X_.H_"2PERF_4-P2L6  *J%S
MD'1[ :PKHMST+T\4SXMM\">N%$^+PR4E,16Z ?P^YUSM3O0-ZD\OT_\ 4$L#
M!!0    ( #9\-U7 =B\8D@,  %D,   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8S+GAM;+57;8^;.!#^*Q8]G5JI&[ )A.PE2)ON]JZ5>AMUU?:S Y/$*MC4
M=I*M=#_^;""$;8!=[:I? C:>F6>>\;QD=A#RN]H":'2?9US-G:W6Q:7KJF0+
M.54C40 W7]9"YE2;I=RXJI! TU(HSUSB>:&;4\:=>%;N+64\$SN=,0Y+B=0N
MSZG\N8!,'.8.=HX;G]EFJ^V&&\\*NH$[T%^*I30KM]&2LARX8H(C">NY<X4O
M%SBT N6)KPP.JO6.K"LK(;[;Q8=T[G@6$620:*N"FL<>WD&664T&QX]:J=/8
MM(+M]Z/V]Z7SQID55?!.9-]8JK=S)W)0"FNZR_1G<?@':H<"JR\1F2I_T:$^
MZSDHV2DM\EK8(,@9KY[TOB:B)>"3'@%2"Y 2=V6H1'E--8UG4AR0M*>--OM2
MNEI*&W",VZC<:6F^,B.GX[LME7"Q,'ZE:$E_&KZU0J^O05.6J3?H MV9>Y#N
M,D!BC4Q4E:8\97R#1&%953-7&Q16EYO4%A>51=)C$1/T27"]5>B&IY ^5. :
M^(T/Y.C#@@QJ_+CC(^1[;Q'Q"$%_(!<IZY6J'P,6_(8EO[3@][%T).%VC6Y;
M)-Q6)*"KE=+27+ N-BK-XV[--NDN54$3F#LFJQ3(/3CQGZ]PZ/TU@'O<X!X/
M:8__W>4KD#9T"]@PSBWF%<TH3Z +:J4L*)79=-['?CB>D)F[[\ 0-!B"00S?
MRL0PU^MJ#](D.KJY!YDP!6@I60)OSZ&AUXRC:Y%E5"I4&/QE'-^@_UJQ[8)?
MX9BTX!,<C/R@&W_8X ^?R.'?DG+]ZXVM3(?GS&$3PV[+D\;RY&7,U8">RU=E
M/6J#'H]ZHATUF*,GLG5S7S )J6N*YQI8#V_1&6\7V&3QM!O$M $Q?1EQ9]B>
M2^'T[,IA0D9^U(T?>Z>J[#V5QJK2#&1MK:I-8A"$GM^#H=49\ M9?!Q:W7S\
M!P1%HZ GP)B<P)'!BFQJ/C0U_[+3-OD-A1>?.@8>+.RM"'X%95DT+0-!Q2!=
M9=UT^6>1)"&.>E(2G[H 'FX#CT:R&^)SDZ)&\Z 0FZ!'DQX_3IT$#[>2$Z=?
M^+Z$W&D^.&=Q.B:XQ_JI#^#A1O HBT=0S^8M/./-GY[W+[<U[>4@-^5,JU B
M=EQ7@U^SV\S-5]6T>#I>#=V?J#2]5Z$,UD;4&TT,:;*:8ZN%%D4Y.ZZ$-I-H
M^;HULS](>\!\7PNACPMKH/DW$?\/4$L#!!0    ( #9\-U7CT#I2:P,  $\/
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;+6776_:,!2&_XJ53=,F
MK>2#$*"#2"W9M$VK6K7J=C'MPB0'L.;$F6V@_?>SG32%-KABRFX@=OR^SGGL
MG/A,MHS_%BL B>YR6HBILY*R/'5=D:X@QZ+'2BC4G07C.9:JR9>N*#G@S(AR
MZ@:>%[DY)H433TS?%8\G;"TI*>"*(['.<\SOSX&R[=3QG8>.:[)<2=WAQI,2
M+^$&Y&UYQ57+;5PRDD,A""L0A\74.?-/$]\(S(CO!+9BYQKI4.:,_=:-+]G4
M\?03 854:@NL_C8P TJUDWJ./[6IT\RIA;O7#^Z?3/ JF#D6,&/T!\GD:NJ,
M')3! J^IO&;;SU '--!^*:/"_*)M-394,Z9K(5E>BU4[)T7UC^]J$#L"Y=,N
M"&I!\%00'A#T:T'_B2 X) AK06C(5*$8#@F6.)YPMD5<CU9N^L+ -&H5/BGT
MNM](KNX2I9/Q-U#0T.6<DB76"R'0VP0D)E2\0R?H]B9!;U^_F[A23:4%;EK;
MGE>VP0%;'UVP0JX$^EADD+7HDQ?T@<7 53$V@08/@9X'5L>S];*'^OY[%'A!
MV/) LQ?D)5=R[Z \L<N_KHM&'EBBZ3?+UC=^_7]8MI_?U&#T14(N?K6M7.4<
MMCOK/',J2IS"U%&)1 #?@!._>>5'WH<V:EV:)1V9[1$-&Z*AS3V^!ITE2;%$
M$GC>QLVJ/Y9;EV:)/3(?W0/F:(SRZHWR1RC#]\+";- P&UB=+TO@:OLI9M3L
M1ZZ3[ E;G*Q5 PL!4K2!M)H>"[)+LZ0RBXR9_F)NXF$P\OW!Q-VT8(H:3)$5
M4_6R4H+GA!)YWX;$:G LDB[-DN@9DE$P"(-A.Y)A@V1H19(0D;)U(9':/] &
MQ"H_%DB79DEEYGL[1+R>%[;S&#4\1E8>Z@P#*182_;R ? Z\-7%;+8YETJ59
MTI'9'KIQ@V[\WSZ%XRZ)=FF6=&2V1]3W'@^%GG4[?L=<92L*B#49/F6B/9O;
MK8Z%6+OMYIMQ,(X>7Z_Z]-C1I/M\=@[-OI7/1R&)JCD@0YMC2/G/8HN\L1_M
MQS:SSWWL1NK*K2+E[E0:.?"EJ=@$,KF\.HLWO4U5>&9JH2?]Y_[IK*KM'FVJ
M4O,"\R51;S&%A;+T>D/U4>95]58U)"M-/3-G4E5'YG*E*E[@>H"ZOV!,/C3T
M!$T-'?\%4$L#!!0    ( #9\-U6F!E=:$0,  )X'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8U+GAM;(55;6_3,!#^*Z<P(9#&\M:F[6@K=1T($-,FQLL'
MQ <WN:863AQLI]W^/6<G"V5D0:H:^^Q[GGM\OO/\(-5/O4,T<%>(4B^\G3'5
MN>_K=(<%TV>RPI)6ME(5S-!4Y;ZN%++,.17"CX(@\0O&2V\Y=[8;M9S+V@A>
MXHT"71<%4_<7*.1AX87>@^$3SW?&&OSEO&(YWJ+Y4MTHFOD=2L8++#67)2C<
M+KQ5>+Z>VOUNPU>.!WTT!JMD(^5/.WF?+;S !H0"4V,1&'WVN$8A+!"%\:O%
M]#I*ZW@\?D!_Z[23E@W3N);B&\_,;N%-/<APRVIA/LG#.VSUC"U>*H5V_W!H
M]P8>I+4VLFB=*8*"E\V7W;7G<.0014\X1*U#],@AC)]PB%N'V EM(G.R+IEA
MR[F2!U!V-Z'9@3L;YTUJ>&FS>&L4K7+R,\N/2&< UQO!<V;/5<.+2S2,"_T2
M7L$M79JL%@AR:\EY41<@G$?%[BF71L]]0U%8+#]M&2\:QN@)Q@]U>09Q< I1
M$$7PY?827IR\_!O&)Q&=DJA3$CG<^ G<+M;K+5RUL3;J;MI88;711M'%Z0NZ
M 1_U@]M:.M<52W'A4;%H5'OTEL^?A4GP>B#TN L]'D*G)&@-9L=*D"7"/3+5
M%V&#D3@,6YS[Y2@.PV0V]_<]W*..>S3(?4V,1L*6BLDQ]V:T@1@?4<>S)$G&
M_=3CCGH\2'TE%3:RA]D'4?I3 P-92;KPDL'P/DO#!-1EQG4JZ])@UMY]P=F&
M"VXX]H:;_).G:329QJ/NL-RV]3#Y]_#'@(2)]\@P[31-_P?[YBX5=88:4!M.
M?9!D[9DB2;;,*U34!LH<4JFI8*CL3V;1Z2P9 2LS.$F"TUF8@&V_]E?6=$#4
M1+F]O4K6^<Y>I56EN'BH\,9Q5>?4RB .&]LI]7]=H>O@XOZL3ZA_U-(*5+GK
M]!I<(IK"ZJS-8W)!CXEKNH_LJ\GY>M)GG[:/C_\'OGFYKIC*.35"@5NB"LXF
M=/]4\QHT$R,KUU WTE![=L,=/:"H[ 9:WTII'B:6H'N2E[\!4$L#!!0    (
M #9\-U63?8]AV (  (,'   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM
M;*U576_:,!3]*U8V3:VTDB\(T$$D/E9MT]JAHJ[/)KF0J$F<V0YT_W[7=D@I
M#:@/>X'8ON?XG)/X>K1C_$DD )(\YUDAQE8B97EMVR)*(*>BPTHH<&7->$XE
M#OG&%B4'&FM0GMF>XP1V3M/""D=Z;L'#$:MDEA:PX$14>4[YWRED;#>V7&L_
M<9]N$JDF['!4T@TL03Z4"XXCNV&)TQP*D;*"<%B/K8E[/0M4O2[XG<).'#P3
MY63%V),:?(_'EJ,$00:15 P4_[8P@RQ31"CC3\UI-5LJX.'SGOU&>T<O*RI@
MQK+'-);)V!I8)(8UK3)YSW;?H/;34WP1RX3^);NZUK%(5 G)\AJ,"O*T,/_T
MN<[A . &)P!>#?". =T3 +\&^-JH4:9MS:FDX8BS'>&J&MG4@\Y&H]%-6JBW
MN)0<5U/$R7!*11H16L1DGF:5A)C\9$*0!7"R3"@'<C$'2=-,7)(KLL1O**XR
M(&Q-=CH@K*=;X/B^25'E*T3A4L3R'-^04'B!L(?EG%Q\O!S9$@6K;>VH%C<U
MXKP3XER/W+)")H)\+6*(7Q/8Z+2QZ^WM3KVSC#^JHD-\YS/Q',]K$31[/]P]
M(\=OTO<UGW^"KPGTUYH\[@.=U('>F4!Q:68"79I )RLA.7[^;7F:[;KMVZF.
M<"U*&L'8PB,O@&_!"C]]< /G2UL6_XGL53+=)IGN.?;P#AM8IKY$;%1$)D!*
MX"F+VSP;HD 3J::U#:_<0> XKML?V=M#0VV5CN?XSF#85+Y2VVO4]LZJ?3E%
M<7V*M';4;$Y!FVS#V#\4X_N=-YK;ROJ=8= N.&@$!V<%/[[_]*Z.O;69,;OU
M#E3V F?@#8_,O"WS@D%_Z!^9L0_Z60Y\H]N\0&55(<U9;V:;FV2B&^C1_!1O
M&',AO-"8Z^F6\DU:")+!&BF=3A]%<=/RS4"R4G?-%9/8@_5C@K<D<%6 ZVO&
MY'Z@-FCNW? ?4$L#!!0    ( #9\-U7*N]6"N0(  #D'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8W+GAM;*U576_3,!3]*U9 :$BL^6B;;J.-M+8@AC0T
M;0P>$ ]N<MM:<^Q@WS0;OQ[;24-7L@XD7N*O>X[/N;&OQY54=WH-@.0^YT)/
MO#5B<>;[.EU#3G5/%B#,RE*JG*(9JI6O"P4T<Z"<^U$0Q'Y.F?"2L9N[4LE8
MELB9@"M%=)GG5#U,@<MJXH7>=N*:K=9H)_QD7- 5W #>%E?*C/R6)6,Y",VD
M( J6$^\\/)O%-MX%?&%0Z9T^L4X64M[9P44V\0(K"#BD:!FH:38P \XMD9'Q
MH^'TVBTM<+>_97_OO!LO"ZIA)OE7EN%ZXIUX)(,E+3E>R^H#-'Z&EB^57+LO
MJ>K8P= C::E1Y@W8*,B9J%MZW^1A!Q#&3P"B!A#M P9/ /H-H.^,ULJ<K3E%
MFHR5K(BRT8;-=EQN'-JX8<+^Q1M49I49'"87(I4YD,_T'C0YF@-2QO5K<DQN
M;^;DZ.7KL8]F%QOKIPWCM&:,GF ,(W(I!:XU>2<RR!X3^$9>JS'::IQ&!QD_
MEJ)'^L$;$@51U"%H]O?P\("<?INRON/K/YLR,F<ZY5*7"LBW\X5&94[E]ZZ4
MU8R#;D9[4\]T05.8>.8J:E ;\))7+\(X>-ME]S^1/3(_:,T/#K%OS6ND6*)4
M#R25JI"*(A T";&=+O\U:1@X5EM9-DG0BT9C?[-K[+FH1XJ'K>+A0<6?I#A.
M:<&0<F+^E28I5>KAV!3 BJK,''HFR%QR3I7N/.TU>[RC*8Y.HW!T,MQ3_V?@
M,#@Y'8V"N-M W!J(#QJXAE2N!/L)F4OQ @0L&6I2@$I!H*FU7;+CKESN2SZX
M\;^>)'^G"N6@5JXXFW3+4F!]V=O9MOZ?N[*W-S\U[T)=QG_3U(_*)54K)C3A
ML#2406]D<J[J0ET/4!:NUBTDFLKINFOSMH&R 69]*25N!W:#]K5,?@%02P,$
M%     @ -GPW544(,I+B P  RPP  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C@N>&ULK5?;;N,V$/T50BV*!&@B4I)E*[4-Y-*B*;#=(.ZVS[0TMHF52"])
MV4F_OD/)47RAU:+(BRU2,X?G#(?#T7BK]%>S K#DI2JEF00K:]<W86CR%53<
M7*LU2'RS4+KB%H=Z&9JU!EXT3E491I2F8<6%#*;C9NY)3\>JMJ60\*2)J:N*
MZ]<[*-5V$K#@;>)9+%?63833\9HO80;VR_I)XRCL4 I1@31"2:)A,0ENV<T]
MBYU#8_&G@*W9>R9.RERIKV[P6$P"ZAA!";EU$!S_-G /9>F0D,>W'6C0K>D<
M]Y_?T']IQ*.8.3=PK\J_1&%7DV 4D (6O"[ML]K^"CM! X>7J](TOV2[LZ4!
MR6MC5;5S1@:5D.T_?]D%8L^!I6<<HIU#=.R0G'&(=PY-Y,*662/K@5L^'6NU
M)=I9(YI[:&+3>*,:(=TVSJS&MP+][/11YJH"\@=_ 4,N'L!R49I+<D5FF#!%
M70)1"\)QPW(E<U$*W@0?YT3K:!O'*_)E]D NOK\<AQ9).>@PWQ&X:PE$9PBP
MB'Q2TJX,^5D64!P"A*BFDQ2]2;J+>A%_J^4UB>F/)*)1Y"%T_]_=60^=N(MP
MW.#%9_"Z0'Y>D-OGPSCBU,$&W,Z-U9C9OC"VJR3^5=QIOS%KGL,DP.-L0&\@
MF/[P'4OI3[X0?!#804"2+B!)'_KT=RQ.I3*&S '+T"Z%?(I;F+2!<>5H,[UB
MHY12QH;C<+,OQV=)(QK34=99'G ==%P'O5P?NRPG\(*ETP"Y<&=A _KUDG!+
M[ J(L=S65NE7HKD%GY)VD<$^OV3(:)IF1T(\AM%PD(SBQ*\C[72DO4F(.K#(
MM^R+NJF@EWB$#T\Q;C46/R&79*%5=>,3DGYD$GX0V$% AEU AKT;>[_B<@DN
M!!M>UNUIY"5>:ESFWBT<GNQ,PEA$D\'1#OKL:#;8LSO@.^KXCGKYSC#'>H[*
MR),W2"YC1^QZ%_&'G/1$.^O89[WLGP!O7 G2DD(L%J !@^S5D9WH2%D<G1R3
M4[,L2S+J#S&C[W<A[:6)C0%>^Q*/>MZFQ[^PW<'M\QAD+$KC([H>.ZQ/PX32
M<Y3WKF_6GQ<KCB54&%.[Q"6Y,I;D?"TL+\7?4+@$AV^UL*]>_NR4UV 48;TY
M%N QC#.:CLYD-8O>^4>]_#]C =5>;M')DBP;LO@XHWUV-!F=J9?L_=9FO7=@
M?^7W$OX?=RKQE<4/ &HUAWMM805ZV73+!G.DEK9MI[K9KB._;?K0H_D[UZDW
M[>8[3-OF?^)Z*:0A)2P0DEX/<1]TVSFW ZO63?,Y5Q9;V>9QA5\;H)T!OE\H
M9=\&;H'N^V7Z#U!+ P04    "  V?#=5;E,O( 0$  "@#P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V.2YX;6RM5VV/VC@0_BM6>JI::=G$><\6D.BBJGOJ
M]5;=:_O9! -6G9C:9F'__=E)-@3B^!;=?@$[F1D_SWCL)S/>,_Y+;#"6X%#0
M4DR<C93;&]<5^0872%RS+2[5FQ7C!9)JRM>NV'*,EI5305W?\V*W0*1TIN/J
MV3V?CME.4E+B>P[$KB@0?_J(*=M/'.@\/_A&UANI'[C3\1:M\0.6W[?W7,W<
M-LJ2%+@4A)6 X]7$F<&;6YAHA\KB!\%[T1D#367!V"\]N5M.'$\CPA3G4H=
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M5];Z + %)6NDOVS-=13T:421'WOG- QV21+#H1HZZBJT"^N+CL'0'O3E<93
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M(WE]NR8X(TP9R/=+2L7K0$W0?8=)O@%02P,$%     @ -GPW52F+!SR*!
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MW]WO[(NOXR47]S('4.BQ+)B<>+E2U9'ORS2'DLA#7@'33V9<E$3IH9C[LA)
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M-WWT!1%SRB0J8*:EP>% [SG1M*;-0/'*=G=W7.E>T5[FNIT'82;HYS/.U?/
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MQD"_7W"N7AIF@/;Z:O(O4$L#!!0    ( #9\-U6:;]PP=00  *<6   9
M>&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;,5876^C.!3]*Q:[6LU(G8(-(:2;
M1)JFFMFN6JEJYN-AM \.<1JK@!G;)--_OS:A$!K'"6VD>4GXN/?XW(/A'GNX
M9OQ1+ F1X%>:9&+D+*7,+UQ7Q$N28G'.<I*I.PO&4RS5*7]P1<X)GI=):>(B
MSPO=%-/,&0_+:W=\/&2%3&A&[C@019IB_G1)$K8>.=!YOG!/'Y927W#'PQP_
MD"F17_,[KL[<&F5.4Y()RC+ R6+D?(07$Q3HA#+B&R5KL74,="DSQA[UR?5\
MY'B:$4E(+#4$5G\K,B%)HI$4CY\5J%./J1.WCY_1/Y7%JV)F6) )2[[3N5R.
MG,@!<[+ 12+OV?H?4A74TW@Q2T3Y"]95K.> N!"2I56R8I#2;/./?U5";"7
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MN_U[;"<-!6452+PD=_9]G^^[TUURD.I>%P &/91<Z"DNC*DFA.BL@)+J@:Q
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MT[/L;3N\Y+/I+[[K/U!+ 0(4 Q0    ( #5\-U4'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    "  U?#=5 =AT79\%  "9%P  &
M    @(&\&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M-7PW5>3DHUFV @  GP8  !@              ("!D1X  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #5\-U4;2T\PF@@  !4\   8
M          " @7TA  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    "  U?#=5G%S8\<$'  "X(0  &               @(%-*@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ -7PW56840A;[!P  M!(
M !@              ("!1#(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( #5\-U6B(LODPA\  ,-?   8              " @74Z  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  U?#=5[P;X1[,"
M   3!@  &0              @(%M6@  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( #5\-U5$ A-<H@(  ),%   9              "
M@5==  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ -7PW
M5;1#-;Y\ P  D <  !D              ("!,&   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    "  U?#=5A)^\'&<'  "@$0  &0
M        @('C8P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( #5\-U5?A.P@SP,  $8(   9              " @8%K  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ -7PW5<1];)>8"0  =A<
M !D              ("!AV\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    "  U?#=5H/K8)/<"  "%!@  &0              @(%6>0
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #5\-U75/&$W
MM0H  /@A   9              " @81\  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ -7PW55YYH]ZO!P  V!$  !D
M ("!<(<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  U
M?#=5<&OVU:0#  "$!P  &0              @(%6CP  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #5\-U44@4T6=P,  ,4'   9
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M970R-"YX;6Q02P$"% ,4    "  U?#=54UH>(0 *  !S&P  &0
M    @($RL0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M #9\-U45-[?[Q0(  .0%   9              " @6F[  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ -GPW5>-S4LIF!    0H  !D
M             ("!9;X  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    "  V?#=50'<_!/ A  "U<   &0              @($"PP  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #9\-U5..F*45P(
M !X%   9              " @2GE  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ -GPW5?RG%\+< @  '08  !D              ("!
MM^<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  V?#=5
M:QHHGPT#  "[!P  &0              @('*Z@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #9\-U684E]UPP(  (8&   9
M      " @0[N  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ -GPW57Z]Z,(#!   - D  !D              ("!"/$  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  V?#=51+>7I,4"   K!@
M&0              @(%"]0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( #9\-U47;.(\\0,  % *   9              " @3[X  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ -GPW51SB'7"K
M @  O 4  !D              ("!9OP  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    "  V?#=5V7,,='D"  !-!0  &0
M@(%(_P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #9\
M-U4;G].UG0(  +0%   9              " @?@! 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ -GPW5>D;VU%+!   0PD  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( #9\-U5KJ0Z#[ (  #<)   9
M  " @4P6 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M-GPW5>9W5:9- @  O@4  !D              ("!;QD! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    "  V?#=5$H?)U'@"  !B!P  &0
M            @('S&P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( #9\-U7)L2IIDP,  / .   9              " @:(> 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ -GPW55EDQ6QD P
M"P\  !D              ("!;"(! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    "  V?#=5RM)D?D($  "$%0  &0              @($'
M)@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( #9\-U7/
M7"0APP(  &P(   9              " @8 J 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ -GPW53CIDPBO @  U0<  !D
M     ("!>BT! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #9\-U7!98<"B@(  &4&   9              "
M@<(_ 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ -GPW
M59?4ZS7S @  4 @  !D              ("!@T(! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    "  V?#=57$+,Y%L+  #=@@  &0
M        @(&M10$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( #9\-U4>"F<F@P0  .46   9              " @3]1 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ -GPW5:24S$GW P  LQ(
M !D              ("!^54! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    "  V?#=5ZM@06QH#  "A"@  &0              @($G6@$
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( #9\-U6%LG@V
M" 4  (89   9              " @7A= 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ -GPW5<!V+QB2 P  60P  !D
M ("!MV(! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  V
M?#=5X] Z4FL#  !/#P  &0              @(& 9@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( #9\-U6F!E=:$0,  )X'   9
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M970V.2YX;6Q02P$"% ,4    "  V?#=5+D]9#MX#  "3$0  &0
M    @(&]>P$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (
M #9\-U4IBP<\B@0  !P@   9              " @=)_ 0!X;"]W;W)K<VAE
M971S+W-H965T-S$N>&UL4$L! A0#%     @ -GPW5<F?VE=H P  + P  !D
M             ("!DX0! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"
M% ,4    "  V?#=5D5<EM&,$  #*$@  &0              @($RB $ >&PO
M=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( #9\-U6:;]PP=00
M *<6   9              " @<R, 0!X;"]W;W)K<VAE971S+W-H965T-S0N
M>&UL4$L! A0#%     @ -GPW55_U<*I$ @  Z@4  !D              ("!
M>)$! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  V?#=5
MZKWZZ<8#  !/%   &0              @('SDP$ >&PO=V]R:W-H965T<R]S
M:&5E=#<V+GAM;%!+ 0(4 Q0    ( #9\-U6<4KA%3@,  ,X5   -
M      "  ?"7 0!X;"]S='EL97,N>&UL4$L! A0#%     @ -GPW59>*NQS
M    $P(   L              ( !:9L! %]R96QS+RYR96QS4$L! A0#%
M  @ -GPW56QT.RB&!0  &S(   \              ( !4IP! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( #9\-U5S?'@L40(  /LL   :
M  "  06B 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M #9\-U7.%<Q?#P(  .HK   3              "  8ZD 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !4 %0  Q<  ,ZF 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>419</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Nature of Business and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern</Role>
      <ShortName>Nature of Business and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Customer Concentration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration</Role>
      <ShortName>Customer Concentration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Property, Equipment and Rou Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet</Role>
      <ShortName>Property, Equipment and Rou Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Impairment of Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill</Role>
      <ShortName>Impairment of Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Share Capital and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves</Role>
      <ShortName>Share Capital and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations</Role>
      <ShortName>Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Basic and Diluted Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare</Role>
      <ShortName>Basic and Diluted Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Non-Cash Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions</Role>
      <ShortName>Non-Cash Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Financial Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement</Role>
      <ShortName>Financial Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/Inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Property, Equipment and Rou Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables</Role>
      <ShortName>Property, Equipment and Rou Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Impairment of Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables</Role>
      <ShortName>Impairment of Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/Acquisition</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Share Capital and Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables</Role>
      <ShortName>Share Capital and Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables</Role>
      <ShortName>Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Basic and Diluted Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables</Role>
      <ShortName>Basic and Diluted Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Financial Risk Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables</Role>
      <ShortName>Financial Risk Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Nature of Business and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails</Role>
      <ShortName>Nature of Business and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Customer Concentration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails</Role>
      <ShortName>Customer Concentration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Inventories (Details) - Schedule of inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable</Role>
      <ShortName>Inventories (Details) - Schedule of inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of property, equipment and right of use assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable</Role>
      <ShortName>Property, Equipment and Rou Assets, Net (Details) - Schedule of property, equipment and right of use assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Impairment of Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Impairment of Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable</Role>
      <ShortName>Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0</Role>
      <ShortName>Intangible Assets (Details) - Schedule of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Intangible Assets (Details) - Schedule of amortization expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of amortization expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails</Role>
      <ShortName>Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Acquisition (Details) - Schedule of total consideration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable</Role>
      <ShortName>Acquisition (Details) - Schedule of total consideration</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Acquisition (Details) - Schedule of fair value of assets acquired and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable</Role>
      <ShortName>Acquisition (Details) - Schedule of fair value of assets acquired and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Acquisition (Details) - Schedule of pro forma consolidated results</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable</Role>
      <ShortName>Acquisition (Details) - Schedule of pro forma consolidated results</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Share Capital and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails</Role>
      <ShortName>Share Capital and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Share Capital and Reserves (Details) - Schedule of private placement offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable</Role>
      <ShortName>Share Capital and Reserves (Details) - Schedule of private placement offering</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable</Role>
      <ShortName>Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable</Role>
      <ShortName>Share Capital and Reserves (Details) - Schedule of changes in agents warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Share-Based Payments (Details) - Schedule of outstanding options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable</Role>
      <ShortName>Share-Based Payments (Details) - Schedule of outstanding options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails</Role>
      <ShortName>Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Lease Obligations (Details) - Schedule of minimum lease payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable</Role>
      <ShortName>Lease Obligations (Details) - Schedule of minimum lease payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Basic and Diluted Loss Per Share (Details) - Schedule of weighted average number of common shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable</Role>
      <ShortName>Basic and Diluted Loss Per Share (Details) - Schedule of weighted average number of common shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Income Taxes (Details) - Schedule of a reconciliation of income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of a reconciliation of income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Segment Information (Details) - Schedule of reportable segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable</Role>
      <ShortName>Segment Information (Details) - Schedule of reportable segments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Non-Cash Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails</Role>
      <ShortName>Non-Cash Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Financial Risk Management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails</Role>
      <ShortName>Financial Risk Management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Financial Risk Management (Details) - Schedule of fair value and carrying values of the company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable</Role>
      <ShortName>Financial Risk Management (Details) - Schedule of fair value and carrying values of the company</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f10k2022_inmedpharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents</ParentRole>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityPublicFloat, inm:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment -  f10k2022_inmedpharma.htm 14929, 14930, 14931, 14932, 15009, 15053</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 3 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommonStockNoParValue, us-gaap:CommonStockSharesAuthorizedUnlimited -  f10k2022_inmedpharma.htm 14918, 14919, 14920</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="f10k2022_inmedpharma.htm">f10k2022_inmedpharma.htm</File>
    <File>f10k2022ex21-1_inmedpharma.htm</File>
    <File>f10k2022ex23-1_inmedpharma.htm</File>
    <File>f10k2022ex31-1_inmedpharma.htm</File>
    <File>f10k2022ex31-2_inmedpharma.htm</File>
    <File>f10k2022ex32-1_inmedpharma.htm</File>
    <File>f10k2022ex32-2_inmedpharma.htm</File>
    <File>inm-20220630.xsd</File>
    <File>inm-20220630_cal.xml</File>
    <File>inm-20220630_def.xml</File>
    <File>inm-20220630_lab.xml</File>
    <File>inm-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
    <File>image_018.jpg</File>
    <File>image_019.jpg</File>
    <File>image_020.jpg</File>
    <File>image_021.jpg</File>
    <File>image_022.jpg</File>
    <File>image_023.jpg</File>
    <File>image_024.jpg</File>
    <File>image_025.jpg</File>
    <File>image_026.jpg</File>
    <File>image_027.jpg</File>
    <File>image_028.jpg</File>
    <File>image_029.jpg</File>
    <File>image_030.jpg</File>
    <File>image_031.jpg</File>
    <File>image_032.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="556">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>128
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2022_inmedpharma.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "inm-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "inm-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2022_inmedpharma.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inm-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inm-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "inm-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 591,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 76,
    "http://www.Inmedpharmaceuticalsinc.com/20220630": 58,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 138
   },
   "keyCustom": 115,
   "keyStandard": 304,
   "memberCustom": 21,
   "memberStandard": 20,
   "nsprefix": "inm",
   "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Customer Concentration",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration",
     "shortName": "Customer Concentration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Inventories",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Property, Equipment and Rou Assets, Net",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet",
     "shortName": "Property, Equipment and Rou Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Impairment of Intangible Assets and Goodwill",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill",
     "shortName": "Impairment of Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Intangible Assets",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:AcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Acquisition",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/Acquisition",
     "shortName": "Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:AcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Accounts Payable and Accrued Liabilities",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:ShareCapitalAndReservesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Share Capital and Reserves",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves",
     "shortName": "Share Capital and Reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:ShareCapitalAndReservesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Share-Based Payments",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Lease Obligations",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations",
     "shortName": "Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Basic and Diluted Loss Per Share",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare",
     "shortName": "Basic and Diluted Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Income Taxes",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Segment Information",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:NonCashTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Non-Cash Transactions",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions",
     "shortName": "Non-Cash Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:NonCashTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Commitments and Contingencies",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:FinancialRiskManagementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Financial Risk Management",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement",
     "shortName": "Financial Risk Management",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:FinancialRiskManagementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Related Party Transactions",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Subsequent Events",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Inventories (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Property, Equipment and Rou Assets, Net (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables",
     "shortName": "Property, Equipment and Rou Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Impairment of Intangible Assets and Goodwill (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables",
     "shortName": "Impairment of Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Acquisition (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables",
     "shortName": "Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:ScheduleOfPrivatePlacementOfferingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Share Capital and Reserves (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables",
     "shortName": "Share Capital and Reserves (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:ScheduleOfPrivatePlacementOfferingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Lease Obligations (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables",
     "shortName": "Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Basic and Diluted Loss Per Share (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables",
     "shortName": "Basic and Diluted Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Segment Information (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Financial Risk Management (Tables)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables",
     "shortName": "Financial Risk Management (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Nature of Business and Going Concern (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails",
     "shortName": "Nature of Business and Going Concern (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Significant Accounting Policies (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Customer Concentration (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails",
     "shortName": "Customer Concentration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Inventories (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Inventories (Details) - Schedule of inventories",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable",
     "shortName": "Inventories (Details) - Schedule of inventories",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of property, equipment and right of use assets",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable",
     "shortName": "Property, Equipment and Rou Assets, Net (Details) - Schedule of property, equipment and right of use assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Impairment of Intangible Assets and Goodwill (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails",
     "shortName": "Impairment of Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable",
     "shortName": "Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Intangible Assets (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails",
     "shortName": "Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0",
     "shortName": "Intangible Assets (Details) - Schedule of intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Intangible Assets (Details) - Schedule of amortization expense",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable",
     "shortName": "Intangible Assets (Details) - Schedule of amortization expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockOtherSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Acquisition (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
     "shortName": "Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockOtherSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c51",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Acquisition (Details) - Schedule of total consideration",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable",
     "shortName": "Acquisition (Details) - Schedule of total consideration",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c51",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c52",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Acquisition (Details) - Schedule of fair value of assets acquired and liabilities",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable",
     "shortName": "Acquisition (Details) - Schedule of fair value of assets acquired and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c52",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Acquisition (Details) - Schedule of pro forma consolidated results",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable",
     "shortName": "Acquisition (Details) - Schedule of pro forma consolidated results",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable",
     "shortName": "Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c57",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Share Capital and Reserves (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails",
     "shortName": "Share Capital and Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c57",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:TotalCommonShareValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Share Capital and Reserves (Details) - Schedule of private placement offering",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable",
     "shortName": "Share Capital and Reserves (Details) - Schedule of private placement offering",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:TotalCommonShareValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "inm:ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "inm:ShareBasedPaymentNumberOfExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable",
     "shortName": "Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "inm:ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "inm:ShareBasedPaymentNumberOfExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "inm:ScheduleOfChangesInAgentsWarrantsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c92",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "inm:ShareBasedPaymentSharesNumberOfGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents warrants",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable",
     "shortName": "Share Capital and Reserves (Details) - Schedule of changes in agents warrants",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "inm:ScheduleOfChangesInAgentsWarrantsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c92",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "inm:ShareBasedPaymentSharesNumberOfGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c93",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "inm:IssuedAndOutstandingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c93",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "inm:IssuedAndOutstandingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Share-Based Payments (Details) - Schedule of outstanding options",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable",
     "shortName": "Share-Based Payments (Details) - Schedule of outstanding options",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Lease Obligations (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails",
     "shortName": "Lease Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Lease Obligations (Details) - Schedule of minimum lease payments",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable",
     "shortName": "Lease Obligations (Details) - Schedule of minimum lease payments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Basic and Diluted Loss Per Share (Details) - Schedule of weighted average number of common shares",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable",
     "shortName": "Basic and Diluted Loss Per Share (Details) - Schedule of weighted average number of common shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Income Taxes (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Income Taxes (Details) - Schedule of a reconciliation of income taxes",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of a reconciliation of income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Segment Information (Details) - Schedule of reportable segments",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable",
     "shortName": "Segment Information (Details) - Schedule of reportable segments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "inm:OtherOperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c108",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Non-Cash Transactions (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails",
     "shortName": "Non-Cash Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c108",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:CostOfServicesDirectsMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:CostOfServicesDirectsMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Financial Risk Management (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails",
     "shortName": "Financial Risk Management (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Financial Risk Management (Details) - Schedule of fair value and carrying values of the company",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable",
     "shortName": "Financial Risk Management (Details) - Schedule of fair value and carrying values of the company",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c116",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:LegalService",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c116",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inm:LegalService",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c118",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c118",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Nature of Business and Going Concern",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern",
     "shortName": "Nature of Business and Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Significant Accounting Policies",
     "role": "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_inmedpharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 42,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "inm_ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATMMember",
        "terseLabel": "ATM [Member]"
       }
      }
     },
     "localname": "ATMMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_ATMOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of ATM offering, net of issuance costs.",
        "label": "ATMOffering Net Of Issuance Costs",
        "terseLabel": "ATM offering, net of issuance costs"
       }
      }
     },
     "localname": "ATMOfferingNetOfIssuanceCosts",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ATMOfferingNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM offering, net of issuance costs.",
        "label": "ATMOffering Net Of Issuance Costs Shares",
        "terseLabel": "ATM offering, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "ATMOfferingNetOfIssuanceCostsShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued research and development expenses.",
        "label": "Accrued Research And Development",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_AcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Abstract"
       }
      }
     },
     "localname": "AcquisitionAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_AcquisitionConsiderationPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition consideration payable.",
        "label": "Acquisition Consideration Payable",
        "terseLabel": "Acquisition consideration payable"
       }
      }
     },
     "localname": "AcquisitionConsiderationPayable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_AcquisitionDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition (Details) [Line Items]"
       }
      }
     },
     "localname": "AcquisitionDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition (Details) - Schedule of fair value of assets acquired and liabilities [Line Items]"
       }
      }
     },
     "localname": "AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition (Details) - Schedule of fair value of assets acquired and liabilities [Table]"
       }
      }
     },
     "localname": "AcquisitionDetailsScheduleoffairvalueofassetsacquiredandliabilitiesTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_AcquisitionDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition (Details) [Table]"
       }
      }
     },
     "localname": "AcquisitionDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_AcquisitionOfBayMedica": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of baymedica.",
        "label": "Acquisition Of Bay Medica",
        "terseLabel": "Acquisition of BayMedica"
       }
      }
     },
     "localname": "AcquisitionOfBayMedica",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_AcquisitionOfBayMedicainShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares acquisition of baymedica.",
        "label": "Acquisition Of Bay Medicain Shares",
        "terseLabel": "Acquisition of BayMedica (in Shares)"
       }
      }
     },
     "localname": "AcquisitionOfBayMedicainShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_AcquisitionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Text Block",
        "terseLabel": "ACQUISITION"
       }
      }
     },
     "localname": "AcquisitionTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/Acquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_AgentsInvestmentOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of agents' investment options.",
        "label": "Agents Investment Options",
        "terseLabel": "Agents' investment options"
       }
      }
     },
     "localname": "AgentsInvestmentOptions",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_AgentsInvestmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agents Investment Options Member",
        "terseLabel": "Agents\u2019 Investment Options [Member]"
       }
      }
     },
     "localname": "AgentsInvestmentOptionsMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_AgentsWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of agents\u2019 warrants.\r  \n.",
        "label": "Agents Warrants",
        "terseLabel": "Agents' warrants"
       }
      }
     },
     "localname": "AgentsWarrants",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_AgentsWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agents Warrants Member",
        "terseLabel": "Agents' Warrants [Member]"
       }
      }
     },
     "localname": "AgentsWarrantsMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_AggregateIntrinsicValueAtBeginning": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value At Beginning",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance (in Dollars)",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance (in Dollars)"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAtBeginning",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_AggregateIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value granted.",
        "label": "Aggregate Intrinsic Value Granted",
        "terseLabel": "Aggregate Intrinsic Value, Granted (in Dollars)"
       }
      }
     },
     "localname": "AggregateIntrinsicValueGranted",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_AllocatedToAdditionalPaidinCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated To Additional Paidin Capital Member",
        "terseLabel": "Allocated to Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AllocatedToAdditionalPaidinCapitalMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_BayMedicaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bay Medica Agreement Member",
        "terseLabel": "BayMedica Agreement [Member]"
       }
      }
     },
     "localname": "BayMedicaAgreementMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_BayMedicaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bay Medica Inc Member",
        "terseLabel": "BayMedica\u2019s [Member]",
        "verboseLabel": "BayMedica Inc. [Member]"
       }
      }
     },
     "localname": "BayMedicaIncMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_BayMedicaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bay Medica Member",
        "terseLabel": "BayMedica [Member]"
       }
      }
     },
     "localname": "BayMedicaMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_BusinessCombinationPostclosingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount of Post-closing adjustments.",
        "label": "Business Combination Postclosing Adjustments",
        "terseLabel": "Less:Post-closing adjustments"
       }
      }
     },
     "localname": "BusinessCombinationPostclosingAdjustments",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In-process Research And Development",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIn-processResearchAndDevelopment",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash",
        "terseLabel": "cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other Shortterm Liabilities",
        "terseLabel": "Other short-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherShorttermLiabilities",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount of patents.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Patents",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPatents",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of trademark.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trademark",
        "terseLabel": "Trademark"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTrademark",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_COVID19ImpactsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COVID19 Impacts Policy Text Block",
        "terseLabel": "COVID-19 Impacts"
       }
      }
     },
     "localname": "COVID19ImpactsPolicyTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_CannabinoidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cannabinoid Member",
        "terseLabel": "Cannabinoid [Member]"
       }
      }
     },
     "localname": "CannabinoidMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_CashAcquiredFromAcqusition": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash acquired from acqusition.",
        "label": "Cash Acquired From Acqusition",
        "terseLabel": "Cash acquired from acquisition of BayMedica"
       }
      }
     },
     "localname": "CashAcquiredFromAcqusition",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_CashAndCashEquivalent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent.",
        "label": "Cash And Cash Equivalent",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalent",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_CommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares or common stock is a class of stock issued by corporations that represent ownership in the corporation for shareholders. The hope is that the company will grow and prosper, driving up the price of their shares. Being a common shareholder is a way for investors to benefit from the growth of a company.",
        "label": "Common Shares",
        "terseLabel": "Common shares (in Shares)"
       }
      }
     },
     "localname": "CommonShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_CommonSharesConsultingServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares consulting services.",
        "label": "Common Shares Consulting Services",
        "terseLabel": "Common shares consulting services"
       }
      }
     },
     "localname": "CommonSharesConsultingServices",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_CommonSharesNetIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares net issuance.",
        "label": "Common Shares Net Issuance",
        "terseLabel": "Net issuance costs (in Dollars)"
       }
      }
     },
     "localname": "CommonSharesNetIssuance",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ConcentrationRiskPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage",
        "terseLabel": "Concentration percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inm_CostOfServicesDirectsMaterials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of materials used in services rendered by an entity during the reporting period.",
        "label": "Cost Of Services Directs Materials",
        "terseLabel": "Materials cost"
       }
      }
     },
     "localname": "CostOfServicesDirectsMaterials",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_CustomerConcentrationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration (Details) [Line Items]"
       }
      }
     },
     "localname": "CustomerConcentrationDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_CustomerConcentrationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration (Details) [Table]"
       }
      }
     },
     "localname": "CustomerConcentrationDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One Member",
        "terseLabel": "Customer One [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_DeferredTaxAssetLiabilitiesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net deferred tax asset, net.",
        "label": "Deferred Tax Asset Liabilities Net",
        "terseLabel": "Net deferred tax asset, net"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilitiesNet",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_DeferredTaxAssetsAndLiabilitiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets and liabilities, gross.",
        "label": "Deferred Tax Assets And Liabilities Gross",
        "terseLabel": "Deferred tax assets and liabilities, gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsAndLiabilitiesGross",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_DeferredTaxAssetsFinancingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing costs.",
        "label": "Deferred Tax Assets Financing Cost",
        "terseLabel": "Financing costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsFinancingCost",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_DeferredTaxAssetsIntangibleAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets, net.",
        "label": "Deferred Tax Assets Intangible Assets Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntangibleAssetsNet",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_DeferredTaxAssetsLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease obligations.",
        "label": "Deferred Tax Assets Lease Obligations",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseObligations",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_DeferredTaxAssetsPropertyAndEquipmentsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets Property And Equipments Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyAndEquipmentsNet",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_EstimatedFairValueCommonShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value common shares.",
        "label": "Estimated Fair Value Common Shares",
        "terseLabel": "Estimated fair value common shares"
       }
      }
     },
     "localname": "EstimatedFairValueCommonShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ExerciseOfPrefundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of pre-funded warrants.",
        "label": "Exercise Of Prefunded Warrants",
        "terseLabel": "Exercise of pre-funded warrants"
       }
      }
     },
     "localname": "ExerciseOfPrefundedWarrants",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ExerciseOfPrefundedWarrantsinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares exercise of pre-funded warrants.",
        "label": "Exercise Of Prefunded Warrantsin Shares",
        "terseLabel": "Exercise of pre-funded warrants (in Shares)"
       }
      }
     },
     "localname": "ExerciseOfPrefundedWarrantsinShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ExerciseOfWarrantsin": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "Exercise Of Warrantsin",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ExerciseOfWarrantsin",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ExerciseOfWarrantsinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "Exercise Of Warrantsin Shares",
        "terseLabel": "Exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "ExerciseOfWarrantsinShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ExercisedCommonSharesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercised common shares description.",
        "label": "Exercised Common Shares Description",
        "terseLabel": "Exercised common shares description"
       }
      }
     },
     "localname": "ExercisedCommonSharesDescription",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ExpenditureBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The balance of expenditure is the balance of spending against the amount of available funds. While this may seem to be a relatively simple process, balancing expenditures can be complex when credit accounts, payables and receivables become involved.",
        "label": "Expenditure Balance",
        "terseLabel": "Balance of expenditure"
       }
      }
     },
     "localname": "ExpenditureBalance",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_FinanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of finance expense.",
        "label": "Finance Expense",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "FinanceExpense",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_FinancialAssetsAndLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Assets and Liabilities Policy Text Block",
        "label": "Financial Assets And Liabilities Policy Text Block",
        "terseLabel": "Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FinancialAssetsAndLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_FinancialRiskManagementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management [Abstract]"
       }
      }
     },
     "localname": "FinancialRiskManagementAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_FinancialRiskManagementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management (Details) [Line Items]"
       }
      }
     },
     "localname": "FinancialRiskManagementDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_FinancialRiskManagementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management (Details) [Table]"
       }
      }
     },
     "localname": "FinancialRiskManagementDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_FinancialRiskManagementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management Text Block",
        "terseLabel": "FINANCIAL RISK MANAGEMENT"
       }
      }
     },
     "localname": "FinancialRiskManagementTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_FiniteLivedIntangibleAssetNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Asset Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetNet",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ForeignCurrencyRiskPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk, percentage.",
        "label": "Foreign Currency Risk Percentage",
        "terseLabel": "Foreign currency risk, percentage"
       }
      }
     },
     "localname": "ForeignCurrencyRiskPercentage",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inm_GrossProceedsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds Member",
        "terseLabel": "Gross Proceeds [Member]"
       }
      }
     },
     "localname": "GrossProceedsMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_GuaranteedInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guaranteed investment.",
        "label": "Guaranteed Investment",
        "terseLabel": "Guaranteed investment face value"
       }
      }
     },
     "localname": "GuaranteedInvestment",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_IPOWarrantIssue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPOWarrant Issue",
        "terseLabel": "Warrant issue"
       }
      }
     },
     "localname": "IPOWarrantIssue",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_IPRDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPRDMember",
        "terseLabel": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "IPRDMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_ImpairmentOfIntangibleAssetExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment Of Intangible Asset Excluding Goodwill",
        "terseLabel": "Definite lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetExcludingGoodwill",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment Of Intangible Asset Indefinitelived Excluding Goodwill",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets and Goodwill (Details) [Line Items]"
       }
      }
     },
     "localname": "ImpairmentofIntangibleAssetsandGoodwillDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Line Items]"
       }
      }
     },
     "localname": "ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets and Goodwill (Details) - Schedule of intangible assets [Table]"
       }
      }
     },
     "localname": "ImpairmentofIntangibleAssetsandGoodwillDetailsScheduleofintangibleassetsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ImpairmentofIntangibleAssetsandGoodwillDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets and Goodwill (Details) [Table]"
       }
      }
     },
     "localname": "ImpairmentofIntangibleAssetsandGoodwillDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_InMedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Med Member",
        "terseLabel": "InMed [Member]"
       }
      }
     },
     "localname": "InMedMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_InProcessRDPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-Process R&amp;D policy Text Block",
        "label": "In Process RDPolicy Text Block",
        "terseLabel": "In-Process R&amp;D"
       }
      }
     },
     "localname": "InProcessRDPolicyTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_IncreaseReductionInIncomeTaxesResultingFromAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Reduction In Income Taxes Resulting From Abstract",
        "terseLabel": "Increase (reduction) in income taxes resulting from:"
       }
      }
     },
     "localname": "IncreaseReductionInIncomeTaxesResultingFromAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_InterestIncomeaccruedReceivedOnShorttermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income (accrued) received on short-term investments.",
        "label": "Interest Incomeaccrued Received On Shortterm Investments",
        "terseLabel": "Interest income received on short-term investments"
       }
      }
     },
     "localname": "InterestIncomeaccruedReceivedOnShorttermInvestments",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_InvestmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Options Member",
        "terseLabel": "Investment Options [Member]"
       }
      }
     },
     "localname": "InvestmentOptionsMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_IssuanceOfCommonSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Issuance Of Common Shares Issued",
        "terseLabel": "Issuance of common shares issued"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesIssued",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_IssuedAndOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued and outstanding, percentage",
        "label": "Issued And Outstanding Percentage",
        "terseLabel": "Issued and outstanding, percentage"
       }
      }
     },
     "localname": "IssuedAndOutstandingPercentage",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inm_June302022Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June302022 Abstract",
        "terseLabel": "June 30, 2022:"
       }
      }
     },
     "localname": "June302022Abstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_LeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability.",
        "label": "Lease Liabilities",
        "negatedLabel": "Lease liability"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_LeaseObligationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Obligations (Details) [Line Items]"
       }
      }
     },
     "localname": "LeaseObligationsDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_LeaseObligationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Obligations (Details) [Table]"
       }
      }
     },
     "localname": "LeaseObligationsDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_LegalService": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Service",
        "terseLabel": "Legal services"
       }
      }
     },
     "localname": "LegalService",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_LesseeOperatingLeaseLiabilityPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payment Due",
        "terseLabel": "Total undiscounted lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentDue",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payment Due After Year Five",
        "terseLabel": "More than five years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentDueAfterYearFive",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payment Due Next Twelve Months",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentDueNextTwelveMonths",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_LesseeOperatingLeaseLiabilityPaymentDueYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payment Due Year Five",
        "terseLabel": "One to five years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentDueYearFive",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_LiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Assumed Abstract",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "LiabilitiesAssumedAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_LossAndComprehensiveIncomelossesForThePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss and comprehensive income (loss) for the period.\r   \n.",
        "label": "Loss And Comprehensive Incomelosses For The Period",
        "terseLabel": "Loss and comprehensive income for the period"
       }
      }
     },
     "localname": "LossAndComprehensiveIncomelossesForThePeriod",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_LossAndComprehensivelossesForThePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss for the period.",
        "label": "Loss And Comprehensivelosses For The Period",
        "terseLabel": "Loss for the period"
       }
      }
     },
     "localname": "LossAndComprehensivelossesForThePeriod",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_NatureofBusinessandGoingConcernLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Information and Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "NatureofBusinessandGoingConcernLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_NatureofBusinessandGoingConcernTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business and Going Concern [Table]"
       }
      }
     },
     "localname": "NatureofBusinessandGoingConcernTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_NonCashTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Transactions [Abstract]"
       }
      }
     },
     "localname": "NonCashTransactionsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_NonCashTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "NonCashTransactionsDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_NonCashTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Transactions (Details) [Table]"
       }
      }
     },
     "localname": "NonCashTransactionsDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_NonCashTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Transactions Text Block",
        "terseLabel": "NON-CASH TRANSACTIONS"
       }
      }
     },
     "localname": "NonCashTransactionsTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_NumberOfUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of unvested.",
        "label": "Number Of Unvested",
        "terseLabel": "Number of Unvested"
       }
      }
     },
     "localname": "NumberOfUnvested",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_NumberOfVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Vested and exercisable.",
        "label": "Number Of Vested And Exercisable",
        "terseLabel": "Number of Vested and exercisable"
       }
      }
     },
     "localname": "NumberOfVestedAndExercisable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_OtherOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Other Operating Expenses",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OtherOperatingExpenses",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_OtherVariableLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Other Variable Lease Cost",
        "terseLabel": "Estimated variable operating costs"
       }
      }
     },
     "localname": "OtherVariableLeaseCost",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_PatentsAndIntellectualPropertyCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Intellectual Property Costs Policy [Text Block]",
        "label": "Patents And Intellectual Property Costs Policy Text Block",
        "terseLabel": "Patents and Intellectual Property Costs"
       }
      }
     },
     "localname": "PatentsAndIntellectualPropertyCostsPolicyTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_PreferredInvestmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Investment Options Member",
        "terseLabel": "Preferred Investment Options [Member]"
       }
      }
     },
     "localname": "PreferredInvestmentOptionsMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_PrefundWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares pre-fund warrants.",
        "label": "Prefund Warrants",
        "terseLabel": "Pre-funded warrants"
       }
      }
     },
     "localname": "PrefundWarrants",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_PrefundedWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants",
        "terseLabel": "Pre-funded warrants (in Dollars)"
       }
      }
     },
     "localname": "PrefundedWarrants",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_PrefundedWarrantsIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants Issued Member",
        "terseLabel": "Pre-funded Warrants Issued [Member]"
       }
      }
     },
     "localname": "PrefundedWarrantsIssuedMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_PurchasePriceConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price Consideration Member",
        "terseLabel": "Purchase Price Consideration [Member]"
       }
      }
     },
     "localname": "PurchasePriceConsiderationMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_RecognizedTaxBenefits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized tax benefits.",
        "label": "Recognized Tax Benefits",
        "terseLabel": "Recognized tax benefits percentage"
       }
      }
     },
     "localname": "RecognizedTaxBenefits",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inm_RegisteredDirectAndPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of registered direct and private placement.",
        "label": "Registered Direct And Private Placement",
        "terseLabel": "Registered direct and private placement"
       }
      }
     },
     "localname": "RegisteredDirectAndPrivatePlacement",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_RegisteredDirectAndPrivatePlacementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct and private placement.",
        "label": "Registered Direct And Private Placement Shares",
        "terseLabel": "Registered direct and private placement (in Shares)"
       }
      }
     },
     "localname": "RegisteredDirectAndPrivatePlacementShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_RightOfUseAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right Of Use Asset Member",
        "terseLabel": "Right of Use Asset (leases) [Member]"
       }
      }
     },
     "localname": "RightOfUseAssetMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_ScheduleOfAReconciliationOfIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of AReconciliation Of Income Taxes Abstract"
       }
      }
     },
     "localname": "ScheduleOfAReconciliationOfIncomeTaxesAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts Payable And Accrued Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amortization Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfAmortizationExpenseAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfChangesInAgentsWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In Agents Warrants Abstract"
       }
      }
     },
     "localname": "ScheduleOfChangesInAgentsWarrantsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of changes in agents warrants.",
        "label": "Schedule Of Changes In Agents Warrants Table Text Block",
        "terseLabel": "Schedule of changes in agents warrants"
       }
      }
     },
     "localname": "ScheduleOfChangesInAgentsWarrantsTableTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_ScheduleOfChangesInSharePurchaseWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In Share Purchase Warrants Abstract"
       }
      }
     },
     "localname": "ScheduleOfChangesInSharePurchaseWarrantsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In Share Purchase Warrants Table Text Block",
        "terseLabel": "Schedule of changes in share purchase warrants"
       }
      }
     },
     "localname": "ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Shares Basic And Diluted Table Text Block",
        "terseLabel": "Schedule of weighted average number of common shares"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value And Carrying Values Of The Company Abstract"
       }
      }
     },
     "localname": "ScheduleOfFairValueAndCarryingValuesOfTheCompanyAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Assets Acquired And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Inventories Abstract"
       }
      }
     },
     "localname": "ScheduleOfInventoriesAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfMinimumLeasePaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Minimum Lease Payments Abstract"
       }
      }
     },
     "localname": "ScheduleOfMinimumLeasePaymentsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfOutstandingOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Options Abstract"
       }
      }
     },
     "localname": "ScheduleOfOutstandingOptionsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfPrivatePlacementOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Private Placement Offering Abstract"
       }
      }
     },
     "localname": "ScheduleOfPrivatePlacementOfferingAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfPrivatePlacementOfferingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Private Placement Offering Table Text Block",
        "terseLabel": "Schedule of private placement offering"
       }
      }
     },
     "localname": "ScheduleOfPrivatePlacementOfferingTableTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_ScheduleOfProFormaConsolidatedResultsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Pro Forma Consolidated Results Abstract"
       }
      }
     },
     "localname": "ScheduleOfProFormaConsolidatedResultsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Equipment And Right Of Use Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyEquipmentAndRightOfUseAssetsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reportable Segments Abstract"
       }
      }
     },
     "localname": "ScheduleOfReportableSegmentsAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfTotalConsiderationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Total Consideration Abstract"
       }
      }
     },
     "localname": "ScheduleOfTotalConsiderationAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Number Of Common Shares Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfCommonSharesAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross",
        "terseLabel": "Options shares (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Share Price, Beginning balance",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Share Price Balance",
        "periodEndLabel": "Weighted Average Share Price, Ending balance (in Dollars per share)",
        "periodStartLabel": "Weighted Average Share Price, Beginning balance (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageSharePriceBalance",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, expired/Forfeited",
        "label": "Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Expired Forfeited",
        "terseLabel": "Weighted Average Exercise Price, Expired/Forfeited (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, granted.",
        "label": "Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Granted",
        "terseLabel": "Weighted Average Exercise Price, Granted (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Shares Based Payments Awards Option Outstandings Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Aggregate Intrinsic Value At Beginning",
        "terseLabel": "Aggregate Intrinsic Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedPaymentAggregateIntrinsicValueAtBeginning",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Aggregate Intrinsic Value Balance At Ending",
        "terseLabel": "Aggregate Intrinsic Value, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedPaymentAggregateIntrinsicValueBalanceAtEnding",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ShareBasedPaymentAggregateIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Aggregate Intrinsic Value Granted",
        "terseLabel": "Aggregate Intrinsic Value, Granted"
       }
      }
     },
     "localname": "ShareBasedPaymentAggregateIntrinsicValueGranted",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ShareBasedPaymentNumberOfBalanceAtBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Number Of Balance At Beginning",
        "terseLabel": "Number of Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedPaymentNumberOfBalanceAtBeginning",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareBasedPaymentNumberOfBalanceAtEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Number Of Balance At Ending",
        "terseLabel": "Number of Ending Balance"
       }
      }
     },
     "localname": "ShareBasedPaymentNumberOfBalanceAtEnding",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareBasedPaymentNumberOfExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Payment Number Of Exercised",
        "terseLabel": "Number of Exercised"
       }
      }
     },
     "localname": "ShareBasedPaymentNumberOfExercised",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareBasedPaymentNumberOfGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of granted.",
        "label": "Share Based Payment Number Of Granted",
        "terseLabel": "Number of Granted"
       }
      }
     },
     "localname": "ShareBasedPaymentNumberOfGranted",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareBasedPaymentSharesNumberOfGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Shares Number Of Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedPaymentSharesNumberOfGranted",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Weighted Average Share Price Balance At Beginning",
        "terseLabel": "Weighted Average Share Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Share Price, Ending Balance.",
        "label": "Share Based Payment Weighted Average Share Price Balance At Ending",
        "terseLabel": "Weighted Average Share Price, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedPaymentWeightedAverageSharePriceBalanceAtEnding",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_ShareBasedPaymentWeightedAverageSharePriceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Weighted Average Share Price Granted",
        "terseLabel": "Weighted Average Share Price, Granted"
       }
      }
     },
     "localname": "ShareBasedPaymentWeightedAverageSharePriceGranted",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_ShareBasedPaymentsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareBasedPaymentsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareBasedPaymentsWeightedAverageSharePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Payments Weighted Average Share Price Exercised",
        "terseLabel": "Weighted Average Share Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedPaymentsWeightedAverageSharePriceExercised",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareCapitalAndReservesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital And Reserves [Abstract]"
       }
      }
     },
     "localname": "ShareCapitalAndReservesAbstract",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalAndReservesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital And Reserves Text Block",
        "terseLabel": "SHARE CAPITAL AND RESERVES"
       }
      }
     },
     "localname": "ShareCapitalAndReservesTextBlock",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inm_ShareCapitalOfNumberOfBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital Of Number Of Balance",
        "periodEndLabel": "Number of Ending balance",
        "periodStartLabel": "Number of Beginning balance"
       }
      }
     },
     "localname": "ShareCapitalOfNumberOfBalance",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_ShareCapitalandReservesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Line Items]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Table]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants [Line Items]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) - Schedule of changes in share purchase warrants [Table]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsScheduleofchangesinsharepurchasewarrantsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) - Schedule of private placement offering [Line Items]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsScheduleofprivateplacementofferingLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) - Schedule of private placement offering [Table]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsScheduleofprivateplacementofferingTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareCapitalandReservesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Reserves (Details) [Table]"
       }
      }
     },
     "localname": "ShareCapitalandReservesDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_ShareIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issuance costs.",
        "label": "Share Issuance Costs",
        "terseLabel": "Share issuance costs"
       }
      }
     },
     "localname": "ShareIssuanceCosts",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_ShareIssuanceCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Issuance Costs Member",
        "terseLabel": "Share issuance costs [Member]"
       }
      }
     },
     "localname": "ShareIssuanceCostsMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_SharePurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Member",
        "terseLabel": "Share Purchase Warrants [Member]",
        "verboseLabel": "Share purchase warrants [Member]"
       }
      }
     },
     "localname": "SharePurchaseWarrantsMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers",
        "periodEndLabel": "Number of Ending balance",
        "periodStartLabel": "Number of Beginning balance"
       }
      }
     },
     "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Beginning balance (in Dollars per share)"
       }
      }
     },
     "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_SharesIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued Member",
        "terseLabel": "Shares Issued [Member]"
       }
      }
     },
     "localname": "SharesIssuedMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_ShortTermInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investment",
        "terseLabel": "Cash and cash equivalents and short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestment",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Issued For Private Placement.",
        "label": "Stock Issued During Period Value Issued For Private Placement",
        "terseLabel": "Private placement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForPrivatePlacement",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Issued For Private Placement Shares.",
        "label": "Stock Issued During Period Value Issued For Private Placement Shares",
        "terseLabel": "Private placement (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_TotalCommonShareValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total share value.",
        "label": "Total Common Share Value",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "TotalCommonShareValue",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_TransactionCostsAllocatedToAdditionalPaidinCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs allocated to additional paid-in capital.",
        "label": "Transaction Costs Allocated To Additional Paidin Capital",
        "terseLabel": "Transaction costs allocated to additional paid-in capital (in Dollars)"
       }
      }
     },
     "localname": "TransactionCostsAllocatedToAdditionalPaidinCapital",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_TypeOfCurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Currency Axis",
        "terseLabel": "Type Of Currency [Axis]"
       }
      }
     },
     "localname": "TypeOfCurrencyAxis",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inm_TypeOfCurrencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypeOfCurrency [Domain]"
       }
      }
     },
     "localname": "TypeOfCurrencyDomain",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_USDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USDMember",
        "terseLabel": "U.S. Dollar [Member]"
       }
      }
     },
     "localname": "USDMember",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inm_UnrealizedGainOnDerivativeWarrantsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on derivative warrants liability.",
        "label": "Unrealized Gain On Derivative Warrants Liability",
        "negatedLabel": "Unrealized gain on derivative warrants liability"
       }
      }
     },
     "localname": "UnrealizedGainOnDerivativeWarrantsLiability",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_UnrealizedGainOnForeignExchange": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Of Unrealized gain on foreign exchange.",
        "label": "Unrealized Gain On Foreign Exchange",
        "negatedLabel": "Unrealized foreign exchange loss"
       }
      }
     },
     "localname": "UnrealizedGainOnForeignExchange",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_WarrantExpiryDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Expiry Date",
        "terseLabel": "Warrant expiry date"
       }
      }
     },
     "localname": "WarrantExpiryDate",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "inm_WarrantModificationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of warrant modification expense.",
        "label": "Warrant Modification Expense",
        "negatedLabel": "Warrant modification expense",
        "terseLabel": "Warrant modification expense"
       }
      }
     },
     "localname": "WarrantModificationExpense",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_WarrantModificationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrant modification expense.",
        "label": "Warrant Modification Expenses",
        "terseLabel": "Warrant modification expense"
       }
      }
     },
     "localname": "WarrantModificationExpenses",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_WarrantsIssuanceTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issuance Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "WarrantsIssuanceTerm",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inm_WarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued.",
        "label": "Warrants Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_WarrantsModificationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Modification Expense",
        "terseLabel": "Warrants modification expense (in Dollars)"
       }
      }
     },
     "localname": "WarrantsModificationExpense",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inm_WarrantsToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants are a derivative that give the right, but not the obligation, to buy or sell a security\u2014most commonly an equity\u2014at a certain price before expiration. The price at which the underlying security can be bought or sold is referred to as the exercise price or strike price.",
        "label": "Warrants To Purchase",
        "terseLabel": "Warrants to purchase (in Shares)"
       }
      }
     },
     "localname": "WarrantsToPurchase",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inm_WeightedAverageExercisePriceUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Unvested.",
        "label": "Weighted Average Exercise Price Unvested",
        "terseLabel": "Weighted Average Exercise Price, Unvested (in Dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceUnvested",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_WeightedAverageExercisePriceVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Vested and exercisable.",
        "label": "Weighted Average Exercise Price Vested And Exercisable",
        "terseLabel": "Weighted Average Exercise Price, Vested and exercisable (in Dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceVestedAndExercisable",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_WeightedAverageForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Forfeiture Rate.",
        "label": "Weighted Average Forfeiture Rate",
        "terseLabel": "Weighted average forfeiture rate"
       }
      }
     },
     "localname": "WeightedAverageForfeitureRate",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inm_WeightedAverageSharePriceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Share Price granted.",
        "label": "Weighted Average Share Price Granted",
        "terseLabel": "Weighted Average Share Price, Granted (in Dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageSharePriceGranted",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "inm_workingCapitalSurplus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital surplus.",
        "label": "working Capital Surplus",
        "terseLabel": "Working capital surplus"
       }
      }
     },
     "localname": "workingCapitalSurplus",
     "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220630",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r166",
      "r261",
      "r262",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r166",
      "r261",
      "r262",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r98",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r98",
      "r103",
      "r235",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r98",
      "r103",
      "r235",
      "r273",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "verboseLabel": "Accounts payable and accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r479",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r479",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Agreement payments paid"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r11",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land or leased assets).",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Excluding Capital Leased Assets",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r40",
      "r47",
      "r48",
      "r49",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income - Foreign Exchange"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r38",
      "r39",
      "r40",
      "r489",
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average estimated remaining useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r420"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r312",
      "r313",
      "r314",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Items not requiring cash:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based payment transactions (in Dollars)"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r72",
      "r207",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense on intangible assets (in Dollars)"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r14",
      "r86",
      "r141",
      "r152",
      "r159",
      "r184",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r363",
      "r368",
      "r384",
      "r418",
      "r420",
      "r475",
      "r488"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r86",
      "r184",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r363",
      "r368",
      "r384",
      "r418",
      "r420"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-Current"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r272",
      "r274",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r272",
      "r274",
      "r351",
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business Acquisition, Description of Acquired Entity",
        "terseLabel": "Description of business acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Acquisition percentage"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of pro forma consolidated results"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r359",
      "r360",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Estimated fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Estimated fair value of common shares issued"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "terseLabel": "Total liabilities acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Estimated fair value of net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueofassetsacquiredandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "auth_ref": [
      "r1"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital expenditure attributable to discontinued operations.",
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Expenditure amount"
       }
      }
     },
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r9",
      "r420",
      "r508",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash and cash equivalents subject to floating interest rates"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r9",
      "r74"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodStartLabel": "Cash and cash equivalents beginning of the period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r69",
      "r74",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents end of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r69",
      "r389"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash during the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Exercised warrants (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r236",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Issuance of common shares (in Shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common shares (in Shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".",
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "authorizedUnlimitedItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r420"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value, unlimited authorized shares 650,667 (June 30, 2021 - 322,028) issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonUnitIssued": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common units issued of limited liability company (LLC).",
        "label": "Common Unit, Issued",
        "terseLabel": "Common shares issued (in Shares)"
       }
      }
     },
     "localname": "CommonUnitIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45",
      "r52",
      "r482",
      "r496"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss for the year"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r126",
      "r127",
      "r166",
      "r382",
      "r383",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r126",
      "r127",
      "r166",
      "r382",
      "r383",
      "r507",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCustomer": {
     "auth_ref": [
      "r124",
      "r125",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).",
        "label": "Concentration Risk, Customer",
        "terseLabel": "Net sales description"
       }
      }
     },
     "localname": "ConcentrationRiskCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "CUSTOMER CONCENTRATION"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostDirectMaterial": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of material used for good produced and service rendered.",
        "label": "Cost, Direct Material",
        "terseLabel": "Materials and equipment cost"
       }
      }
     },
     "localname": "CostDirectMaterial",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r57",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Inventory expensed to cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r58",
      "r86",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r384"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesVendorAllowancesPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for allowances received from a vendor. The disclosure differentiates between those allowances that are recorded as a reduction in the price of the vendors' products or services (that is, the entity's inventory) and which ultimately will be recorded as a reduction in the entity's cost of sales and those that are not.",
        "label": "Cost of Sales, Vendor Allowances, Policy [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesVendorAllowancesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CumulativeEarningsDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative earnings (deficits) for relevant time periods.",
        "label": "Cumulative Earnings (Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "CumulativeEarningsDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Exercisable term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Gain (Loss)",
        "terseLabel": "Effect on gain or loss"
       }
      }
     },
     "localname": "DebtSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Financing Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of deferred costs.",
        "label": "Deferred Costs",
        "terseLabel": "Unpaid financing costs"
       }
      }
     },
     "localname": "DeferredCostsCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Non-capital losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Property, equipment and ROU assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedLabel": "Deferred tax assets and liabilities, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r332",
      "r333",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Employee compensation, benefits and related accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r72",
      "r223"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Amortization and depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r72",
      "r139"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Amortization and depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r307",
      "r308",
      "r310",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED PAYMENTS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share for the year"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r104",
      "r106",
      "r108",
      "r109",
      "r110",
      "r114",
      "r115",
      "r375",
      "r376",
      "r483",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share for the year Basic (in Dollars per share)",
        "verboseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r106",
      "r108",
      "r109",
      "r110",
      "r114",
      "r115",
      "r375",
      "r376",
      "r483",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share for the year Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effects of foreign exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r87",
      "r323",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income statutory corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unvested options (in Dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r47",
      "r48",
      "r49",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r118",
      "r185",
      "r256",
      "r258",
      "r312",
      "r313",
      "r314",
      "r336",
      "r337",
      "r374",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r410",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r72",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of warrants issued to placement agent"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r377",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of fair value and carrying values of the company"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r249",
      "r251",
      "r252",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r378",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r249",
      "r263",
      "r264",
      "r269",
      "r271",
      "r378",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r249",
      "r251",
      "r252",
      "r263",
      "r264",
      "r269",
      "r271",
      "r378",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r249",
      "r251",
      "r252",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Acquired at October 13, 2022"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r250",
      "r255",
      "r373",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to existing tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.",
        "label": "Finite-Lived Intangible Asset, Acquired-in-Place Leases",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetAcquiredInPlaceLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r12",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable": {
       "order": 5.0,
       "parentTag": "inm_FiniteLivedIntangibleAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable": {
       "order": 4.0,
       "parentTag": "inm_FiniteLivedIntangibleAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable": {
       "order": 3.0,
       "parentTag": "inm_FiniteLivedIntangibleAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable": {
       "order": 2.0,
       "parentTag": "inm_FiniteLivedIntangibleAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable": {
       "order": 1.0,
       "parentTag": "inm_FiniteLivedIntangibleAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r208",
      "r210",
      "r213",
      "r215",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r213",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intellectual property"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r213",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Straight-line basis",
        "verboseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.",
        "label": "Finite-Lived Patents, Gross",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "FiniteLivedPatentsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Realized",
        "terseLabel": "Foreign exchange gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r73",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "terseLabel": "Foreign currency translation gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r72",
      "r221",
      "r227"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedLabel": "Impairment of intangible assets and goodwill"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Impairment of intangible assets and goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r203",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillFairValueDisclosure": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Fair Value Disclosure",
        "periodEndLabel": "Balance as of ending",
        "periodStartLabel": "Balance as of beginning"
       }
      }
     },
     "localname": "GoodwillFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r199",
      "r201",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r72",
      "r198",
      "r200",
      "r203",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill [Member]",
        "terseLabel": "Goodwill [Member]"
       }
      }
     },
     "localname": "GoodwillMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r56",
      "r86",
      "r141",
      "r151",
      "r155",
      "r158",
      "r161",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r384"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentChargeOnReclassifiedAssets": {
     "auth_ref": [
      "r220",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date.",
        "label": "Impairment Charge on Reclassified Assets",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentChargeOnReclassifiedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r219",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r228",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r324",
      "r326",
      "r331",
      "r338",
      "r341",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "auth_ref": [
      "r318",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "terseLabel": "Income tax positions, description"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r101",
      "r102",
      "r140",
      "r322",
      "r339",
      "r342",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (recovery)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r320",
      "r321",
      "r326",
      "r327",
      "r330",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r319",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign exchange differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax expense (recovery) at the statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Share issuance cost capitalized in equity"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in non-cash working capital:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r82",
      "r212",
      "r457",
      "r458",
      "r459",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r206",
      "r211"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r28",
      "r420"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r26",
      "r83",
      "r117",
      "r195",
      "r196",
      "r197",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r61",
      "r138"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest and other income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment Owned, at Fair Value",
        "terseLabel": "Fair value investment"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r183",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r86",
      "r153",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r364",
      "r368",
      "r369",
      "r384",
      "r418",
      "r419"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r86",
      "r184",
      "r384",
      "r420",
      "r476",
      "r491"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r86",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r364",
      "r368",
      "r369",
      "r384",
      "r418",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansReceivableFairValueDisclosure": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.",
        "label": "Loans Receivable, Fair Value Disclosure",
        "terseLabel": "Loan receivable"
       }
      }
     },
     "localname": "LoansReceivableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r119",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF BUSINESS AND GOING CONCERN"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Total cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Total cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r41",
      "r43",
      "r49",
      "r51",
      "r73",
      "r86",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r107",
      "r141",
      "r151",
      "r155",
      "r158",
      "r161",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r376",
      "r384",
      "r481",
      "r495"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss for the period",
        "totalLabel": "Net loss for the year",
        "verboseLabel": "Net loss before taxes"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow",
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofareconciliationofincometaxesTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r141",
      "r151",
      "r155",
      "r158",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Net loss",
        "verboseLabel": "Operating losses"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r237",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "LEASE OBLIGATIONS"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Non-capital loss carry-forwards (in Dollars)"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMinorityInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of equity interests owned by noncontrolling shareholders, partners, or other equity holders in one or more of the entities consolidated into the reporting entity's financial statements other than joint ventures, limited partnerships, operating partnerships or interests held by preferred unit holders.",
        "label": "Other Noncontrolling Interests",
        "terseLabel": "Non-interest bearing"
       }
      }
     },
     "localname": "OtherMinorityInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r29",
      "r480",
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-Term Investments",
        "terseLabel": "Guaranteed investment"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Transaction costs allocated to common shares (in Dollars)"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLoansReceivable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services.",
        "label": "Payments to Acquire Loans Receivable",
        "negatedLabel": "Loan receivable",
        "terseLabel": "Loans receivable"
       }
      }
     },
     "localname": "PaymentsToAcquireLoansReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredUnitsIssued": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of preferred units issued.",
        "label": "Preferred Units, Issued",
        "terseLabel": "Preferred shares issued options (in Shares)"
       }
      }
     },
     "localname": "PreferredUnitsIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Shares issued for cash"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from private placement",
        "verboseLabel": "Private placement (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Gross proceeds from warrants (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r41",
      "r43",
      "r49",
      "r68",
      "r86",
      "r93",
      "r101",
      "r102",
      "r141",
      "r151",
      "r155",
      "r158",
      "r161",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r362",
      "r366",
      "r367",
      "r370",
      "r371",
      "r376",
      "r384",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net losses"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/NatureofBusinessandGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r230",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, EQUIPMENT AND ROU ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r10",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r226",
      "r420",
      "r486",
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and ROU assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r226",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.",
        "label": "Property, Plant and Equipment, Salvage Value, Percentage",
        "terseLabel": "Straight-line method percentage per annum"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, equipment and right of use assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r270",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r270",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r270",
      "r413",
      "r415",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r411",
      "r412",
      "r414",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-Term Capital Lease Obligations",
        "negatedLabel": "Payments on lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r317",
      "r456",
      "r519"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development and patents"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Acquired in-process research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r13",
      "r79",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Unrestricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r258",
      "r420",
      "r490",
      "r504",
      "r506"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r185",
      "r312",
      "r313",
      "r314",
      "r336",
      "r337",
      "r374",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137",
      "r150",
      "r156",
      "r157",
      "r163",
      "r164",
      "r166",
      "r260",
      "r261",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofproformaconsolidatedresultsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r86",
      "r136",
      "r137",
      "r150",
      "r156",
      "r157",
      "r163",
      "r164",
      "r166",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r384",
      "r485"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r126",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r351",
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoftotalconsiderationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of total consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of a reconciliation of income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of minimum lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.",
        "label": "Schedule of Impaired Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ImpairmentofIntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyequipmentandrightofuseassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of fair value of assets acquired and liabilities"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r154",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r141",
      "r142",
      "r154",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of reportable segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]",
        "terseLabel": "Schedule of outstanding options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r141",
      "r143",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Acquisition [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Weighted-average vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value at grant date of options granted (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Weighted average dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted average volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Expired/Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Number of Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoutstandingoptionsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r279",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised (in Dollars)",
        "verboseLabel": "Intrinsic value of warrants exercised (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinsharepurchasewarrantsTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Issuance date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expire term"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Number (in Shares)",
        "verboseLabel": "Common shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Issue Price (in Dollars per share)",
        "verboseLabel": "Price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r29",
      "r477",
      "r478",
      "r487"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleoffairvalueandcarryingvaluesofthecompanyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r47",
      "r48",
      "r49",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r118",
      "r185",
      "r256",
      "r258",
      "r312",
      "r313",
      "r314",
      "r336",
      "r337",
      "r374",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r410",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Cash provided by (used in):"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Other Comprehensive Gain"
       }
      }
     },
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r118",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "negatedLabel": "Acquisition consideration payable"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued for consulting services (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r256",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Public offering (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Common shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Shares issued for consulting services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Reclassification of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Decrease",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "StockOptionExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r86",
      "r175",
      "r184",
      "r384",
      "r420"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r396",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r396",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofprivateplacementofferingTable",
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails",
      "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "auth_ref": [
      "r8",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Price per share (in Dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AcquisitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademark and Intellectual Property [Member]"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r250",
      "r255",
      "r373",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "terseLabel": "Unrealized gain on derivative warrants liability"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable operating costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Warrants to re-price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants expiry term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Weighted average outstanding common shares Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r105",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average outstanding common shares Basic (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r104",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average outstanding common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2459-110228"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r523": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r524": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r525": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r526": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r527": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r528": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r529": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r530": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r531": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r532": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r534": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r535": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r536": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>129
<FILENAME>0001213900-22-058355-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-058355-xbrl.zip
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M%]OW3\">W:Z 19<*&#$04)*FA2=(2"4._IHEU;P#5Z24$3EQ"9KP/:)FBI(
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M]YKF!=^$I_,IO,=O^;DN:/[>A-ASA"?B*,?72VH5B.:7].(/I6(2.[M<!ZO
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MJ!?*!%=,JH *&28I96P=F2/1=U04P)U.P0#G(QEU1PEN^UI9K)7%O5(6'Y"
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M[' FS<OUYO@Z"7K<H)H,: /))E<+BZ/V@5NCMZIB))U&C"8]'J-M^(8FH^S
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MU:Y)TRPCG@ Z5W1O51FI+?KBDM\3^M6KR*G9>=?V/CO9/!CFQ;DJXB[J.2H
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MN&1#1V4ZBO.*2@BL.<AP2;S)=K^LZ!R<%?, C%\L)*(FT_ TA'%6C'$D+Z,
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MP[T\G4T&B>J(JX_7[>[M[NUTT(I_#V9A_U4'_O]EWR3R*69$%X\PBJ7"#&[
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MI"RX9KO(89L8?4(Z*4:RJR5+\?^L4\]72#V_6*>>%U+/S]:IYWNZ]=_E:4J
M>X*T(Y&H0+^#Q=.*#"A78>.;U:A:9U-FH@:;;Y@49860-3BN#L.:CSTW&JH:
MS\.S/)W!UB2^P<01-84;\$>WO]7O_OK[9G".86FLYJ$2@:/\C(M,GE(YYRNO
MN$=C-57$WSZ7;R7T<D2E2ZDBZIE3*@A@[/22,6+V?<:F(^'<$3_9@2E)=2%]
M[P16+6<C'"MH4M)!9UZ";=<+WC;#4R8E"DBT5/!L8I9D[T*LC^$;&4:S'$$!
ML2(#%#-,",9,<JK<ZC\-8S7'@IPT-:T+'&$X+TJ]9LJS8YP%35!WG@ ZQN#$
M$&3M"RKLV8('>!LA\#?"N<]RMS,MDC3LRZ\Z,MX2>][$RV;>4D#6Y@L=8;"2
MI 8DJF-:_66AA@.&RQ'/<C3AZRN">W6"6%\Y%W%"0S>A;A(]$&ISN]#D=:0<
MB5Z'IU,V[K;=N!%#P[6$X(DHS4+_F.$'GY\)LYS4JH5G&HR7E'&R!2;H#S+X
M3TK+,] C188)^!8PYG_,X ^<7YONKR]Q<)4E%B(?S16 KI*+5_O4RH"_OTVG
M<POD'9@&$-HRX^2SBLC_K,'JETP_-%>FMLO.#:*2=Z=7@8][H'7S)TRTU;+]
MB6Z0^:^H\H/D&>86?4;F-8G/&*Y-<6;)(5MGF[F&%#\U.#QL*@&*3/DF+)B\
M&R<DCKB?09%V#W8W>1^X#XPZ+R5OP7ZVIHT*P\1_P*:T-YZ5?,K@ ^ 8E\\#
M*4&R=5E@BT9CLDQC_04#=DI*]^!E\@DYYTCP7IMKY"$6@=G(F(EPTZE?A69]
M%C/!;H:L3DP;0/O7*/J@:MWC&XYRT-R1?"8J(]*(ZZ?F"AIK_%4TY]"_)F!R
M/39&NL9:YE3/IL+MEUU0-9Y8LBKO!*;4#56>J'<Y7CDVX;F GE?)>G\H%-'H
M-TGE,QQ]5']PL/L&E_;$>#/[<W"%\BG,'(5'_B%5!7!3BI9D<?!/F#C8OEA&
M'!<8H* (*@B#;1%#6Y%VP@^+7)6BD&%2,AT;,G1A4X\"JZ\"RX;G[3 02F5;
M?="Q/*1>/C$6,SI1'.>MYW/-5"),B.5\6QH*L_0?I'BV&QH %YLD;JKIU<)]
M'.![\!XKQH[O28FFMH1(^^_W'&DGULNB5* RP%>4,BO.I(A*H/XA5)>"9,(1
M;7=Y4^0.&%()( 8FJ+:DQ& [O/0Y]O;FY !6JVB=_;#;['3A:,?IKA0UB.%V
M0QC<P'D*J1=MD=1*>G:H7ELANP%6_8$%^PLL&](@O"L4T2$<5@J+W@_+0DEU
MT@F&B7K\XIX)PA6%M'C>=B/#!#>:M<*1=\M2,G+'&];?9EN'\<S4)F!H!':?
M*HBS@0K('YJ%(!4M5-&^E(PP\,@(!>TC)N:%_) =PVQK."Z)5*<UQ<DD]*YL
MPRZ@3[C;"X3#TGU?UBY LAN8!#:;HQDQO<<:51$=],-TEF#%6Y+&73 &1/WH
MN;:$]6(:<W'8XBC%Y _DM6QC.*_ON*D<HZH/8M4U]6C"N<UQ/31_"B4)(PHN
M8F:F,2*J(RZ\JI-:[4O@Q,A+1#&'N,9Z=&PUP?->@]T(D_  #_+Z>K6K:SO[
MX3$W3JL:!)2!_J(FIG-9R[0M!F8=$356TDTH,>C-U)F)%R-O F:LD2S49*]@
M1 523Y@?(64%1S #\SF(_"BEQ R"!>SQ\/&7/=OT@:/<=F<T'!ZOMJM>;N2F
MW"OHZ4CA/4] G(,]ZTZM:%[E9 X9H R."29#54B-0AP""76[,V%Q?%F8KRZ]
M,-P21[TX>5BJ4U9<!T:GMCP"\1U6=WE+Y!HN8;B>B\8G-G-,TH^);:IQHB2/
MR<,B.A-#OFH*2Y5C M:%\AMY<QHIE2.)GR_6-PR2OA_/P5[#_DU)%)@M_]#4
MZ3NF0IT0D3TA07%JI:$;^5LM8D\J@3.):BJZI&=9P5EI6F_*3SS6R+[^T()6
MH-+B(4F" !9 ,SDRI8WWR3ZR[A+I*4S7BZ=OF/BT$QS,]=['8R29W QK-J*V
M17-D)@I%B4<'7QH_V^M[)_7I6$^<SDR$BCEWS+ H;B(\-UQZ#)-+71"%O_B'
MMJRD)9D-:- !)!LAL+Q%4H,LJKO><(:R50O(2]1]$XJ'B0JEGH&9.Z/,(=8\
MO^@AQI=<H(S'(5'>X +.>)/L;.&.=PS.K13RMH(S/#5-,DK0WYPPLUZ?M']#
MKB;47G,,IVNI:)]PU3BRAC%+OL]D+<P^"P$D>/M(FU 9H5:$PQ@$C/@C*+((
M=@>>GP8Z::*@A>ZV19D,,OK!*3]\:YP_L=)P3J4C[N5T[C5.<HZM$]B4%(87
MSH7S_&A_I]P,-WC')X8^4$F< (O^J5"M@HM <Y*=,<&ZMN!/L.S+F$$1M=/<
MMFW1"<&V8'=DU"^%EMU;NL>.GHN04]G]K$>Z4H^S2#AN;#LA8G0)!T6NR-6B
MG0Q&RS '8TMDI3+MD[UYHN6!F] Y5J\<L9B)MDYG$5@+I3E<[(46765Q#W3$
M<O-4USZ AU?;-ZY#B*$ K_.%2_NH]I97<!Z#*5P0#WQ'!L4/P1;+I*.IMZ_3
M,9[>E/)\?^_4$)Q\.WM&-QH^WO]SS]68>I6EKCF,N#V_<ILM7.H_P$@F5I(3
M8F>]X_4SWY;D9*_;,O!A/,JQ=">.*Q8^3Q6H,@Q%=,+/&C$325XP*M,<_\9D
M2$R+,_+2QRHE ).$ S&.P7X@4_%S,L#?GJY15H!)%/28,;:/QD0^F)65C><[
M^2</GOH+)#Q8;#S@=W\2(1B[53XWJ\QT@O5F-^:QYI'!@L9!WJ>%SC=^/X\&
MJ8O'+.9U"!.Z3Z]OCFEGX&>/1=2Q@Q\'2'4:&YO!?X: GMB+;D6M6LR4>6+#
M:18D[,-2 *M%KCE'RW2-F$C*LAP;FQ,.6/8*Q4]RXS9)V'JQMPO_'8:/D$>O
M0=/^[[7N3@DS2J<*'H.)'O!/*M5]!>,#;XW<5KD3W<=VDCS]=<_>I\.=_HQ
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MY?>P-L@/*DRR7$Q14/M4"1@@!@H?48.M@ [K\%9RI?+*9,6P9((+'%JW#Y@
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M(].C6E-,K@MU8#PO=<-,,FCT@66""1J;P)G7_8XE3Q;F4E*-"]W7ZS4O\)^
M )3,^</9?:\'J>U+>)J'TD\VMJ$B3\19+,0(]@,\7FNCAD(OP^.=3KC_^TZ'
MNE=T OCS]QU3UH)_J] &YW9V['<([00)G52FV_B0%R\CE<U=O@A'ZL.>!"BY
M4X&6RJ(QF#U\"QL "UP(BUL]M"35M-L=36Q& \MK'2T#T_2@GA2S*ADID6K;
M%J9J-J:HOV);AN^A80(.78M1$^0W6JQN(@Q HU*GB@L!WLE"?YHZ@)OEOW:D
MUSC&'=_!(B#=>'^4MY6JVF 1,6[<MYLAI;X%_FDRBG^=#PIXY_<"ZR5CY8-1
MFW?<*+[9'2N'#NO<$7(B"?:]M@LI7( 1(=PAO.N\$[Y3WX(M=8?>MN4S:E;6
MXPPVHN^E7=OK'VDG^YE4[UCPJNX8E9]YG2[%CN="-V/#>UJ^B8NEX =E4-I$
MF!HL!J[!HCU:0//F<ZJAE.(1ZO)\CK$L*DVHM4M:Y+SGL#]G29**!X$P(DR*
M+N:I'YK^-&<.I<(\&C!_6QC>L!:&?2] 3BV'3,[%6!MNI]@*<6JD(!/>Z$M,
MQ@<MP&(]!D5Z31H0_; L@QLSEB1-0;WCR4\5CM)92UETZW19G84/);5%%V&]
MEJIL+\(P2"U;@Q$L5%PT[L-\FHZ_PJ_&N ]V-4-<8#TUYHO.$!]G\)2W2B+^
M;7>U'3:ET#?6J#TP &^ZG\'*M;(6>;M^LMBSCG+.7F?ZBZ@7U^Q$*W&JK\(Y
M5(N];4@EG9=V&-;22=BN%_'3UD'C@-"F ,7IV&6@4;-5CO1#ZS@B7-?')-A0
MZ4AISK5L2H\*ZJ$@ 9RK\Z*M=\JW[)2W)_;8M^;0:N1BZ_G_IOG?6VQD7&IV
MQ;II0ADJW]!XT,Q?)PL<$QNEIC+<H@H&8':=;Y)Y)+%E4XN]C'PGQ#VCO59)
MH/E^%UZ*O5T$M!=J2J8'#'L/]E@R0-#D7I%G.7SR2Y)]SO$WR+X!__YUKDAO
M4C?90G]!DB.FM\#,:2?\#7\>:P9!62X,[N-B3"'I@_X0>BE]5<OBI=V47SS(
M;LJKIFF?K=.TBVG:)^LT[6VY+O_4\_!]@OUX\TS?'Y=EE:;%6?A>S4/$B6YO
M]9_50=%!M5AI2ZU]:^G)R^IMZTV$!<*NG-/M^>(&5[I?],+?D\^%FB!#Q%P%
M_U*Q.N/$ [.8H5=OAK3KT%',I_=_V7O7YK:19%OT.WX%8D[T#2D.J=;#KV[/
MG@A9MKLUW;:U6^[I?>^-\P$D(1)M$.#@(9GSZT^NE5F% DGY-99E>7@>/99$
M H5"558^5J[E<3M=><LZYGXO-&33ZN03@,?JF42EN41O66(]@&S  <%>+%$K
M\$N6E)(#,GJ1BI<AEF+<N[K/M[&ISQS]=1GMM0+TJK+[Q#K^O6ZWHTC8B^U%
M'>F+>LCZLU.TZW@;E_%QC=]R:H)>78>.>\_SNZS-%7(BBL$KQ?_T ., ZXP:
MJ>&Z(FN#:[H7%)2.US@9X*>D;XV7@V6JN"J7<@AR3 $1V'<@&5%,;25?+X#0
M#J5GZH :L,>$U>M,;SW/1C HUF-=!#?)IEG3C:& B-ZP(R5U]]Z378>/L$T!
ME/7)4@D(T9 IJ[@5+V@Y'"V']L]HE)"R17[(<D7ZL5U7\YX5"_A%R7*\+CH%
MB<F+5]*YMDC?+K02IW^!BAY19>X7;KETTTZYRS1D1AZP $<(*$?E5Q(V.[K?
MN>4!^@)OI2*Z>\FQW]P^]<O)837G"8KQ!+_"8U=B E,5Q?Z4=[^0N3G:]WCH
M: +FYRM9=G([T+-DS,I^X.KD6BG"JB;Y;-E""VE$WIA+!Q>3Y6.OE$\X*4D'
MPQJ<*HY2]X+1?3%V1,,9C4IMB]9BCZK"4M4_?.!8OPF/]M/:&0<JS;O>*1#U
M#;WK7_HPTSSP;:\T/@JE6"T\+,)BD14Z>[B3%1N\%[U:46S'ET#5QS2T:[-5
M<D0Q>&G>O?],F:J#VBQ!&A"O?(> />JKPPVROU%7^ETA2EYV+ K7<R5@]6]X
MDNM&<L7\DCODNOY.W)IG_LO$-IC?_"=(G(L9D^-*CF)[9UD5$$;W;N8[]F7N
M7F#\*<B7_[M-1^G8X=*[38GNKW&V4"S"$BQA5-66"9>'56P)REQBMB6(Y*95
M@R<&%/K&+:)4OV-ICRQUD-4;<OL*Y;[^$;7W 4^)8CBU<\!;=GIF/6!6_.#1
M.(C9Y39<)-D$-?2@>Y$@HE5H@#M %78UDXMV. Z^#+R:KO]-9N^5+,916D4D
M*K&ZDU&[6+Q?IWB#,JK\PIB";Z&+_\:;,IZGHZH%58=RDUQ1.09EE8C%G\0)
M97>T"Z'+T3<]\' 2X]IZ(6Z;+!PC.-GD,ZTJT3"!:RXA_V8^VB#"()*ZA$]&
M(O9^>57[K?5JW6M&^:I)ZC=I#].=7&LIPE8GIY.RNM>C/A-*0%;7?.C:)S+/
MG;1=XUM:3(F T*? O(N[63=N*?9C!3EGW3S),0Q0.1P*5]3=3+>R1GQD8NJJ
M7.003J,4OK:G8>E5'I-Q5=:UQU8U53O?@)A@VT,(H.NAJ>B978GMD%DUB*&\
ML&ODDSA5#*+V#_=UJER=D>X4TF7J1RIN$!V[VJ^BLTBRFNX))QWY'6[;3G4!
M*\=9+_0R/%4H\GH=//#U+ VRB#1@@%%&[GUF1=@-")EW++R<M*_7YQ.]XKT#
ML6ESABX^YW6W"UO%/5R+''7SD<+&K/$P@ 6$**0-2Q_&!%-#U8-T17)\@*UG
M#"Z6%UT#R\@>GV2I([U%V\>XRDB*I5/: RX$-,MN]RJJEZ ;QW4T0,7X4EZ?
M' 8R>KSZD,NH:VZ"[EUA?[3YNK2#:X$(\B)CE^18QE]'6(2*5>")CP_>'SS8
MWR?0%<W5;[*<#3;B.)5%@79O7?UR5M@1G*6!C';\K,51.K!V4N7GK\5=54X&
M1GPXM[HP#V=HA.//"W3Q[-9YT&]T#5OZM6%Y,51N:-D_;8TL;['JJ;$%WHLM
MN.]W. _:V TZ\4:)@1?0692[I[:MH4J768)^@(GO?5O*VEFQGOC$[X)2U?MJ
M2QO=A$\N./6OEJ<7S4?J5WE1AH-#S<1X,/D?H>'7PG%NR:%$:;=JFHK(HO>
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M"V$&%>;DDL/N1LH!<E Z:&*(&'(!_Z'JG"JW&>28/6V/NW\5Z$@YF(9A6$.
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M[U*W4&RW&O YV*WL=7S'AOO&S*I2%<HF8V#:>$8>=OQ$)AM+CA19Z+.K9.D
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MZW9YW V""!"92N*58V1'OC\\V#\<_OR/W94S12[@XB6-#[NHB;X?L-0!)4M
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M%TNO$(=X; T=XQXUN"KH_:[)VQDY=-HYW>7(0Z?)<P,%(#V]YWV5>APKRG/
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MW8W;U$1]L-5$O2.KZ40W9^1/)(UJ$<J )J^BT0"N'A&GA#'51MOH"(%'2^4
M<U:L=PJYN!B;T^(2VLTXJ5BR!PC"V6O\T6SV.,LSQFH+W",G3SZ^Y@^(DO<-
M3B(]A?P)YPX]NKHO]F1R4+J62\G826"XRDLHMIYT!@5"EHJ(GZHL214>&U6"
M\Y;3MQ(9D1^Q:J=RM;D<,!WMHV%W'1<$\/YB]B?B4-2#G@3 RC&:S(&XBISN
MI=)#R L?:6V8G.]YIE*93$[HN46PA,)I!S90=T7[O \Z>5UF0OPIJ2=*\/(
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MD<,$N+1O=W*#U>75V1KXTO5L62RKM#*\"CM2LKE8B'POQ@S%;H8X$H(O._
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MLF3/.!D?EN7)?%]NW@6231)C$&!PD,Q</+_]K5U5W6@ I"S/6-;!N!B/+9%
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ME Z=PK07<3H;@=TJW*D.X"&0M![N]ONB[]]GPK"K;>2]*<BF[P9D4Q_9]'!
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M\ZRS<"V+&C *2CW"WC3PBT8R3<.K=40AA8[XR>%!V*EW@*[O3[S^)J',F6=
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MS$>@  &J.6'V-YTN2-H7_7O:VQJ(,A5L3K:V)DD'RRC/N)N!0T9)IV!A9@Q
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M1<G1R8J4'>= )XC7TJ1<:.'7Z8JX_'#Q&[>N+<4(I+5(($FFUR "IA#H<,!
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M22<GI"O2OU:+=<D2?C2IXF#GV;.C<$3+MCPTSV*=OWTB73"[&,F7FGBJ9#+
MV"@1YZ]Y+8 ;>B+%]X]Q-[.$WI!<74-P,S>,:M1I)=)ALQ*D@A&L I.A\^\E
MI'!]..*.4" 2LP<VYZ[U"1*J183AXO$X)Y4ZBL1'02<(Y"32T57+.G,_DX2(
M7EB'CK=>=V#?,?A!4X':@WDN+B8+?PH70^\[73III/, HV[34<,HF:_<"VSF
MOYQJ/L7R%H&.U9LKZH\.9:M4%V?)F?AMMNEC'F?S%%=F)15A+[TD;=*<.^:\
MX]8WWAUZ/#=L-),QYK@"?W(94RSW,> SC%E\,@J=^V&J(K>$JFB.Z8RM_7JE
M<?[ST?[>DX=0G2THVNCPT=[]AU\52S^8C;ME-C@N%"?Q<+/%X'O]O=+E@5I8
M\R.6C,PA2J:VT\1USHD2Q6K@X076CUN]?'WBW#<_@B.M17JV=!USG&C=.]T+
M7^2Y-/&QI]A!-=O+OC@Y<E<MS#PN6*%WF$"\^<6!54;<R\?-7R[%XR/)@+#L
M,$AY.>C4W9_4HKM_IW%CVB%^;0W&"NR.PKS-I9V+WWC3GX5NGMP2B#)QE7KK
M&B>';Q<P(P>CPTZ6"IJ57@3J:_3D:0)ZK&(M8Q+U@F4\,TU#HPQT]O!RWJ!%
MF!*L!.OD6!S=:O,ZF3)[FT68MK;.-DW9[KC8CFIT,Y,=8ZK_9K"^R(/:\1)U
MN*,VL[HLN$W]Z;VBT Y]Q#[I!$E257H8Z>@UB"=_F+4>!C&IQ];"!Z_\XR._
MDT;6LGGOKX[=>T\RO/E8>@KIN_%<NNS,QQ5;(! /@,M&:%2K'#Y$(P N+R$%
MVT6<SG2?^L#<^XQ23!3:A0%E&Y*4=S%RN4E+_>L8^)4C=[P"RSBN[[+=;BW
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M,9*[P(*E$DO+@E]JE]AZ;%=M^)',P!G GZ3XN'KL*?] EX:K,+.D%"8\,":
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M3 R[]JF9H[B,N402BO"$QD!ZJC1\!! FT> HE-P5#*_0N+O,9830)4&$)7$
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M4[0R>HW.O$VZ3!X#V>^*=XU'GB-T<3^3.IN_DM]6XC5B^#F]NWZZJM7IJ:N
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M\@$)OG>[*U57A!"Y$:FI&M+'=:%$%R6&C7QJ2I\6MP FI+O);;J1N]W%%Y3
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M*$=V/:SK!L+8N^!(-TS!A]>7?<R6$$<P0#EG*" NL']-5I7T^K*3B-4(6 Y
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M!,\PMPJ2!8A-R BGXJDAR43R7HK(I\L$#UE?2+C-'\GXJ+%.H^(X]DTPJXP
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M<4H#AJS278YMW4[6A\T:7&V';/;[J]T 5W7I<M(Q$(G4!J?<^:H 3;YHXAX
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MM$^-F!+ SN(1Z0-:B")EV)IHDHX4&XUK#F7#+CLLYFC'-?B%Q6I(.2!_0,N
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M)=N :V01B1(1+#^FF4AO9=]00CGZRN@ DB15@Y/4)LQ9!.UIE1F$6 5]W\P
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M29PW:!I,! 3Z)*4B5F?F/*><^S*/TJPB1CU$,-#0I#Y!46!6TGE:")D6@ZA
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M2W6J@$<3\$-V&6\%:$IM%%?P8LXLIEU,0\]@PI35ZQF71J7IF)4:^#GV&QZ
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MNNE\LX8]KQ=[GC@@-\K=E^=17$M*CU*N5V&X0/1[\Q(]<.":F518CV0WP.6
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M.#\+_ZAI\N"M(AW#E[N(JB\_42CR!_C98\CR+[YIX?9*&99<CT[S:==,A\[
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MM$)J1_K0>VE1,#6<7I+*EJC4LS$3MR(I14[[PCU680[X+GZ]H%;H;B\(0%C
M].-[S[VS=C^0!(09/SF*#>JB_A*NP5,<!;50K4Y8!4D=>"VW;>6SPJV%CWQW
M2 3,:(!3<U%#JG71E7P#FPS'#+R8IG7CXZ^A</"+H0A@0^')(H6!!FE0PFGS
M@F!'!!Q['B78N%;NVOC&ST9^($KR!+AA5@ZK!;&P<\1G,@$70]"+Q "F5= K
M]";]U_\^ZG8.7^<.+'TDLB""EZFQ\ 3<,(6-*6@[@D)>PP)W*H&M*.&H"YI/
M#@+3Q1ZS.]8!8&J6^28\);#Q-7S)3<=CF$J9<"M;F)8S3K%Z%X>'6X^];+&5
M;EZ.Q_&]2TVR>=>8>5(G3U K?.YWBQ^IL?((= WICJ^\$X8=1H'KQZ I)#X6
M-.7JF.H6;UKE;BI?W@+IJ6N^\83?3=1[?^)Z;_=4IS-LLA1=S6FM5GQ6CF]&
MN;YFM,!L@,^!<-W]?HZ^XU[#7Z.$NW[C>[+%I@*L.6265?"+XC*?$J(FHX9%
MPT/2-R36>$W2$1?JU$L;5TJ;#6[4O05L1]7!3M? 6KE3#;-9+V8SQZ%I%M-^
M>A93SS"<)V,8,]33AF$\^_R!85CU"G/4*C2<8['YU[$3NT:DMC[$L?><!/K+
MW:<P%G?<]_"-6S^+1'&/(R/]DQ$"!EM9Q& \D&E[#K:'>^!(AH"&";HZR8(>
M1(F?!&R6P =DUGAH*L+8L$%HK0WHJ>G9H<V(YM@(GLLB:1O[N33/1$B&/#Q=
MM6\=M.,$/#&BV14WTF@#+H2/(8L<P%ZZ:)WIP4^0V23WRD"T)I,)--Z0::$!
MAZPO1LL47@O["K<] 'OMGKP8H[1,"H_9(5KUCCH0FJ<OV2#9F9E RQ]78TX-
MC] ZV,B<.(:1%^..#:6MFBWVWWR(0)Z%47%/Q'CBCZ,"+CU8!4!Z >I0_883
MKI4.=064*AQDC/C#&!41(LX;'UA$FL3W[I"T+.1B<32*\+_2L^<.LG2D_)#L
M)_*0*MEC1'\$;B(=,_("$('3NV&X,B./#RPM&@"705&JU24D=_GU1 Q9J0O\
M_,8=@/8DWXZSED\ L]UQ_[2G30X>6%+H6JX>GAKY_AYR:M+E1:9[+PKK<6:]
M"<D '%LM_02^3HQ>^J4F76@@$=0F5O=.NWCQI=-O<U RY?  *+DDG6!_HP'Z
MWWSDIVJY@Y)D5G4W<%!\B3O.(KAE<#=XV>,L#80(Y0ZR'R\F"8#K1+?SC0\\
MNE$NUXI*>[DS)>*92D.F"G*1X@\";C0(=7)NH(OZ8*>K-*#F3-?J3$&5<2QC
MD+28O!PAL?X'N0+& 2R&!ZQ ^,&-TM4XS(#1")%C*#S\=6F[L\*#Y%T(1!S+
M/,;?7[1?T._P0*!^5P%V3C*@R, XAR'43[H?<J?=_HDG,<^R7WQC@_G'DAWD
M-BRKD?FWMU,W910Z_P!GO=R$LX>ZH'_#3BZ[6?V_0.S2E$]1R/[6SWYYH_DP
M_X;,>,:.UV[ODJ_#@YGAS158UA68!1ZV)E=@N45:DMT>'BRY-_$YJN,H$\M<
MA#0)=.IHF\%'QP;%EV<<1M.\>JF9L)U];_]H5N.P%6W"+.'7'/U2C_[8.SR>
MQ0*?Y>2_&VIP%2P,V5>4W(I<]X>9R<*V)DG_^2K77AT\"X;*VN3I;]%)SE*X
MUY&_?'/5^[(YT#A+;R/T'/;O58"JX4)+O[N@)+4/&ZCA+3K0MG>TO[\>!_J4
M6L\*7 .G@X$(BEPA/F*E# SOBJ_!#6;_8CKT3._V(O;V:G7^QUT8ST8(BTUM
M926O,YPDS[9-S25:XTNT=SR+V:['-5JM9K@"+JV ''3FXZM0\$\_HP';<.@G
M<M8\,UV]ZGB=HUG@+L] 6K,\><W]6<_[T_'V]P_7Y_H\P)D;((%E 0GL-D "
MTT "G09(X%ER2C:&LG^+K"[Q/<OWUI0-/#;_U:9LO:-2?>>1RG+!L1U2AV?$
MIQE48'_G0.7F>5:>IJDZUUFNB> $>'[NR#R'=<Q]2O&G[,Z7W9U#7?"@(DSL
M3,E5 422)BV:VUV:?<%1 L[2ABGX&99.QYC@.LAAR/Z]^3;EA;;Z?LX9M9AM
M[U/BK,J\]YSHX?J,2DT,9\I2F7?ACM*0,H#M]\$VQ(P^(.LIV"4$BZ@6+LAW
MY%SC0(66,$_834S]#1E;01U8DP&Y8>3468"<CG>.OHF:VB9#=I*:;'R'E5.3
M#LF8VA9X6QHHHM 7GVQO,RO<3@9=D&GM##:1@5E.6?3ZN3@"A26.BON=C2\\
M624>S7++"G4V0*,'/#GC>L[:Q7=5252#N .J0WUBR"2C:ULRGKD;5A@B<Q-Y
MD*5WP'GN&3@%L6:054QAO[@W45ZD&0')H,=.UFL%:4*^2I39H>@7[DT: ^>
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MJJ9/AJF$;B(D.7<*24[S'VG+!&7L9PA?B<!3CL'!9.25^I=0^3^#K 8Q,*"
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MF<F0HI9@DN&QW5SK.4D1Q&U<9J <YJ:,CED!IG;%<1JHA'6ETSCT.'$=="#
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M$X5K(@T-]KZ(6C)6(06YEMNLRM&C9:ZP6Q]T.N5& 0-[<;;Z0EK4(V7^6@M
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MJ^>VF;^_B+X6OR;EJ!6F14M^0>4JEWEKZ/OC7Y%N>TF(_SDU!-LK3OPL0[P
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M*-Y*HVHFE),MXAV_G0CFN)TW=CM=?3"H8)&DT]&IUU1*(8F_]HOAKR4O9G"
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M>3$PBP*>U]B/\=1P'AFY>5_W13@ 1UM%G2\<JE<"J&FXE][O-RHD8A[E!B:
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MX5E+>2Y+WW_0-D4UUKX&YKD>9=KIVM>OE_"WY3X"M[\?DR&'ASYR^>/^F;$
MZ 3=(6!1. T5(;N(9J/T.8 .H[(DZWD#E$[CVK!49B'SJVV6'75AQQ&/\YR\
M"269"@%K[CYCJIDK<G5$&J,$)BXWRO^3=BO.].7:?)?&DHDYM1'(5!,$*1FL
M*&4A;'L)>[1M*E:/@:Q\*_'D'YI0&/7\V"DL')$"85+)M1E;-N/!Z?CX&)\1
M1Q>#UY8'1]G3QB1'6:^-"U7")).Y7G[E2%Q)&#CV.\I#Y889.?@7WG[T$NN
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M:"C/3):*I40YTZ=:N].G,A.43EY*U%:4J&*4Z*L4;,BWE?9_2T*0I%PH*?(
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MWK@E$23!N-EM;B] $/(,QP^U$#+!K==J#0+/&BT"J2SQHEE+0;X@H?H^R%?
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M\L2N:K%M*6GU0"B?LQQ =W<Y@/1(+G7!+->B6GB]*O$*?NSQ#5/?A*7P0Q\
MZD\LP;)%L5.>O3Z"54I95DBIP/H8UD+ET@PL"TOIBE)/\(=KRXX-(&*#)!+X
M)/6BX92[I$4A+BF9N+P *H !N"J7UK /0XQG"B.Z'^;+6Z80L)=VP04W7Y0X
M9E0!%SV,2\-CVCW[(60P+B:2Y"&6JL67>JY=W%]JO49/UR(RP<>\%-OF)ECM
M4@Z/MX^W+4:C$'#W)U;W S;71$ME67^93J0F#T3L\L^%A=4(_F]A/H:%#V3O
M@J6Z#=Q5/7F1TG)X"+08^D8L2%][=LOIQLH1T%!Z6#)8OA@O+4"^:9W$SC$7
M#S8^(67-;1BU.F=-5KI%\'#Y)X:QU,DB83RR[0M,-HLWHC7.6T<, BE--8)\
MF\]6FZ"M:A,LL?,\M0DZJC9!6>_OZ?>B"B7L%*!5H802SZT*)52S<($JE* *
M):A""6J5I2Z4\#K$PZWU$AIOKA]SXY NA4P5#JID--QJ#$^1ME_\ID_2$+U8
M6W?.@A3=W04ITENNVYEMW4=H"7$6VE+'O$T<V9)AT 5V+%MX(LB@9L)/5"@6
M(8"=2>FYT<+^0_,H5-AP'&-D.:YE^F&-=$]VPETO5&MH<]=R*-@V@,5O]5O'
MK8ZUT*8=5H*5IN*I\<2T$45*+-NSXP98'BT1FV=J\.@3YJ.)EV@TOB-JRIYK
M][1/?$ND!&%(2BV,?A!6XB@Z868%PM7KL<>%;02N]Z(9BV#J>E%0=51GWE\.
MN$8+\P^1(D:&;0+SN?;5@G$QJ@771V#W&)R,H]<H$MDV+.X ,(V9\<B#(QS7
MJ6,_!QC?"4(HZ3 ^-@(,+=.K4?"A9?XHC<E*9)<MEMCDK/_1W5W_(SWIZ&0F
M-E7KZQ!WK.%%#KNN$%U UP?F#Z(CRK28=%]1<(Z/$5UQYX^HMS'FJ0;P%B_7
MC.%C(PQL(2(8<Z]1ZS\1A*'7R"$";R^0YNBR :"HALU/452L7NISO=8>E&C,
ML^4SD39"-&VY(;?K\#@JRAQAQ79H>;/U>KHY"W)T-Q7DR'CIJM:C0>S,KXD<
M9FI6/W;GE! @/+2:Z5)XF,PF1I>I1X5P>/<2GG\#WY#9.^Y"/@^=MY('^RM"
MA$GE;33#?$*'(P9GT>V3@L&Z/SO._[F0@>)&&%=I.4\NS\I"]DMCQ2K*TVP^
M;2:6J%252U>EG("<I22Z@XSA5Y= V&\G)-?]BSFFZUW(:$T_6R_VG0-5[&)S
M9,%=X:6B?:G J\,@>R]G]G5W4_8U#90%JZN%EA(AN<8I5%0,:($565C/@DM4
M\X4W!AF0B5 7^!9[=<N>=[SW>1CTY#$,GD)1;>(QTOE(W .M%7C-U.6![^(K
M"L+E@V,S9_H6N)0<DNN'MN]&W3^$LD61X!C1;HRHJH(?1.D JVK7LK8]P@4<
M1+9[BX&]O9PIG[U&1LYR/[7F<QCRPC'_ 0=OPT=$DYS1O>E&J]AEYA1:;HT"
MS.3F*L9K-J-\.;A+SO3*WJ:>N'R@K)A=+:S<E)(F&</(LFVN1T0QL4+SN0$5
M7ACH)("(X$\%B&3+)]]WQQ9E@)#9S7)&<!1F. .^PGF5CZ,PL[8TV9+!T'(B
M9L9GOB6SI+]]?EWS%VB)Y<SGSX5!N6Y8[<)#\4!?FR!,,JD=(LGDU/)?69A2
MSD317BLC4[HR/#1>^7?,NY_"4>?D1CN&J=B%YX@B]U1[]]7U_?<:[$VCS56,
M%55'[<F98M7;U%N5!DJ/W=5"T%]!V1C7F-@=EF)&!)WS'MTS]+_A;K5WJ$"T
M&A^O[N[I4_/C>XWZ$<[F"U&]#4[1,F5* &:9BGQ)V6X<<W;A($3OQ_CH,JDZ
M9(VC%QKDF=@6>J^>@%$\PJB+V0A6AO5 EE^/]3B6BH_';/9$'BFRAY]KGRV;
MEKIKKS6Y5_G"@?8L-NDO9E*S7-UO;=M^J0^]R9V%\?;.6,?$MC6,[$7,)>="
M_#UR \0,_N3$C(U #H6Y&V#F"#>!(@BL)U:+E;B%97ID2\68,DS#O9[(; [X
MQA?UB^+K @%C_ =P^Z@W/&B_'A:XXN7#ES -FVO"]'4Y-15,=_A*0&*!PY!F
M4N%+Q3[T;&Y@0K6L+0@/*4FB>**:,XFOU\FLW@(B_(I%P) @@&!(B[\E_ '%
MX-K!T#) C3O;<#*:4G,,73&"+A5?V&>="JG5[H1[0PD;![H7.0-^>KL#?O:Y
M":%NOM=MJA;RHWX=%;G394&&1V0V6$P6O@+>A*$T 6PRJCC(68\!;,FD1-7Q
M%$LX\"3598Z^VA@:Q0U99(2%11;0C,QF<]M]8?&@'I]7G^%,450:#DW%&VN0
M4#JKJ+2!M<VXLCV;NPX3WDW8&ZK3\D<YJ]C,<IV5&)_D$4"D=9O1IL("$JBQ
M3UEH-9:C2UGJ@?B]!PP85B);BE/]-,0E43P# 2G5_1HY4D.Q9&Y89AU-#,;<
M"@R;#RA2?^.Q6_'@!Y(,1#%_'E$1E=B,!"5^DE+6(($'%T\SU);[L\2.V[#'
M"[[SJ!0-Q3S7[\=3EP+0YF%Z*SXP<TUFBX.7;F51^.0'\\:6= _H&H5J.%%Y
M3_Q65GJAS&J;4G2YA*9'&&!;D[").*U4USS+_Z,^\=A*;_/82T\N%DGF=A<1
M?T8B*H,_J+SSFS7T'V.OV9)?.RKY=8G=YTE^[:KDUY+<SM-?-I7:NBH^J]36
M$L^M4ENKF6JJ4EM5:JM*;56KK$!J:\6$/Y7)6NWS*Y6Q^\C)JR>H:'I @W;.
MI++>[J2R?8S1[0(,VD?(<BT4P>\#@XIOU_ZYL%^T)HIHS<%R#^FPG<5$)&.N
MF(!C]1L?%Y9)Q?.X&1K-G?3;Q?UW&KC>Z)/=D-I2"\LK-T=CIXK K7';Z=(D
MTM3J\O*-.&5]]%*G#U@JW#I0Y> WF#S6RYD\UMN:/+;?=:S654('P#)""^OZ
M:HA\B-K+<0N8HR6[O<?]!+Z%N<_D1N)%_-=2O\-:GKRTONM-F(6U^?V:J&0:
M^:?H$D<S8I@'=XZD6OG2Q5Q;?;SDYL*PY4@U:G E'J.5L Q;T%)MX16YG,M"
M"W)FL?6R9K%]8S[#1F% #C[S1G$H7UUQGURVX(L40U6,ILC:*7Q?E&40VQGE
M[JBPBP/=@'[.U+;>UM2V;*A>+4R-9Q[ !G@E$T]LF,B]&4-<D ^!H,]\T?YW
MO/!\D6,0:S'!VT52/V/>+RU6J7K[R,SS7<=A=FT<DSCT* PB%$VI[:^H@A .
MYWJ/AB,J'?@RZ4WS%QAGB4D*W[;-*S(D1(P%13WPE/(:CVE8ZA;#7NA)66=!
ML:_B+V_.5+E^UE2Y.P.C67T29@-F8\0(R#YW'N:>!"]$H#,F*EC.[$/V42M&
M+C@JB6T27XMO5),[51SNH)<D9WI=?VMZW5ZWH5H83'U$96F=B67+W( Y!P$/
MRIL@N\&^NH&,GY\9EB/+\%AQE)]+E!>EL998B>&'S"+6]5-;.*)W;_!2\^%7
MS,:3:J/I+1Y7>2YUBI"J5^QEV@)OYR8C#,^UN]A&-J_4&(N:8104'TPMSZQ1
M>VG&C474WO0)?@]+FU$P(X;W!_0O!47:H"<Z1D!M-?@:N'F("K%1^!Z/U</D
M UZ':#FB<":@&0MHJ_%#J$PP6I48:\YTOW[6=+][1LU*OLGV@)QNY$U!3S-8
MQ0B0\$WPG=6B-HH5XY8E3C_OY\SRZV_*\ML'NT,^G?%.5 NA8RID:'&,M3R5
M!5.0Q#^[L0Z"O+D/@H0B]'P.))][,7B,FO@NY'V_&B_P-1RH_$7Y$(JZ,SF3
MN/J;.K'E0/JJ.> 0Z9=QU/)Y@T^L",2M$2C]D&PG))XM)@AJ8Q]6KN7^:FV^
M$IVYU)!LZ2K4TBQ S$>Y&B &>A8+L,WO<M6?@(VGCFN[C]3YS15SLO7BNB0E
M8OD'V;%KRD <Y';.9Q XL700_&0"W&&2=_>,:3=NP+1F]_U;OK!'VFZV=(.N
M2C?8.]V@I](-RG-'2W'E5-*!2CJHT-PJZ:":20 JZ4 E':BD [7*4B<=5%4$
MW)IW0!M2N0<GZZ)5K.$K9Y66?C>C8^0K4EOVE1D^RQI:(-TA"4-4S'S&SYOO
M1#D^"L/EG D:_=T)&FFP5[H[TF%ZM1#V(JA9SICQ:B]8)"8,0EO)NH"MX_^A
MOYP*X\9Z]E@P'!5BIT@"K.P./ * I'&3K^N$+\5#LGD!O1<>84T<B,KSNKS;
M"$4$^+QN#1K>,2Z?8LYY@Q]RY\=;_\"F4-AC/\93PWGD0=GCI?XGE;Z&9?&F
MY,S(Z&_*R,A^$=L9+F(5'2_\ULC&=2_H^;"PQQ'5I@RK6AF^Z,/%6^N%]9U$
MM H?).SQP]O>D8-$?C4S3"9+A6$M2C3JDJ>%*H9A.T(ZT:6LCZ4*3!JE@(RM
M0/I)^)RN)SIT&>(Q]*VX :_L99C84R+**-$W9G3$&H750(?PW&>*KH7!SK7?
M9*>B9<I$T3E6L/2NMORN!)G<F1CP(5SY$L@C0 =1A _%5L7@P283-J8@H1 R
M/!OF7+L6E<#JX4#4^XB'&&%1+TW0* #>YC,S/(LFHCBFV.,U)(6 ;3^0W/)2
M6+PCVOK &Q-]1%)+6&:+%R!;*<(&JR C+T^5,]"_9YD89\41[7%A4,X,( HL
MPEI*S!'S\^/@'$-Z B4'L+!%HFU'9<.,L,$(UO4*F.-3?#16M25,X;2"Y]><
M:_\6D%P]M]H*Q D"\-VS\:(3JUJJW495U:1OD6Z#[&9E>!Z5)Q.@$8 B[E1W
M)W7D2)P!X=[]I>KN<\^=6$%-%LX3D$D_(O;9HP*UL/[%F!_'7\QS*Q,U5F[.
ME3-_J#\HA'-U,G"N*B8:QIM%\JM)%8\?&2=HQ!)DS[J1&TSE0XY)27S\KZC0
MXW++VJ6,7V:,IV%A1VWE1?+46\NM(3:-3Y46-:2Q]MH87+8$$@575=*Q0*/B
MF=5IV%#JNSC(F<G4WYK)E.X*5OM:A3U872JS_K*]&:LK>QU+Z1$$'X^-95*0
M[%H"PAFR]2AP3732XL'381E5"N?<SK:$'&D*N4+.*"K!<ZX=O\R9MH+28[R9
M;&U] 2(K:DD<D '?_A2DMSKE_=(#@A!1+7BIH\K\XB2;%^@=,!R(3G\_L^!\
M?3;^8"X\;!:[V9+U!<06D*D)'Q]@_-O)I5!ZFV>?FJU5PXHV@U^G?MAX-B:8
M1B)A2-!JLL6TS^2NA"2RL8HLUBD ]/,,@AR R&&\3$$4LQX!HC*R1H4BU <Y
M4[\&65._ %BQ<3W7<1="L?/W"E;/.F[%Z*S,:49_4RW:J+:\4PSTT_X7Z-V%
M";H(,P]FW#VJ<%X*Z^X@9]K78%/:5T%70BYICSMUL&"I%(&$2Q%5N)*MCGP8
M90NJU>(1 WPTNI%GPI>ZX=?6VH7=TU=H+3GL8U,6>SF^&)9''NRT_Z/(4NWW
M2$!:\H63F[FZ7N9B>6>NF]W:)NCO<:$+XTK]H["E:Z?VSP7(:A@NI&M?+NY_
ME6V0>/6J5JO>:.L@MA+VKF.D]N[!G8/,,&B]_X#,2MOR&(B^5]0? B8>+SPN
M/-\O1O]'O0;<FI1<457 +LA8<B  AD%),+*1 7-,SB6EW0W7""HS[.1EN1(7
M/("M[ >MAJRD$VM2,%M>%TJQM+2:SY?V(@P)J,/(!<8<4;A$BM[WHB6*;!Q*
M#-7\.1LC&I(AV'9]*N@3J_# -2,YJR9GQ5U:?HWZ.V&5+Y@_,O^BGC&!X6!N
M5 C0A@<80QF@Q@1D:NTS2!;4K:'9I>"O]K(^9+J,MW?B9EA>8DG.!&L2RHH?
MW:":!6_"DP)^Z.7"D!K:Q(0T#U3 8(R 7XSSO2YW8>2KWS@?GJ).8(;^]53^
MB[L+OUG^'Y]#+,DL,Z<9:Q^*=/H8GO9Y[?+[_</M[U??,'[U\NKFX=O%P_7M
M3<%2\?$1:%4PSLCK,J+1P96E?8XY^?KL0/E+T6EWU92%>5[8U"7JQ&N*/"V@
M9DA#-6PB;VK$_F3$K"Z*U0!SQ08O"W*)/I)'$.E>L_$3FD]FKL>V%HMC08VW
M]EVSOSR0,276&7@L':!(W044OI!]2J@8(1A:_3/-!*XR,VS_[V>M)4/1!V<Q
MJYMN4!</Q"NJK$'KCGGXA?$(M 2Y"3Q7A^$6CL5GF@/^G'WJ#.3BY7(^_;1M
MP[39L#_D-L">:Q=4,F(%VL$R2#"?.VP_F R0P5$!TD@/CZ76D=*EP%M.H:2^
M@TT>LV9P"8-&4R\\6Y9>3V7I+1'</%EZ?96EIRZ:RLU3N7G5FEOEYE4S5T[E
MYJG</)6;IU99ZMR\TPE^62R.U\X3 -+U7O:P-":-<1 +XU&Z$W7.:]<W_P+6
M>OOM^NJ^:$?[?FN3"+ ><9+/:I@#)Z1[.B4"52L@0V[*8GY-%%ECIC3J3(!9
M4&#_AY(@1!K_Z4%QH9T%%W97O4PL6SF>,G-AL]M).-DE;_?]@%0[3G<R*:-;
MM<H5[3/MZ>951@ME<9LIQ?8P!FF!2F'!*GQ)(2  \/@M&6Y3BPM%@PU-T;0B
M$,E_&7D_P_)0,,\(1X%WD9$*EZS.LS3GV2SM>697L0H5A(L=+@D5"CWHOQUP
M$PHFA=A%7L&1D!)2K.*IX'(4N*1%5^"8P)$>J;XKBH2N![M['+UK-3IZJSW0
M6]WN^PVF/BXG]GL_%:J*?C.>-4R9]2S#]K<P*RFB'M@T+V<I='\;CWUERN'*
ME/NB6F+X0#L>/=!(%3VP9@F!0_M=GMF%8]Z+;DEA&$$C%D6P\$$ :PU;>K??
M7PLEV'7@1S^*-X=C,<<TIEW5K1_UJ66:#![A_ZUCF><Z9086M#[2RT]UXNF)
M9++VNN?*_NUZ?XB<=NS1<@S^5OPF$O&N4@0-C^/:N>.'L9V,-?5^JZ,/NLVT
MA.S0P'X+B))$E@8-X01+N9#Z2<[IL()9@6O_8CF6/V6F]NBZYC9I[(#FEB)<
M:\="VVPK*3T%E$?_&Y[\=@K8Z;?U3JN7EOYM-"F5YXP4JJ9$U40:W"R&!I\$
M5_*(@X4XWK(<%>9GF.YB9+/C(VPT]XGQ==M"2D]9;UB0H!CKG6$#),I.7HK:
M.3D]5=B9$3L3B6GK,,3T"&@B26E1 48GJ<60/@LM9>A M2)#/E.>6"TY3\R2
M.X_:U5)=6=ZJCU0'E"M,[=GPM;\ETM=&?OJ*O85O)R2NH@E2='N_AWFW4]MN
MIZL/!L,U6JN]0W>I5H?5IKZH<+0WEBUP[/W1<YL2:A6L8$2=/WJ(D*QR;&NO
M"$'9JOK.QM()CHFI^M1=;X^(P2QC%D4@\@!N]*E[KMU]N[V[^O;POWKMZO_[
M?GV'T?84H/WM]KMV<7]_]7"O:S=7#_SHCU"3+V&U<20L," P%PK( ,&<^'.$
M^%NY,IVJ+<S#=JAXL+RP6W+P7P%GO7*6\BCE.18:RI?K(-K[G.)^H7Y;IWR5
M07X)"1DK\O0H7;C4I@%WQV*E'#PY_50$7$7!5IMBYU9WF<*Z\59@M1:75@RL
M\H3K;(!,6FAEA\7?-NVY9$LX(1"%JIQRM,/-L)>[YK\O+Z^NOGQ)"I_9=4;?
M<)7(D+_[3+O@%5C?\3JDB1E<L0B&I/2W+$^E#DQ9NO*)Q2N&^36^K1SS-\]-
M]MHV>WV]TT[V6AP!G*<">GL/-3LOT#OMH=YN)3O*TX&I*!O]4IZDW,5>)#E+
MI$/ZPVH>_[!:S98^V!&>E14Z1X18Z_@0Z_7TP6"]5%!A[#45;]D!-*J./45#
MW/5L[KE/O%A=!AO[F@2XEVQ:H&!; ,[LX=G)31(;>J>Q;GS,+ F?[A3*=82=
M$QQA2Q\.LLD1NX]PKYA$.3SZ<T!VV%T\26Z=;$&LQ'SP%()BI]70^ZU611GA
M"2Y$MS/4F\/NB1EA[LN W20^8*VZQ6S!B]2:6(8/^T#(TK:B01E]\69XY[M#
M7<V+"-2?8Y"&SS;##X!Z%S& ;T7+!(QL]O1.?[UJ80X:G0RC+.547C,V[$%U
M#H\-K59+[S6.C0V'4%EWNW-TK,":&2D[A!HR@"<K8A7W=N'BX0&886(HUQ"C
MM+OI9(>$,)U3GD&Y3O 0XDSB";9;/;V;4IA)>X*%AT5M\:GNW7'F4.LJ+H;K
MF.4_-T95;0HT60\,R^F(/D)$0)S'QMN7S==92RWL^48&)"MF0-I9\%KG@5]P
MF3JM7A1:U6KJS4[[_;D69^GA,F)-(E;[X-5$&[JT\PZ&<(L[T<3]GM[L==\3
MM\0GXCUE>8%SFTOZY@R3(*A"]A.3*\-JYML#%4Z(C66^6,F==+)5L.ZK"M9+
MP7AY*E@/5 7K?1#V%5TU5<-Z-;15U; N\=PYXE$2EIE[::J&=<GG*QI/5 UK
M5</Z356'KL8J?SE #>MCB7Y9LE(PK>G9LNT+Q[QV L-YM&"_/!9PC[R4;*/N
M8Y'8T3NWV%+6O?/:]>]W%]??*'?E]HMV??-P<?/;]:]?KT0&"U'KWVYO/__[
M^NO7HFM='][P552B2TZLDJDNN9&R6O:15#F0L?9GD3WI40 (@W>3\Q[W<$[(
M4]@5TJ<W6FV]T5Z/-])AZHD%#S/-MI[(#"8/4SB2=J\_1T IMJ"[!H!9'EH1
ML<#U$@I=_1C;"]1'Y?Z2HA5[>F.#3T_7KN^^_8\QFW_\##NH[3B![BFWT-1;
MG>'&39 E<FX$9&G=C4>]T^ZB.6QNWH5%"W487_.S%4SIRACC/Q>6;]&7L+E?
MC1?0O4$LU0'S8"/^V+-&W#![XP)^#LZ+)-0IS2694L-+Z88HA.JW]Z/Z!;8#
MW^[0B+=YGC,/D=_']M*&XV"K:BO$\EK _$ S>/-GC\W1 >$\$CJ# /+$;,2_
MJ$<G?F3&>!KO.[V]C6>XA#]A4BL@[X']0K04U1@0E!D\Y6E64+-\WD'5MO[
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MGWC^7/OG#YM<IRVZJNRE 1^,EW_-2T&-5D)FGC</H;V2M/E*R,0*)F%-Z%4
M<>0J[$H*8:^Q2B^N]=5O)>GFDG5MU!:6H,+"=K7<LZ9,\2@/8Z@F[:+>]^I+
M:98UR!3N?43'WA'Y#/0URE-4$W7&.J&B2FJ6=6(6A9;_M=/78;C.Q6^6N;R$
M5^+K_Z$YBTNXH9MPS[W^A0XPS/-#)ZB-S5A_197R=OH]:1"_E+=25!2]W'(I
M1:T,+XY -;;EV @1]6G1=KI0/,.$;ZG#P1],^YC2+U?3GU$Q%*S3/Q:EU$/<
MC;;G;P3ZA@3(T)<(:_KO#\T#.1I)2K\-@A2[^TZQ!+LHPW@,N3_6!<TKFJDR
M:.=<F:HM#=H]J3LZ1TNGBU!M["6KQ"ZNKW\:140P8S\TMX--.#9F8PY+&:C%
MO=+L*9P9:XN&1$^BHR,I7Y\EUE=JBLX(4W0N[W[>/CV2^_$_QU^_7[/$1/CP
MX>?U%?E^,_YZ\_WFZ>;Z<3]AIS[,M2\WZ4O2LO':MHXX*\_6*Y3LK;=Q CTV
M6.[&:M:\\'-Y<=^]=2NY @95J5XK?*$G,]IRX5\E4\#Z<;J@L[5.[^9QYO&$
MWZ2.7L>+27,/01P*)8Y>!U.RTX0=PU+ T[K2XY38><E*?YE8?_Y"> 0P;=BO
M]FN7\UE[BA! S*W+=X\^8+@DR8A5GEKF33\U_XB?9WRZ++]]F"W*>E9Y*/%V
MA#<SJC8ERML5SCXGO(D% 07MG3]L[5Y'86-V:QI3_H_(1G7]OM3N#T/NF@E<
M@)&;4JG=[IYSMP>#GB0K86V84NYUO@#SKO&"&92LZ:?;;7R+[^#E\D8JB:.O
M#Z=E">*"F.ONVI+V,QUV1E*_<UHZ3JWV'#N5@M4S[%2G/9)&[; >RDEVJNR&
M)-?+E6YN*,_O!]YFEPR)3*A!YYJ+4^;5!; +(VQFS;C?4U]7=$Y!/V%DB..4
MP!_>9V[+^<O )@#=O[J[X&V2]^^H1MHC4'!A[2#?I+B4N;7#85M2VF'XL,7(
MUVGI.7KO\<Z1&%4A,=/^(M@A#=9Y.,.DPRHOSK3;<R0 U[#6'K& PY5!6^J&
M-GR,=2&,NV5OBUS9;,,LY)+[8&9T3Q^>J<A5[IEZ!(<]?@.OZ!5WT_!7- !Z
M O8Z!6!>SCTOU,]X>>KRH4A=N2<I_; $I)-[GEXEU)=@^5T5TQ),[G2EX>#T
M[2,%P=*&=L\7&MC-4,X2LGU<J!:]5%>:H^I &KSI6"_4CAV;Q5O2J7?4)@ K
MMUN-Q[^.'Z[)Y?C^YFG\G85?'ZX?KQ_^7ES,-?=4]1RCK+'9PPNG)N"G>L5-
M[XS&(UTY=(F@!P,/S"!854OG<SIEEV-B&K0)*K*I].#&#!:&36%(6#VQ5Z#P
M,*2*%VK-MEFK (016#NV W]@42Y<OY= "!MWTL:R_"EH<_A"WT@(Z-X(?B^Y
M[S57_+*^@LD%O^<EZJIEJ8;C-Q/ NG9XD0OI8'N5Q E@(?"U#<-T6+,":E''
M#(!,J#/<?^8[<RS3ZWZ@;Q -P:)S'?X-3VEVV-8(Y,^2D3\[ OES1Z&F0?[L
M"N3/"LB@0/X4R)\"^;.J8V? $1#(G^]HO+SY1"!_"N3/=X6I68]9_D4@?QZ]
MWI3KU7KW2*"Q/5:=I"XN)6F&<ZHTYKA7YN-'"#P(Y\=ASA7SK'TXEI'5;BF]
M3!XU-;\2O?':69@6-KTY4#*YZYBS.8YR8N-N4C;.L7'3H)P2%[NA.ONPLP%/
MK:OL;*+Z;.-Z2VW'6F.K/.I5OR#LX?P3^:A=8".EM:%K2PT_--;,#XQ-GH+>
M6M9^SUP[9*6Z#9X^,_C.C]KQ%X"1Q+-CCKZC16[-D)\QX-%P%S+OJ[>S VP>
M:.B^ Q=K3I+22RHI.0)"ER,IB"OJA2^6ZH:STR&K(>O UY+7K-&!E[ @!OQ<
M-:94VNOXR"+*MN2^B#E#>:]DX'U&$1MC#P[O#.8V3[-IPXMX_-74P62U0X4#
M9SFA!-MA.CKOO&;1*<4\*C4XWDK=L#1=-Z*!B!$L[H(KU;5_K3&XP2(F,UB$
MJ:\9GY@6"!^3H,9ZM0^:RCVR[ 7^RW$^,^JU?UMLY[T;PZE3U+!D&>LGE;&>
M,*JB:#O)SZBZY#S,*&,7;U>]R2-DD)2]^W4[0JY88^%&%$[Z;IA\"RA]IK+B
MNO/4,"E/#>K&4PQFG#65N+>T%^PE<:^K4Y9Z0.[F<,0+?DE _E%2?AF>+ G?
MFXE?!.Z2RZ>61ZS=PN]8.64)WYG4*HC/*,5 H<=WS^:)HO5DJ8;-$R?91*Y@
M^RV-Y0Z=#Q@Z'CAGNE1W+ZLDS_G>LJM[E?;KW.-7FUXW>*EE4P15,J55VKAS
MCU]MPCUAAZ J;5<YU?S];B847NXG84P_.[)Y L@T1R#3P4YMQ,WMMT35$9Q<
MG%JAY0_<A?3A2Z<G]=MAU:31%!;HN''&_:VR_-1)S4WLL+NG%OOL6&4-?.\Q
MV*#;ZBAI$)D%@]6,P5* >^*5C!W'W"G(>(KEC4>5;/6[/6DTJ)[.RE+X';OJ
M-/6$[RW:G*^9%^T?O'##9I.(/-'S;A%S6DZ*WX@TYG)Y0M0OY=27E9XT[,7&
M)J\B46K.A<<T=[48L%NNF:#T!4>FSK<L:^WI0"&*8=9!*2;'2.KT.M) KC9W
MEHWKE'KNOUNF;9-[RYQ2.MMO\B#P]%,.5,2"!#$$,?(R;,H[%(:E' JR+(U&
M(ZD_C'TJ5$7]G^/V.=9U<\KJ_AV3C&$TW"A5Y^$359LU-8.X,>3*F%Q5M#'S
M-:ZRCO^V3.PJ+EC06URI\KY21;=H&HP*.CZ/]V+J==M2OQ,[1E \HX:W:,KW
M8O4^K4-AJ@MB"&)4\MY43OA.EKJ]D=3NA0&QUOS6E*V/%-L\%HW#TB=R:=K.
ML0:H^0Z<W# ^@GU9CEUX,'BI1O&YER[H+.A<S,4G&@\X]V,M%91P,3>>88I6
MQUEN/$IW('4ZJ8-)>;-F=#_:"M25AE>[)&J26T3]B]Q.6@ SRJ]@JBQL6BR9
M(@JKMY/WZNUTTV:@M"NWEFKEUU*Y.+2[$ 98J>W#"A#U^=FBS_@8_#C:+,T
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M"$^-9PHG[O_M<^">1O 5PEO@Q;Q@1#J)8424_)!G!F7![(U7EJ831?$ CX)
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M>=25!KV0T&$"1TKCC(Z4:AD91:\J&8! 3P (9 80Z L @0K(X'F%K/0!!?Z
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M$\;(0$L5MCPXP>"/]KF"TY5%L;S9K2P-* COV95/V"J0+_8LV.C+_1=YPMB
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M4_Q U^9![CB&4YBIK?'AZB='2H@""41\?D\F?G2\FO!89V/YPY=.2S[2V_@
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M>LQ7.^-^/;+K0A<ICGEISV1P5OON5T:GD\P>;&S7"4->++ZQ77Z8-N^18S(
MH&7GF$%K=!A?+YMCSI#UFF'N_X@9J6+S:+I1M8"V?9\)?P6DPZ:^VA=D_>[A
MV7G-;'DH+0"7>B"E!ZUM>_VV-%1BVR[%)[)&4D]P;B4X-X-YG1_G*OVA- @!
MG*H2Y^XGI,;.[:Q/UE>.,TS62W?XV>L\\0F'>J2,_'Z#7654ZPZ[:=O ?6NF
M:JH[.MU4]_UVTPUCS?<MF*(=[GX$1[3#K?#8&1([1#O<=S1>WGPBVN&*=KCO
MJM%L/6;YEV+:X5:CLH8'KY[47QE0+*/>487ZFA!YQX*;;JMQ<WMY]^.:/(W_
M[_5C<<4U.>?KYU&<$XOL7GU.3!ZI5XD.=@CD&'!8+:+9#!035C+5=$WUBD\T
MMG+BJ+_H3B,HU7&[."TGK$3F4C74F8;@$G3FXWZO+/,%7J#!/]WWV([JK!W3
MV@1P.>'=*9JN)0,YO)[/>4FA3TF$-GS86>[8^<;G_NA-<N?'43B(RB 4"/%C
MUH8M-5CD!59'\:J?7QY*^*<BM$BUVU&D4"Z=),HE70W1(7Q@'!ZI=RU1>?YK
MD>DN:@[J0(FZUAP4D-P@<NS%1E6M&"%7P+BBD[YYJ(K?!Q+"')62L!O#@5)^
M2F_L28EL\MA<5$J2N6#EFK!RI?/7S\C*%4EKO_&]2)Z+@'Q$7Q-,9G/A^9)\
MWQ";"'J$1.[R>;3[UC>PXQ?P/W9[MGRE!IUK3ER7TG&1ZDH#D*I^?/QKD2!?
M$2;+H'?+9C)%&O2Z2> Z*Z"4TUP,\E7;%L/$!64]6[/-NL#0\$Y0P*+V6D<(
M1381!(WZ)$0JGX&*6) @1F6(D0= -LX*@5KEW)%:+Q?82A/%_475>92#34+%
MB*%J3(5U=L(Q5*YQQLEU8US1.;4L!(3[Q7KMV7_WJ#?V"!?1A@1NZ(K4[L;N
MPR"T5868*G]C+"^F:H^D7E68JARW;'%Z&0W@< >L$);SWH\99<;&[+L)S.3_
MAL9Q*BE*6^J.#OO,B_MO$4P4W:&EYV;+Q9Q)L^):[!PZZIZ"+!G4<,A,F\/1
M@;510EM5TEZ\-F \=K+O^U'V\/[ECJ2<Q4,G#,/J&H9QN6<T@N/M,'NPXJJS
MF@;@-].B\!X$:N=7=*%C*ZIC74KM>*JO7&(Y&K[FF+ST1C)HV]BU^D+;5NEF
MD;^Z3<)(Q\+64GO0E=KM<RCA_&+2)5RO65L-S;;7Z-5@;:'8)*;J2G-@B'_S
MSA[8_\/9"#&IU 7\UL1N"1BHFNC4C1]ZX%MT=FDN\1-NO^SUMCHB-+VA(O6Z
MP[.+C&"M<VO@W%FK,VI+_>$Y?*)G!WC[3(I7XZR=G0#%2I&_5V-[&SZXM.A,
M<VQ&_N/FM3P:2'(GMKM5@+@)?BWB4(G/KVVI.\S:9[@J7I73IT0WY^E&II_&
MW,3N.40.!B4S<PTFQYDE[MA$DD=7^OE$5XIFF40*6?!&/KPQJ"UOE-5(79%;
MG8(!-3*U3T]1!M]-4@;?J1G&AI<XT\"S1V6I,PP9 PR "5@!CD9Y-UP5VZE@
M*HU="'9"G6$2>DGXHYL33,)!PA.F=6QI)A 21%V^0$AX.Y00" FB\%]LU!M#
M2"@*"L$TFFXPD$$B',5!$!W*<G2^==([WPYLN4M./:SWOE0M:P/O>E6MF1WA
M?QM([79'&O1C-^0Y'UD$O^7!;]WS\AOP6E>1.L/8(8K2R%(11(%[RUS!N!MV
MF\9DC-42#CZ)&-1YAY'S:+?:L X)[>^#4.?43YJQ/-1-GAR-C=FU)T7V+74B
M=!,<A>>HH2\]DS?/E%W-4 UT [%\,I&E6ZXA&,KX/DGV\W5VN7W05J3N0)0]
MU)%5\M*1,5FEV^E*G5%%6*4B9MIX.K76=.:%W87FJ\@5&,,H[F=N,N,#M:GU
M0C'0P8@&H[C$"\0]HC*J.E*O6Q'F?Q^,%6WTC^I@]-?&@+LQ'-5XQMQ?-XK[
M7F^:E=1FOYOF[%73==!=6T+QKR)*K'H=.*X5H;$JHK'D]MO26(7J(V!],N6I
MH^^0CRJIA/QDWI@^7J6+YU9%/"GO@V^B]8_\MO1/CN4Z.2[I.\.3]-+?]@LH
MB\JY$!4/9?K:&(V/W!J/%5K*TFA4[0('P9T5X\Z4[KUTW"FW8U<!U[[\1HC3
M>Q2GO (KNYG2OUM[714.^H(,X![>C8_*+9A5,&M^H9UDS JFLS*4AO&=1A4_
M"H13M0[W4J4.]]+W0:C\$$KR4F#[_NZ]U)VC[;AD:7@60.9*MB<2R83%,'D^
M[M7  >T1ZEY7#2>8LA9Q:/>E7C=VVK9 <"KP(.O4X2![&PY6<P(O4Y'3$W7I
M%!>9 BXRN>O(4$. T?UN2_8X;JV>I/1CXT$6S[J)NG *5BV=5?.R65.PZF @
M]>4*7;OS1S05_JQW+5MY9B($#.;(2HX!7 +;L4UCH?_?.X_F61,9ET>5WDCJ
M]K)V#:^ YC^SKQ4V&8C'B4!\,*)W>$6M9.Y8=,'=4.H/9:FOG .'6KAZJU1)
M'LTG'6G4!VW9J5VCO7-8Q7X'PZ,-387Y42WS(T^%FZ1_97+]*TSE]\ZK>2K]
M1+R:^ QX6Q:S@ 5^>[# <K>VL,""-XKFC9R:M0K(Z-AS3P(9710F<#\))G#O
M0[TPH\>-^5K7R<OA!84L5)M,*(6/5BM=HS.B/JN:83O$65#,5@EQ\> #4W5M
M4Z(Y1+.)83ID:5I8@_,'U3?P),P2/X0_'#)?.["'^#0R94/CC1.PMA9>0]07
M5=,9TK$W[NM"FR[8Z-@"234V9 JO6SL:-DICGT^H0><:3 ,[7-"Y92Y;05;*
MF>LCR=)4E'S-X?+!L =)&+]?-\:W&\""?UL;E'3:$D&$9&F'MY#]C3WX36 X
MR]HTO7I+8LY1."SS%]C6#C+X;T5=*N]6U )"&L\)@/WZBC129&D0TOB+? RN
M7";-$S//<,5(,_->6QJ.!M(@)&!TL54,#<<$"LQ![^RI$N*J$LT@EZJASE26
M:X?$_0G#@,)Z=(!<=HL\+2CHJG J^T2>4.!0 F/17RO-8F^%/>N?3;.<$V*_
M_'7B#'>F\!_-)OFF47WVB=RKSV#3/=)_K;$?,4Q''GTF>(.%OY41:3;=1YFY
MZJ_&6P*?6-,Q5_"D@G-R/_'LLCY^=NJB'U1[P35Q:&3_G6R4=L@@6:CIFJ,V
M''^<%A^^?&L&-\C;FL_D:;."WXPM=:)-/Y-;D%"^?;<F;E.G'7SJS]YC; >#
MG+)EB/ MG5A4_:,YH2 [\/X5(T]P _HA&X!;']S$ +]\B!HV.&%<R9;<9V-6
M3[;V63;;1,*$H* 6$($^#Q'](-*V@ #[S:%-G""\S#!?+77E#]E7LB )_V7R
MY<;X 8K]?J'"P32E:S8AFX#ITCH*;AYG6@7C&T<,+;^AL6,[XF(Q39[Z\O;N
MZ?J1/-V1I[]>D\N[V\>[[S=7XZ?K*S:/;S>WX]O+F_%W\O@$'_ZXOGUZ3+BG
M9=.PUN/ES2??[AX88?]Y/7X@U[=7UU?D;S]OKWV+GXQOKPAOR1%WM=ZD2_A]
MAMTX'9X('?QC?H)U_6ME4=NF,S8UL)E_MAY;Y J/$,N^R!;D"55=A\;7F4-1
M8I;18IZ3,S*;V1#2+*1XZRVK8<IF+G=;Y.;V\N['-7D:_U\XQ#[B)>Z__G.H
MR(//LPN^I/Q'/F;CYN!O&B;Q-PV*]S=]^/(4\ =A#]=G S2<S?R=GJNQ@5Y&
M@GY(N#!9CHJN OAZ9=H:VP?3T#=$F[L.T>/.4/1.[#SH^4%MF R\%8Q;^)#^
M LXV^ Y/-O@ XGRK:V=A6BR_46I,5)O_EKV13A<&'A@$O><.\UCAY]XHS 6R
MLY[M.F>HM?''L-],6:CH.IES?&)XHXU.% ;A3MP]V,!DIPO_Y8U7<ZW/< U+
MJB(5X>_@Y. D>*:VXPW-]P'=;BIYAHLD:!V^1_$;>RL[GBD,YJ!WZA64H$V-
M8)G @[](8+.O[M)]?U13"3BD5C#Q#U_FVAP!I/;=:"MJH7[D)-46ICG#'9Y0
MI HL06?;N%[!I->ZPYR$Q*:.H[-]:S5N&%,$O(ZN^-JPA[HVW:#7R:<'D .V
M!#<,O5DK:J@Z;^GHPAZC\QY(L,N'/EG9MH)<P5QPPC!+S6]4W' 1DQDW (.^
MXO\8YA&69N^"YW=\I\2TF"'5RM$=%B&8 2U4LE-\E$1)#<M64G--AQ=O*0O<
MXZPMPVZXHLR,L#D%FP $^'_6EF;/-,;*$GE1+<U<VURL=[Z#B2''<5=JB_Q#
M<Q;PCE=01E.Z<G\0])RSP _13>,9)-A>3_Z'3AWD9!R\X0V.;^1#\4[9OE[#
MYJ06+ 1ED6PH6(MD!3.S\ U*6Q[5B\/B\\JH;%X!,@6(@ZYSIK3=L\BED\2)
MQ#D YHLN<OI"==L[''8\ZD$^B;^!%;?_HEN\[JJ01_J,FOV!KDP+8QY1!)=/
M](<]_:K,',,-R5Z+/%[_CLX-,"CAROQC_'1S=^L;D+G:C/O1_+2Z.LE&*Z[*
M3D:<LX0SQ[Z%AC-#*\+]YU=U\X."/E8;ZO1?:XV?Q+MJE[V=66THSJ\F,;W(
M&Q-+BRV;^8UMOA&NVN:>4_<S/U+F#^A]PTU%=[ &?YOM/Z89W/!BAFG0R(--
M4I\I?S6&2E4P$'D@?T:Q_I*I#?PALV[ IG$GBM->XWO0S,6!%QJ=$S^82*[
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M[M'M&.P28J94=4^7&MH3RXV-5K]".6P)2]C=9?S>LPW?2 $^$H\:4I+!#PT
M[&%-H0Y7@I&KX7<JVKUC&ST!0.P$3%"#8M+[W5<)S'XO"H01@PY0()XKH?&C
M+_#YLD>AL9]"<Y="!8E>'"BH8*8YM4AY6<;ZYQ1YV0:6B,AD0L>>*)HPL%5
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M>^&:MBZR=/J+AN-^E+D7$Z$Y.E8AY_4]PWN<$A%=I@'^:YX-PA@+SM2AUW0
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M9,7-\1.1V41JPZM0<:J+K%!8A\9-?'TE=+!,\#1)(98%"W$L>.&SWS9 56A
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M_W-K<-]J=[X\=L&<QRE<[8M]DUPI OUNX/+L^Z1R<9QL]?B4<P@ OV+8+ :
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M$C:C@X 2R3[N53>_0_UM3*4X5@!3!""'<-MEJ*M)YZDQ^10!)Z+;';/@%DP
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ML):^[>D1ZLO" 0[]A35I1VV=',V6L_%N .&;T+\T;DNA9C U=PHP+U@%:W:
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M%=6KH+.!%!GKWHNDH ,'=EU6N"]=ZZWRBZ(.?5%7?F)'7^+] U!+ P04
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M6V;5['][A[Y *S])HR_7_@502P,$%     @ -GPW5;*H*(A$ P  ;0L  !X
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MJN^1L]ZK9[W-S%C$TJ>^P-_&H%.>??\$M\I,Q&82KD9C,T%_ 5!+ P04
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MUTF@_\=5O;C %;W" T7%8&;!=1 :#T3F@>)XH+IAFBX#3!9\[ G(D@,PB /
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M:@OSUL?) "XLBPVKB=L==+6R0I=EIJZSOD89*4\EU^21U1VV$K_PH[A#2H>
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M8/*[:Y0/8,;/'*R_!D8),]6Q!V#P6]&QUE$=OLZ/;0$_YA^6$,E727)R"_5
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M+YY(-FSJ2+%\D ']9H<+3<V:IO%C]%I.3;7_4G/..NP(.A8A$$SJ@-!9$)%
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M/O7K;J*G!U5*,3\RE_+4'0^:?XM][_I":]X!YWW%-ZE-4SG,:12M07H_>^E
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M/@(G8/Q@3__ZH7I1-^]Q=<E1]<E;VPMNVVD>_Z5HN]GT/WN')_=GK#K/MW&
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MCO$.)3@0-SHZ'L,S9O_X9'VC]#.$YM8,8T1W#&;OG#Z%N6FCE5-^4>[G?)V
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MOL^,J;W&GIRQ- 63!]6<DIE2MD9]2QLA40Q+1QI_5)132MB%(SDT#-0NQ/_
M-?[DBZ,V>[6S/U-NZ.7OJ+L0-YFAS;-10)]5;6X\(+5L<'=7Q>25Q_ <GN^J
M5\ 1'(<N0"=-G,04G7H,<.%:LX+BE()NF^X)D.'+]U\&X:TCI&1YPT3M-R\P
M=4V;JWM#%8TO"+)"OD6E=9_[P\MW&0:W4@0)J@_>>@"L6D%EH.0$-O[.!'DW
MH7L=)F5Z%(^L!J92"P9#UV$HUJT*M?HR%EE6I,G$:,A&GOI7SVP$H>*28M<#
MBOWHL$>-!V-;+I<HSN\@;D0Z<G*[$YGU=YX;INCPE?U0TMJ+"MA;_)$NL"J>
MIQ@^8:+NM+.-K?<#>9AXH]AR.RRSU"([6'DHD^<KB#Z>IPD.O?G,E\;!.B>B
M_HR(W8XG @6LAL3 >1U]=[08%,PV_^"B=*!O4>2P9E")N_\+S96P_ ]#\B&R
M-SW<RC/I\G?%S":JN.%@,4<GENBOB$5J )6MXRSAZ%]H<=XA<"$6:5,.5;&6
MTRMY=D"OG:)6!9?7&$JY2A2VO=Q+,=^2'7ZCX5R;@XB/FAV#OVNM"(5-<VE'
MOT2E(\U\ 08:[$XG7H&GHZ0%$-4M@JMQ[N7OPL6<_Z09HN7=NO(H\]W%;'(@
MI:]RX9J6P\=6-MVN/S"V[^RUV)LMRQ9S-U:5 M UHZ2V*OBL6W;"-:HL1#\E
M +-:=+2I1#_2IA)"T!G6/0JGP=/4G(14=;*SIT6'^<,Z1:-/].+VG1_(F,9]
M/K^Z8?PVVF8J K$]=S/H5<D7 JK:X#!(R3.RS<6P&G)_@Y9P=?<""#D@8XM>
MP,4DI93=3R9[6>G[L=]^L)+."[&ZI8DMGB'6-NA6F7PQZ);^%$*$OX-G\^>&
M_V4HY1PX\($H5Z5:W<<[#/0R3GQ:^-7EZP)\JJ/VAXYTBX_YN>'ZN%?\AGW2
MS='/UV'7X*GKL%H4G;B;\#9"YTT%BA4ZE@)&<K#D:*HJ*4E6?K&R#!Y?J:?0
MY;49:/V^U("^TIP1B:I!>WF:W]0JR#_J_/EA:D]H(WI.%[!N'=L#^";R$0VI
M! 4OR((N[WMGG@.@DBI#_/"8B0JQ2?["28 A6# 4V5A/+N@J1:O=[^G$E%A@
M0_6?4 X==5JL2D-L0$J"[^FM!OS]4=Y6 _@-'!,=MG TTI%5<:*6)H'S;H^P
M]RL0R*L?F1T2\QT!S4;\L<CP@M=UC=>V3B;+W17ZL;I$6*OB'\8?H@[06#?\
MG*GJD#T'S5SEC+=VPW'O\"YAY=#"J5J 2BK!D<U\@-EA,V_AV+G:M>VK%M9F
M$3G]AN=,OBP]T_@\>2U-EB\BKMTP@4@F[@Q!QPR.Z?3IZ<1(XH.@P'R9 9ZU
M=![_+SS6FR5J^ 8ESCO!AF^?=D/$(8GE9D2QAF(F)LQM-#7+N"44YR/T*QG^
M>77BT2$<X<-W0]UA7)@ NQ--CS%'OGB].S**-P>1L@:-@T4EVX34NAYPB[ZU
M%S*#3^_-8&(NW:V]^58AL7KM#F&+.QX))0&$F5FV6"E 8BO=1Z)TZ 'K,'E_
MX=8Q*6!FUIF_EW0*B"L7;[E1R'2?69HU*<SP&/5DONGR%7T_DA$K1*?YK<-&
M.AGCU>-TG4T0A^V;P!=13PJUD1AJX^^'@KPY51*6[&<]58M:,BV7@529,46:
M=4J:DHE'5YD_0=G(](Y>5O7(-#.U=^<!O(T @C:!M 2>.^CNFCDQ_XBV@;J-
M=P5" Z0.)=T@J8JA5-[)<>EK%)1:0B)/C57F%U?NS)>A@KX)7'VN[H6F]!^_
M?1O)UMZ*U,EE6CKQA>\;!%,2K:0,CB8D/:8T ]+9K0O2YJQQ<8_O]7Q#*.J9
M_](*_R$K2"K1.\-]U)3N5I=@WV#0R[2;TM#,H%QSH!2_68<!MK3-TR@%ZB&\
M"]B0&+H@Y3>^DZ\!H=C.:<"D: 0?ON'/'%3>L6=^7J*"/5-S_%7\J<%%.WCG
MQ9P',0S#8=^FZ#$;"^Z6_:>.*XD^7H>UN&M2+$NAGP[ .HP>B9:$%*R ;N[F
M"L@V:N-4.Y9MK=%]6^9F5XD[WHK? ]21X_"Z&(Y"E['+2V!@("%17SAK9BOV
M:E+@KC(_0B^Q88@AJCO1D%J'N,,7 <3B0 W;M4R"*+_/[6H1A[83[0$1NOAJ
MN)I3/4'X0X,1A(>J0VF7MCS9VU<UZ<<--8XSZ*7OW,'@CF\B=-"V\A'C^%/U
MP!HCU9&UW-9$E#2OP"N]!K4^C._0] 5+^FFL(Y0>GJE*>J0EWG)?151PY.Z<
MV*5/8[;+68>87\25?W?'TB9RUV$U87$4?<XZ3-0:P[&3K&H+BH^P:!D-O@"Z
MI%35I5T>8C7$57443!!W?/_Y(05;[ [)<U5RZ8X,_S[FV]SB@+NW;L/S&=P4
M#D*(%PP]  IYR)CST$^VSB[^1[)8"*X(NE,VRM.@@#IMI TSIIJ#^BD*HB<[
MWJ_^&:E:GU(PYCES^$+A2F75S;=9@,PNU%7>-6B9HQ.-VD:1+I_A[^P)I0D8
M!#* A8ZCR@%UZ:6AOA.S9"6HGA_I+D,9>I8\^8-.O[4TV&"X+%MS? @K9>KV
MIOKM<\K5@G78IC5(M&PXP'&F@N-IQC :+  87IGLO*&DJ6SV9E(R06PZV&\,
M!MJ2RVJWC(D&6/9IJU>_?C!7U-#/G7JH4_$-_F"1MHO?9;H!B@&BQR>ZTX(H
MCFQ%B=X%\\%K/+NPBD[9="S2Y;'_3G\F.@5+,0O8K73Z-;9DI.AMAL)1;B'<
MA#+8.V*G>7;#[\@)-'-H*1_ZP]H2<^ I>.&GN#YV4'O5"+MOZ19 2Y@"EP3I
M)L97_&Z($OD*JI&3?W5.EW\=<*>+FCX(5LW9?4LFYUW @Y\%\;8J*YGV:Y30
MKNU!*1&$4H!JW+D.BT/79K?"A\?8G@HNKW+ZG"E0GDRVXE02EO.J)OF;)@\5
M7A*C]@*NW_XTVV[LM+/=!0 ]AUA%01H.O8NS6-VVB*&D7^NP]&!^KZ'2/E V
M,3#4QMT%Z@QGA2,11/::^=A1[O+H]XQ.(4S]K:6<:Q)G^MQ&S/;L4 $7YA0!
M#;9AVZ@C.R&1!:)'%LER.&&V;3&KPK@M.X(8J\-7Y>D<1@CA?BR<OF-F7>77
MB7BPQ[WD%]=6I<'Q9:-Q"@R_#%@LK</ !480$V4.^;#0&_'(U]"EY[-$13TM
M7]<>I'=9P+B4J9('3PH4YBGW-K2AM[<46#R%T'R)T8LEG[(XCKD?TF*]NVZJ
M&NBCH/WP-A0<U\16JF#K1*^H);PAQ=/J9,BKN@&F>BD=P1ZX$?NF :UR'EGA
M.W5GPIF,L06+EP/Z-B@;:A_"(<'YD4C*B$AX1<N/\.X_;^Y8 '4F=!B*NFS]
M!A)2Y\FT ?\@)#AP8@XC5IMG-::\]D09Y-=$E?LU$ML0V_P-  C5>AURF%_4
MT2P&!@8+C+O]+Z5AG[R^QWB._S/SE !)TLF[^)IX1W H*71<SHY#9"JM+D7W
M(&5"W5_Q1(IQR5K*#'-@LJ 4BH@\'[W@"<R=\]CEQ0PN;K+9W-7O8B@4#OL9
M0!I995=,15.DP0VF,I!U*W_'VI.0\90<U-QRZ0Q!O:E??U6@(50L!)1^8MI4
M=?I6EN0%IE^^02TP7T 4[YE\W?2I[9R;/Q!>TY#]U7D<< Q*'H<31 D?S^$=
M@*G69O>E.U QL)VS% >:5Y(B.6_Q<N$3%<="5E$O("M1G59FQTO#]- U9W:D
MC8993H>HG)M4AHV+Y(UE1O0Z[)+=[3%A\)3\4MXEMI:%><]3D$+8"D55S-;,
M$#9"D3IMQ7F\\#"6J(0??=@+%\/5;0O4KEQ0[>56:F-K8[Q%/[S_PL\3;-\5
M2.<)AB;&Q1]FHY*INP;X4I5U13AX.],P7?L2Z)4P$458$CV]#F-5^]>XV2R1
MA2S" S.G&TW:Q$)*C[W(AQG<A6]M%O@\"7_J-0V*8P>)\K8G47?B]Z!J)I]P
MU@+:E50SS<"O.>H,+-QV,/!2+U)%*\.D.)&JQ"AU3XL\.Z@DW7\"-^>3SCZ@
M4G6HC^A?13+J3JK3AZ98)*$O4+#5']7SG5Q#;ITVE<2;@>C8Q3Q#BQ>N^@%8
M%T:W:3;F&51L7=W+>D5V KY]F,8\;Q[*UNM).6--2!84[FK#%K+$]+A<"-?=
M>E#;D3/*B [D[_MB63':&58YRD/5UKP$N)]?_?5VL,'>[8);>VCPEN'*U)-7
M0_]Z"-<I(=")&T-1\K,$O:8^WG&&!_2:120YXFZ:8-C -W('7.2S!^8P-&5;
M>\%T %,:(.\QV>EU1X= +V'(GQGL^2!R%_YAG)G)WWZX"D=J&:\CM01MF\V7
MJ@;#XDQWH/$N4#BH,L%(#LUSK;5&B.'M 4;THJAD6TX:/]NW\!W[:M0I?_MN
M5LIH$)UTV:<ZG\W*<"+V!0ET"0)O"52=6,O'*TS0=C!QG>QL1G. -6 7D]UF
ME,KTC:L=R45L[623Q'&9[3EIA<$SB(M](5C3^>EKOT;"@^J,Z=+E6U3V/D"F
M_'&N*^&]46 >VT8^2KTCXB.I"F\R8"KQ>=JM.Z4JZ!I>#>B[ &*+TZOP*BP_
M2J&!3 ;N69<^JL%#?_*YZ]<["VY;AM$.>/>U?*0(F$!7D@3X#3<JOT>0Z5UV
M9X>H"E ?W>739QSMC9=R[S6?7F[=N-B,+G-TA!&Y+Q>Y9'ACS'64Z>G6K>DP
M<O=-B? W]38[)HI3Q86#G"4C"%N <9.-KL7J+CV N$#?4CS0AMB)=W]L4,5!
M1)M*9CI>P)N4X2Z_/SV$W&L2_\2G\@+3O\^]TZ#H6)^^-7$?PH#Z9ZH$%P&J
MG%VKQ&NL'L8IL*;B0TU$^3L]>%? AK8@*5RUS3XMD>-]2!OA^.)/M:/*8X/L
M6?O!A?QYYGSO$ON,7MF%RTT!O^^(QPQ J"5]2&XB=R&624U[/(,8H0GCK3DD
M>2C8X_6 6J;C #X 5+&*4NB@:H'G.W=[>PWICVQ3C6?/?'.R=SUE_SAZ_-VO
M-/2$"STMF!U8  8[]J1UIRX&Q;O\>=&'!OV&<DODA):C(\F9UC-U9_O\SWF.
M@[I8=6O<X+Z3<VU"/^%M-,!9Q$YDE-\G[X!#O2%++:+O"/;O/N@GRQQRX2AZ
MK5J!^W*+H9F1-]EC.P;KFH/I2T:>Q<G<1859ZWMACST#(H1.:7/<)S-Z3^I3
M=06\ZRPR $ Y @EW\'; PIL&FK3[Q&@5PPZ!L[,;I 2%;@,^OGP^,NTF&TM0
M^()1DAB<!'72?>]-9<TKVNOE2>\PM:E_8FRI8-B(\^5O"UL]  68@8;Q\22.
MB?=)$-'J L&5LLMQG0[Y0_1UF#"-I5$-UIIN!GC7M1H^UZX2)2XPB-)S-+\!
MNX?((VCDD6I$*!2WJH[7!Y=3>*(<:!$A!ZEWY OW:/*4\]4 1.*53_IH29S\
M^TF1SWA9=N>=H."UET_4%AN]3J:^&&5^>7=S:?EPRD.GVT>#$(0^PC$R&]$R
M'HO>C-_\=(:/@O* ]U.<JP6R;5V.#@ UFT5+D _]2+H4%7!D^I9;^E.\KW9Q
MQ?!GMVD7Y\'!ZV>S1:/"MM-ULK\13 5;Y/9GGN%:$1X.Z%Y(8770,)QFM!M0
MZ#PF"9Y^^1R:;57:WX.4)+*G,SN<G5?TAV++-56Q)G.%#0V@'G,@HVOWD(Q"
MOT"LG\.[K/U%5>*Y@H;1R. 2--30FF\"$8O]&\7N<(B;9[L+<"2^.'&G22XN
MIG5Y.6-DC!%9$"#J':36YG@\<.]KQU#,C<UTW8:[P\068YJO"8KMS;.I?0GB
M#<T8.=WMQJCM#';G+X! !E7:QG:;2H*H5.RO!_:J.?G-3Q*Y52J-3:^JDR\,
MSGP<',,?@OT>::$!]MW)LM0MO::JN.4)TP06#8X_M48FJ/."(/=G&"\C>>I+
M_:'6NL9<1Z J96IUQZU;*. NIA[T7]E75<S0- "\M+(*-KD8U+R-4G^#KI]J
M$_F.#_<!@]Z@Q0@R 6Z^ B$ PQ, '^X4:;X.OA6Q'7\"Q]6D&'.P6+W[KUZ"
MM@_*NI2R;R 2YD)Q^C=I?CU[F\*Y<^-CS]923#?:L5";(6T[L1G1QSP4%,R!
MQWG)U1LUOS/(WPX.E&=YJ?1.7B,6KE7V.FZTWJ\EL>F-VHGR[D3:"]K<(FCT
M/B!('!?D$#_+WXF&\5!]=38:;LU]BZ(*%I!GQ31?!1#]F*VI52]J38_X^! ;
M[ALRO8_;QSAH=+;U-NIHQ3HL$)U"JT6GT:Y@'2<Z'CX;@5IUF'9+B9 &9V&;
M&9NV$X/:AKQ $^4KC/I70^D_':D]URCFI;C+>M1>_0IE)AJN7;6E8*M%O195
MJ"Q4(.-4;E0&H*4$_"]F3)4&+L>NPWR#)#O9\$WPI.5;?%%38X#(W5#,4QO
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MA\.3'DYL0=X1)(O'L"/:<R9'4UR;I-,D=[_V<Q?1GAP@3;W<@D#* XR5K"B
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M86B7?H1"OIFO_[;![_09J6=DY0>\JW+N/J31YTAJU71&C?UV ^W8RW%TDU-
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MOSF-_^"4)GG[H+\DB$URR]X20!Y=+[>".L<J+)R D<0VU[VV?BNPD*G! 'U
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M^I_W]_^N8NQ[^I.YAM;T)Q<YADM:?3Y/(-HX=A.4IM@VK4"RP((,:8Q8"Z]
M0;%C[L@FE[- Q&GHMH,IJ@'H'NN/Z* X/AW!D:E3-W5//3).<XJ\P7@I;EN[
M_*\\=LE4"#(/DQ(\0L+QB/6H-N"_'O*@LXKT%YC^8 6V.6Q=BSZU:IFQB[@Y
M;:?])71^2EG&]9L?E#Y1+11#-AA5AYM+>R#]\;&)5I*&VY('E.<!C!04%7XK
MN()1&SX%?!'?*^IS(%Q[BI=R-HM4;UYF6SE@\)RZ2)OFJ,063! <VD5+5)BW
M*72@CG4KL#@Y,0K4'9^(CS#\&\+Z]R@0H0.(M?-I_FRW70[G8J[EGEV4,22'
M_IRN>W;]Q([L'9;9G]:E\Q*@(L!>BJ3/"X=RV@?05L! "F@\YITR)W=YT;)X
MK"AFC*F#']T!L(5Q7+]BRZL>I9,<3[QN#_;QZ.NKG(:4B!>!IQ^.>:W  *Q6
MY-A< E4=5&XI*UM"K)5[0>#X;-"LY6B;>Y03]*60G'>DS^%@]3!K_Y'%0XE)
MIC8<PN='YK6W.GFFV;L;T71(>^D2!;'\A.+V'/)LK"%G"GU8 )N>_FL8ITVF
M_A0(I8PU4[D5W].*R;W-*S#"FWZN?6QLX'[G&+UC:\;$FC5UK3^9=U:+P>-1
M_5ZJG3P:<@'#U'#'7P+P]CFXW!00I[*$&Z;_(5L<2VGS79<OCINE!$G[V8HW
M+_M075<^X;T^?SIA7)_YT3\OI,0(>VY)ERJ08:I?M,M8P/K2TF]&&WO0>A"I
MS4BOA^*^*EWO)GVU=D:1"'J*TR"(1BK^NW^_RRQ'TH0O1+7\^-2^UC.H:)SB
MN+1![@BZM"!3;$3MK?GK:;<8>KR#9+=Q>A)7%QY?(&ZK\RH=FXR8_DBQ+80>
MFA+\THQ;[ JR+D65^8?:S,64E"/79^O\]0D&]TM4;-1>.L!)=O"1# LUIZ/]
M<^)_(>\9;>> V4\D74>0:Z%FH<3S+5_C"8"\9^QS"707W]5$Y7FEN*<?3=ZM
MWA'@NK<P+AW,D6^Q;Q[=QEG.1ZFM>GS;G Z>P7)I+8)PST8^0C:++= _HFFG
MV/ 38.4SSLORJ #] :N _E]+]3<'5 )CLF/^%?5G<-O'VN5:WB<ABQ=0KN'&
MX;'O%4]]_"AGZ9+L&BEM_31O%YC 0+2ZGYCVZ&<QM8>G%T=6T3+H9>O\]_RR
MT9!HJ\I"J;O=Y),^?=,DC\\ 3JXU+D7<=M@GR9*(4Z+-LJ3(C=3>:,3L.HEX
MG>_DJ#D7LI6HZ6*!(>!]!<!L7-S+J9S*G4B06Y6W_)B^Y1BU!Y_[N6C&:F?5
M4?9I>"WU+T6W8L-R@1R#ES*-\$8V.0)A4.2+:3MF(F7W"T)M@4[W3/9Z;C_E
M."H5J_XPB""[:ZOYZ439)KS#>Z^#*8BM($Z^!2.[#B2FLK'*XBGTGWU:@L!&
M;_0!\$;<6!?A/&![)X*4;*,?4 *L E? +A#U3"VH^)N1:4W_K)'X#!$8?E5@
MD670H@3B:A=FW,9)HB'6- &3M'@C1?*:9T N:?2=N$-Q"9;ZB3?Z31OMS%9.
ME)HE!4I&:$=B^%KXVA58:.\3%J@U97<T^^JGO,A\/>%[?=R,*3@7 ')F$4"9
M!YB8($<MH2CN '.F<XR^>=0?"HT1ZI %+M"YL7]9F"WN8\/L/H7PJ?N+XX6B
MH0LV19NZSSN]./3^/Y."D<![2K.'D++E90:*EN0M5B,B*9>S\(PM]":#%9C>
M"/F ;RT40P3Q_:.]C5W2WY?T5RT^^:Z;;K(WNT :,LO]\N_)JBM0N&+C[B4'
M,K-1O[UE1(6W/0 Z(I2ZR/<@U4?,!2LP34,GJ6[+T?Z)#Y44^]5E.I'^WH^O
MU1'\PG?4=^33T.Z$D9F)_0\]PX)_ATO@,P1PL%5_H85H+RU)8M'A\G6<Y5>H
M%9CH0#/ZCU7EQ)J!Q16!$A56"GU->8!9.LB:Y)JO4C>V%ESWX].P&?.:):]1
MK_73#R8'3WO9GL3=!R#&^+<I"/#, "()MT9A.276E<.E75@G6R/=?B:;H4'(
M;9U+X#H7"O:L2O,2[CPA:_+'R/F3=6E5SKE#'<A72H/T60Y0B4WP%F^)$*O+
MW0=8(\I^ Q3[<>2FR8#U?=\=KH]9!0IJ4V@5/N1!P?ZME7*,5?Y=F?=''KE3
M)'8Z8!F2M55F2;M&CPLP!LWC*,@Q/\86RI%7("?. 34^'!O8.*JS*L''9)+
MZ,!Y<7,=(Q5%V! P+, -;W8=K*T5Y3G^(SN-_:=J_[%^,+&%!IFUMV 19"HT
M(B?V?.<>'U^]HT!0W&:H_M,%M,D'A*U4<X@A,: I0S2/EQ^X]E+W V<= 2&6
M=8>D+@JMBY\M+B3_] ]]^>;&L4-.8Y@9']!;%@3"$Z] ?B"NV1:M/;@*A 90
M.!A^"L3&D;Z3YMB8.*KAZO)C3X"86\,G^JY)>S!LN5W/T(5)NV<_/GX\=3_
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M2U]NE:94J/2U7@Y^\R( +.S:0SKWGOTW<=:JXNGQ;28_=MXV/DF4GG[\R3*
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M@DEMGXCE(P?C6K4J?<]?R3!1%-""Y](5FLN/%08AM,T4Y/Y6V;=L-9QKQH.
M;W4M[B:VT;%]]J.NR1<<#][M4-2::!H?U_-!_+8'*[FCNT!FFMS5YAUO)YC
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MK;T^.5L:2A,M1'E[!>@T).M%#(\<>S<D]O=-_#GXD6*^A%>\4^R'[HLWR ^
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MAWN11V_D/AQ-7RA^ZY=WOC+;O.X6A@'5*#;N6S(C6S0&Z$-/I,BD8YU-1E;
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M!E\+<5IYRM4-P!:<^@QW!W&L%&TR67>V8*>MG='K/Z9S='5\B46\AM#IP'_
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M!F(2J%90\<^6C*G<&T7!ZY:_TZ6&ZM\)/G-.YSFR9PA2E=_S0*ZF-V')BBI
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M%V<&X1O.E:0^22IQTTZ$ CV.64\?<P]O#C_#O?G@YM.9652,]6=Z;N/KM]I
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M;Y)IP1HFZ66</2%1!^#!(&YV>,D6CU")P":+:/19E/^!UL6HM#F*'C[P4FE
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M->NKSJ."^U(6'W'M8<S8F7(@6*,)0-R.-D];O5;VD"O&^(Z.O"[4'JN)PFF
M!6>'KU]'CT9-PSM7GU2Q'/:ZO^$W#Y>2^T+8OA=%"\#:G]-FY#22"B$.B&%*
M+%Z2N[;P*4QXIF23H"%P%Z"9>#W:F"PKLF2 ,=4@KJMPG^!7ZSS;<=04ER2\
M_\(/.7__X_2%23?+!TF.;@2=/PN2)=H?$1W!G;!3F?4X@A23B98$N3&1:6F8
MWE[ @ Y7D1S$L^":,V#E6MQ%QQ?SC0CS?,FNMC:%F,HP!1F!GW_7O7L;O@?N
M%M,EL@L2K;8QX@[1><&)G&_YG,YF7+3Y#J>:N7S9(BX\K>57.UDJ#BK?CC!+
MIP/"&@/WY+M9<)3F;S;^#.U%YG]0^)VNY3WYL6& /3Z;7,\CZX#NKH#E3&6\
M0!A_#@%L*[U<'*;I+\>*LC.D%86VO#]DGUM<-1?YD-9>WWASS7ZD!&HHW-BN
M J;]R;D+E&=%X63G6F(R"8=*FI*("L1^DKS1X= 8E5[+@=?4-(<=0#LU^M*N
MEZG=EZL[G@7ZATJNV#A%1&"B_G%\>7PZ)85QC<K^^9HDZV!%_,!0DAB"6SKU
MU,<M2:F%1J CD#STBP+ZYU^4' 52@=@0/8.128]70T4M3>[3&.9OHFEM:S,#
M@YR,/S4\8]SG[ +Y91\D_"3HJ>>M0V[[&W4:(^$J%PBGP*5*D2;X"$-ES_M#
MTQUV8K1][A@VFVB7I5FX16 J!W#RM"K?=Z;+INCD>3;/;^AA6TH7B3;P&JX(
MYO%<4BRAZF]6R9T>>NL0;S"G8JY%K[1B3D\I '[&PW_A#(L69WL!NXOU;/C-
M*+R.WMN.<7U?Z!K0VKX95)/.T&>P;A:V,P2E+/+@HQ0G ZA+[D%KCA@]W<9Q
M.V_^!=YP=;M>4\(U@:CP(&!99=/>5-'_-^J<9I.*OW_/\']G>[?+?8)%M(O_
M(43'K 6$,;0LD@1D)BY%;Q>-50RVKD.VHM+LSEE^7=(IG6_?J:?7..1@)+)I
MKW=0R_ =?'JX#\VWMP+GJ^72AW9/RN="5M5ZUB&-UHL3 OZI'"1 ZHH_@A@B
MWR$8 =H+?N338^8FT+NBR.=^W]JAHS5&=;5/3K0;M(^:5#=4:L@*(R)4#NX]
M<V_&GD\%]Z,6IV>KC;C"RJL2&^ 9_B?_0][:4=TC'1)Y5K02IA.F$HT,;FMH
M )+OFVB,^QO<S95OJD5]2/C FW&=V?_!%25]\.2/,+['\F(_$-F)4HD.'J*C
M>%"V0F<LBMELARDW$N8^6K.0+@H5GP4N(L72M4C[@77,[]CK_B/(L!LN^QAU
MK<-FP8I[TD^M,GC4Q1@@SA<8R) 8$VP Q%V7M!IX*"H1!K.SY%+5W2O]0YJ$
M<"61;3RW&LWT__P]!QMA^J2G%/W<CAT]3;>NZ[9S6CKJE7!0B7-;2FIGX<D<
M-2EPK$.X1EU'+PEP9)'UFC/A&&C =5<I#QO^MIK$238QB5;:]F&MBZ<YA!7Y
M4K_]SM-\6YKQ[WVDS775BP$G]/@L+".</$'\A)]1!XO+0S4*-PH^U/'ZG9!C
M5=3K#1Y.3 ==%H.KS8IF*,Y;_U-*3:NR6"(%DR,,'^U='!]QWAXG>LUG&HI3
MZ9'/P>-?C].!\,1KMRHE4Y&2,9N\B3T/E[A2MKYIU"IH"+^^)R[SRH>9N%?5
M9M-><N%W-;W>I%Y-H%O/EHO4-'#)@3O&"2J\@:V$HV#%92XEF:+<KDF L^Q(
M?$Z:WI[$'CT50-BPRJHOQF=T_E8VRYFUC?<_><<R1K#"?BQU\;2F]N$O#?@^
M")160\*L0U*<?$%TA5$6W99+WH0O[I1&0COOF@O2L.T*:*:(PJ,8*=H&9=4O
MYF]J--5.?@QEG\S $?-S&1&5IPPU/"==RIV/OLKWBR]XC=*3P$0N((D$6#/S
M8I\*<@NNC^=,S:_J512'J?I5H4(SSC8-X[#90HSIJ;?%K<,&KGUA*N\2+ ->
MCW]QN4.:E?IZG:@V=VY6)9^AA3_'VY8X:P\7%HRLK$.2X,IVCCR<'CZ&&:@,
M#G!US!5!=ZX!)<.RS5:B"E7#VYZPJL\\N78AP?[D\+N5CM*\D&*\N'*6LIBW
M=H)@)<XGVH@.##N8DI-G]('/]$&"\F #1Q7S)PWVD35;?Z?2&LJV)"Y\.[[Q
MW7A73,MF?D\U[G(T9@\8K*%0II-\6AEZ$S%9+D2O0^ZZ^ '2CG8=>C:W:IUE
M9RX8]QF.%BOX#HO<2O#\'A8G5$!*,1=91X9J4#?_3N<Q0]+LMN9E=5K<]UM2
MODB<@M4_1D$;<&DJX*?I.8?=P)94.R/NDEZO6SNE6[]K1B5YSLZ[I(_[5Y#V
M>U\]G2P6<CK\Z-.0J#6CA$CCO6\0'0Q%^&P^2I,.K\&G=$L'@[I[:92.6/,@
MOF?L7(ZJ9&P'!WA*4[&DUVT'/*P#LM:ZV_>^;!RE!9"ZK%7=GH=J-36-6$1'
M8+3-1O17^\<7G8'ZUQQU,XF=R 2 ,_LQO;GK$#V)+<%QB&[*#_F%1"E"942W
M!#T/N=,^PU\]1ZZ7TU,"!$O?'^)JF(H^7NSY;R]#<V:0)0-'(/%WUK0)I%;Q
M<Q(: 2%$M8PTB$T)>#O'N*#0TOZ(B!"+ JCJ_.J9G+\-6I)G(BUGG@1AHZ.R
MD:\O-^?[G3BEO[&]B/H('C200-PO+B2A&9ND*M:4VH!2!RN9RSSC?AQ*\+W
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M9_-ZYL/A9K\\MJQ=Z/KB8?-N'8)H:$[Q;&M<,V '3,Y]^;Q8UIBKT[&I8I.
M.LM(MKM5)&%ISZ15@:1 (/=1#9$%WXGBDID*F3JH85& X/""5'>V!0L2"<%
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MQJ;OTP)[=*3+(MYSQ*.M*?W;B_%BT0&0*Z#P;U(JPBCRHHAB?,^X2W/RN$_
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M5)UO+TH9;.W6TZ8-T?>7@(X,'$)),C8# Q]B:BZ0KL/O1L.@ :%Z^X9\G36
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MCM@^%5@0]T06-*!-R>W>!S>E:ZYME@S;*/JCNVZ)++E057S?*?$KDW5(V+C
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MJ:?S]O3_(QWZ_RCP]8G_ 5!+ P04    "  V?#=5)<C[*/'/   #V@  #0
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M3=EQ/X$HIG( /@B* T1R@"\<X#<A&TMQY0".N/^N/?/-!YY97WO\4P]BA>O
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M]B#YE]-)?<U0NB5\I.Q7IUJKO=H+^=,#=IU-^(K!@DD;3:(@2HT&B_#J;RI
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ML+\F%#3+00.@L0&YA1Q5219;U.A,M3!9IDX5!3@7>ZHW5ITEF0L/J_-(/[D
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M-^.M">$__B&LT[3GZ[RBM_JEH<*G3RM?7B^MYIFNX'\GT>5G^VUN<A]L<A0
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M?BJ/_Z=^V.O+.QP@F4PFLRA63-_YZT5;I$@SM40[S9&B[WZ?TJKSO+TGK3B
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MIWYD_==*,/XOOI,<OK!5M6/  <B;!JLLW-_EF_U]GB/6?>P/7'LYS.QA>\!
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MHD'-*BM)E'6.)($I *81]N32QQH+]O6[C8E624#E'1U0O1Z#D\-4UGMA*BE
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MQR%NG.(UM '3<#[L*'X#O@MH^$Z\4\#218L"$&"0G,[_IYS;?5V22T0[-#D
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MR3IN!O;DY?T+B:S4R%O+.650F86%+H7L%%2<NYT%14<#N$/5Y,-$IBA9'T2
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M]'#OJ=I<F^?KZ:7OS\<*<TG(+IC>R.OI-^4P\3G.L]AKQ\=:&3:!LSP0).^
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MM;VZ7NM:VKAE\K4DYTJFI(598XF3$^K;'A;^FX)X76CW'87O!5774D66>N@
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M?T('PLLR;\9[4Q^?W2 2 _Q;:H;%#4P0-LG40RB*L!D=2%4.^^^U!D#09CJ
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MF$F;#.SBPPI=9!;HP'C1R_K2_$^LAF^+[)< 0#-)-Z@L\K,:>$=58J'"HFX
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MX3'9,GFE9$I&THZ%E:P^H0,4/B\B8G1GP&'7;JP\8/,X.NPCQ*3BIU./8'0
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MB]<M#_EP;BU4 , .LTS:SY'.%UP)B,UT.B "^/RBD1&8TWDOY+U_U8RDI"2
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MXV.3C]/2VCQ67TS][KB84]O_9$]RHTF'UIB+*W9!'Y[.!Z80:[!B/A"[POW
M!W[_(?I@.3 ^((7YFY_/4R"RZ'P@_QNW%,Y@<RSYP$QJBXWZ>5K[X;<9M^X[
M7=EMJ+=3_M>A^Y*63T0>/!D_8<;*+0W[<BNY]!Q6CKQH6.#RT^-J*N"IN&Q'
M9OO.RV$XFTA0_'BD9_$J\5_78?=_<!WXO7O&+86E&5:!#^Y_4:JK*%4H*\LJ
M>G:@GE ?-=:;-A]1<MNQ@E;OY&8)#WT$VLS6-Z0^\-8N7'2(0J@NVHRZ=D2R
ML,??&!!OIFUK=.GX8$&(.!_C;Q-\D*DCC+O2PP=F^_G IQM0IQ(.G@]LS?P+
MM?VOZ/SQW_J+/'3;7>U$"LU (LW\@,FN1]^[2XP^C=^&774,,?[F'JR%&/L,
M+'\[8>=:E28R87>4CGO16:EFY$AH//Q\7BX2OYA.)%V"U=C^1?*VZ:S"2O\/
M[N+:C1^EM5_4/T3&P'[L?2^2>O;LMZ)S=KZWS# %6V^:("50'PVLU"M^B0J-
M_Z0XBWW(H'UV<QIWSF%[&K'MXG"*MUA]*H^:ZDZ0ZX=O9SV5?NNH*"R%[HB@
MB%/%'8+SYW[IQY=.O'!!5_,!U7GD?S B#VO">L<'2$M,S0%>)QPY@ W_KY 6
M '?ZV)FYSW.O)#]/T>\)/PH_MLWQ?N&+*/O,H6/(-0B4(P-9%51%<_ERPP/=
M-1++G%L'OXO;@Q[&5:_$<JS8+KQ^WG[&2CS\CDZ,O$'SZP6H/&__O/QE0H&/
M\M&!BI6@7)NVA79K/\Q-C,)?&?L'):DS!L??[W^*&; 9-3!->'_0;;NDW=:5
M^U$G/BJ$[':RU/F0<4/L <\&686$UH<NQO$!+UT&D@_8IAPF#OV <8AVO#KF
MN.7EW,.#;R[NW,VZ:*V6'S(S$.X4Y-H7>O!5Z?G:@O*!Y. 1J^OAKV9'XXMM
M#G:&1]+">"UK=5/-:[Q:BPI(K.'2YONWV<M5^9_'#VOIWA?9>>*AFD3T1Z')
M$O&S!QQE9UU?9=RVL\GY(?RN@\&LNF>FXJ_[5&*+N<SOTN/SNR_"K*>'TM6P
MQU<2S]]Z>Q*15:48X]F*3KRF!)HI^#P]=#+QU\$=E_*N_#1M.[O][X:*7_G/
M9]=BKO3&I*D>:, ,\(']>N^*\LOC*^/N&\?:F)0!9SAGBFV!MXD'_YOW(=?(
MJ;VV8H\NM-*)LKR'W$/MCT37UA9LBD5=#VGZ4M Y:W,W1\M< P@O:VW-MM[3
MO5QVF2U:=J<M:T8SY.JWDT8GOQF)"/_YU.4VN GFL)*X!)@BNE?Y1#]J#QTA
M#@ZX#-8U;S&U\@VF-FH;SP_I_=59KEV/#6T9]',]*LQ*BY8_[]!]D.<_<[CQ
M)F.(&6RW2__0<)FZIGQ0_WV?PZO>ADI20PM5N<Z#[VS3G8=4+[]"'^HE:PV-
M\BS([)&1-3CU_/HZ%P(Z3",XIXJGX-P]?" 1 VI_/\D'NC=\$&"$PR?,IB9E
M+Q]@N+S&K&XV0Q85IPN&79)JAN">=<-D])\&HV'?C-KLSN_>9<5?%T>"EZ&E
M_[ME"\ZILG\LK_S+,/QOY'\^^/=1@B<(MHC@P#?^.GQ@&Y[G""5_#.5NOR)@
M$!P?.( N6T$BOPO&&H5_F46F0QDL_"/*&H)W2,"WA--PQ-_4C?7?)@+&(9'1
M0@(Z@8,""HZ:$'R9*>B3;PJJ%:<[=9W\#W5>_I%98Q]0S9W"^'H0UQ0$R/W$
M!]BVZR[AF[PXSL')%N(;/K"34R+HJ;6<[7S@+89I)7"I <('=+SAU"7X%@&1
MX#BV?*#5_S$?Z)F'OZ_))=8$"L+ K&+>87RF\3SW.YBI #[P#&ZW@<?_QK2E
M+"QL0AGX;NQ_R>5_?8)C23S@ V?'D3PQ).<]O.[^RN8N@4>/B;QS7(=_>V=V
M8.L9_]/C8:=./4AVF!8D*:J6(P+_(\C&!A]XZ?\H/%)_Y0\H[R[PT0DMW-"(
M?P0[A-,P?*$RL+;O_.$35ICVQ;7K2YH?.K<_L&!)W"?.N"2"'CI4?"Q\#T^C
M!_]+9^ENE;Y,"JE8.].D<6T#,I0['_%/<O#R#%R'M4FGVSY&7]):KZYCM#73
M(6XM0,J;,7DT5VG<P'@FUZ^$;!XLKU>B]/6>Z_GG;RT/E+])=_VTZ^*?/.5J
M/^/[U@;9 ^=SK%&N\G?&%G["-W<4"F*#\\ZQPGDH^-0,\N_YIWR@)@G4Y@.%
M,!7\8)\\>IC5 @&S:,@GFX:M&"Q<NLEZJD*W;1.?%- B$Z9Y:=@4_M:,;F*5
M1(20K\\W5#:_*2#']-:E#(V_=SDK+%FBLUJ!EL:TMD&5ZP(2* Q$$:-W]A.$
M+$1]I4HGM*5< '-HB"=!XGM(W<,ZM.VI'0%'3*^6?R7'##3D^(;4.OY*/31:
M?#817^_*XS[A WB&@+03.S$-M^ +@T0S\(F2R'?,86?;+L8+NHGL]/,95?>0
M\=>[N \+\/V_+<W/(SS&?N .Y+YHHO6O>RT0.)*V'?;2N/KZQXR5*Z [@][9
M@&G'BW+.OA]&V=(1VS%M-_&@S&7!(6U\0,$WD R>G_G=4P3>"M@S7T_V ;'7
M/]8T#<[T+]Y=Z]U.^_*KX>H&EK.[AX5,$UN10'^W9&Q\@NXSM61&T"CMD&@'
MLDYR,%RH&[8-)<LHCN-8O O+[W10%F7""KTJ*6 9S2OE#6,V!B6?[?DXC.P0
MH\=UFU\U3YRKY^WB;..6P;T1H_?_M#?$+<XQDSHH.U::W'V+G,+>KK3A1K4>
ME#O_[I^T+B2=ZBPL\MESMOX^<J):P4E[0S3$>N:\ &:\'W#%Y_1Q2ITZL9VX
MVP7]PU"^=G.-*..7>:F>Z>YK:*P+AM.O.KT>H%<E>@<=J@SJ2E4XN)1-GI\]
M)J?AK=73<8.I7VJ??OC9$Y]WW(\:2[U,\SL995ZA?BR"GZ+UX:"2MFM_I\4F
MYYQ<*W(WQ^IGUS+91\,DZ-13*YP]"-;5P1;IL.TK5/C2/<&8;((>%[%A0*,X
M@8&T7-_6\(W$NW[:==B$3&GC9DHL#;0K=B2/>R.HN-W>(>&17X^[04X,GU#X
MHWF5&\,'/,X)"BR2@@JIY5:C=\+;XUM.^4XJ#@0/]\..?=DVG'N3\89C7L3[
M&HW B/?F6S)/G+)QK+/"R#0G,'[59U8='-G=Z8Y\@A)A(]&#%+$62;!GRI#4
ME\H'=G/D&!%=&_)#(XE-HJ_GF61O!X*RQK-"IMEH+\MK,,B<:=(4UW[L-Z$A
ML@4_<T%'Y:G),N,Q32D296IZ('NR-$_*U=%W@7J-^!$I7DED;2DT:- [H\D*
M'$9>=%SK&B1/5'[#[;5_>U7JH.R5GJIKT[VF9ZV[ESH(03D3>G7>!4L_M$.J
MRUP@]@:_ L/+#E;:S55NA@<48\;@H%KZ<.X;WC<BXPI2:1)ESS!<7,*#(;,L
MV^H?,!/.6="Z@./=SY/624 +^-?=I\H5-+3O7Y]BP=125WB2UOXLLNS2TL@5
MWO<,FIB5Q>T-? JQVJ$5DDAA7(62^Q=H\,41S!3\"1%B&LPV0FDW#]<&I&($
M#.N)BV&"))I7W-V*OO9(^7Z(1%@GO;U%'9P6;P/+J)C'I@K%SM[X.SW*S1%^
MAEGR&%@VM)T/Q*-E&3KM.C$\969L70'*&&S(4T8F3(K79*N\#9M J3X4L$G,
MB&OL'<_LX.^5TP]KUV+#I#14P[_42JYMCV.'HT<G98?6M2/.<@O1:HZ^\H0H
ME ICX0K1I=F8-C/;*IC!FJA3IX[GK5QZI4V)CNGH!Q]<OZ+?K'UTV;U^4/J0
M@;9=3Z#B<J$\I]+ZC^$A\]%5BF.%2PWEW+I+]\8N.]FV8T&VTY;(=)-:0N@?
M"O&+^B:$:<(2YZ;!O8C1?*!.,QEV@-A)40*+/R$)*_%\X!8\VN8WS("Q\J3V
M=,-(]%INP">> 9@;$%PPR:W4V=Y;)NYKXZ>=O=*>07Y8FZ&@Y>WL.,^C0-\C
M%V/8VAP]$/<ZS(*N)L1*!I5H?3'A\F&8JV!MGMX(S\ EK,9R0*%K<YC(Z":U
M&NOC/XV:FI3Y6-*@HN0>6BZZQ_Z[2DYW8VK !+9[11$M:+F*,/6PB Z8%),/
MM*_L!0DDF!&8&\HLZY37J H6'E96!>LP!4<?1S#%;%.U[C@CI<9_QS=<)SRK
MO5KWFGQS/'0$R91A=7!+84<YQ_O1XJAK()6.A*+T?EQ.#N(#$F$9UD=Y%GS@
MR3T(:)%Y=20U.T]U:,#L$^\KUG:HDEX'/5"VG[S34?'N89M7924'+Y\(G WQ
M-FKT50H)#PVU/I:A\>0YMOHJD7S5P36"#UB9K2VTP>#,D44_/B#\G9N"UD5_
M4=[..(]G:K'2P"_,?"ON&[2Z+U&D29>):=\]WR(TG-W5"A?*Z&EOT(QW.,N8
MQ-_:_CK;[VE]"U.1'"WF^WD)WS0$@V!:X3!YCB\7A]Z/,@,)C(T.W':>05@2
M*XC[%NZ#%08S>3(Z,7JVI6X<_:%UZ_.^F.WH+P9NLL_M^UO$KU]OY^T>U%_9
M#>(N$P<"W#^X*!DNALRIH]TY(MQJN,_*:/1EI@26?0H5#D8S<.9,6[FZ"1F2
M?"Z!I3\!)GV.<XR[,'1D70F.&-%6&57*(Q2[D.?OQ;_N[?DK>7>XG^@?, 8]
M!SY\P,B_+ "PYA@'UES'K,2]"_/WLQF[8FUF!2:/K-!S%:X,Z2P>K<OIE6D/
ME2\J?!A18/VN_E7FR(B,_?#WBW\E*D7DC#\DM!7L+QUA5:6]^CM^TOEJ6LW%
MWM^50_C;#5]]O\<VI:*7TEZXWVD><R-B0OH&=*31GW!5*422'Z9-7A9<O\DV
M<Q+,'#JF_PQQVZN8S1O):^)6U,LXO&9<4*2+/0/"4>EY2UXPGHYM&LG,O.+6
M4AC@][;[1Y<GH4S:"6;$$UCKBT4=8E\ ]U +H+6F4&6T,+H+63.R%" 37[<B
M&^;@# :4$3L*&1,M-8R>RXS<EBSO<CW\NP5#Y[K89LQ#(.G*H,H C9#1_64Z
M<]4&24:RGF2S9FT^@%6TC_@5F*@YVV#2S2KPSI_KJ&U1V^JCJ2[17M/8G6-C
MG4_'QM1\'^P\4!YZ$2B>I]2N+(GCD6$4VR'>,? ;^RJ8SN@AP;>;/HP,Q(A^
M9%JT8;=K5X>Y? I_T7.W,LAZE[.+@J3_=^3Y6\*3!M8>W-Q4(KMWDQ/0PVYT
M8>HL!&%FVS&,?;,SZ*DS F3R ? D(PH:391'&5*1,B@ML)=AR%KGIL!DP TJ
M/@%^![H3Y4=L(8"9-&U-AX8D6MXS*D8,#+4&K>F1,!J9<B6GK=Z9U7RGP>YK
MH"LQN]!EE./!UD)_$W05/G!W11%U#[SIP3;C2(&%# )OYRAC8ZJXO=>VRYD8
MBU^C)#Q'W1["KQ\R13+BSC0S7K]GV/7%^B^-SQF$UN>IQ/YILSF#,6[*-!EA
M.'0(VF? 4BZ=JWON1Y,7^P+'D@E[3IT(;54^]&-17]OL<M@1CAV#?,<?)4HK
M$7:^B\#0 L3'7<;Z/"KG R)*++5KQ4,# Z?W2X$#K#5N'4_5E:,_:!K*OL2Q
M8]J_881V%'=1=JV+(Z]'^?:)@O3@ODS:@F5^33PE+&I8K"=)0<G"7O[)L#P*
M=ZOFV.G2QQA/^B;MU@;[0?BIX:HAY&T6PCINO5OIH$7QJ*M!@-MP,W88$8=Y
MCUL,9$(ZH%L4Z)D<O8 $F :/3*DG+&'9QG=X!QC%*1Q5:K-(&X$HCM[O$V<.
MIM!25-9V_!H,T)!R<O;A*3-6SWB56F$B'JIZ]T@YY\E,83A[BEFWAV:YV!9Q
MSM5ZD _0H4E(PO8LMJ6/LBS8P1BSZ]?#Q1*W^J'%PW(Z6O8QOC-%GGA^7U>A
MRRU[,CX-F08?V:R/GU2L:7RF&KVA%037N OW09 MK ;12O/#4%F.E]\[CAJ8
M1-=)PHD?3=O<RML%9C(E%I8FC9AY\<JC[?)]B3I6$_/]EC.D(ZO=3)+TE(C5
MU,H8DD4$(QBS'411TSUL<\X5!I&$5)Q75ATRM::>TKP>JZ!0Q@=DKR.":6-)
M8K$USZ\**)UZ\,/'#YG(.+.F@:G!7WF>'Q*2L2]6QR.L([U]<C--T_/JV29.
M!2,N_CH5@MTX28%$LA]V-9G<Q%7*P*LH)*PRRHB;;6K%;.R 2\,.<$YP\XA3
MZ3A)^!T_#+6/U,,'Q'ZW'&*B)B5!"IYC.F JSIBUKV-\XT+:]ERWDFY\\&Z>
M"3ZWJ^VW6>IG7;"R<"MAAD[I+&8R*;2-Q90II"R)CA'O,N3LT6&A^4"L':C/
M-*'=A8K48>);#)D6J:;6VP@D2H)@0'9HS?Z615V1^7FGPC]/PL_B7!6V,[P]
MX][Y;\^-H$\F=W(KB3Z0.)@*Z$ C;D'=9V[$<,P9%I\RX6(M^^:=_0OOXJF0
MV!&"C$SFI' M(?N;K]6*&,7M>O/$9&;I&,5,OZWC.*F]J-':A+=S"]M_3OEX
M$YCDP;9"669V;<;%+'+V/:1-V"^<'PG.0ATO6LC&)M3FGO0:7DL"*\;,F=OQ
M)?/D?>OEQWSD]8?&DXJOC[ET[3I^[;T<=GD\4/)YE$__J[3KWQSJ\ANM?<K7
M")[P"NID:N;A_B6=""OOB$74!M.JS3B3Q <2*))-(N6@UW6&?<D47A$L;AN9
MA##UU_-*:'"Q\3OAO9-YFQ+-I7,_.HKGR?59O\1<EFPZ9?WTY>B^GU423V;H
M4[7,'(:"72,<ANJ6(FR)P^L3H;8MPW6]7G:-&>QK0^LI-C,N$U:V@P%>7MGS
MFYNK#RO]BY\E]>BE=E5JP9J[O4OO)5=\RVP:[AWC<)ZUVC[[\D$#/^'"^+A&
M6!3PO68.^P!F]"M*A@\,TB_BUX,11)TA3 7F.6$16U*?P';B]81W>V<7?=1X
MSCZ+TAA\^WW-Y';C\'K)70ZRV%HY,Y_\14]RW"<T]:V6T>WL@[]>Q(3:J8UL
M.A@N)=&@1YW><K&8N[?:W*4^H65 _Y,%5P]NM9,"Z=U"GDN5 ^4>%VZ)FJ*0
M>S68>Y%<8ZO>EM !C(.O\O+EBLLU*^J@Q685:Y4/R+"[-FW+I@5@HM19D'24
MP\0YF I?+49&]UAGRW'P0<EOC.QR+1SP)2-342+E$W<F#W[WPMH-86HJ9ZH;
MJSY(6A4A)SL"/7^XJAR6*ZN-8R6">V\FCZ/\P1//]RK?LF":M=H<J%JL5O(_
M\"E9\:_/R2F'/DNG.NY=K#VN%8H8MC!D7^;UPQ2XF6@1SFEPE@[9&;;0"5,&
M(XN[,"5A 51\7"7*B:YDJ=E,&'C#^]KOE[W7X,?XA,NX3W9Z[U=IXZ,9'H/!
M<NZQ&OL87G$MAWF#E#J<H&"Z:/6Y3 LJ9'&C<,%9?#:!!YFGU(0FZR'(>[HF
MI1B9<7KB2+L1/Y0O??0-<JL+YRQ3\9FC]WR>W$"PT)2'RR\I-Y_ \F>\>)TN
MXBCS]%5FU]1?H=<!B<IB6J05.2&D0CKZVH[[16H7)ERON?_"ROSS"Z&H(! G
MP*2T0'6#LU2=MGB>T7RV0173P0Y48#::@_ *L.O*#V$F"9;_+DRSP]DA4R/?
M+_B!%TVNG%;_@:E4L+*]3G_^AHAT_L'ZRN?61979"-]3W:$U]:P!%]]YM!N"
M)A#8#C09SAX("P*N3Q&38:8U67#/ .FP63JV/1YV\#</8.YR.Y73=LR58P36
M,6W;)U5L=9)XLF%:=M'V0VBU,/MO@25AKUSG0H:9R.O-Y5KK^$5SMJ,3*H2;
MC_)[A[(!X^BNFK2 5(Z^'Q43C0163$^5_E869XP\;H*\G8,=8V[C586>>LV8
MS&>?#9OO:Y>'=\ 5P/M.143P 8/MS,#'#29]"* AK!E>BW6"=K[ D&G%B_&^
MD2&=N0?84]B8%I4P7YIZ)@FY%SW :CG"8+T)G)JM_2@X0.<M4R2Q3HY"C<65
MS+'"%SBPV L<_8>E3AT/(CS@W[!S+0J@"UL(M&+%#O,![PE#6C%I",15NBUL
MCE7T=55(T5N=0Q,XKM0E:!OZ*#,U>NH+!\%-R0?+.F#RW_7\]EP?6M(>=FG4
MA@G;G97+":_S_J985?3V[ZL7:34U?J,+,YE?0@_L+.0N.(]I1F+P7[DR=6IC
M+FGJ-C?CG^D&O%2*YOINO]>/B234NV@&+MB.))JQSW*VQAZD(E+A(B'G$I-P
M"9.B[G6GA3398;>G[M_3'=E:("BK!%"4#YAW3<WR%/L$T\TJ[V,*Q.MMDQT?
MN(-[-"6-2(5N[^Z4F]&DA4;9N<=K"6GAEOH-5/VT,["J8)?9[Q9IIG(.K>(P
MQ?E'<*26:[^.O/W[H5KKLR3[ 9TWEFHIA76#08TYC6(O^^_\>I03D; K0*CK
MN%0L(%3XO_T@]EGJ%ECT@"9#J==\)H+(9<.R^  \T]G;\/VKM(D"FT%]G2J]
MP'(-)_5$VK7Q!7G)K?X'RRD+&K<<[FK%WIYD/S+#O>+M00\X8SITXC%[8-)6
M4U#9,)DNJ)@V2KML8=,B:7LJ8QR,Z*RBC(->C@/KI\1LANXZK8M9GYBF7&A,
M&[.O<Q=#W-4>OXR.&7S#OKC[#6=%(SCV7$S>N:=%O]3/WLU0NU$CJYYM5)RF
MED**^H229.!8R@--VMZT"3A=)&F$OL+1R-/[ ,95+#A38CP9V,1UN *R]Z$O
M]V-%V'-2WO[ZQJ&@B3TDAV.@+XFL5E64]=9[>-(NI=S\9<L@'3$ZS,J<]=VP
M;WX^8+^<3I@XY>Q[;J"MH&C>)FC>]@IBH]2F-GN84Y8^,=]0H8-.WH DP6M;
M<A@!G12))EU!V0F%O0X3H#JYEABW&=KN*Q>4T'2\*(S0+MV0/AQ3/$F&Y4LW
M!@<8>PN(GIR=$IMSJC)^6\WDGKU]>A@]'S[ L(4 CG="C3MP) C46GT21T7L
M#=.@.#<Q-N(6.1&,E4Y#M-K['Z:8@OD!'YGZ;/^L=TC0P;:_ME?&V0J^VR=\
M:#BAR.5G0K"OYZF01K;L:3ZPKTF4WB<:Q@$QG^#B04I(DF JTBT'3Z*<J!,2
M*QT.(U7@0ONF-+%L0<BIFHE+/J*90_I2Z6KY\ &U5ZXHZ4*BK/]MAVX&9-&0
M#^PX^KS,^SO'@9E"[V.LD##"35KAIJ<*'>?1NT"5UV%Y[([[8;!.7]?\J\SS
MQ:<6R1XC[6+#\AVYY<9V,UG;<M?0/JZR-]] T2>:,PT/3\SU5G*Y01>_3E>8
M7IM=-GKWY\[D%]?11NUZM%5S.D_@(I-@#7YK41EJ.OEZWB!/LG]%6Q!G>W9*
M1RFFS39"J1R"[RGV?E]+,""[Q95:&<:-7&F^DVDW%-3L6ON[Z'U]XBKF@<A^
MZ-5L\,^4S"*>2GF,DX*I@QLD,JM"(Y?>$Q&AI-6Z^I/D?9-J?:!_*<"O]LNR
M2M:O$8V!K)2,F(=AIDM:9M#1JY\9 &(DZI)$*!3<,B4!;T(3N6B)?1]/%?XN
MB8 ]\SX4_(= "[%Y\4*JS.CD>J!?5X!>PL+?90'+5T<)-$@<V_$='XA!^,L&
M[\KO,%[I224IAN)_Z_0JI_ !%)2G-8 ;P._CL#&M3@^YKV%0W&8!(Z2+TVN\
MXD^YN"DAY3<;%M&!'Z>%$CB; ?F16!UXVD,WC5YX+&O=:[I>AIWT%\K,%^-V
M<+#@#W,T 0%>XP."WD*XP&&=N)BK19E"OKN)^4!\Q@?DCQ''D9_Y0(IS]7OB
M8.7;ZH&[.G4F/3$/MJ7F>#]\Y[.GW/P<WNNFN]>#!_=NA29H'"^G'3^1F:H2
MY]._/=92Y:5LT6/R(6JZ\Z']&0:'CNB::Z@E7BBP3SUWK[*R7/:0\,Z!IDC%
MM[C>DQHM=^H.KJ>YV:>/3$B'+S]F&-(@"9PM7DS5LP-!O1:DC99356# OEJ'
M^>!?3.42_=RZF([.E%^U++)*0TM=;>.@*VYQ8,)EYD#JHG[PRBB)UA7+09:%
M(:XP/C<H0YG2<53,[C#<6:]ACG;^/%KE^>7$ULI@!<=AFDN8B_U[]NWWH\;Y
M7[6?Q(:F&@JZ!2N;.=*VLJ-KBB+F#$;6@F^9 Q81[UJ#@T/\T2H:+R5*]OJ&
M,<Q"J64I,H@61N^G9(32N+CJOA/-X1M/B+Z4O<<'9Y@RCVMO3O7TNK=]YYQA
M9L8%121-^/=<JD6(6Q8[C?OH^F0XGYU<B&YEA=9;OOM6)&20O^NJE<HV-$;)
MUKC0.#6-9"S95&)&/J][F5F?N%D8[#>6%F(_DC\Z78]LJHC46;XX$>"!;N34
MCR#R"@4#P.WKG1E(B2;;\KF1/+461F5"Q5S#OOXYWH&A\I5UI9/;,S)IPZLF
M5J-K/475+<U18BXQ43-J+WK]#N".$P=6],H6)G1L:PR<,W(>:*>^\=Z_U<IE
M[+[4S$1;X[8[GA2Y;36KR_O]]ZW/X-DNJ'/?UT<&$8]KQ:$V@VF=OWSDEUJ:
MO2M ["?)23!C@\IZ%GJ7\-W;/CNX2?E0:"32<F"J<>BHRNHR_FB^K3HJP;UP
MWG#N'2S7XYU/U9QTC4_VU^&0#9F48F_&EUTR,MFOZN<BI^.7C]Y(63[J$7]!
MYNO#K*R4T!N'W8L19'?5\Y+UJ?H'QOSFF@1=]4__DO:+R[)&6C]*#$_M*Q8M
M]&]>;VY L0?;^$ @1I6G]Y\8KGG@\= CH&C"E7R]-:#4_$%@X3@B0+NB!;^M
M:6:B\HB_FE=BQ+F/XM[:[;L^UQ1]/V.TK^R'C<UHL=_B "?G^/W$!<PY/G"-
MN.7T=6['[PGLFXUW!2HV]R4Q]$EDG_N-C1(+9"OQV3L-/N!@R(WHY0.O]4\&
M\0&\+(ZKGF50Z!;-^\,>(G[EY:.%=#B.E&A3'4X:-@XC*#B;6.R*N<F4(><I
M)1K.N@A3X@/S*OD_D"F# 61!2>+3X6N_.'T"+3:4^5>2(V<'KT<N%5R0X[5S
MLU+OZ>+ ,YQKNKCK@.X($+Z3([ 7G>40RMEC'COQB?>=(K)%=N(ILCU?^,:L
MVN/47X^'B9?1NS!?IGED.&L+-PN^+LJT"R'641;C&%:L,? "<1L:?L>Y+QXE
MW*+U'>6IQQ5KS\;'!& (3?JLSGXO/X1%GEB-L"=KRM+GZ_=N5_ES&FH>J^^'
M\N,Z;LY;&LK:)><2JF=@R\V&SBG.5\'2,ZWAC=!IU3_'1#)Z+C[X\D77,CKO
MKVL3'P@-N&OCL"F'!0TM>*(>THL<;?"9K)$17*XI@A!SKIMN:^IUQ__5GX&W
M!(Y"B6#(P]N%8F+ADNG7ECP#DO/@.YN!'J4+ $3!Q4B-ZIBGM:#:_O+"^?Z8
M<^GI?\/YP)2]*6)1T!3[H(V\+;R'^??F/G@-F/*N/5)D2$36X!"\.LR;-X),
M!6.F,H!27"Q2TBYGBQU/-VSSA%/"SD>P(HG5O;DOQX$OP(,K>(Y"A<"!2A,G
MM"SG_ U+A;C. .B)V5<II*N?5+T_JRDNK>]#+AR50 H?-@D(&^N?9&#<AWEA
MN-G"V%-FT&\Y4<;)#IL*F'9C#,-*MQ$JUJ*F]&3[&/-YU]*7WS+RSXX^%!)[
M_BHZZB"4X9_)D6J-YP-)[LR]JU/N=!WL2R&HA*A\UA6[Z@(IT9NI%SXA%PQ$
MO0\.(@@ZEW,^PZL6^(!I.&XV/>K>/<2;KM7\F;D_D2?Q:[I(T-"!)^HV*LKH
MHNG&?#9!ZX;]K7]TPLK=]N_IN8Q/?7)]^Z0PK0U$QL693HH@K1^U:W@ZAMA8
M[NOCAW+/!0#*3O=UGXIVZ+>_="@MMAF;J!C!)+W_5UA\P*WX[^^I3>CG[U;W
M1(T6)3"71C85##D*A8(<U9Q>I(CQU+8H<RG,A[#]BG==NQZ7[.G^5;EE IL9
MK ;_5X1MOW3-!6[IQ5?45G,\F+R)G\)3N9>V?]+*N)Z<]O'S32NNUZ>0,C[P
MB ^P/JV&4_J@6;R'9J%W>7*\%Q[-B!E?KKC:OZ]N=Y4%Z,Z4"ZG<$"2MA\ZM
MJI1=?IIRH=SG[$>;7]L/M]X_\UH0)89QD?672'7DF-^R2H6= +D)8:NN1H-?
MCC9-PYB\.1IV';>%C.=M)?[=S^NJX##A?3I'PKZ<7/K21ST/><-)P;S)%EC!
M,2X.3]10,]O/_I@R$K3E7OJ4N]IMT2V#?^3V\P'E@P&@H2U/])9C%Q_82:2=
M"?S6*KCB7[^V7L2"68H?%!>A!L?: 7/H?P!%O\;?!/ZB481U"B.0C0\?'?L-
M:=&U^L,'ZC9'-F6P_W%[+R<8/;03*Q[F.LR<KGFYGT_?B0Z>GKQ\?C)?^-DC
M;Q)/_*=@4G X$8>,Q>WNSOUYDXGK^ME=_48@ +SO61D!RDW/GLH^9AIL$^#%
MQJ42F<UVC68KUV>^"J[B/1P-L.>B<7V).]#4YC_9?. L09#2$/A4>B+5A8IK
MO]+;5,H'VF:8+,?]GO?SV><R=NZ-5=U_[.=E/I"1!Y^:P('J=V.>HDZ V&?1
ML> 7^IKZ!?'F4!^S^S<>N8;NO_OF!FDO'QB^9(!K?#<P9D'@;9N!_EPGYFG^
M_;V+U4?%_2%GSO(!WW7\VC$![(LY4AV.$% @5Z1$;^T[+3#'&K?D*35@C82.
MG#^;ZOA(5((/Q <3IS+DA'C[L.UWTRR@<DVH\. ^SB6PE:XIQ*3%M;_TX -'
M2R/[^$":R/,17AB7\@N3YPFYA^F#]V0?BX3\\N6*C?'$A__)V?(]02E;[&J^
M)L ?P_W3_M)<BZ,2]\H_[J(<5/]0XL 3'Q3L<FS9RCD.)EO:&0D.BVS2NJ<0
MP'JZ7VCUU>/8;9=WZ&'*7_K!@VV1FGS@B]0JZBSY"KJ2,H/9A:FZO,ZMA=_6
M<.WN85_BR*AD[L=S[#>O:*H^-4B#5.UG6&/*+E7E6\I7'[)5E=H959A<)75!
M52'A5]['&:(,1R#DA 4W&'47=9PY$H56!TVHQ>UB&!F."=,SFHX1<W7C7&=V
MK%<4QZ/TWYF5>CO<'[WN@P@(V=_P6-'E6Y'<CC&-O<^1U8S"-E/D'>'<<K=+
M!R5F:*8&W[]V7[IYYM(2X+7BT#OK"+J7]I==/GK(W-;'X3*G=Y("_[I^3];G
MI;--C-7)B]:C2//;S]?'P3B6-_AP"A*?MP^D>S.%/O%V,WN+,MD>Z$$98S]\
MLJEA/IA&07Q\3H-5^*EWO!#,Z[]":IJ)R\J.^Y3>:!C<>N7P/8E]G-?[YC2T
M9J/UV+%C<*H=J(#EO'%(1W<==B$1H>]UL6-[6+F:!"%:2,5"(GOO/9'O#L(M
MFJN<MR'F3NID/I"#*:%!&5]Q-:%<A8U6.$<?O9T/3.\38MWFYL0A1@5D7\R3
M[Q,2R-[4YK;$9WG[,9[(T:8HR.(_FDCX!A:TRQ-I58[CJ:%2#XDL?F$; @ 7
MUR(Z)250.#%.4ZBMX8+I0.JHZ$KBQLZ#0H+^2<V">])'6&A0<+6Q^$\4SMM\
MGMQSEC\?R/__/,/?>_O(U(CWE5@3=IC$PH '=]R,@DF'*4KBSNH=Y^VC4=Y+
M9Q7])FX-7H):#"S65FA:<5\3O7N4=*T&*MY4#ZR-*6"PN-WNA.KW-80+2TO:
MVO2M1MI3J4:W3N^3O':KA:PFT?P-+@_VL 2%E*9/6V$;4<A)@N%BI7TGP#9(
M//AZZ[_?$JHTCXZ.8A(F7B;D>8]OJ.\4;M]U\OBG)476R.X[#JNMIE):G3]Z
M=[VK-C_P.3FUM'O^]$TZ3*"ZIGIMV_)D!E>"(?$#D_,P^>\Z> U,(D5*&!L:
M7#C6&ZA5CC[DN+=7M28]Q:+WU=0-ATJ.D\ 7!Z8.[PL?2":N*PZ6KCS2%6@[
MPZB/=)ZDCAB3#]SS13#X@%$%3-XF>\[$A3<A8(R$%W31R\=?^(\'A?ITKUB?
MTGG0!_D$ >IU@YF0_5$0CC8VP73W_1U\(+'LW3P$7^P<"&Z;,@#T*>WGVZK%
M*?MX:HI:D=-\X%GQ<MZ3(-5WZQO'AUJ(WVT&_Q#G*;]TRG[P$)RL/'FX%Q^(
MHVLN(7<_#G%XP ?$O&CV3H- )896RNX&@'4 ,+9%+'(9:TH+@4SA"[IQ4&F8
MNHS<MWL8ZN&5YWG-UA&%>S\63LQ[]R@X=P\3>OSZ!,48LV7JB/L21O)XVC]P
MP3.A<NM=''79/ORZ !1\X),%#PE3\<HC2L/4L,6(O8^Y$1$CC5<OKCIW7J_^
MO81QE8-U9JZB-6,Q)#@H7#D02N?L/@-GU,/4A;ZTDB#[_$5$]D<_^SE#W$><
M*I,N\V .4"O2:RXRR!SHP!(];<;;O^C86%BF2XQI3\G$;)[GM>U.1>DS6:NK
MC9_;<;_O$W?!I]Y M[?HH.YQ7]]$QO !R#I%QB4,2EV)6ZL(64!\[-]?%[7@
M.!B<XHYXO/W-.V?+K />!0\EW?1WA%8;?$='QP;NS B(*XMOMXDQ:BN_OJ!_
M^= UK)9W!;EYJ6CL)_,/V8;7B]]UZFAX^I&/MN&CA!_PA1)PB8?!K\XD8Z_R
M+L-Q4.?-')XLAE6U[3&H1'MZ[9V:C[*\"F&W2&9NP-V7=!.Y*,C+J9WWN'$"
MPM_Z6%!>%B!>)&0O)>SZA9#<@OA4 E'D;2[1:/K^2?Q@GD>&;9W1C..A=UJ'
M(F[CRR*5:HD/J!DB<E\LK43C ](,6?=F$B,K%U=&_+)/0J+RX(R-Z%I<8L/V
M*IIKQ*=0RFZ4_IO?F]!VQ"[O3.=Z/%6K0@$9[?2Q)B+2@(T8V3^ LMNE>K&I
MZ?ML1))K_,8.E5;81B'G)C=[#;<==!MV/3';B3[Y@\H\-S*IPH237(\O!XL+
MILE6GNK HF9CQJWA\.E\L'J6U***9;NQG9H3C7YE<QP_8XM[9BQ84&XY=D*0
M@4ZE$SJFQTBG=G0OW+[M[JUT1E@Y/?TA6PD]4"]?B7WKQI%CFAH3XL\7<E,\
M-[)%LM!Z21[-@^?N9C>:0T?]<CT.>*O^T:W77DG':]2>D%_WL<]SM[Q<\''Z
M2^H+FQ"K"\7+9=KU+KGW*G*N/O$F'2VE;NN1.;)77:,N_ O^X?QZ@*N)]T)X
M7"=NM)]MW3R@T.H<60 [4,\T**3YEL%C&RX9OX*I-#"P415K6A5;5QWBV(=E
M.0X%8(]3ZK>V""45/\_4\[%:)M@:P[>&2Y+LH^3Q^0QC@QQM8MQZI.XG)"/-
M>1ZZH_QH19.[H.Z+XTTM2ON*W.Z\.;*V9.@RV*1?_G/..2 A!8LK_F9SQS-O
MKU71WQ&>;"BKA@^\W4=K_<P',OF ^"NI\Q+P^D;%/7G;3UP0TAOFQA-]]_E5
M,,PZO*9WR06@3GRV>QR0<:;B91^0L:7Z@_JCRH<W[Y^\J#W##$RR[EKHG5"O
M^YOCK%XZ<F[S>EUB[YA#3ZG6,B_?&L6R6ED.3UGIPH[2V);5 Y#H6TUUS3_H
M_?H%0TTRWB4^+&//+$:EGY!Y]8#^K/8[\OA/SMGZ]T/JF1?R^FG"3OCI--\
MV"'_7N8(RR=%_Z!#FWBP[[O?(QG#V9ZY#!ZI;:DHS.O*L*E(I!>#Z$@D?$P&
MB^8I;$A'YBK8O^1LJ3IXH^J%Y&'ZYZ[%,VR'*@ EP?3^/,6M::,&+G>YD(V#
MU!1OT(6]M%RXJ41OBH2W?&QS!4>6>1F7/W=%(8D]6KFV]>EI)56=Z3-EED>2
M6LX!9HHQC\>W7+D0(/[TB]/,LVE*YD(_Y5JVOPO9_N_1SP-C,WWFCW+XP$=Y
M9-$PKSPB-*7%!"7,-(Q;;Y98^#*D7@TZX,-<VAK2<6TF4/$)[^R.D613<YJU
M1%?;9G#']+=GU&;M(_JN4B,=A+33!/*+D!_SQK?G3MY&]JWQ 5LYHXF8\4C&
MF5]_1D9PG2TET/=\8.G6M6,"C/<7FFTEM,C>N)9"@C)-OGR[;_1%\]FK 8M%
M,[;#L7'8CK#R9 GKE9C.!ZU"(?5BQ^!:AZ=?<,JWT!KOV=V_N_7=.\]K:J5&
M'R.N.]361*5=)Z"7EE<FOZQY&1S(<X^?9OU4//?PY,?(//F]&SZ<X;HE#W^*
M[O2CTZ<L]M.9PI!O;W*XU[L(SP[/UJ]H?],=,)I5"NR-=*9409;<FJ"/>4<T
MO>^_W2 )TU4/GUVX_??)[G..?W;\.KIE?\!/#*OF3CSR\>21B<,7DUHV2+A&
M[5WQY5<6%*Z.3CB<N'NC.+#-(^Z-Z< 1E@V.E2J6K3??=HS5O?K OGDEV#_;
M9.-X*C+I?C&\A'ZJ<Z(Y<<2?L/H''@83JL8^IFP_X]''.8R-B^SB[I2'-^^C
M0G>VG+C#DP&1# K)^1N6YNOJ3FK9RD#'E))S])Z.^3A;Q-4NP3:W,FK:9Q3*
M'KKK[&FZZW#P:X&4P\P>4O').K>DRP^\2Y_6"#[C,9[9OE_RL$>U>(\"<>"1
M#9UHZ.I#3#V6^PCCB>">1=DA?8Y][FKQI1'_RX+O;8GB?7_V92<EYW4[</J^
MH_G \YJ_NJUP[X#4R5W<ERT[4%;@!G.7SYXP$VK DSK(W@4#8_.W2)_-KM%I
M0FW_FKC&M_,7BH;JEFZMDBX,F,Y<Z)C^==92%1N![>U+Q#&N8L@F4Q@2/@ZM
M#S:S5<+$J)XU__S]8XSI-@;=BCF[Y#35+-963X8GF"K0$'*N"W!)3K!.;&K.
ME+8O*1L3IV U6&M5VSR@,:3O(EL1;'G-ZC#Z!:\?M]44PKZ,@H"9# C-D!45
MIDLKCM'A:%:XW1F)OCR\UOI 328\I";?9YN:BY_+V:&*(\&YQ\?U?#$>_OU=
M:C=_$$_RU#"M1BT&*#>&S"-33:8M:WRH12,LC@KI0(IQSH$W:1AY="]E1]V$
MEL5[!C&:8SZ5^;W);LHAH189[XR-K^4#DCV8LH6&[^:^8UK>KVL(]EG0RB>_
M+=T*;*UAW-IJ9]=3 S\J.^\G5RQ?M)P(T%B;K^-E9L50 T M1.PZUY>E;$QH
M5<*06G9RWS=IEH-Q[7G'B,R0A%"95BD>O!:THFJ,V"(2+Z#LIA#RJ+/- T&]
M"IWUV3%U3T+0*M_71:FQP\P,> O<0P>+9UNC% ;01\= -\3VHR5T2#QO-Q]X
M$CY[13Z]MX)"PL;G:8#H$7Q(_7!_M4\*M6,PX\N0!,[O7OV9HJ#T,GI?K$#H
MZ\3 (1S#PC 31R8EOBF0^HZWE1, 'J=%^#F8_0CZK.]+3,7L"<(D*>]GXN.6
M:E^^J6( C,Q$/6TX;S="!'03LU8EA;!"<*/?.UESAY8QMY&CH73,XD<\1P6T
M<&?ZTSOY0$UQF\ OJ)1MNS$A06_I@(X\QPM<8AK2RGG&M4S[.H_",0)'U1X'
M:3+:+,I5_RH#]V):KR30&E9M?$6/%UK$#HRV:E.>-SYW&"W*/!)>IK4\BM,.
MF,VDS/&!;9RE:GOZ7<&X_Q8JA?*"="$3H6)\P&,!OY?73=SJ0L](*$$%#:(U
MP0!2]D8RYR9#QGSX*,>&)P$ZP'*"2^;1D :F9T+H5$2 E"4F(%*C<,;5Q;O:
M^<R1*K"KC0@>:4FBZT1CI'D'P,8I$WQBDU @^]0<3(@1UZ:3I"P%=E I26Y&
MW.*7 E]VP&3F)DWZ'2Y7,?#M*7 [T0"FJAE3&>>3MZWJ0Y+=X+)ZC-OQ96DH
MXS)V7]@15" #0D*2B5UH*6XFS["726HWIBRN\H08RLTB<2@'YMCYX2531YXT
MF//N/,JV +P(V>,[,GD\KJW(\-R0TI15JY?:,WA\F QO!V$J19<ZFXK2I6.P
M,.WAIL!*T&*J+YJSARE")9#@<;AMKT'?0+8IF V11^F T<6@(4D^J$$F":TZ
M%I8J6\B$I*!LM9??T/P.(2T:[:JS.JZI/YF^SFALF=^8[A]IYJSX'5FKN7#2
M%V.*GUE#($%IHA]B@ \\AAF!HW2HV.1U3B2H7LB!,%_(CV>P\F2^\P[.(?<M
MZJ<<='$9-RO["<995__(&R0%Z]6'AM_=#)==]JN45@V\>^-CSBQ2$OT3OD<?
M07;OPM04+\ZQC:V9%;"=<%(5VPQU>HAW,"R46ADW985--*BHN .39Z!SRW_.
MRR!WF]H5@_8G39W*G3.^EU=HNXU<PEZ)O#@OZ]-%PL7@ZI'1:&W.X3KP,1L!
M%2@D,91)$><2$](1B:935Z),1=Z%D5R9V_(>YZ.TP<ABT*R-92-N>(E!K19D
MHPXGTU6B_:VJO(^;-3W6812KVX&L"DA9X@/>"%ET_S__;N"-DT5MSZ2?!$-P
MM9J/RCF0*1PT+)1FP]&O]U,E-73%S3!/%8^9BM"2B!*6FK'!?@B$<93;S]K0
MJZ/<>K(<4J&_<</=/^'!_4DN/L)Y3GN=<MNAF: G4*<ZH'0S'] Z6MR%$R5.
ME5/VH(U1YYF(-D%0U93'G*OT^EIP))(Q<!'+>LF(=K/R8FC2U(L?F5H9=FF?
M&"&-.%,^I8]45%XNGO(.7M*U3VHWR:^/=73R3$>/<!\3?2&)R+K9U@5X"L\
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M@OP,=W "(\S1]L@HPEEG 7U2%PWWFC+Y>(3?Y;V5$QT<U60=7"9X==I^NK"
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M0);UV);Y-.+@,IK3"TF&1).  -> Q-@6*,VX"Q:UQ[NFA5=!Y?7D<"F,>NN
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M"82(&5.EEO=D;=,2_WG!U=;?ESBG4%\[+&./.;]'5Z>11;\EWQT$ @X4T;P
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M-QM8N^*@Z38:*^WJ(OV:![33#>W=YZ/>2]]4&"9L7U_OQW #Q_1$&$>QJ>/
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M#C3DZ_BS[>G$"%74J8Y[=*.4"@/2-!5L._:4-5E'-_7L2^O=]0?SH4U]*)/
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MVH;ETX42=;!X&R+T#BQ@PW?CU(;/?^XO-S1EQI.KUQ()IZ?JX(S9%(F9;-0
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MJH984Y_\L3[$M 6S6.-81BW]HD)O',6(NXNN7Q04) 793&B9. )>8,.D\7:
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MK4MQ.0@,>USGQB!!'N\)'BD M5FD)^5PWY*%,KT'5$-.@Q%4ION]X\=JH*U
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MS^Y:)0N]M%DFW.8$RBN,S+2!:HXIGE;MPN]PG^]:AZ4MLGZ^(GDL'[$7\'K
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MF\"[_S9]4#F8SRILDTOYUZ,+)K]HJ3K93S^H/IV[W]F8Y_+,5O^8SOM,"]*
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M8,(E_29?$#TFV6N0KW-_A<_M<DN='45I[H0]+I-M<Q>'M2-AS!O,>\SM=',
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MSQ4B30&84DT/2:*8? ]A)ST"+,W^ &:<>^D'OHP2#"<[F>HV!EO(RCP4T6>
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M'U1/\OPU>5:4Q@)0+YH0YO]_$P!02P,$%     @ -GPW52%3)?J&(@  >B0
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MALB$[DW/W]Q*(5Q)7[/0F4,=I6?KTSF*T+6@#[#;P"7';^PW4^*]/]KHIBO
M+)MFAHR?)LZ3VHT%,^ 9;.$@%:WNB&ZV/>P":/QWV_' AL+U<A/))A<4<G16
M-2>_1-T1?'7D&4U]HO,S5H!5?XDKL.&K4[S@/36#9/0*$+T"Z P5B?:*KY$C
M4M<1G>"?W)B\$K.(E =16FH]-T!>O_"J-1NF,Y<[-A6&1QD/ZW83 N0 (9N9
M-%JX"NZ;*]ELE-=/,DT^LZGH1'OFKM; J;+ G(\;S C&5_$I.:A2O0;M7J/"
MYU38R(R)$JFI"S8'<[K84O!S[D[@GP\>)#.87\2]GE&\276G.]W\\J<@%1GN
M(=( NVU9I'&*BU8G]WF1C-L7?@IW!S]3K;Y+[MM%#Z>O^^JS9K[CW.-BUI2@
M25R54!E*%>WK_GZB/1C72T91G,"D\D].%GR6W%$H8F%XQV(_5I>X'YP3K=46
M9(P['*TB&D+X' N,%;E/=P6(ZQS1@)4#P%:!7O7W>;V1!0:7HA=(':!>V7E1
MLBT1K])6@\K#J,]OXFQ[:-D:>A8<DA)'%#ABJFQIOU*$ZU> OF,]TJ3QBNV4
M66S>$D5;\IS=9I?%SX,9 HRX*E:[#ZO9J&)BPJ*DG?FF ,X-+BH<$-Y#9@$*
M#TW,=K1Z8SZ-#2[OH]\7E&[@!#\Z?J/_QE;?XMQ?0=]?_ @U,0MW#S^BE*:<
M\.\%]N^HJ N_Y_\V>D_^QXKR&O] KQ1R[5?M[?Y^;Z9GAL(JOG[_]LF=SV^<
M=0R)NE^\J\KIR5O "X@Z')+*(>>\EX9>YL1S\;*$N3Z2-3CQH'U[$%S87[%Y
MM,OM#FLXK/,;IV-B*48XHQP5%[IZXW//L_??VR:;?G_EZ?.@Q_S5=:_FR8.T
M2N=[T>I^@^%UP_7^;O=QSVJ?%DV[A->VO@A/VG3O1R"C)K6"BVL;WLK$?[(R
M A+_/GJ\766V8,!0P;C6]BOP9P/^IR8*6@'2FT1>L#"*2WEC*0B MT M ]B6
M!]BV%8!O_T"D#M^"R+V_,3FUQ,-@.X.OSO'-ZS%Z'T"T??T3IMJ.*!$H ]HA
MAGFN*\"5\H07P\X>;1W%/*\"L\<;BGJRQ9?H82O FPA!.$@O;,6_F3\(4K(=
MG$)Y<?B^%<" 9.'))</^%'T'7PCG7+:%>/P^,0)N?! <33*?$ 77C"3+EK(V
M5:;B56\(KNQD)=X[MX%2BIVM\^P43"'S-DQ\*NYVN'!1;3OV=&&N^?D"^7?R
MIH\;**#K,9='R/TR\]C!$\@W33(%-ECM^QXJ66-G:7QWTW>]""74\WJ-$SQ;
M*:'ONLT;UO[S>HO7U9O/K[DJ[)5Z>?"@=<IUG#2)A06]V-.W!#,80TA[@*SX
MM0<%OYK=/D[<(KY/6C.?1%;%1N*NL.[6TQY6<BRS65)9QSO&9\MV'9!H3=%I
MQ!VUKJ=S%[W"B[W8=XQ.A)J(#WK)AIV8 W=AJP&R_3+]D39_+T0=[$ OU"#R
M8 HG@PS!HK@BH1OK/TE:A9#[+]'&>G^B@OB11&:>9=$1!)]C,P.2LGH&4^6O
M?KKIT&C&1??O/:B\U_FH2P=T,+W?7T-H)U(;'Z*C17;0G$1)6Z@A"H A[B++
MNQ_7A!NPO%1A"%M!;MP+Y=4N4"9.5N0/AR;R2L"1 8I&)#@="/\X! X\B[L7
MU6-*'[\[20OT"^^>J"G[=$2>?[ZW<SF\4"K9Z.=BL4W%02PC5^2-('NQF#Q;
M1P:#K@K@&J%F82_I9?NI-"Q>[JS-E PV(&#S'6 )NU_D@O2\&_D;.T1GX26*
M*<*-Q)#.'G2+/',%*,#J_L1>#='8<Y7EEBFQ)-R:7>PW<&.BY26J\/.OD]R7
MJ6Z,D/707W:&&^C@O98\;VURO[WJS<15'Q\5OZ.?R7YJM.2@]ZM40!'_W2,O
MF4(K?\-HB!+!>Y+-X+_T[M_DK@ H]I>RR48.7H=@QC343_[69<>C (1QQE0
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M5;%G=&E1.ZK,LI^>UG;N'8P_"FEG\>@%+W&&\$^B%U?Y2=QDBL^CR$O8^RL
M>.0D!39E\AD%BN)B9.;K*37];/6?F&F>H60B#^%5&T^B2!/*4N.%1J01&<DO
MV)^31@[Y6VK91$MKU"5&XQ!#Y4*1B^R:/CTWO,J:S>YQG!Q-XP(=1]S67:^T
MC.JSZ],L@EE[]Y)5?E\\/S)9D@M\(KIQO%%P@\L$T9[KI>T.;;KT\(UW]7P(
M>FJI$>L_2NO>P]$U;9JTS=_/^L0XTGS#OR30\[%)^S7[S.S24^1_L#,\@1\T
M)5++<@/1@XOPQF7FHAKI^7M-\3URU.)E= N^$'MZ;XQ+"TP76A-B L5WNW#X
M61H\!=[B3.7^5#@-^_+(<N^"&52WNX3 0UE]/4:$L>="E_;VX&'Q85\.4Z3=
M3IFF"UR0G AO=1.ISU^KS!D9$MM=4P1^]CTS0-& %/3"GRWW2UQ,CJ#G&EK#
M!3WV'>+&%>#,ZLU^7\CZV"AVP?OMXR13T<7115H*CJ\?;#A^(&ING"0#XX^U
M^72.BO1GA_49.VV^K%+:6;=N4Q36)Z-^PZ.@DM G[2>RSG7ZWSZQY;2NBN,A
MPE,N714[>[L(T;OT*D3S$O=M,*,/L:>!KCS#L4'R:>%.G+4CYH*2(U#L*-^V
MFO1Y5+X7W>8M4L\3G!*W\1.\8KA35Q*Q*L0@T$R?GD%I3>J/N[C(&>$K@@W'
M75?'U1%LN.2L'N9#1DS<%IMA#O^45RBC=.Y<R!>J?AO9O"M>J$N:Z+&#4 R$
MM\82)2LP!LDHX%'OZ2Q_2.^-R$#<TZ4<7TU4$S\BAW?OTP_,ZT8/XK2-QA83
M\CIC&BWB<IF0V^Q0>TQ*;73Z*)S77]H<8JXIWG0\BM^U0/SHNGU?FK7-;2W@
MFLW+[4Y&J9$RB&4$("K? $1+E%8+'9&2;21;2:,A1N(ZTAJ1L;BT1UOR"@&_
M9ROQ^*M&BYZ]<-)?T$@!;605M7\QNV+'J^KV)K@JCB-,->/K)5VE>6U],:!]
MZ)GLGIR28S='OGVW"E>)OUY1OLO$EX/NSV]8 >2U))-")R7L; GBY&XR'\%?
M>(Z[OBP[H@/$,U<S78PK1W!U=^1?_3^,6)9=]I)G<HAR?H1[>X6U[#7O.C^&
M;5C]8_\-)9PPU\W/9X*=6+T\V:-8CNFH%87_3MV0SF*1L%B:[Z<58&@1-D8(
MAA-<@^NXB_D4Q+WM56:2U;N2DN-J"=1!NQ [N/+><$,(RV\FZE&01PU,'NIP
MO7'F67B4K+F%^0D/I>1B8W?/J5*Z:(V,1%')& \SO%5"=9@B<VI^]-Y,[X'N
M*M/7H6^6[J!JL;-599*\1 0YL;B=USZY%!6.;8[@RS3OF(A=MXYH">TD'7MB
M[O&\%CTPN-;I-#"!$ YWP((^>XO^Z,!Y\QRLR&IQX>N05O[8@6<@E2%_(WS=
M=ON^D;=2$IX9>HXB43)%ABY#'DJ(QJJO !%HV#1KH5!H24CJP[:2^4>I+WBH
M'+1:*]N0Z#.)QT;@WOS@M-6=3(92N+3WE(?P>Z'7Y1#HA0)&F[@SRV_\FSF5
M-GSAV^?U<;LS2&EO)/]"@X=0\":#BMOT1]ZY--1,J< &;"RGT47;:_B*W*=+
MBX58Y2Z;4+S**:8@4%Q)VVPX->"S4^M:4$\IR.06OXC"ZPW61'9\K9I9 "27
M_\X\Q#!96^&*&BW8[K9OR[0NDQ@!4H<MIV<D2C>%IL14.! ZS_46;?Q-[?-D
M3S<XE_J):TA:I%&2P21&2W1,7#[;TD+O?(S/P>A-<C<F_*H</S.41XWTU1O*
MYQZ6TG/A#[]NB-U5F(4%?2F70G9#A?T&^H,4.7KT8IJAHK@R\19:A2@-3PN=
MB,J3&'VB(5S-38U6SBM4@L^,#RQ?+'^W?&7'R#IG;191_B3O'9KAS?U<L=FV
M>^IZG^P=] -KS.#;LW*.)M> D8,>!@<!*H,"6YKGQ0MWDYX^&LS9B 6/X6#3
M3TM!''>84W/"'N@[N^^#^O71<RZIID(<N>\(-@+9SH&# 4E]]O9H+=(8FD;-
MK<KIDD=$_N7%7? EJ"6P.!'7'&VXI;G]1BLV$Z.V[=D.Q*#T&'W5T[H5?G+#
M^[]*_YG!R<%5$D6.\ RY[^"&9BA)I'&+AQQ_"^W@U%^07"$D,TM9B!'JS_\.
MG$>K8$P(%SQVH+)6 '723M+H'DE^ZGE(AIMTB78TJO&S1 \<NED#*[M-6DR'
MEAY6JD[#/!!GD>1$.!B/1!TYA%A=Q.,0\Q*-NIJ(@2$H1A UV8,BU$L\G6L(
M\_M!WU[8P9+;P->R3_YX\^XKVN.7Y><% Y>&^Y-C=/.)0V(BM7>CN)8\6XD&
MO8RU2H47"-K'Q1W8L,;U8ZP9P;SXEDA] Q$/QU6:%_66DFFF"[Q[^@V-IT;V
MT]PC)GLV$C<6"-[[A<;PCS**#HS5BK-A;:$+45=<BS&()&LA?&?G2.3@3G!J
M8'OU4"GBY:1C!&639=\.;ARG*?"*[8>U_2YE>W:;^K6UO%[Z-1D8,[_Y]+Y6
M*?[WM\X*F]R4KZHDGCIHE;9[KYMW (3*I;12>RGI 4AFUN>R!ZG2Q-V3DFTP
M<S],!ML9$DMH=68^E8#H1\!;Y)_';;'*D4G6JWW]GE0X-[O1VF)23EN)[_O)
M9@__:A >DDQ@VY,&\(@55D,ZX][DS984@L[.<. &%O$4 NL5R9L+IDZP(OC3
M="R.EO>"DFX("%-[ZJ#QX/'6SIF84DBU.O&.:->8I>QDV81XH.WZ/GHQ6]H[
MH\L9RL--( +Q7FJ*/MM ;M__PBY+8H8H-HX>=^N=$SV,G7[QMG5VH@&:@ZF+
M.F4;M\] [2]" C43W>*3M^I.#($[V16?B"X_ZXCUQ&A)YB6JIN+&3S<.G&T7
MJ<T(XLW,TIL>80U$YVZJGE4J.7+SI=UZW:<[A'5X\R/]A>IRKASWEZK).D\_
M.\D:7EGC9'09]Y*//(@6](+8JU1Z'#KSC[LI1,^3P2/B)*?+SG#&G^CR7@H<
MG%LH@H[V^I0Z'QO#2(40E5XMS$YT:8,O^G\WO LFX 9"#*8>BJ+NLH."8]KQ
MY.3D#10R[(RP,!*-ZDI"\L7TB$3)%T2T] 2;I3V@E_Z9) OALQ.9D.E"EM"1
M_2M=9UN/$FETGW(JROOU#M>P%+(4T1VC#[G\4Z'LSC[ZMY41FI;@LZ/D_G(\
MTZA RV/?T^N#UK1.QE;%D\5;CI>?=LN_,18Y77G#G>#/6U^82WJ%IEGVDJ?M
M.&TU4(J@ *Z>'4'ROVIK!N*@NT(;7,)V*(_9J!9RAK>HE$WE[IAA9(POX5!1
MK)+&6@^3>);_?@\C&78 U_97^<VCN][Z?I@ON!,&$$S [1Y&TLX;N]K2BLQO
M65W]&,0S-DZ[MV1LHK+-E6MM!CI)L.0^-R1.WI=]0WI:H0[)B]2O"_:\?K-Q
MCA\'+?8UC0A]1+[@TJ)1A5! @*4:US?#\=71)>?,ON#6]&PMJJLK7NWF ?(T
M%<PHTPT2)4_DA/BL2)4\9>MT!2-P&HEO-<8-5?-PT\Z")JC\'_']I?M*4X;K
M)Q&>%K*T I6][/RZ)DSM2A^)[.#K8;;7SY^S%<OXM!8NS.O(+P$*1FO.*<BB
M#R7+E= QV% VO,5W85QX^ED#;-<;\+(=_,&;N\3)M<S%-4\-=6LM<NA\%#A^
MR/W-N[Z'1/LI+7TQSB/K15(;A,M AX 38OJ->'SMJIO'4A>VS1F;K3NC&!YD
MI?+R7OIM70W+=;N2X@:V7%DW*RWL&%+>S9+?/=<^OD,ZJ&I./NFY_@>?\Y>O
MAFWB[BE0D-^M\S26%$5Z@P./4:;G!,<AUUN@S]#((+DUBQ_.?>PF,J(WRR]\
M09QW/P/F<15-S32[$5;:SLA+F#".L^.T/U7D#RD?'EV:\;019)?,A=Z!!^FA
M2*!(XO\RE]B(.^E19$W2(&5U:'R#R$Q<2#^)T\]'#Y(4IN+*["FJ<#MOA*\;
M7X.IA)2'0M9UY+Y<@FWZ?;3(JS>\7I^B_R71/O'FGQ<F=NX!.YP?N_<Y 6FH
MH+ TS,GE\_F,&T\;C.9V_33^/BNA-Y* 0:$7LIF=Z;-EC>)R83QL["-&YAK6
MN.U#:JF A2CF&@'94*)-B#9WDZL2'B(-=V@@6JUH2*EA,06-H5S??AS-O+[4
MKB,KLZL?$&?!**&'2 V13/W/;&UR1&$N1@%F@#.X8!8^ST&Y,7!^I]FFX3&_
MZ+.N4,CGB\.M64^[1W^^2+7S:;J]H_OC YOU1Z06-8Y%;3JFU8N9-@;G70"/
M$!MHBF?'&)E>YO@.T/,I6EW.41Q\)D61J-U(=(3:.B\D;:)PV*NGO6IQMH>3
MFU+O"N:>>^ZU'O;QI_Y4OA7C;ESBKXEJ\?U$%6F@!590*?]9K61X!5"B4?4_
MEVDO4#CXJSYH37(T/<LZ\*LWM[!0SXWQ^<14CS;1LJVK_66I?-HW4:I!12.D
MRCBZ95-3]9>2-JW'J&V.#H@?<P,#N:@"/L8"07'_"A"U5SI.1G!=W/,P :L1
MB5&=>,6EPXI"$SCV);N%V?LBH2C$,Y!WYRT3.145LF?:JGC8M>Z613/[,\P$
MU_JO:!H]VNNLYIR:^EU^+Z%>2RN>53^H8A78)QO?MZK+:G#=&H:>;*XRX=6^
MP3CIK8.R^]>&YAS9(75,JLX1_3<9],-/SP_]>9%UPIL5X0C;S.H03T(')2\X
MY*N+Q"U541VI]!R2#8R;G1H8422Z3$@TATEJK-1XV@JP&DX)>M7J92CY[G[&
M\J="*_R7QT4A'4/'%\[4"! ?D9Y'>B%1$1=C0\M)RSPT?PNT G#;%WY@LD"Z
M&UB:TSJB*QDNP<C![;/4[) ]<!$TQ/0=;:1S]@>*UH\Z6-0[)=EE!WJ^?IAX
MOV6,B-7\^M5LEZ1T8WZPCIKO!=6/)FMZTW5"JZ3EC2D7AUK!EUFA2)3PN1AR
M,ZHN^F5A0_3.LKC\:DG]JX>O]Y1_[%K[-GJ5VSMAT/70RZ]5@&3ZE9Y51",0
M-X#.QFJ*=,$7O1(=N! Z%:-,S\&N:<6K?KD08@V).KSRVTKOT7.Z7#3KY_?\
M'4"B1,3AXV1+<V)K*>9AG!'JO:T:9X!VDZOAUMZ[@C8S[S !J>M7;Z9G   @
M(_/F8NJ62.D; _;.#E&&@ORJF8^B!_JMN9C?W\\U]LU])AMB[,E]&[NL*>H[
MJ*P\@1),>4CJ9=.&&DU*6<NY&-TO;:S27E2^;_:!^TQ!AK@B@M"ER3.94,K>
MUA5X-^!SQ?:FB#A7"]=O?&UL\]\9SJ%&Z]9=%=A*P6:(BO198Z/H,[Y^8_]6
M5!+\BT//K5 &/W[0-M02(R=@.(=+ST(WATWIQ=89]-"AO&-=W;ALLO[BCMTG
M]Y3!@0-V@A#55]Q_HIJ_=-QV^D?RCJ#?*U&#DSE[U7LE<F!A9I?R[*+*M',U
M(:D?H_8JX9T,(T"K-+8GF%905!7E,WDQ-?^>E:AN=?>#K7>N'2OV[P!SK2Z-
MFR09W?[PX<?+Y)^B57O2-GPWWO74(6&N9GRL*XMGVH?.H*.)BEQL!DX?8T"P
MY[(96*T9CZB'L#ZS8W56#M$^57T(,L\_6<<TN;!\0<@*#)SW;>^F_9,3^[!Q
MH\NU% ,-*5@S40B0V.PF10D23-/]26,89<BT=V2-YZ9R9-<*+[PC,+G8]!Z9
MG?>^:(1L@]=",>XEWMF3OU%7@N^_#H7=N W=,:ZO+;A:%TEU)Q24OU$ [.SU
M$ 5P;F#81G!;W$(R)EP7+(L?+71U\NVYY*$8A),ZQ V=Y9[/:D@OL=(;A+BT
M'ITO E5V!&TR8.8(E  -E9;JL8*ZBNSF?S#UQ4L^/%VC"-UGNO.MR[I]NK)K
MW&M&5Q$X_487MO6Y^DLB'$KZB-)G/9@ B@/$>W\/74( 8F.S',3)=9%W4".+
M,VB)X@NAK80%?F91!PL5O_88PD]FGWE-]8^PL!S#ED1P1I !'Z_/P(;10?S
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MD)0_IZ!X_H*&II;VE:LZ!K<,C8QOFYA:W[.QM;-W<'1[Y/[8PQ/NY>OG_SP
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M):;P 3HH1@&]HATVL3FW#UKKH_VQ;AC6A)*U.ZWP$OT%WW]XZ42&ZBJ=?69
M67@-DAQT(GD/\_P-%)"OB7#R2##\PLM7W3YA>&?GZM?%>Y.QG3:FSVR=:W)&
M/_6ENZ[/'SF7]CRC:I1>'ZH989(\7VV:%.86GGNU\-K6^:W!Y,PRMY/N@2;,
MRIAG0><P7/N@(^+[H- L?05T8B?V%(!@'OXM&1"J>SY_13+BI6HW1'SYX4&S
MZBN](CTF-(SJ\N:]-WPK>2GS;%*?57VZ@[3Z@,JDP)M_< INDH/-@Z1GM&'/
M  2**AG%>#FJ*U/0H[>W34JD2H4H6-0SE5%ZHSK/PSD%VHO:WG19W7;($SKS
M[YFHJU*[+FX?Q%D+]-%VYK;W09W7!@70WKN;MWYT1_GC0>2R!;N@BS%ORCJ9
M$RO:"M\:=%#O%)J<T,FX[S&%I\;-F5H'(L:<@)O8!\T]!0Q\:<-\0EZRLN;V
M@)EC G##77J\TK2<7!;K]"\@FK,T;EGEZXD7H36"QMM8A]8FN22*\Z4O*KH#
MS=Q=5V+JTTR'DCZ$+-GQ?_'2]%#UJ?/?**I-8JL-L.RI+7+A3P(.+XD[_VH!
MBT&YW\_]IL(IGA3XO6))FS%MQWO%-CZ%Y[>88OKNHLD9U;@@;">>]FQP/9?&
MU9EN'$[T,JK;R\$*3L(F[-&IOY;N)$*!$@KB]L^>X$"WTN4V\GB'MII156"0
MS6+I@X7X^X@W$DJPF;2U0:8I2VFO3)\?,)Y/:X4)3*"K*;/Q?C^W>15LJ],A
M.N2Y(T[34G:5RAXCA'BM9S]<'7N(?8_:JZYNK;+JB.[[H)^Y5+'U!+8&W04?
M5:-Z%$#=(<F_8KJ,)9FH%-(UY\U\Y<O34(\ISS]F\#W=X72Z>"SANAIL",>2
M2IG?C(%5$=?SZ7UL[DVZ@N4?#(2Z#SHVQ7*DA:E=C856DVH:8Z]LHFK0%V52
M9[H[)>V2GS+NWBJ0&+V4;I?B H'0C5]4Q6FYUH<J+.0ZYJ0X CK"HW"C"UL9
MS1K%?Q0+1F*:/KCN02QIXYWHQ\[&9J&5$W$^5^,O7+@2I[ET]4=ZC.6O,L7Z
M<_F>#<\^Y24G-F3M@R;CA2UA TM_/UL:"H/^YX,+).@3YYOU;A/O!6(_/RB?
MV/&C^Z!Y.Y;(!@_BM^7@NG]17E0==X".,\X=G:T[877UW4>[>A,'J]OB%YS"
M!S^P[?Y0*(,3L5\E"UE"VHS6O3HW.C2^!A9W0"X0))_P!$:7.*P+*U[6EZ"E
M+^/Y_\:&P/WBA4SK1];V034$,XE',0RS"<E+E>$HC2N&; 96&G,<T*,E6M))
M%;1!RDX$2Z(8 R79=6 A+3_6>9N[8_UKQ$S3LRI/)QGX/HL-\?LT[VGY= YT
MC",FE'%][YU*BSBZ9*Z9^'4P\BY+B=[5Z$_%B:$E(7R3%T.I?/PS?9SCC@.Y
M3_0#"1*+==$+#8+*^:&9LRT9WU?M>XI-G2MW/DB9R-.44(@6]]R_/Q;0MZ]T
M7;3:$1X.P"%G$61Z4 7@]L]@K]9_4YJ%V6O&><Q&0,3+F@3H/!3"SMKE.9P0
M2Y>&[U:-=QQOY8O$GJ?7Q;*$"OJHB=+V0-( HW?0F3Y6MC=I<D*H-]Z[351
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M\^4-G=&7;J$;96LV=RY%/2*<.)=H6Y].4DC=FJ%*G$6N==0D=&VV#4ZH,GP
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M4PB>QQF9PZ;T@$6DT52_+VIL(O??X8/4?41OSD$[P3*XUINZE@?*Y5<&BF[
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MCZ[Y*67(#R&Q?:?J:M_D61WYYI^VB3N)[<<=P<B#V^N;('-(;8M$BE$CM4*
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M@=G+;,F&']Z;&#EJ9DC.2,6#3+]FUXDU74O*KZ._:-_>="//^AS]@R>',CX
M._,5X1 1W<NTK,FO^M* +\T+.C';!A,@Q-MUIO>G=9@[60*A![*71*!>2^2:
M7DZSQ#UV1.-,FL)5]&>6/Z'#-UF-3I[9B7[$ EG.O? #@PN.=/2(^8L[B;EB
M4  ,&D2V-?37EE4 L0X\%![$.Y0*YG1!?]%*\A3<58K0$%T0:OXYE=/:QR]N
M4[J34__:7AC$'1_M>K:.#HO#BCMZ!37IH,+\>DP1DNOQ!3EXOH4(U.$9+Y*M
M3GQS;7$18.HIZB+*^'<NE5O60 V/Y;!1+$@/'9IU1^S"S#6:R<1FI)]MB7?Z
M,MUO,]AI@$0TPX-QK;>;+.?U()9[;S54>>$X\2:W_%57)7KF>#1&BF;6R=&F
MKT/7=94%?#^M/D_N+.KM$W1R\+*<G%%YNW"$Z'0>4Z%.$H;H U &9>^C+@?-
MB0$#$'/68O]A&XX?R\>Z 0P&? +P!Y03KRE$P8& A-6;D1370CA%1HO7""4Q
ML](O%GD1XZ*73\C*+%JNHR(XQ-Z*,?YT@(]C> ZH -#NS#KUH\Q?!4<9W='&
M<HXN_K%=;=L)J-T'N34UC+R7%Y!8JCKWK8G65SOT*Y+3_#3J^!CN 7ZBSKJF
MNBZTU:Z!<Q<5@[&>EU&UH55$-QE0RA!FI":DCWL E;BV9W=[5,5[O:;_V:\>
M;U4_OV2F\M24R[0!7&1TYEE,V35Y1=?Q8(7G4W6K[M^;'==>ZSA^.=^CE3JI
MY(1RO==4ODYBR]$2&:4 D\ZD?I^1H.';-X]@E&GC[6 ^S-468)$R&!.45807
M5,88TY7:JQ"I+;*TC8P"IXS;D,^.,^BSHYJV$9.VK\UDOB28P?D!A0,$ ,[;
M=8&C@@;JYG%\++$DYIQ?)>9)5>VH1>B\DHH997&S309LGVQ!8H50,_;4!UMW
M)(WC"?WR:SF50YN/QS3J\U^4:F/=>L"_O;\PSV".TL4Z5$]BK,<P\H&J"1CM
M@F7).XYKLN?H\ID#7SP^:NU)8!R?;-_FBP5;O*YN/=>$>I?FH_HNSO:+V>#/
MPKFN=P=:QK_BT.^T%@&Z0B)&=3Y3ECH"I8M%R]%N>K7HC!!X]!".^EPZU6A_
M57_1IAN!RL^]M";;:&<OGWX3KB,64'!@85J*IW=:XE5$6IG>'^I6RW<#*]*R
M=L%XR9WU.J:S(:VZHWK%%G]85X9*C(94X6+W09ZJH8X5X?XA;BY5!U6'MII0
M:!S1=3E9DMN.H/(@XW;CM+5^-)<.W]SU'^Y<4H($YF/']D&$!@!A0'N,+V!Q
MT2$=JF'$ZLA0G*=J7)8J7;:Q8KE!(?[)-I2O_=-_/R4=6?X!)Y(E7;,_36JD
M"0&I=(7AOZM?SHP,E>?#Y5%%^R /,* POK;#U,/HU=$BWE,TQ_W-B!$TC"I=
MM+G,R[&EV ='L91N^V,\0B42OR3>'*DHO^A=45[Z%U_=@;I8Z.\&3BVN+L:U
M0G#NR /IAXK<:)&=W@<] L1NI+5)RN>@JSN#%6CF7;GNGZ8 .1=UA"#X )J#
M&X_Q_"9/M+Q\J-XND'#5Y8YK*GFS(1&J8KTU'ER(%)>W"T &. ]"+S9N+B)<
M?@]^J %/&C,2@>9Y51$3F@$%]K*B26!N\ 7V"%"J 1'R2J>R;M(K8K!R:*R>
MF1FM/!:1/^$*)X?4AC^705TL=W7PSPC.@*V5#4C7C8*K^+KC?><'VX]I[H.$
M5V7%OM!GWE3,H''=,[(T1B(5QCN-%NM(-6,T#G(!^.MTFSB=@3?ERXRTYXJD
M'<_8X%JG>@6!SQ$0ZYH]/%MT@AA30* U1V3XSJ-.>&;QT^5)H8P*OJGIW_J2
MU9%0VG9X*=EE2G#9QS/UZ2=X66%S<V=-Q=E5G\9> 0A%[*MJ!(X# X%$8F4\
MD87M1:LJ5!F<S1@*Y;_)#Z2YO#Z%=QPG])M2G?;,;#/Z[LQ,F:[%_C*65'[6
M()%<Z-'G][<VRV('VP@').655F:SB,_Q-*A'3HR2^JL8Q8^'_[^#^%X5T.%A
MW!G':K&[]"6!;0KO!1>S#GRU0JP\7>N3<DI^XSXH/*2B]>A[JH/IA;2MFN5;
MDN%M1E4;9H_.=MWH_COIG!:G*Y>-'FEEGZ(%Q&B4(''M;+DA@AX8-N1]W[B:
M]$33Z>JZIM35CV\;.!L3J"XOJ@/5WRU:.6I6V,GU>RV\K^6ZG/>AI<3U<HF(
M@IA5J$]\D!WLSU9:34*#BK;N]R75PG3W=]]Y[8UR*@R+VN!73'V:/A:4;G+)
M]YU-F7(_2R#L@[HLH#J/_CBGNDG>EGL=OY:P(O=A?98=[2\!5U[DK,D^]NC.
MXX9XI;;-X *3$A6JTR#WXXBC\5&!<IPY[T\>W[A_58]+[S*L 2>Q#YJ+(VNE
M,'W9(S!.E@C=",S#X@',RY>3?Y.+AQ?&",WG=1%'2!79Z-,Y61L:7P[TGNL,
MZO1CIMEWY,:MK+L(/[Y_U71CQ@W@/:V$D?P#YQ[,)^R :!A,0-6\I"#MJ3QF
M>U+.]ZWOIA_N]Q6:)!L':Y!^E":#J\/#U#!\RP/J@_0FXW;@ZE-MP0=74#(1
MV6']EY4;;.2TMGI,4QR'&..+OEDR-G$?\;I2F!Y[8)#[Z8P,+5'@5V!=K#[X
ML2ZLW;KPW8*]\DFC+,E4GJMEJ?/N$2D66#O;\/,-_H6VQ^]-/5 LOFJB0'<I
M8OIW]GJ=[-%5?^L>%AAW_:RHD?S3A27/;TL2<E<KU@+8O(9[29H9%9(LW[T:
MC$%!#U=D62EX;JD=T2.GUEGD*C\:A(]759Y_0%AC33QYTCGJWC'^7/#9"0Q6
MFV6Y#WIU$^%Z=%1?Q+@ \V#$/P3<111LXJ.M=N\VI=\?[@Y_0,^J<,N+#X9F
M*96$-U:J^BIK0?V0WF<;#.-SKK>#?V\S5;"#$#[(H\178-X#-$*%-SS2"0AK
M :.?CT,_B_Y^,[4RKM;]1'/:U^ZT+KYN13)E<J8J-KK ,\Y3_NTM,PP^BN5K
M(-3FH&_\HD/9H'/(QB=EV5=30;QS,-UK:KPAXD//GVL_:0 N3-%J'C.IEAO&
M_M[[%,KKI-PC/>_R .YV7MGBN$6-<_&TE5?>0:[/OGW\MD;_S4$'_?N]%Z68
M$P/Z'X^\GA[Q>="2'.?"@EN%.->5UL'*3VW+O'V3'PZ79$X2HT = C_Y+4:2
M>Z]<D1,>]EX/20E8*$\Y0"8/G9KE^O,]AF-%Q=86J^FYYD45-F(>U;^W#3]=
M:-KA/D:^]$?]V\,PG5S3H=.O/SX_+;0(#C*RD3$I*!M^>&KR5M6U,UWVYU$7
M+87C&GN3Q#:?=+]_)5STY(5#?D#.2(AV<XNCWO,O2+*IBHGIW;?4+^ZE#X</
MJ/8YTG5:<T)]3,0VN$(.4I]UO>))^;<71L4^Y^,+U-5LU"85+SO/_;KRXHG,
M5YM/!O][+YB*RL]NW4]W&:I($4[R?A_3T<A?N^Q@H-Y5W_>:^S@W*!V4&@/
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MXW^\/D[%2\/+--[Q[:+XO5B2ND^ZU7+.,VA#;?SE,<J:-X<2]42:1G]5;^
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M8K2*QTA-W>C,HD;-F]>!(RT%I#2SPK)2H8SQNGHSJ&X; -HUC:';$SUQKZJ
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M4!'(8,+5Q7#0O7/9LBI<0$VL(Y[HR$,GB(_6XII%#]]7SJ L 7&SR]?F,.X
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M5>1/SHZ"(4+L[# P[@!PNC R4)3H?!L4OW**9-AOO /XF=LGOC$DV?Y#'SZ
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M4EL#M#XAPA^\*-7\[7+P1<H!I_^MJ0)A7 Q_.T.?+BN^ %ELK=)/&E=![JR
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M$8L\6FG;W9A_JYSKZ5@!O0"K7[0,^4<1EHXVUFFLR=R6_(-NT$RD!%+NK\G
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MCAVL;WACI:$/9T1M$M0-U;>AHBVH+C4-<:"'2^"5'+S]>5]8Z,H=20=*+D.
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M9@HM5+IL=9.X%>KWL)%S\G3H8,SO?@T6GR*2ZCL;.;^2[BWY2+3\VO0J;ZZ
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M'1#ANZ[@<JPO5JQ(0<XET47\^5)TK-FA_XN,P71C^>&>#M736-K\1[-X##?
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M]VXJ>: BX&JFEG)%#6]Q'Q_S:K_6:I'=R,;T6]7R#[4Z#N&*G3T7.T>OX;Z
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M..7;)J"-ITN.&HVI;0AZ#%6YMM34-_#YU<U(=)I__>"H/\:TVB=B(*BC9)I
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M_OR8G&AR,2?KI5>I]I?WN7\OSG^&KOC\)DZN1/QNKRX<V97J7F8*[#!>@(H
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M+B_IA>K6=H#TC0-;(KX)O-%.A0N/D@T4J&'Q6XT+)_K:U.(5&B:".RU1W/9
MO0USKFD2<\Z#NE2C$]NHXNQ5UU$?P2US1T-E*L?]YNGG;W?T")M#--M_@%("
M<,JU<0IZ[!5#?Q:#I:I)H:,FK6:*&Z885Z@^F@:H?XY L4C#,8*6Q,_@OQ-7
MWFU1N,_(>^^):2C&GJ 'D7&#<-+JKNO_=%6(=O!*QMQ\BQXBDA3>1ZB=P,A-
M,\^,1E1%33;A>1\$:&VG=//]V99V\$GI@G32;*JQ86PU=8L^Y8BVIA=_*O4/
MDN-?[D=5_$\[\_(.ZV)?Z9. 1<5:'<.!1NB-8 ?2M69[#8P<TBE'H'ZQ;N]U
M).BOSF,GDDU>WIPYR%?&H7ERHU28E(,7?)S:1^\7^7>I',_?32[&UH7%=.B4
MK4N?H1?&T.$#A;* .;4[9?$8+2R6.BTWU6%,[CQNKF W)4?G3L.]^<D\D[:U
M%_+T*SK3_U+GVJW"N_5&WW4:&+*'%<SC&)MQIJCO(A\=BY.=@2FK$OQ*O"\[
MCK1MSG123*6T5_M)M^G#ISH_A\&$LBP:$<;;;I\3H0+S#1F7,Z/AG%A?+*E^
MMV$<)H$Q ?CH"LO:160I'>-)N$_WJ722DC$@4+TNGMZ/%0#,S>LA/!B!,C32
ME#E9-Z:%>#SG\N)/LE]P0Q[J\@/49JF1,>SE87&7.@,%Z-!0NQ8S3"'OL+U"
M%H/%V].S]_WT\#&-Z8*+WDPM7,^BI+A@6QI>M^!5=_O4%NI=:?RFPWYH8UN3
M[:E?+LO4;D I;*.?LAFU;#+U.UU\J 1MM9LX=03R'$UP&&BE<%3G]A;"ZED'
MS) +;:O.R1<J'2FF^L,MQXO;4TQ?S3N9"KV/[HAR^'IE_]WJ[L9AADK(4CQ,
MN@.8)X>K,2^3O&WQW/>:'.<!+7TDGV8.Z6S75%4U2G.3'X&TB$?HWT8$1"IL
M/HXQ*G>LVHN8 F'\*%@IYDR7W&$.*RF@CJ/GJ>!$K>XD"!C*_LX7?B;J$CJ(
M4@+CF";,N@#>A9?31F^,EZ?Y:UC/:*J812SP:]?5W3S=U#0NFSM>#XZ&"3*N
M'U8&PQ.%D5*L70^DI_<-*Q@!IPX$@0BJ%BXA"N)+JEH29U@0_!X/)-(YJ1+Z
MG=K#4!&JE((9JG9QM/2JRH?IWY41PVY1><(7L*_ DLSI)1!,@G&K%KBZ#$\0
M#TVEB]P=#X'PE>,D$#-_A&IHN_D>86^<UKL4IH/]E:S&&3+%$DI7%))8F-5I
MNZTQ*'L-K/7M+DS*AP5SP<,$!=IF=[(F/!4F&:FZ2N7)I[T;F+P^QC /JU[#
M\S*LSXB0;-(]*%Q2)PYLK5JZFO(,D(AIP_P@CW /Z2*#EQ/GA\^!_@HP.18.
MK*)F60H/'AQ-UK,=6+#M$5>(:W@#==7"/MG+"QG)I\M0;)K+T1,1X-/V[W>\
MM0-]F<)TA5@WT_4%FW7KZ1*1K%<UIFA[?O@(ZBFD";R)I#GV(/D9YVBX ;TC
MT(!$ ?@.\*L*O?W>10DPIN:K&.VZC;L!2U+Q6<OMW;R^O/,NP 31C!90_P8=
M#P'[3/K^\LUQ\(Z4UTR:81%(/5(83B['UPT2L:=92IL;PPBDP!-9-^YU[.;&
M]@92ML%&*H6=\C%5P,I@CPAI)B,(&MA/_0#5B'CL.EL\YM&=CYC:9,N.\/,(
MPZ($8;A(UN[Q'"8&HX[YP/G58-IH1\08QK_2MU"ZH:5](B0"X;!D,\'(CW20
MBC!L&XMO+_'91PQ_5@IYL][VZ.?#TJ\!64-N#:_8O[N\.'!D+D#X'LC21GO3
M4ZS\"D],:HVFYC7'=OLDXY_H".]@'&G-O=OQ>5ZIF\%HAE:X6\G@:V>=E,*#
M'MO]YWF(FJXG%&<5X4T-K?0SS,6E9EP*W!O+A?:R; &":$%FYB &?%J!!N[K
MA-C6Q0SNJR5T\7]%X_N86N.$38;6&V/A2DJWY!!W_MS\FEZX.(9M9-7X$0C;
MW?#?+)+>=FQR&YY($$:[3O9$\= .1_O;48#=7NY8T_-]VV@MM3/V)-^9Q\'B
MP6&&0P-\ -ZX0%@Q4R)(KGU4.1GJ!ZG'V!^VP=TA,>=07<H,2]J[] C_:M]"
M@:<D!)?=-,IU%G/%3^H(E#"CV%"M;Y]KWCC>X'Q-!6F=8\'7,)[CURKM?I47
M1%,#Y(] FP4Z Q#0'*"V#$_;:MQ."W.! C&4>?VA O59TS'860= 7E^IP*UO
MB=-&1<.P<P8F:2_WF]?!=X\4V/KTYV+OSL[:BL(SYB/@Z=)N&7UIH'())VZ[
M:4IWG:=B_[.;KZ,T8)(=TU&27WU#(5PP?K4>/._2S\>(SC1\N;TW3)ZVFH#J
M_V3OYU"]5>'E%732JH/?:=#M>U3..K9I=:.HVN$'7C(*K!#;==$%;3H8=0+0
M62:(^]!A3ZAJ\2ZG@/R("J<?48HUF=N&INF (?1Z%=9C\>V<8Y7X5D'DB86!
M,=5U5!<F8GG[&$:&EE-$APS<WE? _0Z.Y]HT&3)JGU;M&I:EGI9W5.&?V6>N
M"=E$),0^-(;:;.O:Y1B[B("8&(;& 39J,4H#&#W0 ZY15RFK1!4E9Q:F6M6R
M!O>%NTO_&V^]'6(N#B3WX@55?Z<:JES<=5:SIVT69*>NY)=VY'GDN4"#D(U_
M8H.JEB9*4#)9;09OV(2&*KQ"PFS."0KQU;TUEMC^^@GP7E:*H:4<@6AWMN>2
ME);BFV:Q(@PEN=E^?YWK+./3J!=0@6YNTTEHK.BXX%;1032)0()).HD;7F-;
MB,W^JL"U 5U95)-S0JHI&%#$]2 %F3-1H,,LF-2:\*(>'96P"5,PIAXB;[7F
M'TCTZB"Y-WZWJIUKF/K6*.PB<[]BP?E'V-A<FT'U5V/=C**D&\].;.__?__9
M8OP^;#\"N8/9F3-J-.<0;,*^ I$ 8:C0"UNIJ/@@=.Z-"8P]990/\0YP."!&
M*8QK(4_Y.LQDZ"0*_@C+51T8V1_?R+1^7E6Y(G3(1?@\"BA:EV\*!:F]W[3:
M1=?0V<JK?1QP Z'3*,8%MU,+,UD&@[U@$3O U\-':E%B8%:NJ;9YYZ/Z@GYE
M'V^#[[$=W*8,RZ(2Z+,)#"&ZZAYYML]9ADC::C_0=V"(T5:)YNP8_;$NX?]:
M8'_6$?<H**RDJUG$6!42^_/@<>7-XO@XJ$ZE7=L796.4UQOD%V6+TD-;)@=7
MQ#+]%<,,** S(7S,\8_4_"5!='T_:;47R=U#FW>B#1331N8IJM5DO_38)KV!
M_+(2&VF)QC19.E0OR3@P1'WI]/>D;Z]VD+@CT&DX^146##4N!1H8R,,J1CCK
M4GD2W*,BN)L3O;+%[47,*RN@*U&F9QF:P7D#+_,P)^ZD$UT4DH0F7YW)"XM^
M)W?)WN'?DF 7\5ER,T,09<H^<('NM=LQ'=("X_L)$<)21*8:O5G[#$ZA18WG
M[%L!U_;,XOMELTS@;)9<+Q@R9VKU[>=5-IK=#>]$1RZ$L+:KW5$(H)"QIS$H
M\Y,,'F"O%'UM?0#.I7D$BB/Q.2M0(3C-2"[B/C:A0XS:&J*X]1O!OE$H,2D\
MV:-=\]'+3?:RDM.G>EW\L"WS]+;47O\2A&%)QV]>H2Z)?J0B1/J8@K3#^'**
M 6S;?NRW.3]03XRZTC:Y'>*CY9/OJ.<Q&E_]H"'"ZC[J5&%^4.BVY$2'"ON(
M^%Y?-Z#8G8@QH&['24-HV$UCRE)"%Q<M??."2!(TS(."JZ<U550"6=2 _$A:
M)%/,3^5"'1U66@Y<6[=#J#*(X+FN@<0KCYHE?L&@:"23\PKY7#@MMP?/=P3R
M_MO%S2I-2,#O*6 (]<H/R\M4-[Y/8"C4S03[7]WLD"Y;=0(B2S$V[>T(2PD[
M<F;(\Y^9GW:YA4I!D081K VK:YOX;Q#?W&Q?'D]SR%N&+J!/A:04:@'$RJ71
M\GD7- UH[M/IND)C?P*UH+1,_/ 3A^.@MA'AD66^F8L!-2U-=7Q*> VX ^;>
M83R!*<M  S%T-R)6+(25AZR6;7LC=<BK@]VXGY14D;ZPQ8NT+9QT[6$\4X#N
M4J^_"/#LZX,%U@*=WN$#QK]"=QVB%<>@MBY<!_>=F5/2DD#(@<!:E\ T3)MA
M00_(K41;@I.[0( UA859Z?5EOD[:"+[<MVTT!>I6[O1E'B.G!RL/U$E2:2#P
M=62XK#%MXXOM45:CV*<8"[K$[BZ]J^# $=!D& $?V#=,Z2>(2]Q0> AMB;AX
MEJY*.##WE5:A9W?WM00/FZWWC*F,9+9!B"OC7>+HW'[>KQV%8IG[J[93*LZR
MF=,@V!+P']Q2:;@XIB0Z@O)GM*]3S).&2JS.)W8ITV:)W.#>KDO3'6I%: $D
MC2V=LB3E\JXB,H*J8FLR'I+3F>SLV YO^'"B*?M4I1'O[A'HR_(N1RY99) ;
M0GT&-*J6EZ&]*"(X&%]Y#%2?G"K1<PG8FOUGO*K!&=*'%?S#)7'00!]-V.AX
MX4C,S?4I<_:QZ&WZT9S@XL[(PA.QS49/@D=)MK9 ('F;=-"S>)$5_<K)(GW;
MTO9K""HD 4)+P_#-=@CX^"\CV"ELY2?O&&+\R,.ABTK^8::T3_/HI&^)[IFD
MRYKOF.U5&,4CT-,8-+''16RZJ@O&G!9Y//BT2Y"AT$!;;"1O<JY2*'3/6BH^
M8>\9,&M%-WK:85YR^&ZUCZ1#E$B.D'BAJDKT&9";LIR1NM$P$1UYH?J_!E%_
M(L.HW0/I27FKF^*8H#"Z?J^+ <T05X0Q!6Q+ :+1&%1_^0C$9P?D^:D\&F>8
MNOE3Y6D%3+P?)$;U037#(*CT^DEPH,KWSZ97"H] 3 YP"%44<[D$/;2;3?=L
MIBQPD=TP4G2AF5SRIL8-((Z.>-68J7)\FSJ8.NF8ATPH%*5%?FGJH W&,*S=
MWLS/'2:)>DQY&>5_/HC85:3M]6,Y,%!Z<PQ,!8T;A"EUT&P'X F/P4\8"#K7
M'6?3_L=[Q'_5J%F]8:298D'M8NO6"/U$V\WZ?ZH?5@KUL-F$(S=28[ O<K[R
MENDT?>:7T->H:3+BL7TH!HJ^=1:21D(R^/<&9PH5Q[NNX$EU?MVD=B+S'&WR
M)MTCB@=]&2J*D:(@N8?(\VILQK0BM9%TR6U*<GN"!YUO:M[>]&_FEDC2%^'/
M-+PXRW>DD9K[,Y0%HJ:EE<=_@WF!(1<ZH0_.0R0[J_NS]^G--+X#PIS3G289
M!N5K.7J>^52$-I*;Y+/K\';>7-+&5L1<[N5D=L@A<4[G[XM[H=GO0^>NGMVZ
MO'H_ZI+D.UJK$YF*_P?"$FL6TY"SFKN@[9U8P.6.7%/BP35T_2X.<"MGN:C"
M%U0I=F(>H<_\M"-:B0J.8=B6JB4$UR_#P>MZ3L<:5EKS/FTC-)PO?KU5U^ _
M2V (''=6HL+C0M)/,KQCWG>S;[ \ZB@5G@+C9EE/ABK)LW%Y*>ZQW$@&91W/
M#CR-2-\TQW4)M43,5W::]I*\=F-55Q0?J/X^"$9_/_0^>^GB>Z%[5T^Z\QJ>
MEFF1>:IH??=_FD996X,NODT!@<@@$(@'1(V&G^OV'P5D4<3M>=MEN>T!%11U
M-"U*RG<'<[&-9I.!HB@^,/DA#8_?6L"HT9/-?#HJ) :Z>,8A]N.:.BUYCJ*;
M6O,K$5;:'XW,60&_1TMS0<":EM-)RZ>6SA)'!=%"1R"O@W0NI#FY6K]?7*MQ
ML"=?HA-\M[UC'"6;-+&"E;+W#2NWM&Y/\H?MKR%<./IJXPG3@C=2KQDF);3V
MON(LELV*OL1F++N?B="+AG$"2@>\/OC3'8ZTK('+:-*R70=P'SS =EK3T>!*
MQ]4P>H2-L\GNJG4>-^'RA/_GG*;DN@NR&9DK/U?13Z7-K[$*-NIC&0/110\H
MIC_>LZ,A</WF"=W"':?(2OA30 1,8#;JPH_+/UQ4)SUG9_T7JXN_=C;H-98$
M.1*#?"(,OG>$L0W/R.Q?O\WWNK[M-2XK8!?$%AGCNV5@-OY^].I$-%R,*8WM
MD>W0IVTO0Z*CU.: R5MT37'8"_(\5AQPI"H0-Y4&1!YW-9(E1OFZXQ@(BHH#
MPF9BJ>=Q4SZ*<+&O*32LZ2'7O1GA7<OZ>N;P^/_NH\]:7TX\#Q2[\UWT7(CJ
MDP_ZIF\\E%^1Z^(MB6<O*9R;IN(;TON44'&0>E:L2T\4"1LJNTGNCH_2F)V\
MXZ789*NMQ[W^Y6LN*)O/111RUMTM:2)5S/7B1-&I8;T_/N.QSM479EY>N*G_
MQ?[3:[-]^_:?07K3;H;9#I,3FCY3E?*_G1HH>FG;CDI7U[W\EHJ8+&VE69J3
M5ET:67M:RYR"0Z*X6)SDM\W#N-E!"\U]8^XZ^]A_)8.2[ZBB9#,9<JOZ%=IE
MR*(C).S)BN'!]5'>K(\WA/8@##X6SH6ZR6^P-,O1XXR'P*&FWNR3(Y#'$8@;
MDF!^O\RG;+"WJ5 FKKIA^[1W3LU59J)0_];KI?F]T!VV'+NJF MWT@O3F1P'
M!S;_S:E]??@\) *?,HL':Z8G/5ZI7$;R8GS',:A7@Q4 8?!Q=U+C@MO=3 2_
MW[Q\6][BRHB=,%=E1$*!U\XW(\0K,.((%..)]4GG0@?M_CHL8QY#F\F4,LX!
MASRMR]@XDL%7/^[-ZM$G(5XM=6E&]SSM9O_IY)N?CT^5@%P*Y:Q>>ZB6@G$>
MG#L"">GZB9!G@M[_B^*D_4;[*2PK#YVR/=F2DWK!")S8[]'HJ^3V0\^DVCJQ
MV!L6X">;W26B1Z[BN8E\6MN 7@+GD74G)1QAP^@ C7)%C[E$!5MN,WXKS%[U
MQK)FJ\3,OC8V/*/X[+G2<(WF4[%^*8I63\3/_DU0?L3#<?8>2(DVQ.11F56&
MZK-$N 38\P]3'U@\/]TA\_H+^\&$RYK>OM.@^*F!%34.SDNWG/AY!@(/BI&?
MC!A2J717*?;=FX 4+4"_)&V/&C:PJ6:7=_I+UU0PGLU'O'%A2 C<O#'Q==$A
MWBLQ_<7INQY#\;]U%3@DD2(/&4Z.N_:I%_>2 DPTMZ]\\8ORN^I 4JEVCX"Z
M)=NIBH[X&7256A948ZD*@IN=$V8SZ_[B\.AI"95BSP\8PW?@?VJ7"U^,L)D9
M[_/X'C9F]T_1'1VN!QE\3:GI/]56/ZHU#\E0F;B\TDPCJSK52MB;7:!*A+5D
MBCPZ[T1^&;PG^HV'["93M-*YMVL/%%.PL1!IC @=/ @3.P+%XGN[I-I:\ZTG
M24*MF1+)->?B=TG#M'J#Y^Y.\T;RFY/G*T4@%YCKU39W+PR\M;3J;BGZJ%?S
M/"3ENXF6\ZW!%_+Y3\T_,+4'1P6N<R3UCQ?_>6D&/EXO%(]3+D^PC*FX#C93
M=VI4LLZ+NV"9,Q*:7^_%31V6H7I&MT4]H1YTB_YLBZ2&-^49)?HW(JX$J$Q(
M_=PU56J%3[A!%9\9UV9!SHTHQ1XX,_$^@7ZGYGM.<-A;:ISCWV!_5%_UZ*9[
M'W^7-3'WF;N2:A"R!D^S,)]WVXTZ+&*<H)B?PFC6M=-U$C0[G;7"&;9OO)-+
M$$6.\[WR_L<4["8V:2"<^Z-_/YX\*=\)WY4"%@ZX@>N[!C,=E^GW&7Q^R]KI
M?8$,HW&M!56E;7Y@T;3=]/EX%G&V.50=X:8LEWEIS"36-'ZQ(V/GI<6_T\/>
M9%^OOT(N<@3#:G%=M:JK'^\_?SL9Z_=HJ.#Z7.O%9,05M2[<!-J@,-"UR%2Z
M%C@"<=7.=71+F)0H]I8A]>B$I%2LFT[VR',/\8;PJ6S3WE_!WUZZ?P%0DKEZ
M-W=?1+Q>L\W)>UVEWK>;*[]HN?4^Q_'?9]\,Y^2R==**,QQA6A/0P/N1?A'+
MD?K]-KFD/QVV-K-=RA.$C:U&Q5?'C3)G(B8^AOC6,,9&.0<N-R;(),T!X?]-
M*X.+="@MFQ8<-XCH=9&DKP/Q\\2L\Q]W\6#5EF;A/)\DI\0]TME$MV=Z5W3/
MQB0=FK(X+"7JRQ'H6+<W,MX%3&ON78#Y.]HWS[C-FM57>!<;PH0FV/"2"L0F
M6V7CUO/?-%WNFM1\>/OV+<?)_=]!R@]V-J2EXQS&B=;]-KU$=E7?AW&WM19L
M%5L5>U^Z<3P:/JAK/)S'RQ2LAC>)P#_4$39\O*8"LX-^N-8#_9\>5CL*.73X
MSN0E9Z6KK)E856RU-#S/FZ3'2W;VD*5PWP>=GH)&'N_^W+?=TS@"L:4RKC6V
M E</[!GR.]$=M.T^PAE@..!23UG]; =<.I,W<]X\.ZC$A&W*N8CI:LK)%#\+
MNFW*#R7^XDMY:BZ')N][G77MKDP'-%>IMQ\;;08>&&(NZ<B?I'?WIJKU-S5-
M= FO,ODZW>V=DD-DC[OF,!4>GG"+MOL. I:$+F&=R0\P%TQ2'5J@!LHSQ:4V
M0FZ2ZOW7\GSOEEOH9>3O%053"?)?K> FM(GFFF5E25]38\MLS<D]R5+V4S[Z
M"F$J^K_KO9G[B>\53I(%GGS473VQ--&=C >NQ%!$TKO8, \.7_[WD1&+ND@H
M\/JS^:\,"!!796?/<;6#6[J<PA$REYNHHK8L\..1\HZK<?%3:-Q7PF&Q^I9E
MJXS,FP&CE@\ROTY*DY.8-UEWV8"3CG7('$ 9G(<O@O/QVMO4U704-(Q::3M8
MH! 'Y8.&\2D'#3S9=,]RFGI]RSU%(^%UR!T),/*S) ?TAF[Q\0I*CAKXHFYS
M"M'YE^O#WS_,JATXE)9(O=+#+GO9-S)G5G^+B%O&W4XK*4U,XYLD7+M+%PA-
MY9Q\4S%1]8UDHEFN98/8%$>LN_WEHR,W\73S9:/-4[2@99'^;@&'SN;>] 07
MOBG-(7_.@743VN*+\I]M*_@@@G&YX:+O1[GADJ#JOFLKML_K7Y^1*C_TPK!X
M16-0FH>6GOJ;H[1MO,.#LLT#Y")R*X?*UYNTV^(:=GC?0L>YIXP?A3(2I0>X
MLF48C"AXU#B$AD"Q+&J/^F@T1@4<+4>O9^B,!4/8 1V3\;/I5,,X^D513B=T
M$G-+__2[KB&Y78>5G;7P\U]^J:=X=E>C@'.C _9=.MB>2RQ%)O":A^['UU+2
MV0G$X8!]VU^>.DR>%D>NN!??,[YY':A?]5=Z.KC)]_+MAC[LN@K=5H,><79P
MF<X4]I06'HQ&ST(I4!B76%QE',8XU[#1%WU['KQY7R2A2.X:_^XS3&V 2KNO
MS0E<!:TK#*E6VO]<M_+ 2^;3KQ27BW%V4^@'3LN(D10G]ZDBGX_ZCCDS3=7X
M=W<M;FJL/4UB$4&'%\MR6_C31\GI?4NQMH\/]^*JF6?15G=H&X6RDRH; =N_
MX8VQ[M,J_B'J;9%]39:&]56VN(WMFJKHBK,'6IBB@Y#_9F\*=KMUD^"4I3C;
M?C4J6)2A0'>)*R,\V5ZZ34\VC7#]>!%P95X:]7^GU?U2\PMO@(ZAEJC*LV,[
M[.\A@$(Y#B-'5[A*7TJ'>Q]TI^"E.M@K?N8-)A(V,#(4,.?/7]Y-+L>ECP/N
MJ>1Y@;<*N( &%<XK?R+U^T)GY9?[Q*=F=3Z/>D"^B'Q@Z+#@']182\]-PP0N
M+Y%P_:R4T0CA!_ ]L',-'=,=*B5'(/^KKQDZ=%P"U.*5@]_CTMUFK'0MUO^P
M)=@^Q.[>1-6FYH(>R4#_=NVS3XZK2!SR6+</_ QP8''X.HI'9_,ZQ<!P]OU2
MS>K3:J@2_3C9YQ*PH\:.1CF/,R\,TF6NSS:LQV!(:@7^]\/UUYIBS',<8X^)
MWYF(5&.]L;6VPUHD56&@,V*70!_M:^>J-.!B.:_8+,I@G_GQ=0=4-%2?^@.#
MH#I?OSW;)8H^L% @DK;C<GMJ?,S?.  /L5X]$0;?)BH-/I=$1V;0N';OT.#$
M2"QQT8!&2/D#$?/>A9QH1$5/#OH))WJ4KK79,A3:RE.^T?D+U#WB5?YQ62,5
M9I^_^HTJF.8Y]^%&]\L9.,T<3%(8W&\FII_^L231H41&QG7QT!0&1Y_"+M'3
MXWD2Z;"]@6X>V#G,S4[Z#1?)<?\0^TU/&BY9\Q!BV3FVU?AOWOJ!_%49@P)2
M]_.H1X S%3[?3H4D8-U'^0%;*K*O^S2&=T8YQ-^V=XD/PT<^M!J4/D-G:Q<9
M[!8] O4:@_N54)P&6ZG2B02,9F-S XW93&VI"FZHRYG9=U4MXH?<H(4-'H%(
M0Z: 1T0UH-#;+0E3 R*HL&2Z[7_SM%.MR(;)@505$2*<OP%/.C=_JXLNMYL5
M4CY(Z90?I:0@RK"]]U5>/ERX?B;'@]%G<99],J^<P5?Y3S> KP J[QZ68,+?
MHB\SN*L8>C3;6*TCT)D?;>\J*/[LSI,-*AH'IS#V!I^P/C_$ PHH;R81X^X3
M_L4^6YZ93-/W,W2U2:0(]IX&G;TO+*P-V;^^=!H-Z4.>A"K0W :[^)/?+XK-
M.#K5T+3K2_P>*R0$'[JLG&3E-E?<#5..JN)?O__*M&6B7>-7%,.8F)_2PO^I
M*.!(%-_K2U8388Z[R-/WDG-WGS;3V9_\J=A8I8W&^C-DN\1FNL1-*5+:CH:Y
MYE-_N%1T[HP'?_G>F<$P7:E.UM2XE*'RU0_?-+OI7+D>9&?/G$/6;Q-1@,D*
MSC1MW:B5!D[YHX3D8HCG!*M_0:H6\^"+UK!"_*)S4,]5V];8?YKY>K><3OQ<
MAP#RA&2,%CDUC&+$RA.^SBACF@ZN2Q8(6PY['R&Q'><B/!V2'B=M,*'UI?$O
MJM&<MS^\? W)'\RU4KB*P!EW^ 6=ZM@6W+/Z+",3W\1ZLIOKXZSL>7%TMP)X
M4H:YY:^W@S"BJI3'/]BL#AFV<@&RX'U87OLUIA3NSN1R&VVQ0O-CB>GK+XMV
MHIIS]^--6U5E,O!CW??QG,QI/+B$GMH]8"[$>  0/ B8DS1<BBU3V'DE;2]T
M292X7@ND$PNEVY].2&#!'RM$'[QCR_Z&\/"*E'T<:ZD9IMX'.P48PLFOCD!B
M##\Z^/W^;RPK58-CHM2!:9I#1*?1G3;Z#:8&+3T^8!-S&R_XF\"%'K)O^A<>
M\UUX42H!Z?UF/Z2@>KK[RWD[F6<U[/-XKF[ROT@>N!<^UN4RK:F;/H3,(?9W
M@T3(JNW+$@LG;M-ZO7/$"7W<8?VS4><FY0K_I!5HC111!4KG?:P6%[B\SS>]
M$!OZL'J=#-F((Q^!O@SM+@&U!U?160,D=ER'!!49Q[*%4'9:5@]I*;E#QP,5
M1@TL]=&#]X$3]8QPI04")C.PLVOC/_4"B@P*IKQL.QJ:G^K;]C?D0O*08HPK
M!\$80QJ8B,5UBS5TSZLYMR+T*;L%M!&U^$5(*HMND()HU/*4Y7K8$:@!SS"1
M25J<0)Z<LW>^*5S\<$:O[$7YU8H>3B?U6[ CT&%[ES0+F!K ,'D(@HLZ1?=L
M)D?J4+"]J9:&XYKCVKGLJ0P5^B,5PY&!\$WSW9=*97-?G187B,IEX+HWA=>;
MYM&@O7_A]_+?P'3@?=RVU-*%O:??@;\5C$@:(5H5*E?LG,X#M-O2LK=C0_S/
M-<[/MCHNL#EZQCC4Y6[,Y%&1'S5#?Y5V%\;T8Z189!I),XIF*F*T@?1BX)<9
M7=9%NI;6GYN"@=/5*._PU-\SN"<=%A5 ;D\>/B[ RJ&IB<933SFHMC_?$*E'
M6INY[".T62)<9_3(G66[R2NU_XW,',?HTQVIYGTH 4SD#,.18BX)@*V!9)K-
M$F6FV1^EG7&?KF,EK3S#Y 2:[_BA>(!T5EI7#K7)7>2F=4YM"N8TZUCV' M2
MSEM4PC$YA0YN (X#75#:: +6#_FD*33/?!.\S'+(DOFF6 YTWIX54N@G"=ZK
MCQ3TWD\L)''98Y14Z['W*8BQ@0=EINW$W=@T:] A%/AXP.Z,00"#=%.J= P=
M=X=F&]/M;8[C96@>OL(<AXI0#J.6!_)@N90(%E8?8[G177_(TPPAU7P?J)53
MCY?4GZY2Y:#P#\D/>Z!#NY&L:D1ZPT\AR0Q2>@H#0I5@7>CF?=!A3SF,N X8
MO0:L^@H5QH)1;$YH-2()G!X2-],8SC"J\,[1B'P]V/= 94O%/2+!7T6%G*F%
MFX7?QYYAA-%,&6ZTL &(,.86?22Q!(TGBN.(VX*8.]WY=^E"F^4)4*'7OH6R
M]<E6F:$Z#C8%U"O;FQO5I)/"(*T.95?K$[_9HN%\_G!RZJ+T.,L)6+V'"0.=
MY3]"HV3;:Z:C1-##3 'O_?*^T?A,!\:M>N#EODL1=?W0UQ0L!D1M]PD_<G3Z
MT:QG]J+[]LNJM ".ULS<1-:9INZZ7,"; SCJ4JHV3!OX&4)-3R!M][$ WTR1
MC@NG#5&EFOM6)D2LQV4!BU+?75)HHH^/<*Z7EU^DT/>-CR*DLHYX\NFY*.IK
MV?M/+[[R\KKWBGOD6WWMH(VG;.V:\<?R.^S+LVG=Y,Q% 7I*%_Q H=_9D;A$
MR_66UH\QF6S G_FYVP:/T\*+FI/;-\^OFD?KWPPK0SM:T@QJ:B;<W>V##_!*
M%J:M;@TM:7M/L>3<L-#'BT545!(>\@>9)*U+%V $34$1[PC1#!U*LE@I,$L>
MUGF_S8W';02\\Z_V[]#W*-?,<\O)=)R*6#<PM"]Z>3&J??S)R^7"%]OI)B#&
M0R"#525+,\$+%]6X,%JSW^EL&701R\.L#AGZ114S%9VK"!E*\T;_L3S_H-MM
M]7$.6$'T.],(;G538^;XR8<UF;+>12VI78GTT8WQ@W^BQI!U%8 CW6K9#P,%
M&M\ WX Q-(&RE2D[$>RO8$;GWBJF$(Z[^(PC?]J*#R1*/]O5ECZ;&H)V[\Z\
M0DGZ4QTJ?,A6)NLCJB1^\?C6-T5.K@_]"PE2]@LO_OTCF^E]@EY)03'X3_1V
MG^F2\(.QPT7^&#SZY0BX4> X$=(HX^R^7,E3R!F,:ROP4;O(#25?%*3)OT;J
M/YQY/F[\1M]^KK_<&!6:-3^R)UU DV!RC%=A6-&=#$ZHIJ\<]"UQ,7G]\%*-
MH[%XKC*:V1-41#&>Q&Z9[$BWF\5$^"L_?M?1E/=O3J267(-SQ3F!T8>A+&]B
M^>;GQ/_?>#--T37.Y+KXC;AOSZI\^4P_;<J^NQ:M8RRCF;9@_^5%HJLQ^NSJ
M24E)R:"86<B;TI(\WY]E[65Y:\V(ZDG'+;SGL3OY:%/AG6=7G@UWG-_ZE0>I
M?_'HZN%JQD'!H,+07]BVD);@^[*F^Y:G9\*M_?MK$I1#/_$Z/DT3L@&]577U
MC+_WY)JAR7P"A^SGL4J$($,Y X?HX:T?/"OQVLM#54:U]I.UV"/Z.==_S@[?
M!%W_)J,!C38Q53J7(0.[8Y,ZS1O+[CO$_[DT6?<9&_=.V5>$3&^4V)AJH^F"
MP-6)AOP"/\LL^^G2R2K_C9&B*H3 U<!*YRJ^U\,5"__<T G;*EM;DTVZ\CWC
M?(K:]9L@K3'8UQP)>Z<'8;>SKQQ+$E(N.?SVH)A'E*__^F[P9T9=]<#$.M_.
MK8?M#M8Y$%74Y:GS]2\XCFMR-;^<^]]=3/\OB['$HJ,N7T(QMD<3_J#]Q]B'
MCS2KOJ0[(A+%0?ZK,J+,$'M7,-<E&>]GS;HD["TEZA$(4&PF.MLNLV]</K!B
M!;3JN,5:*CX&=KENLCII6\"II[QQ9\"6_6%(HX=23*NQ2WR[^MJSTG_O^4XE
M%^BA/ZL8]\-L%8E\AI8F2(^&*KR1YZ/EGVUSDAYRG4[R\GB" 6>M7_6[DNG-
MTNVQ(]"YG7O"/N&/BF9F1K[*[[C?.SYX_E3VD-EK@W8^_IL(W"D>OST-)L<\
M[0@TN%2+8PA-[G)/_/GKB&@!7MPG0P1?"-E[M=!T!E#LD5T2]E>MN9LB$JIW
M!T791/L\W)]M$SZ,LE"^%:6$L05NT@K9'/W-![&"T'-D!=-OEP?]@R*H?@CA
M7=*^,.>/W<_-'(]BW_TS,"W?W0X!+I@S!(H'5IF<2JR:?P%LTB)Z]=(J*833
M0%8/]C13WE=/OK">2#$0H6RFB.BQM;[5=/FG<<*],0FA"?W<L^5U72SNWC/C
MP^N#5[:0<6D6V52?Z>J8D;J7GN=3=:GGC-80E(L1<I8E,I J4L HZ=<5>\=P
MR'"'7"8U\$^0Y R*+X% ;,T1X8HILJDV<PA>O/C2_56I?+5H)>DB=-:O#O[6
M]PBDGP[HV2Y'CO:!YP]Z\!RO.G+\(>3<7F>=D&=M\QXH5F1<<O'54?]<W2F\
MX;,;+?.V*%654[WU#/*0;YU1 2<W,)7R!^"TNTOS$,N<X+9D,R 1]=IG0F-%
M<_+WX?DOU<M#.7=4\@RC)</1O^P&?VTBAZ"B[ZT&Z+%RCB9V&*EPO5S;<KV,
MY^<4%W<S U=6#B[J!,R:_U$3NES)W?OG0I"6LC7Z>K;\MNB7D4WOS)7USMVY
MOUF[EH=)S"O,+Z3%SF*&Q.1OI$SOC+!MERQ=(5%+: (#+W5RZ=M&E1M,)46-
MAP1_JIU_6Q?@*7F9VI%,7>I-AS!. "^HZ2S_QO?;K1A8[7V<1/+=Y=<0E6_T
MX/9Z\\5%2=E6>))&OS@@M7Q1Z,E?W.12S?;F$8BNLRLZP_#3B8,JO0)^]2["
MFFH06"),?KCT5<=$1EQ\L=^CYDLR6O67LA(^-4V_MT#J,\?ATM#  Q.&*QT[
M,)I@ZEMX@9[]5=W8RU,J>$%]8.QD34UCGG&YO:7LZ:*K7X'>EA&CR8<S2C^/
M)="74VJ^WKP>JPB(&9WOI0!^5WKN!?)2\_X.2]M:ZG;<+:%M/?\N)&*O=!=!
M4LHW']&X+7)"#:SNVW+;PYB>HR1@X6EG/_[\TI"J<9N);KKWU+=L@MFEE&)_
MV2_?)K\.0>-]7D>#M5;O%;K[BCVKU+;\I^_MCFCF^^B@O+%ZVB&SV$>[2*@]
MZJ?3H"QQ>('7TD$QI3W-V5 H;>5D"I\=UJ?MH04U86#9#X33=XS_DC-P"VX6
M3C <^T;'%)Z9;3S@YM]!<@*A_MJ#MC,ILJ2?>FD$><T#_?@SQX?". [?ZTKL
M9HJZ0Z9U]_@&=,_4'TLDK^(&/84"-6422],JS\B)3F8[6+Q9MGE8*3PEN?'<
M>J%Q;A]\_&$AGYL&(QCC6%UX;^>VL&U:CB-,DJ",,%ZN(-/5>PV;>#IO6DSD
MG!<4<KS;'I/GT!"^7/(.4RO!X4^UTQ&^_/DVJA/3=.V)^X=C=A4G4FR+&# @
M<!F<(JU)PQ+5<(^ABV?IW:F-C@@98I=DVK>;@CO&TG]7=40DBAJ;&K/X1Q^N
M[MV2>A$M1M#-,0PZM[CAD34<ZO8K8*$=E +JK$W9'. ))U@!"O3T_J5C44H
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M8V<YZR:]M(->3K)P%J/@[A9RN-FX%KV*N?BYI+DPZBN>9H%*0C:K$*(;L&*
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M8E^%NO; G):3:O^/7R/\[V4=DOU9_C;W?,+ :=%?VOM9O7M_I)0^,371ZY9
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MOK;/3,DML%6DYLQY6_G6B7>,'R^%"= $[D2F73'E=UV(F$+RUOG49C_;FN*
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M.H/3H(P7^I>U6?27^,8C8Z@80'FFWYF7ZQ QYWD@EXIY@O8V4F%ON4WKC!P
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M/Q1=KL5(-,CQ'Q9UYQ,<:CID/2_X-:SOF<TN2%@1#7WJ^)>G)7I".=J/J)Z
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MY^5]I)2K3:0V3ROH6RS4,F"15EAC[S7Z*8/!:31\0&9&F.4I=P\7?QYE>*K
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M8;IAZS?S1V_AZ<*B%4GNP0FL(MWD;5/T/4^5?*46US?'/_GMV7#P;/-=>_$
M)6\"(>&2V@I@DCH8$2#N?2AY95!EQA!&V49T.6+E'AY8T]D0_MH?&ESSU>-Y
M66O.06?I\^&6#*DM L!'A\03CJ!T.,9 7"EB]?TN2""HRRZ:[MJ]=W6D8[R@
M]YQC)#GCY71]P\?@J"AX0)/?8@A;H[+"/Q0>=6"L.4\%5L*C'AX,9'E( '#F
MQ@"*CZ77?PCI&DKWY,&?"%XXP'':0Z!Q;-'".H5K,(4Z&O@O/R-"I>)-@.2Y
M.)O.I@DQ:^<K!1VW1'?POZ)P*D[<A)U"PIU<MA%G/U#!1&W8,RUY_M/XY$_]
M@H0(L#Q@T!NI*%?@] 20P"L":"=69D%U8,<SEQ_)0<W2#.,9W?)6A[:['RZ/
MKF>>^KKWQ]H&;W7J.\5<'4"=RI?<94E'\W-T668D(]F9?N-]0'3M:BS=-8WX
M>+Z?C##ONO1 XU7SV.:(Z)R+I5%)QN/I;5$+P:UI=)!?X=5_>OV>+?"U'U2(
ML!NBJ@\FRX7X&4/:F+W U.;<3LA4\R)@*N:12PP+#!ULC"_I-7K(-^9;HNK=
M.NG=%AMDKG-*]8=/*2\QROCLVT;#T>F-PTR#_K-(F4D\%'#9[M&76,SL<J6!
M9W=!-UHFD%)HRH;,E>E:2OF,5]OO+G/?@\759+D/>7^2F_NZ"%+RGU_PIBID
M";>%OOD"#&VE6XL@P"9,5 ;%.@$%;@+<2P<,H50A&#VO;2"P%B8:$"G;-\U5
MG?[>WEA '&N>?BAYT]E#I^"AHY3DD#8H.INEQSWLRCZ*U 64'[&FT6EXN6G.
M23(\+23\D$[[CP([EG 5Y5TVY])K%__77U<DMSONY<Z9H&8>OB7Z_8[12;7I
M_2?9QO;G[ 4>,4E4W[Z1=,(1)(S9.$3C)GC1P(>644J= Z61\"@OW^KA8+A$
MX;S1ZK)^-,UCI>#,JT3R@$#G7V2MJ_.W+-I_'>>8%NZ^_=Q3+%(&2@+IPYQY
M8FA-9[$(EUA"E3@F\0K+*JX"D*+'.\#(A1X9I?,>'ZOF@ *3=TW:_JAC.:.7
M5U8E!HKT\N1KR]C6J+Y%!</(-Z@/BI* ,GT7M!>P,P,DF-LT:^)(LK$ABZ?N
M_^"D4_Y 99&P1J9N\V-8HDKBUSE$[%_!F=H:E\4O/560IT1#,?-]H.C875";
MYUHM'(OX;8:A8YZ4%U#S4TH11211EY6]M!EB!S0]F%'/D?Z76<J?\Q%N:!JL
M/U+^Y=+IF9G67W-#6WY=H^ \9#C/%Y9P!ST/X@67T=*W@6(J6L8%Z+24PH Y
M1M3N2RV6\/Z)?EJP:F]A'K:B)=V1'WXNKS;PX;DV&P^+D%Y62-V+LGP^I1^\
MW-H?QQ3W;$+W06:WKP,%:E\1&-ZN/-.,(:QX/"33@@%S!2*I.]"K#1.&9O*R
M+R.-CS._#^_D5Z%:SZSH>[F@_79*AAEW6F/$"EE0CJBJ6S<S"@'G 8 X7@%Y
M%JX("-P @ED=(T38X9(?Q([%I#7\<1?.U:XI%&2Y Y<<4L&,3&TIMH&^FMJ\
M]6+"1FHU.E*0G)&''7^"2B:R@[F?LH&D/I30%!<*:%]CH>.Z+KP!BOH+=;>J
M%1I_.N@KQ\MF)1_KFESBKXCN).9/E"%BQ]5G3XS+>+N.'4F\ZB%UD7=26=R!
M!8/NB6;/)$PSF(@31V <TERCE8CW P9XUN)6YUCSBY;P"1?7-]2V">7)M;*H
M';7 &9L:)]>O;O[9\WTYYI !8R7>/%?<5IL 8N_V+DBNSI$RZIENK *$4K<
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MX4<>>QP<NWTG^/3X3K<OVY>W1X6N'0Q>S91:1BV"I4OJ>0IS#M!_4QZ.Z>!
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M I=P_MN*RD QRW;[ ^M ?7&8PB<6> ]'?PS)< @^W@\U=#;ZI*9)N10J:,:
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MV7XW?%I6VX!IW76L^87>L/@-]?_#VGL'-?5%\8-1%$1Z%Q#R14! !*0K+39
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M@OC]7[[TN#MWDH7?7*FI.'9>X$?<_"!+-'K>.A4COX+E-#J3+[<'>8KMH1Y
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M\LO*DLQ6&B;VTZW,71H;VR8Y7T=UVZ@E7MB5;(EAG5-@AFE[.^EL+I49W&I
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M2[SLK6=_K>+4B=1S@UA/&,N"]LG)=;<)>Q.;W*'%CE"ZS=XBRWG,RZ9'">Q
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ML6_TV( W:_9]=\U'#7MX>?%!VQ)_IVFR_#BC_\WK_X\ZM#?]+U!+ P04
M"  V?#=5JSR6A%+F  "][   #0   &EM86=E7S P-BYJ<&>DN7L\D___/SY1
M2)*<B54J%5(YE69+DI!6%"'V*LDIK9*,9@LAQ"K)ZT59D22'%48Y;#FN$G+.
ME-F6Y+!<5Y@K._VNWM_/Y_UY_WZW[Q_?V^\[M^?M-MMU/9_/Q^/Y>-P/UV2?
M96.(-:Z'7 XAY.3D$'_!?PC9",+QSW__5Z\_D_S?SB$G>XM05T+\EKLF+[<1
ML4Q=3EY=3M:*0"(0<LO_UP6(_WK)+9-76+Y"44EYI0I\ 7T-8IF<O/PR!?GE
MRQ44X&_CX.\1"NK+UV[8Y;!"X_@9Q8V7-7?'WWVB9'S@59.61P^PR?+LE03E
ME=HZNGKZF[>8;-VVW<K:QG;/7CO'@TZ'G ^[N'J>..GE?<K'-_!<T/G@D-"P
MR*M1UZ(),;&)-Y.24VZEIMW+NI_](.?O?W(+"I\6/2M^7O*BLJJ:7E/[^DU=
M<TMK6SOKW?L/O7W] X-#GX?97![_V_CWB1^34^"ON?D%X2+T>^E/7'((^7^'
M_K^-2QV.:YF"@KR"XI^XY)9%_[E 76'YAETKUCH<5SQS66/C[G@ES0-WG[QJ
M4C:V] "TSE[I6:F]R8J[&?P3VK\B^S\++.'_5V3_#NQ_XF(C5LG+P8<GKX[
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MX$>^L[>>KY?0R!'73U7@=UR=]JE@H(E1]+1ICU=9[QE]YM]>@R@W=''@+O6
M4,"JUNOVJ=,L=>>5L&R(H(UT=6F^J9>\8D88J(2>:TQ0:73DRQ L4Q6_O P;
MQ]6%H1&7HWG/S[YIZ"OR2C].3V5/'/U'7^5'^;@!=AXG.DEN<I)JDS[9#8DU
ML<WY^R1%TG4$/I>3P!Q[CGNIV(K_G.)B2;AFJ.,(N<-:-DTY#FQAD94/48I&
MJG[TA$C/EX+(UE2S6M\JM[CG4[6VMKX9K$?Q(BQI%*DH0X3%D"-P*4B8]"Y@
ME2=A02_>!9=7NN0!*E"$A.I;V+9)4; CN(FLNF"T%51EMEG<1BHT6 <_>1]:
M0;A^J"^WNY5D\OI-%;-Z*.I,% U*,SP[X5&OXP.K W>7R&_59U;TW3^Y]_K=
M,'/ST(#IW!UNS^I*0\SV95W.#/5I]' ]L1"V6#7QZSJ#Q9^8><6?A;:1!4$B
M-^(F> /&HHND 88<N-@>=V"II9E=VRI#L!6%29]0>R_FDE.LF9KHPN=J@O=1
M+M5O9JX:/"^?M9I6>6?$.^QRV6AB74[3;"8'.(:]C=,5[P-.PXRR']X3\F9=
M;6H@:+84G4&REO;+$$9HI'A?,JO%UZNJU%XB;-Q2'G/%S+JGX'3HJ&%=9>]L
MQ(+YT9\?OGPY>,^2)=DSA:O!S21R+3)D".#H/OANZ6<90HVQ=9I:-2O6W"=,
M!8\V@BEM,&VOE Z@=WS"G)_5DG8R=O<2U7DRA!;Q,"Z%(5\-,),;@GC:/7@F
M%TL(=^L78\:P:Z:N2;6J&7%.XWUEXOJWN!IJ$T5%' ++MW,F@E 10=K%I"NV
MDU/(^C($7NV6=(/D*=&PG$4>PR?A*F6(-OR-44N@NXF29+0;M!Y*0NVH4_U9
MPJNO-^U$<FG"J\%O][<],;A^)E2C^W:5GATM9]N3F2#7GH /IWO*BDS[HY]F
MI5.V'X_8EUMF%OANZORIFUQ;ZUF'KWN*(K8L,/V9QK\3R2.>PH53%17>PF9)
M]4159;H@VBZ#"3NJS*S0GM#9ZSNH$2\8CQG;1!M#O6OO-#;F%YJ]#T6-F_?B
MJRT/W*4)JD2Q[Y]]G=XI_4RNR>BB%'<]R%GJ_-?]WK'F&>+7OZZ*&GU0WI)_
M(IX?.7)V='#JIW)0\(&T=^]ZR0>8E32Q)H:+3VRPA(&_4_*0/LMVY#*21#9?
MX'.U(L.L#GLL.N?&@BT@(H1-\ 9+=-HFT6LA4]Y,K;Y_>]&.5UIM/^.CQG!J
M7P,N5-<-[-C2]P0G*,UYW2=Y"!L'SO!T,Z:*-D,KHX[(CY$3R6=P*53 '9M*
MEF>&8R&3:\7/.R/ =+Z.(+X<PK?G'F$_Y*SH3IIEM?J364;6 \3-O$>*/''N
M-VTILO=JC'&$(W9NLT]=4.9XQDE)ND/DB<M%VSRS^6ZC(P^R)./\*.$%J7E4
MYYF'S.^A?DYQD_07OJ&F"[597E63$ YT%MZ0,*2Z?N+-=\EC3W!(]-8 ,0YR
M*R3Z]\Y3;F+HWBR<WG2 ^LM!OV->@#>E>B3B/'O"&4HI9#W#7JX(\=KVPK'8
MKP._*3=9'VO*D!2*X>PLMY3\(_8'LIJ,-DEJF6&4=>$</7(P+@E3W9T<03*0
M?D)6;V%:P\IK1TBM[\_4IU,UQJ?3/>"V3W2LI-^!4LMG)GH%AG><2XX\S97$
M07M%)XC+:P%6"VZ5>+VD@K1"C)"4!<&UJD[JYE1U-V'8R/;<*0*YA:E #L$I
M$7U!M52TN=@:1%)XGQ:^03$P(B'5QFOZ"@>_OPSOK[58Y1VYKRP:#?>2H!8H
M;.74^O\LQHO.DCZ.FD!QH+Q4F2/2)*Z6%))#98B5TEX[YDP>F-=",H6B>%B]
M:>1:]$;I!Z2&.5%AO,&!VTBR!G4RI6IA=BO2(T'YEEA.RM60ZKF@ZY'/G![N
MRBKVA&V<FN_.EI(K7;>S2HZ_-S$)N^:5'NHSQ=<Z]_[4U?XQ\-?%B&=?Z%Y5
M#?3ICNM%18,CU X=L:VS@)55+QR4T%J2@Z(PU=1VI^U3KI65MK<=C4V7&:Y;
M<6CYJ14*Q_^WST1HFZ!AB^0MT "8AE<@#/E _XR5D+:+';.:9(BU8H>SN0&-
MH$'+6JCJ1,Y!\#NSZ*E-1_%T@-DK KW35:&VQC$ZSBIA\/.>!(P5K;@XN?ED
M\<JLIIZ;Q9I?-,T*2>E?)B=H1U,>@%I?BG52R_HW<76TR_K]?])_QAW%_'GF
M$\<9"10V&&;.LIWY*@EV\WB]2P[B):/E%F);;\$' J:F6W#-89K"WL=?ANPD
M!MWEW!W:A,1G_RA'%\?+$(]],1!,%"%&[%J)@O?T /F7<S\'^(JLU<& N7\\
M'V;ARG\_^2E"UF(%K78D]I_/I9N*V]$D)N@3"0UU:'H0S R\,C74MMFO?8@S
MC1CQ.["$G[HY-1A:=*O\Q=1 =0##><F7W%1*U91N)YZ#:^D:--=&U9&:$!VA
M5[QT-78]+S,E@H=/';4"32A$QQ4I05RU%,_//X!PTM;^*/NC]CNZPJ=+T\/E
MHH1NU]/K2XQ3?<^&+YVCC5.DJAHRQ/T@L;-]MR )Q&-2$DFZ<DO>"WMQ]\]?
M.C%G%F5U[UBKJPVEN2S[_K6^;Y37;_>BM/6Z+D;T8G/]?L[_7JYY_+3)J3^/
M__Z,^ .WY=S^Z[VG?\T.GC+BER*N9?31X5.KOLWK88Z2FV]@NJ^SF$#(K*"#
MC[F%6R/V?T:"G65ET#,J7PT)3;3;Q54\P8.7.'ZG"*5ML8S&4#S!G+@5D#P;
M53VP=0?QP;WE^;;JV-UK%CK(K48R1&VQQ! SD\B2V!'/3< DK4E!9I +3'),
M7I"87&FD\Y\W#1*"]!3M/,KEX:%=MR_O<MUU/&VIH"= "%'%>\<;BA'?OOWH
MK*U?K/\J,$5.1,L0:ZY+1ZGS5^%=J?7-,/4L?\L0S<9I&)X:>:1/FDD5.J!Y
M0_PMBOU(I>_,'HV.K $TC)3)9%_4&WO/!;@+R=,VD3*$ USOS4Z_IB51K\GG
MQC 3'V6(7_@<MK0.!N9]3"B1(YR7(0J+)7?(@ [?!(.%GA*Z+TBMR*U(9&WQ
M<9&G]!V:\P->G8K[K7F9$B9#',3NP)Z0Q$@PV4:G\TN69(@DY'\L)"4/N2D*
MC\I+B=TRQ);?$MKT.W@=*I0X)/SU[HS(0\KB0K_;J.T[WR;><8'AR_DRN^T?
ME\V)ZWZ^/>Y*'NO&CWQZ18;"J,-*>Q$ZVDP]YP,^AUDW'99'9M8?E=ON9T;N
MT>G(RO=<X,]+8Y[^^B;])66*W=UXJ*_5HQOSPL\#EV8A<9_&AYVK.6]*"L8#
MYN>]&W.82S'(B6N8/Y._6Z7&SA%B5LJK4@.A5CF+Q;_CN0CY7>,?!!9BGTG_
M"5BR]5.A;3)$2X0M:PG3PAS)$5X T#F@7U,M<C5CRZ14IQ$:?NI'F'VKD_,R
MS):D MJQ(9=-_0W64=?#0R.CBAH25%++SX0F)K')GTS^\U#VCF,",-B)7*3Z
M^<KHJ.?U]<-CH?2H\XTC5W[T7K^8]</C W"<G>T4SNZEXL'?S&E'\4]GL=ZD
MB"#?+7 3K=\IKQN.O7UF_UCV29SB\Y4?Y7<+V+K:E([ NH=P9.21=VLX0#_S
ME71\4\(@67<X_JQ*4C"0OKOP3GVVS]'^DUZ(2.DMTNG\TH4)\:XEC]]78HO[
MJ$#WM!=$M7L Y>(C@!-+IM=Z_ HJ?YF(C"TN2MNC(VS+%F6(MS)$Q0-,UYQT
M_:*D(5Z!U,^L5/JKZ"2C$_R[<AM+CG*S\LG^E2^2O"]&F^[Z>@0)!!<+^&\H
M8FO;F?@'(LX/LFYSC67M=M2& 8<@A8D->==<.LD%MCDFJ.)IUJ1XSF7\_10S
M@-R"+#K 0PW[+<Y74[;+$&<3*QM[!V6(.-IWV^R_?$-[2\[33_<-=EH+Q7>E
MT610L5; T]PN[:>^$H<57WEZC:P[$!T1]$5'JKY6*WDV^TYA?&.TUC4%>#.U
M@F_,:&&1A#*TUR2(VFZMMVGM490QIS1PWZTO,=]DB (+N#/C8 .Q2EH=<R7R
M ZF!1.VVXJA__SE$<_L:BREQL(XH&\B7DFI]U406RZ^+ME-M;7N_GNN>>X,!
M@FD"WBE;L;7%#+EAU44;JM[J$PM'U)1*V)QV.S0ZKB4-)IE$>U@-[H\FM\"-
M9,)0A?'6;^^.RUR$2BVHL9CI\GXOYD?*OW/P/YNAX^">^EB\D!OF4K+-3%/C
M.YWVLZC\GG?T:V;E)=6O/7G7\1BIV[R(,E>/^1/E]X_K_FCE2N4[9+UJJ/W:
M_)@\=]4->^5 COU6V&#_V03J#89N.Y/XIFL"7RD^WU&S9IF?5'WC[Y5YSAOV
MFYU8<98E4?^?(H5[_.32G%17LHU<-MSYA4'7,=EQ?ORFQT5_R81Y!+OCG?;)
M^-LQ)[>GV4UVVM!)D61 ;:[^7_G^_N3 OW:R\D7"$])[D'*C994FN7G#RV67
MVFQ^7T^^=NW)O[J\\P#M7S62I'O,3+I;M92NF4G<^/5@F-^+!\MKDL]BES;^
MNT2=_Z=:P"WX;7M13K9;?HXT.4H- !WA(9P,@0ZS<'$G>4K(?Z#FK@RQ(D8Z
M*K^!'(8;1BS;U5;<OM_NYYX1KEP"[OL>>5VE^L"5\2SI*J&D(5,LA:M9L0L1
MI$W5?1OYQF<QGJM:A+OX]=9&)VSV"1B"#V+^G0<BC*J3W5#PPK/7>7M\S9PV
MUXK?]OV>U__PTA0;Y#FQG3(4PX30SK^_4"%+&.OV?A5YDMXIO-Y &4;O2KAR
MXLYGX,8JI9->F_1T-VILF?<J^G,J9+SA2,J?YE[Q=GD2K?UT9?R-"E;SYB]R
M;[TB_NX:OQ*)^Y$^_KY[VQ*X1$;UQER)I0U1 =;D =Z%[[8U6W+K8.K?&CUW
MQ&W;6_/G_3CA/&P#;\,IJ()3$"L=57U-96<)]V\:FPL'[VC_%:V,Q-_TOAH/
M\/8?3UP6.6=S#%;F^<S:!S ,)\,=(@WFU,[@= \K1MJ@\8KY2MM3'D8X5 5J
MGX?3@(<A?RE2JB<)^?5M 3LDWL;8TN47P0O]6N$E+3HJKK.J^=E(9$FR;C1*
M,MR^3L<LX/B8KAEX?BJR]HF)=#=,5M\F,$%01V8,3(Y*F9<_QQ[_3X)36F*+
M8=ZD*('0T-+&F"N!+^)BNG^Q)IW_%X$Z+W4^K"?3G9WPBX=I[]-%)@CF^$?I
M;_R0@!S@_/NK#/$?%#POLF@_0HG\0\'&DYU(4)$I@)=TQHK62^!RS$'FB#?N
MI<T?_*\X8*[TGNZ& N>+I%7!F'DMI'@3;@=SR(\B,I&#"RM8AL@B,H86!B=^
MC_Y_>%[\;Y[_UQH_R-\GF>>,9\Q)N\_%D7EW_WL)*@W9H3GNK)#U<IX5@'$-
M3ZW*DR$:VI;.%"+%_]0\J)NB_D .[U'[/8=AN,'AX.*A3MA P<8U(4H,6_2$
MOZ0?C,PD#Z4[H5DNIQ6K,4U>1PP%/3@X*!B9NA$0VWFGH>RYJCM&W'*D:S,P
M1_H-/.BO@?$OM2OV!5[<\+IFV-CF%SFX9,5U@=AR\$%#+#ULJ-2K,73;R5+;
MO>]-;=A?YYD%;N_FMWEF;#WT<._]C>6Z'3,5'1WTD>GGQYVT5L0[:1Z3^X^A
MX(G)T:2\8]_\%KQ7/O,AW_YREV6:6!L:$7F*78'16M%1<03HS*+<1JH)R.>Q
M;(HSY/),O ;R>T94'+AJH4+<4-6+4BP=$;M 3&"6EU\^QC$DGGX)C6O7O[!)
ML8@G!@=63-K8#::& R.'&@?%F#)_?^F"NVZN[:U[3]I[#UG>GKN=L'=RRK))
M42%&)Q43/)L V^GB%,8FJ(6+;,%HBYV =%]F$O$ZCRQ'\/0'*2GZ[=[Y;=4X
M]:E8]_;R8NNDUGO8XKSPI]+N7)?-E=ISAW^M47O/3,8!'MW:A.@66.U;X6^%
M/H:8K:.J4"<@<OA442%V+PJ)74Q'V8,30B$T*=HSZ6M$>>P;*OP5YIO2#'>;
M&-77E;WB$=Y^*'5!E]%4;J!"LUOR)ZN1FYS1*$(5G 1\ 2%:>+A/["=RI^>D
M25>R>&IL^=:U(1Q5$O(TP9BG1JF =1C;U="VJ?M%" .==P2*B7I,N(942G^D
MX@M&L=*K?[05T5KL _A>2WCA$,R.P1;#9*XT'NQNI2)(^N)#T#]G>!!*"]CG
MV@AP;E@9GN?S3#*C_)W;MPP.\9QO68662W6AL]W'>L4.((YG0O'_3 @\! RE
M-D0(_=W\:D_AR?G480NIBH-(E]2+6TM:+]X*.C=1/D?S\,T4'8*H970S-(YL
MIL1++0'[Q92?45B=2;1Z#\,^7-^VG;G24$.8!>@D-43QXK0[6 %[7M5 T:!!
MDR\VM8^G@%L=A5U-2WW6MQ_CQ!)KM[36Q%Y[!1H$0 9%D[A5SF\?>?+P\=5^
M.)TPV+!DDC80. >AXP7$HP,-&XH(U!:I_@#:,/0N6_6H)!B82-]!-.93(&]]
M=V:[H3%VB&A?UE34MH03J9)ZX?,CAV*5"+ NY=%:""0#B,GE9$X 1Y^LR(O:
M]8GHIC!J!,RF6W6O"6';T"Z;I(MW:W>T)CKW6^%U1MA3:T<G\663!7&*7GV;
MC&;Q(GNQ*GH[ YPA*TEU6?S2V57D9OD7A$8TDH"1KG6;7>X<8M4-.58L9!5:
M2UA)G,/JD^3/D1_9H;UK.5@_ISYNPK =.9FI#!_/ND]G 6HS50ZRY-;>?'R/
MQU-;":DTUZG=1-FK"KXUAX] \U2USY]]RL?Y-T7^K'OGW_QZ,O?HX^']B@4]
M3GKR)8;, "HU#+&UT+C_\M"(/<9N*Z+@-N5X'R:%UOMWF<N$KK$Q1W=R>O &
MTDDSZ?ZZM7+MESGKYN;')GIO:*?M=^A2VC.=V#?]&_GASTWVUXU2?L2%R(7
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M$R)#K&C @1\^C/CUB4^:))&V0L\X+,8N8#$9M;P"*G7M7:#<0BM*J&)% .<
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MCQ\\IB(JE52[)X;WNK!0FD6JX\YZ"<XT-2313+&2AHC.WE?DD!?>2 >X;5/
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MA;@JPO\*^?GL.V;8 _#MDW73JM+'H4(J1.X@&H,&_Q8VA_<W1-XL6N7G3FW
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M#2YTP,DZB&3>4E,'8V<XT1H@%@IZI"&J@)TDD@=UO0!*$DJ*J(G+*&3(H+1
M1'L1C97) J63SQFCGX3P((+'B_"!K[Y?'=EPQ=TE(8_XBG&D7[H?<#=J*H"X
M1;266%_8+C&A(ZCK"Q+N>$@1AHYVV<0&4+I7TDF\L0W82!Q?IYB&7V6ST3"H
MZP(%3CPDZ; X)C9%\T8%'YE)W LE@'7\G'2T*L3U@.QK\)TSIX#;$B@JO2_
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M_9CMPU,*>&H@4$A&.+T!V)W[";*1F'13;&HP!N2DM>SGVU0ER-NYO!9MD:@
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M>!-=%J^UO&7]Y5F(MEP$O1'@[HJ/ CED5&P9OHKO/E>#O"V2O\F?<UF^TS)
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M'L%33_^S7LA<4?AC7=]X=Y(J<%<@'(1 R8X0<.9\'T]R7\6E,,*SI9;KH &
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M1 )P[U8V8*IY7O]R&'RCUE<M;P(HBE,C-O@$=S!J(G5D0:S@TJ,UU:R0\_<
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M971V,,J$E,N ]"UF*8"%4'K.&\FD9"+D-V"AW/]^*DI7&6HY)UR0$AE AB%
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MEKOUJ-#K7M[UVLSASJ*HMN"6O*B?6:B+_8PG5TY$%DA5R2A9RAVU-VAR>61
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MP6EV9GJJB>ZV^-.)VBY.,=RW#IND_/^Z6AM3-TI>>;S3=//%%^_9C:E1LIM
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MH)..N"I2H- $(.^%-0D)1/S?YH':IDN5[/YFE"_+SK13U)7;]E3R<'_8\HX
MIF=&4LDLV0OLFEX=)/0)R7RR9AJ]DXG#MDY)%('#;+H2QL2N./%)R;F"PV!D
M(1_!74[0]HY-&)Z8K%'--LES8(B[C\U.[JRUSH6]^?)?LQP7%',^(&\FE\48
MKI@;3"L1.U5B4\11?/VJ8111VKE;XU/><C2<0)+,]=4O_1AVRN1)5'%*X5FC
M *H9U76O?;&;7HFCW%$CIV>SG47S/<[WLM*-BV\,T[Y>?A'3Y.E.%,\P#RZ
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M6E0$1,18J4)4#D+ & LE0DA0A%"$'.4(1S@0E*J4B"0@ 1(AE*-([XD0DEB
M4'8H80LI-]YWYLZ],^^=.W,_K ^9R>39ZUG_]5O_)WOMO<Q7G"3F#PU/X1OX
M, T?T,8CD>$^5VY!UDK1F-N6M[8T\5O-OU]URD.&,/ @0HPN3C4L6M3*6U=
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M$B9,F=1!F0YA2"B'_!,&^Z\Q^Y2-Y^00F4Z:N%L.R:^2]2+!&W*(/T5VKX_
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MKE0/Y:4%%_+ED&C"@IU[#-RJS@/H%?>1!=!F<B),A5)JO\.9C]G"GO#&9Y2
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MA;(M;:_RA>8)<"VE9N'Q4-CV(#^CM*:>">_96-R1XO(R'E,%]&ADE_JM3D8
MLC>\8[:.8W+(*O.D!;BRYV3.SKYO ^:$"X%R"&G$6,;\(8?TH"99A-:O,+$F
M20XYPXZ!FUHPXY#51.*TY0I!!9O&RM&K$Y6-_KXO&.SNS24&ON_%1?/1$?R
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M1!P:SX?0,I!D+/Q HQ'7! C0;M5.7(?M-,&_Q6J#1;CK/)!"[S889V2G!$9
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MO*,^6]0TWN%N=5;V(ZP\#;97!Q4V7(SW]MNJ)N&\/KSO"XRQ29@)26<FC?#
M*M5LP%,%M-?Q )IC"P)4C+(HS$*U$_;I+\<WJK)#8N^O+N^SI3>HV@ %)5R#
M?K*B3%/M="U5 GNA )6$*D(YU[X%(F(3\*0+11[Q+PZ;H,726["9OS2"J<\O
MG5G*7!I:<_78JIC^\MK3[UYW=[#3R,HX:;7G?1Q7(1)T]KRR<AM, ,[J^5=D
MXT;&<]#<BW\FSC:C 2N<P),SZ:S0/<(58'G:8V$]WR2L<B,@F2L<"JJ%L>UJ
M/3Y$$I!I#H'O],MNPXN7U;L$T4MEL4A:^,<;]2SM.-]Z=R9,#%-J7\E6V$)'
MF:#H5%&/,=08*=K$/:@0\W3$YJ/-)[T^V8=YMIW< P?6ZU@G&F@VA!28</TY
M.B7.E0]I1X $(1:TB&]6T@203-N'1C@-5$YP&CTEO-7U3G:RW_T@4UA;6K@9
M@0Z3GI,8!T2<V$=+^J9'^EI[6?7&F@_/0]TC9K8JMH2KNV5^D[(W=1<O@*H3
M]B>KG)5Y$K!'B:$]7)<?_P@DO@!/L^_\6O;1Y"="$6QE'PISI?9$*K<A!>(5
MK0"3Q_M:53 OF*8)3:J1/5*;&R1\LQD?<J\=+XG);J;NTW<&W#S9A':X,/9
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MQ TF3]WXJ,D+)7GGGNMK2QCFCK_AM$P0QPY7^9!<Z>U7*U D<&&Q1[G1XIW
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MBUC4#F+"I;B7V,N)4]H2LQ[P>G9;EI)(']8JIYS26M>S?_RZ&^#<87:8-<2
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M+\E?*_<PK]&QX$.^CK10D_D0*9PP[QM<3A\?C5-'"&%R.Y UMI16SG:8EL'
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M;9Y&R#8W(Z&NKC.4'SR;,_@<CN;N&1UO$1GA>"]".9INT91$;8X#KNMWP>]
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M5D%#=(^:.4?4O;A^]FSR_!F,'DNW+XJ%8,3W+@$XF5'##D(PSK([DYL%YZ/
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M,&ER((]\G/!L_X#S57/;VV.@<>-D#=7-AKF5.$^YQE#S0<F_+I9VZ32>!WH
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MVW30:6I*N;&1IM&:D[Q)!E 1K+!V__K[./[1%I?\&2EJ(LE=;37#Y?5W7Z!
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MVXZH4TTAQ#4I_!>TFSW#T?>[W&NR'A$0C^"QBG^605QLUB:B:$%O=M42^*=
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M;;V7K@$0NFCUT;Z'H5*B[IWC?UJ^[B1*4\<IWH@?L>N-0(LPDVOF%V*@-EU
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MH,<:D'L"8RJN5W@GBU$)]TGZ8$/UWTK=<RA\%O+B:\BMD.%5VI [1,8+I#(
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M6AI'EF+,N_8W1UU73!S%L2LAC3%%A!^E/ZN)Z/'9R?FI/@WKEF;J=MAM>(N
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MR*A0!O\[C)J9;[I,S=!BY6$TV0H^G,%[V'TLT,E\U;HD\QIF&U''\K#G1?'
M1/6<ACM!;N/(05A^QJ84NXS:M)I^K:8M'9FYUB6L3+#]5DN*A)NDN[I[CA'
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M+RX+Z+IJ8V0;+$M.Y*A;]I)TGXBQ;Y@(\\^FC5]@F%1_DBD)1VS%12EFSMJ
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M)6W:Z/S$X<<*8J!=(>!#?XAKF)"A8X?1SD(/B!OE#&8%LLK.;\*\-F%/!?K
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M%ME"<+[[T"^!( 5E>0BY\0K(C+69H):PB,,>]D.\4T O5#':3#A- WVI_Q9
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MT0>U%4H;Z>'60ZC2&>9>V@.$O+&'A_>X&J0%$IO__.3AZZG59D=JF]+ILM#
M2MB6H']\-77F0^-QD8]Q6&&?A0L$WS"R!"/!9\1VY '!5_(VGB\8CP$HBVX
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M-?U'_;+_Z3RO+(_^:U09]]#NW)=L_]GUE?F;7;H=-]IO?5C*3<5+.UB<3)B
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MF)\J6>G*[(D!Q7CKU!\PAV4WIV2S/U<6,N9++NPYF?L$I4SSP2($HR-ZBU&
M4_,F;*<[4@Y2?.?I*DG5KX1DG$%2%,]OP@YZPF7N,Y0!X3> 35@$WL*?+2J*
MB9[=,10=:,#<AY-H%S-?7[[I:W-#]O)(&#[/'VS@?L-NG:E/:N(@1C+I^@/3
MI$;L6T)ONL)!_FN>#@67R>J)6UD4N?D1<F#!_UT_D"U1]QZL;8%+X=XR+6I
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MV:8!(1=2)L>8X0*QGW4A6C&G@ O3)QD(%_D^1Y4&$MIY)A1'-QA317&_YD2
M#Z8;F6KT1YVIER2$@R9S( @2H#6#ZY\/,.XK$NI"0^@CE6B<4]NAG\31>^^#
MIW:.1]/HII^^T'Y,IM\,.E8#5V)6QUPH 1[5\RX+U$<=K1FF'@,*H%;*!"%=
M=:B8?77Q$IPCB:R?O)>N89//?*E8ME2G@DG:G822)TL<7#K)Z9)=CXB:R-3F
M/07X^K5EONJP(Z1;[O8/TE1_2,R$F0L*TX\0OB)4?F@:5J9N"3NWD.CCY.65
MF%[>3 %!@![A>9+/Q;/,&TCT]R[>I/](_41'##]Y"?1BA!B>X9=K@7I']8S?
MOFJ&L::43&MZ$6M/.,?(#XAZK93,:C"L/Q]Z\_U]4F(3,9&TG<":C(!?]L5J
M5]?,^=J&\_"8>O,EM&OY'SPX^4 U]*_]N7$*8 DM=!]SZZ0T5?NK%"0<- 6!
M/N$@(:@F!*4J+(ACW8FY2S+)_(O<5\XUJ[GY19\S*E:0*5MS9KW_[_)M+?J5
M6W1$A6, =&07[+[35Y#4SP?1]:@V)LS7N5F1]=,[H@DP;O^H_/3F.H$'F/U.
MT%#!3O(.U:[6_\>:D.!_-^J<!!_;%UN3RM4OO8(HAE5HOWLZ*9NT27\LLW;D
MG;CG28FL6?(MXJ7$U5+M$M%VE'2RA*-I-,$6%5/EA^I2)??.=#B!:5ID3L?Q
M-Y4;CD_+B)<PE9/[J0;[UR0_;Z=^Q7DM7WG!VI?WXJ[Y>8IT_RG@"D08/W$>
M;+MT,-M?Q#D5$&K*/6\QLQ\ I5W3'M%L#VW'[&]L&3O,R)T_M[JT'G&8WX1T
MC5P)MM\/_5_<_F=7G0N1?P7I7OU\8=WRE4_XU@7DE2L .#<Y(;&J>IV'[!-A
M[%5K2CH<1$:9-8A%C?U<PP[VLOG^=5YP>%.BASR491ES&J,_J&5@1&:[CS=&
M.R\KF57Q7J=[S3"D%\QP/?/38.2?%Z@!::8D9/@<7M9(O-5?XYW'HZ.*-PKU
MI<I<C9G?+C,B B1_O9;<W7:W+Q1+UBDTDYTS>Y^ 66O?@(X><ZA)Y:RC\_LM
M/Y14IAL95DC_<_.JP_PFHXFP5]I:E #A%&U^Z PW#Y2.,H@'<0BS.?L==?>O
MDI\6DD.L&_)<M,<(L-Z3!YB[H=V7:#\*B@JX98V'TJ_-QD)B\*@O,YJ&9?K$
M:Y>GMG?6<3^3>D\!UWZ;LRV"VWL*?L>%PJXM42*[&"&WI[=V/H>)ECK)E015
M4TJ-.RWX=VGR;(LN3F.$8DY_ 7C85F3@?NTGXA=CL 2M+$SX,MC-T9\> U'^
MN XO'Y<+K9IN=E$_:1Y[ >#ACW9Q_/:L\IPU8T":F4KF^Y>.YA4_C4-8-N:P
M6HL=(3J@"/%FUC 0RW">W(U$/$%1AY-F\L"'&&;XT"+)EN$C3!;<ON>(W^%]
M_I8J%%U$^)+3='E._$P<V_3^J+[K%6GK)=C/%9MN1/U;]NI;?G.?S3"^PIC-
MG-7R1T&09M?%OJ<=K -@R"F KD!Y7WC+L05RD[O01%/AYV<<DPR7W[]?AN/E
M30R/_QC)R_<-9[,:=8C:?KZY /_73YCXF0'D!<.6B][50G0[IW9H@E1'!*7_
M\\W\*BSN9G4T3U)8C!"Q'\IC:N#R\P]9&5/+?&BWBW53*?TAT"KKD>>L+PKM
MQQ31D4']$P*T<9H4FLI&.(,QB% 5_QO=$5'N2IE]0+[YCISDW$2V2Y'?!\I;
MH)5-@0-7*<6FL;M33GQZ*<\D6K[P/U,P*G);NQW+AKDU<N.^!H_8+8'@H.PT
M9N_*2PHOS=B&&&Y<9<MBL+G C7]%3.^O5S^$X^Y<N8P?YQN]TY$D,?K\Y[,F
MR1)SUMCX6N(ZX58_JU$ALT:"X]MWU4:YZDJYZY(A:AJ+BF4"+\HRA]R;F!^N
M3PBDY%PS6AB5_$0-Z%.)+=3]]NN6GJ21:44 Z[!Q,47\X$T$/EV^/PHT),_F
M(]K?W62#ZYDWKM/H/_)456U+K"73.9.72@C?H^:FMC72A>UB_$X!1C"F>YA9
MX\J3HK4P@\"2Y*00V!D'4&+7#PG:5?Z$8D874R*0B\I##D^N6(<*D06C)&+W
MW>+<KLSVJ-26N_Y9DIVBZCR)#$W)?^T'B@X)\^*,,VG/.+HM#JPQ%0RL<%4*
M$[WH8).3YG'AZGU>0.@?A?LI(L$>:<66*>8>"U$UQ12&/:YMV-,G4=6G@&7S
MH^.ZOU$?-L3&:--2B'GLV!&UN'::"I^%/09QK0NQD50R0\CFNABJ_S*9N"$M
M_(K_,![T+.Q$P)R\M;O.L;;$W4$J?J5D(5OTCO5=5;/V'20&-Y#9%>.^M5)8
MQMEA=_9F^ 9R166K-Y$U^0X8.SR IGVSI-0I QG^8)\5B3:>%(;BV.Q=L-^Y
MXX]B"M.',V[.LJ^YF:1,L3(MK"$5YT1'^"*!=B9!V=G\[/<NY%H^O[)\1_\>
M[O:>YGX%0USIK=^:MP1)BCT;+RY%D;1NT;[U'12/FQ_M[\Q:2GG>#9TRXA(-
M. 5$2NSBSC!;^>7DI:9N.?B]!26[DAI#YIH8-+7#RV=TL9N2@8.NUQJF-9VN
MO">DZ_3_H#R-4=Z"R\H^"^B@PP?<=%$U:<Y@;7;9B$K?209M!X;QY'2W0;\5
M-\;2OA7=).<L72:O(JHA&N3,)$T>KE/ 2^7O&KH%A\9D5,)>;\E_:^4K_=JN
M(;.?BI-9DPCHN@X#E+K3@E\;LJCM^^ *BL- >MM<3AOZ\)=1<6ZDK5ACT5U;
ML2QU=D/-R5]#E\Y?!UR]---S(4O?+#[+O%6BT_K.$>=JC4ZAJ>OW$43]D<O.
M;&N]@$0OOD;JM8USWFSU301.;^G(K?/-;YI24SM&*=W."-46N[BS%WW,^_LQ
MKX/+HH/YA0@9;LGX)8.0(,$'C&5Y!I#2=H<$*"-T%,BO?07LWP=$9%(YF@X&
M* G:^?44]_XA,L2,DDOL9O$IIJ<);4 9*8.!7=S3FWLP]E6<P51'*^*M#%6<
M8,XN($DUESV:6\/,6CD:,IY44G+)&SU 5FJTUW) H#S[@I\%6/OWL-"-Z5#Y
M*PM^!3PO- 58%A=3P+7#ZN6J5UF$==JZFMJ;7SCV5KL:'>1;C02 O$"R_= G
MU*#B@TMG#?M'L)Y;O#"']I4%B /%FWB!A*RJ6?\[\HEZEZP4_ <J]N,)R5K!
MCR:4-6^+T00*0M40Y*>IG-C%D_3XF_Y.BW(XNW@Q5XP %S_8V4R S11CX_)G
MG-UZ45II*LO/>8-@B6CVK54.VZ<PKU<*B$^T0*W_D?C&):2_U?'P3I>]7R%7
MZ]"_RBD(!'O'PQUSG36=G=='N9P"Y4X!.<4D"V"&\!?<IL<9ZNN;SF(%TOJZ
M@%-03>JCD](]_U/ W/%R9CQ5@L +E5F_O;YTFYR>44=(MR)(I&J*9?D6W*P+
M4:DY$!)$_YJ+.CRTM?I>)9=9Z>P\?,(#ZU6&/4T/.5 [B3\%>,'FJ@;M\@Z7
ME"B&)% ?C9^<.Y-3K94*KL@+L!L(1X9\M&Y%H)6WC"W06U7I*F/,3+=[WO[>
MS3_@I\B?159Q$GO61A*$8[L;BRI(ZS!F0_R6ZS"QJ)8G&2IO7.L&AN,O0\SC
M#$G%R1V6.[44CR'5(MYBZRD9I0"@.;H>(2W-6[<R73(MI_OF)(-$OQ5!"AG&
M<7?C]?X<0F^AM46Q?P@'IX#^(A'2 B;.N-V4_C[9"Y<8YM3NWSY93LDT(1TF
M=VC5N-F[<"%3<'9-"&1[2Y?QJS(B8L\Q7/.N="7\Z1%<XFA^V[N:]J.89P\V
M=[A</ C+H(E]F=X'L4"N42*(\LFNUZ>4'J)BO*VG(,(EBQOY&$?'Q3&6+YT%
M2^,V"55O1&R'_C:OP.15BDG@B$V9@Q\CP,W%8VM]L=2.H2-0?WXHL^&C;T6W
MTPWGX]+CTCRS3&'WW$A6')D4";>M[XCDB<T*,E%" E"<I'U=+\V;WH?N@A"O
MPH6KIK#T/5%NY/U+BEX^]K>&'$HL[8G5'M-%AG WV9[)P;_J;<%K86$Q(H<N
MJNB)KQ2:Y 2Y59.DT-^7AG]5=5?-)C4KK:1NL:!K?1&QJ'AR)HD)MR=^ZM/2
MAP\J3P&];OW=M&=_3@&O^H%/A(]4A;'O3P$785=. ?^:X'_;Q%]B#5EBP[/N
M]Z4U]/X&"&;_N-)\T2.+\W4W^(79'4:^O:\7_O[DP'8:>E)L FTD(YJQJ"5(
MU1&Y /9#F_7,D3%U8D_WS'G?*> )QRE A7AL25/W[C_K>CY2)H!H\J"^*E6(
MYYA1Q@Q'&G=#J+,)CE>$3B1U*R3>?%O:!.Z=\0S58]MY]!E,'V'^MS<SZ?>+
MN\](@.M;9Y6?)KB_]?"???V<H=6!X=?KK\&&EU_KEXS0-ZPME7BI/5W]X,W#
M\!<8T[YTL.NF:.0,>C?ZO')M,E/QF.U72KNQ=T1$=&<,ZX$V1?48!)8FNO4)
M)[CQ0>[BX9QK2T(4% G7@^,(O0:T2>HOLVZ8[(@\8]Q!1Y>B\AMD^ASYK6=A
M]M<[=KLC#N*SO<=2I)>[*1)G6F#H$G2@&$C%RF_.4]WV]3KX=G2#.[CY=Q:B
MNYN/CXK@1R,%IX")43<*'1!<.PCT@;\ ,L'\S&-Q5Z$ B#\I'9ZAS0,Q_U%)
MPJ52[X8$:64O_#07"]&)K%JWS7;"^:H/O8&Q5,++_ XX!F,J_<)54,C,WP]2
MEF9UP2PN3FB2[_PD=F*D:4_K\(S)[YXE7<=)Y5GZZ%+\JV&])C0@.'-9/NEZ
MW /2]IM:JB)%*^A8YT\7$WI&9*I#/N#8P+S<><-B80WSIB(!GKY%51#.R,*J
M2?"O1+V-WCMQH]PG]?<!+T$%P4[XS!=4+1 >Q@C6,:>-38:"Y;;#)$51'(::
MJ(*,NABQML2F.K]\*_,:_X+Q,N6ALIKUPWS4X2R/JBJ[N43YI(.,,@-!VKW,
MB WNH*?XJ30GQ[V+M]U%4ND#XO"#S<&7''>$10HH/*\JS\^5CN0)52XF))S4
M.%*RT/V'4(&66;DPR:TMCOYMTH)SQ6!YH_B+1-4,]D/+ ,9?E[P?>?J1=UC
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MK0FS4.4] O ;A:9[/*@ :Y5,4)W;&L\L\D OP-&W!/E724LDK#'6H+E3FVB
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M3W@^=!7J645(!UQABU1S/F-A)3.UA9=(UI$:-C\_/CA#^)$+29BR\0S\>P$
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M1+&S\_"W68N<S'&MER,V7U-SI!$(GB9W>SO;E_.9!9O/8,DQ?!Y ^T!?NG/
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MDPS?(EH O%IM"U\L[^/=)Q&XDG.P=4P3\17Y$G[M"%H([T@8?K:1K8XM#14
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MK5\Q,FK>FC&K=(^^6T;T5HHH.=:K(%#%?"V7YA._#!=.Q^9=1)/"SP9]#P7
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MC0[T:+TR5 P,T0CT>]]M-\]<,C*97=5M_T,V(=)>.S3]QID_"V /CL"/S0J
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M? ;C7LB:9^*706\%EEX;5&S<^P&EW&0\?1X)*+9R]BXV(-D['4!Z:GS!@XB
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MDP3FX#=C-XC[VTI<&.>>R[]\7) (<@TH&,]2_D,.!)4UF_@%\7OP_Y6('%8
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M8(PX$$J5K?,><T-+8;+L >N<JTB:-KE07=^$II&KM2+\SG51J!1W]_4G?M/
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M$\"+ XS$!H2HK:L4L<EBGP]7$;#C'B"7$_9>=<NX>Q1S8X8'<>A55R@IKHL
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MG@J%J5,>I7S)_GZ,A"EF6E>1IB#.M7CL)I!*_UZ_I>-42SD8TK+.7-Z#6V)
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MDG_XTDW^LP PK/YG+M-F;0,>V/LBDG(>:?B/K"+EXV?P(>+&]PV*1+R0>:?
M@;N%,I>2?UL6(D:N"A1?$SF;H6@:)-)Q[D]@:M2+F]=,DZ#'4EP\O2"B[XO3
M+M_YK2H<=_H N^/K5$=AV ZB;.(/./F7/NKB]?]5>R1!^8[-VI\W5T12VCS.
MGG]3<5_VYR6&R>'<E/XB>+FF%&C@@WW*^YA/#JJC(O?/!1]Z'!Z)$1**LGY[
M9N5I1XG0@3>5)^?XBQ>AN<"FZW$^9Z&<[*-'F84!MR8O7KQ7.^AUYW$:78QK
MH+*A0_F+<9WSTBKU4*&R%S$;XOOB[BF$WTNA!!><YZP$U/Y,%(9?@>"U?@YR
M[6;]<]"1S.->6F<H^F>26:#U#9#]H(E ])\XGWV[] [\CCS]U2GUSS9(W"[I
M_>Y$T0^'CZ(T+O9\N<O7\_/%UJ Y2$?&*Q-T[V'4ZI7_#Q.[_C6Q6^KV/Y\'
MCE0TE_I[6[C_O6(ZCY^!;<D/_MOK@%#-?\E"M6S?!OT1],>S]L.V=A],YJG]
MYOQW$E+_,3L&^LO._,Y_.NVE%AQLLV<COZA0O^+>8]R-+>;P-JC<1(;$QQ;:
MD;B_18EU7..LK^4+L*K4YR^SZYK78K.U#O*131OF9.F$N[BFT]:&^EP8SY)S
MG-\P<?#KSJEMMT%/MD'[SN;A=YKZ@6^//%M<?FB>LK[3?3 C[W^A-N\%L:@<
MX6O&TVWVG#BYHY*KKCA0::VR-68?GIZ?$!#[F;KK0_KQHVI*GN<.![T4:7&(
M>IC\XJY^Q("MB1M@NC2A \X,^:6'HN3J!; ;UC9#\6++M^^?=<I@M_V>PONZ
M^7M=;_3"U&;4NA9$;V8ZZ77).,1_5RE>:XE3P;QZ:J:=5E4=7>SZN9D9VCZA
M7JYVN9XY%[?>NW*/='0(I0L^"$!'ESK/=J@X9MZ=OPOW;Y_K=#+T*4 %%ADW
MO;:!2%P\X(2Q,Y&\'4[X8C_ZRD9$0E[S^D65,\\T^>S%]CVV,!4Z'/5162C+
M)PAMS5RID^6 6K?V@;Z^K@[\EP&2_V6JER*+ZI;_,M=_,-7_5>V-?\!]^K$X
MY_(YV.\]C2NKUTT'K4#<%CFYSR^\('.)Y*$QB^Y7K#!M*UYW/4_I'(1.*KH<
M'KC(]^F? Z)::I[M!$-_%?):6"_X7S@AO?733'CNBW7._/KF8?'[X7R+MI[3
M-5)^914>QE<N#M])3O@)NG2H8E7_K;'>^B_#:TXRN?)5:;M'M']I:.GZ.I=I
MH"O6&T)'CMV\'.*X5[>K<=/I]YNS'<BB*CCDWN?!O),7379+[$O;<SCU)<-R
M1,F2;O-Q TPL<HT',JDEHZ\9>4"5K=*)>[/X=CDTC2@"/M@CP?OM<HS1U%VD
MGYB,D*A.'G*MM)0]<_J:?8<_:ZY#_K:3TU9*WU="@2L5.E'JCF"%V&D->3PH
M+8U-E=7,L[^=%>:=>NZQ=,C5O2"YZ/WZ^\]OY0K-#:4W&]'/K1)N!/<T.8PV
M^C)ZVC]Y:R=BT=35/:JD*K8BQX'6OP_CCXKP5OZ<WF'6*=]IB*N1BHR2=)4Y
M4V+_7,7)ZN<\_'UG?772/7!.T73[J&<%ZJY<I#(HUL-4H'37OA?RH)[7U:%^
MQ%;=_<360[O8^+A[-U*^=R\?\CU'^Y^"X43@*[P\1;_P&G,I-0?S4L@O,L=Q
M@A^FN4,;/OT;;4BIR+8P5&,5D)XJ_EJI,VA_L<+6^;#P8HUPJ1?\W>63&U7+
MNUL(MG1E%1>UL?E29.N_!;3_'BS_=VMG;H-<(\_6IPFI>)U;R7V^WG]G8\7R
M^K3!E2O,SYQ&_;[AGQ!]V(D96JVTXI&9IZUCEZT5>H^2)SIBZ^.C$.HV1Z-^
M7"A(:?.JD5*ZBTF<QHN[][!6H!&65ZO=NQ?G3) V#M;>L8<6K47L DQ5KNRI
MYRV__.&;QI?%9\QG;"AN]^1/JF7Q;/*!$?#G:ONECE 9?99ZJ,96!D%COW_M
MP&3K&&L;A*RS[C->U5D*G'6U&+65+TL#E1\^;E!J+9:AL&F'5+TJK'&OU<.)
M;'']2+:ZP>%M4 FH*GGFD#RH7>#@Y![UX;L&-[9\BY:L.48M<81L(.S<H?4?
M#(,?Z^7FF1U#_BBOW=\FLQ)=&U<\ ^ZD<%#5<6[</>)GOK^]]>9+9*8?%W$$
MJI3UVT9K-.+B8DC(0HGU:TO-@I\L8A$%$C)J4_Y=:[8:H:WY*X/RY3JYZ^Y9
M$[FP0X>2)2,#1[;$'5:L71W'H I-:33*Y<:T/ZA9))(+L\SH<6JN&I%ZO%3\
MQSS;*A@;*W%G(BJ]ZX0-2%K0;<#TR$.YPU&/]O:?@T@.;+P4^:Q^(4?JKN@?
M_LCSN99>0_^_P>2?M0O:#L](IGQH_0H-+A?Y5_4"\'??! 5[\\\_7M[A;LS0
MA= D';XEL,@>>9^B--B/O]>&GX""MT&^HOIV;/XO@WB$'OV$T=K/]0W.I]>O
M>I[7/4"B&IS%;&EP3NRK/_0;;FIBSI+L\?=\F+;-7\:ET8]%OPOR1Y[MO6L+
M;8FC>F33N>;ENK>3W5POBU:>0U#/&+[+, <=X$#NBF,W*H[H?KK]%14TTR&W
M#;(("'P1LD(8??V/S2*\;N*'Q;]L@U)DP>L=:S"ZFTW99R'I+6<#GE$(_QJ=
MR&LZR_;'_Z'G;8,HZ3S=MW+_5L]"B'N*TP^,MHX6?>1VIX8M_,B-J-_<X0T!
M.V:!NL*X?V"<ZZ!;_[5URL19?+^H H\C'[D4N,-F\A::;*UO67KT*!H;%_,K
M\_.>X7PY?JW;H$+P\VV0/-G]/E;$94%MZN41PLAMO-9?+1/IH95#?^\&_*5C
M;8YX9^NJH.H_>S*<[E\O\1'JR2N307O\Z1FMQ=>IKG@7X%M7QO%:SS>7R(25
MHENQUL;';SF;C O/S3ZYMAZP>+$'.R#@=%_\K9_*QWO<Y_I;73>+N-HC]\7P
MT*<YLT6;5,YTO?6*XX6J@7&4SE"+3[T)B7]Y3YU C,"39*6(_J&J'3)6L TB
M*H)YG+IMT$$3.9P_'@?NFU]S8#-X:%?BA/TVJ#^5L W"N6V#$O/8_O _S,%M
MT&HOGGF-[[%+@@K$&4+(V0I9M9CE<>";$_@4*YJM+"F68T#3EH0CGNCE4$DB
MR&G5AL2>*XX-&>)[%V3(4^MV)7^EH37+.R,$9UY&-H[UP@^T!!#CP"(P'^T]
MO%'#GIC@%60;#E;#V.B)PQZC3HE-V#&]+-_TWAW;4^_=M_)B:&J![%U;0O)_
M/7(#-;Q>D&"2=N>JT,@MDSP1QAQI.K!G-F+^3$#W6%QJRUE"T;U5^%G"1"#U
M*67E+%5\/,!8::NG"[:?M]OT[UMM.%CSL.8,$+P-VE.^U1$F%$MT2%Q$G9_H
MCK*6,7RA)]A^$=J+"DK0B7$N2MI1*+NM 'WM5DHBOEJ>8P \W#F*N$,Q4^M[
MEMFPF"MQ1>+R0$^7JR+9%0X0VEPO^6N-38L]EUUT='W:X3:I"#5()']L.:?-
MQ<-A[\5;?O>47L#/H'BZ5[9!UX?7%=1S'C@WL*4)KSK)S:10--IXHZLVVS,I
MJ>3E\(Q51;"<W=6#[VIBD=EI(>:2+Q+_Y-%L5YJHE-CFTX -M1#PI($5 #QM
MD%%0F,T$=UB]=)TGZVZFZNI6,T:<H/M;1H\P,QIKNSA-X3MA'5J1\:[4>* F
M,FQCGB@'\[<5X.S[]G.0XUZD^;.+$-D(9^H[-0ZOH/(C8.TXN6=NQR;#(>DE
MN2CD];_\M@XV.JFN!%Q-H-M4WN3_C:?.=2EJ4T,[88\H-7&I0;8)C[&[1SF6
M[%N 1\1]2FNNWDB-J+ #LR?A5C,#FE>&4; =TFJ\[HF@)R&=ZH96:T1/:*[_
M=!Z2\WSX24F2BAZ7I(UU$Q6Q_ PRH-T&51JJT8[$'X!X%V,::*381JO0,D#R
M/!.V<K "F#,!BY*8ODHI3%?Z)3>!#];9;/=+GS_?=HSNCE7>\L;O_%_7&/!8
MQVZ8(D<"B&.P>S(]CC!(<5@[!J5S#,=?-X;5I%(DY[<\&JC:\6/A#YGV\\U'
MAC9RU!QKWF^#HO$7&UN8-LF/I]18AGL*)E@]':LI]4Z=J\)+.(.A,OF.ML?(
MK8%W3-OX(*;GJR7"*S,)=V2]E.'3KN>9'9Z:VDF+1VY6I\[V7_WKRZ"9PF>^
M ;/=-65Z+"**>%7O\;CSG_K$:@<;T<(LS6/U6=?Y\C.LKGW227:9AD^?E5;Y
M-JAR<[?$>1.0V&T(W\.QW-P:9EUG"W "OYP](QZE9 @L%6+-&"V=_>* L&,M
MHX:7-'//N+NE&$BZT6 8DE+@AB!/&MJW%<&G_ZS()$B'8:&ST_KNMI^-"!^F
M<"/@/5A=H79U6+R2*J/G(=:%F6XQN$$0 !2<K(J8/J5%_H@[0P7-Q"+S4-$O
M+"<9Q]'*Q:$;IC?M+??K?+8_S[<8\RS-K"OJXQ]*4<!Z 'JU:QL440>,I0*A
MK&9N#L=+)LF;L=I%V#5-QNS6#F@^<EF'S95 "R^$2%@)37@I'8ZZ\N Y="!6
MX5D09L.A*5!II=7>C'T+]U5S9@]. ]9%Y"-U( G[K:C9>(GRU!)U=TSB+M2J
MS@/18\NTD1KQY<T)U5?G:B_4WG+)OOD)Q+([;!>+"1Q;-:"O0=>;_^' EGX2
M%?%M)ML@'\(N"L;!/),F%,WQI1&DX$ (65L84/V^**-7*T^^8-%2LOBD82%+
MD%#4IN-$_A%>TU?["A5P>72T3J#,=^EA1<-!.Z^\76_;)^B/7#0#TIQ'G2N6
MT<?VVT3X0NXH";]"'Y(XHB!;>PWD\Z>$"^#U\_IL5SO^-/GC4=8[<<1P)XZ@
M>2<)*R7XN1[+;5"+YC:HZZH@/(M(26),V\X8$4TG1S/252DK(M:'OQ*"SDA%
M30QL] N-K'49L7T<VBJ'3H73I+\:-P<T/RW)7RQ/,>-*[OB*Q^9CG+>9QA;A
M!WK6%,-F(PV\G^J1^L5-1YK#[?_9C7+=4>]]><NNL!V7I>$VS%V$_T^Z$+<6
M#AGA<6#9HT6LD9:U?\3(C&T0K9A'SN1A@_#LWY2=&'B[>D"Q&5'WS+)^QO7G
MJ%O4/CUIN>S3)HO.I]-N#D2>/5J9[$27X4C%F7%?\U0X;HQH_&Z>(!!%JR"R
M3V*T;8#OS<?>,KW['RE7 47!-$5]I^&*ZKK8K[_!8']Y<'20#=K&7=^VSOJL
M=%6(W-,INQ:48-WQGBVQ]-^UU-IQ8@Y!;FJSLD E^/BXA4CHB</[WRW=S[_;
MIEB>?-HM;4#CWN5'RK]3BJ]'";3R]_9GUMU?)G_9([0V%3@#5P)6696-W/Q@
M<*P>% RXT]!D&!6>J :0\@$SERIN'D0Q O:PG#.E]:#D94(>H$4>GD+DJH_@
MOK(<MQZXN[N;>"7$L[U8LTP/$MN<UY\K#CQ@ZV$,X037T)4#3#X=@S*.43D<
MT+:M!R*HJ.L;8,5%^;AD[76Z]//\)>%"=TP V>^ZV-O,7,?<R,JY==J:(W+)
M.DF]UP8Z.[HXZJ;PS$/.)/<S30XU5_64?D*=W+N[<]#X _Y$WM.!0E&?^?Y"
M(/!B-8/W\*6?H5:<)SC=,W^A/JSZ767<[%%U(\RC@NI+7[Z6B'59[7VZZ]/:
M@-#:ISQ,%#5?GU+YD[2RP#!R_3#8+()5 BALV&*S!%.H@R2+]7.'=34K,15<
M,- UTY%UF!C$?JKWM>R1*N:9Z+3EUWA?6Y&\+^ RXMO5N,; F=5Q/-4GA2E!
MZ917>N?E6^9O*)U :_@V@D52B7N06]^Z\ZCNX,XU>-BFQ)39RUX42B7SS*=[
M :"$SY4H,$(M8=7+XD+=VSU,C6.X+YU[AG^A/J>E%LVZ7"U[U7R3_>'-:H7U
MT:=IO3;I*AD(E(<5//#YGK!\4?6*WY=*#:[/OW)*U.1&;(-F!2\&F[Y+/M[[
M^R^MK]=2W[C<+;-\$RE^<[?2/P>ZP[\XB:PSN#- %IK'GSORGP9?Y!G./T ^
M^$\^5 /[3XS'FOM..;AJ*%-1SZ0'YF%+!0;X@UPL6>4E+E+[Z\"+=6FF=>G%
ML(X7N'-EI%,! A_#>SOR=F^#W%*=@WI,%R-2@EVURBCDC);Y^GLT.L]]$M_;
MF/L,!O?_;-@0^[%J>"_W%[^IZC![>"2];2DU;+4/Y!/VW_,3_S>#-'UGD/:W
MCW_DB!LHQ:E&GK%.NT^2%K?-Z=G8R)^D4))X;#2S0K^'J!"$CLL]"KA35]PL
M9/Z^Z$:'!U2P>%.T-*)P8;.V/HA<\(5W]$'#>[7*NKKJV@QG-.KU!\2S>.6'
MDWPW J+8[CO@U\#+Z<<VJP/"=K6 =Z&'/W$_F37AQ%A@?"7X%FO&S!9AR%]S
M_#9/%WQN:BJG6;S5$E9L-]?A6\[.9C/Q%!1/Y_^,$OW- MR=X.H-BX<>96R#
MHK R;%/.469H4J-91"G"\$J2=W&9?&I)\3RKWVBAQ_;]Q=3LXH^WZR[F-Z;I
MCO)'%'YR/?Y#!X"A^L<7OZYV&&JG[+@=8R"0+BZ])%-_Y0E5%/=K:/7J[2A[
MWI?4+9:U4<+AH;)?Q_YHDE9O)TY>^5@V\?ZE./Y?]LD+Q..TV2LMW<W8%FXM
MCP\#7WZ"O0 \_#MUL[ THF+10WH8JT]#+CU803H9>B]4V4KDNWI-XGT0,E5/
M$R,NS6LV/[M4T#VZU,2VY TQ>5_A8AJX(Y,<72)-LSF?9F/8?WX4HDG-1C;M
M4K@7%E:F54=7]#T_.%>/])5 Z&5%K,R6EK6DHST+;37F\_G'0_4W:=N@Y@F.
MW[\Z2'KBRVUL/"W>27S4#$JBZJ?Z#C>?\VN6_0;1IB?L2#7Q\8[7TY@\T^S.
M\) G=/&XH25EFG&B:8#"E3'=&D;;X#K*1K-<6_LH8J N@H%F5271>CJ)8*SJ
M&$X8Z)A9)32#%^HM$R@7F!QY"!/H:<W:^%I2-(_3'O1A_"HHG9AG4. +AG'$
MHJ6J[\B] E?YBTJ53(PYEUZ"/ ZEBFN/-8'R*W>+W],(S,8\5_Z0>/I8)_K=
MG=>3S;?]!S__ECN;,9&A4GQP9@!'AE5A6Q2P=FR(-=.LE461@TAJ):!IXKL7
M65NQB1F;'FJ$+PPBY\I<M6'$I&MC<\2+=QJ#'X<C$D 6MT[VQ+?<V0:-I[>1
M.4H*3'2/>(PA++Y@M RB0[Z=_F;:&3D$83UVAKN>\!FFUGT(C=T&.33XY;75
MXD_M.OZ'[\]U*F5'P1R$V+"]L"8,2BST#-:?">\$[\:-YQX!W!",D(ZVL^Z<
MO37<G)O#F@7,G?$=7T/-=UE EXTK?Y%F (4*O8AO]HJJJ\&8L9YMD!QO ":,
M]T5'&?IVV$IR[ 'KLN9W.UK"(ZZ3)>UQO)&QF:![#NM]#QK'Z/ 8"(+Q WF.
M+2/!#;M=UE,L?K$[MNZ^/6H0\"U>ETW,XR"YN5AEIH(]H$M=E>6<8]1U@64\
M;BR1ZQ[=*:_(_\"42=1MN%<R.=U7^KTG\)6__'1!H5O89D:4@WQT1G(9:L59
MY(\EH67FY;0P@*"MRF#/-3+ 2;KHQ%S);P$I8QT1:C:#<-<FAGE=W.VQ"MXI
M\H3M&V'G9L6%43M#*TR[T2=?^'*UE=K=-CQ\;&-$O%?4H0=<:_%PYVIHH5V*
MRA>!F->(9GU E"%N7]7$Z(GY%5 PM@U"% 'Z^>H O/O %-G#,@^C-!+Q9N5(
M5?6)4-JY+ZX9K_S& V=W+ [SUT["BT.%,=D.@!MSC97 S&SGVF_.L))HL'BB
M%$JKD8^I9@J4E)KC]7> R-$<)?$4N&\4%6Q,$<%XB)(X\UAY/L7O46]G9N(+
MW  27M??X2[=WR[?G)T'Q'D,8FT9RE>XKU=JC.7;1_>4-1_R)[?/UXJ7<]]L
MG<@;J2'NAXR&^Q"-FY<>8-HMSVKWV@%S=,)R [-AIJ5SRI<5/<!1]&4X49U2
M',R9YF-=YU0K!X*V01)M**6\ HI?INM!-E+Y2]V(P*D)A&G!A_H',<(U=\'/
MP(1F&69FEZC:%0:), M0F4F=%.'&!S.D.'G?'A*YB%J;70PTT'83HWQ&L2[W
M*CJH2:6PW5:L7HK89&$ZM67_$MGW4::;J/]PBI;)N;4(R1Z88C4E"780@GZ#
M=>"6-1K3(MRHJ^T19UF&3"T"8_-JZB;K4>40[QB0,6'V#ACT L?4(!44%H(4
M:M-^K=Z(:JN\X5>EZ&6?09X=50AD4V<(9%O61< 3S0BDJD4W'\&J F&>M!7!
M=G1TKD"UVY12._W2V*JO/.IG=%5>#Q*)9?8=)>RW084&M8ED%[S(*$"S0[!Z
MM<S"/&J$[95O'$,-B T]1^@&4ZN@\%CW$T^U1YH:/[XUFB05N=^@+$F'Q^1,
M[G=U=IZHKHW,*V\(N'U7_"M%R@4W[&'(?:5+BAW$K-$V6U?YD/KX XVVM#X'
MJF#":^#^KPC?=AS_8(VQV"A,8M%5L(:O;@2",OXBV1&^EN-_S+N*3$CD:G"?
M-3K1T;*XKS#!'96B 7?!FHYR#A8M*IVJ&2T;)?\V1FC7((7T2P[9G;PQ.;'
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M\NYD[P?%]ZI/CJK^.UA#.!&+!-E,9#1."R#&\OZIEW=_7@EZ=. ,ALVN+5O
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MLV[=-O(+Z*;N;.(8Q[A29'*MZLOLBN9-PJ[Y.-@%OIL(V+[D4'"Z]^&M!_#
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M^/+$0,EB3,XU,)]SU/]0=ZO)LUZS6P]])HE2F-Q^B\%:\1-NKLBJX>&V M@
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M;>LVY%H[T_,?N8/AOQ&)L=MG!O]GL)JFVZ1^?U&5_(ZC -SG+6>XZ<)8\3Q
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M_"64E! ^P2!MQ=)S[K.:LX$.?9FX?\1T7L:P/G>=#+.#)RX>L^53\>:VIYS
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MN!S7RWO9!@NO&J:8*ZHE%[9$;KC],]5[[>:Y*/ZP5E7+I(1Q49@X30&I>%2
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M]"]959GXD^A]#+JXH/4I,W,QV_UV3<W^QZNF/+26*FQHQ#YGV*$$;:+1?*V
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M7DSXI54(D]+Y8F!5=ZBD.?[W\-S-W$RW\4#YQSZ!?%?M</V/OE_Z#"DFW9@
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M.\,_F=C"09<5_LGAS!O!BMP\!\#+ I:S@VH+ J_D9OH5<)W?]MR?>*;?ZAE
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M?VIH9GC)/D'1L#W*N-VPCII%=\<B'[I9Y"-J"DL^R>L&U!4E*90/:Z&]I6I
MV] *FUT_UFSD-;.]CU\ZVWL_B(QT[-$6K$WA#V+P\_ X&8#5I&'/3*,Y-4LK
M\JBG[.,E)AD2/5,YJ.[S9%<'S-,I^TR$H6E\#/E9ZGX$M^)IUU?7&U8"NH:
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MU/3,[-SJVOK&YM;V]YW=D].S\XO+J^N;VQ]\@0' P7Z__BE?R,]\O8"  (>
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M8;8JTTH)K/Z9)GY74E&W5[+>N8R%CRJ?C>!0'7D&Y?$I)OBJ5B<G">\DE)X
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MH"HEU'L8U;9T4R3EV9##XM@?%W_QG/W;&M$_86AN])J0_V5*PFCM8U=M=<S
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M-W>ZH[O;;$L86Z#IHEC4ME"I,<1"O!0I^PXT;6]E14?*%;\,OHNWNS+R/K3
MZCO4K'=^?,4)]Q$??,R\Y/"0^$XYVN:C425C*KGMPQ;\KC%XM&> 6FCGY,7W
MZE2I,DW>I348"Q)EVBWQZ@%,'KA(-> )MJOGM>C'"6:.L66Q6A42XV25'JFW
M2+D:VSE4#\WM/"^7QH#NTV>PZ6$O#&L-J7'-:Q6,TJ"*%ZZIVM;69>/?-%6[
M\Q=(;TC)6!)T0>OQMUZDP58NO^+-,7<PF::$[,Q//8 H$ YYR8J"1-YHR]K$
M,FEXO!6:QSD?6,+B5QZ]<?->-\GZNX>L)F_DJC@>8A%B^!PR;=I;&F$Y&1\;
ME;"#(X6#>[ LM=UVF0!-CT/#&K_)''T(QFIEA9T4Z6W^5\:IK\Q!C6IS[7>,
MER.:@9)99Y"4;+&B5F]=]1ME2Z\#K2X=3W>QT3KDA/+Q>,<P-56+28=>7+20
MU'(KIL+>\_JW5PBZVW)/NWS6,@ZI_-SYRH%F'O5AS'6R/M7_EJ=[WILM\J%X
M0_-QUZ9)8CV5D>\P 6!ZG;.M=.R7ZYDQ,U"7G>XDF=4'7]CGK/$2:55CL"3T
M(C&9%QZB+O!B+_B\PKZVXNU#L TZ630?&V"M7AT);M9D#G=.LK9694N?M"(P
M('XA*8Y^V@'(]8BV%&$W:YY<DE4;95\+W*IYL]*7"==Z>_R2 CPUN.OV5A4^
M,5@T@9HKKJH^EB)0+(AW3,2^[Q2ZR$[-,2@MN-WQ=BC;'IZV^&,4#)0:ZB,:
M;]%X0JW!R@%CWU#?+(I2T.B<@:JV8SR)O>/CF>NX^3U&UKS)U26O1/3\4DD,
MU<!&)($!?IL7!Q^*F] $Z?'%F$F=T$'LMQ++4PGDH$YJ70W;D!1A+GS0A*D6
MF3F^.[4D.H9:6+8CEN4;VG2?/)SD,.MND*#Y\9F(3Q_0&?MRI9^49GR8PQDF
M8!/#^GLF'K6(^G%C3KV]@2UWG(RF6O3F,) A]-@EG^1:.AM@4^5!/T$R:1!T
M:-9QVU'5D_-6-%1_L9HGO)':33+L2JP^95FZH3S2G'?:[ JND(Q_%1: WW%5
M=+*B2:KA?)UJ5>?:])'\*BP1:37(]Q'ONZ4)6KIX*A47B0Z?D^<D.N+-!AS@
M(R]+D'KP1+!47>Q2&]]Y\(BB/@KD@LS'[9,=E8A[(<M736&W'WCR.,MG%SOI
MIFFR':T$NDG0FJU7$*D.7:<B2U!P>BXUU+,VA(CFJYVUC_0;V:2OG;-,BEYW
M747UXLUI6<;J=68ISL'R24V 1:^EXB[,[XJ(C]$6"U1/T!X<EE1]0HDCH?2Q
M'0DS)D"W<P9QW5&K4_>&UO7U](9(Z&^VX(E(751XKB 2/P%4W>6D087#-+;]
MN/)H86+R.!HE[ZP[)7.=J*7&0)0EM-B;^A'U[A%]$C##5P':+H">"5X*XTM6
MFX4 \@32TW>,,2_$R#1;&:4A7M9^TSXN(TFY$Y\8S?HD"L2)/TR+9%S-I&ZY
MV.OB 6H1^,VA%0<^1%OB#5@7#<]E)AL0JVSN"[J^I)H]9HVFD1&QB<.@1FRH
MNDF1ZYQZQV9QP6V]PX]%OJ99:=5C82=^;:G0)C=.,4S\P2H$AGUOPAZ5K:/>
M/A#"A?:^NLGL1-(8SM\W \N\F[V+HR=G^9ZARIU&;59S(7"CQD?,HMC(A.QT
MG0.F**D8^L,DZ/AEI&'IU\=)TL#M:-(*E%,L/]P*1_8TA+PFRAV]MMW+P[;+
M*0KSS-K@(3B)DQZK+)V3'I($<<\@=,=;^\*I!)[S*S8V)(NJT1@:/(6R=B,(
M'7NT OKVQ9>NNA"E STTF>7:2TG?2"SD>%J/Y%6=6/L&]Q>W&VL3QD3BR5+T
M!E2_Y/<>M:8A>")<'ZYW+%$#<=RI5,[7#:LIK0[KOT3[8-F.<R,HYES[&\;>
M^JZ.6X:EFE!ZT[6%5O3AF"A@#6LQ.A7,2?O8#;Y\G#KL6,B*:#$?/A)#R>?
MZ;:!79ETO';-C':+KV.MKD\1U^9IR+(1H"N8V3 B]J*0/F$<&YL2KAT]2F\*
MVC3/ 3E(='TXA&AR6 EW$5S?^\I2Y()3A+*B8A([NN \6FJDTQ\!=YOZ!-!4
MYT,\#V2N+?R8*OMF3?**#=&F2SV,P=]B'5>O\#FT(.5D+XRK@S;S8R=I,04X
M9&2A7CW'26@7P.CQ9643X1CQ!,IB4?OVAI%2ZVT)5)6"KI#^M6M[E1;V^&.G
M3KFSV0%)0[%J?&\O:<(,'@68<480@.(_*!^;=Q,?QC4F[<I_C_"R;P2$4!6C
M4&6% +\5!E]4G=%/H@)"F+Q??D)KS.>(_OD/'0#F.\LG*\WRRB(?LG]'U0<?
MKYCA*$J8KA.FHX%SD*%I$UEG4YX+)F<!R5_I%**<6KA'H',^NHQ]M.[9SG9V
MSPWDELWJI_6] =5P\GZ)4VZF-'EC@]2793T?K<!\1'#][:R]>IK>(!>VJI.V
M/EZ&0GD7[E,O>*[$&3]^<XT^!V9V#\N6BV/HT86YMD2ESY&$W^+^V):)D9*\
M;6U03 #^UTYYT(E41;ZZL4OH&3])W60"# I"OJ)F.^VN%*<,=,&&2Y!&N-I)
MY E\AYI?O$WIPDX&,)1S;8W$#+/76,_,H/M.,+=1FCR$!>\-/(_PFC$()WN$
M=^QC:$#H0IW7A["OPV^\>#R"3IWN;=<PHN]8.<[K$]M=(>NT.C!;VA07??@:
MFB: 3:3-$X\8H,6!M:E#'DFS0S*0+2:1X4S'ZQ%D?OPR(:>C>U+'1_R:*;-S
M/(G=!#=YM4Y+EKV; M2HJBG)]3Q<[.F&DZ'<G,6EG>EP/<NB(W/:40#U%NFG
M;1TD\CDO'FJ2"1E1/-&+$M9C_Q"6)P"*4]TNM+K"6!IC(*JP8+X251K!VA"C
M]3C+)Y.215[O[-DG@*F$O?2UZ(!<V\>!)A6;#Z5[U9:K_/BC"4Q#U#VDU_$%
MLSMS_=*(7^)&) (A7IV693:-=-Z^/5+:;]!=*_ANIRX<+EW=W- 8N[AAN(Q#
M3&'>;L%OAJOGQ2,7$JYV>N#"(R)S76%I0#!W2*M3'F04!#],I,_50R=RXDZ5
MDWA"KE4_9;D1+>E;F0?9(MKNS5@I&,84G>0B UWTK M8\/P2QF.C,)#YAW&Y
MQFDB4- 8O( S:B3G\4L/)4#JP!2&KYM^WDYX@:1'PN<C>YVYY$JV2&:='E@R
MDF%%."4OGKP(SDCQR#TM,=LU:90>-X:W)U!1^:[.58;56.&0;# +MY>W$RFT
M$_25S0'5V(F,&FH[+M2:G29G+]2=-4*LDZZ><Z7)<AX3&QY@U_IUS)HH-XNM
MO7W.'$N_-(+2F/"N#"P8WUOH*JZ+01/-ZSO-BF.TJG3KW'E$)>!1F4]Q$8%V
M<VNWU.P>/WZVL) SWG:'IJOTJ%U!03V0R-KA5'T0NVD52PD@'3G*X_Z][#JP
M9/':9PO,P'3.CI89LMW7O.?S$2 IPCI)/ST-2;WG(M.JRX9A+^$DZ_K3VD2I
M:[4D67JX=+B\SK?5AO(["?WE)J! @W,A 4JO"8Y)SB((62>VAM<9(5Z5-WC)
MBT>=.)ID0CG8!)]F<J5J[(B%:\:><EW\DJ$%KO0T'&Z]68H'4BU\C:ZA2AF.
M=,RB&)_:9"T%X);7, V_V5P#7:)% 3[#R!0RJI'ZB:514$GSP[+"*YQ!SI,B
MS8-6F&LL"'!- \ ?'<%_4AA_R^'K5#TGV>YR:K_E13\G\U2]<!097K^5KT/0
MRF%G*M<I<VR7BP>^7UR,D\@*TQEOKO+=-/&.?'EQ36F-BK06-&XBRQ<E5I/!
M=& @7!5IM07&&P1/@M0EI<BC2,?>!Z$+OWMYV&#C$4,?7@E$A%Y52C?*[3J9
M#]2/1B2R< Q)2DJ(C%HVQB<<9;8M-%YZTUR7@OE^V,33/\P G-055ZEAB:[:
MTM]\[<N[] /'+.?>,VDPD7OX&T5$]>X$7"U\H#GG+8^@7,J,(&11L>9BWWJ2
M'?A4;<$!CFRPZ'&<ESD^T@$DU./1(&F&+P>8USXL,UCS"IZ@2M6$9272J\7$
MX%$$Q]*>!P?V?K!SED7EKTZ?G>+>G;P)7$NV6)>,7:)LZN0H?Y<E_ 18&M8!
M3L#V+L 0GL(<\AB_TWMVPAU_=L*I)UO-1]CU"I7#UV?:5Z&:A2E;WHI&(!_U
MO$/20&QCV\T>99KXO4_S+*8%"QI"8/*D05Y)+S; 4J6+ "*7XHK)VZ<DKT73
M\=]ETF6FD==\,UD=1*;-!4D2#^K4<&6']V+:'E*+EG^K0 '@)B7I);^FSC/0
MZ1,6@"8, @R[8XA'S%4FN)<!M0AY97B5[W*?81-5R_M2VBRJLJCO:("9[GQM
MP2,U!"OV!ZK7Q-09%=^BKQ2_OK#>V>/'O"7PK0Q'FGU(Z9OB&<C64I;Y:"7&
MKK]@.U;4F6EBE9'%BC[Z+3W8]#T QIGZG(4G)]W(965NJ9475GZS!R=RPGI'
MV>D\#:&'6?/-$*K?O!0HB#UUZ+UHFZ_G$9+@D?B;R)Q!([*D*M8C( F&$X).
M01D':=@V2[;WCNR''5QG1P6!R6 =.$ Z>F".P,=8JYW+T3D2Z%>%_(0Z-B]Y
M;*5J1L_GZ\L<>7PKJ[D< K7>JN/YF:X01HCP^%$IDKSP8A\$7YT*7ETTOP"*
MU ']E@#.C*\8^E]R3@LG""<D?#*EU#6K[M MAA!TO@<*;@Y9?V!XQF61W]4D
M9#6$T!.-(Q>2!@I@.E*/7,;3QICG1=/"IKJ62*M)VU#><I>[1.XH;Q )Z+7R
M8Y'>*CA4(VNV5;12B;\.*4COX0L%"%=%P&<ZE';1J4(82B!VB@BD?O#C(9 *
M>A2_WC>/.A3P3Q(&KYZ8G$TF#G<+R<LL8&A!I8.%#A\& 8S:TW;01Q:$H!*!
MN([D3!D=@.B]/3E0:%*T$$WL2?T[N(X!KWT('=]SS(+!*TG%.PGB?77GWFVT
MY<W8FZKM8LX12*$19N,#H8P=!Z!%N7,& \P<P=W,Q56!I)'IE;"#SYNOW9MQ
ME&>HY\/9ZFMA/!3@=+3@S[F&.+M=OP(H,9Y(Q4OY-LAZM+(]]PE@A -O6:9/
M8,00^O4)X%"XH"%@<1*X^?X,Q]3?S(+WT\2D=V@FL1>3L'\VS3NR4I"*$@F,
M-(4.T6[-^3#SQ,AYWN'C5(+]MP6STX'@5XL5F%WN#)VF)RDQFL4Z&)Z&9YEG
M;9:GU6[SMM/X7\"4[T@D3P<,VV;20]XKZ[3RVU;CQQ\HV W#[6 ;/$QEH]6!
M%CL&&1*$$'JD,>5G7)6N6U$;9* T..GB+&W&VW/51;AB'>Q#7J@\K!\E$(W8
M!0.="3])5(1A?43A)"6$,MLF=9E*:]D1?0+8K9<4 92K0=55L<I^I*'9[J=H
MF'1+.44*HE;\^<;_ZNWDORM_Z2U,E\B&P&5XI;/8]L'\EOY6=XX[I4$01X9Q
M3BA9:%UF\8HGN'1&!-K!^1T.!W>_.HX* >8BZH?<LQ=9K][1\8YNDJ=6&R6&
M)UKFN%-]H$#&/1:P1PY:(XUEZE7&@LI: 4 +M/P3$#D_SK<^Z+G$XI!O\IL+
M4N49!$Q_O5<,FI'.U>IE%+<U"],;+R9R]#OB:X_Y_ABS,S&.S61!!8L'BT<!
MWJNM.4EGCZ@V=[FV)^VT+SUS;@NU&8G ?TB_\"ERJD*[(X4J6&5D_^!PO;1*
MG4L0U4:X0Q,=?  3L!$N-7E@2$I.!L;>)9K6$2*L@&NWG@UPEFS*75,ODF.\
M+1JI;IBP.'\"$+Z'_A*,1;5:M\V#:&2,HBV9<6TZL8L1+26T[X@RB'5&NR#L
M(>.*Y'%Q@*_VK#X/A90?OY"R 4Z&7K==OADFPSGOSS01X4RFW0@8F[]",2QX
M1X?EU 6GOEH4..X"WB'J7<E^[8M\*&TM6Z<1MNU>Q-K3^HHL<)<YGDW<%@#W
MS2OWVKI[DQ^?R'*=[S4BB4#*E6Q235TL5H8/TM(BX/I=+28)GHC6A>$3H -[
ML-^I?,BUUM)!9.M=/ACRNR9C,!AVHI-K?-!^#N808W"W%*?<#</9*3V/TS/"
M(%J35-9J2M0>6YLX"H(7H&&8?<_OK4 Y-[M-GB)L*V_J03^U#RI!FM]QB5FX
MS.#2.Y6*QS#=1N#O)G4<8M :(PI!<0A)R<5-$$3!=0ONEGCY!6RCZI'PQ*!Q
M33-[?]IO5_Q:OSP*@,Y'L<64JEVBENF^-FA##SLCKELRS%Z3BC$]/O_UL6>>
M:?.8TV*M,4NX!E.&UR><BJ?>@6Y90@;ZRQXOX71T>PHV1EU([*@6:<:93&45
MG:I/<G!I2.@2*%CWF?KV)G2?/O):K]ZL]U,4I:_C&\8(JJ$M];56] 1#\MB_
MPZS(/-]D)-GU[/#C2W];VJMV\0PJ-FI,4*&E(_29&^_%D9+X6)W/07Z1(>G8
M$>M!Z-KNR5 JJ5KHT3?RN"^TN>W@<NPZ71 @*T8DPCQ+JYO %J0RN1[QJJ^=
M\-.4%W?FZG:@?9'YA7A_J,[BAUA#T4+,8O&D^S[H]RL SFDN@^(]))[#\CK?
MR:&\!&IT9]H/[BGZ5)L88?SG)?JCW 1IURXFAF/GW].B9$%)'Y,< "F?YJK<
M\IX -<TQ &?\ZC6^5TYFBZK#^5K2I',*-JKBEV[QY MLYSO>XME.B2J3'N3P
M6/:CYD#$=LHJLG=#Z4Y">.)&'"4:#/E=S\;<4\C.C;-Z9VY^\;6R1^EFH7?+
MA6.WQ0[B=@0ZP90SI2#_>FL*9[98S57SXPVG<34Q2Z >&>GR,ND3($E!C2W
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M2+LXV+@A]_KL:YP#](0=?B78WA?E&($3+OD[>,U!74.]VM+8VUZ25%NJ3+!
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MMXUNV?QYEH:9@%.^?7;KRYWZ_[@:J#,JO]03-"?J]T\U4&"_&\B!SGYKQG7
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ML%&[GPF&M6)?ZGK8CPC&Y2*"15H.>+(SST=MZN*M6KQ4F5Y0^P1/L=2?E9$
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MN[L$9W!W]\'=9?A)OKWWOR_.Q3FGYV:>I[NK:]6JM]ZU1E[F7]8!6-+B4N(
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M(>*M^&0S ]%$G6_O)?O\>4[/,FH$FZG 7E^2/PKT/AR00WKF.0X'9:YAB2K
MXWT!2 F^ !:X=NSO3S" +AY8EC-_F *<K 4P[^] #V\JV+^:L'7DD/3=$V*$
M[=^-FS(HQ+5\*LM,-(B)8C)RCWC2$UDM*XOM0U3,]3*J:=#KL&/X=K\=+<?6
M4(EG\X8 0,I>N-==,#YA[TGL.QC>4!<%CVN0(4Z)][L$-8U?WC,ZZGTY'Q(\
MYDWP=7FYC'$_G0,FQ5<>-MX RRBJC\6IV>&) U<WV1M']+X,O);,2C)YJTM3
MEM:/"TA[EI1=#VG'D)\?*-(/)$+P!HL$66<FM=5KB2*LH*,9/M3]C\G;]LO
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M4F%P'S%=&F+<YX'551>A&'/@OLW>_IHC*U*'ZZV3]P+HIQF#-M*^SKF<+R^
M:)6,9SOY9WA%R3VF!NG+%P":!<^EVRIT=A/*I4AU2AVUN!5?,,R]SF!#ZB!B
MPS'9LO_;ZLN"HI^<^KH/%P1*T!K1:OJ>>5L-\83>!L7\(6F1>=-Z*&V@UHI6
M@/1A'#X#KVG2:>/0SO<*1]?3NIF>*E9 WY^0RL/W>L0#V/NI069*SD,[XQE^
MCB0/?).8R,X10 7\"0%&FL%F]CE@B/M^K#/#6#E8$SJU0?)(T8)K#.JGK&>
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M93,7^P'8/Q++@IR/%A(<:TU]U@%D;R"A<*\DFR",=7GS?APQ-$8?*<%L:<'
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M(CLNUPK+BV7UY+TRCDF^]>COBDP]J+%MDKC5\8>Y-K17,Y([-MOQ_\?!O]&
MC?$;%.?0D0T:;VY8UL.<F!M_\&8,D3G$2CW #ZJ*NL[.#5-M:$CR(D[+)M4/
M9!$A#W[Z5X=LIK(Z(W>[8K9.Z-=NG_5*?Y=V0).@94Q@SPTCU@=OBXJ,EMT
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MBY,Y<VT_]5<@._MZ1M:(*3K2YP1'C-\V6H]Y<A)5%<HM#>R?IS[WD\1,5;P
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M+SA>01W_ !H T,A-4:%UVQ2X8X&-I[XKF_%&,284;2>3CIS77I) 44RLQ=@
MI/5>.N:XSQ'@,L7F.P>4<GC/<T >?^.DQH((''G+D^^#Q3O#*AM!M03QM.?S
M-'CEL>']A/S"=?ZTSPZ2?#<0&01&W..O)H V;>1)8X\J=S MG'&2>OY5MVL8
M"?>SM&?2N?TU3Y:,6.-H(R:W;=U5B&X!&.* -,P_NV*N2%&3Z"J%SADW9SQR
M"*G6X81&+< ASSWJN\T;+EOX.Q]* ,M22DJ#:R]<DTR,DR)V('-2WK#:S1*
MA!'7K[5"J!)8MF3P 1Z<4&=;^'+T/I6T_P"/.#_KFO\ *BBS_P"/*#_KFO\
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M389/K2]J**3*@+1112-#_]E02P,$%     @ -GPW59$-4"8-*@  $#    T
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M$<G%>0=45L3,ZI,8S<20N.33(T2)+LP5F>X.8Z^68 B4!%^2@2^G2 <KELC
M/GVB%0DFA,@#7]6>1]M@%6U(1\E M\O5\=5IFE4RH-D*6T#D%900Y>/N@X**
M:;&6+A>C5!T,] 'V_F3'#<YDY?;7UD<BNZ]<?Q;>(<!P)^9N8!S>G'LHZ*"L
M0I:5"/T%!O&^^]OW+*4%'N:8,7.P8],&))7: H*$(NEFC^$OTU0ED0&FZ5K[
M;R'Z38=#JK]DB'9\^)23^HWY--M%-,IRR-!-G*NFC3^/(^MRDBI3)#=534^9
MLGI U?N5@\[@,:3!?9,D[@-#^]%E G<=E#TV2K0H#E6(.73HIM.>X^*9_W*R
MG'^?"#LDV!\=:ZE;, <7B_IF5_FH751? &!0>,'XO7YS@.3G/BW6KW[3<DS&
M^&+92,T>U%D>@4T8R?F+ /\+0Q=JOX-13G9F3-KA@<R;*%MEQY\D6+#IE74;
M[]J[>1ZI3Z(?,VGR^!.[<'37#G.4N'M=E](Z*[G#)*7!\WB(I?.;IYZ+W^5G
M5H[;">6&[8+WGJ$%@2*TFCY780F=S;E<G*_X S?!RD^G[:+SK#$X[:T6R:]A
MBF*0;#B^ /=E)7QOZ"_=+,%MGP<A1X<B666I@>1KLWB9,$"XMSE,!CY6H#ZW
MH(S8TS\3F_A_9I\/?T:R6OJ]27 [ TF ,E;)GQGK.VI-.AYU?N&M/FX] JPN
MP>;E\_SZ6M 5E!$^*)H5=9Z)HF"@OI,7&PAS#02@2/L3%+$!">AGT,&/$-7'
M[U'9M\^&$F4M1)TNHJ#1]#0I?Q^"H?BC-<))*R,% 44;SYHX;#7Z4Q7J5XC>
MM"/NYA;,W[GE?3T+HG7<YU?$5B2)X"('W2=3MLG &LD)O=I&O&>W,*:)>(*8
M^U#D0@9P8#D9\(4B4\1\*7;Y%!AM^8!3JN*SZ\G+L"1]TL&^]2V(O![Y(R2]
MJFC<M^VZ2#O.>,COR<"3^E3H=4@BYFZ\/4[*CG\U1WB?OR# IW+MG$#).;/\
MRDSD7[HQ;Z9D,8*?[?>"$HH^$&7Z?,]6]#I*LHO'*K:STGU]Z^K01\2<6JFY
M^U80(L@%8;GPRDN?$H1=C]W!.,1<18D[#@(AH=W^BN&] P_\%T'-*^?G#X&/
M++?(P'T85K\<09@BZ9HB)IN[6(D:/K()KJ$005B<7,?W5]B-D/ -BY-D(-VS
M>2'E\;Y+V&M+>'K$RJL2."Z;# B0X&#]]&XXWSDXKJ([/@8CL)LCB8:0<:%(
MR#A/: C%'X.RXX.D!AIA$,KU(Q;3$.T#90./B6P0K2 Y@-5H8D?0,:]O\ >=
MT?#5SX;JG __HB0N4V5]4(D,3+@0%V:,>\G 5!=(W]#Y?%3_1B$TNJ+79$!Y
M@ "-L .L'.E9VDMRL4QKB_Q@T<NSHZ8JY-Z(KK LUC%86XD\L6D?'F(IE#24
M?NQ*H6^:MPAGK]6HNI\;9_,^_N,FBJ>7&5METBQ'7PIM':,D_)>%!VHDYO?E
M7F!=EP88^-IH69L/S]9S2\G=3<QFB9".;V^LXMVD!1@)@'AAS4-419+0DY;.
M' 8F'MB="5"VT_\ =F%=/:5X5BM')SG6<^1!H,=G0)1Z:2RI\,M8^2%Y"Z:G
M=&\=Y/G3/'#]O=>;+_*&3[ T>W<H1@'9N9$?&CK0:?+HTL)T%U"YAS1 ]"\*
MT5R&.-^ /:A1)HO$;>MOV^#-R@G<)@NJ7L\TQO&WD'(_4^2A7RDRA-FKY@!/
MK+(\&;C#A)_=!M4@4K!!!@C<Q1]MV!7$O%7RRUFVY%7<\3?KZO*MY;8;M&-Z
M0*4)R$%<B/G.ZU\Q@8.W>';&7W*YKX0^73C._,>!*-4;Z']B2M>(NY37>@EL
ME<VR(@DQM;5"VL2 @%AVM?1@2\)CW1TL$?&.POBPP;*GN,B =D1LXV)I,JCF
M'A&1C %IQ6-PR7&3>9Z>H0,,\(@!:T7>A*$4&/TZ&=@3T@7'SB$VCER=CP2W
MYZ\>6G4!-7:0A TX!"&^A:7PYC--".;.>H:E_A3E'%"MK,*KE0S<W@W)E3\B
M<@$^"B-(.@N8?*RR2X2='$_21V^[V< =R0#V4$]IX\XE&P)7R8MB+/7,:VP;
M&<@:K@_I;I@^]0IZU^W0I>*/",>9O!J5DB9$T$9^S9/K*/WUJ9G%F$3/?&<$
MEOD-U$WMM)]RE!QQ>',90K="'Y$=V3=3+L'CZ:Y7UZ#PH:8D1\4(4AK:CQ*J
M-7EIZZ-K"#Y$*R;7(>/O!#@A1Q0GP68AIJ.2,5NK2<F.X[^R(P;4 B$ L4;D
MY3<C]@G[([Y)YU)&4YCJ7G=:!+P*P_?70>$Y_R-4!T[H57-]MM,_Q5-OB ON
MN(I8TP3/$1"D$(IQ_774O"DSPR.AYR#HE0V F D,SP -<G-;!(*![Z@:><QK
MB6"VKI'-#,1,FDW[0.ED0QW!/.8_0C0*UJ3AMI',XK'EB,)&7+"Z;9WQ)K\H
M=W1(+K[]I-6TJ9";$J:D1+O")W;)=!/+"MZSJ'D S?^EVWZ:7:1M8X[T^V?Z
M6MV5M )>.<GYL3?ROK9J%&IB"1L)0.LI1DW5PM=<#/N(YQQ0GUY9Y?AYG;B>
M=/Y9(U&A"'D L\-JW-9%8"8#K>;Q.!BH&<(.UIOC#\^9O.B-YK/($YPO/*.R
M/6\J*S!NMS/>4E>WL/0;-:H/8JPKQ?21BB.E.VJ0L.IOW"2)"\^$:]UJ5Z7V
M$0+I7UWQTG.JS?2L?J<@,('YFJ]5=N.+BNO:-7349@EA)QG_G !OND8&WDN^
MA'ST9)PO&; S[P E%-:N5E!0C@Q(VUS$N8/JCT^!=;90$*I[?PME3,,A8C1>
M<AA:.UC0S:>[SKC8LYRVSGI]C7T^H^\C44%@SL]&.MFJRLSLIMN;=^_&.GQ%
M,HN-)W>D_0/5L/B2K12_ZK&TY3D_P$N5[PKG8Y]O7">&5W78;PS:\<:F;:"K
M9$MX'A[58M  8EO"Q'ZFZ]9^E==@)FLPQ+%#5,.32 $I02$N@I;R5?H06HOU
M9\Q!V;IZI!ZV$@#Y3283?N$/="C)?*AP?V:J2P\QH58?4 =!>,4 *00.1KJ4
M(9L[M=-9\Y?@4YVLA-F&CZ]R);CVRC/ %P:J*G3>V"J!IIBZKG.NBL^_'"TK
M4(R\%991 ?2>B*XW>!O1#JX\D]:29/%SPT9\\N$?RV.N4#^OM,1LU2^%$;!]
MJ1.7YH4WH.ZW0(_<6N\)A.@T=?DGM^\(*HN CLU9*C)PN1:VK6[B=S2(Z\O4
MCMYO,GZ90L:O4,BX]$;@]QSY/B&(C:]1& @Z6$<$9,OS/!W:QP#;!9>R!;O@
M?R3[@O>A+#!<P3)B\3.EN;I>WNAU7/]EY#>>ZPV1#N-D $U"[9)QRP97Q"ZX
M6,W2$SY[;=LM?1<7-YM>)S7V@#42%YA2S#"WNF.7?R!(:#<9^ DA\%UT6:_P
M?!MJ(4D&0BGP@NLKGR(#^G_F^Q8*FK!0T*0($Y67=QKL1.92V'?,=JG&!B(+
M=J4-N3-G)K4$=KFON+DO6IE/AR2 M!2\L8?P)O+KF2IXNH\J)J]ZBE\1LJ^?
M#/R9V#=V$[L_(J9AVKM799<-W,+=G@(YP=@F1)YR70>4\R_LYGR?.+?MV2Z;
M<A6X8M\Z0S9B7+BL*,8RM&%QG (L><^ZW:3;WNYDP[9[S*G^!2S4%[!+5\8%
M.A%?G:'0B()C62%!M[@,$:"*(7UO3_V;5CA!,@ C=)&\8O'/M[372L)%#E&.
M'D%'NDWCV.)@S37N[OO@8>GE,+";.>A\+#&PK.)@QY?(G;=99&!HT6SF_M8#
M+DQ;%ZALH7CGPT*8'%^W!TZ9@T"G]TKDH0<I(F]I?HL;<M<2H54X,88@0@HN
MP<HNA@I#IP[FQ45L<>.(= $BX?!IOV[XX@PBKCB7**5@OW:!X)NW8+,&!0*-
M#<:L*LPCDIC_*N?=L#<\)"AH@'IT):G%-X\,\#?U(,"/?4DSH>_?B/ <@K]T
M=D:N+260R  IL4#J4BK'QZEM%]Q&\3-7B'F]#S:%Y(_&Z[]!0>L?H! \] V)
M/RR+_($H.DVN\$FN+YVLQ$#U$5*<Z4/<43V>;W$%ZASFW(/F]0'Q[R=?: 3<
M=34TH;8H?0<\@2MBB'M05YUJV-$A5.$!(D[<3%..R@S,7K&6\\)Q-^ZEWQ%C
MD.<NMII<R)\SY_'J&+V?PMTIC;Z*/!>GRF>>R#_K+N$G9QRC"W_)84"G_#>O
MJ(B%Z!2Z!E%#8?.;L+?N9.!*,J%?HP+,5+Z-)Q9<YNI=.!?9KC01,(_^GU2#
MR7?EOL(8!@4%%:9@!;]W##$ 3?_<S9IYXJ7IO,^$8HA8O-@E%GD#L+6E4SOW
M\<9N\*F/NRB2#B<&?0(G0=/&W@U%KC+T_B]IA8;A HOE#B_-=#[-YXQ6J4GR
M2.6R1: OF58W3'- K#F#-]0TE?ZSW1AR\W%L9]5=X[K.@#.52N/?#CW<_(38
M?XZS,L^+5M^)]S&O;H6.W7KL^SK6R=#,H#R<[$GWY9?5::,7E=KT]*@FS!.(
M$"&.BQ\!:V^ ;E>1J_?!"Q!?6IRU(3$5%QKEI#]\*;SPNK80FDC80$B#?RT9
M>$?G;$:IA'UJW_@*B8]BQV7O+MN#>CXB&(93%"R=JC\6KB1[2@'N'(%L7"Q+
MA@WKOWWU4Y9HHXF"4I"7YDKBE7V:,MLD4A+^Y#4^)7MPLI#?A'21 BFU@;=F
MOZ"(UV88MF4'\9Q-:PA<("C)+'*&&D5O_L2GXK,P_,T?10%[JQ=JQ5;P$TB"
M1 %FB></R4^@QMSJ&T&^%8:D@/4_<(I"=881CM,9_\"BOBL7XE#MFE?J%CLU
M7WP\].+1^8S4!(HE3Z"Y=) <:^F?6B]Z!"F@+?GOQI3S46\1KT=V1JP( Z;2
MSX,RI*=*\'RRK#DV! F7$9"7#+3!H2X78S=EO_&?A5Y[CP%!?1<]&B;1Q(0E
M& CU:FQJ@S.4;B(#;.FZ=B,A%%KS%C/^O+\P%=$ +\G $1>31$S:'3T=$AA@
M I#O/8>FY%LL,8*2NG:@P:D7!=):!>/E$-ZVL)6_.<[\'QQ'0>2UQ#\)C?\X
M)$G OQ6)N8H@+GHNDRCC,(K$/;LS"@WEM1DT3+D(WN!NA$A14!K"T2L:#]^1
MM5N@(1WWZO&^ I_P-AZC;=<_ )&2O11V0DMA)W$XP5_L9+/A@.T.@_%(SW=I
M2 M>U9I X/DV] EXFVF78CASC$6PH4IZ_O-D8B#BW0"^KR8O#X%&$5D0Z0&+
M7G7?;T) \UW9#TFB*Y!258^W?[U3 2;FY5-M&<:D=H'A?4]W0IO?,"R?1&C/
M1[;/9F#N^1> &I!TJ)\!;]8GK(X3'QVV(06BR<"+*/SK#W"LC(O-YO:I==D-
M9"3D )>_0*^X'TZB-;T1RI@0B<MQAJ17B^_^L12ZM*^7Q)52]093*N^KW!TX
MOCJ*VJ)K?=QX+D" $:!6"5T!]JDD]HY;\7SB7KI;POK\GE)K)[>G8E3VY-C^
MN<,.@QVC50X!7C+9LZX$PF?Z1]9JJ=LZ7%@0O!S<8*/]U%-*7.P*V]6@%*/)
M)UU-+"_6TN)P8&)N%!NG*D!U)PI Y9):X8M_[0J>S3WS%5#4A_57OGBQ-Q2U
M_6E\L%\/0B:56/2D9<^<O4%8PC.-KTH;%$F!21W_C3_UD8W"L-18A=\::/N7
M!D*PRR]XJQ1 4B%6'K[X'.)%WI#"7Z%@DXEOE J:"LIL9G6DO)[<':5:Y)N@
M'7,DA$_<TAXOX20/,#']UF69-];@6D.Z(\1%!)(A=(-]>>W6V/[,-10ZZ6V\
MX*6?.6W#AB::)(UO3AU:=X;ZO0O#'H%"T48*&ISI#.3D+4I:;F3@JB3B3(D^
M3NT%;I^*/C'XTS@IOV:\\8(A*'YVF%+H\ ,)NXRHDM6,V''SVMZ1SH80R+7#
MHF9B,"9;DI#R?I(ZE9!,*0MX( _$$HV-,!%;N?)$_K?'&2  1O,VP%>/6/LU
ME\:RZ"0D;.7"$W[2H=W:1\WOVD<H2S2N'E-"#.0G TM,V[H1?0W2%C<0#]PB
M06X-,@#"B^!C"7BFMCYH-NH9P&C+OGJN^O*%4(NS.TP?^\_ZX1E^EC^ZSYJ+
MQ_XH?RS_L_Q!XXURIH@M7.@2!$^\#F8]#8NSITC,YO;P<D^3,=CE/EU]\-SK
MZ0FW@K.:><2%XASJ^9Z$^#,;'0&M*T$<)6$[Q_FJ1*#A'O$BI37!3O9CUHN"
ML"PH_6^[4BM<IO_LF^'14)^^2YA<?S2%\S20@<K_@B#%/R'H[>3'"$H9<A%$
M#8SVW8#?9U>"KW'WF>E6C2/!>DADY1J<17:6N?D[0:8GWP=]/K'GW[R@L#XS
M+!<< 6&?\_H*1'KV_2(]<_LC,)\BT1_A&\+_KI%<>;JM*;1E7Q(.AW@JE'4'
M(.],*;$O.8P[*HTHW"0#YK#SRRZ#6]!D+R+9B!K>U\E 9/1B"9ZIA'0;3N"\
MN2!_*,I\%I\U$;N]J#VCVHL64=$LV3%-023XUTXL0X#LD,5''7))G]UA9Z]Q
M:^,.\W_ 42PNSCD80Z(/15!!<)01[)Z%&("00/"*(<[.\].WAQL_9%,/1385
M)=)NPM.->Y_NU4.ME" ")ZS2L8-=?8BI042]/^2&%?:M5M^U$FDH_*=(UQQ4
MCD0T#(#4+B<-U*-^H%4/2XS3LK]Y5,.T$X2SRS:S+O.G6*!1E;Z$S"]$$!A+
M4I6@#"*H]YLQ^;LAOCW[@H>OS<,06^IF(A,/Y=VC-(HH,NK:ST6-W\MF<84A
M#B2U$!C>K#Y[&PJHW66SUGY$K\A.";' ,BC%9$'5%_^$# 1U05X"L9?Q/]D+
M2^=U'O_UG^MID/KW^K,Z&?.C.HG=+4FBK!'H\H9EV(PN!39$?\"&#_HG?\%L
M*N^+5!K'[@DF UVL\Q9/W-I3&$BVMNM%"@W34'+8;"*8^91>LWO7M<*#']!5
M02G%'L'%=CV4:%AL.37;!V4I1OCT^5BPWAX:5D&["D286]M^P\-Y,G"4%[&Y
M?@J\9VZ.$^U,7DOYNDM%1FHWU@^1 57./ L'$%Y,\BL!P\3CSZ9[#K9 ],/(
MX1_T8TI^QP36MEB6\%AKK>L'8PD]!B5.QMYJ+HBSQ#8N%O/MTW)MCXVPP<J-
M0M.328&5H I_\\82/,\OJ=3_>]%BYS<LU#5@GD$N_LBR:K=8"GY'MII=+1C(
MJ(=DVN?^UW>,Q:R7WB\Q+$-Z9NM_%$;IO*V<IQ',/W@+[!]+%;6[2Q5,!7D'
M9.9;%ZNB*DQEX7AZ:X>=1(Q@W7?#^K9RE6I*^%,DTJU]2T4DEYL[H++^3AO%
M/K01XG5JS*Y&,E:8A3#AS=J?"Q.(:>0<-#=HPO,U5CY$ZSQBXQ&%1@0AFF+Q
M(@0*UK_*;UC]YD!9EGC>5@E3&M\<6_M1$YTGJ7S&_V0DE?@OM[K&N"!<_"]*
M(O1P>E@:NZ]AY;_*+O]!2?Y5)?W%2:Z(*CX0 ?TA <E?6'1A=NF\]]@A;&!?
MM:OSN9#K%&4DAS\4P9L.$14( E#&[,UOP,;>K8V=7482[_^[7K+9]2]T@"X]
M_G%I,;9),,F&0Q_EG '%!S]R51;T\<Q;0*QA=B72U4"*)+JU*XGXY,C ]R(+
M]_+!5U0[CY!?*F3UW.ZL0/;/25C$']PY8&>[[1+[I>9Z:8=RUYXU<^+CPUVD
MD$_$CA"1R0;\09D&PB;D N<XU]UWD:'AW\@ ,4?&_&8BFPC+VL7>K"CQZ.^4
MA8#CSO%C'QP/=^A<M*:I\-NO[#%>815=_5@GC/?.FWTMZ>J >?4=%-L4C6TD
MH>_LDL2*(!.?.=5]ZTVN(FU,18&;K]47[Z(;_9]EKIWP>D6LU)??!I_V/A_4
M.[YL :*3/6&RM\O$I^:\KKK &Q_-EQQ#[MP894C,03_U_^3 .=SD]HV]H,G/
MKV3PD:CFRI%'85-*22*KL/MUWI6//$OEAE_&F)_4?C;@N'?09W'%++_#M=7[
MQ?;Y28THQJF))8/JKI<GHKIXA(%1QDYG;7'I\\K?^;X/\^8**Z=T\:DDFBD?
M-#D1W#?SR&,Y-%'E397N#:1M0^3'ZV)Q0@W>L<L[L]4[;T\=2C6DS3C:\^+F
M$Z2"[> (%9\R839/3^=&P-%V??;@D[4#FQ=+!'LS[QZK43-]DO9$'U[DD[%W
M=?HKYRIV/KXSF;FL]L[G_:?1LB@'/FQ%]?/EXYD')VWV?FI#=[)F<G\KZ4G4
MTO*LNYO7<BKEEIS$'%PQ;TMSYP+6_F+<'=XI+@"A_=;0.O+,EWL>/!SR7MUZ
MBKVH&\^KGQ).%'GV[#%P\(,9(^<O9XBM*G<]\$Y^';,E?^55C&Y[3K2H^UJ>
M8.R'_7'(_?-&>0^D'K)S3[,,\6ENRB(N5?27CRD+]/JD!BQ'-[:7,=-PT=RF
MB>W,,XD_UO-( ?(YHF+-:A(4(C5WS<6%A)4?<1LI='H]WX"E?@[UKG-\>;SZ
M;&F+F%AK@?+;#@]FY$E!9D:18G63NB\Y-2U\'&XT&8@'L'G+BG9G@T6TP9OX
MIBNEX6Q'0V?M6*KN8!-&E/..R_XU:GQ2*TOG:-C-J]$*VT;*RHN=)T*9;8:O
M#G<.U[UEM-=B9*LZ>YDW-''LLB7NCH]9[ZF*MUHGSG#N;SX=$4VOL((,'/_+
MR;*;=OV#TB*V=>WVR_KT_#ZGHI1]3_GG_I(>9>W,?/NP6"+G+B 7;?<\(ZK]
M<Z9L=(*:L=@^$XS2[7,;^>?//[5Z%CPSS8;O)?05HSRFSZ0B^#*C2Y_4+#-+
MDA0*N2$HX=)W<^5I/L/&,N24%4O7)4]3I0!+-$I+:I973UMYH,)^U<5RIB6;
M/X]6Y_0E00TM+@-%D/,KSO9BLNKJ3%*RT$-IJU=-1U=951)]>[N$RK1O'4D:
M"L>K2;8*7"\;PQ=XSQ@9F;D*ZDGZG?<<'X.EF\9T3TF%]-2HD3SZBTV#<,4B
M?V6(6]2F##%J,>Z@^E]M'2](<<FZ5'9VSU-[CY@0+;"B$U<U28)RF=NW*((H
ML[1,M;W$$Q/FT,07_?R2XEY,+C4!-U7W/[OHB&55"L*J)&9G-^9_<')A'JX]
M%,OS6E]83N9!Z!Q7BTI]GW-.4OM][5.9#R?@U-8XQ6\$+?<;-8?$HLYDZK[I
M&NA_&USU@CCOF/LT+7W((RJJ3$S'%7OE8;VUZTCT^H!*HA%&.S[@0M1"#B<\
M*:1NT;(Z*!7.+IP3VE4TE"-UJ?U)![^5PPN5K'O"E>Q10;%]2K(JV:@KPT7O
MQ?7=A<X^$*$+PVP4RYW#:09ENU0>?N3\6;ORRT,FQE:)F#&7DAZ)X'/N(0'"
MF47#VNO"@]<,L<T8'G^E#*KB)+:C[\-OL@@8UCV]QC[:MV,Q5+"L7W9OY?J0
M^SE\K]SIBN:S\K#3RB%B@5#0*Z[H!3VKI,[W<Q#"E/)G;.J6*T13PQ4\.4X&
M+$7Y5KL5MIWP='J><]!Y?R:[\$2[/FS20N/3!RDM)P^Y!R?,^IFY+^F4Z[0R
M"$7;1A)UC=+B3K(Y'"L(YJOOW0Q:[.L7>'CK9H#:LT><HUXQ676:.N4A<.WR
MUS?W?58K3>9UH.%&#7.G8)Q.'DV2/H)MMN5AR%3N=.Y0,'D:?\D0Q?7V15:4
MV-[=U5;*/A.L3Q_A$UR0KZ5D],%U*$E$C(UKB5LP#2./KO,QI=WRK1*1'OEP
MO&6TAGZJYSFP_K)J]7 ]NT$-=OI\JY^H9\""8AIFM;CI/?K28=?N>6E=V5H_
MYL-::=4G56W;,+S]SWJ^W]<YZQ&F2<CLZ7FIPU)[IOM[N-!#>$T40!*EUA8M
MU'4P[CNQ;,1W]M+.=<ED!;?L;+_Y7M;.L$/-?\U[76XD%;%W,+[1/WD,5&!E
MDAS/6_S@$3_LSW;LF0HJ0#Q-O.68W[#6Q!37%%_(XUOP!SX%34R(]\=EGORE
M<N.CAAQ-C'2+U![,\).%9*=;[?5,<<_2GO49"Q&PDF#H4RK8_>NKY8&C#!=K
M:]Y48Z<'#YN)%K3XRQ/AAY<*'E?URP8%Y1&[&!-]6BVNM>S;IS@E$CMC]F)-
MN$+B/?I4Y*VBS_?<):>9%:Z=F4#L9U!),V P-!@;T0QPDBBOQLZH/8Z(B# V
M5.6MS:#^<HR-/GYE6YN3,97NMB>KOO6.E^[;5?K$W*NZ7B&RHRN"K\52;I=&
M]*EN*)-<\K/"V#B.BD5/:M [.4+3\S[UO2^[]17=6>LC-8GVB:8M_0(8+L%7
M+KY1P.PM(NNKKR--;B>V;>S/'W$TN\3P=>2!RKLM_HJB[+G^YWP)ED/X#"N%
M)_B8RTG*6B+SEC]^2T1CIYYTYG&DZ1TCY<=>YO7T/;(TMQ(Z_+:"_)/D)[5\
MPTSB>6*F9'NZ53DVZLZ,:/9<_ZO<J'(U?#][/)401+FK?Q+SB*!)G;/5)V=T
M'A4$N L]QOCG"%2^4Z7IB12,2CBW6IDZV23YE\6YIW3NDMO7F"=8]5#K1?F[
M/^T%"L?.7ZCH=2\J$9;:4Y38K&X%W.(2X5O4ADR2(0/4\V:'UFSPR5YC+8W$
M-OO.61I(PH7I*4NYH+*B %%H+T"@&O.L&$_2<.PK8T'1<BKP@IP1'A/*)V?[
MASNU5EC2&$W.8VX/N:XOQFHOB+Y@4M1+<,D:?'3V]#>!#_6^)[24XK6V"WH-
M5>DX_F.7K2>$RABJ[N,P5 ?^O]H1Y*'_!5!+ P04    "  V?#=5?TWK#^\J
M  "E,   #0   &EM86=E7S Q,RYJ<&?->@54E-WZ[SL,W4A(=W=W(RT22DM(
M(](@(,@ "B(UA(" TD@//72I@(#2Y1""=(?$@,#<\8OS_\YWSKWW?^Y==ZW[
MSGK6FCW[W>_>O_W\GMKOH&90BP"ICH:V!@ "@0!;] = S0)J "XV-@XV%BX.
M#@X>'BX^(041(0$!(<T-<A(*!EHF1@9:>GIF=D$N9E9^-GIZ;BD>?F$1<7%Q
M)BX9!6E1>4$Q<=%?#P'AX>$1$A!2$Q%1B[+0LXC^QQ>J"R##!>&";,$@5@"#
M# 0F Z$^ DP  ,("_78!?UP@## F%C8.+AX^ ?J&!E(  P0&8V""L; P,=&]
M3]'] "89U@T6$15L<L,'.*S>%*+A27FX;*HUW91&HP?L8G8^$7CX5#>I:6@Y
M.+FX>7C%)22EI&5DU6ZI:VAJ:>O<O6=L8FIF;F'OX.CD[.+ZT-?/_W% 8-"3
M9\\CHUY$OXQ)3GF5FI;^.B,SOZ"PZ%UQ26E9;5U] [RQJ;GE_8>//;U]G_H'
MQL8G)J>F9[XBEKXOKZRNK6]L;AT>_3@^.3U#GE_\P@4"P* _KW^+BPR-"P,3
M$XR)\PL7""/@UPUDF%@L(M@W5 QQ'GB3LXJ&XU*H)N75=..QB1D=4-KYC.)3
ML8LO<1S^@O8;LO\>L(C_(V3_ /9?N!  (1B$5AZ8#% "SBZX\\/PQ51@ELJ=
MG4$2P>X:5XQ+$CS,#8]C[98'3?!O-M$HG'?G$K^+69?G""Z90QI["!6ZM:ZF
M^?'?TURC3)JP];,&RELXJP1+!,>^]^_L"3@=.;Y<,5U_6,U<A?D@$G S5*<
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M<]-OT[:ORLGVI\&4"^ AWNRJ=RH5KE)/W ?V(K:H(OMJJ(>GVVU#E";W)(A
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MT:362MET/4)<<$@!H,]<[F#Z\(Z]\8M;P;S%\&EKTKJVQZ=6^0_/^Q6>MI>
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MM'Z\&[[+&H]V^AC@[;N6@64]ZY:6D^EZ;1Z8-\M7TY1VX(\;%_4 CU'M3 O
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M9:891, U1C'2Y"T%* ,%X*Z]0 '*[G(H '3WDI=D!TK$F.GQ"A*T"BF![J.
M@&(;CX9:M\^>(32PGE)]2/$Y4^=D85LF'B<O,3C(B(?)OQGA/8N#3LJJD7>5
MK;RLL@A(=Q_94:W-"RL_2N\5R_8V10%+#".=&T3%D$5>2&307L;2/KV*AY.8
MN*]:AYO+N]8Y@N^L9 EF.W:UX.304S=]K8.SF$=M]D0]:WG^WK9)<9_&(^(Z
MS+!HM(="/L.5-Q."#7!LY>7RDE  \Q_+YD8!SWW5T%25?(L"PDJO*0N+PW65
M:7(.$EP@Q]CCG0>42N\SKYE&6#6"Q.,ER#1T)>IM0><FE?:!=?I9Q@?9I<6S
M&K5ZOH\.R\1L1=BHOP!&4R$22ZV5HBY.]>,5HSI:/W#MK<*$/;3IP7'W]AV7
MN,=XV.M'#9UHXC.EP[RW%-S0Y>9S-<OZR077RKOWQG<60)A$S-^\\0OSU+ 7
MVQQ[I;QF<"JU"P*YC+.,ZULF6",&<.VR\!CJB=Z.X^!_4N.M 9+O3E<" ?8?
M6FB8COY8,!2I*:YT 7;]AL3/6;+0">P1 )P@: 6BF49W!P5TH;F/K[1$/X(.
M6']LK>L8(Q;@])N6_WI347&@W*WJ&)>A+&>I#/D4)UV'@7V[QPFRA(LF#&<Q
M$CT3^^+U5%1U$!=-=\P]6O4$R<BBP;BXFMDX+VQT%MMT> G/IA^3H!K+_.XV
MR]66)KV&RZ8UJ9MH6;6P&)!+G'Y-]H7D.NQW3AG^C4]\*4RD>\0%IQQC] OI
MPD]?#86K103]4)"$WCF9V4"\>C(4[URJ&I<TKUK'VVB,Z8P=QOHW35+\'?%X
MH3P^\.7O^M:[9,E7K,0Z.W5/)%,]#+)QTJML*NU?+IF]R/QP&!!SHD3\T$U<
MU$+?@2RI\C1DD^O54.N,I(I= =A#&(_]'CR4OZ-NU-^\ZCEM?&^.+R$!!YQ5
M^W.^:$&R<G<*3G9$F*P24M/O'[K0O&3+9+H"U>]?8ND?P&3U7XJIEDT_N6M)
M:E6=4I%M&]?RJ1W[6X:T0E^1/R/M].JT;<M/O?29/?<BLG[25UJ*#J9&U/9(
MLU"97 *EOQ+TG_7M9X#M_-=YRC)SGHOK:=YNJJ-U?,7H0_'#'JXWF+T<4[XL
M1&Z%#)6CKA# ZIF<;;+ZM%=6$CF3^.:8^G1[UUA<B6;^X<4$&5WP@V)KFN0I
MLT+^G_GX9G -R;=]#$B:;66Z[:5V4FX<C?%:G,N+8J31O[!G#;+D:%ZC=,@W
M81\=9K(T*NG._ZE"^=%B"UE"^X5)5.RRKKN-4<Q'\WD-!PT>KP%,'U$LP9O)
M&E()G6-A$IW_Q$^FO\*MW\@E'/XK9)6#M1?0\S\:AH$YIDTC]03M.HCA74^/
MK,LJ8>8^'^T=A>8*(N?>)VG0TD&\\=WBL \M BDY(MH(RA7J]P5R[O3K$4&Y
M1+%,.!MIGGYWLIR%<KS&+T_[CQQ ]=[CT"G8W]G4]ZR7B#C.0X* A_9$:%;/
MA;_#F[TK49*J;\ [^XDQ$](\\\%++LGI&HU[VK5:BD%DZ3ZB0'"BIO2F,H/4
M7[53+IGI'A^U7V,^.^O9[<G)H3=STE5V(5A#U> P+?)!G(,CT"'*$;3L)^TH
MS1ZJ4?]/;X/ <<A83U_?8E<W_-LCE4=9.8(\[!A* M='O6ID;]M)[IORV9<%
MC@W_9.SE>WJ+5YG*4W'Z,R%N"LFX##5TU0G32SA(8KO>+DP^F2BXS^==6H1<
M6#P;W[! AI*+^W:W05B9NT"$ZI'L&Y]=17U:BYD@+\T@4 18:-B#/3C*D)$L
MUAFVOCG,.+DM78 1)@W!>:C(U3YU0C'-)C+[;C?I-7YT5A!^&1(4?INQ<CMI
MK#7F-LF=5_4@38L?G=4-)'6>/ZZ_<*6O7NW.WA'9SSQBD+IWR G-GU-X/<'^
M@VJ./P+A;+8Z\[.;'/M1\DT.%6MEZB&W61Z1+T"0>E_,I0O4Z\:84R)"C<6X
MCL7=AVVACU=7>'"1:%YQHT_@Q;W#<$A#!;GX#]5PFYT]>VO\/5SO")5^3/_C
M*O,>ZEP24:CUX1M%]NKQU5C_ZC?OG8)5%2?R34SL&[1427GHPX>"Z$W?5>F(
MH%-CG"1U"E!.<-YF9IQ83_ #=V^&;I,,ASB&U=!-Q<+'I1QC.\6WM-V9_;0^
MZU12LQB$X4/M@.\P0V4*#6@Q ;3^:=3L\'SKYZ.HG8OUZ<PZ3T_*"CQ,LD)#
MC3Q#4EMNAK!2%W0"NM+F"*ER37:M=36=\NKQ#Z#,8C]]ITJKT7N@1IR=4VG4
M=/AUC*NYO@7>,N%1F:G"TA!I;ZQ5$+_BF7%.'9)P50(N3]<8?S=!=6U)Y]QV
M3^0E@OD^SY;8YK6XI4N+^]OH&G@-/&9$$ETBL8*DG&7Z8,H2G^8N#='UM^+3
MR!4I#76SW;7 D1;Q4-NG/?#PQAJ98>K*K.&;7V>1UM/6,33O&EOP[4P<H^,_
M( <3;QXJN(#-CY]*JOV8L6A<V"95T.;ZP9YR(F%'8"8P^/I!@A@+U@ W732
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ME[>/;^CK-V%OW[T/CT](3$I.^? Q-3<OOZ"PJ+CD4TUM77U#8U-S2T]O7__
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M?.:!1+K/?6&/EJBGZ)\($4FG;R=PYWWX<.O6?2-?'%78;#M:?R,Z)*'L0S^
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MB?W#?2ZKAM;F\)6^3^\F^FLW46DC,QV5D%2HGU0;Q6HI)W4$MF'I9V?-<#!
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M^C%>8^;<Z13LWA%X!^NNC;SO?9AY&6\WWL 2FUSZXL?+]G+JU85]P&VQ2CX
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MI288:F"1-AV#1X'.EWX&#6&^^NRMOU J>(.M[%77PL)R:;68D<.U]X&=AYW
M0K:2K6;5,Q>0B$3'>J8S6R^_H:$LER$K]/7+#\Q+IW6YWE,+&YL2#;!T- 32
M4>BI>>.;A]!D:U===QH(?\!.DW&4==X@,>ALJ1^919NDH75L@K_\=):U&286
MSR0(OHW'S3H67A1>];B.^PV(U/ K.! 6YM_BH1Q3B5T$343YMJ34W3(!Z23X
MP'35/Y>$A.I-EKX.6@(ZT/*+0*.J(E04?68+R_.)$(>"'&.EPRV]U)#L11F
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M:7.#UK//I6JR,9%T,$JN?W.)OVTO91$^G8:L!G@XKQXX<*',,\]\?!E3J)T
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M4WXEY*<+R9).LZ:[_M'.'G(JU\7*P7';CW)B8/N<=0;#!]$PUT=MA:1Y+TQ
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M34VJBZ\2JF'&A](."A_,9!TC^L#K\A/ZV@O[(.Q6%V,]B%7HQ:L)[1C#XOG
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M_ ^5I:[5!#X(DV.0^KWPWP!02P,$%     @ -GPW50+GV? *'@  ?!\   T
M  !I;6%G95\P,38N:G!GI7=U5)3?]^X[##!TCW0)TMT=(@PADC*$TJ)T@X P
MDNI(*R AC31(#(U(2TM+2'?GT,SE\[N_N/>N[UWKQG[7_N.<LT\\Y[SG.<_&
M_,$L &2::AIJ  @$ BSO/@ S Z@ >+BX$%P</ @$@H^/1T!$14Q$2$A$2T%)
M2L5(Q\S$2,? P,(NP,ERGX^-@8%+DIM/2%A,3(R94UI>2D1.0%1,Y)]!0/CX
M^$2$1#3$Q#0BK RL(O_7AOD)D.,!T2 F,.@^@$4. I.#,!T ,P" <$#_9L"_
M&P@+C(V#"\'#)R"\"T"1 5@@,!@+&XR#@XU]UQIXUPY@D^-0L HKXU+J64'N
MNU.)!,=EX;$]K&B%Z@\?L(M:>X3@$]RCIJ&E>\#!R<7-(R8N(2DE+:/R2%4-
MIJZA:6#XU AN;&)J8_O"[N4K>P=/+V\?W]=^_J%AX1'OWG] QG_ZG)"8]"4Y
M)3LG-^];?D%A4655-:JFMJZ^H:V]H[.K^U=/[\CHV/C$Y)^IZ<6EY975M?6-
MS:W#H^.34_39^<7E/[A  !CT'_8O<9'?X<+"Q@9C0_[!!<+R_2> '!N'51B7
M0ED/8N5.>5\D&(_J85Q612L^FZC^ =3:8YC@'KO8XH/#?Z#]&[+_,V A_T_(
M_A/8?^&:!HC H+O# Y,#BL#9)5?V6X+_K1=-4L>U'GVJQP -BN5Y@/' HS.A
M+K=!,,++ \%J/.E?-L;/ERUV @$?;R$(.C^9^($)U4UBO1%U&1\P )W^9YN2
M9+=\Z6NN;6:]*!A>4,E##" 3MO5+<3WC!HUH:[I=[_#Y76\69==[;Z^"62BF
M3USW=0[,\]@QB?;TWCZR<\F>[9L40<E)Y[@-YZU)1F[&LA'%Y3U:YUYY]5_7
MG7[5=(/)"MA,]S]RGMOIMPRBK"6WLK7\+.LL]I4Y2#>UK>T5[W.&%5(V:N@K
M?[9L'V,8W7[_T22>%JB+RD' Z75N3F0FQLMJC$$9HO+1X"!(U@VOMSUOY^Q:
M_.>@!S8^L6-"S[IEXF/2W'X>&%XADUA&"),GYUA'Q/IBJN8=)-!'"<25L-;6
M_:<MB\('ZS>X3AA@?Z&,M^LM,TU/+.DEPW/8E;9Q&!=#44Q;313[^)[MEMB.
M_[MK#@5Z#) YD'%S385HLUD<NB2:P@#SK>86*!U5B]ZW14^P0H(2S#M].:<5
MN@O^QPC875>&?^\*7;V"7Q5?Z*$0#2T)3)V^I Y#!A\[_7$Z#MM)2AV.?K7J
MW7N<R)D)_<[;N:M$5Y/T%G+I) ^Y>KH+35#WJ%+72B94I3*\1Z6G"OQ+'_DS
MA.)FP=+XR;A-ASY0I]F;PHJ,?_UW+[# -)A_(MN"%S0-,5%LOW;\\F-B.9R=
M3(2LJ4<L*LS"(V"<V,Q$%"8P<;3+AO.U@0+BN;MK#B_8\MRF3(I+=@Z^&9->
M(-67S?!ORPNP!T^TO1@,.ADL-SC\?%\%S2XY>G*\_BM*YXIW[%:JS&7O2G?\
MB:O+:D( AUOH1@X2.0"RI(4M\>965H<M"V5=(A>_SM3O=GVEXWWD.6S*U05
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M$?1B?ET#*J)3,^3EUX@UO=_QHC/?R[X\R2V;15WW\XRTJ3F$;7KD9SO"?V"
MB1I)\5W]2=-#HJ0)OA$S^E?+)'!:2PV6(&]7I1<Q5VIJGDQ]^FVJ2OWOW%;
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M-@D.#@D7-3DUU__I#=X(X*,#U:!R,(@&0,('@?%!\&8  @ @%-#/#?BU@9#
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MYG6131NK%P3 4U/0R\/>K0M/[?"5HDE8.Q["KE>0%?.;?@81KC%$D/ _=Y-
M;H9&6;4013O\7P1_Z0RM*K.'/ +!R(8_;Q#"_NFA)RIB5B8)1RVDX!RD4+D
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MD:#_+I0E>UTA?AIP^ E!-">C.'6_TP!;#V S (I8ZV9PA9:U.%%(O@]OFGB
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MQL!2[DPX\98 SN%.*T8KFH"H94_;&\48@F_6;GORK =*!_>>)HXW0J8W>YF
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MT02<#"TY04RG6/1^HI,/_,??\0V+Z:SBS5*.$#QVJ^!3:9A@ULB7?-GP14+
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M;I6U].72CB8:%4H;^2N!O-CB#1K=13EVF^V68@E?E31M<(Y@9W*6'C#[%2#
M%7KNC4&!1^&VKG/7.?JJ?"H_31K/)F]E.OR''="(.14,3DH8*A=F4[-@HZ2A
M7"8:KH71,>.]O)TX93_JS>]2O 5CAB[%0D>--*HKY*._MHT_2[8;CVAU'*-*
MSB(:/5D_4P$I&QX37&G%J7&<OWV5=V4.\I%O!:T&05>=$X6UJ^N^\"DU8042
MW+Z8KN%;KF3:DF_L:RCG3-MG8>NWH&?N"1S%)Z$67":Y)FT_3L&-314\5Q$L
M?,7$6Z5&AR2#Q)W,+GUQ :!T]'4E'*WRZHU.MJ#>TUN0=0^=99)3H9E+2G%M
M 9P%CE)&<8(]UFMUV>G?Z^=EZV0RZ:2BV5NG%]H'N_#JTNRK]S@I?J1]W(,4
M&>!HMJQF?PJCE: 0A?16NVT?=Q!KAC]:Y7X[W+EAIVE':.(30Q=\CCU2YJ<7
MT[NEP!K':4PR'<YY]E8X\)JMBI3<48*L2G2MT"G$6#C:=Q3K@U4Z!K7$QJ"W
M$B:JE:\,_RM>BH,?;R8F9,H(2E2Z:Z#%RZ%2X Z!5LY6CWXTY5#QN\J9C@R3
MS1*\S6KM=!.Y$8KM#C4?A8LYJY"$/%4BW$+T7,UJ3%T,V;!:J@G!;8IF HR3
M63R@(=>TZE7#6V=F5Q8?W:=4VDJS.F7<)Q-V^L2BWQ_^J&#Y89W)S1$O+Q/*
M^S3!:U"BE;L_007->I+'I<>1_^V"8)K%=J0<@_570KG7*=,'^_T)ZD_]FDMT
M]6VY>=LBB<UF24VH^D2"K?I2>IG V:N#03V#M,.+;ULS&3]L98\O!E#M@,$I
MBZ0%S !36M#/_=X '"@(NYJ_7"^[^6C9=KUW[00:PWVO(J0J]PS',1EO0_S7
M#^$*\+1&J(I]AQ0K7!.$ U<T&4&-[4=HR\B.AM _:\Y5"D@+I\4KLJ!. ?H7
MV:N' =W(-@+S-8L3-YE._E(SOU/2T_11]@92\]<'%?)G'JXB5Q:;"ST. @RO
MQUO5=$F7>VI>3AX>)'=?C/CO7PVV1A1^M"06.*&:LLM*LE_O6(B[$[I+;6:^
MM8 ]2,HU6.H@QWA,3OG-1]N61A5;C'F,C9@NM)?'/!S]^V3]7"YG\B<!7FWM
MD=W5P6VGC^W!SV=DJXR5.59>=OT E,3*T_'";-.BGWFRN#]&Q4^<9#GPG[M8
M9"AV]CP:MJ6-$>BDLY/%?-.J-/)5Q'-(#I/WK]^:#$+.3S\BDGHA]!_I[P .
MK/$L%T=L\GM8EQ^5R M5<V(#A1KXX7:-SJ1(\3QY5)T/99GOXRZNS5ZJOW)V
M"5KEY:;MYUFSSO056-%9"D$L$&RC):>0X(!KDEM&[+?1VP8*/$W:KO@A6W"
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M1XO V8EO+^1)Y8;N/-/7ON^ N(>PU\JV)0L<[_W&8)*K !WRYP4/?H?\5#.
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MW=P"%P"L.7JW*S=V?XITFFK9CW9K?5$*>LW>P6=XJ]N#6ZEY8-,JYO#0$]'
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MQ44?T[DCO[:13F/-+K)D-E&[_J#4'!TK)F>?;(T'WB8IK7W# \LV@1+YF9$
MSU^ 5UQ3#0&ZKJ(B\ 60@:7HPPHX(7"JO#?*N%O=1QOA@X*!,+ 0#8WX;O++
MYMOG:3LHKR(.L(+TK>X=S8E39E9^JHO2C:T%VXK"ZW5:)P_')Y(2;2E][*A<
MJ:,EEZ(62P<NT7A8J(JV)>Q<$2N[_C+1?:FP/+@K=/Q*&A/+9DFJ?4U9'^/L
MNFM-V*1$FY)/X-)^7F_!RLBN6MST1,=.4(-\($.OUJ!G)DW0<V6<B"395CN
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MZZ?PXG!-5_.]DE3%Y1,CZKFMH_-R0M#(LW:4;1Z/+NI5A>RVQ)Q^@^TM3SP
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M[]'..,N:=5@TT ANE<U-)PV,$%PGF[9-D0ADPQ:=-^;Z)_O%R!WJ,M!,ZUU
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M2[7R--A/=1;!+)@4<*"T\D20MBP\I;_!KF,R.]WG>=F+"S<>,!L[T[CF#3P
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M<WP!!G#E1OYAA<@(>KPY/5:A+NI!Q&<UU@!?63D/!<HA96I QY)U%!$>;P\
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M -)E6>DOVTN3,II.EUEUN\[B#E.!T00R^]L]E8JYP3+D5PR%M\\8L&0#J6(
M&K/LERW,V_-$PVLCB#@JD]<<R7WSWMG(O>MD35W,1(?I7#C-R8;7II189K=E
MOQ13WH^H$O:Y\=3C,+=,6X'ZR,D_HYGU>'X@J&;N 3A?-\BC^SKT\\2-'(>S
MS?%G)0+/II[UNLCUE-LM!&V4CRO,!)-;I\[Z;M!,.OKPVA68F2*V<3JH)%/B
MJQZ2K+Z8V#2]'5[+HFN*EFTIXI_[8I1LCRS6CB;;DL2E.F!5"FB7L13,(;^G
MFU+,.#R4>$_L>TI"?>/;3H9F3>;T=\]WX1<M J,LHOAU:)%$8_Z-I)L+\2$/
MGM+JIF@4.3MO,Y*L9FDR4(-F I39KZY%(8,&38(NF5/&)M+@]083>P%TE&;V
M?/%]J6ZR"]/: ?6W&1ZO7>Z1TVPB &ULOZ*'%9PN9/8>=$WGSZD"%-Q_U8 !
MYD6^!2QL9U^N/,PA=[],;UV5K\  $V5!9PR5>=L;Y%,?KI3.]B_]NC# ^_0S
MN6 B)Z'@IY_]L[C'=## H]K17?/I8]PL_#;[V2?,S''CP9+2@XPP9='==UWA
M^ZP; 8[Q0ET9\1TA20-TKR>7&CY#FO70$Z\1,:I+[Y;"SN9LD+611BZK"08Z
M9=]4>S.'L\E.K:1=] O0HB,J E]'ODV'V X_3X- N=MX0[,DBN#;JL-E5PSS
M42;2@:G'U5UNMS[W%3/<76K$EE4+9"&I"<]_G.E\!_VN>O]AICXQ"%[B&+8S
M.%*0M:C$[!XJ/T&1(<'H/5''VU@(Z]'DD )ST<MG&E(L8L,[<$?9VUIA@E1T
M(:+)\3G"./DHWWUST;_'D]U5X!-L%&QO$F'+RV0,D!!^%RO9QO*'4L !!@!C
M?7XM88 SK&Q@-9MF;P$1?A$I97@9!+T$)EZ>0J]4!\FQ&WL!/:.O]+G,:Y.C
M& [& -G[E_'?(?V\?PD-&I1CYTQPV_:FA:]#]@%A#;8M)L2FT4B@]E_0X4A]
MR&,'OK7C4L0K*[G8N-BXUAU7J>(2GUA'W"V^P--4!@#@CI0NKF#LZ[P?W$=K
M9Z,MUVNOQF/-E S\E4<[-W>M>=GNN9RP=5)#W_1/$S+L9QV"AB^4F0*H?.-^
M;;MA@+S$QBI!<Z?E*>0#SA!VNN-47O#-M(:$HL="/2VR"]?-&N;VS1.%8^U!
MORM-'DD,L#*O>4)^4/+G-(?\Q3H6$@;89[21<SL:O$(7:D$^/>^W.(!.!&V/
MRU^23 P=_0S?&<, -RY]KIJML5O<'PA5P-,;96M*[U^I::*M2104?*V.L,M.
M1@^7CTEO[O&7PTR<) 4*<*WHY_2R HU>*##3+(34-D7-S'1$J9/8OEJI-_LB
M'9-E.3L;D*D^LO[KA>P6E [NJ"&\Y/]A:Z)O7.S.Y^]=UZ^IZ17WZ @/CA>;
M.<[SIY_ I**E.K/M[>HDZK0ZYYGO$]Q-XTADYU.M=&Q:WHZC?H!JCKDL>!NS
M8RG^5)V7K^V@J46A"=L/ $>@$V7^Z^=YFP\4\*BU_[MA"\O[0=WM6#$NRSYC
M"82:JZ/]E[+J5YI--!J&"VO4=G/L%W8IA3)3!^GQ@^7\4?(7<5E0+*U.Y0\%
M+9QG51C9 O)3PNY_B"6\2OFI^:*%[#3FR(S)PB1&9JH-SO%X7>Q"]0;IB_HQ
M3;\SY\,<,MYV6L:YEMK2WM(?8@;C)S\OWYM+IR1WO;Q''),G.?TH<+O6HE&B
MBX7WMMIPA4@74MA17+S5_EV!HB"T 7)JR/)![]E?V]>\558,\$K=U.XKL?_Y
M.[%^YZ7F++QW_5\-'AGHGM=3)(20X680GFGA8H!KV'9$#8EE:ATV#B1YRRJ@
M1D,RNN4_*#;=? LZ8TCP[5(E&2U$Q6J>DLT;!['#'@<XJV+CA3QH(:WUM!38
MM*]P<HMIW6@-;]WO6[C0UZH;1=IYEBTXO$?@^4LL>WM23[J<5\=EU"U@D^4_
MZ_L/65,K;K_VE_;/?XIC$X(:^G0L(:4(=470=OE[$2! ]^]M(N^<R;'+*$MO
MT!=5IT1L2,?98@#&WF$YT/S68'&IT_A0!F\7POESEX<6F:K<(2CH+RUDY0T4
MYY?6:Q?RS<B&D=I @<V]/*-94Y-NG&#/SO&*74CT^#VAP1Q?7Z:Z=C&/!:@X
M#/BQ5;[WWJ%HNK9_]ZOW\9:"PTW+4B%W(0UCW00-N'7"_>[(+?\[W3GD,M!K
MHF(-375F0E,"I-UAW[C??>]AW6!U8OG$$U 3T[#Z0E_&9<7EMLZI#Q^N:8=O
ML;&2E/*Q+X/*L0XH7F#!_&BJ->1"DL,GH2[!U0#]-6F1HN$%QS7/@P/U%1;-
M<E:.[_B52[S]9$,K",HOU5_OKUW#(:!G^=0!N,:&I#:4MXB"+X/"T=@@M?V=
MPV\_')>Q*=F"U2:R@)@TWEEZ"SY42HS\!16'^D-? 3XBAJ(UG0L_%]H73M;=
MKGAJ6FMEL))%"#T6VP7WG7-.(P=YG*V?]UE[ =ZC_^:Z7ZO),+F5;A,E%KP;
MQ)'P@: 0)/;^^7-7/ZM@:1AO^A_'B '^.$?CZ?&2%5G:3ND2)H5DV:]:+D:%
M]$(2#R_WIOK_MG+]OZQ<ZEC?(C*,\-]57D5=1#BX<>R$<+^P+#5AF-M58'FE
M-\I/>39@XG SB\,+&S."G_;;R53O;SP[SV;<8O0J7^[)89N]F_A*\*$:2<[*
MOO]83);HOGPX5K#^1A]#E&AA.&T:WSRTL3F]I\ >[2'\R<! NBY\,U%]I=RK
MMNW431?MW92K5&)2&5Z^DK*J#4T1;%-],DBZX.IDX183?E&/.KG\E8$!(G/(
M4B.7$;NZG;"8XR+'F!QV(U,"^K>%TCW* 7$9<<UQ7Q!BIS-7_J?^5Q?]&*!#
M"_) V4.]%-Y_H2P0RZ1 J6I?KZ+)XWQMH#?:%0/8(L3@_^XLGEX4O7,4(_Z(
M/T=X@>'NIUA+*JN]5=<-T;SZSO8KDW_U-:@Z=YNB.E?,<<I>$5M\>2'<3PVR
M_1WMT>3WN7+ X.&/2-4@@3=+<P^T0NW>.;EP=$/W$DO5!FL=1W7;:/HT2=#Y
M"1+3Z,:0,ED"667 5_."+_#IYO TL='N7JJ3O^\2;;],PK>A[CT:)=)VKGSF
M0^?QPRO!AN'#&*ES_1!B$X1]; U%3*LG50@8?[.=AN/)(I59R*8![U,!O)2J
MM]?NA=QHNDZCFVVIQMI9V( (.9Y^X%1LG46(S\I]3:CJ!%(.^%X618O.I-'M
M4FTR^B2XN7E)F>/CZ[^+'=,A9](#96*[ CPO5L&Q"L1MHGE'6IX83X88:[*F
M\+ZM9B'AB5&#Y#/]F#Z4IFQ,68T)!BA)5--/ES]19WY.(SKVKOFH9L:LC1HE
MT=[!@V]P%CH>+#.CA7:+<BFH1M34F61LEA=F]YS3&G^3*BV9ND%1,OL\(&O6
M(*QUQ6[(EM2!A"\IOVZK11=\F2N6')U)VO911?7$;^*Q7>[FM =^9^?X9+">
MKR#>9TX.C^T7O_2CHB0$+BH12M0MNA'L/Z^)=;'0V[UG18"Z[><YQFY[=46N
M_[P?1N!FH>ED2,*9,"1D1N:?&9\?..]IUL+S=GA'I> REV_W:MKP\:>#-WWL
M(]["AG__,!Z?:?"\LL*AD31[^D@ZOS[TAL\=CJ0?0(_\*X!QH-SE_:8X+&9@
MA05I\XUSWMD;&D'#FE1,'+IF-J-J78*T\G6^&$L8>ZHG:+-XV.$AQZ9A8CY^
MS2';<MREO"#R,>L(A=I-4QF;6!U]^Q[9UXL39OEPG_NHR703S3MT^BJIZ][Q
MI>2-+]ZB\F3(_8 IGWN2MEID$$[FK)1>>W/AZG%1!_Z;=8G#^X.I\S<X[-8/
M?G&9T)/'9=@^PB>UA/?J)6Z877T>WQUUH#(U>9T7D<;YEE*0PU7"Y:-[]YW/
MP.<)LP+X,^/FYOD\B5%1)AO[7*2[DN\3U/T-UPMW(T #<)4DRD\$F!.=$I(Z
MQRG@Z2Y2>]-J2\%?J^>=!?)[O]0IW-!*I!;SE60I;:E=9B*U"GS03N<^#VMC
M#WP]_QZ7KT.))V5 97^)XW&5LOB7K&O/ZH2VAF!(N:>F4S/W*A*^G/[*[G5V
MGG4/:+D;[X'-1(ERYJJ.JT?[]+ ?T_VU,6/Y'Z=[P;.U7SW2  +?:4!RYN0M
M^D5L0\E1)0/LA]^WR5F8J<@#@JSEI3OW!%-YF]P,M%3[%*2?$I9=LK?5$;/T
MY^L.RKT2M+Z9\MWMJ.W@B4JW-%-F7*-?;&&P-+'O<M:\Y'*".;>>E,2/;RJ*
MT%>/X1E?$^ !D_G'3V=O[EPI<KT*06=:XAB_7A20/"Y/6_1X@H(UMG$FZ] 2
M'W1ZO)(X9/8PO1V6@^:??2.E@JC/'=,F>4.G(+F0*:7,%F],']!6163'F@R:
M<8#%9'TH;/.W6MJUL8C?G8EV5V1Y?3W:NT,7K=+8POQ];70:_YTU3SXXN.DU
MT]MC[<PDPQW$MHO8 *^T1"HO/(P"XH:6_;EO>N']_%;MF-OU]'6F9KG+ K@-
M%[$1<T"IWDJ?TJ_0707&1MK*QQ^F:B8_J-R([^*[31B1]YR,*)Z@^WJL)'[Y
MED]4D8./83E)#3$\78F:]XT[OCO$4]O!3[DPR77(N*M*;=W8J-K61]8H45T6
M\GPL,$R%"_P.U1HILD^A )OT-501R3(ZOM/M"N:])EZ)Z\KL809Z DX%RY"7
M:]<,.9?==A7872*6'9#IXC-:?*:==%#<LVBI!SL)WT4J%T7Q-MR*O<&CT0B9
M7$I><V\O)"-?4F"08T:G9#44^]ZVYL\<CL!K^J:/7(NIVDXX,=/4<U51K"A)
MTW\@")#EC^.'+]F+;*9>'?'O>44+R1ZH:'V3PK<9$$\!**4N>77U1JS&$$WE
M4MY>8>NW(N^&DR*BF:$%@.=&9RKO<L:[6WOC<%+D4#OS/M4UF&(;!PE;]2^]
MI![\QEE#T4*X.G_ )R]L.X"X_O&M7*;MW/K=3TNF&^2(RV$5U?'&?_F)]1_,
MB=EZ(1)]^0A;G7_UZQ]_4Q*QX_7)YK%5529"\<HBGKR5,)J*XV7L(WR"2JM"
M7T'?Y2!^F>]-,OUYWK,;#(?]@.)CQ[KTP-I/L5S(XA0QI1,Z@$3 W\_ , H!
M7F9A<4E8HNP0ZF<T%3A]PIN=JKR73RFKBONL_$Q0@7G_%4*Z65KCE9=DWTA'
M YNB\/VJCD_)6GT@*U#G#HX*Q/%'=:>TMH:=GDY?FYX7QR(1T(=$C<<%E9IL
M^1@(]OB[Q0E8J<DP1R\N5?DR#)"SU>*\*A1!O=<:SDT];[ 4/BSX:;VQ84Y&
M+GO)!98V0JTG5>:KEQK?_!P1<5==IV%+B$""/42*]2@_(=^1AIKG13#P&3P<
MRL8-2E.T?I$T.KSJ]QU0L9\6GH^.@YG&P0!NHA!%V>)96?O?'U"9B;A;K&AY
M/[FRJ/CIK+(> @@=-],5]T%3VW2;:$&=[7@A%3]R&!!(/98 3;9YO./YZ#__
M&_J?K '*:&2Z(); ]3%):Z3<C>3-N& P[,EDVZ-A!<LRQ9D%5$5C>C=3.0 ?
M?!T@&NC+1VJWU-3[P#K_ 2YM+Z[/+8:'9=_R:Y[OQ'NFR MX9/'XH"8BEL<U
M=@P^(NC\4MY,[T9GO'2B5 D8E=P@83&9"#5OH5!<U*[R_PX!+?/?,I8Q\?$)
M7#J/>3KN;V1512&!,ZUL9<&14".IBPSRH4DK55U)\/J0P5[BV^0:\)&!A-4<
M,G61=67KMW%9=ERI,\U%@ ?XONJOC]HM3)W+']][=EIYZ\!\6JVC]VI/F((/
M+K@O%)KMC-:>:U^9"(1'19VNNWR9LKXGN"O$F6KMC&H3MXOU'70\TLA-ZC7=
M2 <.^"W4T2\]-61KMNGH:+]<$1,:Z'-"'K_*SKE^<<KAC5/I:,#**W5H(-9?
M)I=][!UB/._%RX,@_TDI6(L<SBOT1_&.'$>*D5U\AR1NG@5%E"%.DTVVM6&[
MM0\27'N.ZXC!.#1QINK1/S.MYRL=CN<EKX:K&UJS3OPTK9(ZF#@3T<ENLJ_W
M0^LY)PK\;#L&[+'@W!ECWP<6GH[HIE!D&7..+$:(N?*[SISLLC:%VFV:#I3D
MG-;#QG6UQ83;/7R+E K-ZPE*8X=]RP!90X*@1?V=, X^^N)9*6;/!U5:$!!J
M>6!?LR%KP'[^!GZ&#<M75\\Z]\JN0F_GP27S4 T]?8Y@D$S2]I\<(L=,_1=0
M2P,$%     @ -GPW54ZI%Q'S$P  5A4   T   !I;6%G95\P,C$N:G!GG99W
M7%/;EL=/#)T TJ2H%$&*% &1XD5"D28B104A0$04"*%(DR(0NI0  @)*;R(@
M14H"4I5>1)JTT'N7WDDR\;XW\^Z\.W_,S#Z?]=?99YWU7;^UUM[$$>(T</ZN
MNI8Z  *!@">D!R". :H %04%)04Y%24E)34U%0V$A0Y"2POA8&)F8+G,R<UU
MF?/2)1Y^<4&>*Z)\ERX)R0J+2DA*2TMS"\K?EI-2$+\A+?7;"8B:FAI""V&G
MHV.7XKW$*_5_7L2O ",5$ E4@T%7@'.,(# CB-@,< , B!STYP+^N4#GP&3D
M%)14U#2TI V8\\ Y$!A\C@Q,3DY&1GKK0WH/D#&2,_%**E,PZUM07G%BD?*/
MR:3B4RG]QFK0M\5_XZES #7-!39V#LZK H)"PM>D;\K(RLG?4KVCIJZAJ77W
MP<-'AD:/C4TLGSVWLK9!V+JXNKUT]_#T"@P*#GD=&A8>&_<V/B'QW?NDK.R<
M#[D?\_(+RLHK,-C*JB_5C4W-+:UM[1V=_0,_!X>&1T9Q,[-S\PN+2\LKJ]L[
MNWO[!X='QR>_N4  &/2?ZW_D8B1QG2,C Y-1_N8"G7/_O8&1C)Q7DH))69_2
MPHGYBI0_%8M*3&;I-VJ^&P9;K$^=^V@N\$O/7-W^C?8GV?\.+.#_1?9?8/_B
MP@$0,(@D'I@1@ *')ZJ]_;U>>I3I:]4A#4C/3]T(=P^L7@\$?$BS("M^Z'KL
MK-0IZ%MDHCVK\[1#.GI#C,'./=*1+)'V149.&2BE#>W''C-4/'[4I(&-W39>
M<D$(!9]5&9?S$LC;#.3;#VYJ-Q\.)2:80+##C.WEMEAG@:&%MY]YYDI4E2Z_
M6%$[%PY0M\AZ3$3M%>&JB "-QZO'_?MX:_U!<<-'M7&'0OQBI>Z2F^L/?5E
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MI%+R?]RG5\J@A?_E5Y:H;=Q'!7/)" -,!>=D2M<MS5;=]=;CEQMS>&MO0OR
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MVU$E=0:^_K<0O7-]_P(!$4?_ U!+ P04    "  V?#=5^)E+T(PO  #T,0
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MS+U!:JF9[ ]G;QH521USUN"!HE$Z/+A^W ;DEJ06<G<MVB*E@SJF/WVUM"/
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M"U!R'5*2,.\/8-U>(>+(65\J'MS!=^2>:2L'2)T(AGPJ3^A! &>DM4CT.1&
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M\[?PS:!B;X25<RX+_0A128@K(%#;M#KH]F)XW*HEK&@7S!>L3$T[D(R%PNF
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MJYG-S<<X\]K!++\Z7?#ZYNA(, BFX/IV72;Q.:\*?DZZ,HP\JJ;IB\%U >H
MIM@U;5W]%F8G&XSDPZ*EI6&TE+ZA='7R]13WY0)T*NGJ)'EZ?#)=Y&[H7T'5
MRDWCZ1=B?ZD@69^4!-2_KJ+D$8MDBJ7;:)5U;(LLK'22KIDXU/JA:T9F;RH]
M5E=\6Z4*93I1[9'>+CIU;J\[F5K\)LP$@*BJ[W5#5!@LE"&D8=/%?BP.MB=7
M-A3J3W^@^?B4H2J#F\,Q3"?CA>6I?9,7P;$&U$$*5EL?^@9,U7QR(P%&[C[N
MP91D6A]_S#KNPE.V<],]#%51IV ^;4&@H4'?^F#@O$=UA#N\>>H%[!EM>=#*
MXSUF(SM[M01VG5NUN/;D.9YGZA$1\TT)[])WM$]*?S8VU NI%[=B/GWSLI(V
MZY4'68)%9QG@:,\+VCODD<JB2=LSSM@F5\);PI*6Z-L-G&%T*(&*=WDZ<7SU
MIGLDG6?:&Y+,%NVPK01'Z?A-X'?0@W$<6D[BBO=NHF\!#4KQ$G<K.WKK,0 .
M3)F1'/:<-B#FCQU[:[B^ZN@A/"_<ED[W))!M;J$F?*27&OY7"F2%6N:/1B9T
M3G^MN?N^\\8RCG$X?$1 (B0V)*'$A)0,E>%P<<.""0HV@]<E9(V#+[WEOH4*
M!KT0V1GE^/""--/?G C7AYO9H]->#VM'XCC!XC$81^WU5?K[5TY71GF-7*-U
MOJ7.>K[62=DJBLJ"*Z*<'SA-M0G,!ZR$@%RJ[ISY^LV$],$^Z+J;U)0E2(MG
M'N.?L!C\ Y:(J5^J&V!U8+ A>5N;ND#(+[PKMT6O#NK3B(-)C(7S %^KMVNK
M]9)CS78*YA^*,*P?+SC7P?T0:: H/+#6G)3%:+)F/141I,->KMEJ/M^>]&PT
MA8J-F9A#G."9VHCJCFQIX4UTP)L@OBZS8=?M :(6OG>J.$.&GN$8BDF]G*&"
M&<#LJ 7F!&Y'L4(Q1NJ@V>_O(#'_D1$AZ>MRL/:47>;ZD_G^[^9LCV3>T]?X
M[CV6[-A6@,D23-*=>#S#HFU%;2"]>2W0JFIDX]?F1CJXBMR+CJ+071YD;3<N
M\3^+E+&-_;F"FU2L>38OW-J7S_!*K<K0 :VOEQH!I(42*.02:O[[09B2@!_X
MWH7F\E6]Q,D<NFQ)I27NDZ5N*I6EJ3GE\]V!>1:FVJZ\77I= Z>*'>8]4H_8
M@) B,I2D-5HC7N>M>-J%P'8*@?'Y#C*W*""\Q HD<2&+\3@ZUKKQWB\>'X<[
MS_EG.L=485(_IV!^21+UK@?,\X^C*UIM[(Y.4W7]I/Z7<4D^?@J!JD,T0O[!
M6R.\1-7CQ8U8R#N:V+3YPRS<8/8"96:V,M?B&F$!O!!=1GD!;#X%"<QO0H#T
M7L1#9&]R56-L H<RE6="D_:S -M*&4%G*6$SM=S.?+;$O ]^A08]V#(EWSNH
M+UEJ*[(X$MPY%'!!8IK+EB<( *J]A@ "ZTTV0FA7^OW%<NU:D]>M*F."&Q:5
MJ#9?RYP%>'1E)<4+Q@ IO?-9/E*1L0X.^8M+_;3^D'F*D07*?,%$M]*(B>1
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M@VY?0_\8]^:8Z6<X]=A<Q-,PH2$!HXWB#IF<YP<F7O^#UAD1<_\/4$L#!!0
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M@[J;9QS9MY:=(NF?Q+$_4X1\<&J_3HY3K?RH7![<L^S<@7,@:[%8[0X]H\0
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MHU_4)8>H!C1E*#!C#HO294_VG=1:">NZKB\G6[QMH/KLNIEE!G[JH]0C,7S
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MCW+/I@A]1E,QS$XTOG?I%&PYCU;R'UR)9AJA.2:)C>!21DE!%BM4VGWQ=[_
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M_"-M::F,^I@I336\&;L^%V(^MVX8ZN5W_,A005;AW8I@V3)+1Y!S_W,DFWL
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MN<1-QO"-J&,Q' E8# *-?W),.C?<&T@1])8_:W6G9@GJCS5+?4HUB8<?F)*
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M+O7X(T6V2&$TS?^0!FGR/P!02P,$%     @ -GPW5=C;^AA6%   8A<   T
M  !I;6%G95\P,C4N:G!GG5=W.%S;WMYC,'HO@U&"1$GB,'IOP8CHG:BC1HA>
M$[V$#!E$":*/SD$8-1$EB1 U(DK"B$Y$KQ'SR;GGGGMRG_OD?M^W]O/^L9^U
M]_M;[Z^LWUKX"3P.H+FNKJD.@$ @P/;\ ?#3@"I 0DP,(28B@4 @I*0D9!0,
ME!3DY!0L=/34#.RLG!SLK# 8%Z\0'Q?W%1X8C%]2X(JPB)B8&">?M+P47$Y(
M5 S^@P1$2DI*04X!I:2$PB_ +L#_SP/_ J E 9Q!-\ @;H" %@2F!>%[ $X
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M?I9\Q\>S;U1*V@%*&<LES!$-A+$^WZX*CV4AM(V4$BN+((8H"4,P@,P/WE3
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ML(P7%I44-Y[&C>@DRR?P]A1)5:(N?K&'^<>Y_0>DGP7<;![=+$P2J$[Z9KY
MHSCKI$:$6"ZU!O:KVN[0WZ(LPW1,;_ E28_0C@HK3%7-F96P)8;OHO:6&:?8
M A]W/S+H'TF(U)A'8+>%!LJ*G#]U13PLQ0 ( 1?P/U*!@(;:PN+G3/D+Z#U,
M/@K%"BPT!(SEYR[^SC7VQ!I>[Y#^?05.-[*PU>8?D23:]/P6YI'% ^T2G<J*
MWS8M_:I[4QV\GNZP]%/4)V4W@8=-;[WDL<F, 1Q25<2\\P,GK: .\)Q(^41
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M(:W$@Y&E/F$P2TBOOM"&B@^IA*=SWB\XQ96G+?V%4E<K%22]9JBOZZ(,WD4
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MUQ04;,+<SS1!482@J:2 8/+7_P!02P,$%     @ -GPW5?:6;D:4$P  M!4
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M%4)I!A   (%!?A_ /P:$"DH-HX'3TM$S@!>4L@!4$"B4BAH*@U%3@[/^X#Q
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ML=MU.!G8NM8S="Y]J8 "+$_:SEK#LBG _>(P@J.)Y/TI_A'N+^[K%.!#%07
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MDS?1.IGXK<=R3,_)B>T"M2'K*>U08Q5 '/77?UW] C-EY&]02P,$%     @
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M>16^LAXKOU!]Q#ZCYN@RS_:$ZTRGAHI<@V*>2H,2OB,X]=(?!3# :FZ]ZU#
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M ?5*]'23@OV7ENTSR1_SYKYRKJKYVK_YO=S>^LVR4>]5"AVO^3S_G4#7'?U
MRLVZ7!^^0 '9:R59M3$@(S/IW[G@.RF.$KO!848H8+/R1]^DZNU[3Q0@Z[_X
M<T,:R1#$+^&,-QR>APA62\'C:L#\9O^&B)$HQ@KKAB,3[K.!D>W:2FUGX#;Z
M;M:CYN*^\,4[7>F,+Y->E=L[N53;[77K,FH.DY\!%VVS.7<+I8J:\[#6DTEO
MD.@F^4_$8^:U\1S+&3*<VE7&)XI(<1GJO"Z"-Y1YP5RGPWNS_L9AAVD5 9E&
M^S-DY&UT"X(11YHKI 4K3GDCW,7[-E7C>WJ=HQPN(O;:\<HT!)^]%E@O89\O
M!V&&9DW?6$QMNKCB&:RJ^4=]MSAB)F^HK(]>M]?G1;QD<_,FS;@O$E%GGX2-
M>!L7A0#M)1H.?"*Y[%Y5=_E*^>J]9WXK?6V"4^I^K!"/)I3V>PP*P%GM3C^]
M5X4"6N50 #9P/03?9*S^?N A[O\>9N!5GTR^-LO01<2$YO=PHA(QW2@?X.91
MG&_#H3R#U8/U(0SOY*;Q=OEZ!/I4WC?]AJE^:."VJ3(2!11J'A4*SVR4.@5P
M8N7WZ&.VV:F=0L<7@B3QX>NG72U-(VE(=8-U.] 0"6-W_X= @BI?[QO.4N(K
MTQ:$[= <"NBN#PP#_ =)5F9:HF]4K0O-9CH*P-3VCY*#L=9E-V/\5$MI+I/Q
MI#5JU>55YW(BKX)YL.NTH^^4WE^?9),6?>*LA5CY5<U,3CY7I[U$:K9E4X-H
M7[K*J1XZ*WJ\S([_"#A?\DZ/V-OR9F;GU3U)$&QNPM>]^H##=5J5/#&@?0?#
MU,L^V8++@N?A28R8N.!]Z6DGCO(?PJ\.W%>M:"Y%-IH$(N$G=!3RMKD^HTQU
M::,I'MXNF]W/H[^,P3K]8RMC95F8W.[X>BKPG^7IW9OKX"JKB];SH? N@K<6
MF#G07^MST76*>3797%03N50;?Z+C#1\9R(-2[$@2^ ']E[[_=NPO_HNX<_ ;
MHP!]LI_=5P8?[7=9+MP"&P.3 (=9%/#E[I,2RV_:#BB K@P%-+-Q7<$WD76!
MVJI_?\,*SBF5O)Q' 4S9!BC C^Z6O&I+?\AGM_UPE0[+?"O"HSIW*?.'L3!L
MIJW>SD\+VBM-(+T6.(H"=FN0?4[O2OV/2ML*/ 9?;>I1KJ@(F.8J1,X2;L3=
M<\8_D$)*8Q_I3@1)'8T&KF'DW9T#B,!KS*)T@@ 40!0XI:%Y2T+S;*M##)*.
M BS*4< 60R4B"FU57BRQ8N>"+.LX[8FRC3SVFE4< K\5UU\+FDYWYK!M>!9X
MA3-W:WBW:TD^*9U<1R=E%@7V6*SNM%QC?@%7'<5".T;!MQ<H8"1*9E3QKJ"Q
MR&Q6?S*W_!XXK*U[J8B4OVQ9#+S%_ YI[N[,T2RW)$>VPFZ.GR,-3I:/6\BW
MQ*Z/=: )E]U(14E;9+/F"8FE%@J(Y8Y  69W!$9SBWS^S.7PRQ4DGAYZ%Y6S
MF(L[H9K>_;;;+T6  DHGI.=?HP"'4MV_=!#_0.-PEWOG@E1ER/KJ21A"+4*P
M<Y3-E@WJ&*5D._[@<OO0(MDI9/*E8.F\3SR>S$+@LZ<1[A4HX FBBX +8 0(
MDM6HA0>'R3/PZW=5$$T_'[ZG6IF095*ECH1CGF'+,$X=Z^TU/K3&*/Y>-<"[
M("^Y5]/@$*6D^.(#:'_$8,PC3PO*<;1-*HUAPL"J;UR"ED\.8"W"=PI3_EAI
M,AB*/!"6'CH/%, >7V@Y-'%.U)=\,L>7R< JPXWL8"*8"!(]Q"&XK*$T/CQG
MVLBM1 $Q4]*+) 3A]S<(@!F3!6--!S<8$+;Z@5N9_"Z3\+1AI+05"GBI!?W5
M6T 9EPN*2P\E]%WPONE0"))"^V-YL:TC'6)>(O4WU(]P9&A9U#E^ZNJ<S/26
M>-^\KX'BQ#2,0YJ:AY7'$5<6IAPXID^9R+W"21[-;<9#!<-/+&+>Q/4)O.]X
MPAE5WD ET?0U=//0N0LBYIF!'SXT9V(L^SPG*5PP2GE'AKS@#;I5)-R$%9PH
MY-5R5(:1/IWYDW<L,IR.$S:_$=Q 6[N2\I4R($?WJ0YSX[,+R@^\ X]NS^C7
MZ)RAZR:*'5ZO.VW-?\H?SK3[^K\:6; 8/MC;COQQ]J69K7SBX:(ZLA_>.S&S
MS6TV-] ;7]<>R;:;, @XFYJT.6"&+S##>92QL\%I*<1LS I[X&@W51DZR?^J
MXHAWH_B0NQTFYO--'\9F97$WGFJ[EZ\\TM!T%LW ;UE" =>WMK=3@>=^9V(_
M7,+\[)&?KA/N,N"<P*GP6Q(/]<MY:5Z+!!D,8NU_X@4M_5B5?__79)SIG$J,
MP)&E1-/8UIC46@HWY)#A<<FG!. \ _?VL4[5^$WB)Q_;M/6;!KNX\ZL*+ZT
M)ZK'Q[861O-FB[/6UO5"_8)P90GW6!"S:]T##;T/MHSP;9;J\ TRN&-'=H$.
M02:YM$IASE::5YC3N;G0[-X1K@W/GDPW@)L0O,<*)EL>AQZI9P?)/"W![&G;
M\-XWUW=' 02!:^K5=_IU(7TMI;+#"F3!6=&H\M7.Q^1RT#J M/8QQ9DSJL['
MB.T+!@IA@D8OCC5_ZZ\>GD.73G0S2);N6_37R#?P(#'V/_:=6*UWUZ%C3;)+
M0^- HKGYMWHG#P_E# ;L+3^^<X>(!XQ/U.<_SSVZ:.?2&#<X*7Y".LF(Q[[*
M2>4XY);P*:E@U70+YNR!X5-BEIN5T)+@PA2LK1_,XBBR'@9SZG?U$$^I* M!
M;NMZD/Y8XFAYOOD94,TV>_PB:UH5O8 3A@;SF>+[!"S!F_0]OCF>SEHS([S&
M?*T:>4%5Y)&QO(<&^;]8_BLJ/9WZW\J]D;5W<V6RJ5"&S+762HNBKY=O\6E^
M=E^@^>XY+5!X7A%5%4ISWN_[D)D'\GN&Z)PN<Z@=(<)J#3\1E/>'9JCL)4WN
M_#8M175%B]+8MH5AG&W SN<UAU81BN4F#K^_AFA#@A?V^>N79UW=,F)V98-K
MC8.TBXCHAL0+BD-SR;\>B7\ **E(N2CGVF<LJ\8G;0FG@_^> ;6[X;?38A/6
M?U6^OP&=GA8!(T9HH5F!C%-F;L,_NJV9(5;4,UN\84RA=/HZ'%HG;+S1B:#@
MAY&G2D0O)\EX2QX=.+$%]8J #[Q9B'^L[-.CJ:7XT)VN"J, 0N65]_E6XPRF
M;YWJLOU394@S5:'WV2S((]>#J/6+=0U"-83*S8JZ]RMQ/'@S'Y!'%_F!#F5(
M&(Z3(R24.77G>JFB^G;M>7$E9:<?^0S+)=9&^Z?P5D_BV//.^"W=?*"59PFO
MXL!JE("DC0\[6==_-RHQT>0$)8%+_/V^FT/-QM>;'3/"KUB^.:0],<ZFLO5I
MS^9><KMA)&=I LREN,< IEXO8"W!]M="U6.Z3#A'F<HUW8]K<8NJ=>^U7D#M
MGST31IM5K_V8[4O"R%1D!V%LYI.Y&;2;?N8U8QBR?]A)EFY;4VEHE"8Q7/:0
M0GN1&%B[6SF;&_4%IRVLA+3/%G'6=B5VPD80><HK'._,_7*^X3P _GQ_B#_J
M([]RUC,QC_KJ@J?VG!4:QMR;\Q=:]4'$=%K$=EZ#NBF69:&=_'.#L'SF 5K]
MY/%[[/V<J89+1\+@B_(N?%%BT-WM#2L\"@5(.K<<00*1#._I(A'*WKXOYIJ[
M6&>?YXI8?Z-+*'8^$)'PV.. =AAJW<TD07KANG*N2U^'@RS[4#V?LRZ[NH.9
M@8$"?A^6^]$8([4YR-'B,)4[7R,R).0Q2+#*=9_KD]T%6U,(]RY;^(8D<"7V
M75S]A7+S,?Y'3RISKO4](M-NW(@:&\;X@=4O:YG@R;'<R2I5I3,J5=-^_R6K
MWTY$K2/YZJ*,$L&B$@X974H4&T&<**#=-"=P6+7E!G377+S)1P'+ B,W&Z_W
MR:2>Y=NDV[RGIPYRJ\R#GA3[4R%:RFL:W_!UN]WORZREYT%W6$SKK:X+N[%_
M%;*P[ZPS)N@ :U:6&3!$IPY1=B:PSP U.F1F,S1][4N!Y>,E=KAUN4II:("R
M+"D<8^7&!B4'W#+ZQ8W5 -J<O2]BDQ$"J<[&AWAS[D^%M??U8V@]XCE8<=(;
M 1OE+9X ]D-X*5?VF,G8.4=N3:.T@R]7JY3%"D1#LP  Q0>P@C:_UBOP-Q^B
M ."NP5CA>$)AX*.CQY0=U$$?&KKG2Z*I^IWA>V::TGT[(P<?<I4P\HH/1*%3
MYX5+-D&D?[+A?@'[PL!U@1QW]#6/RF\Q+ >UZ.#K--A\6-.)0@HOYUOJM^RA
MXZ[;9X5Z6A#[W.#<[7-#4B^#N%G3.7Z)",PI')XV1AH1\&?FZ."\[5$311@1
M1B5NF7/<>ROK$(BF!H<.' @Y&..8I2AF41\9"*-Q5Y E9X0K%S/4(N(G]/!P
MXU*GQ=!RK&+ZBK1E**K32-]9^W+M%R?>FU<EARMKNYK+]D G=_4SCLX3*.H)
MN\S,AFJ(V#ZF4H"=\4)\1,$GW;*FBC43C3%J1]T1 J>^B%OB[8N1SWW#'MP)
MGA?ON'4!HKX2):YH!?&-(,GGKNQ-29%"I/TNSID,.@-DHNL1-KX73),?M[N[
M%)"3*O4M=3\&*^?FFK40\I3R$2^B6AKQ*"32SQPFZEL@\B4=.1)^%ZG.I#J$
M:['\8DON,CT6+[HT)ZL "TN\;39/%Z_J>P&Y\_/+B27&JJ1<PQ9%BQ_%U"%]
MZOI50HH_31^O\6-1/=5X95[7_6(&L96!"8/95%:'+Z!C$;,RRM,DXH*N=1DJ
M0J@*WZ:NHIF&Y!KT7E5'$HP5C<I0B+T.1T3IYSG=2N$D",UO:*<W?*P]W?'3
M2PN/>/I%U8EK3-1?\0<]&^-O75W\;12KT0%.*G"@&&:/E_=^+4-3R"#I^$;-
M+ZWRW]7Y3Z&EH'"G]51E?A_\=//_M_^E64'2J.G_ 5!+ P04    "  V?#=5
M5N !M*(3   &%0  #0   &EM86=E7S R.2YJ<&>=EG=44]NVQG<2('2D2N\>
M0)I 0$ P((8J($6:5$$A(+W74*0W0:DB*$7$(R E%$4"(@101 'I1GH/34IH
MR8OWWG/?_>.5^][<8XZ]QUAM?V/]UK<F:9PT YS3U];3!D @$.!(?@#2%* %
M4%-10:DHJ:%0* T--2T]&P,]'1T]%PLK$QL?MP _'S<OKZ"HC)B@L)0(+Z_X
M90FI2W(P&$Q 3$5=65Y-1@$F_WL2$ T-#3T=/2<# Z>\$*^0_/\Y2!T ,S60
M". A(&$ S R",(-('P$!  !1@OX6P#\"!(904%)!J6EHZ<@=T.< , @" 5-
M*"DI*,BMD>1V@(*9DD5(3I.*U<0)*NS+)A^3]9Q:Y%I=)[OIMVU1A3M^L32T
M'.<YN;@O_"$F+G$1IJAT65E%5>LZ0EM'5T_?S/R6A:65M8VSR]U[KFY(=_^
MP*#@D-"PN ?Q"8E)R2G9CQ[GY.;E%Q26EI57O*A\6?6JOJ$1W=3<TOKV0]?'
M[AYL;U__T/#(]]&Q\8G)V;GYA<6EY975M9W=7WO[!X>$H^/?ND  !/17_)>Z
MF,FZP!04$ KH;UT@</#O#LP4E$)R5"R:)E G7U9A^1AJMFM9S^LZ:4043+?9
M[_A]H^40A<U>V/DM[6_*_CUAL?\O9?\4]I^Z)@%Z"(B\>1!F  X<'HN71M/^
M:QKB>EK@O.ZJ^/;W3AYET[8Z2[?5HG46'_RBR(J7/T^DY_BB4F/8:'=M";<[
MK=.TY.DZ&.J%^@[C61"1JO<*[+17QK:+\Q5LS+:L(#4'0A:?-M5Y^U:\[RZS
M[RUQ,<]>6_9I0G#FL_!Z>DXXCGMV 6-O>CKS+OHQ:6G 1N=72E,HV$P0P/^4
M[):FF#C]82_9S> CI167R!2KF3#0:+4E?%X2TQ#BM4I12V>DEI-C)6&J><B?
M/Y/1""HK<S]XN_2$[^R)@J:0D(&,*J\ ";!ZN3"VUUN932.+S[5:M+*[O%NC
M?:U$*\,],5;7FU[#7)RGR,GJC8#<IMT@4?W(U(&@BKW97KAI?<&B$!%L+@@&
MXR6'6WJ,[<4A-@P6_4M]6T*M*08A?4S"Q52JWSO\;>,/'P3@KW0]>J7XJ1%4
MD=YV8.3S#,P6W4%ITJNNOE[)X>N\N;?Z2V#G@ UT+V[H576:OEQSVO(6/Z;D
MS;-Q#?_=0!+@1@(RWSRC#7Z+2[WKN^#@;F'Q2WPP#]9?';=AZ":L(YQPLT*W
M5Y">V8I[(!USL)SXBY;%JYPBJU@MCP303G'<C 9L0<-+,,J^ML?$-:+Y=LLK
M$G#GP>91U*%#_E!D@K"?F=C9//'J4K2TR2W#M.N.-=IZ)]B?/W&/)ZYK4H:1
M@$8W<*?RRU,""6@OQH282SNQ:O?%0B3L.9<I',=42YA@5I/R&+<I+DKS3QTB
MVV>JKL5M7Z%ZZF=H]+MI0S4]-G?KZ3<?8D:^QWMV*6(Q778,W]EX&A$]M_[H
MN ^6#UGO6WJ[9_<*6@&HIDADYS*K:.9"8K8TF$KKX[]49!(.20#6W<ZD]KQ>
MMH%6ZF.PQCM_# 5+RR&0V1,-$Z]A,?3^.*BJ29F<9BCJ)YK]$17,\T99,$P6
MVN[G;^C-$I(^0U]HGGPYOQRQJ(*DBG+DX33I45DN2@&VW%Z7,/W\L:;J4WPP
MK2EQ!QRM(3D^LPL__EZM0<EF\O=T(>08A'B;T/!]3G-T:OI^H!^RC-SPL&EU
MX)^VTYJM,AW%XMO#D\I3^T+]6L0V*]4>GE>G6@/J9K(N$NY,&^5)"KI.R_QA
M+;#%O]ZC_LXBM^KU!!(\C1M83%YD%IHTLCJ3%.E0(@$NVXT^=&;W69 :9CS8
M%B^QH+%%_U6;R1>)SJ^I*3?NST%QT7*\AU^NW*0*W$0[OR+<.P@WB'<1[[T<
M45X$^7IR+NK!+;R9;?V0&#IETT*[]4X=_MJ$H,O>ZW3C#X47\A)=S8=G'W=4
M2QG+)[I-99@7Y].696K:*=S^N/OZ=8K+C0T_*DMUG_";4!6Q]-<B!GF[R\)<
MS,"1YJ-@'YIY?F+9:./]P''O@&1%X6PM^O#/2?-23Q1:>(/GT9K><^K"6R9*
MY]H& J@I&8I2FVOD]6<@<7%X"W3YK>VEBN:8 [V0'GCTL#Y>4&W+A- YLUYM
MK-.20?3G:]P2?3#9TB$GGX$KM_2=S>1<(<HT%\_K/EU,@3+W#C+?D./:<N!A
M>GLU9PL#?%O<KDUBD5!KY9ZY"#_4RXQS0!2XC%QJ\?:@VJJ<<Z;-,,*B-_G?
MBXN"LD-J+(G,K;FX3F_%D\3<'SF'>FD*:45I)5%'RNPRCV;+ZT>B<(5%S:)'
M,3&=#"V9_FG,4]41LW680#K;VVUZ:@\5TFB$1?Q.TF+A^EW;I3@]3_4!7&5@
M4-0WF-"]"?0UW7[JR;(B1H]!XJ53W;%3NFID4R%\(N+/5'_)HQUO%88,%?9E
M>Q["][EO51/(CG%J&6^= F+FX);H)^>2@W0@T@0AR#D@_0\+LY[<&3G?=1R'
M%%%-:O9WO\3H,AFT/U^C^I4J R'4N6X//=C*S"<?_5LD !-$ N;M?SH?E)7;
M/)E.;0!S1?=$#)0%R6T5 BU!81F& A)\*)LY:8%NG^Z+;;(7C\2[!KKD'GI.
M8\+AN*M%OEL^#H1:>JJG'/@'"7<!*BQD*T LEKSEEH\%E! R,^%CYQ4'4S8]
M%S(WKAHT.H;6/:3V8H($UVB[=Z,/4]3&11X9I]^1@K0"&UP">#\FM8/Y:B"P
MT50FM.(9.$7\&;B^S4!]L39AGRX=+KRI;'!=@R*.L&.#_DQ8V[8A&!$47^?1
M74R*+3<6I-B38EW"MJQF:7"T70CTCYPER'B]"*W(RC_*3'O3A]6 KEHH>GJ-
MZ7J8MXCR)(I7"H)BLO6NYIAU]K%%\3U >'T%[RI(*M1)667K!5KT7?V KMD[
M,=@Y][8YPXDUT7!>&0;ZC"-@=$;4%*Z@AV[#9LL2KB10#_%*\&B']MX]7:^6
M>L;W$51\:B%3^6("2>1YGS(Z*EY&O<ENV;KFOO0:J)\_F8N6L+[$+_U]O$CD
M]A2 ?=[Y2!F>;CM&?95O)&GU0 ^U![%Z7S>)5A0X8JM%K?<;GP'#F1_?WQ3@
MJ/W!OB>PL8]-W*\]/C$^ [='.+R57)&=6"<BSCR([<,D0*.V91 U[?#:R!W%
MO&*O5(=^MUU<>:&[S0QF,02[=YW^)GY-X>MH=\Y3='QI)]*;H<TA_%,\6%RL
MJJ.6:X>MG@1\T*S"+O4UX!F5MI1[PNZ@U6A@]2'U/_B17#>\NU1$-L>64]F*
MCJ0B17=5M.AW>-<])K%<)WHDH'>@E 2,/4&MW&O+ZRK9A2'A^R=,Q 3)40P2
M?L2UYW#\R_N,?BR;X$_43A<C8IQ(P-?N0'ZA0\?2&,0_6<5_7\Q-1 4Z09\&
MTS-N=S<V'4($'?U"7^1,VG5\*VU3('+ NWE1O>4*F4<[Y'LGI=:F\)<9"7@0
M1)?_C 08ALPAS\GHN]2<ROJ![C.YKW4[OG(R]4?^;##>_4/>='RBM-5@"N_.
M=UW'4_37[7,%J(:TZ.L%(AFZ'U Q ^JRZ,[R:<4/JC^TMX7;?.^ZF%KZOUR3
MI^F%!\39QO,AV =M/51K)UUNJTM4)!OW?Z'-Y74DNIQ$EQ];])3 #I7D#'UI
M8BVYY/C_W(A< 0_\9>[^[3+O6AJ&13QN?THU2)9Q3N?&3=_8*LI^;LP;'7K
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MV'A."'D6NG]C52AIXC\ 4$L#!!0    ( #9\-U6.N56<L1(  -\4   -
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M/Y<5FH%M3L-.F"=Z_NIY/:\&28EX-!&?04VX\LZ<&%FOD.<DBDI0*>,R!2C
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MWP0#FGR9H67J=?[P]K(6MJE+79F<'R;AX=G:^2)PA_X[C'($YG4B  M;U?A
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M^D(<FID,#,7_<G;B]#\ 4$L#!!0    ( #9\-U7>F4&6;0\  % 0   -
M:6UA9V5?,#,R+FIP9YV4=U#3W;:&?Q!Z,8(00@T2I(.41(H408HTZ5U0 4%Z
M1T"*B*!&BH" TGN'$*6&WD&D(TA'BC1! B@!(3EXYG[W?G/GGIE[SKMG_;%G
MK5DSSUY[O<0OQ"7@HI:ZICI 0D("W#L_ '$6N E045!04I!345)24E-3T= Q
MT=/1TM*Q,EX",W&RP;@XV3@XN'G%^+EY1. <' +2@B+B$@@$ L8OJR C*2\F
MA9#\TX2$FIJ:CI8.2D\/E;S,<5GRWQ:Q#6"@ NX"&! )#T#*0 )B("%V 3
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MOM\?^GM9BH"<"+A[LVZRY<(F5FWD[/-D)E-ZR-A<U$E$!-Y,+ABCOF.=UL*
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M>2.Q>3H()5 L()"+ OZ* [[Q66.]2]-6>%]KZ\'B3YB[#3$0R$R]V_'"M<P
MSOHR-I\MK&*&7W%O*2)>K;Q::E9>N/;&^(OI.CM/U]KOZYP8ZYV"F)J7]==P
MWZ4O(?;W;Z_+]*]O"(%R-W><D"5U%*R5BF/;]0=\>[^Q1"  %)MTIP/3M1B
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MH!V@40@GUJ_QY!_6IG4;Q]%!JW5_?__"P660XT& P@0Z )$?K,U-3# GV8.
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M9D*^GL$PB?)&/$Q^L=C*T:EY8BZSQQK[BH2(!J,/*#NR:B"SM6#K2+9\2-=
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MP;;SYOOQPLQ'S%DTQHA1PX##9GHBXN&%YO'_$,;$"=C[POY,/"%YMP7_ ?Q
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M"F%4@.$5S_Z"Z_!([H7<RBW@EA*VLWY<[GA%_+G.<_#&"CM_57(7<>R 7 6
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M^)B;M:E<H%OR(@[T.:J00\BW7) _B-7/>-XRZ<:B<'4>,=&?\II\4=\N>:P
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M^:)07G>,O-&!I$30>#M]64>1CG"&G4$FLM@-ICG*W8_+[M]E>^]9>D;H,)R
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MS!,C D*Q_8LE#R)+(PBI>)N1!V9O#P6E[3XR$BGN0,3)^-V9O6K/%ZP]!ZN
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M-WV85 (0M.W1EL"YNXAGF>?3?YVE*4G2?'"#_6@"LI.P-$6P5"]4L)?=?1Q
MF#E!X=8 L78:!"=DZ#2!J$ '"]-M/)'MMAH@[AVBTU _?$PJ$4!>;_>.C2)D
M&\B_4Q*;A*KI0E !#7N?K:*+W"BF\LS'Q'RFY)@5U(RWQY$'$>0AIC\!]:,$
M4R4AL"8O>\YWSM.Y1\?J+WPWYPZV,7B4IZ&7).A4$H$*E]VSG'E>3*]\Y7_8
M^$1-1%2%T4=U,KNC%Y)* F QLB)^[U!$\&[*(GBW%P%8_]T.OV/ZQWE\%SV*
M,M8U!5"C.9VK<0\>%?K@]^.*5W$" 0)?$IS:HM\!42$NNA /P_PZHE>_X-_^
M!L@\ZB4[(3.U'Y8JN!#V1LSVUBPFSF#H&X3&[_!LSKO"%B:#G-&_B-@#PBH*
M(>Y<'6*36,Q=""J819=;_25<YA]OW[Z[O_/3@9D-'6*3@+H+004U[/6VXG/Z
MY*Y8R[C!20N]!"=P5/8#48&.<&/-2VZSXA@/Y,1)'7D-8'5?0B_AZ1B)/&0J
M80 &&Y?.ZL&KODYG$OJE,?$*6.#PXH(%.S326M&Q(?CN:$U H72F7Z$,>LTL
MN9SY\?I\V/M?D](4M$5K[A6^XHLD)U_U[Z\9:=8EE?W:_P=02P,$%     @
M-GPW5=*O3&F#SP  -RT* !0   !I;FTM,C R,C V,S!?;&%B+GAM;.Q]>W/D
M-I+G__<I<-Z+"7=LR_VRVZ^9N2A)I7;-2"J-I&Z/=V)B@R)1);I99)ED22I_
M^@/ 1_&!-T& \FW$[K@EX9'(_#&12"0R__Q_GS81>(!I%B;Q7[YX\]7K+P",
M_20(X_5?OOAX<S2[.5DLOOB_?P7@?_WY?Q\=@0\PAJF7PP#<[<%)LMG>^"&X
M3;TX6R7I!GR9;UZ (W"?Y]L?7KUZ?'S\RD=M,C],89;L4A]F^!?@Z @-6 UY
MDD(\X _@+ W!#=R"M^_ F^]_>/OZA[?OP<?;$_#V]=NW19?_]><HC#_?>1D$
MB.XX^\L7C9F>[M+HJR1=OWK[^O6[5U7#+XJ6/SSA7[3:/[XCK=]\__WWK\A?
MZZ992&N(AGWSZI\7YS?^/=QX1V&<Y5[LXPFR\(>,_/(\\;V<<%)(%V"VP#\=
M5<V.\*^.WKP]>O?FJZ<L^*+@&P!_3I,(7L,5()3_D.^W\"]?9.%F&V&"R._N
M4[BB$Q*EZ2O<_U4,UYCU>)+O\21OWN-)_J/\];EW!Z,O &[Y\7K!7-/WK;&*
M3J]J.B/\\SFBIT4I?,IA',"@HA6/P&$:F8"(J!H7CYSXK3$CS/PDK88D$__E
MBUUVM/:\[7_/L@SFV<DN36&<]UF4H7G)G"LONR,3EQU?8?2]@E&>5;\YPK\A
M?**/7:R](A)3T2*S^A)4EIXGN1>5XA"O[K^CNXA@&;7"GS&,CS[>?/'76SP(
M\(LVP",]_OR*#/37-KVSM,U9+_6K>=$_!027+5[Y"?HXMOE1U"1[E28;@4SR
MA+>L5W\=)/]1!(^)<B!MKIAGDQ$O6ZX'@6I)]#ST[L(HS$,XTF=-F<#%M]TG
M0^H#CP[=W,* +:<F)!BKU/[>&^.-!POK7WYC;BX(SB<H?('4!VJ#FSSQ/]\G
M48!LV?EONS#?&Q8[90(7VJ!/!A<(-_=>"LOF?_*V2?8C*'HU8.$"%VQQ->'!
M6.RKOQKF^A:F81+<Y%Z:J_/^-87YQUZ$SP8')C\S%K]N?XD&F3R/ W46OY%A
M\?,#\ALSUL\L#D;7?L+IC'^3*GLAE239#1)X<3!9/2DK9L:FRF;,P7)1@MV'
M-,FRJS19A::M[>;(MLVJQMP,U) 68$N:N+6H*!)H"K^[%'T-L]QB3U\8K^=/
M6QAGQNWH_OCV=4B/!J[22*K6 );-:R@X  )3/DTXT!>H^?%?PGP1^\D&GB.,
M&49#>VP7EG6+ @8.4!L084VP2E*0WT.PAU[J>(N@2J6)@?["S']H:'.!2LRE
M6<T][A8FHU,K6IV[8]C.#S"]2Q0Y3#.::P[?0<1C"'+OJ>DA>!;\'6(UXQLK
M9.<A31@^P&)8-/YR=>L]&=9GO)GL[W,<:OC.Q&:_R6D^"6DVD21B@N:N2(X.
MV7*7X_M ?'%JVO'4&]^9_Z-+"0,[Y=$<?!G&Q<$J>^'6$\*24.N(3EV<X9.(
MG ^$1@G'RT3E\[-B<[%EZKE]O1QN8)P71UO\B2<Q^C&;/86F353^7*_^:O:;
MC'@(X5'"^"B+IN#0%OP+M_ZWV].LE/S:GC31TMMG!]4#SHF7W:/C\T,8P.!X
M_S&#P2*N#U$S/P\?QKA34IC8OO$@3QS?ED!C@!WJ"I"Z.AREO;JW2]VE+OF.
MC:K"(?WC-VV61?P ,Q?HI$T\&712B)-'9UAUGC8Z.9*70">+0V;1>1;&R$9Q
M@$[:Q)-!)X4X,3JWY2 X]')5#4!#J#M'E"(")%#*XI0F2O$4^/^Q]?#@1=AP
MN$9?01KZ.0SP'V9QT/Y%H^45L=[1R3&%7@9/8?%?]'.T"XB+U;]'HH/7R$*9
MKU;0-WU%8IEX\VXLL9_"Z@H9GUPU O@R*,=X@3<%\@T&NQ1_=#3GI",?B!-
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M>\M3S_6 ARL+\9VA#<J+?H%>.H^#4R\?]F$S!QVCY@,/"RQ"6*E&RKJ*17N
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M8+WA5.'6*#Z=,>*_A=/9?VLE(HF]#1\<A]NNXW!JVS S]EMJ];HA*X>QRT/
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MOW%]]!P(DR:RAS!0UQ][R,<F,[NES((:I#C ^Q!Z94IS*E]M.LT8J \?>GI
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M2(6&\9IW0J<C1W5(JZ^P5:F3NDHB X%M-1+Z93&4LR![7;'6@-/ATI *%:1
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MX4F+P0_-+&R]:9B6M!FXJ0QOTQLTA%"MDQ@;H^Z/9!H88,)6E8^&_$P,C]9
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M7*.OVB^FK\>%V37,=A%V;YPAUB@$M>J,:O=<J$$A&]AD) SG<JP7.+5]<Q-
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M0]3;22'JK2:BWDX846_5$/56'U%9FO_WA?=KDI[LLCS9( ',GD*I9XJH9P-
MZ*<#>!B#FC_ 1Q2LT"=G9=DJVX!_X4:N=B2^$+#T.8L:E @7D13GQ<T1SDIY
MO#^&L7^/;Y]E8:"2F4TTG7&%0L.'+#4LQ#2[ =P/U-UZ*'*2WE9.INV$MA*L
MT$[73D^L<KQO_F4$M"E,;!5W\G2QPJ&+9H"TFP+DU$4LDWF'P0^S,+2'N\D
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M\]-PZ[ILT2!8]&_J=3BF?6N#BXQ 6-BDD"3TNX7I9KDZ26+BTW]C&+[B^5Q
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MH)1BD[8#JY[WA/!R&5]#/T)?=[@*1RH-*S6E;0M+ABAU/#KQ/2E(M.5JDN6
MOJEU#3.(5H+C@DYQ=H"D++U*+-0:US/_MQTNE;F(261 EF'3SS &AU!B_0Y^
M +',8,*B+=K1C[9%:Y"6LY!8L^ P3W6"<&D=&@!.^_WE,(8.N)UGWVIEUW#C
MA3@TLE6PF%0V->USU:7"@?],DU2I:_L[+PLSQU&T P$A=V,J9I5II281"3>
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M-&N]-Y%MYQV;%%9JSR0^JA('1SB=NH\['56])N4.%PN4;M%36:'WI.S@R48
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M;!)N/);-R)_+ILW(I8194!'W:4175+TF8C-*2;*Y38J9,.3M1_,ML-:>QQ[
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MWBW?N]1364Y?HG5N)YM-(C@;%VVJ@W&2 K_\!2DDC7=&X$=>EI'3<_F[##L
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M7!H5;?*[/*8MSGJ,;?U4GN9SO$JBT-_?PJ?\&)V$F4%<AWP"C8I&C6% ,0[
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MTZ/5UZ ,O?*J^3_1FK6LJF=PS##E02<S@O>U84H#R.5KR12:NFD?F HA=1]
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M*ZO<:VE9"*LX0W,=$C*M0(N/D>RDP59@@J0NP5OSI:.[??6QW'FW1J1&C!B
MP @+==0,),[RU-B<0=L>DPT[KO:DH9=23?9VK:Q)>=K<MGH'?5$SO9<GF368
M 3E:@6(60Z:!K-YEE LWJWBQB_.!;@.%%MS:S/!%8G[2+IEFEF$O[.IIXM,K
MVXNS# 7G&"Q-5':.)SW,9<ACR#BD_LT44M]IYN3A<KS'NYMEU!V(TN*T?88)
M1SNQ#UQ)SA4D ?9\![SK#$@] J95$\4G%2AA-O/0*_#/OD!>342(2IPV]?,X
MT>YR]Y$11.D,  ?1 5RSRL_!AUJ-L1O\ 3@YG2!1HH/>D426H:9GU)L69G5*
MQ7\O:J7E2%1S_X-(="!O5->WI*R)UOUD][SJ>)0Z3SQ-"DMPW2O324GX/ ,+
M8::HU  &4$3NS)@$(M,DYF/.@0AK0S5<'[2IZI143=D["%ZP?7PRO@(H1GED
M/WQM/@]JNJBFI8Z#K,!R9KN! F;#(RPC#=B@8.)6"]")>[8>4RV3>&7&'U[E
M(>U_/<L)F']<F*_@B+P]XHMZEC1G(EB/3YGU.$X7CAT=G'O0=9(T(-H[=-Z\
M$FX9:QAQ\0Q1W$Y0T&R7SASA3B^@9(XAX;L-&X=-X0.MZ:[T6P6,HPL,OZIY
MKB1YY]QMU@<(1"T"6;00Q-I=@25))(>5&R^4GFP,_GZ1N;PBO$/6)[*3!-?Y
M'* 5.79&;ZZS;\6#O"H^EK_1JKQOFNWE[DN]*YZ:%NZ*S[3O*QK"_S 248SA
M5F08$&)KC"'),&;^9]=\/GC>88<R=$'!BH>&*6;=?D&*7+)*8 $FUF5<7W8I
MM'EP*\/ZITM9Q%S;@S;ASC,VB\DRX?,?UX^/+=V4$B'P[IZIQ0#.L(8<.UY=
MC^W8>'GPM%P<OGU$64[SLT1\=T741T,VX!PI-Z_-5M=:0I(E:CV;45(&Y.^'
M@<TGB2Y#E]P'KI,.SUD;H!E)EY_BK]S=M?2NZ.E%S697,RV,0][]Q(M3;(.[
MW(;*42,1/90$&Y:#97/JS21Z\C([A&=X1MRIP2(&9.9RO.9&,_-388LC1J]Q
MCAU:$IT?H?=-M:5M)Z)+7[\F>N";J*&K25/R&6S,JJEF[S\4CTWW;RJFV5&!
M+,==/D?>GEJI$0XAZL["CCD#'EZ%%D=!X7/(QDN-2QX1TG%WC];5SO=0-N#G
MLBX?]@_7;+5 NI! 3#EO6BL:(%&W5O900(WAPQ,Y/A$?(!I79M>T=FA%M[1X
MBJ/P*JPPOU@(R*D^Z[K>%]4U?6Q:[^VM,WU$8R):9\1E<DW>%$N80$Q899'#
M9Q7D"N0R^JJ-Y<E9#-4:\U"&> $%34GAM(J838W\*OKG/:X2")QM8IODC&9+
M4 H$>SLSDEA[N(9"B4G+J +G";GV,P!%#D.IL_5VVX*CFOWSLKUIOGIA$$5S
M(MNO"/0 !&3HDX?G 2+L\S](ZXL<Z4Z@<5UG1B#.'.)/GS,N&I3R(;-+<*[[
M8.LOAQI$ D1Y":4W7R3ZJ;=]+B<7 96:@*FLWT/<2"*LPW#K@ 'RM'PJM[3>
M7@<2RDU#OA<U^U:B9ML&?YC Z&EI3&)%U#2(F@='[5L>;.L1N>Q\IN"(]G>0
MAN8,NQKB,+&CYSS%BW(G)+T2<UU+\U7EF*EZT8S"1;SI2B(NY 9-LRAPB<M-
M)?)-Y:[W)P&J_$C(WNJ'JF=N6V28+I<X4CB!^MH[:C2L@-5+0"U\K=AF #54
MJ?\38,/?^;D\Y>YK'\\^>:(5#Q9PGY>[*_8JV]=;NC4WBKN*L$1QO028*MG)
M>5P@OTP"M-COCRC9>/YCF4,:K7XEFBT@N<>:L,U:)SU(=^%@ZOBEJ?9,\6F?
MS\N*MGX,<V'4T:V):)[C+>2=N]N6XR00JW"%F +_\@D3]UW3>G$E)8=Y6Z(:
M9T-%<TS<S5X';:@J@P=/GOWBA-TD9=]QQ(.70_/#'\2(*\*'7# >OT6\ZV:>
MPS:\(][(LAN!J%T5SRHK-I96.$:JDQT74'391<_$.Y9"/N:K5%[U(ZASE;;L
M+2TJ^M@@]BNB.N:M'!J@R+5/XAS S040!];E[NS;YA[,;W!67=:O N8N/@4O
M7/4Q<3+")CL2SCL'ENS+>L]16A_E<L^: OH*#':MJU>3(]YA[7C<735=#S%-
MHU*Y\X!YC"&,:L.+ MIQ4VD?YC/9@WFL7[7-KNP_2@ XU]X'K[G4B 3R\@I^
ME'#*5U#]'1PL/5N(M_N>FT7ZAL>Z0V$+40I>(\+F+12F2?48P$:,0-5<!P#G
MSVP#=PJZF6UQ_H^A8.[)?='>^9T+%CXV# :'MK13P0G,_TF,>L1RQ*R2F4N^
M2WZ'L1 1MP3<8A)V71S=M'VB75IRDD:B7XM+E'<U@B)S*;4QHB8N["0F(#XR
MQK;&6(2=#0B7W:SDGO_D+1&@$H_71M5O&Z]&P_,K=$B?FF"<6PX4'P/F7PV4
M%>1X!L&VR.8S"_6^"E=I$'_-&U/G+Y9@547 ?+$I/=!XW$/%O/.F?2B8FB6T
MK) NIM5D8X05U*P@? PRT=66@* 3I3;D+DID%7:$T_ZVH__<0U#L$^CM\5M<
M=R"B!_EU*>G!/E*<X3]ANG&KUK$7U.4.#D&>0<P4B7)#N\]-Y<T A1Z@#O,^
M(IM;]B+0+>^!Y2?''3T1)AXQ0\&,.O3=VZ.(S&SO=W.F]H4[I6*D&1T0Y!L!
M73\HP#=US!QPC(ES2PCM38'ASYW[>["<I]&\<QB':1J:0I%&BJE-85D=63!9
ME$$/)4[U,$@U8G(2P$N!&4/,A^G[HL*>^-^HPL%[<]N/[K_4:H1IA#J5Q!DL
MPO7-K!_ ,/H_&@QO#,_JW4%&+Y#=!*8V<UQGF"KG;DK@ ZK6^*FI&Y5"*QX1
M,JTM9OPQ.^HWENS[U@4/D$=$4?I<4DID"NX6XE$']HH)I/R)LAR3+6.79<E5
ME<-!B4L48:H1KQ\#$H\O!8DQF80B*#)@W\@N;[/Z%CQT! -A7"0C^_95':VP
MRJ6;N12M+"[S\;R=[FX7::AWP!>(83WK^O*AZ/V^--:*!SRH=DGJ4QZNCPER
M,=U%,N)AHC(4-7K%9WH7K+$DDSD9_P=$$-4G]PWKH\5YLX8)-Y?]+. G<51I
M5)]7@GKR?24+W.UD&AY+@KR)!EPGMVZ6[R[R2FUZ%[EIQBNO?@=+=5*%TQM[
MR9N3:<71G%XX#PT3'VF(5*2\$EU+8GW74AJ__8>:&43WF!9WQ0Z2\A!A,SQ,
M;"8 +)?7Z<.S\=,LO"N7MXZI$;?/YB\6BQ:;S@NGI^A@GL[%0AP;4Z_:\HF=
MF5=5L9%X=SO:0I#=(>;VZ&"(;I;T6258V.401(]!U" +@\M(%>?4JI[$)33<
M'(4EQDO ER+Y,0DP;>@P 4W+!)EFDV"*($[J;(UW+-4!1J+>GA1M^\PDRG_N
M+G<W]Q1 *8K:@WP:V>PSA\Y0EF;>#!.. 1/LI(:0?#&F^%4'+=BP1(Z[@'"W
MEZZ#Z2EQ $N1E$%>E%MEY8?U0-Z4:%0"6P-$%I)CXC;_O;3A;2IP]"N< PBF
M\#YJ1/RM!GG@;;/>C9.93U:WAS9,X[$5;7T)N?Y5T77EKJ3;L!-L$IM.1(UF
MW7WB"\OQDD\@T/FL3V8,LHUEO6&W]KYB&M.6NR#@Y&OI/657^!,=HNU.*5>K
MV._^[[ZHRAV<E^ONW^GVCHJX5 $,U=2,0ITE(I-$S!R1FV:<(:(21*(1!FJ2
M(O&6C*9IIZD,DR7#;$G1$3[?%5$S)GK*+TAM60;@YZ+$Z FO6,X$L^PTA9D!
M^0^\RLGEON_ZH@8*;FC[$$FF%8&+HB<QNJX(=,YMX8P1YUH2:0S!PJL\)D[-
M<2')WCV"QM1U;G3>.8A&R8!&DZ@[67GC508=*"0:77D]1E?.%>WW>UT4$Z/K
M[Y0.Y-?!":P&=F?(4E3=;U>TA5\4=U[<B5$7 GW(T"G?BSE B;TVHD0CYTJ:
M$**=A7C+&W  !H7&L V_WT98K]T4/%BTXB-JL(I,"0&',L#Y##R(B7B"OFGZ
MHC)"[S42I$N2O/$(W%D8JK)9.IRSM\40(!$SF'L29'Y17QVB3CB!]<N:7-DW
M=^&YN3,IIG/I=RFJA_%P?AZ) 4GP2-O^^8I)H)=XAX^O&.X1_QX^/&MX0AX;
MM^JW(KRG1MY\],>#Y,&C2!.O!5.1P!+D>A"?[VE525MY!-..-U4NA5R'@GOF
MMB/+1UN.(-PQ--NG!L W]YL>0H1EL*H;F1W,OR\'O!M]3\7WKMPP^F;=7 L5
M+\\V.PH/_2%:1Q$.XI(R<+?#QE837GPIX<63R;ODXJ$0&57)?4ISSU< 5]Q_
M;:T([YL;02E UJSKRF#$[Q96W$L<,KJXM6Y6XX7SOZ@"A)?AKJ6'*.FQ6GQ0
MU)I M@"HSZ8JM^ >86^*?36%C$X,7(N/AU6]>\ZDDD+7%-B).0Z1 SF"5#+&
MKB4+U16^EL8LW+0D'2YS43_N^^XCO'6_#ZL10XP1.%>AUXKP?N3[I6@5 :I<
M!TN4";C%8BRK[5!*.!JK[+!9#[W= #6YU+XXD6Y-,)4YF!5=;WY6L:B?*,![
MI40A&9TXR!.@GWE#DK S+$($V2=< O6XR)NTIBT'(UQO'\JZ[/AJ>:))16!E
M9P&L.>KN+P.; UXSA4;7_IG!'%1;MM[%O.:A?D]?4QY7PI?2U/N1AK3I-V?X
M#L0<QNR7,<!IVSX&3W&5D4%9TI:LP23#)FV7,YA;KC[5/K;<&O7S^>):&B_G
M,^J)+BHA\D*(%H["EX[N]M7'<N<M6."IHBB>XBLB!B P0FZ5-8%(I^Z:S!S,
MU*9#BXIZ'=H?B@J4"J#D?20FP%LG]H.L$TL<=6+# 03RZTL('S@R0_TQ!J\B
MN1<F"RDH+UDS!=28S:;=TQ?#\,T:. <6WYP))MA<-+*;'(^'Y<D1%XK*=XCL
MIU:8V7S$5(,A6;UF>R 5$DZW3T,RR>*J<U/D]KZ%J$<R;O(Z+-)P#)53X=\B
MY]$;)PAE;[1)'_J0H5,^9%0O'?;>B%&,#%"I<@E.Z6-+-T(#9?^N*+^'V'8U
M\.=FNVO,=!/S Y!9(C\AGO[&1]*],7FS0U[$,-=^/*XPL*+]K^E=V4%*R/:4
MK>@-S,1.' \C&P\#$#$"OQNG^?4V]#'Z%D^FU-[Q,UF4J5(Z3R82\S#21U)B
M&V0-1RFAE9E3DQL1/$)=)/@AQ!)<2\T-?7ALVJ)]AEW>/U_3+?N%. 68RG\E
M9^D3ENY-1'?PF*L!Y(OK2LDOK\32Z'2);0Z'$$NVZ$+P)CPZ_-8?;Z_=$NS=
M,()])Z)?-ATG1(Q]YL4)1PT"%#F+(V36 !"JSDBU46IM*-1,.KZ;&K>.'Z(<
M*X#!D'W8'31:YU,@KCQFH-',G?8;!VT(K(4(V_5^6[(GW$>PY<@7A%,/%\V(
M:I?GD'=,V&2GEYXLAE1I:XN9V=;]F58*$I.GDDR?9-V3,UN%RI]%E<H.OYGS
M(+XB0P<_/%;-,U7HQ;P^C--,ZXT+EP,0-8(HE6-X1\U1\FI<R<2ZKI>9G'IQ
ME)_ P0)#HD*!/<CZ'!@F RB5?S8)AN6ALT;W75($7UQ@4Y-QA!^8H,NT!VO=
M5=L\E5NZ_?#\I0.OGX8B7H,KEYNPO2C,M!=UNM48@%WY!H8A9?W6@&8>ALH-
MSIQ,L^M F,LQ3%N'9V[G9<TNG&-(4X^T>&DZ:)XA32_'L&R.CC129[D'ET+F
M*HTU*7EA/_.0S\\4^NSS,YTG:#@P"I^8/3Z'IY&S=OT P\S:VN^^7/#+>MHV
MJWV$(=Y,#B=J+>"@C%\%O#(3OS,HJ,**:_PV=[&D%"(]GI14[F!M!FY/%F:"
MTSW$[E[1MFRV(@J>__J\:><Y3D1>H;25B$&)&%4BDLH_L8&7Z$YY 4<FNN-+
MF8NF]7-XKLL=NT?YH1RVAO'&H.1#(151GSLW-KUS_A-_EY](3'W/'ZG7F7Y4
M:12]%O!V_TF+]IQ-XZ#XQFXU\F0/>=YR< *C$Q@^[YO_19QQ';A'8#4R,,9$
M73HI'LN^J  ZD<,8[YH6PNR\EZ@3QD4.0F 4,AHF\U6:3*Y+NC-YE072_ZQH
M:[:F.N7HZZ"RY0;09,IJW\/<[:!JYY5J6%;4B(-KM"-\4 &I)X8E=N!ZS@OU
M0&;X+3&',!7CA!^P141H!8!??BH>O/YOB9PR-";0.I.H?).W72%^ A$WV->F
M_8VM +GA/^_;QVKO54AE8WT*RN:Y'G+.N=N+/4 @IJXB$5S#^J!LY$SZS0A5
MZ\]^<U"%G."TO^WH/_=,VS][BA:#&AH3WGH9>-1.$ES,#M"*K%OQN^(VGM-P
M:^<TR))AO]"NYS 2H"]NX)YIX%=&");E/;RF#T4)-]4)X%07FWY?5(![_'U*
MHJ(W?>7VV8W/!#-=J<)L*R)F*V)4Y7P!Y!Q^O1K#2T_\OGK>Q)CX(E"HER-"
MYU)?S.PP#S50"DZ82K!N:7'2;+W:#K0AT(A JWRA'N9<;>5F2D=&;%Q58O0G
MN*QFX> 26665/1=DYVQY.Q&BH@$93B;@WM87]88MB8Z>4O'?BUJEJ 2,V:H3
M>:.ZO04T5:-G?O0\/U6NTRV!#:BQDS)+Z+KX^G/1T[8L*A[GL7]\K()RT;E2
MK"?1744HC.R\!$BV&(%N$:4P!>LIO&;[=PM[^+PJO '[NA&!5AG?OJ/9VO>"
M@Q3$M>[Q(Y@QGN=-^YFV3^7&O_+]?IF53I&0?]TU+5'#Y7UES*+<J9,=P+M,
M-E]1.*I+3/K4AE[9+;6*?4XSKYO"D&TWQ).#:ZQ#Z'_9BQ"N>@NZ,UL7M-ZP
M$W) 2WDE*.YYW\95=&;-S1,$:(S!K]31*",4LBE8=Z94K-E+P4[+FL<S5%]C
MT[(78WVR9WNI9AL(*K>R>;#'YD_LX0B.D@^4'?8 ^.+U+(HAB!J#&(,0&$57
M9;OE0X'C*:=$9Y#L=!G.Y1C>(UM8WD\X[EUU46_IM_^@,51VV9KPYH2USU9E
MV#E[MW/!22+FMM%QH4/=.M_K>PB5'=4HS.M(=\S?M=:]9"+JMA_A*7G?5-N+
MA\>V>>)FLDA57-V%F'V6@CD:(,@E@RC]R[@NX'+C/U;<IIFJI(8N#Z$?F(.F
M:+"+NE$B7)EWOR2Q&->-O=YN6PZTO6<'<NRJD8U71#;/7P-D/'WW7>,B$?G]
MIX]A?A:H4% ONX<;A[=?Z<C8;!R/$!*\>EPT+\#FKM/]/M"[LJX#B!-A\[N1
M-JE'6E3FI)_@9-.\CU>X<>='P:@1)8B'P N^.B-ES5\#3$B5L#;#5L1<)C72
M?\]P0R%VNTX-/#'C IM&WYS7M*B@NL7+'^EJI,R1OLD4'_9&'_,+4X4V,CG$
M_$;UVYS/F:''2@IP.:7L_.0X'S,1XK$#?E+R+U[B-E'5+T)>DSQRFT7Z#+])
MB'<O!'4UPEQD/,Q!2?2!83(DT?MGDY!$;W16<5U+2J*/"VP:NAWA!Q+R#\^Y
MTT\0F?[A-_'Q_,/AV:7:YTMW<L_?YGJ(2ES'4HJRYO=SIJG46?W4*02ZW9RI
MC,D1*WL(_C?_'XA:U%?&:T:["LQV^3EY+6>V_QZ3<\Z+^>B20<S;^$COBDIJ
M#;[CEK=1BE2V:\Z<J7VP3JG /4Y_:IKMU[*J(C6,9*MEY N,Y^Q:V"ZJ4!U1
M3*CGU/\0$.L26N16[O54W0ZE$1VX<):C%%LC^U;X,@*XEG:^LIG/G!C9E ?R
M,DRQ2T");,(S@I]]H^VF[)AV+A.CNK(.0SRH'O!(&?I,L!N0CVP_'?8!'J,8
MTV#TN2]Z?F]?[@#4Z+QJOG8QDY'N ]6L./(3[[88JU&()K>Q(<8#O-T@4:2*
M2N($R&E\%T!>$.UU66?5(]M&\)%@;X,PJ:@F<%UW;$:54Z-X6[RZ:9X,"R]-
M[HLAQH/1+I@5\BHA"P6&(4"DO4YTJ_<SJ">J9Q(^BYMH3G1[YS&:XQ2-R&QT
M@H9H1K8=##4$1_4#]:^E)4J"LZ[[<[J%8J1P">PA>654@] ;=)):P['HB?P
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MJY@L?GCIA^M7C(%OOOWF#8/P?^@/?HE_.8W") I\CW'^Q G80NY6A*0O7S#
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M@%T^Z/6.7I3,M4$(#DHE[K*'A/R640:</YI8^288V)._<JLXV?(_;<W.^RZ
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ME R:^F]\55<ZH_>#P>>+$V?[@7B^Z\@<T=T?CO=L$*VT9+OY!=R<[PH[8 #
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M>VR<XK;H%W:-B1K/-I CF=O4W<3T@/>]TB;9Z'D@B13[#(:6>S=G-=YA! H
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MR@[?Y>&"67I"EGX8^N%2YB%F&,@1*H0,Z_0/!D##4BAC:?7>LR4U(]P#]D$
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M>!6N $8^;8>E4]T8588 CIO5N_IFZRR@K'HDY323,[*@*X!6*S&>28FNAUV
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MOWQP?HWBDCCIC@+TRXJRT[_M%5T %,F-DMX@3$8B?J (YMI9D_FB1HY\5O6
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M[%U$\47&"@J[)TP"^<$J^*=T@&MP%VN(94GR68&2]XH]S6+&D5GH40:X^5^
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M 9MHSO[V_P%02P$"% ,4    "  V?#=5(*8S#!Q6 P ,UQX &
M    @ $     9C$P:S(P,C)?:6YM961P:&%R;6$N:'1M4$L! A0#%     @
M-GPW5?-\]AOU 0  2@@  !X              ( !4E8# &8Q,&LR,#(R97@R
M,2TQ7VEN;65D<&AA<FUA+FAT;5!+ 0(4 Q0    ( #9\-U6 >,$<$ (  .$(
M   >              "  8-8 P!F,3!K,C R,F5X,C,M,5]I;FUE9'!H87)M
M82YH=&U02P$"% ,4    "  V?#=5I90F!BT'  "0)P  '@
M@ '/6@, 9C$P:S(P,C)E>#,Q+3%?:6YM961P:&%R;6$N:'1M4$L! A0#%
M  @ -GPW59&KP.$2!P  P"8  !X              ( !.&(# &8Q,&LR,#(R
M97@S,2TR7VEN;65D<&AA<FUA+FAT;5!+ 0(4 Q0    ( #9\-U6RJ"B(1 ,
M &T+   >              "  89I P!F,3!K,C R,F5X,S(M,5]I;FUE9'!H
M87)M82YH=&U02P$"% ,4    "  V?#=5*YJ4IS,#  !("P  '@
M    @ $&;0, 9C$P:S(P,C)E>#,R+3)?:6YM961P:&%R;6$N:'1M4$L! A0#
M%     @ -GPW571#]QM2/P$ 7T@!  T              ( !=7 # &EM86=E
M7S P,2YJ<&=02P$"% ,4    "  V?#=5)<C[*/'/   #V@  #0
M    @ 'RKP0 :6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( #9\-U4BLSWU!00!
M /H) 0 -              "  0Z !0!I;6%G95\P,#,N:G!G4$L! A0#%
M  @ -GPW52%3)?J&(@  >B0   T              ( !/H0& &EM86=E7S P
M-"YJ<&=02P$"% ,4    "  V?#=5OZQYG261 0#=F0$ #0
M@ 'OI@8 :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( #9\-U6K/):$4N8  +WL
M   -              "  3\X" !I;6%G95\P,#8N:G!G4$L! A0#%     @
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M2P$"% ,4    "  V?#=5<,_I8_5+  "!30  #0              @ &N)@P
M:6UA9V5?,#$Q+FIP9U!+ 0(4 Q0    ( #9\-U61#5 F#2H  ! P   -
M          "  <YR# !I;6%G95\P,3(N:G!G4$L! A0#%     @ -GPW57]-
MZP_O*@  I3    T              ( !!IT, &EM86=E7S Q,RYJ<&=02P$"
M% ,4    "  V?#=5&\]7%PHA  "\)0  #0              @ $@R P :6UA
M9V5?,#$T+FIP9U!+ 0(4 Q0    ( #9\-U5ZPJ39D7(  (%Z   -
M      "  57I# !I;6%G95\P,34N:G!G4$L! A0#%     @ -GPW50+GV? *
M'@  ?!\   T              ( !$5P- &EM86=E7S Q-BYJ<&=02P$"% ,4
M    "  V?#=5PDR 8\0N  " -@  #0              @ %&>@T :6UA9V5?
M,#$W+FIP9U!+ 0(4 Q0    ( #9\-U4-">8#WA<  & 9   -
M  "  36I#0!I;6%G95\P,3@N:G!G4$L! A0#%     @ -GPW55#(7I D%0
M,A<   T              ( !/L$- &EM86=E7S Q.2YJ<&=02P$"% ,4
M"  V?#=5G\KM <H?  !)(@  #0              @ &-U@T :6UA9V5?,#(P
M+FIP9U!+ 0(4 Q0    ( #9\-U5.J1<1\Q,  %85   -              "
M 8+V#0!I;6%G95\P,C$N:G!G4$L! A0#%     @ -GPW5?B92]",+P  ]#$
M  T              ( !H H. &EM86=E7S R,BYJ<&=02P$"% ,4    "  V
M?#=5@&H2KJLG   G*0  #0              @ %7.@X :6UA9V5?,#(S+FIP
M9U!+ 0(4 Q0    ( #9\-U7K84JVSP\  "H1   -              "  2UB
M#@!I;6%G95\P,C0N:G!G4$L! A0#%     @ -GPW5=C;^AA6%   8A<   T
M             ( !)W(. &EM86=E7S R-2YJ<&=02P$"% ,4    "  V?#=5
M@16,(Y46  "D&@  #0              @ &HA@X :6UA9V5?,#(V+FIP9U!+
M 0(4 Q0    ( #9\-U7VEFY&E!,  +05   -              "  6B=#@!I
M;6%G95\P,C<N:G!G4$L! A0#%     @ -GPW5:%]@^PD%@  &1@   T
M         ( !)[$. &EM86=E7S R."YJ<&=02P$"% ,4    "  V?#=55N !
MM*(3   &%0  #0              @ %VQPX :6UA9V5?,#(Y+FIP9U!+ 0(4
M Q0    ( #9\-U6.N56<L1(  -\4   -              "  4/;#@!I;6%G
M95\P,S N:G!G4$L! A0#%     @ -GPW5=Z9099M#P  4!    T
M     ( !'^X. &EM86=E7S S,2YJ<&=02P$"% ,4    "  V?#=5WIE!EFT/
M  !0$   #0              @ &W_0X :6UA9V5?,#,R+FIP9U!+ 0(4 Q0
M   ( #9\-U55NR*,!1P   9H 0 0              "  4\-#P!I;FTM,C R
M,C V,S N>'-D4$L! A0#%     @ -GPW5: V/]M0#   X(L  !0
M     ( !@BD/ &EN;2TR,#(R,#8S,%]C86PN>&UL4$L! A0#%     @ -GPW
M5<C+(6653@  %L<$ !0              ( !!#8/ &EN;2TR,#(R,#8S,%]D
M968N>&UL4$L! A0#%     @ -GPW5=*O3&F#SP  -RT* !0
M ( !RX0/ &EN;2TR,#(R,#8S,%]L86(N>&UL4$L! A0#%     @ -GPW5:5P
M_C0X3P  G P% !0              ( !@%00 &EN;2TR,#(R,#8S,%]P<F4N
9>&UL4$L%!@     L "P M H  .JC$     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
